TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 52	44	6.25 (2.04)	2.37 (2.42)	2.0	0.0, 8.1	-3.88 (2.95)	-3.7	-11.2, 2.8	<=0.001***
Low Dose	25	5.92 (1.78)	2.39 (2.25)	2.3	0.0, 6.7	-3.53 (2.52)	-3.6	-8.7, 1.8	<=0.001***
High Dose	19	6.68 (2.33)	2.34 (2.69)	1.4	0.0, 8.1	-4.34 (3.45)	-3.8	-11.2, 2.8	<=0.001***
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	119		6.21 (3.27)	6.5	0.0, 14.0				
Low Dose	66		6.09 (3.44)	5.9	0.0, 14.0				
High Dose	53		6.37 (3.08)	6.7	0.0, 11.6				
WEEK 1	113	6.19 (3.22)	8.01 (4.45)	8.1	0.0, 16.0	1.82 (4.46)	1.6	-8.9, 10.7	<=0.001***
Low Dose	64	5.94 (3.35)	7.41 (4.59)	7.3	0.0, 16.0	1.46 (4.54)	1.3	-8.9, 10.7	0.0122*
High Dose	49	6.52 (3.05)	8.80 (4.18)	8.9	0.0, 16.0	2.28 (4.36)	3.0	-8.1, 8.7	<=0.001***
WEEK 6	106	6.18 (3.30)	9.39 (4.36)	10.0	0.0, 16.0	3.21 (4.46)	3.2	-9.1, 13.8	<=0.001***
Low Dose	59	6.04 (3.43)	9.41 (4.62)	10.2	0.0, 16.0	3.36 (4.87)	3.9	-9.1, 13.8	<=0.001***
High Dose	47	6.34 (3.16)	9.37 (4.06)	9.9	0.0, 16.0	3.03 (3.92)	2.9	-4.9, 10.6	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 13	57	6.38 (3.07)	10.81 (4.46)	11.3	0.0, 16.0	4.43 (4.43)	4.8	-6.5, 15.2	<=0.001***
Low Dose	35	6.27 (3.01)	10.68 (4.71)	12.4	0.0, 16.0	4.41 (4.59)	4.8	-6.5, 15.2	<=0.001***
High Dose	22	6.55 (3.23)	11.03 (4.14)	11.0	0.9, 16.0	4.48 (4.29)	5.1	-4.7, 10.0	<=0.001***
WEEK 26	65	6.39 (3.30)	11.32 (4.17)	12.5	0.0, 16.0	4.93 (4.48)	5.4	-11.0, 12.7	<=0.001***
Low Dose	37	6.44 (3.35)	11.90 (3.46)	12.6	1.3, 16.0	5.45 (3.53)	5.4	-1.2, 11.5	<=0.001***
High Dose	28	6.32 (3.30)	10.57 (4.92)	11.2	0.0, 16.0	4.25 (5.48)	5.6	-11.0, 12.7	<=0.001***
WEEK 39	60	6.67 (3.20)	10.97 (4.18)	11.6	0.6, 16.0	4.30 (4.17)	4.6	-6.4, 13.5	<=0.001***
Low Dose	36	6.58 (3.21)	10.97 (4.23)	11.2	1.4, 16.0	4.39 (4.12)	5.0	-6.4, 11.4	<=0.001***
High Dose	24	6.81 (3.24)	10.97 (4.19)	11.6	0.6, 16.0	4.17 (4.34)	3.8	-3.8, 13.5	<=0.001***
WEEK 52	44	6.78 (3.11)	11.45 (3.68)	11.8	1.3, 16.0	4.67 (3.95)	4.9	-3.1, 13.8	<=0.001***
Low Dose	25	6.75 (2.86)	11.71 (3.64)	13.0	1.3, 16.0	4.95 (3.55)	5.1	-2.5, 9.3	<=0.001***
High Dose	19	6.81 (3.48)	11.11 (3.80)	11.3	1.3, 16.0	4.31 (4.49)	3.4	-3.1, 13.8	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	119		2.69 (2.40)	2.7	0.0, 8.9				
Low Dose	66		2.88 (2.32)	2.9	0.0, 8.5				
High Dose	53		2.46 (2.49)	1.9	0.0, 8.9				
WEEK 1	113	2.71 (2.38)	2.64 (3.42)	1.1	0.0, 14.9	-0.07 (3.48)	0.0	-8.5, 13.6	0.8200
Low Dose	64	2.93 (2.32)	3.49 (3.67)	2.6	0.0, 14.9	0.56 (3.98)	0.0	-8.5, 13.6	0.2661
High Dose	49	2.43 (2.45)	1.53 (2.73)	0.0	0.0, 12.8	-0.90 (2.52)	-0.2	-6.9, 8.1	0.0157*
WEEK 6	106	2.72 (2.44)	2.20 (3.44)	0.5	0.0, 15.4	-0.52 (3.25)	-0.2	-7.8, 11.6	0.1019
Low Dose	59	2.91 (2.34)	2.55 (3.48)	1.3	0.0, 15.4	-0.35 (3.52)	-0.1	-7.6, 11.6	0.4465
High Dose	47	2.49 (2.56)	1.76 (3.37)	0.0	0.0, 14.6	-0.74 (2.91)	-0.3	-7.8, 7.5	0.0896
WEEK 13	57	3.15 (2.41)	1.90 (3.79)	0.0	0.0, 16.0	-1.25 (3.94)	-1.2	-8.0, 13.2	0.0195*
Low Dose	35	3.49 (2.31)	1.95 (3.91)	0.0	0.0, 16.0	-1.53 (4.24)	-2.2	-8.0, 13.2	0.0398*
High Dose	22	2.62 (2.52)	1.81 (3.70)	0.0	0.0, 14.4	-0.81 (3.45)	-0.2	-6.9, 7.2	0.2822

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 26	65	2.41 (2.33)	1.86 (3.31)	0.0	0.0, 15.2	-0.55 (3.42)	-0.2	-6.8, 12.0	0.1964
Low Dose	37	2.60 (2.19)	1.57 (2.39)	0.3	0.0, 10.8	-1.04 (2.97)	-0.6	-6.8, 5.4	0.0408*
High Dose	28	2.16 (2.52)	2.25 (4.25)	0.0	0.0, 15.2	0.08 (3.91)	0.0	-6.8, 12.0	0.9122
WEEK 39	60	2.45 (2.42)	1.77 (3.25)	0.0	0.0, 14.6	-0.69 (3.65)	0.0	-7.8, 9.9	0.1503
Low Dose	36	2.94 (2.42)	1.91 (3.26)	0.0	0.0, 14.6	-1.03 (3.44)	0.0	-7.8, 9.2	0.0813
High Dose	24	1.73 (2.28)	1.56 (3.31)	0.0	0.0, 12.3	-0.17 (3.95)	0.0	-7.8, 9.9	0.8335
WEEK 52	44	2.46 (2.62)	1.70 (2.86)	0.0	0.0, 12.0	-0.76 (3.07)	0.0	-7.3, 6.1	0.1070
Low Dose	25	2.59 (2.24)	1.70 (2.97)	0.0	0.0, 12.0	-0.89 (3.38)	-0.4	-6.8, 6.1	0.2002
High Dose	19	2.28 (3.11)	1.69 (2.79)	0.0	0.0, 9.3	-0.59 (2.70)	0.0	-7.3, 2.8	0.3493
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	119		1.06 (1.90)	0.0	0.0, 10.5				
Low Dose	66		1.47 (2.23)	0.3	0.0, 10.5				
High Dose	53		0.56 (1.23)	0.0	0.0, 5.3				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 1	113	1.07 (1.91)	1.04 (2.02)	0.0	0.0, 10.5	-0.03 (1.92)	0.0	-6.0, 10.5	0.8544
Low Dose	64	1.51 (2.26)	1.62 (2.46)	0.3	0.0, 10.5	0.11 (2.31)	0.0	-6.0, 10.5	0.7076
High Dose	49	0.50 (1.11)	0.28 (0.72)	0.0	0.0, 3.4	-0.22 (1.22)	0.0	-4.9, 3.4	0.2145
WEEK 6	106	1.02 (1.95)	0.41 (1.24)	0.0	0.0, 5.8	-0.61 (1.77)	0.0	-9.2, 4.1	<=0.001***
Low Dose	59	1.42 (2.31)	0.63 (1.57)	0.0	0.0, 5.8	-0.79 (2.16)	0.0	-9.2, 4.1	0.0069**
High Dose	47	0.52 (1.22)	0.13 (0.51)	0.0	0.0, 2.8	-0.38 (1.08)	0.0	-4.9, 2.1	0.0188*
WEEK 13	57	0.91 (1.55)	0.21 (0.64)	0.0	0.0, 3.5	-0.71 (1.57)	0.0	-7.2, 1.7	0.0012**
Low Dose	35	1.18 (1.73)	0.29 (0.78)	0.0	0.0, 3.5	-0.90 (1.76)	0.0	-7.2, 1.7	0.0048**
High Dose	22	0.48 (1.13)	0.07 (0.24)	0.0	0.0, 0.9	-0.41 (1.19)	0.0	-4.9, 0.9	0.1205
WEEK 26	65	0.91 (1.78)	0.15 (0.55)	0.0	0.0, 3.7	-0.76 (1.89)	0.0	-9.2, 3.7	0.0019**
Low Dose	37	1.10 (1.96)	0.14 (0.62)	0.0	0.0, 3.7	-0.96 (2.11)	0.0	-9.2, 3.7	0.0086**
High Dose	28	0.65 (1.49)	0.16 (0.47)	0.0	0.0, 1.8	-0.49 (1.55)	0.0	-4.9, 1.7	0.1039
WEEK 39	60	0.72 (1.33)	0.28 (0.83)	0.0	0.0, 3.8	-0.45 (1.20)	0.0	-5.1, 2.7	0.0054**
Low Dose	36	0.86 (1.33)	0.29 (0.83)	0.0	0.0, 3.8	-0.57 (1.25)	0.0	-5.1, 0.8	0.0099**
High Dose	24	0.51 (1.33)	0.25 (0.86)	0.0	0.0, 3.4	-0.26 (1.11)	0.0	-3.6, 2.7	0.2594

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 52	44	0.52 (1.14)	0.48 (1.39)	0.0	0.0, 6.3	-0.04 (1.90)	0.0	-5.1, 6.3	0.9014
Low Dose	25	0.74 (1.30)	0.20 (0.68)	0.0	0.0, 3.3	-0.54 (1.49)	0.0	-5.1, 3.3	0.0823
High Dose	19	0.23 (0.83)	0.86 (1.94)	0.0	0.0, 6.3	0.63 (2.21)	0.0	-3.6, 6.3	0.2318
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	119		8.91 (2.51)	8.9	0.3, 15.0				
Low Dose	66		8.97 (2.72)	9.0	0.3, 15.0				
High Dose	53		8.83 (2.25)	8.8	2.6, 14.5				
WEEK 1	113	8.90 (2.51)	10.65 (3.69)	10.6	0.0, 16.0	1.74 (4.07)	1.6	-10.4, 11.3	<=0.001***
Low Dose	64	8.87 (2.69)	10.89 (3.67)	10.9	3.0, 16.0	2.02 (3.93)	2.2	-5.9, 11.3	<=0.001***
High Dose	49	8.94 (2.29)	10.33 (3.73)	10.0	0.0, 16.0	1.38 (4.26)	1.4	-10.4, 8.3	0.0277*
WEEK 6	106	8.90 (2.51)	11.59 (3.46)	12.1	0.0, 16.0	2.69 (3.82)	3.0	-9.9, 10.6	<=0.001***
Low Dose	59	8.95 (2.66)	11.96 (3.77)	12.6	0.0, 16.0	3.01 (3.80)	3.1	-9.9, 10.5	<=0.001***
High Dose	47	8.84 (2.33)	11.13 (2.98)	11.5	3.5, 16.0	2.29 (3.86)	2.4	-6.8, 10.6	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 13	57	9.53 (2.11)	12.71 (3.37)	14.0	2.6, 16.0	3.18 (3.41)	3.8	-4.9, 9.2	<=0.001***
Low Dose	35	9.76 (2.02)	12.63 (3.68)	14.1	2.6, 16.0	2.87 (3.33)	3.8	-4.9, 7.2	<=0.001***
High Dose	22	9.17 (2.26)	12.84 (2.89)	13.5	6.0, 16.0	3.67 (3.55)	3.8	-4.7, 9.2	<=0.001***
WEEK 26	65	8.81 (2.65)	13.18 (3.09)	14.3	1.7, 16.0	4.38 (3.68)	4.6	-5.5, 12.5	<=0.001***
Low Dose	37	9.05 (2.82)	13.46 (3.21)	15.0	1.7, 16.0	4.42 (3.72)	4.4	-4.1, 12.5	<=0.001***
High Dose	28	8.48 (2.42)	12.81 (2.94)	13.9	6.2, 16.0	4.33 (3.69)	4.8	-5.5, 10.6	<=0.001***
WEEK 39	60	9.12 (2.42)	12.74 (3.01)	12.9	2.7, 16.0	3.61 (3.38)	3.4	-9.1, 9.6	<=0.001***
Low Dose	36	9.52 (2.23)	12.87 (3.17)	13.2	2.7, 16.0	3.36 (3.42)	3.2	-9.1, 9.4	<=0.001***
High Dose	24	8.54 (2.61)	12.53 (2.81)	12.9	6.6, 16.0	4.00 (3.36)	4.0	-2.9, 9.6	<=0.001***
WEEK 52	44	9.24 (2.05)	13.15 (2.51)	13.4	7.9, 16.0	3.91 (2.99)	3.9	-2.8, 11.2	<=0.001***
Low Dose	25	9.34 (2.01)	13.41 (2.27)	13.4	8.8, 16.0	4.06 (2.60)	4.1	-2.2, 8.7	<=0.001***
High Dose	19	9.09 (2.15)	12.80 (2.83)	13.4	7.9, 16.0	3.71 (3.50)	3.7	-2.8, 11.2	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:NORTH AMERICA									
Average Daily Normalized 'Off' Time									
BASELINE	89		5.54 (2.32)	5.4	0.0, 10.3				
Low Dose	39		4.96 (2.40)	4.9	0.0, 9.9				
High Dose	50		5.99 (2.17)	5.9	0.6, 10.3				
WEEK 1	83	5.50 (2.29)	3.41 (3.08)	2.7	0.0, 11.8	-2.08 (3.32)	-2.2	-8.6, 5.6	<=0.001***
Low Dose	37	5.03 (2.42)	2.79 (3.05)	2.0	0.0, 10.3	-2.24 (3.38)	-2.8	-8.6, 5.6	<=0.001***
High Dose	46	5.87 (2.13)	3.91 (3.03)	3.8	0.0, 11.8	-1.96 (3.30)	-1.8	-8.3, 4.8	<=0.001***
WEEK 6	76	5.49 (2.31)	2.99 (3.29)	1.9	0.0, 14.9	-2.50 (3.57)	-2.9	-9.9, 6.7	<=0.001***
Low Dose	34	4.97 (2.31)	2.40 (3.23)	1.0	0.0, 14.9	-2.57 (3.49)	-2.6	-9.9, 6.3	<=0.001***
High Dose	42	5.92 (2.24)	3.47 (3.30)	2.5	0.0, 10.7	-2.44 (3.68)	-3.1	-8.4, 6.7	<=0.001***
WEEK 13	47	5.16 (2.43)	2.50 (3.15)	1.5	0.0, 10.3	-2.65 (3.43)	-3.2	-9.9, 6.3	<=0.001***
Low Dose	23	4.50 (2.30)	1.45 (2.09)	0.2	0.0, 7.2	-3.05 (2.94)	-3.3	-9.9, 5.0	<=0.001***
High Dose	24	5.79 (2.43)	3.51 (3.68)	2.4	0.0, 10.3	-2.28 (3.87)	-2.1	-9.2, 6.3	0.0084**

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 26	51	5.19 (2.29)	1.83 (2.33)	0.9	0.0, 8.4	-3.37 (2.34)	-2.8	-9.2, 1.5	<=0.001***
Low Dose	25	4.81 (2.24)	1.35 (1.90)	0.3	0.0, 6.1	-3.46 (2.31)	-3.6	-9.2, 0.2	<=0.001***
High Dose	26	5.56 (2.32)	2.28 (2.64)	1.3	0.0, 8.4	-3.28 (2.42)	-2.8	-7.5, 1.5	<=0.001***
WEEK 39	49	5.20 (2.31)	2.19 (2.60)	1.3	0.0, 13.3	-3.01 (3.13)	-3.1	-9.9, 9.6	<=0.001***
Low Dose	26	4.86 (2.20)	2.21 (2.85)	1.4	0.0, 13.3	-2.66 (3.41)	-2.9	-9.9, 9.6	<=0.001***
High Dose	23	5.58 (2.42)	2.18 (2.36)	1.3	0.0, 7.0	-3.40 (2.79)	-3.6	-9.1, 1.9	<=0.001***
WEEK 52	42	5.36 (2.27)	1.80 (2.40)	0.5	0.0, 8.8	-3.56 (2.65)	-3.6	-9.9, 2.8	<=0.001***
Low Dose	21	5.06 (2.27)	1.69 (1.80)	0.9	0.0, 5.9	-3.38 (2.31)	-3.1	-9.9, 0.0	<=0.001***
High Dose	21	5.65 (2.27)	1.91 (2.92)	0.5	0.0, 8.8	-3.74 (3.00)	-4.4	-8.6, 2.8	<=0.001***
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	89		6.91 (3.64)	6.8	0.0, 15.4				
Low Dose	39		6.95 (4.09)	6.8	0.0, 15.4				
High Dose	50		6.87 (3.29)	6.7	0.0, 13.8				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 1	83	6.99 (3.56)	9.25 (4.26)	9.0	0.0, 16.0	2.26 (4.33)	1.7	-8.8, 12.0	<=0.001***
Low Dose	37	6.90 (3.96)	9.06 (4.70)	8.6	0.0, 16.0	2.16 (4.38)	1.7	-8.8, 10.7	0.0049**
High Dose	46	7.07 (3.25)	9.40 (3.91)	9.2	0.5, 16.0	2.33 (4.34)	2.6	-5.1, 12.0	<=0.001***
WEEK 6	76	6.91 (3.72)	10.22 (4.83)	10.4	0.0, 16.0	3.31 (4.87)	3.2	-9.1, 12.0	<=0.001***
Low Dose	34	6.92 (4.13)	9.88 (5.15)	10.0	0.0, 16.0	2.96 (5.17)	2.6	-9.1, 11.7	0.0021**
High Dose	42	6.90 (3.41)	10.50 (4.60)	10.9	0.0, 16.0	3.60 (4.65)	3.4	-6.7, 12.0	<=0.001***
WEEK 13	47	7.21 (3.88)	11.29 (4.62)	12.1	0.0, 16.0	4.07 (4.72)	3.3	-6.3, 15.2	<=0.001***
Low Dose	23	7.77 (4.14)	11.46 (4.79)	13.0	0.0, 16.0	3.70 (4.54)	2.9	-3.9, 15.2	<=0.001***
High Dose	24	6.68 (3.63)	11.12 (4.55)	11.5	0.9, 16.0	4.43 (4.96)	4.9	-6.3, 14.1	<=0.001***
WEEK 26	51	7.28 (3.81)	12.04 (4.04)	13.3	0.0, 16.0	4.76 (4.31)	4.4	-6.6, 14.1	<=0.001***
Low Dose	25	7.85 (3.88)	12.60 (3.68)	13.4	0.5, 16.0	4.75 (4.17)	4.4	-2.4, 11.5	<=0.001***
High Dose	26	6.73 (3.75)	11.50 (4.37)	13.2	0.0, 16.0	4.77 (4.53)	4.6	-6.6, 14.1	<=0.001***
WEEK 39	49	7.49 (3.79)	11.21 (4.58)	12.4	0.0, 16.0	3.72 (4.83)	4.1	-10.6, 13.5	<=0.001***
Low Dose	26	7.61 (4.00)	11.19 (4.71)	12.9	0.6, 16.0	3.58 (5.28)	4.5	-10.6, 11.4	0.0019**
High Dose	23	7.35 (3.64)	11.22 (4.52)	11.8	0.0, 16.0	3.88 (4.37)	3.3	-2.8, 13.5	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 52	42	7.22 (3.84)	10.98 (4.95)	12.1	0.0, 16.0	3.76 (4.84)	4.4	-12.0, 13.8	<=0.001***
Low Dose	21	7.42 (3.81)	11.93 (4.48)	13.3	0.0, 16.0	4.50 (4.07)	5.1	-2.6, 9.9	<=0.001***
High Dose	21	7.01 (3.94)	10.03 (5.32)	10.0	0.0, 16.0	3.01 (5.51)	2.8	-12.0, 13.8	0.0209*
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	89		2.82 (2.83)	2.6	0.0, 12.2				
Low Dose	39		3.05 (2.74)	2.9	0.0, 10.3				
High Dose	50		2.64 (2.91)	2.0	0.0, 12.2				
WEEK 1	83	2.84 (2.84)	2.42 (2.99)	1.5	0.0, 13.6	-0.42 (3.43)	0.0	-8.5, 13.6	0.2718
Low Dose	37	3.11 (2.76)	3.02 (3.30)	2.4	0.0, 13.6	-0.09 (3.76)	-0.4	-8.5, 13.6	0.8888
High Dose	46	2.61 (2.91)	1.93 (2.66)	0.3	0.0, 9.7	-0.68 (3.17)	0.0	-8.2, 8.8	0.1506
WEEK 6	76	2.88 (2.94)	2.29 (3.52)	0.6	0.0, 14.6	-0.59 (3.48)	-0.5	-7.8, 9.6	0.1441
Low Dose	34	3.13 (2.79)	2.88 (3.43)	1.4	0.0, 12.2	-0.24 (3.64)	-0.8	-7.6, 9.6	0.7027
High Dose	42	2.68 (3.07)	1.80 (3.56)	0.0	0.0, 14.6	-0.87 (3.37)	-0.1	-7.8, 7.5	0.1005

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 13	47	3.01 (3.17)	1.87 (3.81)	0.0	0.0, 15.5	-1.13 (3.90)	-0.6	-12.2, 7.9	0.0520
Low Dose	23	3.00 (3.04)	2.62 (4.37)	0.0	0.0, 15.5	-0.38 (3.97)	-0.6	-8.0, 7.9	0.6477
High Dose	24	3.01 (3.35)	1.16 (3.10)	0.0	0.0, 14.4	-1.85 (3.77)	-0.7	-12.2, 7.2	0.0244*
WEEK 26	51	2.80 (2.78)	1.69 (3.10)	0.0	0.0, 15.2	-1.11 (3.76)	-0.6	-12.2, 12.0	0.0410*
Low Dose	25	2.45 (2.18)	1.35 (1.36)	1.1	0.0, 3.4	-1.10 (2.73)	-0.6	-6.8, 3.1	0.0553
High Dose	26	3.14 (3.26)	2.02 (4.16)	0.0	0.0, 15.2	-1.11 (4.60)	-0.6	-12.2, 12.0	0.2299
WEEK 39	49	2.68 (2.84)	2.18 (3.80)	0.0	0.0, 16.0	-0.49 (4.03)	0.0	-7.8, 15.4	0.3958
Low Dose	26	2.67 (2.43)	2.37 (3.77)	0.6	0.0, 15.4	-0.30 (4.32)	0.0	-7.8, 15.4	0.7267
High Dose	23	2.68 (3.31)	1.97 (3.91)	0.0	0.0, 16.0	-0.71 (3.77)	0.0	-7.8, 6.1	0.3737
WEEK 52	42	2.86 (3.15)	2.79 (4.55)	0.6	0.0, 16.0	-0.07 (3.94)	0.0	-7.3, 12.9	0.9102
Low Dose	21	2.74 (2.73)	2.22 (4.23)	0.0	0.0, 16.0	-0.53 (3.45)	-0.6	-6.8, 6.1	0.4911
High Dose	21	2.98 (3.58)	3.37 (4.89)	0.8	0.0, 16.0	0.39 (4.42)	0.0	-7.3, 12.9	0.6909

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	89		0.74 (1.24)	0.0	0.0, 5.1				
Low Dose	39		1.03 (1.39)	0.3	0.0, 5.1				
High Dose	50		0.51 (1.07)	0.0	0.0, 4.9				
WEEK 1	83	0.67 (1.09)	0.92 (1.73)	0.0	0.0, 7.2	0.24 (1.73)	0.0	-3.7, 7.0	0.2017
Low Dose	37	0.96 (1.26)	1.12 (1.71)	0.0	0.0, 5.4	0.17 (1.61)	0.0	-3.7, 5.2	0.5292
High Dose	46	0.45 (0.89)	0.75 (1.74)	0.0	0.0, 7.2	0.31 (1.84)	0.0	-3.7, 7.0	0.2651
WEEK 6	76	0.72 (1.23)	0.50 (1.55)	0.0	0.0, 9.0	-0.22 (1.68)	0.0	-5.1, 6.9	0.2570
Low Dose	34	0.98 (1.39)	0.84 (2.19)	0.0	0.0, 9.0	-0.15 (2.22)	0.0	-5.1, 6.9	0.7033
High Dose	42	0.50 (1.04)	0.22 (0.59)	0.0	0.0, 2.6	-0.28 (1.09)	0.0	-4.9, 2.1	0.1041
WEEK 13	47	0.62 (1.12)	0.34 (1.07)	0.0	0.0, 5.5	-0.29 (1.04)	0.0	-4.9, 2.6	0.0665
Low Dose	23	0.73 (1.16)	0.46 (1.35)	0.0	0.0, 5.5	-0.27 (0.83)	0.0	-1.7, 1.7	0.1385
High Dose	24	0.52 (1.09)	0.21 (0.72)	0.0	0.0, 3.4	-0.30 (1.23)	0.0	-4.9, 2.6	0.2380

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 26	51	0.73 (1.31)	0.44 (1.80)	0.0	0.0, 12.1	-0.29 (1.76)	0.0	-5.1, 7.2	0.2522
Low Dose	25	0.89 (1.45)	0.70 (2.51)	0.0	0.0, 12.1	-0.19 (2.16)	0.0	-5.1, 7.2	0.6644
High Dose	26	0.57 (1.17)	0.19 (0.58)	0.0	0.0, 2.4	-0.38 (1.30)	0.0	-4.9, 1.6	0.1517
WEEK 39	49	0.63 (1.19)	0.41 (1.30)	0.0	0.0, 8.1	-0.22 (1.60)	0.0	-5.1, 7.3	0.3383
Low Dose	26	0.85 (1.43)	0.22 (0.63)	0.0	0.0, 2.4	-0.63 (1.26)	0.0	-5.1, 0.8	0.0178*
High Dose	23	0.39 (0.80)	0.62 (1.78)	0.0	0.0, 8.1	0.24 (1.84)	0.0	-3.6, 7.3	0.5430
WEEK 52	42	0.56 (1.08)	0.43 (1.37)	0.0	0.0, 6.3	-0.13 (1.84)	0.0	-5.1, 6.3	0.6524
Low Dose	21	0.77 (1.26)	0.17 (0.72)	0.0	0.0, 3.3	-0.60 (1.53)	-0.2	-5.1, 3.3	0.0882
High Dose	21	0.35 (0.84)	0.69 (1.79)	0.0	0.0, 6.3	0.34 (2.04)	0.0	-3.6, 6.3	0.4532
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	89		9.72 (2.47)	9.8	3.7, 16.0				
Low Dose	39		10.01 (3.00)	10.3	3.7, 16.0				
High Dose	50		9.50 (1.97)	9.6	5.7, 14.1				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 1	83	9.83 (2.43)	11.67 (3.27)	11.7	3.0, 16.0	1.84 (3.34)	1.7	-5.6, 8.3	<=0.001***
Low Dose	37	10.01 (2.94)	12.09 (3.25)	12.7	3.0, 16.0	2.07 (3.27)	2.7	-5.6, 7.8	<=0.001***
High Dose	46	9.68 (1.94)	11.33 (3.29)	11.5	4.2, 16.0	1.65 (3.42)	1.4	-4.8, 8.3	0.0021**
WEEK 6	76	9.79 (2.46)	12.51 (3.36)	13.0	1.1, 16.0	2.72 (3.53)	2.9	-6.7, 10.5	<=0.001***
Low Dose	34	10.05 (2.90)	12.76 (3.48)	13.6	1.1, 16.0	2.72 (3.35)	2.7	-3.7, 10.5	<=0.001***
High Dose	42	9.58 (2.06)	12.30 (3.28)	12.7	5.1, 16.0	2.72 (3.70)	3.3	-6.7, 8.4	<=0.001***
WEEK 13	47	10.22 (2.40)	13.16 (3.38)	14.3	5.7, 16.0	2.94 (3.57)	3.3	-6.3, 9.9	<=0.001***
Low Dose	23	10.77 (2.54)	14.08 (2.60)	15.5	8.6, 16.0	3.31 (2.83)	3.8	-3.3, 9.9	<=0.001***
High Dose	24	9.70 (2.18)	12.28 (3.84)	13.5	5.7, 16.0	2.58 (4.19)	2.7	-6.3, 9.2	0.0062**
WEEK 26	51	10.08 (2.44)	13.73 (2.97)	14.9	1.5, 16.0	3.65 (2.92)	3.9	-4.5, 10.5	<=0.001***
Low Dose	25	10.30 (2.76)	13.95 (3.32)	15.7	1.5, 16.0	3.65 (3.25)	3.9	-4.5, 10.5	<=0.001***
High Dose	26	9.87 (2.12)	13.53 (2.64)	14.4	7.6, 16.0	3.66 (2.63)	3.5	-1.0, 7.8	<=0.001***
WEEK 39	49	10.17 (2.45)	13.39 (3.06)	14.3	2.4, 16.0	3.23 (3.47)	3.3	-9.2, 9.9	<=0.001***
Low Dose	26	10.28 (2.70)	13.57 (2.95)	14.3	2.7, 16.0	3.29 (3.45)	3.1	-9.1, 9.9	<=0.001***
High Dose	23	10.03 (2.18)	13.19 (3.24)	14.0	2.4, 16.0	3.16 (3.57)	3.8	-9.2, 9.1	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 52	42	10.08 (2.33)	13.77 (2.52)	14.9	7.2, 16.0	3.69 (2.51)	3.7	-2.8, 9.9	<=0.001***
Low Dose	21	10.17 (2.65)	14.14 (1.85)	14.7	10.1, 16.0	3.97 (2.25)	3.5	0.0, 9.9	<=0.001***
High Dose	21	9.99 (2.03)	13.39 (3.05)	15.2	7.2, 16.0	3.40 (2.76)	3.8	-2.8, 7.5	<=0.001***
Geographic region:EUROPE AND AUSTRALIA									
Average Daily Normalized 'Off' Time									
BASELINE	120		5.97 (2.18)	5.9	0.0, 12.6				
Low Dose	66		5.83 (1.99)	5.8	0.0, 10.2				
High Dose	54		6.15 (2.40)	6.4	0.0, 12.6				
WEEK 1	116	6.01 (2.20)	4.08 (3.63)	2.9	0.0, 16.0	-1.94 (3.92)	-2.3	-10.2, 10.4	<=0.001***
Low Dose	63	5.90 (2.01)	3.73 (3.11)	2.7	0.0, 11.2	-2.16 (3.53)	-2.5	-10.2, 5.9	<=0.001***
High Dose	53	6.16 (2.42)	4.49 (4.15)	3.1	0.0, 16.0	-1.67 (4.35)	-2.1	-8.9, 10.4	0.0074**
WEEK 6	105	6.09 (2.20)	3.41 (2.90)	3.1	0.0, 16.0	-2.67 (3.49)	-3.1	-10.6, 9.9	<=0.001***
Low Dose	58	5.97 (1.97)	3.20 (3.07)	3.1	0.0, 16.0	-2.77 (3.64)	-3.2	-10.2, 9.9	<=0.001***
High Dose	47	6.23 (2.47)	3.68 (2.70)	3.1	0.0, 10.2	-2.55 (3.34)	-2.9	-10.6, 6.8	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 13	57	5.76 (2.15)	2.94 (3.10)	1.9	0.0, 12.6	-2.82 (3.43)	-3.4	-9.3, 7.8	<=0.001***
Low Dose	31	5.95 (2.01)	2.72 (3.07)	1.9	0.0, 12.6	-3.23 (3.46)	-3.5	-9.3, 7.8	<=0.001***
High Dose	26	5.54 (2.34)	3.20 (3.18)	2.0	0.0, 10.7	-2.34 (3.40)	-3.2	-7.5, 5.2	0.0017**
WEEK 26	65	6.37 (2.21)	2.49 (2.67)	1.7	0.0, 9.8	-3.88 (3.34)	-4.5	-10.6, 5.5	<=0.001***
Low Dose	32	6.36 (1.76)	2.01 (2.45)	0.9	0.0, 7.4	-4.35 (2.97)	-4.8	-10.2, 3.3	<=0.001***
High Dose	33	6.39 (2.60)	2.96 (2.83)	2.0	0.0, 9.8	-3.42 (3.64)	-3.9	-10.6, 5.5	<=0.001***
WEEK 39	56	6.29 (2.17)	2.62 (2.70)	2.0	0.0, 11.4	-3.67 (3.06)	-3.4	-9.8, 6.4	<=0.001***
Low Dose	30	6.10 (1.85)	2.10 (2.58)	0.9	0.0, 11.4	-4.00 (3.05)	-3.7	-9.8, 6.4	<=0.001***
High Dose	26	6.52 (2.51)	3.23 (2.77)	3.1	0.0, 7.7	-3.28 (3.09)	-3.3	-9.2, 4.0	<=0.001***
WEEK 52	50	6.10 (2.37)	2.68 (3.05)	1.5	0.0, 11.5	-3.42 (3.43)	-3.6	-11.2, 5.9	<=0.001***
Low Dose	26	6.29 (1.97)	2.77 (3.17)	1.5	0.0, 10.9	-3.52 (3.56)	-4.1	-10.2, 5.9	<=0.001***
High Dose	24	5.89 (2.76)	2.58 (2.99)	1.7	0.0, 11.5	-3.30 (3.37)	-3.1	-11.2, 2.6	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	120		6.41 (3.24)	6.6	0.0, 12.3				
Low Dose	66		6.35 (3.20)	6.7	0.0, 11.9				
High Dose	54		6.47 (3.31)	6.4	0.0, 12.3				
WEEK 1	116	6.33 (3.21)	8.33 (4.69)	8.5	0.0, 16.0	2.00 (3.91)	1.8	-8.2, 10.4	<=0.001***
Low Dose	63	6.17 (3.13)	8.19 (4.49)	8.3	0.0, 16.0	2.02 (3.58)	1.9	-8.2, 10.4	<=0.001***
High Dose	53	6.52 (3.32)	8.51 (4.96)	8.8	0.0, 16.0	1.99 (4.30)	1.8	-8.1, 8.9	0.0015**
WEEK 6	105	6.45 (3.18)	10.06 (4.29)	11.1	0.0, 16.0	3.61 (3.85)	4.0	-8.3, 12.7	<=0.001***
Low Dose	58	6.38 (3.10)	10.10 (4.51)	10.9	0.0, 16.0	3.72 (4.06)	4.1	-8.3, 12.7	<=0.001***
High Dose	47	6.53 (3.31)	10.00 (4.05)	11.1	0.0, 16.0	3.47 (3.61)	3.2	-2.6, 11.2	<=0.001***
WEEK 13	57	6.45 (3.05)	11.25 (4.00)	12.6	2.7, 16.0	4.80 (3.51)	5.5	-3.6, 11.0	<=0.001***
Low Dose	31	6.24 (2.89)	11.58 (4.05)	13.2	3.4, 16.0	5.34 (3.23)	6.0	-1.5, 11.0	<=0.001***
High Dose	26	6.71 (3.27)	10.85 (3.99)	10.6	2.7, 16.0	4.15 (3.77)	4.3	-3.6, 10.4	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 26	65	6.72 (3.08)	11.38 (4.09)	12.0	0.0, 16.0	4.66 (4.41)	5.5	-11.0, 11.0	<=0.001***
Low Dose	32	6.39 (3.09)	12.45 (3.21)	13.4	5.2, 16.0	6.06 (2.67)	5.9	0.4, 11.0	<=0.001***
High Dose	33	7.04 (3.08)	10.35 (4.61)	11.3	0.0, 16.0	3.30 (5.30)	4.6	-11.0, 10.6	0.0011**
WEEK 39	56	6.77 (2.81)	11.04 (4.26)	11.3	0.6, 16.0	4.27 (3.63)	4.3	-3.8, 12.4	<=0.001***
Low Dose	30	6.79 (2.42)	11.98 (4.17)	12.6	1.4, 16.0	5.19 (3.40)	5.2	-2.8, 10.9	<=0.001***
High Dose	26	6.75 (3.25)	9.95 (4.17)	9.9	0.6, 16.0	3.20 (3.65)	2.6	-3.8, 12.4	<=0.001***
WEEK 52	50	7.06 (2.88)	10.78 (4.75)	12.4	0.4, 16.0	3.72 (4.05)	3.9	-6.5, 11.3	<=0.001***
Low Dose	26	6.55 (2.76)	11.20 (4.55)	12.9	1.5, 16.0	4.66 (4.26)	4.5	-6.5, 11.3	<=0.001***
High Dose	24	7.62 (2.95)	10.32 (5.02)	12.2	0.4, 16.0	2.70 (3.64)	2.3	-3.1, 11.2	0.0014**
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	120		2.46 (2.28)	2.2	0.0, 10.0				
Low Dose	66		2.28 (1.97)	2.1	0.0, 6.8				
High Dose	54		2.69 (2.61)	2.4	0.0, 10.0				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 1	116	2.50 (2.30)	2.48 (3.02)	1.1	0.0, 12.8	-0.02 (2.46)	0.0	-5.3, 8.1	0.9352
Low Dose	63	2.33 (1.98)	2.56 (2.81)	1.8	0.0, 11.6	0.22 (2.59)	0.0	-5.3, 7.1	0.4948
High Dose	53	2.70 (2.64)	2.39 (3.29)	0.8	0.0, 12.8	-0.31 (2.29)	-0.2	-4.5, 8.1	0.3331
WEEK 6	105	2.53 (2.36)	2.04 (3.22)	0.5	0.0, 15.4	-0.49 (2.49)	-0.3	-5.8, 11.6	0.0477*
Low Dose	58	2.35 (2.03)	2.08 (3.18)	0.7	0.0, 15.4	-0.28 (2.64)	-0.0	-5.1, 11.6	0.4304
High Dose	47	2.75 (2.71)	2.00 (3.30)	0.0	0.0, 13.1	-0.75 (2.30)	-0.6	-5.8, 5.7	0.0304*
WEEK 13	57	2.89 (2.38)	1.43 (2.12)	0.3	0.0, 8.2	-1.47 (2.59)	-1.2	-8.6, 4.6	<=0.001***
Low Dose	31	2.77 (2.15)	1.23 (1.92)	0.3	0.0, 8.2	-1.53 (2.16)	-1.5	-5.0, 4.3	<=0.001***
High Dose	26	3.05 (2.67)	1.66 (2.36)	0.7	0.0, 8.0	-1.38 (3.08)	-0.7	-8.6, 4.6	0.0305*
WEEK 26	65	2.03 (2.01)	1.85 (2.74)	0.6	0.0, 11.0	-0.18 (2.77)	0.0	-7.4, 7.2	0.6007
Low Dose	32	2.20 (1.97)	1.49 (2.53)	0.4	0.0, 10.8	-0.71 (2.56)	-0.6	-6.5, 5.4	0.1253
High Dose	33	1.87 (2.06)	2.21 (2.93)	0.7	0.0, 11.0	0.34 (2.90)	0.0	-7.4, 7.2	0.5086
WEEK 39	56	2.09 (2.04)	1.97 (3.32)	0.0	0.0, 14.6	-0.12 (3.01)	-0.1	-5.3, 9.9	0.7747
Low Dose	30	2.30 (1.98)	1.56 (3.06)	0.0	0.0, 14.6	-0.74 (2.89)	-0.5	-5.0, 9.2	0.1709
High Dose	26	1.85 (2.13)	2.45 (3.61)	0.0	0.0, 12.3	0.61 (3.05)	0.0	-5.3, 9.9	0.3213

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 52	50	2.14 (2.11)	1.87 (3.50)	0.1	0.0, 15.6	-0.27 (3.02)	-0.2	-6.5, 9.2	0.5286
Low Dose	26	2.42 (2.02)	1.74 (3.35)	0.1	0.0, 11.8	-0.68 (3.58)	-0.4	-6.5, 9.2	0.3413
High Dose	24	1.84 (2.21)	2.02 (3.72)	0.1	0.0, 15.6	0.17 (2.26)	-0.1	-3.9, 6.7	0.7119
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	120		1.15 (2.00)	0.0	0.0, 10.5				
Low Dose	66		1.54 (2.34)	0.2	0.0, 10.5				
High Dose	54		0.68 (1.36)	0.0	0.0, 5.3				
WEEK 1	116	1.16 (2.02)	1.11 (2.40)	0.0	0.0, 11.7	-0.05 (1.89)	0.0	-5.7, 10.5	0.7777
Low Dose	63	1.60 (2.38)	1.52 (2.81)	0.0	0.0, 11.7	-0.08 (2.16)	0.0	-5.7, 10.5	0.7662
High Dose	53	0.63 (1.32)	0.61 (1.71)	0.0	0.0, 9.8	-0.01 (1.53)	0.0	-4.9, 5.9	0.9541
WEEK 6	105	0.94 (1.80)	0.49 (1.24)	0.0	0.0, 5.8	-0.45 (1.49)	0.0	-9.2, 4.4	0.0026**
Low Dose	58	1.30 (2.15)	0.62 (1.41)	0.0	0.0, 5.8	-0.67 (1.73)	0.0	-9.2, 2.7	0.0043**
High Dose	47	0.49 (1.12)	0.32 (1.00)	0.0	0.0, 4.4	-0.17 (1.08)	0.0	-3.4, 4.4	0.2881

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 13	57	0.89 (1.39)	0.38 (1.25)	0.0	0.0, 8.0	-0.51 (1.44)	0.0	-5.2, 6.0	0.0105*
Low Dose	31	1.05 (1.43)	0.47 (1.49)	0.0	0.0, 8.0	-0.58 (1.80)	0.0	-5.2, 6.0	0.0833
High Dose	26	0.71 (1.35)	0.29 (0.91)	0.0	0.0, 3.7	-0.42 (0.87)	0.0	-3.4, 0.9	0.0215*
WEEK 26	65	0.87 (1.72)	0.27 (1.14)	0.0	0.0, 8.8	-0.60 (2.04)	0.0	-9.2, 8.8	0.0215*
Low Dose	32	1.04 (1.94)	0.05 (0.16)	0.0	0.0, 0.7	-0.99 (1.95)	0.0	-9.2, 0.4	0.0071**
High Dose	33	0.70 (1.49)	0.48 (1.58)	0.0	0.0, 8.8	-0.21 (2.09)	0.0	-4.9, 8.8	0.5601
WEEK 39	56	0.85 (1.43)	0.36 (0.96)	0.0	0.0, 3.8	-0.48 (1.14)	0.0	-5.0, 2.7	0.0025**
Low Dose	30	0.81 (1.26)	0.37 (1.01)	0.0	0.0, 3.8	-0.44 (0.83)	0.0	-3.6, 0.5	0.0063**
High Dose	26	0.89 (1.63)	0.36 (0.91)	0.0	0.0, 3.4	-0.53 (1.43)	0.0	-5.0, 2.7	0.0730
WEEK 52	50	0.69 (1.29)	0.66 (2.04)	0.0	0.0, 13.5	-0.03 (2.30)	0.0	-5.0, 13.0	0.9283
Low Dose	26	0.74 (1.23)	0.28 (0.65)	0.0	0.0, 2.7	-0.45 (1.17)	0.0	-3.0, 1.8	0.0592
High Dose	24	0.65 (1.38)	1.08 (2.84)	0.0	0.0, 13.5	0.43 (3.06)	0.0	-5.0, 13.0	0.4985

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	120		8.87 (2.59)	9.2	0.3, 16.0				
Low Dose	66		8.63 (2.58)	9.0	0.3, 14.2				
High Dose	54		9.17 (2.60)	9.3	2.6, 16.0				
WEEK 1	116	8.83 (2.59)	10.81 (4.00)	11.5	0.0, 16.0	1.99 (4.07)	2.1	-10.4, 11.3	<=0.001***
Low Dose	63	8.50 (2.56)	10.75 (3.91)	11.2	1.6, 16.0	2.24 (3.63)	2.2	-5.9, 11.3	<=0.001***
High Dose	53	9.22 (2.60)	10.90 (4.14)	11.9	0.0, 16.0	1.68 (4.55)	1.8	-10.4, 8.9	0.0097**
WEEK 6	105	8.98 (2.49)	12.10 (3.17)	12.6	0.0, 16.0	3.12 (3.55)	3.7	-9.9, 10.6	<=0.001***
Low Dose	58	8.74 (2.41)	12.18 (3.44)	12.6	0.0, 16.0	3.44 (3.64)	4.0	-9.9, 10.2	<=0.001***
High Dose	47	9.28 (2.58)	12.00 (2.82)	12.3	5.8, 16.0	2.72 (3.44)	3.6	-6.8, 10.6	<=0.001***
WEEK 13	57	9.35 (2.28)	12.68 (3.31)	13.9	3.4, 16.0	3.33 (3.24)	3.7	-5.2, 9.3	<=0.001***
Low Dose	31	9.01 (2.04)	12.81 (3.42)	13.8	3.4, 16.0	3.81 (3.20)	4.4	-4.9, 9.3	<=0.001***
High Dose	26	9.75 (2.51)	12.51 (3.23)	13.9	5.3, 16.0	2.76 (3.27)	3.4	-5.2, 7.5	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 26	65	8.76 (2.76)	13.24 (2.79)	14.3	6.2, 16.0	4.48 (3.65)	4.6	-5.5, 12.5	<=0.001***
Low Dose	32	8.60 (2.72)	13.94 (2.47)	15.0	8.6, 16.0	5.34 (3.34)	5.4	-1.7, 12.5	<=0.001***
High Dose	33	8.91 (2.84)	12.55 (2.94)	13.8	6.2, 16.0	3.64 (3.79)	2.9	-5.5, 10.6	<=0.001***
WEEK 39	56	8.86 (2.51)	13.01 (2.86)	12.9	4.6, 16.0	4.15 (3.23)	3.4	-5.9, 9.8	<=0.001***
Low Dose	30	9.09 (2.31)	13.54 (2.68)	13.5	4.6, 16.0	4.45 (3.28)	4.1	-5.9, 9.8	<=0.001***
High Dose	26	8.60 (2.75)	12.41 (2.98)	12.5	6.6, 16.0	3.81 (3.20)	3.4	-2.9, 9.7	<=0.001***
WEEK 52	50	9.21 (2.64)	12.65 (3.51)	13.9	2.5, 16.0	3.45 (3.62)	3.5	-5.4, 11.2	<=0.001***
Low Dose	26	8.97 (2.51)	12.94 (3.16)	13.9	5.1, 16.0	3.98 (3.66)	4.1	-5.4, 10.2	<=0.001***
High Dose	24	9.47 (2.80)	12.34 (3.90)	13.6	2.5, 16.0	2.87 (3.56)	2.9	-3.8, 11.2	<=0.001***
Geographic region:JAPAN									
Average Daily Normalized 'Off' Time									
BASELINE	27		6.79 (2.05)	6.9	0.0, 10.3				
Low Dose	22		6.50 (2.09)	6.6	0.0, 10.3				
High Dose	5		8.06 (1.42)	8.3	5.7, 9.6				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 1	26	6.78 (2.09)	5.25 (3.32)	5.1	0.0, 13.8	-1.53 (3.77)	-1.9	-9.7, 4.7	0.0490*
Low Dose	21	6.47 (2.13)	5.15 (3.26)	4.7	0.0, 13.8	-1.33 (3.66)	-1.9	-9.7, 4.7	0.1122
High Dose	5	8.06 (1.42)	5.67 (3.95)	5.4	0.0, 10.9	-2.39 (4.56)	-3.1	-8.3, 2.8	0.3067
WEEK 6	24	6.72 (1.95)	5.88 (3.71)	4.9	0.0, 13.4	-0.84 (3.94)	-2.5	-7.5, 6.8	0.3088
Low Dose	19	6.37 (1.94)	5.32 (3.62)	4.0	0.0, 13.4	-1.05 (3.86)	-2.4	-7.5, 6.2	0.2497
High Dose	5	8.06 (1.42)	8.04 (3.59)	6.4	4.8, 12.5	-0.02 (4.60)	-2.9	-3.5, 6.8	0.9939
WEEK 13	10	5.81 (2.19)	6.67 (4.86)	7.3	0.0, 13.4	0.86 (5.02)	1.8	-6.6, 8.1	0.6010
Low Dose	10	5.81 (2.19)	6.67 (4.86)	7.3	0.0, 13.4	0.86 (5.02)	1.8	-6.6, 8.1	0.6010
High Dose	0								
WEEK 26	15	6.67 (1.31)	5.79 (4.43)	5.4	0.0, 14.3	-0.89 (4.46)	-0.7	-8.1, 7.1	0.4534
Low Dose	12	6.17 (0.82)	5.92 (4.57)	5.4	0.0, 14.3	-0.26 (4.49)	-0.4	-7.0, 7.1	0.8468
High Dose	3	8.68 (0.82)	5.27 (4.67)	6.9	0.0, 8.9	-3.42 (4.07)	-1.4	-8.1, -0.7	0.2834
WEEK 39	14	6.68 (1.36)	4.36 (3.22)	4.5	0.0, 12.3	-2.32 (3.40)	-1.7	-8.1, 5.1	0.0241*
Low Dose	11	6.13 (0.85)	4.56 (3.30)	4.7	0.0, 12.3	-1.57 (3.14)	-1.3	-7.0, 5.1	0.1294
High Dose	3	8.68 (0.82)	3.61 (3.44)	4.0	0.0, 6.8	-5.07 (3.34)	-5.6	-8.1, -1.5	0.1196

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 52	12	6.75 (1.39)	4.34 (2.99)	4.5	0.0, 10.1	-2.41 (3.40)	-2.7	-8.1, 4.1	0.0315*
Low Dose	9	6.11 (0.79)	4.40 (3.00)	3.7	0.0, 10.1	-1.72 (3.33)	-2.4	-7.0, 4.1	0.1609
High Dose	3	8.68 (0.82)	4.17 (3.62)	6.1	0.0, 6.4	-4.51 (3.21)	-3.5	-8.1, -1.9	0.1352
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	27		5.68 (2.73)	5.7	0.0, 10.1				
Low Dose	22		5.30 (2.86)	4.8	0.0, 10.1				
High Dose	5		7.37 (0.91)	7.7	6.4, 8.4				
WEEK 1	26	5.55 (2.70)	6.23 (3.84)	6.8	0.3, 16.0	0.68 (4.00)	0.9	-8.9, 10.2	0.3968
Low Dose	21	5.12 (2.81)	5.49 (3.48)	6.2	0.3, 11.3	0.36 (3.99)	0.8	-8.9, 10.2	0.6805
High Dose	5	7.37 (0.91)	9.36 (4.06)	8.1	5.1, 16.0	1.99 (4.19)	1.3	-2.8, 8.3	0.3494
WEEK 6	24	5.79 (2.86)	8.38 (4.05)	8.4	0.0, 13.8	2.60 (5.07)	3.7	-6.4, 13.8	0.0196*
Low Dose	19	5.37 (3.07)	9.10 (3.56)	8.6	2.6, 13.8	3.73 (4.65)	3.9	-3.5, 13.8	0.0025**
High Dose	5	7.37 (0.91)	5.65 (5.05)	3.5	0.0, 11.2	-1.72 (4.59)	-3.7	-6.4, 3.5	0.4491

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 13	10	5.40 (2.89)	5.93 (5.42)	5.2	0.0, 14.7	0.54 (5.57)	0.9	-9.0, 9.6	0.7668
Low Dose	10	5.40 (2.89)	5.93 (5.42)	5.2	0.0, 14.7	0.54 (5.57)	0.9	-9.0, 9.6	0.7668
High Dose	0								
WEEK 26	15	5.94 (2.87)	8.34 (5.26)	8.1	0.0, 16.0	2.40 (5.01)	3.2	-10.1, 9.5	0.0844
Low Dose	12	5.60 (3.12)	7.77 (5.41)	7.8	0.0, 16.0	2.18 (5.33)	3.2	-10.1, 9.5	0.1852
High Dose	3	7.32 (0.82)	10.62 (4.80)	9.1	6.8, 16.0	3.30 (4.19)	1.4	0.4, 8.1	0.3053
WEEK 39	14	5.90 (2.97)	9.83 (4.24)	10.3	0.3, 16.0	3.93 (3.21)	4.0	-1.9, 8.1	<=0.001***
Low Dose	11	5.51 (3.25)	9.36 (4.38)	10.4	0.3, 16.0	3.85 (3.32)	4.9	-1.9, 8.0	0.0032**
High Dose	3	7.32 (0.82)	11.55 (3.86)	9.5	9.2, 16.0	4.23 (3.45)	3.1	1.5, 8.1	0.1679
WEEK 52	12	6.26 (3.03)	10.48 (3.47)	10.2	4.2, 16.0	4.22 (2.22)	3.8	1.7, 8.1	<=0.001***
Low Dose	9	5.91 (3.45)	10.24 (3.44)	10.7	4.2, 16.0	4.32 (1.86)	4.5	1.9, 7.0	<=0.001***
High Dose	3	7.32 (0.82)	11.22 (4.21)	9.6	8.1, 16.0	3.90 (3.64)	1.9	1.7, 8.1	0.2043

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	27		2.74 (2.76)	2.6	0.0, 8.0				
Low Dose	22		3.30 (2.76)	3.1	0.0, 8.0				
High Dose	5		0.26 (0.44)	0.0	0.0, 1.0				
WEEK 1	26	2.84 (2.76)	3.83 (4.01)	2.6	0.0, 14.9	0.99 (3.82)	0.0	-5.4, 13.2	0.2002
Low Dose	21	3.46 (2.73)	4.52 (4.15)	3.4	0.0, 14.9	1.06 (4.24)	0.0	-5.4, 13.2	0.2641
High Dose	5	0.26 (0.44)	0.92 (1.10)	0.6	0.0, 2.6	0.67 (1.16)	0.0	-0.4, 2.3	0.2677
WEEK 6	24	2.64 (2.71)	1.70 (2.87)	0.2	0.0, 9.6	-0.94 (3.53)	0.0	-6.7, 9.6	0.2027
Low Dose	19	3.27 (2.71)	1.54 (2.56)	0.5	0.0, 9.0	-1.73 (2.93)	-1.2	-6.7, 4.4	0.0188*
High Dose	5	0.26 (0.44)	2.31 (4.17)	0.0	0.0, 9.6	2.05 (4.34)	0.0	-1.0, 9.6	0.3496
WEEK 13	10	3.31 (2.90)	3.39 (5.59)	0.7	0.0, 16.0	0.08 (5.72)	-0.5	-6.5, 13.2	0.9655
Low Dose	10	3.31 (2.90)	3.39 (5.59)	0.7	0.0, 16.0	0.08 (5.72)	-0.5	-6.5, 13.2	0.9655
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 26	15	2.91 (3.04)	1.76 (3.26)	0.0	0.0, 12.1	-1.15 (3.11)	0.0	-6.7, 4.6	0.1730
Low Dose	12	3.64 (2.97)	2.17 (3.55)	0.2	0.0, 12.1	-1.47 (3.43)	-2.6	-6.7, 4.6	0.1657
High Dose	3	0.00 (0.00)	0.11 (0.20)	0.0	0.0, 0.3	0.11 (0.20)	0.0	0.0, 0.3	0.4226
WEEK 39	14	2.92 (3.15)	1.72 (3.58)	0.0	0.0, 13.2	-1.20 (3.18)	-0.1	-6.7, 5.2	0.1826
Low Dose	11	3.72 (3.11)	1.96 (3.99)	0.0	0.0, 13.2	-1.75 (3.34)	-1.5	-6.7, 5.2	0.1121
High Dose	3	0.00 (0.00)	0.84 (1.46)	0.0	0.0, 2.5	0.84 (1.46)	0.0	0.0, 2.5	0.4226
WEEK 52	12	2.64 (3.29)	1.16 (1.98)	0.1	0.0, 6.7	-1.48 (2.55)	0.0	-6.7, 1.8	0.0687
Low Dose	9	3.52 (3.37)	1.34 (2.23)	0.3	0.0, 6.7	-2.18 (2.54)	-1.3	-6.7, 0.0	0.0329*
High Dose	3	0.00 (0.00)	0.61 (1.05)	0.0	0.0, 1.8	0.61 (1.05)	0.0	0.0, 1.8	0.4226
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	27		0.79 (1.74)	0.0	0.0, 7.2				
Low Dose	22		0.90 (1.91)	0.0	0.0, 7.2				
High Dose	5		0.31 (0.43)	0.0	0.0, 0.8				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 1	26	0.82 (1.77)	0.69 (1.59)	0.0	0.0, 7.9	-0.13 (2.37)	0.0	-6.0, 7.9	0.7790
Low Dose	21	0.95 (1.95)	0.85 (1.74)	0.0	0.0, 7.9	-0.10 (2.64)	0.0	-6.0, 7.9	0.8639
High Dose	5	0.31 (0.43)	0.05 (0.11)	0.0	0.0, 0.3	-0.26 (0.38)	0.0	-0.8, 0.0	0.1899
WEEK 6	24	0.85 (1.84)	0.04 (0.12)	0.0	0.0, 0.5	-0.82 (1.81)	0.0	-7.2, 0.4	0.0370*
Low Dose	19	0.99 (2.04)	0.04 (0.14)	0.0	0.0, 0.5	-0.95 (2.01)	0.0	-7.2, 0.4	0.0544
High Dose	5	0.31 (0.43)	0.00 (0.00)	0.0	0.0, 0.0	-0.31 (0.43)	0.0	-0.8, 0.0	0.1779
WEEK 13	10	1.48 (2.59)	0.00 (0.00)	0.0	0.0, 0.0	-1.48 (2.59)	0.0	-7.2, 0.0	0.1039
Low Dose	10	1.48 (2.59)	0.00 (0.00)	0.0	0.0, 0.0	-1.48 (2.59)	0.0	-7.2, 0.0	0.1039
High Dose	0								
WEEK 26	15	0.47 (1.12)	0.11 (0.34)	0.0	0.0, 1.3	-0.36 (1.20)	0.0	-3.4, 1.3	0.2645
Low Dose	12	0.59 (1.23)	0.14 (0.37)	0.0	0.0, 1.3	-0.45 (1.33)	0.0	-3.4, 1.3	0.2682
High Dose	3	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
WEEK 39	14	0.51 (1.15)	0.09 (0.23)	0.0	0.0, 0.7	-0.42 (1.05)	0.0	-3.0, 0.0	0.1610
Low Dose	11	0.64 (1.28)	0.11 (0.26)	0.0	0.0, 0.7	-0.53 (1.17)	0.0	-3.0, 0.0	0.1630
High Dose	3	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 52	12	0.34 (0.97)	0.02 (0.07)	0.0	0.0, 0.2	-0.32 (0.97)	0.0	-3.4, 0.0	0.2748
Low Dose	9	0.45 (1.12)	0.03 (0.08)	0.0	0.0, 0.2	-0.43 (1.11)	0.0	-3.4, 0.0	0.2814
High Dose	3	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	27		8.42 (1.76)	8.7	4.6, 11.1				
Low Dose	22		8.60 (1.84)	8.9	4.6, 11.1				
High Dose	5		7.63 (1.20)	7.7	6.4, 9.5				
WEEK 1	26	8.40 (1.80)	10.06 (3.19)	9.9	2.2, 16.0	1.66 (3.85)	1.1	-4.0, 9.7	0.0372*
Low Dose	21	8.58 (1.89)	10.00 (3.09)	9.8	2.2, 16.0	1.43 (3.78)	1.0	-4.0, 9.7	0.0996
High Dose	5	7.63 (1.20)	10.28 (3.95)	10.4	5.1, 16.0	2.65 (4.42)	3.7	-2.8, 8.3	0.2511
WEEK 6	24	8.43 (1.70)	10.08 (3.69)	11.1	2.6, 16.0	1.65 (3.82)	3.0	-6.0, 7.5	0.0448*
Low Dose	19	8.64 (1.77)	10.64 (3.60)	11.7	2.6, 16.0	2.00 (3.75)	3.1	-5.7, 7.5	0.0321*
High Dose	5	7.63 (1.20)	7.96 (3.59)	9.6	3.5, 11.2	0.33 (4.19)	2.9	-6.0, 3.5	0.8681

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 13	10	8.71 (2.05)	9.33 (4.86)	8.7	2.6, 16.0	0.62 (3.76)	0.1	-5.0, 6.6	0.6148
Low Dose	10	8.71 (2.05)	9.33 (4.86)	8.7	2.6, 16.0	0.62 (3.76)	0.1	-5.0, 6.6	0.6148
High Dose	0								
WEEK 26	15	8.85 (1.64)	10.10 (4.38)	10.5	1.7, 16.0	1.25 (4.00)	0.7	-5.5, 8.1	0.2476
Low Dose	12	9.24 (1.58)	9.94 (4.50)	10.5	1.7, 16.0	0.71 (3.97)	0.5	-5.5, 7.0	0.5513
High Dose	3	7.32 (0.82)	10.73 (4.67)	9.1	7.1, 16.0	3.42 (4.07)	1.4	0.7, 8.1	0.2834
WEEK 39	14	8.82 (1.70)	11.55 (3.17)	11.5	3.7, 16.0	2.73 (2.94)	2.3	-2.1, 8.1	0.0040**
Low Dose	11	9.23 (1.66)	11.32 (3.23)	11.3	3.7, 16.0	2.10 (2.62)	1.9	-2.1, 7.0	0.0244*
High Dose	3	7.32 (0.82)	12.39 (3.44)	12.0	9.2, 16.0	5.07 (3.34)	5.6	1.5, 8.1	0.1196
WEEK 52	12	8.91 (1.47)	11.64 (3.00)	11.5	5.9, 16.0	2.74 (2.86)	2.7	-1.2, 8.1	0.0069**
Low Dose	9	9.43 (1.25)	11.58 (3.01)	12.3	5.9, 16.0	2.14 (2.66)	2.4	-1.2, 7.0	0.0420*
High Dose	3	7.32 (0.82)	11.83 (3.62)	9.9	9.6, 16.0	4.51 (3.21)	3.5	1.9, 8.1	0.1352

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years									
Average Daily Normalized 'Off' Time									
BASELINE	127		6.04 (2.24)	6.0	0.0, 10.3				
Low Dose	64		6.05 (2.17)	6.0	0.0, 10.3				
High Dose	63		6.04 (2.33)	6.0	0.0, 10.3				
WEEK 1	122	6.02 (2.23)	3.67 (3.21)	2.9	0.0, 14.8	-2.35 (3.42)	-2.1	-9.7, 5.9	<=0.001***
Low Dose	62	6.10 (2.15)	3.78 (3.27)	2.8	0.0, 13.8	-2.32 (3.22)	-2.1	-9.7, 3.9	<=0.001***
High Dose	60	5.94 (2.32)	3.55 (3.18)	2.9	0.0, 14.8	-2.39 (3.64)	-2.2	-8.9, 5.9	<=0.001***
WEEK 6	112	6.05 (2.23)	3.44 (3.00)	3.1	0.0, 12.3	-2.62 (3.39)	-2.9	-9.9, 6.7	<=0.001***
Low Dose	57	5.97 (2.07)	3.29 (2.90)	3.1	0.0, 12.3	-2.68 (3.46)	-2.6	-9.9, 5.7	<=0.001***
High Dose	55	6.14 (2.41)	3.59 (3.11)	3.0	0.0, 10.7	-2.55 (3.34)	-2.9	-8.4, 6.7	<=0.001***
WEEK 13	64	5.63 (2.38)	3.04 (3.44)	1.7	0.0, 12.1	-2.58 (3.48)	-3.2	-9.9, 6.3	<=0.001***
Low Dose	32	5.85 (2.27)	2.42 (3.13)	1.3	0.0, 12.1	-3.42 (3.04)	-3.9	-9.9, 5.0	<=0.001***
High Dose	32	5.40 (2.51)	3.66 (3.66)	2.3	0.0, 10.7	-1.74 (3.74)	-2.1	-9.2, 6.3	0.0130*

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 26	72	5.81 (2.31)	2.80 (2.98)	1.7	0.0, 11.2	-3.01 (3.16)	-3.0	-9.2, 5.5	<=0.001***
Low Dose	34	5.86 (2.04)	2.95 (3.24)	1.3	0.0, 11.2	-2.91 (3.43)	-2.9	-9.2, 5.5	<=0.001***
High Dose	38	5.77 (2.55)	2.67 (2.77)	1.9	0.0, 8.4	-3.10 (2.95)	-3.1	-9.2, 4.4	<=0.001***
WEEK 39	63	5.86 (2.31)	2.74 (2.66)	2.0	0.0, 11.4	-3.11 (3.05)	-2.8	-9.9, 6.4	<=0.001***
Low Dose	32	5.84 (2.14)	2.58 (2.70)	1.9	0.0, 11.4	-3.27 (3.26)	-2.9	-9.9, 6.4	<=0.001***
High Dose	31	5.87 (2.50)	2.92 (2.65)	3.1	0.0, 7.7	-2.95 (2.86)	-2.8	-9.2, 4.0	<=0.001***
WEEK 52	60	5.77 (2.39)	2.90 (3.15)	2.3	0.0, 11.5	-2.87 (3.22)	-2.9	-9.9, 5.9	<=0.001***
Low Dose	30	5.95 (2.11)	2.96 (3.18)	2.3	0.0, 10.9	-2.99 (3.53)	-3.3	-9.9, 5.9	<=0.001***
High Dose	30	5.59 (2.67)	2.84 (3.17)	1.6	0.0, 11.5	-2.75 (2.93)	-2.6	-9.2, 2.6	<=0.001***
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	127		6.79 (3.45)	6.9	0.0, 15.4				
Low Dose	64		6.61 (3.83)	7.0	0.0, 15.4				
High Dose	63		6.97 (3.04)	6.9	0.3, 13.8				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 1	122	6.73 (3.45)	9.04 (4.69)	9.2	0.0, 16.0	2.30 (4.04)	1.7	-8.9, 12.0	<=0.001***
Low Dose	62	6.45 (3.76)	8.41 (4.96)	8.9	0.0, 16.0	1.96 (3.92)	1.6	-8.9, 10.7	<=0.001***
High Dose	60	7.02 (3.09)	9.69 (4.33)	10.0	0.0, 16.0	2.66 (4.16)	2.6	-5.4, 12.0	<=0.001***
WEEK 6	112	6.96 (3.42)	10.60 (4.19)	11.5	0.0, 16.0	3.64 (4.26)	3.6	-6.7, 13.8	<=0.001***
Low Dose	57	6.92 (3.84)	10.59 (4.36)	11.8	0.0, 16.0	3.67 (4.32)	3.7	-6.1, 13.8	<=0.001***
High Dose	55	6.99 (2.96)	10.61 (4.05)	11.5	0.5, 16.0	3.61 (4.23)	3.5	-6.7, 12.0	<=0.001***
WEEK 13	64	7.16 (3.60)	11.34 (4.50)	12.9	0.0, 16.0	4.18 (4.66)	4.5	-9.0, 15.2	<=0.001***
Low Dose	32	7.36 (3.88)	11.84 (4.80)	13.5	0.0, 16.0	4.48 (4.85)	4.8	-9.0, 15.2	<=0.001***
High Dose	32	6.96 (3.35)	10.84 (4.20)	10.6	2.7, 16.0	3.88 (4.51)	4.0	-6.3, 14.1	<=0.001***
WEEK 26	72	7.33 (3.37)	11.29 (4.29)	12.4	0.0, 16.0	3.96 (4.45)	4.6	-10.1, 14.1	<=0.001***
Low Dose	34	7.46 (3.75)	11.63 (4.46)	13.2	0.0, 16.0	4.17 (4.53)	4.8	-10.1, 11.2	<=0.001***
High Dose	38	7.21 (3.03)	10.98 (4.17)	11.4	0.8, 16.0	3.77 (4.43)	4.3	-6.6, 14.1	<=0.001***
WEEK 39	63	7.26 (3.47)	10.88 (4.41)	11.2	0.0, 16.0	3.62 (3.72)	3.2	-5.0, 12.4	<=0.001***
Low Dose	32	7.49 (3.73)	11.98 (4.05)	12.0	0.3, 16.0	4.49 (3.77)	4.9	-5.0, 11.2	<=0.001***
High Dose	31	7.03 (3.22)	9.75 (4.54)	10.3	0.0, 16.0	2.72 (3.52)	2.6	-3.8, 12.4	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 52	60	7.36 (3.34)	10.24 (4.94)	11.3	0.0, 16.0	2.89 (4.06)	3.0	-12.0, 9.9	<=0.001***
Low Dose	30	7.09 (3.64)	11.12 (4.71)	12.5	0.0, 16.0	4.03 (3.78)	4.8	-6.5, 9.9	<=0.001***
High Dose	30	7.62 (3.05)	9.37 (5.09)	9.6	0.0, 16.0	1.74 (4.06)	1.7	-12.0, 8.8	0.0257*
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	127		2.35 (2.64)	1.7	0.0, 12.2				
Low Dose	64		2.36 (2.65)	1.7	0.0, 10.3				
High Dose	63		2.35 (2.65)	2.4	0.0, 12.2				
WEEK 1	122	2.43 (2.66)	2.46 (3.22)	1.0	0.0, 14.9	0.03 (2.80)	0.0	-8.5, 13.2	0.8929
Low Dose	62	2.44 (2.66)	2.70 (3.34)	2.1	0.0, 14.9	0.26 (2.80)	0.0	-8.5, 13.2	0.4626
High Dose	60	2.42 (2.69)	2.22 (3.10)	0.6	0.0, 11.9	-0.20 (2.80)	0.0	-8.2, 8.8	0.5775
WEEK 6	112	2.39 (2.75)	1.54 (2.81)	0.0	0.0, 13.9	-0.85 (2.58)	-0.2	-7.6, 8.3	<=0.001***
Low Dose	57	2.41 (2.78)	1.59 (2.72)	0.5	0.0, 10.4	-0.82 (2.77)	0.0	-7.6, 8.3	0.0296*
High Dose	55	2.36 (2.75)	1.49 (2.92)	0.0	0.0, 13.9	-0.87 (2.38)	-0.4	-7.6, 5.7	0.0088**

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 13	64	2.72 (3.11)	1.41 (2.82)	0.0	0.0, 15.5	-1.31 (3.22)	-0.5	-12.2, 5.2	0.0018**
Low Dose	32	2.48 (3.06)	1.65 (3.48)	0.0	0.0, 15.5	-0.83 (3.11)	0.0	-8.0, 5.2	0.1425
High Dose	32	2.96 (3.19)	1.16 (1.99)	0.0	0.0, 8.0	-1.80 (3.31)	-0.7	-12.2, 4.6	0.0043**
WEEK 26	72	2.22 (2.61)	1.69 (3.02)	0.0	0.0, 15.2	-0.52 (3.28)	0.0	-12.2, 12.0	0.1797
Low Dose	34	2.11 (2.50)	1.21 (2.33)	0.0	0.0, 12.1	-0.89 (2.56)	0.0	-6.8, 4.6	0.0501
High Dose	38	2.32 (2.73)	2.13 (3.50)	0.0	0.0, 15.2	-0.19 (3.81)	0.0	-12.2, 12.0	0.7568
WEEK 39	63	2.28 (2.81)	2.03 (3.63)	0.0	0.0, 16.0	-0.25 (3.19)	0.0	-7.8, 9.9	0.5318
Low Dose	32	2.30 (2.75)	1.27 (2.79)	0.0	0.0, 13.2	-1.02 (2.88)	-0.1	-7.8, 5.2	0.0536
High Dose	31	2.27 (2.92)	2.81 (4.24)	0.0	0.0, 16.0	0.54 (3.35)	0.0	-6.4, 9.9	0.3755
WEEK 52	60	2.32 (2.86)	2.22 (4.23)	0.0	0.0, 16.0	-0.10 (3.34)	0.0	-6.8, 12.9	0.8226
Low Dose	30	2.43 (2.91)	1.67 (3.73)	0.0	0.0, 16.0	-0.77 (3.28)	0.0	-6.8, 9.2	0.2109
High Dose	30	2.21 (2.86)	2.78 (4.69)	0.4	0.0, 16.0	0.57 (3.33)	0.0	-3.9, 12.9	0.3550

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	127		0.82 (1.65)	0.0	0.0, 9.2				
Low Dose	64		0.98 (1.94)	0.0	0.0, 9.2				
High Dose	63		0.65 (1.28)	0.0	0.0, 5.3				
WEEK 1	122	0.82 (1.66)	0.83 (2.16)	0.0	0.0, 11.7	0.01 (1.78)	0.0	-5.7, 10.5	0.9292
Low Dose	62	1.01 (1.97)	1.11 (2.64)	0.0	0.0, 11.7	0.10 (2.11)	0.0	-5.7, 10.5	0.7154
High Dose	60	0.62 (1.25)	0.55 (1.48)	0.0	0.0, 9.8	-0.07 (1.36)	0.0	-4.9, 4.7	0.6815
WEEK 6	112	0.60 (1.31)	0.42 (1.35)	0.0	0.0, 9.0	-0.18 (1.52)	0.0	-9.2, 6.9	0.2131
Low Dose	57	0.70 (1.53)	0.53 (1.65)	0.0	0.0, 9.0	-0.17 (1.90)	0.0	-9.2, 6.9	0.5010
High Dose	55	0.50 (1.05)	0.31 (0.94)	0.0	0.0, 4.4	-0.19 (1.01)	0.0	-3.4, 4.4	0.1699
WEEK 13	64	0.50 (1.00)	0.21 (0.74)	0.0	0.0, 3.7	-0.29 (0.85)	0.0	-3.4, 2.6	0.0090**
Low Dose	32	0.31 (0.65)	0.08 (0.32)	0.0	0.0, 1.7	-0.23 (0.71)	0.0	-2.7, 1.7	0.0747
High Dose	32	0.68 (1.24)	0.34 (0.99)	0.0	0.0, 3.7	-0.34 (0.98)	0.0	-3.4, 2.6	0.0574

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 26	72	0.64 (1.54)	0.22 (0.63)	0.0	0.0, 3.7	-0.42 (1.60)	0.0	-9.2, 3.7	0.0271*
Low Dose	34	0.57 (1.71)	0.21 (0.70)	0.0	0.0, 3.7	-0.36 (1.90)	0.0	-9.2, 3.7	0.2729
High Dose	38	0.70 (1.39)	0.22 (0.57)	0.0	0.0, 2.4	-0.48 (1.29)	0.0	-4.9, 1.7	0.0274*
WEEK 39	63	0.60 (1.28)	0.34 (1.24)	0.0	0.0, 8.1	-0.26 (1.39)	0.0	-5.0, 7.3	0.1448
Low Dose	32	0.37 (1.00)	0.17 (0.65)	0.0	0.0, 3.5	-0.21 (0.61)	0.0	-2.8, 0.8	0.0655
High Dose	31	0.83 (1.50)	0.52 (1.63)	0.0	0.0, 8.1	-0.31 (1.89)	0.0	-5.0, 7.3	0.3668
WEEK 52	60	0.55 (1.17)	0.63 (2.04)	0.0	0.0, 13.5	0.08 (2.28)	0.0	-5.0, 13.0	0.7808
Low Dose	30	0.52 (1.11)	0.25 (0.80)	0.0	0.0, 3.3	-0.27 (1.23)	0.0	-3.4, 3.3	0.2325
High Dose	30	0.58 (1.24)	1.02 (2.74)	0.0	0.0, 13.5	0.44 (2.96)	0.0	-5.0, 13.0	0.4233
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	127		9.14 (2.67)	9.5	0.3, 16.0				
Low Dose	64		8.97 (2.86)	9.2	0.3, 16.0				
High Dose	63		9.31 (2.46)	9.5	2.6, 16.0				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 1	122	9.16 (2.66)	11.50 (3.65)	11.6	1.2, 16.0	2.34 (3.53)	2.1	-5.9, 9.7	<=0.001***
Low Dose	62	8.89 (2.84)	11.11 (4.00)	11.1	1.6, 16.0	2.22 (3.24)	1.8	-3.9, 9.7	<=0.001***
High Dose	60	9.44 (2.45)	11.90 (3.23)	12.2	1.2, 16.0	2.46 (3.84)	2.3	-5.9, 8.9	<=0.001***
WEEK 6	112	9.34 (2.53)	12.14 (3.20)	12.7	3.7, 16.0	2.80 (3.44)	3.2	-6.7, 9.9	<=0.001***
Low Dose	57	9.33 (2.64)	12.19 (3.23)	12.7	3.7, 16.0	2.85 (3.41)	3.0	-5.7, 9.9	<=0.001***
High Dose	55	9.36 (2.43)	12.10 (3.19)	12.8	5.1, 16.0	2.74 (3.50)	3.5	-6.7, 8.4	<=0.001***
WEEK 13	64	9.88 (2.45)	12.74 (3.51)	14.2	3.9, 16.0	2.87 (3.50)	3.3	-6.3, 9.9	<=0.001***
Low Dose	32	9.84 (2.40)	13.49 (3.13)	14.6	3.9, 16.0	3.65 (3.06)	3.9	-5.0, 9.9	<=0.001***
High Dose	32	9.92 (2.53)	12.00 (3.76)	13.6	5.3, 16.0	2.08 (3.78)	2.6	-6.3, 9.2	0.0040**
WEEK 26	72	9.55 (2.74)	12.98 (2.99)	14.1	4.8, 16.0	3.43 (3.21)	3.1	-5.5, 10.2	<=0.001***
Low Dose	34	9.57 (2.77)	12.84 (3.26)	14.4	4.8, 16.0	3.27 (3.44)	3.1	-5.5, 9.2	<=0.001***
High Dose	38	9.53 (2.76)	13.11 (2.76)	14.0	7.6, 16.0	3.58 (3.03)	3.0	-4.4, 10.2	<=0.001***
WEEK 39	63	9.55 (2.64)	12.92 (2.97)	12.9	2.4, 16.0	3.37 (3.36)	3.1	-9.2, 9.9	<=0.001***
Low Dose	32	9.78 (2.58)	13.25 (2.73)	13.8	4.6, 16.0	3.47 (3.21)	3.1	-5.9, 9.9	<=0.001***
High Dose	31	9.30 (2.73)	12.57 (3.20)	12.9	2.4, 16.0	3.26 (3.57)	3.1	-9.2, 9.7	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 52	60	9.68 (2.58)	12.47 (3.46)	13.2	2.5, 16.0	2.79 (3.08)	2.7	-5.4, 9.9	<=0.001***
Low Dose	30	9.53 (2.57)	12.79 (3.16)	13.4	5.1, 16.0	3.27 (3.25)	3.1	-5.4, 9.9	<=0.001***
High Dose	30	9.83 (2.62)	12.14 (3.77)	12.7	2.5, 16.0	2.31 (2.87)	2.1	-3.8, 8.4	<=0.001***
PD duration (time since diagnosis) category:>=10 years									
Average Daily Normalized 'Off' Time									
BASELINE	109		5.74 (2.24)	5.7	0.0, 12.6				
Low Dose	63		5.30 (2.16)	5.3	0.0, 10.2				
High Dose	46		6.34 (2.23)	6.5	1.5, 12.6				
WEEK 1	103	5.79 (2.28)	4.33 (3.65)	3.7	0.0, 16.0	-1.46 (3.93)	-2.4	-10.2, 10.4	<=0.001***
Low Dose	59	5.35 (2.22)	3.60 (3.14)	2.9	0.0, 11.2	-1.75 (3.77)	-2.5	-10.2, 5.9	<=0.001***
High Dose	44	6.37 (2.25)	5.30 (4.08)	5.5	0.0, 16.0	-1.07 (4.14)	-1.6	-7.5, 10.4	0.0944
WEEK 6	93	5.80 (2.25)	3.68 (3.56)	3.2	0.0, 16.0	-2.12 (3.85)	-2.9	-10.6, 9.9	<=0.001***
Low Dose	54	5.48 (2.17)	3.35 (3.77)	2.9	0.0, 16.0	-2.13 (3.86)	-2.9	-10.2, 9.9	<=0.001***
High Dose	39	6.26 (2.31)	4.14 (3.23)	3.9	0.0, 12.5	-2.11 (3.89)	-2.9	-10.6, 6.8	0.0016**

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 13	50	5.38 (2.15)	3.14 (3.53)	1.9	0.0, 13.4	-2.24 (3.99)	-3.1	-9.3, 8.1	<=0.001***
Low Dose	32	4.97 (2.11)	3.34 (3.88)	1.9	0.0, 13.4	-1.63 (4.30)	-2.6	-9.3, 8.1	0.0407*
High Dose	18	6.11 (2.07)	2.79 (2.88)	2.0	0.0, 9.3	-3.32 (3.18)	-3.3	-8.0, 4.0	<=0.001***
WEEK 26	59	6.12 (2.14)	2.38 (3.08)	1.1	0.0, 14.3	-3.74 (3.34)	-3.9	-10.6, 7.1	<=0.001***
Low Dose	35	5.68 (1.89)	1.97 (3.07)	0.0	0.0, 14.3	-3.71 (3.30)	-4.0	-10.2, 7.1	<=0.001***
High Dose	24	6.76 (2.35)	2.97 (3.05)	1.7	0.0, 9.8	-3.78 (3.46)	-2.8	-10.6, 5.5	<=0.001***
WEEK 39	56	5.93 (2.12)	2.55 (2.94)	1.7	0.0, 13.3	-3.38 (3.25)	-3.5	-9.8, 9.6	<=0.001***
Low Dose	35	5.43 (1.77)	2.51 (3.13)	1.7	0.0, 13.3	-2.91 (3.36)	-3.1	-9.8, 9.6	<=0.001***
High Dose	21	6.76 (2.44)	2.60 (2.66)	2.2	0.0, 7.3	-4.16 (2.97)	-4.4	-8.1, 2.9	<=0.001***
WEEK 52	44	6.02 (2.11)	1.99 (2.40)	0.8	0.0, 8.1	-4.02 (2.89)	-4.1	-11.2, 2.8	<=0.001***
Low Dose	26	5.63 (1.94)	2.24 (2.31)	1.5	0.0, 6.7	-3.39 (2.61)	-3.6	-10.2, 1.8	<=0.001***
High Dose	18	6.58 (2.26)	1.64 (2.54)	0.4	0.0, 8.1	-4.94 (3.10)	-4.7	-11.2, 2.8	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	109		6.19 (3.22)	6.2	0.0, 12.6				
Low Dose	63		6.10 (3.06)	5.9	0.0, 12.6				
High Dose	46		6.32 (3.46)	6.4	0.0, 12.3				
WEEK 1	103	6.19 (3.14)	7.71 (4.22)	7.8	0.0, 16.0	1.52 (4.12)	1.3	-8.8, 10.2	<=0.001***
Low Dose	59	5.96 (2.94)	7.54 (4.03)	7.3	0.0, 16.0	1.58 (3.97)	1.4	-8.8, 10.2	0.0033**
High Dose	44	6.51 (3.39)	7.93 (4.50)	8.0	0.0, 16.0	1.43 (4.37)	1.3	-8.1, 8.0	0.0358*
WEEK 6	93	6.04 (3.24)	9.10 (4.70)	9.8	0.0, 16.0	3.06 (4.54)	3.4	-9.1, 12.7	<=0.001***
Low Dose	54	5.80 (2.91)	9.09 (4.65)	9.8	0.0, 16.0	3.29 (4.71)	4.1	-9.1, 12.7	<=0.001***
High Dose	39	6.38 (3.65)	9.12 (4.84)	9.9	0.0, 16.0	2.74 (4.35)	2.4	-6.4, 11.2	<=0.001***
WEEK 13	50	6.05 (3.10)	10.11 (4.70)	10.7	0.0, 16.0	4.05 (3.99)	4.1	-6.5, 11.0	<=0.001***
Low Dose	32	5.95 (2.87)	9.47 (4.82)	9.6	0.0, 16.0	3.52 (3.93)	3.4	-6.5, 11.0	<=0.001***
High Dose	18	6.23 (3.56)	11.23 (4.38)	11.7	0.9, 16.0	5.00 (4.04)	5.5	-4.7, 10.0	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 26	59	6.27 (3.30)	11.29 (4.41)	12.8	0.0, 16.0	5.03 (4.46)	5.6	-11.0, 12.7	<=0.001***
Low Dose	35	6.12 (3.07)	11.75 (3.96)	12.8	0.5, 16.0	5.63 (3.30)	5.7	-1.6, 11.5	<=0.001***
High Dose	24	6.48 (3.67)	10.63 (5.01)	12.3	0.0, 16.0	4.15 (5.73)	4.9	-11.0, 12.7	0.0017**
WEEK 39	56	6.63 (3.05)	11.06 (4.37)	12.0	0.6, 16.0	4.43 (4.48)	5.0	-10.6, 13.5	<=0.001***
Low Dose	35	6.36 (2.75)	10.57 (4.74)	11.8	0.6, 16.0	4.21 (4.66)	5.1	-10.6, 11.4	<=0.001***
High Dose	21	7.07 (3.53)	11.87 (3.63)	12.6	5.1, 16.0	4.80 (4.24)	4.3	-2.9, 13.5	<=0.001***
WEEK 52	44	6.59 (3.22)	11.62 (4.20)	13.4	1.3, 16.0	5.03 (4.14)	5.0	-2.9, 13.8	<=0.001***
Low Dose	26	6.41 (2.85)	11.55 (3.93)	12.8	1.3, 16.0	5.14 (3.91)	5.0	-2.9, 11.3	<=0.001***
High Dose	18	6.86 (3.77)	11.72 (4.69)	14.1	1.3, 16.0	4.87 (4.56)	4.8	-2.9, 13.8	<=0.001***
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	109		2.95 (2.42)	2.7	0.0, 9.3				
Low Dose	63		3.03 (2.07)	2.9	0.0, 7.5				
High Dose	46		2.84 (2.84)	1.9	0.0, 9.3				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 1	103	2.94 (2.42)	2.79 (3.09)	1.7	0.0, 13.6	-0.15 (3.31)	0.0	-6.9, 13.6	0.6497
Low Dose	59	3.11 (2.07)	3.40 (3.20)	2.4	0.0, 13.6	0.29 (3.77)	0.0	-6.4, 13.6	0.5614
High Dose	44	2.71 (2.83)	1.98 (2.77)	1.0	0.0, 12.8	-0.73 (2.51)	0.0	-6.9, 5.8	0.0593
WEEK 6	93	3.01 (2.42)	2.75 (3.69)	1.2	0.0, 15.4	-0.26 (3.45)	-0.3	-7.8, 11.6	0.4726
Low Dose	54	3.10 (1.93)	2.90 (3.49)	1.7	0.0, 15.4	-0.19 (3.32)	-0.5	-6.7, 11.6	0.6711
High Dose	39	2.90 (2.99)	2.55 (3.99)	0.6	0.0, 14.6	-0.35 (3.66)	-0.3	-7.8, 9.6	0.5565
WEEK 13	50	3.31 (2.19)	2.27 (3.81)	0.7	0.0, 16.0	-1.04 (3.87)	-1.1	-6.9, 13.2	0.0636
Low Dose	32	3.40 (1.93)	2.48 (3.91)	1.0	0.0, 16.0	-0.91 (4.06)	-1.3	-6.5, 13.2	0.2137
High Dose	18	3.15 (2.66)	1.88 (3.72)	0.0	0.0, 14.4	-1.27 (3.63)	-0.7	-6.9, 7.2	0.1557
WEEK 26	59	2.70 (2.28)	1.89 (2.83)	0.8	0.0, 14.9	-0.81 (3.21)	-1.0	-6.8, 7.8	0.0577
Low Dose	35	2.97 (1.96)	1.89 (2.42)	1.0	0.0, 10.8	-1.08 (2.98)	-1.0	-6.7, 5.4	0.0397*
High Dose	24	2.30 (2.68)	1.88 (3.39)	0.7	0.0, 14.9	-0.42 (3.55)	-0.2	-6.8, 7.8	0.5680
WEEK 39	56	2.59 (2.20)	2.03 (3.44)	0.0	0.0, 15.4	-0.56 (3.79)	-0.1	-7.8, 15.4	0.2718
Low Dose	35	3.03 (1.96)	2.55 (3.93)	0.8	0.0, 15.4	-0.47 (4.11)	-0.7	-6.7, 15.4	0.5000
High Dose	21	1.87 (2.43)	1.16 (2.23)	0.0	0.0, 8.9	-0.71 (3.29)	0.0	-7.8, 5.8	0.3337

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 52	44	2.72 (2.50)	2.08 (3.30)	0.6	0.0, 12.0	-0.65 (3.44)	-0.3	-7.3, 7.5	0.2194
Low Dose	26	3.05 (1.99)	2.07 (3.33)	0.7	0.0, 12.0	-0.98 (3.55)	-2.2	-6.7, 6.1	0.1730
High Dose	18	2.26 (3.09)	2.09 (3.33)	0.2	0.0, 10.6	-0.17 (3.30)	0.0	-7.3, 7.5	0.8336
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	109		1.12 (1.81)	0.0	0.0, 10.5				
Low Dose	63		1.57 (2.08)	0.8	0.0, 10.5				
High Dose	46		0.50 (1.10)	0.0	0.0, 4.9				
WEEK 1	103	1.08 (1.77)	1.17 (1.99)	0.0	0.0, 7.9	0.09 (2.03)	0.0	-6.0, 7.9	0.6507
Low Dose	59	1.58 (2.08)	1.46 (2.00)	0.6	0.0, 7.9	-0.12 (2.08)	0.0	-6.0, 7.9	0.6572
High Dose	44	0.41 (0.89)	0.78 (1.93)	0.0	0.0, 7.3	0.37 (1.96)	0.0	-3.7, 7.0	0.2108
WEEK 6	93	1.14 (1.88)	0.46 (1.25)	0.0	0.0, 5.8	-0.68 (1.66)	0.0	-7.2, 4.1	<=0.001***
Low Dose	54	1.63 (2.18)	0.66 (1.55)	0.0	0.0, 5.8	-0.97 (1.92)	-0.2	-7.2, 4.1	<=0.001***
High Dose	39	0.47 (1.06)	0.19 (0.57)	0.0	0.0, 2.6	-0.28 (1.13)	0.0	-4.9, 2.1	0.1308

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 13	50	1.26 (1.77)	0.48 (1.47)	0.0	0.0, 8.0	-0.78 (1.95)	0.0	-7.2, 6.0	0.0071**
Low Dose	32	1.69 (1.90)	0.70 (1.79)	0.0	0.0, 8.0	-0.99 (2.26)	-0.6	-7.2, 6.0	0.0195*
High Dose	18	0.50 (1.23)	0.10 (0.29)	0.0	0.0, 1.1	-0.40 (1.19)	0.0	-4.9, 0.7	0.1689
WEEK 26	59	0.92 (1.47)	0.44 (1.95)	0.0	0.0, 12.1	-0.48 (2.13)	0.0	-5.1, 8.8	0.0907
Low Dose	35	1.23 (1.55)	0.39 (2.05)	0.0	0.0, 12.1	-0.84 (1.99)	-0.2	-5.1, 7.2	0.0173*
High Dose	24	0.46 (1.23)	0.52 (1.83)	0.0	0.0, 8.8	0.05 (2.26)	0.0	-4.9, 8.8	0.9071
WEEK 39	56	0.85 (1.32)	0.36 (0.84)	0.0	0.0, 3.8	-0.49 (1.28)	0.0	-5.1, 2.7	0.0058**
Low Dose	35	1.19 (1.45)	0.36 (0.89)	0.0	0.0, 3.8	-0.82 (1.28)	-0.2	-5.1, 0.5	<=0.001***
High Dose	21	0.30 (0.83)	0.37 (0.78)	0.0	0.0, 2.7	0.07 (1.09)	0.0	-3.6, 2.7	0.7769
WEEK 52	44	0.66 (1.18)	0.31 (0.94)	0.0	0.0, 5.3	-0.36 (1.51)	0.0	-5.1, 5.3	0.1254
Low Dose	26	0.91 (1.31)	0.14 (0.35)	0.0	0.0, 1.5	-0.77 (1.32)	0.0	-5.1, 0.7	0.0066**
High Dose	18	0.31 (0.90)	0.55 (1.40)	0.0	0.0, 5.3	0.24 (1.61)	0.0	-3.6, 5.3	0.5396

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	109		9.14 (2.31)	9.4	3.4, 14.5				
Low Dose	63		9.13 (2.47)	9.7	3.5, 14.2				
High Dose	46		9.16 (2.09)	9.1	3.4, 14.5				
WEEK 1	103	9.13 (2.31)	10.50 (3.66)	10.6	0.0, 16.0	1.37 (4.00)	1.8	-10.4, 11.3	<=0.001***
Low Dose	59	9.07 (2.46)	10.94 (3.24)	11.5	3.9, 16.0	1.87 (3.84)	2.5	-5.9, 11.3	<=0.001***
High Dose	44	9.22 (2.11)	9.91 (4.13)	9.9	0.0, 16.0	0.69 (4.15)	1.3	-10.4, 7.5	0.2733
WEEK 6	93	9.05 (2.33)	11.86 (3.57)	12.4	0.0, 16.0	2.80 (3.77)	3.3	-9.9, 10.6	<=0.001***
Low Dose	54	8.89 (2.43)	11.99 (3.83)	12.6	0.0, 16.0	3.10 (3.78)	3.6	-9.9, 10.5	<=0.001***
High Dose	39	9.28 (2.19)	11.67 (3.20)	12.0	3.5, 16.0	2.39 (3.77)	2.9	-6.8, 10.6	<=0.001***
WEEK 13	50	9.36 (2.21)	12.37 (3.75)	13.4	2.6, 16.0	3.01 (3.48)	3.4	-4.9, 9.3	<=0.001***
Low Dose	32	9.35 (2.36)	11.96 (4.12)	13.3	2.6, 16.0	2.61 (3.51)	3.0	-4.9, 9.3	<=0.001***
High Dose	18	9.39 (1.96)	13.11 (2.95)	13.7	6.0, 16.0	3.73 (3.41)	3.8	-4.7, 8.2	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.4

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based On Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 26	59	8.96 (2.39)	13.18 (3.54)	14.5	1.5, 16.0	4.22 (3.89)	4.7	-5.5, 12.5	<=0.001***
Low Dose	35	9.09 (2.56)	13.64 (3.74)	15.7	1.5, 16.0	4.55 (4.00)	4.8	-4.5, 12.5	<=0.001***
High Dose	24	8.78 (2.16)	12.51 (3.20)	13.7	6.2, 16.0	3.73 (3.76)	3.3	-5.5, 10.6	<=0.001***
WEEK 39	56	9.22 (2.28)	13.09 (3.07)	13.7	2.7, 16.0	3.87 (3.28)	3.8	-9.1, 9.8	<=0.001***
Low Dose	35	9.38 (2.29)	13.12 (3.18)	13.7	2.7, 16.0	3.74 (3.47)	3.2	-9.1, 9.8	<=0.001***
High Dose	21	8.94 (2.30)	13.03 (2.96)	13.8	6.6, 16.0	4.09 (3.00)	4.4	-2.9, 8.1	<=0.001***
WEEK 52	44	9.32 (2.24)	13.70 (2.51)	14.6	7.9, 16.0	4.38 (2.95)	4.3	-2.8, 11.2	<=0.001***
Low Dose	26	9.46 (2.33)	13.62 (2.34)	14.0	8.8, 16.0	4.16 (2.84)	3.9	-2.2, 10.2	<=0.001***
High Dose	18	9.11 (2.15)	13.81 (2.80)	15.3	7.9, 16.0	4.70 (3.16)	4.7	-2.8, 11.2	<=0.001***

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

表2.7.3.6-25　PD日誌に基づく，標準化した1日あたりの平均「オフ」時間及び「オン」時間の登録時期別の要約（FAS，日本人部分集団）：M15-741試験（更新時）

[redacted]20[redacted] 10:49 <[redacted]>
ABBV-951
STUDY M15-741 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0153 - CLINICAL/STATISTICAL

TABLE 14.2__1.7.J

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Enrollment Sample
(FAS - Japan Subjects)

Parameter / Time Point / Sample Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	Change from Baseline: P-Value &
Average Daily Normalized 'Off' Time									
BASELINE	27		6.79 (2.05)	6.9	0.0, 10.3				
Sample 1	18		6.79 (2.31)	7.1	0.0, 9.7				
Sample 2	9		6.79 (1.54)	6.1	5.1, 10.3				
WEEK 1	26	6.78 (2.09)	5.25 (3.32)	5.1	0.0, 13.8	-1.53 (3.77)	-1.9	-9.7, 4.7	0.0490*
Sample 1	18	6.79 (2.31)	5.08 (3.03)	5.1	0.0, 10.9	-1.71 (4.17)	-2.0	-9.7, 4.7	0.1001
Sample 2	8	6.76 (1.64)	5.64 (4.12)	5.6	1.2, 13.8	-1.13 (2.87)	-1.2	-4.7, 3.6	0.3036
WEEK 6	24	6.72 (1.95)	5.88 (3.71)	4.9	0.0, 13.4	-0.84 (3.94)	-2.5	-7.5, 6.8	0.3088
Sample 1	16	6.90 (2.32)	5.84 (3.48)	4.9	2.0, 12.5	-1.06 (4.00)	-2.8	-7.5, 6.8	0.3057
Sample 2	8	6.36 (0.88)	5.97 (4.39)	5.3	0.0, 13.4	-0.39 (4.04)	-0.8	-5.1, 6.2	0.7928
WEEK 13	10	5.81 (2.19)	6.67 (4.86)	7.3	0.0, 13.4	0.86 (5.02)	1.8	-6.6, 8.1	0.6010
Sample 1	6	5.01 (2.54)	4.98 (4.02)	5.0	0.0, 10.4	-0.03 (5.33)	-0.7	-6.6, 8.1	0.9903
Sample 2	4	7.01 (0.68)	9.20 (5.46)	11.1	1.3, 13.4	2.19 (4.92)	3.7	-4.8, 6.1	0.4383
WEEK 26	15	6.67 (1.31)	5.79 (4.43)	5.4	0.0, 14.3	-0.89 (4.46)	-0.7	-8.1, 7.1	0.4534
Sample 1	7	7.03 (1.68)	4.53 (3.67)	5.3	0.0, 8.9	-2.50 (3.78)	-1.4	-8.1, 2.7	0.1313
Sample 2	8	6.36 (0.88)	6.88 (4.97)	7.1	0.0, 14.3	0.52 (4.76)	0.7	-7.0, 7.1	0.7661

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.7.J

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Enrollment Sample
(FAS - Japan Subjects)

Parameter Time Point Sample Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 39	14	6.68 (1.36)	4.36 (3.22)	4.5	0.0, 12.3	-2.32 (3.40)	-1.7	-8.1, 5.1	0.0241*
Sample 1	6	7.10 (1.83)	3.96 (2.50)	4.1	0.0, 6.8	-3.14 (3.30)	-2.4	-8.1, 1.1	0.0676
Sample 2	8	6.36 (0.88)	4.66 (3.81)	4.9	0.0, 12.3	-1.70 (3.56)	-1.4	-7.0, 5.1	0.2177
WEEK 52	12	6.75 (1.39)	4.34 (2.99)	4.5	0.0, 10.1	-2.41 (3.40)	-2.7	-8.1, 4.1	0.0315*
Sample 1	5	7.49 (1.74)	4.32 (2.99)	6.1	0.0, 6.7	-3.16 (3.37)	-3.5	-8.1, 1.2	0.1037
Sample 2	7	6.23 (0.86)	4.35 (3.22)	3.7	0.0, 10.1	-1.88 (3.58)	-2.4	-7.0, 4.1	0.2136
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	27		5.68 (2.73)	5.7	0.0, 10.1				
Sample 1	18		5.43 (2.46)	5.7	0.0, 8.7				
Sample 2	9		6.18 (3.30)	5.7	1.1, 10.1				
WEEK 1	26	5.55 (2.70)	6.23 (3.84)	6.8	0.3, 16.0	0.68 (4.00)	0.9	-8.9, 10.2	0.3968
Sample 1	18	5.43 (2.46)	6.19 (4.03)	6.4	0.3, 16.0	0.76 (3.14)	1.1	-6.0, 8.3	0.3180
Sample 2	8	5.83 (3.35)	6.31 (3.63)	7.5	1.0, 11.3	0.48 (5.75)	0.0	-8.9, 10.2	0.8185
WEEK 6	24	5.79 (2.86)	8.38 (4.05)	8.4	0.0, 13.8	2.60 (5.07)	3.7	-6.4, 13.8	0.0196*
Sample 1	16	5.57 (2.57)	7.79 (4.05)	8.0	0.0, 13.8	2.22 (5.21)	3.2	-6.4, 13.8	0.1079
Sample 2	8	6.23 (3.52)	9.57 (4.04)	10.3	2.6, 13.8	3.34 (5.04)	3.9	-3.5, 10.8	0.1030

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.7.J

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Enrollment Sample
(FAS - Japan Subjects)

Parameter Time Point Sample Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 13	10	5.40 (2.89)	5.93 (5.42)	5.2	0.0, 14.7	0.54 (5.57)	0.9	-9.0, 9.6	0.7668
Sample 1	6	4.04 (1.68)	6.02 (5.31)	5.4	0.0, 14.5	1.97 (5.47)	1.9	-6.5, 9.6	0.4176
Sample 2	4	7.43 (3.35)	5.81 (6.42)	4.3	0.0, 14.7	-1.61 (5.74)	-1.2	-9.0, 4.8	0.6130
WEEK 26	15	5.94 (2.87)	8.34 (5.26)	8.1	0.0, 16.0	2.40 (5.01)	3.2	-10.1, 9.5	0.0844
Sample 1	7	5.61 (2.12)	9.69 (5.22)	9.1	1.2, 16.0	4.08 (4.07)	3.2	-0.9, 9.5	0.0378*
Sample 2	8	6.23 (3.52)	7.16 (5.34)	6.9	0.0, 16.0	0.93 (5.54)	1.9	-10.1, 7.0	0.6492
WEEK 39	14	5.90 (2.97)	9.83 (4.24)	10.3	0.3, 16.0	3.93 (3.21)	4.0	-1.9, 8.1	<=0.001***
Sample 1	6	5.46 (2.28)	9.41 (5.15)	9.6	0.3, 16.0	3.95 (3.88)	4.0	-1.9, 8.1	0.0546
Sample 2	8	6.23 (3.52)	10.14 (3.76)	10.7	3.7, 16.0	3.91 (2.90)	3.9	0.4, 7.8	0.0066**
WEEK 52	12	6.26 (3.03)	10.48 (3.47)	10.2	4.2, 16.0	4.22 (2.22)	3.8	1.7, 8.1	<=0.001***
Sample 1	5	5.57 (2.53)	9.97 (3.54)	9.3	6.9, 16.0	4.40 (2.67)	4.8	1.7, 8.1	0.0212*
Sample 2	7	6.76 (3.44)	10.85 (3.66)	11.0	4.2, 16.0	4.09 (2.06)	3.1	1.9, 7.0	0.0019**
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	27		2.74 (2.76)	2.6	0.0, 8.0				
Sample 1	18		2.98 (2.84)	2.7	0.0, 8.0				
Sample 2	9		2.25 (2.70)	0.2	0.0, 5.6				

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.7.J

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Enrollment Sample
(FAS - Japan Subjects)

Parameter Time Point Sample Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 1	26	2.84 (2.76)	3.83 (4.01)	2.6	0.0, 14.9	0.99 (3.82)	0.0	-5.4, 13.2	0.2002
Sample 1	18	2.98 (2.84)	3.89 (3.87)	2.6	0.0, 14.9	0.90 (3.34)	0.1	-5.4, 8.6	0.2665
Sample 2	8	2.53 (2.75)	3.70 (4.59)	2.2	0.0, 13.2	1.17 (5.00)	0.0	-2.9, 13.2	0.5291
WEEK 6	24	2.64 (2.71)	1.70 (2.87)	0.2	0.0, 9.6	-0.94 (3.53)	0.0	-6.7, 9.6	0.2027
Sample 1	16	2.70 (2.78)	2.32 (3.34)	0.9	0.0, 9.6	-0.38 (3.93)	0.0	-6.7, 9.6	0.7019
Sample 2	8	2.53 (2.75)	0.46 (0.75)	0.2	0.0, 2.2	-2.07 (2.38)	-1.6	-5.1, 0.3	0.0437*
WEEK 13	10	3.31 (2.90)	3.39 (5.59)	0.7	0.0, 16.0	0.08 (5.72)	-0.5	-6.5, 13.2	0.9655
Sample 1	6	4.98 (2.27)	5.00 (6.80)	1.4	0.0, 16.0	0.02 (7.32)	-1.8	-6.5, 13.2	0.9952
Sample 2	4	0.81 (1.63)	0.98 (1.97)	0.0	0.0, 3.9	0.17 (2.94)	0.0	-3.3, 3.9	0.9141
WEEK 26	15	2.91 (3.04)	1.76 (3.26)	0.0	0.0, 12.1	-1.15 (3.11)	0.0	-6.7, 4.6	0.1730
Sample 1	7	3.36 (3.51)	1.77 (4.54)	0.0	0.0, 12.1	-1.59 (3.82)	0.0	-6.7, 4.1	0.3145
Sample 2	8	2.53 (2.75)	1.75 (1.89)	1.6	0.0, 4.8	-0.78 (2.55)	-1.2	-2.9, 4.6	0.4180
WEEK 39	14	2.92 (3.15)	1.72 (3.58)	0.0	0.0, 13.2	-1.20 (3.18)	-0.1	-6.7, 5.2	0.1826
Sample 1	6	3.45 (3.83)	2.63 (5.30)	0.0	0.0, 13.2	-0.82 (4.70)	0.0	-6.7, 5.2	0.6878
Sample 2	8	2.53 (2.75)	1.04 (1.59)	0.0	0.0, 4.1	-1.48 (1.67)	-0.9	-4.0, 0.0	0.0407*

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.7.J

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Enrollment Sample
(FAS - Japan Subjects)

Parameter / Time Point / Sample Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 52	12	2.64 (3.29)	1.16 (1.98)	0.1	0.0, 6.7	-1.48 (2.55)	0.0	-6.7, 1.8	0.0687
Sample 1	5	2.95 (4.06)	1.71 (2.91)	0.0	0.0, 6.7	-1.24 (3.27)	0.0	-6.7, 1.8	0.4441
Sample 2	7	2.42 (2.95)	0.77 (1.06)	0.3	0.0, 2.7	-1.66 (2.16)	0.0	-4.9, 0.0	0.0893
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	27		0.79 (1.74)	0.0	0.0, 7.2				
Sample 1	18		0.80 (1.94)	0.0	0.0, 7.2				
Sample 2	9		0.79 (1.38)	0.0	0.0, 3.4				
WEEK 1	26	0.82 (1.77)	0.69 (1.59)	0.0	0.0, 7.9	-0.13 (2.37)	0.0	-6.0, 7.9	0.7790
Sample 1	18	0.80 (1.94)	0.84 (1.86)	0.0	0.0, 7.9	0.05 (2.69)	0.0	-6.0, 7.9	0.9440
Sample 2	8	0.89 (1.44)	0.36 (0.63)	0.0	0.0, 1.8	-0.53 (1.48)	0.0	-2.7, 1.8	0.3453
WEEK 6	24	0.85 (1.84)	0.04 (0.12)	0.0	0.0, 0.5	-0.82 (1.81)	0.0	-7.2, 0.4	0.0370*
Sample 1	16	0.84 (2.05)	0.05 (0.15)	0.0	0.0, 0.5	-0.78 (2.01)	0.0	-7.2, 0.4	0.1399
Sample 2	8	0.89 (1.44)	0.00 (0.00)	0.0	0.0, 0.0	-0.89 (1.44)	0.0	-3.4, 0.0	0.1260
WEEK 13	10	1.48 (2.59)	0.00 (0.00)	0.0	0.0, 0.0	-1.48 (2.59)	0.0	-7.2, 0.0	0.1039
Sample 1	6	1.97 (3.16)	0.00 (0.00)	0.0	0.0, 0.0	-1.97 (3.16)	0.0	-7.2, 0.0	0.1880
Sample 2	4	0.75 (1.50)	0.00 (0.00)	0.0	0.0, 0.0	-0.75 (1.50)	0.0	-3.0, 0.0	0.3910

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.7.J

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Enrollment Sample
(FAS - Japan Subjects)

Parameter / Time Point / Sample Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 26	15	0.47 (1.12)	0.11 (0.34)	0.0	0.0, 1.3	-0.36 (1.20)	0.0	-3.4, 1.3	0.2645
Sample 1	7	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Sample 2	8	0.89 (1.44)	0.21 (0.45)	0.0	0.0, 1.3	-0.67 (1.62)	0.0	-3.4, 1.3	0.2780
WEEK 39	14	0.51 (1.15)	0.09 (0.23)	0.0	0.0, 0.7	-0.42 (1.05)	0.0	-3.0, 0.0	0.1610
Sample 1	6	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Sample 2	8	0.89 (1.44)	0.16 (0.29)	0.0	0.0, 0.7	-0.73 (1.33)	0.0	-3.0, 0.0	0.1663
WEEK 52	12	0.34 (0.97)	0.02 (0.07)	0.0	0.0, 0.2	-0.32 (0.97)	0.0	-3.4, 0.0	0.2748
Sample 1	5	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Sample 2	7	0.58 (1.25)	0.03 (0.09)	0.0	0.0, 0.2	-0.55 (1.25)	0.0	-3.4, 0.0	0.2892
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	27		8.42 (1.76)	8.7	4.6, 11.1				
Sample 1	18		8.42 (1.75)	8.5	4.6, 11.1				
Sample 2	9		8.42 (1.90)	9.0	5.7, 10.3				
WEEK 1	26	8.40 (1.80)	10.06 (3.19)	9.9	2.2, 16.0	1.66 (3.85)	1.1	-4.0, 9.7	0.0372*
Sample 1	18	8.42 (1.75)	10.08 (2.89)	10.2	5.1, 16.0	1.66 (4.07)	1.1	-4.0, 9.7	0.1009
Sample 2	8	8.35 (2.02)	10.01 (3.99)	9.4	2.2, 14.2	1.66 (3.57)	2.0	-3.6, 7.3	0.2306

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.7.J

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Enrollment Sample
(FAS - Japan Subjects)

Parameter / Time Point / Sample Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	Change from Baseline: P-Value &
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 6	24	8.43 (1.70)	10.08 (3.69)	11.1	2.6, 16.0	1.65 (3.82)	3.0	-6.0, 7.5	0.0448*
Sample 1	16	8.27 (1.72)	10.11 (3.44)	11.1	3.5, 13.8	1.84 (3.86)	3.0	-6.0, 7.5	0.0757
Sample 2	8	8.75 (1.72)	10.03 (4.39)	10.7	2.6, 16.0	1.28 (3.96)	1.6	-3.3, 5.8	0.3922
WEEK 13	10	8.71 (2.05)	9.33 (4.86)	8.7	2.6, 16.0	0.62 (3.76)	0.1	-5.0, 6.6	0.6148
Sample 1	6	9.03 (2.32)	11.02 (4.02)	11.0	5.6, 16.0	1.99 (2.94)	1.8	-1.1, 6.6	0.1572
Sample 2	4	8.24 (1.79)	6.80 (5.46)	4.9	2.6, 14.7	-1.44 (4.30)	-2.8	-5.0, 4.8	0.5510
WEEK 26	15	8.85 (1.64)	10.10 (4.38)	10.5	1.7, 16.0	1.25 (4.00)	0.7	-5.5, 8.1	0.2476
Sample 1	7	8.97 (1.68)	11.47 (3.67)	10.7	7.1, 16.0	2.50 (3.78)	1.4	-2.7, 8.1	0.1313
Sample 2	8	8.75 (1.72)	8.91 (4.82)	8.8	1.7, 16.0	0.15 (4.11)	0.5	-5.5, 7.0	0.9191
WEEK 39	14	8.82 (1.70)	11.55 (3.17)	11.5	3.7, 16.0	2.73 (2.94)	2.3	-2.1, 8.1	0.0040**
Sample 1	6	8.90 (1.83)	12.04 (2.50)	11.9	9.2, 16.0	3.14 (3.30)	2.4	-1.1, 8.1	0.0676
Sample 2	8	8.75 (1.72)	11.18 (3.72)	11.1	3.7, 16.0	2.43 (2.82)	2.3	-2.1, 7.0	0.0451*
WEEK 52	12	8.91 (1.47)	11.64 (3.00)	11.5	5.9, 16.0	2.74 (2.86)	2.7	-1.2, 8.1	0.0069**
Sample 1	5	8.51 (1.74)	11.68 (2.99)	9.9	9.3, 16.0	3.16 (3.37)	3.5	-1.2, 8.1	0.1037
Sample 2	7	9.18 (1.32)	11.62 (3.24)	12.3	5.9, 16.0	2.43 (2.67)	2.4	-0.8, 7.0	0.0528

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

表2.7.3.6-26　PD日誌に基づく，標準化した1日あたりの平均「オフ」時間及び「オン」時間の要約（FAS，部分集団別）：M15-737試験（更新時）

TABLE 14.2__1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Female									
Average Daily Normalized 'Off' Time									
BASELINE	33		1.91 (2.35)	0.9	0.0, 8.8				
Low Dose	23		2.05 (2.24)	1.2	0.0, 6.7				
High Dose	10		1.58 (2.68)	0.7	0.0, 8.8				
WEEK 12	29	2.06 (2.43)	2.63 (2.49)	2.2	0.0, 10.9	0.56 (2.90)	0.0	-6.4, 10.9	0.3045
Low Dose	22	2.02 (2.29)	2.21 (1.98)	2.0	0.0, 6.1	0.18 (1.64)	0.0	-4.2, 3.8	0.6081
High Dose	7	2.19 (3.05)	3.95 (3.56)	2.3	0.3, 10.9	1.76 (5.25)	1.3	-6.4, 10.9	0.4094
WEEK 24	27	2.12 (2.44)	3.70 (4.35)	2.5	0.0, 16.0	1.58 (3.33)	0.1	-3.0, 13.3	0.0208*
Low Dose	18	2.30 (2.32)	3.61 (4.50)	1.9	0.0, 16.0	1.31 (3.79)	0.0	-3.0, 13.3	0.1621
High Dose	9	1.76 (2.78)	3.88 (4.30)	2.7	0.0, 13.4	2.12 (2.24)	2.2	0.0, 6.2	0.0217*
WEEK 36	15	1.87 (2.89)	1.41 (1.95)	0.5	0.0, 6.5	-0.46 (1.87)	0.0	-5.5, 1.4	0.3596
Low Dose	10	1.50 (2.58)	1.07 (2.04)	0.1	0.0, 6.5	-0.43 (1.87)	0.0	-5.5, 1.4	0.4853
High Dose	5	2.62 (3.63)	2.11 (1.76)	2.0	0.0, 4.9	-0.51 (2.10)	0.0	-3.9, 1.2	0.6134

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Gender:Female (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 48	17	1.70 (2.39)	2.44 (4.08)	0.7	0.0, 14.3	0.74 (2.46)	0.0	-2.0, 7.4	0.2338
Low Dose	10	1.36 (1.91)	2.19 (3.43)	0.4	0.0, 10.1	0.83 (2.53)	0.0	-1.2, 7.4	0.3276
High Dose	7	2.19 (3.05)	2.79 (5.15)	1.1	0.0, 14.3	0.60 (2.53)	0.0	-2.0, 5.5	0.5509
WEEK 60	11	1.79 (2.92)	1.62 (2.67)	0.2	0.0, 6.9	-0.18 (0.86)	0.0	-2.0, 1.0	0.5137
Low Dose	7	1.43 (2.20)	1.31 (2.59)	0.0	0.0, 6.9	-0.12 (0.69)	0.0	-1.2, 1.0	0.6523
High Dose	4	2.43 (4.23)	2.16 (3.12)	0.9	0.0, 6.8	-0.27 (1.23)	0.0	-2.0, 0.9	0.6922
WEEK 72	5	1.33 (2.56)	0.94 (1.56)	0.2	0.0, 3.7	-0.39 (1.13)	-0.0	-2.2, 0.8	0.4827
Low Dose	4	1.53 (2.91)	1.17 (1.69)	0.5	0.0, 3.7	-0.36 (1.30)	-0.0	-2.2, 0.8	0.6160
High Dose	1	0.50 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-0.50 (N/A)	-0.5	-0.5, -0.5	
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Female (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	33		11.60 (4.92)	13.3	0.0, 16.0				
Low Dose	23		11.61 (4.88)	13.0	1.3, 16.0				
High Dose	10		11.56 (5.26)	13.9	0.0, 16.0				
WEEK 12	29	11.75 (4.70)	11.71 (4.13)	12.9	2.5, 16.0	-0.04 (4.15)	-0.0	-10.9, 14.2	0.9586
Low Dose	22	12.08 (4.44)	12.12 (4.07)	13.4	2.5, 16.0	0.04 (3.84)	-0.2	-6.6, 14.2	0.9599
High Dose	7	10.73 (5.70)	10.43 (4.37)	11.3	4.2, 15.8	-0.30 (5.34)	0.4	-10.9, 5.4	0.8874
WEEK 24	27	11.36 (4.92)	11.05 (5.29)	13.5	0.0, 16.0	-0.31 (4.99)	0.0	-13.3, 14.2	0.7509
Low Dose	18	11.51 (4.85)	11.06 (5.52)	14.0	0.0, 16.0	-0.44 (5.38)	0.0	-13.3, 14.2	0.7315
High Dose	9	11.07 (5.32)	11.03 (5.14)	13.3	2.6, 16.0	-0.04 (4.40)	0.0	-4.5, 10.6	0.9789
WEEK 36	15	11.67 (5.44)	14.27 (2.61)	15.5	8.0, 16.0	2.60 (5.01)	0.0	-1.4, 14.2	0.0638
Low Dose	10	12.91 (4.89)	14.79 (2.36)	15.7	8.4, 16.0	1.88 (4.71)	0.0	-1.4, 14.2	0.2382
High Dose	5	9.17 (6.17)	13.22 (3.04)	14.0	8.0, 16.0	4.05 (5.83)	1.0	0.0, 14.0	0.1957

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Gender:Female (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 48	17	11.39 (5.68)	12.80 (4.33)	14.9	1.4, 16.0	1.41 (6.67)	0.0	-8.0, 14.9	0.3952
Low Dose	10	11.85 (5.92)	12.63 (3.82)	14.0	5.9, 16.0	0.78 (7.00)	-0.0	-8.0, 13.7	0.7330
High Dose	7	10.73 (5.70)	13.05 (5.28)	14.9	1.4, 16.0	2.32 (6.61)	0.0	-5.6, 14.9	0.3884
WEEK 60	11	10.81 (5.72)	13.49 (3.14)	15.5	8.2, 16.0	2.68 (4.52)	0.3	-0.5, 13.9	0.0777
Low Dose	7	10.58 (6.76)	13.82 (3.48)	15.8	8.2, 16.0	3.24 (5.57)	0.0	-0.5, 13.9	0.1748
High Dose	4	11.21 (4.16)	12.90 (2.81)	13.2	9.2, 16.0	1.69 (1.94)	1.3	0.0, 4.2	0.1798
WEEK 72	5	12.98 (4.02)	14.20 (2.02)	15.2	11.9, 16.0	1.22 (2.06)	0.0	-0.8, 3.6	0.2559
Low Dose	4	14.10 (3.63)	14.71 (1.92)	15.5	11.9, 16.0	0.61 (1.78)	0.0	-0.8, 3.2	0.5424
High Dose	1	8.50 (N/A)	12.15 (N/A)	12.1	12.1, 12.1	3.65 (N/A)	3.6	3.6, 3.6	
WEEK 84	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Female (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	33		1.76 (3.62)	0.0	0.0, 12.9				
Low Dose	23		1.56 (3.43)	0.0	0.0, 12.0				
High Dose	10		2.23 (4.16)	0.4	0.0, 12.9				
WEEK 12	29	1.57 (3.30)	1.63 (3.12)	0.0	0.0, 11.6	0.06 (3.84)	0.0	-11.6, 11.6	0.9292
Low Dose	22	1.08 (2.63)	1.63 (3.36)	0.0	0.0, 11.6	0.55 (4.09)	0.0	-11.6, 11.6	0.5357
High Dose	7	3.08 (4.80)	1.62 (2.46)	0.0	0.0, 6.1	-1.46 (2.62)	-0.6	-6.9, 1.0	0.1903
WEEK 24	27	2.13 (3.91)	0.66 (1.45)	0.0	0.0, 5.7	-1.47 (4.06)	0.0	-12.9, 4.5	0.0717
Low Dose	18	1.95 (3.81)	0.84 (1.71)	0.0	0.0, 5.7	-1.11 (4.04)	0.0	-12.0, 4.5	0.2605
High Dose	9	2.48 (4.33)	0.29 (0.63)	0.0	0.0, 1.8	-2.19 (4.25)	-0.2	-12.9, 0.1	0.1613
WEEK 36	15	2.28 (4.37)	0.29 (0.80)	0.0	0.0, 3.1	-2.00 (4.52)	0.0	-12.9, 2.9	0.1090
Low Dose	10	1.33 (3.71)	0.09 (0.22)	0.0	0.0, 0.7	-1.23 (3.63)	0.0	-11.6, 0.0	0.3120
High Dose	5	4.20 (5.39)	0.67 (1.37)	0.0	0.0, 3.1	-3.53 (6.12)	-2.0	-12.9, 2.9	0.2661

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Gender:Female (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 48	17	2.75 (4.75)	0.75 (1.94)	0.0	0.0, 8.0	-2.01 (5.16)	0.0	-12.9, 8.0	0.1281
Low Dose	10	2.53 (4.96)	1.16 (2.48)	0.0	0.0, 8.0	-1.36 (5.51)	0.0	-11.1, 8.0	0.4539
High Dose	7	3.08 (4.80)	0.15 (0.29)	0.0	0.0, 0.8	-2.93 (4.87)	-0.6	-12.9, 0.1	0.1627
WEEK 60	11	2.58 (4.67)	0.83 (1.42)	0.0	0.0, 4.7	-1.76 (3.87)	0.0	-11.3, 1.1	0.1634
Low Dose	7	3.61 (5.69)	0.87 (1.71)	0.0	0.0, 4.7	-2.74 (4.63)	0.0	-11.3, 0.0	0.1689
High Dose	4	0.79 (1.01)	0.75 (0.92)	0.6	0.0, 1.9	-0.04 (0.91)	-0.1	-1.1, 1.1	0.9405
WEEK 72	5	0.44 (0.65)	0.53 (0.94)	0.0	0.0, 2.2	0.09 (0.86)	0.0	-1.0, 1.4	0.8309
Low Dose	4	0.36 (0.72)	0.11 (0.23)	0.0	0.0, 0.5	-0.25 (0.49)	0.0	-1.0, 0.0	0.3910
High Dose	1	0.75 (N/A)	2.18 (N/A)	2.2	2.2, 2.2	1.43 (N/A)	1.4	1.4, 1.4	
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Female (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	33		0.73 (2.58)	0.0	0.0, 13.5				
Low Dose	23		0.78 (2.85)	0.0	0.0, 13.5				
High Dose	10		0.63 (1.98)	0.0	0.0, 6.3				
WEEK 12	29	0.62 (2.54)	0.03 (0.13)	0.0	0.0, 0.7	-0.59 (2.55)	0.0	-13.5, 0.7	0.2265
Low Dose	22	0.81 (2.91)	0.04 (0.15)	0.0	0.0, 0.7	-0.77 (2.92)	0.0	-13.5, 0.7	0.2285
High Dose	7	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
WEEK 24	27	0.39 (1.30)	0.59 (2.00)	0.0	0.0, 7.8	0.20 (1.36)	0.0	-2.7, 6.4	0.4550
Low Dose	18	0.24 (0.70)	0.49 (1.84)	0.0	0.0, 7.8	0.25 (1.66)	0.0	-2.7, 6.4	0.5389
High Dose	9	0.69 (2.08)	0.80 (2.39)	0.0	0.0, 7.2	0.10 (0.31)	0.0	0.0, 0.9	0.3466
WEEK 36	15	0.18 (0.69)	0.03 (0.12)	0.0	0.0, 0.5	-0.15 (0.71)	0.0	-2.7, 0.5	0.4331
Low Dose	10	0.27 (0.84)	0.05 (0.14)	0.0	0.0, 0.5	-0.22 (0.87)	0.0	-2.7, 0.5	0.4432
High Dose	5	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Gender:Female (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 48	17	0.16 (0.65)	0.01 (0.06)	0.0	0.0, 0.2	-0.14 (0.65)	0.0	-2.7, 0.2	0.3783
Low Dose	10	0.27 (0.84)	0.02 (0.07)	0.0	0.0, 0.2	-0.24 (0.85)	0.0	-2.7, 0.2	0.3903
High Dose	7	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
WEEK 60	11	0.81 (1.97)	0.07 (0.22)	0.0	0.0, 0.7	-0.74 (2.02)	0.0	-6.3, 0.7	0.2485
Low Dose	7	0.38 (1.01)	0.00 (0.00)	0.0	0.0, 0.0	-0.38 (1.01)	0.0	-2.7, 0.0	0.3559
High Dose	4	1.56 (3.13)	0.18 (0.36)	0.0	0.0, 0.7	-1.38 (3.26)	0.0	-6.3, 0.7	0.4597
WEEK 72	5	1.25 (2.80)	0.34 (0.75)	0.0	0.0, 1.7	-0.91 (2.05)	0.0	-4.6, 0.0	0.3739
Low Dose	4	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	1	6.25 (N/A)	1.68 (N/A)	1.7	1.7, 1.7	-4.57 (N/A)	-4.6	-4.6, -4.6	
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Female (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	33		13.36 (3.17)	14.8	2.5, 16.0				
Low Dose	23		13.17 (3.26)	13.3	2.5, 16.0				
High Dose	10		13.79 (3.10)	15.1	7.2, 16.0				
WEEK 12	29	13.32 (3.23)	13.34 (2.47)	13.8	5.1, 16.0	0.02 (3.73)	-0.0	-10.9, 11.6	0.9731
Low Dose	22	13.16 (3.33)	13.75 (1.94)	14.0	9.9, 16.0	0.59 (3.05)	0.0	-3.8, 11.6	0.3739
High Dose	7	13.81 (3.05)	12.05 (3.56)	13.7	5.1, 15.8	-1.76 (5.25)	-1.3	-10.9, 6.4	0.4094
WEEK 24	27	13.49 (2.63)	11.71 (4.75)	13.5	0.0, 16.0	-1.78 (3.35)	-0.2	-13.3, 2.7	0.0107*
Low Dose	18	13.46 (2.40)	11.91 (4.82)	14.1	0.0, 16.0	-1.55 (3.81)	-0.0	-13.3, 2.7	0.1024
High Dose	9	13.55 (3.18)	11.32 (4.86)	13.3	2.6, 16.0	-2.23 (2.31)	-2.2	-6.2, 0.0	0.0202*
WEEK 36	15	13.95 (2.85)	14.56 (2.04)	15.5	9.1, 16.0	0.61 (1.98)	0.0	-1.4, 5.5	0.2550
Low Dose	10	14.24 (2.55)	14.89 (2.17)	15.9	9.1, 16.0	0.65 (2.03)	0.0	-1.4, 5.5	0.3359
High Dose	5	13.38 (3.63)	13.89 (1.76)	14.0	11.1, 16.0	0.51 (2.10)	0.0	-1.2, 3.9	0.6134

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Gender:Female (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 48	17	14.14 (2.36)	13.55 (4.09)	15.3	1.7, 16.0	-0.59 (2.59)	0.0	-7.4, 2.7	0.3580
Low Dose	10	14.37 (1.89)	13.79 (3.45)	15.6	5.9, 16.0	-0.59 (2.76)	0.0	-7.4, 2.7	0.5188
High Dose	7	13.81 (3.05)	13.21 (5.15)	14.9	1.7, 16.0	-0.60 (2.53)	0.0	-5.5, 2.0	0.5509
WEEK 60	11	13.40 (3.14)	14.32 (2.65)	15.8	9.1, 16.0	0.92 (1.84)	0.0	-1.0, 5.3	0.1277
Low Dose	7	14.19 (2.14)	14.69 (2.59)	16.0	9.1, 16.0	0.50 (1.18)	0.0	-1.0, 2.7	0.2995
High Dose	4	12.00 (4.42)	13.65 (3.01)	14.7	9.2, 16.0	1.65 (2.72)	1.0	-0.7, 5.3	0.3119
WEEK 72	5	13.42 (3.43)	14.73 (1.48)	15.2	12.3, 16.0	1.31 (2.39)	0.0	-0.8, 5.1	0.2890
Low Dose	4	14.47 (2.91)	14.83 (1.69)	15.5	12.3, 16.0	0.36 (1.30)	0.0	-0.8, 2.2	0.6160
High Dose	1	9.25 (N/A)	14.32 (N/A)	14.3	14.3, 14.3	5.07 (N/A)	5.1	5.1, 5.1	
WEEK 84	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Male									
Average Daily Normalized 'Off' Time									
BASELINE	64		2.88 (3.19)	1.6	0.0, 11.5				
Low Dose	22		3.87 (3.27)	2.8	0.0, 10.9				
High Dose	42		2.36 (3.06)	0.5	0.0, 11.5				
WEEK 12	46	3.33 (3.45)	3.21 (3.03)	2.6	0.0, 10.8	-0.12 (2.37)	0.0	-8.2, 6.8	0.7345
Low Dose	16	4.34 (3.59)	3.23 (2.73)	2.7	0.0, 8.0	-1.10 (2.78)	-0.1	-8.2, 2.7	0.1340
High Dose	30	2.79 (3.30)	3.19 (3.23)	2.2	0.0, 10.8	0.41 (1.96)	0.0	-4.3, 6.8	0.2673
WEEK 24	48	2.49 (2.76)	2.79 (3.07)	2.3	0.0, 10.9	0.30 (2.71)	0.0	-6.1, 7.7	0.4402
Low Dose	18	3.75 (2.91)	2.85 (2.89)	2.5	0.0, 10.8	-0.90 (2.83)	-0.3	-6.1, 4.3	0.1923
High Dose	30	1.73 (2.40)	2.75 (3.22)	2.3	0.0, 10.9	1.03 (2.39)	0.0	-3.3, 7.7	0.0256*
WEEK 36	24	2.52 (2.52)	2.93 (2.90)	2.7	0.0, 12.1	0.41 (1.89)	0.1	-3.5, 5.6	0.3029
Low Dose	11	3.38 (2.20)	4.08 (3.36)	3.6	0.0, 12.1	0.70 (1.78)	0.3	-1.1, 5.6	0.2214
High Dose	13	1.79 (2.63)	1.95 (2.11)	1.0	0.0, 6.1	0.16 (2.01)	0.0	-3.5, 3.9	0.7829

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Gender:Male (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 48	35	2.17 (2.45)	2.99 (3.36)	1.7	0.0, 11.0	0.82 (2.22)	0.0	-3.0, 6.6	0.0352*
Low Dose	11	2.79 (2.50)	2.43 (2.96)	1.7	0.0, 9.0	-0.36 (1.57)	-0.0	-3.0, 2.5	0.4685
High Dose	24	1.88 (2.42)	3.24 (3.56)	1.9	0.0, 11.0	1.36 (2.28)	0.5	-1.1, 6.6	0.0076**
WEEK 60	18	2.99 (2.50)	3.90 (2.64)	3.4	0.0, 10.4	0.91 (1.85)	1.1	-3.0, 3.9	0.0519
Low Dose	9	3.68 (2.24)	4.07 (3.11)	3.7	0.0, 10.4	0.38 (2.06)	-0.2	-3.0, 3.9	0.5918
High Dose	9	2.30 (2.69)	3.74 (2.25)	3.1	0.0, 7.1	1.44 (1.55)	2.0	-1.3, 3.9	0.0238*
WEEK 72	7	3.27 (2.60)	5.09 (3.29)	3.9	1.7, 10.4	1.82 (2.84)	2.2	-1.7, 5.5	0.1397
Low Dose	2	3.40 (1.10)	2.73 (1.40)	2.7	1.7, 3.7	-0.67 (0.29)	-0.7	-0.9, -0.5	0.1909
High Dose	5	3.21 (3.14)	6.04 (3.44)	5.5	1.9, 10.4	2.82 (2.77)	3.9	-1.7, 5.5	0.0851
WEEK 84	1	6.13 (N/A)	11.43 (N/A)	11.4	11.4, 11.4	5.30 (N/A)	5.3	5.3, 5.3	
Low Dose	0								
High Dose	1	6.13 (N/A)	11.43 (N/A)	11.4	11.4, 11.4	5.30 (N/A)	5.3	5.3, 5.3	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Male (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	64		10.17 (4.77)	11.0	0.0, 16.0				
Low Dose	22		9.99 (3.91)	10.6	0.0, 15.3				
High Dose	42		10.27 (5.21)	11.2	0.0, 16.0				
WEEK 12	46	9.98 (4.96)	10.27 (4.89)	10.8	0.0, 16.0	0.30 (3.46)	0.0	-9.6, 9.0	0.5639
Low Dose	16	9.37 (4.24)	9.89 (5.29)	11.1	0.0, 16.0	0.52 (3.81)	0.6	-6.7, 8.2	0.5913
High Dose	30	10.30 (5.34)	10.48 (4.74)	10.8	0.0, 16.0	0.18 (3.31)	0.0	-9.6, 9.0	0.7740
WEEK 24	48	10.27 (4.75)	10.31 (4.46)	10.4	0.0, 16.0	0.04 (4.19)	0.0	-9.6, 13.7	0.9469
Low Dose	18	9.78 (3.81)	9.95 (4.83)	10.5	0.0, 16.0	0.17 (3.71)	-0.1	-5.9, 7.4	0.8484
High Dose	30	10.57 (5.28)	10.53 (4.30)	10.4	0.0, 16.0	-0.04 (4.52)	0.0	-9.6, 13.7	0.9644
WEEK 36	24	11.31 (3.94)	9.73 (4.95)	11.0	0.0, 16.0	-1.59 (3.09)	-0.4	-11.2, 2.4	0.0193*
Low Dose	11	11.39 (2.53)	9.99 (4.74)	11.1	1.3, 16.0	-1.40 (2.48)	-0.4	-5.9, 1.4	0.0910
High Dose	13	11.25 (4.94)	9.50 (5.30)	9.9	0.0, 16.0	-1.75 (3.62)	-0.2	-11.2, 2.4	0.1077

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Gender:Male (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 48	35	10.05 (4.76)	10.09 (4.66)	10.2	0.0, 16.0	0.04 (3.64)	0.2	-9.4, 7.9	0.9428
Low Dose	11	9.90 (4.15)	10.15 (5.38)	10.2	1.1, 16.0	0.25 (3.57)	0.4	-5.1, 7.4	0.8208
High Dose	24	10.12 (5.10)	10.07 (4.42)	10.4	0.0, 16.0	-0.05 (3.75)	0.0	-9.4, 7.9	0.9487
WEEK 60	18	9.75 (4.46)	9.23 (3.80)	9.3	0.8, 16.0	-0.52 (3.45)	-1.1	-6.1, 6.3	0.5291
Low Dose	9	10.30 (2.29)	8.32 (3.82)	9.5	0.8, 13.6	-1.98 (3.07)	-2.5	-6.1, 4.9	0.0896
High Dose	9	9.21 (6.03)	10.14 (3.76)	9.1	4.3, 16.0	0.93 (3.34)	0.3	-3.9, 6.3	0.4268
WEEK 72	7	9.52 (4.56)	8.90 (4.78)	9.8	1.4, 14.1	-0.62 (5.97)	-0.4	-9.9, 9.8	0.7934
Low Dose	2	12.60 (1.10)	12.66 (0.52)	12.7	12.3, 13.0	0.05 (0.58)	0.1	-0.4, 0.5	0.9198
High Dose	5	8.28 (4.92)	7.39 (4.93)	7.5	1.4, 14.1	-0.89 (7.29)	-2.2	-9.9, 9.8	0.7991
WEEK 84	1	8.05 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-3.48 (N/A)	-3.5	-3.5, -3.5	
Low Dose	0								
High Dose	1	8.05 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-3.48 (N/A)	-3.5	-3.5, -3.5	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Male (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	64		2.59 (4.39)	0.5	0.0, 16.0				
Low Dose	22		1.96 (3.66)	0.6	0.0, 16.0				
High Dose	42		2.91 (4.74)	0.4	0.0, 16.0				
WEEK 12	46	2.24 (4.38)	1.96 (3.82)	0.0	0.0, 16.0	-0.28 (3.76)	0.0	-15.8, 6.7	0.6107
Low Dose	16	2.05 (4.11)	1.91 (3.26)	0.2	0.0, 12.4	-0.14 (3.51)	0.0	-11.0, 5.7	0.8746
High Dose	30	2.35 (4.58)	1.99 (4.14)	0.0	0.0, 16.0	-0.36 (3.94)	0.0	-15.8, 6.7	0.6202
WEEK 24	48	2.82 (4.38)	2.60 (4.01)	0.8	0.0, 16.0	-0.22 (3.72)	0.0	-16.0, 6.2	0.6850
Low Dose	18	2.27 (3.98)	3.04 (4.54)	1.5	0.0, 16.0	0.77 (2.63)	0.0	-4.2, 6.2	0.2329
High Dose	30	3.14 (4.64)	2.33 (3.71)	0.0	0.0, 16.0	-0.81 (4.17)	0.0	-16.0, 6.1	0.2959
WEEK 36	24	1.84 (2.83)	3.08 (4.81)	0.5	0.0, 16.0	1.24 (2.75)	0.0	-1.4, 11.2	0.0372*
Low Dose	11	1.21 (2.06)	1.82 (3.28)	0.5	0.0, 11.1	0.61 (1.52)	0.2	-1.4, 4.4	0.2116
High Dose	13	2.37 (3.33)	4.15 (5.71)	0.5	0.0, 16.0	1.77 (3.45)	0.0	-1.0, 11.2	0.0885

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Male (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 48	35	3.35 (4.71)	2.47 (3.70)	0.7	0.0, 14.9	-0.88 (3.62)	0.0	-12.8, 5.2	0.1577
Low Dose	11	2.98 (4.79)	3.33 (5.31)	0.9	0.0, 14.9	0.35 (2.33)	-0.3	-3.5, 5.2	0.6322
High Dose	24	3.52 (4.77)	2.07 (2.74)	0.6	0.0, 9.8	-1.45 (4.00)	0.0	-12.8, 4.9	0.0889
WEEK 60	18	2.78 (4.38)	2.68 (3.12)	2.0	0.0, 11.6	-0.10 (3.74)	0.0	-10.2, 5.7	0.9068
Low Dose	9	1.65 (2.35)	3.52 (3.70)	2.1	0.0, 11.6	1.87 (2.68)	2.1	-3.5, 5.7	0.0700
High Dose	9	3.91 (5.69)	1.83 (2.31)	0.0	0.0, 5.8	-2.08 (3.71)	-0.7	-10.2, 1.0	0.1312
WEEK 72	7	3.22 (5.90)	1.23 (1.50)	1.2	0.0, 4.2	-1.99 (5.43)	0.0	-14.2, 1.2	0.3703
Low Dose	2	0.00 (0.00)	0.62 (0.88)	0.6	0.0, 1.2	0.62 (0.88)	0.6	0.0, 1.2	0.5000
High Dose	5	4.51 (6.71)	1.48 (1.71)	1.5	0.0, 4.2	-3.03 (6.27)	-0.4	-14.2, 0.0	0.3406
WEEK 84	1	1.82 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-1.82 (N/A)	-1.8	-1.8, -1.8	
Low Dose	0								
High Dose	1	1.82 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-1.82 (N/A)	-1.8	-1.8, -1.8	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Male (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	64		0.36 (0.97)	0.0	0.0, 5.3				
Low Dose	22		0.17 (0.71)	0.0	0.0, 3.3				
High Dose	42		0.45 (1.07)	0.0	0.0, 5.3				
WEEK 12	46	0.45 (1.10)	0.56 (1.88)	0.0	0.0, 11.0	0.11 (2.14)	0.0	-5.3, 11.0	0.7355
Low Dose	16	0.24 (0.82)	0.96 (2.90)	0.0	0.0, 11.0	0.72 (3.07)	0.0	-3.3, 11.0	0.3625
High Dose	30	0.57 (1.23)	0.35 (1.02)	0.0	0.0, 4.4	-0.22 (1.38)	0.0	-5.3, 3.0	0.3878
WEEK 24	48	0.43 (1.10)	0.30 (0.83)	0.0	0.0, 4.3	-0.13 (1.31)	0.0	-5.3, 4.3	0.5102
Low Dose	18	0.20 (0.78)	0.17 (0.35)	0.0	0.0, 1.1	-0.03 (0.90)	0.0	-3.3, 1.1	0.8776
High Dose	30	0.56 (1.24)	0.38 (1.01)	0.0	0.0, 4.3	-0.18 (1.51)	0.0	-5.3, 4.3	0.5186
WEEK 36	24	0.33 (1.16)	0.27 (0.71)	0.0	0.0, 2.8	-0.06 (1.21)	0.0	-5.3, 1.8	0.8097
Low Dose	11	0.03 (0.09)	0.11 (0.37)	0.0	0.0, 1.2	0.08 (0.38)	0.0	-0.3, 1.2	0.4834
High Dose	13	0.59 (1.56)	0.40 (0.89)	0.0	0.0, 2.8	-0.18 (1.63)	0.0	-5.3, 1.8	0.6936

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Gender:Male (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 48	35	0.43 (0.94)	0.45 (1.20)	0.0	0.0, 6.2	0.02 (1.48)	0.0	-3.3, 6.2	0.9437
Low Dose	11	0.33 (0.99)	0.09 (0.22)	0.0	0.0, 0.7	-0.24 (1.05)	0.0	-3.3, 0.7	0.4665
High Dose	24	0.48 (0.94)	0.62 (1.42)	0.0	0.0, 6.2	0.14 (1.64)	0.0	-3.0, 6.2	0.6897
WEEK 60	18	0.47 (0.98)	0.19 (0.42)	0.0	0.0, 1.5	-0.28 (1.02)	0.0	-3.3, 1.5	0.2545
Low Dose	9	0.37 (1.10)	0.09 (0.21)	0.0	0.0, 0.6	-0.27 (1.16)	0.0	-3.3, 0.6	0.4984
High Dose	9	0.57 (0.90)	0.28 (0.56)	0.0	0.0, 1.5	-0.29 (0.94)	0.0	-1.5, 1.5	0.3733
WEEK 72	7	0.00 (0.00)	0.78 (1.85)	0.0	0.0, 5.0	0.78 (1.85)	0.0	0.0, 5.0	0.3065
Low Dose	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	5	0.00 (0.00)	1.10 (2.17)	0.0	0.0, 5.0	1.10 (2.17)	0.0	0.0, 5.0	0.3226
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	0								
High Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Gender:Male (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	64		12.76 (3.25)	13.6	4.5, 16.0				
Low Dose	22		11.95 (3.18)	12.7	5.1, 16.0				
High Dose	42		13.18 (3.24)	14.9	4.5, 16.0				
WEEK 12	46	12.22 (3.47)	12.23 (3.39)	12.9	5.0, 16.0	0.01 (3.13)	0.0	-11.0, 8.2	0.9794
Low Dose	16	11.42 (3.44)	11.81 (3.55)	12.9	5.0, 16.0	0.38 (4.28)	0.2	-11.0, 8.2	0.7263
High Dose	30	12.65 (3.47)	12.46 (3.34)	13.0	5.2, 16.0	-0.19 (2.36)	0.0	-6.8, 5.3	0.6695
WEEK 24	48	13.09 (2.83)	12.91 (3.08)	13.7	5.1, 16.0	-0.18 (2.82)	0.0	-7.7, 6.1	0.6630
Low Dose	18	12.05 (2.79)	12.99 (2.95)	13.5	5.2, 16.0	0.94 (2.90)	0.5	-4.3, 6.1	0.1884
High Dose	30	13.71 (2.72)	12.86 (3.20)	13.7	5.1, 16.0	-0.85 (2.60)	-0.5	-7.7, 3.3	0.0843
WEEK 36	24	13.15 (2.65)	12.81 (2.85)	12.5	3.9, 16.0	-0.35 (2.13)	0.0	-5.6, 4.3	0.4334
Low Dose	11	12.59 (2.18)	11.81 (3.37)	12.4	3.9, 16.0	-0.79 (1.86)	-0.3	-5.6, 1.1	0.1905
High Dose	13	13.62 (3.00)	13.65 (2.10)	14.2	9.9, 16.0	0.03 (2.34)	0.0	-3.9, 4.3	0.9695

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Gender:Male (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 48	35	13.40 (2.62)	12.56 (3.39)	13.7	5.0, 16.0	-0.84 (2.73)	-0.2	-6.6, 3.8	0.0771
Low Dose	11	12.88 (2.38)	13.48 (3.00)	14.1	7.0, 16.0	0.60 (2.02)	0.0	-2.5, 3.8	0.3491
High Dose	24	13.64 (2.74)	12.14 (3.53)	12.8	5.0, 16.0	-1.50 (2.79)	-0.5	-6.6, 2.3	0.0148*
WEEK 60	18	12.54 (2.62)	11.91 (2.66)	12.2	5.6, 16.0	-0.63 (1.95)	-0.5	-3.9, 3.0	0.1890
Low Dose	9	11.95 (1.91)	11.84 (3.04)	12.3	5.6, 16.0	-0.11 (2.05)	-0.1	-3.9, 3.0	0.8768
High Dose	9	13.12 (3.18)	11.98 (2.41)	12.1	7.8, 16.0	-1.15 (1.80)	-0.7	-3.9, 1.3	0.0926
WEEK 72	7	12.73 (2.60)	10.13 (3.83)	11.6	5.6, 14.3	-2.61 (4.22)	-2.2	-10.4, 1.7	0.1535
Low Dose	2	12.60 (1.10)	13.27 (1.40)	13.3	12.3, 14.3	0.67 (0.29)	0.7	0.5, 0.9	0.1909
High Dose	5	12.79 (3.14)	8.87 (3.81)	7.5	5.6, 14.1	-3.92 (4.38)	-4.3	-10.4, 1.7	0.1162
WEEK 84	1	9.87 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-5.30 (N/A)	-5.3	-5.3, -5.3	
Low Dose	0								
High Dose	1	9.87 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-5.30 (N/A)	-5.3	-5.3, -5.3	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:WHITE									
Average Daily Normalized 'Off' Time									
BASELINE	82		2.17 (2.85)	0.7	0.0, 11.5				
Low Dose	36		2.52 (2.76)	2.0	0.0, 10.9				
High Dose	46		1.90 (2.92)	0.5	0.0, 11.5				
WEEK 12	60	2.39 (3.09)	2.49 (2.74)	2.0	0.0, 10.9	0.10 (2.69)	0.0	-8.2, 10.9	0.7750
Low Dose	29	2.49 (2.98)	2.04 (1.97)	1.9	0.0, 7.3	-0.45 (2.19)	0.0	-8.2, 2.8	0.2779
High Dose	31	2.29 (3.24)	2.91 (3.28)	2.0	0.0, 10.9	0.61 (3.03)	0.0	-6.4, 10.9	0.2676
WEEK 24	64	1.93 (2.39)	2.74 (3.58)	1.2	0.0, 16.0	0.82 (2.97)	0.0	-6.0, 13.3	0.0312*
Low Dose	29	2.53 (2.47)	2.78 (3.91)	1.2	0.0, 16.0	0.25 (3.57)	0.0	-6.0, 13.3	0.7082
High Dose	35	1.43 (2.23)	2.71 (3.35)	1.7	0.0, 13.4	1.29 (2.31)	0.0	-3.1, 7.7	0.0023**
WEEK 36	33	1.87 (2.48)	2.17 (2.77)	1.2	0.0, 12.1	0.30 (1.46)	0.0	-3.9, 5.6	0.2546
Low Dose	19	2.27 (2.45)	2.67 (3.29)	1.9	0.0, 12.1	0.41 (1.40)	0.0	-1.1, 5.6	0.2227
High Dose	14	1.34 (2.51)	1.49 (1.74)	0.9	0.0, 4.9	0.15 (1.59)	0.0	-3.9, 3.6	0.7357

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:WHITE (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 48	47	1.80 (2.31)	2.62 (3.69)	0.9	0.0, 14.3	0.82 (2.31)	0.0	-3.0, 7.4	0.0187*
Low Dose	20	2.10 (2.36)	2.32 (3.19)	0.5	0.0, 10.1	0.22 (2.18)	0.0	-3.0, 7.4	0.6560
High Dose	27	1.59 (2.29)	2.85 (4.07)	1.1	0.0, 14.3	1.27 (2.35)	0.2	-2.0, 6.6	0.0094**
WEEK 60	25	2.40 (2.70)	2.74 (2.90)	2.4	0.0, 10.4	0.34 (1.52)	0.0	-3.0, 3.9	0.2685
Low Dose	15	2.72 (2.52)	2.80 (3.24)	2.0	0.0, 10.4	0.09 (1.61)	-0.0	-3.0, 3.9	0.8399
High Dose	10	1.92 (3.02)	2.65 (2.48)	2.5	0.0, 6.9	0.73 (1.36)	0.7	-2.0, 2.4	0.1220
WEEK 72	10	1.70 (2.19)	2.14 (1.93)	1.8	0.0, 5.5	0.44 (2.42)	-0.2	-2.2, 5.5	0.5796
Low Dose	6	2.16 (2.50)	1.69 (1.66)	1.3	0.0, 3.7	-0.47 (1.03)	-0.2	-2.2, 0.8	0.3183
High Dose	4	1.01 (1.71)	2.81 (2.37)	2.9	0.0, 5.5	1.80 (3.42)	1.7	-1.7, 5.5	0.3700
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:WHITE (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	82		10.87 (5.00)	12.4	0.0, 16.0				
Low Dose	36		11.18 (4.57)	12.7	0.0, 16.0				
High Dose	46		10.63 (5.35)	12.0	0.0, 16.0				
WEEK 12	60	10.96 (5.13)	11.52 (4.43)	12.6	0.0, 16.0	0.56 (3.76)	0.0	-10.9, 14.2	0.2564
Low Dose	29	11.42 (4.64)	12.15 (4.16)	13.3	0.0, 16.0	0.73 (3.79)	0.0	-6.6, 14.2	0.3075
High Dose	31	10.53 (5.59)	10.92 (4.65)	11.1	0.0, 16.0	0.39 (3.78)	0.0	-10.9, 9.0	0.5685
WEEK 24	64	10.98 (4.91)	11.14 (4.69)	11.9	0.0, 16.0	0.16 (4.60)	0.0	-13.3, 14.2	0.7802
Low Dose	29	11.16 (4.49)	11.40 (5.03)	13.6	0.0, 16.0	0.25 (4.70)	0.0	-13.3, 14.2	0.7804
High Dose	35	10.83 (5.30)	10.92 (4.45)	11.3	0.0, 16.0	0.09 (4.59)	0.0	-9.6, 13.7	0.9070
WEEK 36	33	11.90 (4.50)	11.96 (4.63)	14.0	0.0, 16.0	0.06 (4.51)	0.0	-11.2, 14.2	0.9349
Low Dose	19	12.54 (3.75)	12.72 (3.84)	14.0	3.4, 16.0	0.19 (3.77)	0.0	-5.9, 14.2	0.8321
High Dose	14	11.03 (5.39)	10.93 (5.52)	12.9	0.0, 16.0	-0.10 (5.51)	0.0	-11.2, 14.0	0.9469

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:WHITE (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 48	47	10.65 (5.14)	11.40 (4.58)	12.4	0.0, 16.0	0.74 (4.92)	0.0	-9.4, 14.9	0.3070
Low Dose	20	11.03 (5.09)	11.81 (4.33)	12.6	1.1, 16.0	0.78 (5.31)	0.1	-8.0, 13.7	0.5180
High Dose	27	10.38 (5.25)	11.09 (4.82)	12.4	0.0, 16.0	0.71 (4.72)	0.0	-9.4, 14.9	0.4401
WEEK 60	25	10.38 (4.94)	11.56 (3.55)	10.9	4.5, 16.0	1.18 (4.10)	0.0	-4.7, 13.9	0.1627
Low Dose	15	10.66 (4.66)	11.39 (3.81)	10.3	4.5, 16.0	0.74 (4.82)	-0.5	-4.7, 13.9	0.5641
High Dose	10	9.97 (5.57)	11.82 (3.30)	12.9	6.3, 16.0	1.85 (2.79)	1.2	-2.0, 6.3	0.0659
WEEK 72	10	11.39 (4.86)	12.17 (4.25)	12.7	1.4, 16.0	0.78 (4.89)	0.2	-9.9, 9.8	0.6255
Low Dose	6	13.60 (2.96)	14.03 (1.84)	14.1	11.9, 16.0	0.42 (1.43)	0.0	-0.8, 3.2	0.5010
High Dose	4	8.06 (5.62)	9.38 (5.58)	11.0	1.4, 14.1	1.32 (8.22)	2.7	-9.9, 9.8	0.7699
WEEK 84	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:WHITE (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	82		2.44 (4.41)	0.1	0.0, 16.0				
Low Dose	36		1.74 (3.77)	0.0	0.0, 16.0				
High Dose	46		2.99 (4.83)	0.3	0.0, 16.0				
WEEK 12	60	2.08 (4.34)	1.70 (3.55)	0.0	0.0, 16.0	-0.39 (4.01)	0.0	-15.8, 11.6	0.4585
Low Dose	29	1.40 (3.59)	1.40 (2.82)	0.0	0.0, 11.6	-0.00 (4.15)	0.0	-11.6, 11.6	0.9982
High Dose	31	2.73 (4.91)	1.98 (4.14)	0.0	0.0, 16.0	-0.75 (3.92)	0.0	-15.8, 6.7	0.2968
WEEK 24	64	2.67 (4.45)	1.80 (3.41)	0.0	0.0, 16.0	-0.86 (4.09)	0.0	-16.0, 6.2	0.0958
Low Dose	29	2.09 (4.13)	1.69 (3.34)	0.0	0.0, 16.0	-0.40 (3.73)	0.0	-12.0, 6.2	0.5679
High Dose	35	3.15 (4.71)	1.90 (3.52)	0.0	0.0, 16.0	-1.25 (4.37)	0.0	-16.0, 6.1	0.1007
WEEK 36	33	1.98 (3.59)	1.75 (3.95)	0.0	0.0, 16.0	-0.23 (4.07)	0.0	-12.9, 11.2	0.7450
Low Dose	19	1.04 (2.73)	0.52 (0.96)	0.0	0.0, 3.0	-0.52 (2.76)	0.0	-11.6, 1.8	0.4188
High Dose	14	3.25 (4.29)	3.41 (5.66)	0.1	0.0, 16.0	0.16 (5.47)	0.0	-12.9, 11.2	0.9127

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:WHITE (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 48	47	3.21 (4.85)	1.70 (3.11)	0.0	0.0, 14.9	-1.52 (4.24)	0.0	-12.9, 8.0	0.0180*
Low Dose	20	2.57 (4.79)	1.82 (3.74)	0.0	0.0, 14.9	-0.75 (4.04)	0.0	-11.1, 8.0	0.4174
High Dose	27	3.69 (4.94)	1.61 (2.62)	0.2	0.0, 9.8	-2.08 (4.36)	-0.6	-12.9, 4.9	0.0199*
WEEK 60	25	2.61 (4.64)	1.57 (2.10)	0.5	0.0, 5.8	-1.04 (3.92)	0.0	-11.3, 5.7	0.1969
Low Dose	15	2.23 (4.09)	1.75 (2.15)	0.9	0.0, 5.8	-0.48 (4.17)	0.0	-11.3, 5.7	0.6634
High Dose	10	3.20 (5.54)	1.31 (2.11)	0.0	0.0, 5.8	-1.88 (3.56)	-0.4	-10.2, 1.1	0.1281
WEEK 72	10	2.29 (5.04)	0.98 (1.39)	0.2	0.0, 4.2	-1.31 (4.60)	0.0	-14.2, 1.4	0.3910
Low Dose	6	0.24 (0.59)	0.28 (0.50)	0.0	0.0, 1.2	0.04 (0.71)	0.0	-1.0, 1.2	0.8905
High Dose	4	5.36 (7.39)	2.02 (1.71)	2.0	0.0, 4.2	-3.34 (7.31)	-0.3	-14.2, 1.4	0.4285
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:WHITE (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	82		0.52 (1.82)	0.0	0.0, 13.5				
Low Dose	36		0.56 (2.33)	0.0	0.0, 13.5				
High Dose	46		0.48 (1.32)	0.0	0.0, 6.3				
WEEK 12	60	0.57 (1.97)	0.30 (1.49)	0.0	0.0, 11.0	-0.27 (2.50)	0.0	-13.5, 11.0	0.4084
Low Dose	29	0.69 (2.59)	0.41 (2.05)	0.0	0.0, 11.0	-0.28 (3.39)	0.0	-13.5, 11.0	0.6596
High Dose	31	0.45 (1.17)	0.19 (0.65)	0.0	0.0, 3.0	-0.26 (1.28)	0.0	-5.3, 3.0	0.2679
WEEK 24	64	0.43 (1.23)	0.31 (1.10)	0.0	0.0, 7.2	-0.12 (1.18)	0.0	-5.3, 4.3	0.4374
Low Dose	29	0.22 (0.77)	0.13 (0.30)	0.0	0.0, 1.1	-0.10 (0.86)	0.0	-3.3, 1.1	0.5532
High Dose	35	0.60 (1.49)	0.46 (1.45)	0.0	0.0, 7.2	-0.13 (1.41)	0.0	-5.3, 4.3	0.5830
WEEK 36	33	0.25 (1.02)	0.12 (0.39)	0.0	0.0, 1.8	-0.13 (1.12)	0.0	-5.3, 1.8	0.5181
Low Dose	19	0.16 (0.61)	0.09 (0.29)	0.0	0.0, 1.2	-0.07 (0.70)	0.0	-2.7, 1.2	0.6785
High Dose	14	0.38 (1.43)	0.17 (0.50)	0.0	0.0, 1.8	-0.21 (1.56)	0.0	-5.3, 1.8	0.6225

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Race:WHITE (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 48	47	0.33 (0.85)	0.28 (0.99)	0.0	0.0, 6.2	-0.05 (1.33)	0.0	-3.3, 6.2	0.8040
Low Dose	20	0.31 (0.92)	0.06 (0.17)	0.0	0.0, 0.7	-0.25 (0.96)	0.0	-3.3, 0.7	0.2521
High Dose	27	0.34 (0.82)	0.45 (1.28)	0.0	0.0, 6.2	0.10 (1.55)	0.0	-3.0, 6.2	0.7302
WEEK 60	25	0.60 (1.47)	0.12 (0.34)	0.0	0.0, 1.5	-0.48 (1.56)	0.0	-6.3, 1.5	0.1350
Low Dose	15	0.40 (1.06)	0.06 (0.16)	0.0	0.0, 0.6	-0.34 (1.09)	0.0	-3.3, 0.6	0.2460
High Dose	10	0.91 (1.97)	0.22 (0.49)	0.0	0.0, 1.5	-0.69 (2.14)	0.0	-6.3, 1.5	0.3303
WEEK 72	10	0.63 (1.98)	0.72 (1.58)	0.0	0.0, 5.0	0.09 (2.25)	0.0	-4.6, 5.0	0.9020
Low Dose	6	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	4	1.56 (3.13)	1.79 (2.23)	1.1	0.0, 5.0	0.23 (3.90)	0.3	-4.6, 5.0	0.9151
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:WHITE (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	82		13.31 (3.16)	14.6	2.5, 16.0				
Low Dose	36		12.92 (3.21)	13.4	2.5, 16.0				
High Dose	46		13.62 (3.12)	15.3	4.5, 16.0				
WEEK 12	60	13.04 (3.42)	13.21 (2.88)	13.9	5.0, 16.0	0.17 (3.52)	0.0	-11.0, 11.6	0.7106
Low Dose	29	12.82 (3.49)	13.55 (2.52)	13.9	5.0, 16.0	0.73 (3.74)	0.0	-11.0, 11.6	0.3021
High Dose	31	13.26 (3.39)	12.90 (3.20)	13.9	5.1, 16.0	-0.36 (3.28)	0.0	-10.9, 6.4	0.5509
WEEK 24	64	13.65 (2.52)	12.94 (3.69)	14.1	0.0, 16.0	-0.70 (3.12)	0.0	-13.3, 5.7	0.0765
Low Dose	29	13.25 (2.39)	13.09 (3.97)	14.8	0.0, 16.0	-0.16 (3.68)	0.0	-13.3, 5.7	0.8222
High Dose	35	13.98 (2.60)	12.82 (3.50)	13.7	2.6, 16.0	-1.16 (2.53)	-0.6	-7.7, 3.3	0.0107*
WEEK 36	33	13.88 (2.50)	13.71 (2.79)	14.3	3.9, 16.0	-0.17 (1.79)	0.0	-5.6, 4.3	0.5948
Low Dose	19	13.58 (2.38)	13.24 (3.35)	14.1	3.9, 16.0	-0.34 (1.63)	0.0	-5.6, 2.7	0.3791
High Dose	14	14.28 (2.69)	14.34 (1.67)	14.5	11.1, 16.0	0.06 (2.03)	0.0	-3.6, 4.3	0.9088

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Race:WHITE (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 48	47	13.87 (2.40)	13.09 (3.71)	14.9	1.7, 16.0	-0.77 (2.73)	0.0	-7.4, 3.8	0.0585
Low Dose	20	13.59 (2.30)	13.62 (3.23)	15.5	5.9, 16.0	0.03 (2.48)	0.0	-7.4, 3.8	0.9522
High Dose	27	14.07 (2.50)	12.70 (4.05)	14.8	1.7, 16.0	-1.37 (2.81)	-0.3	-6.6, 2.3	0.0174*
WEEK 60	25	13.00 (2.75)	13.14 (2.88)	13.6	5.6, 16.0	0.14 (1.99)	0.0	-3.9, 5.3	0.7302
Low Dose	15	12.88 (2.33)	13.14 (3.23)	14.0	5.6, 16.0	0.26 (1.71)	0.0	-3.9, 3.0	0.5717
High Dose	10	13.17 (3.42)	13.13 (2.44)	13.3	9.1, 16.0	-0.04 (2.43)	-0.3	-3.9, 5.3	0.9621
WEEK 72	10	13.68 (2.65)	13.15 (3.05)	14.2	5.6, 16.0	-0.53 (4.22)	0.2	-10.4, 5.1	0.7006
Low Dose	6	13.84 (2.50)	14.31 (1.66)	14.7	12.3, 16.0	0.47 (1.03)	0.2	-0.8, 2.2	0.3183
High Dose	4	13.42 (3.25)	11.40 (4.07)	12.8	5.6, 14.3	-2.02 (6.83)	-1.4	-10.4, 5.1	0.5954
WEEK 84	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:ASIAN									
Average Daily Normalized 'Off' Time									
BASELINE	15		4.63 (2.73)	5.3	0.0, 10.1				
Low Dose	9		4.63 (3.02)	5.3	0.0, 10.1				
High Dose	6		4.64 (2.49)	5.6	0.0, 6.4				
WEEK 12	15	4.63 (2.73)	4.96 (2.37)	5.5	0.0, 8.0	0.32 (2.20)	0.6	-4.2, 3.8	0.5779
Low Dose	9	4.63 (3.02)	4.56 (2.53)	4.5	0.0, 8.0	-0.06 (2.57)	0.0	-4.2, 3.8	0.9428
High Dose	6	4.64 (2.49)	5.54 (2.19)	5.6	2.1, 8.0	0.91 (1.55)	1.5	-2.1, 2.1	0.2112
WEEK 24	11	4.84 (2.76)	5.28 (2.84)	4.3	2.5, 10.9	0.44 (3.22)	2.0	-6.1, 4.5	0.6594
Low Dose	7	5.08 (2.83)	5.08 (2.39)	4.3	2.5, 8.8	-0.01 (3.33)	2.0	-6.1, 2.5	0.9967
High Dose	4	4.41 (2.99)	5.64 (3.89)	4.5	2.6, 10.9	1.22 (3.35)	1.8	-3.3, 4.5	0.5178
WEEK 36	6	4.46 (2.70)	3.32 (1.77)	3.5	1.2, 6.1	-1.14 (3.44)	-1.5	-5.5, 3.9	0.4526
Low Dose	2	4.55 (3.09)	2.41 (1.71)	2.4	1.2, 3.6	-2.15 (4.80)	-2.1	-5.5, 1.2	0.6410
High Dose	4	4.41 (2.99)	3.77 (1.85)	3.7	1.6, 6.1	-0.64 (3.32)	-1.5	-3.5, 3.9	0.7249

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Race:ASIAN (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 48	5	4.00 (2.75)	4.54 (1.70)	4.1	2.3, 6.9	0.53 (2.08)	-0.0	-1.0, 4.0	0.5993
Low Dose	1	2.37 (N/A)	2.32 (N/A)	2.3	2.3, 2.3	-0.04 (N/A)	-0.0	-0.0, -0.0	
High Dose	4	4.41 (2.99)	5.09 (1.35)	4.7	4.0, 6.9	0.67 (2.38)	-0.1	-1.0, 4.0	0.6101
WEEK 60	4	3.41 (2.78)	4.88 (1.57)	4.4	3.7, 7.1	1.47 (2.16)	1.6	-1.3, 3.9	0.2671
Low Dose	1	2.37 (N/A)	3.66 (N/A)	3.7	3.7, 3.7	1.30 (N/A)	1.3	1.3, 1.3	
High Dose	3	3.76 (3.29)	5.28 (1.65)	4.8	3.9, 7.1	1.52 (2.64)	2.0	-1.3, 3.9	0.4229
WEEK 72	2	6.26 (0.18)	9.47 (1.31)	9.5	8.5, 10.4	3.21 (1.49)	3.2	2.2, 4.3	0.2021
Low Dose	0								
High Dose	2	6.26 (0.18)	9.47 (1.31)	9.5	8.5, 10.4	3.21 (1.49)	3.2	2.2, 4.3	0.2021
WEEK 84	1	6.13 (N/A)	11.43 (N/A)	11.4	11.4, 11.4	5.30 (N/A)	5.3	5.3, 5.3	
Low Dose	0								
High Dose	1	6.13 (N/A)	11.43 (N/A)	11.4	11.4, 11.4	5.30 (N/A)	5.3	5.3, 5.3	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:ASIAN (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	15		9.49 (3.80)	9.3	4.0, 16.0				
Low Dose	9		9.39 (3.87)	9.3	4.2, 16.0				
High Dose	6		9.63 (4.06)	8.9	4.0, 16.0				
WEEK 12	15	9.49 (3.80)	8.09 (4.57)	8.0	1.0, 16.0	-1.39 (3.18)	-1.1	-6.7, 4.2	0.1113
Low Dose	9	9.39 (3.87)	8.06 (5.14)	8.0	1.0, 16.0	-1.33 (3.51)	-1.1	-6.7, 4.2	0.2893
High Dose	6	9.63 (4.06)	8.13 (4.00)	7.0	3.6, 13.9	-1.50 (2.93)	-1.3	-6.4, 2.1	0.2661
WEEK 24	11	8.83 (3.84)	7.31 (3.89)	8.1	1.0, 13.4	-1.52 (3.41)	-2.5	-5.9, 6.6	0.1713
Low Dose	7	8.49 (3.42)	6.78 (4.02)	8.1	1.0, 10.8	-1.72 (3.88)	-2.5	-5.9, 6.6	0.2859
High Dose	4	9.42 (4.99)	8.25 (4.04)	7.3	5.0, 13.4	-1.17 (2.91)	-0.8	-4.5, 1.6	0.4816
WEEK 36	6	8.97 (3.99)	8.78 (4.70)	9.0	1.3, 14.8	-0.20 (4.07)	0.2	-5.6, 5.5	0.9110
Low Dose	2	8.09 (1.66)	8.05 (9.55)	8.0	1.3, 14.8	-0.04 (7.89)	-0.0	-5.6, 5.5	0.9950
High Dose	4	9.42 (4.99)	9.14 (2.43)	9.0	6.4, 12.1	-0.27 (2.62)	0.2	-3.9, 2.4	0.8494

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Race:ASIAN (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 48	5	8.92 (4.46)	7.06 (4.21)	5.9	1.8, 12.0	-1.85 (3.15)	-3.1	-5.1, 1.9	0.2589
Low Dose	1	6.92 (N/A)	1.81 (N/A)	1.8	1.8, 1.8	-5.11 (N/A)	-5.1	-5.1, -5.1	
High Dose	4	9.42 (4.99)	8.38 (3.48)	8.3	4.9, 12.0	-1.04 (2.97)	-1.0	-4.0, 1.9	0.5347
WEEK 60	4	8.74 (5.13)	6.37 (4.91)	6.3	0.8, 12.1	-2.37 (3.20)	-1.8	-6.1, 0.3	0.2349
Low Dose	1	6.92 (N/A)	0.78 (N/A)	0.8	0.8, 0.8	-6.13 (N/A)	-6.1	-6.1, -6.1	
High Dose	3	9.35 (6.10)	8.24 (3.91)	8.4	4.3, 12.1	-1.11 (2.42)	0.3	-3.9, 0.3	0.5094
WEEK 72	2	8.83 (1.10)	5.81 (2.34)	5.8	4.2, 7.5	-3.03 (1.23)	-3.0	-3.9, -2.2	0.1783
Low Dose	0								
High Dose	2	8.83 (1.10)	5.81 (2.34)	5.8	4.2, 7.5	-3.03 (1.23)	-3.0	-3.9, -2.2	0.1783
WEEK 84	1	8.05 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-3.48 (N/A)	-3.5	-3.5, -3.5	
Low Dose	0								
High Dose	1	8.05 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-3.48 (N/A)	-3.5	-3.5, -3.5	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:ASIAN (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	15		1.57 (2.12)	0.6	0.0, 6.7				
Low Dose	9		1.80 (2.40)	0.6	0.0, 6.7				
High Dose	6		1.23 (1.77)	0.5	0.0, 4.6				
WEEK 12	15	1.57 (2.12)	2.37 (3.63)	0.0	0.0, 12.4	0.80 (2.45)	0.0	-2.7, 5.7	0.2271
Low Dose	9	1.80 (2.40)	2.89 (4.45)	0.0	0.0, 12.4	1.10 (2.49)	0.0	-2.7, 5.7	0.2230
High Dose	6	1.23 (1.77)	1.58 (1.98)	1.1	0.0, 4.9	0.35 (2.54)	0.0	-2.3, 4.6	0.7482
WEEK 24	11	1.99 (2.35)	2.46 (3.68)	1.2	0.0, 12.4	0.46 (1.97)	0.0	-2.1, 5.7	0.4525
Low Dose	7	2.22 (2.59)	3.00 (4.48)	1.2	0.0, 12.4	0.78 (2.21)	0.0	-0.5, 5.7	0.3861
High Dose	4	1.60 (2.16)	1.51 (1.80)	1.2	0.0, 3.6	-0.09 (1.59)	0.0	-2.1, 1.8	0.9172
WEEK 36	6	2.19 (2.85)	3.43 (4.42)	2.2	0.0, 11.1	1.25 (1.82)	0.3	0.0, 4.4	0.1551
Low Dose	2	3.36 (4.75)	5.55 (7.85)	5.5	0.0, 11.1	2.19 (3.10)	2.2	0.0, 4.4	0.5000
High Dose	4	1.60 (2.16)	2.37 (2.76)	2.2	0.0, 5.1	0.77 (1.20)	0.3	0.0, 2.5	0.2893

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Race:ASIAN (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 48	5	2.62 (2.96)	3.85 (4.86)	3.2	0.0, 11.9	1.23 (2.57)	0.0	-1.4, 5.2	0.3451
Low Dose	1	6.72 (N/A)	11.87 (N/A)	11.9	11.9, 11.9	5.15 (N/A)	5.2	5.2, 5.2	
High Dose	4	1.60 (2.16)	1.85 (2.17)	1.6	0.0, 4.2	0.25 (1.56)	0.0	-1.4, 2.4	0.7689
WEEK 60	4	3.28 (2.96)	4.48 (4.96)	3.2	0.0, 11.6	1.21 (2.56)	0.5	-1.0, 4.8	0.4147
Low Dose	1	6.72 (N/A)	11.55 (N/A)	11.6	11.6, 11.6	4.83 (N/A)	4.8	4.8, 4.8	
High Dose	3	2.13 (2.30)	2.13 (1.88)	2.8	0.0, 3.6	-0.00 (1.01)	0.0	-1.0, 1.0	0.9967
WEEK 72	2	0.91 (1.29)	0.73 (1.03)	0.7	0.0, 1.5	-0.18 (0.26)	-0.2	-0.4, 0.0	0.5000
Low Dose	0								
High Dose	2	0.91 (1.29)	0.73 (1.03)	0.7	0.0, 1.5	-0.18 (0.26)	-0.2	-0.4, 0.0	0.5000
WEEK 84	1	1.82 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-1.82 (N/A)	-1.8	-1.8, -1.8	
Low Dose	0								
High Dose	1	1.82 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-1.82 (N/A)	-1.8	-1.8, -1.8	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:ASIAN (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	15		0.31 (0.68)	0.0	0.0, 2.3				
Low Dose	9		0.19 (0.48)	0.0	0.0, 1.5				
High Dose	6		0.50 (0.92)	0.0	0.0, 2.3				
WEEK 12	15	0.31 (0.68)	0.58 (1.54)	0.0	0.0, 4.4	0.27 (1.28)	0.0	-1.5, 4.1	0.4255
Low Dose	9	0.19 (0.48)	0.48 (1.44)	0.0	0.0, 4.3	0.29 (1.50)	0.0	-1.5, 4.1	0.5746
High Dose	6	0.50 (0.92)	0.74 (1.81)	0.0	0.0, 4.4	0.24 (0.98)	0.0	-0.7, 2.2	0.5787
WEEK 24	11	0.34 (0.78)	0.95 (2.39)	0.0	0.0, 7.8	0.61 (1.91)	0.0	0.0, 6.4	0.3138
Low Dose	7	0.21 (0.55)	1.15 (2.95)	0.0	0.0, 7.8	0.94 (2.40)	0.0	0.0, 6.4	0.3383
High Dose	4	0.57 (1.14)	0.60 (1.21)	0.0	0.0, 2.4	0.03 (0.07)	0.0	0.0, 0.1	0.3910
WEEK 36	6	0.38 (0.93)	0.47 (1.16)	0.0	0.0, 2.8	0.09 (0.23)	0.0	0.0, 0.6	0.3632
Low Dose	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	4	0.57 (1.14)	0.71 (1.42)	0.0	0.0, 2.8	0.14 (0.28)	0.0	0.0, 0.6	0.3910

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Race:ASIAN (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 48	5	0.46 (1.02)	0.55 (1.23)	0.0	0.0, 2.7	0.09 (0.20)	0.0	0.0, 0.5	0.3739
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	4	0.57 (1.14)	0.69 (1.37)	0.0	0.0, 2.7	0.11 (0.23)	0.0	0.0, 0.5	0.3910
WEEK 60	4	0.57 (1.14)	0.27 (0.53)	0.0	0.0, 1.1	-0.30 (0.61)	0.0	-1.2, 0.0	0.3910
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	3	0.76 (1.32)	0.36 (0.62)	0.0	0.0, 1.1	-0.41 (0.70)	0.0	-1.2, 0.0	0.4226
WEEK 72	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Low Dose	0								
High Dose	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	0								
High Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Race:ASIAN (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	15		11.06 (2.92)	9.9	5.9, 16.0				
Low Dose	9		11.19 (3.14)	10.7	5.9, 16.0				
High Dose	6		10.86 (2.84)	9.7	8.6, 16.0				
WEEK 12	15	11.06 (2.92)	10.46 (3.01)	10.5	5.8, 16.0	-0.60 (2.54)	-1.5	-3.8, 4.2	0.3796
Low Dose	9	11.19 (3.14)	10.96 (3.14)	11.5	5.8, 16.0	-0.23 (3.02)	-0.2	-3.8, 4.2	0.8248
High Dose	6	10.86 (2.84)	9.72 (2.91)	9.4	5.8, 13.9	-1.14 (1.71)	-1.6	-2.8, 2.1	0.1630
WEEK 24	11	10.82 (2.94)	9.77 (3.20)	10.7	5.1, 13.5	-1.05 (3.12)	-2.3	-4.5, 6.1	0.2883
Low Dose	7	10.71 (2.94)	9.77 (2.89)	10.7	5.4, 13.5	-0.94 (3.25)	-2.3	-3.3, 6.1	0.4737
High Dose	4	11.01 (3.37)	9.76 (4.18)	10.3	5.1, 13.4	-1.26 (3.35)	-1.9	-4.5, 3.3	0.5073
WEEK 36	6	11.16 (2.96)	12.21 (1.60)	12.2	9.9, 14.8	1.05 (3.37)	1.5	-3.9, 5.5	0.4798
Low Dose	2	11.45 (3.09)	13.59 (1.71)	13.6	12.4, 14.8	2.15 (4.80)	2.1	-1.2, 5.5	0.6410
High Dose	4	11.01 (3.37)	11.52 (1.18)	11.8	9.9, 12.6	0.50 (3.17)	1.5	-3.9, 2.9	0.7722

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Race:ASIAN (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 48	5	11.54 (3.15)	10.92 (1.96)	10.7	9.1, 13.7	-0.62 (2.01)	0.0	-4.0, 1.0	0.5261
Low Dose	1	13.63 (N/A)	13.68 (N/A)	13.7	13.7, 13.7	0.04 (N/A)	0.0	0.0, 0.0	
High Dose	4	11.01 (3.37)	10.23 (1.39)	9.9	9.1, 12.0	-0.79 (2.28)	-0.1	-4.0, 1.0	0.5382
WEEK 60	4	12.02 (3.41)	10.86 (2.08)	11.6	7.8, 12.3	-1.16 (2.15)	-1.0	-3.9, 1.3	0.3587
Low Dose	1	13.63 (N/A)	12.34 (N/A)	12.3	12.3, 12.3	-1.30 (N/A)	-1.3	-1.3, -1.3	
High Dose	3	11.48 (3.97)	10.37 (2.25)	11.2	7.8, 12.1	-1.12 (2.63)	-0.7	-3.9, 1.3	0.5388
WEEK 72	2	9.74 (0.18)	6.53 (1.31)	6.5	5.6, 7.5	-3.21 (1.49)	-3.2	-4.3, -2.2	0.2021
Low Dose	0								
High Dose	2	9.74 (0.18)	6.53 (1.31)	6.5	5.6, 7.5	-3.21 (1.49)	-3.2	-4.3, -2.2	0.2021
WEEK 84	1	9.87 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-5.30 (N/A)	-5.3	-5.3, -5.3	
Low Dose	0								
High Dose	1	9.87 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-5.30 (N/A)	-5.3	-5.3, -5.3	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:< 65 years									
Average Daily Normalized 'Off' Time									
BASELINE	57		2.69 (3.23)	1.2	0.0, 11.5				
Low Dose	25		3.23 (3.40)	2.3	0.0, 10.9				
High Dose	32		2.27 (3.08)	0.5	0.0, 11.5				
WEEK 12	43	3.06 (3.47)	3.40 (3.10)	2.7	0.0, 10.9	0.33 (3.07)	0.0	-8.2, 10.9	0.4795
Low Dose	20	3.37 (3.68)	3.09 (2.44)	2.7	0.0, 8.0	-0.28 (2.77)	0.0	-8.2, 3.8	0.6583
High Dose	23	2.80 (3.35)	3.67 (3.62)	2.3	0.0, 10.9	0.87 (3.27)	0.0	-6.4, 10.9	0.2169
WEEK 24	43	2.56 (2.87)	2.73 (3.02)	2.3	0.0, 13.4	0.17 (2.77)	0.0	-6.1, 7.7	0.6954
Low Dose	20	3.12 (3.12)	2.26 (2.17)	2.2	0.0, 7.8	-0.86 (2.54)	0.0	-6.1, 2.5	0.1455
High Dose	23	2.07 (2.60)	3.13 (3.60)	2.3	0.0, 13.4	1.06 (2.70)	0.0	-3.3, 7.7	0.0723
WEEK 36	24	2.11 (2.60)	1.97 (2.10)	1.8	0.0, 7.7	-0.15 (1.55)	0.0	-3.9, 3.6	0.6476
Low Dose	14	1.90 (2.17)	2.15 (2.31)	1.9	0.0, 7.7	0.25 (0.68)	0.0	-0.9, 1.4	0.1844
High Dose	10	2.41 (3.21)	1.70 (1.85)	1.2	0.0, 4.9	-0.71 (2.20)	0.0	-3.9, 3.6	0.3358

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:< 65 years (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 48	31	2.26 (2.50)	2.94 (3.60)	1.2	0.0, 14.3	0.69 (2.11)	0.0	-2.3, 6.1	0.0798
Low Dose	12	1.91 (2.23)	1.84 (2.02)	1.2	0.0, 5.9	-0.08 (1.32)	0.0	-2.3, 2.7	0.8462
High Dose	19	2.47 (2.70)	3.64 (4.22)	1.2	0.0, 14.3	1.17 (2.39)	0.4	-2.0, 6.1	0.0472*
WEEK 60	19	2.62 (2.85)	2.87 (2.55)	2.5	0.0, 7.1	0.25 (1.31)	0.0	-2.0, 2.4	0.4214
Low Dose	9	2.26 (2.47)	2.00 (2.24)	1.2	0.0, 5.8	-0.26 (0.76)	-0.2	-1.2, 1.3	0.3320
High Dose	10	2.95 (3.25)	3.65 (2.66)	3.0	0.0, 7.1	0.71 (1.55)	0.8	-2.0, 2.4	0.1846
WEEK 72	6	2.09 (2.48)	3.03 (3.87)	1.8	0.0, 10.4	0.93 (2.52)	-0.0	-1.7, 4.3	0.4054
Low Dose	3	0.96 (1.44)	0.66 (0.94)	0.2	0.0, 1.7	-0.30 (0.50)	-0.0	-0.9, 0.0	0.4087
High Dose	3	3.23 (3.08)	5.39 (4.44)	3.9	1.9, 10.4	2.17 (3.32)	3.9	-1.7, 4.3	0.3757
WEEK 84	2	3.06 (4.33)	5.71 (8.08)	5.7	0.0, 11.4	2.65 (3.75)	2.7	0.0, 5.3	0.5000
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	1	6.13 (N/A)	11.43 (N/A)	11.4	11.4, 11.4	5.30 (N/A)	5.3	5.3, 5.3	
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:< 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	57		10.09 (5.26)	11.0	0.0, 16.0				
Low Dose	25		10.53 (4.54)	11.0	1.5, 16.0				
High Dose	32		9.74 (5.81)	10.8	0.0, 16.0				
WEEK 12	43	9.81 (5.37)	10.28 (4.75)	11.1	0.0, 16.0	0.47 (4.20)	0.0	-10.9, 14.2	0.4664
Low Dose	20	10.05 (4.93)	10.29 (4.87)	11.8	1.0, 15.8	0.24 (4.50)	-0.5	-6.7, 14.2	0.8142
High Dose	23	9.59 (5.83)	10.27 (4.75)	10.1	0.0, 16.0	0.67 (4.02)	0.3	-10.9, 9.0	0.4311
WEEK 24	43	10.21 (5.16)	10.58 (4.62)	10.7	0.0, 16.0	0.37 (4.64)	0.0	-9.6, 14.2	0.6037
Low Dose	20	10.86 (4.36)	10.88 (4.70)	10.7	1.0, 16.0	0.01 (4.37)	-0.4	-5.9, 14.2	0.9885
High Dose	23	9.64 (5.81)	10.32 (4.64)	10.6	0.0, 16.0	0.68 (4.95)	0.0	-9.6, 13.7	0.5164
WEEK 36	24	11.41 (4.93)	12.14 (4.25)	13.9	1.3, 16.0	0.72 (4.45)	0.0	-5.6, 14.2	0.4339
Low Dose	14	12.12 (4.21)	12.35 (4.48)	13.9	1.3, 16.0	0.23 (4.39)	-0.2	-5.6, 14.2	0.8455
High Dose	10	10.43 (5.90)	11.84 (4.13)	12.9	6.4, 16.0	1.41 (4.68)	0.1	-3.6, 14.0	0.3653

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:< 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 48	31	9.68 (5.32)	10.62 (4.78)	10.7	0.0, 16.0	0.94 (4.61)	0.2	-5.6, 14.9	0.2670
Low Dose	12	11.77 (4.41)	12.21 (4.31)	13.8	1.8, 16.0	0.44 (4.80)	0.1	-5.1, 13.7	0.7560
High Dose	19	8.36 (5.53)	9.61 (4.89)	9.4	0.0, 16.0	1.25 (4.59)	0.4	-5.6, 14.9	0.2508
WEEK 60	19	9.90 (5.26)	10.75 (4.53)	9.5	0.8, 16.0	0.85 (4.23)	0.0	-6.1, 13.9	0.3934
Low Dose	9	10.90 (4.81)	11.08 (5.29)	10.9	0.8, 16.0	0.18 (5.58)	-0.9	-6.1, 13.9	0.9239
High Dose	10	8.99 (5.73)	10.44 (4.00)	9.2	4.3, 16.0	1.45 (2.70)	0.7	-2.0, 6.3	0.1239
WEEK 72	6	10.94 (6.08)	12.15 (4.51)	13.6	4.2, 16.0	1.21 (4.60)	0.0	-3.9, 9.8	0.5482
Low Dose	3	15.04 (1.44)	14.93 (1.66)	15.8	13.0, 16.0	-0.11 (0.21)	0.0	-0.4, 0.0	0.4580
High Dose	3	6.83 (6.31)	9.36 (4.99)	9.8	4.2, 14.1	2.53 (6.90)	1.7	-3.9, 9.8	0.5904
WEEK 84	2	12.03 (5.62)	10.29 (8.08)	10.3	4.6, 16.0	-1.74 (2.46)	-1.7	-3.5, 0.0	0.5000
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	1	8.05 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-3.48 (N/A)	-3.5	-3.5, -3.5	
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:< 65 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	57		2.69 (4.49)	0.6	0.0, 16.0				
Low Dose	25		1.52 (2.69)	0.6	0.0, 11.8				
High Dose	32		3.60 (5.38)	0.6	0.0, 16.0				
WEEK 12	43	2.47 (4.39)	2.03 (3.67)	0.2	0.0, 16.0	-0.44 (4.23)	0.0	-15.8, 11.6	0.5037
Low Dose	20	1.67 (2.94)	2.37 (3.85)	0.3	0.0, 12.4	0.70 (4.18)	0.0	-11.6, 11.6	0.4646
High Dose	23	3.16 (5.32)	1.74 (3.57)	0.0	0.0, 16.0	-1.42 (4.12)	0.0	-15.8, 4.6	0.1125
WEEK 24	43	2.88 (4.44)	2.27 (3.55)	0.3	0.0, 16.0	-0.60 (4.53)	0.0	-16.0, 6.2	0.3886
Low Dose	20	1.79 (2.94)	2.32 (3.08)	1.5	0.0, 12.4	0.53 (3.46)	0.1	-11.6, 6.2	0.5038
High Dose	23	3.82 (5.31)	2.23 (3.98)	0.0	0.0, 16.0	-1.58 (5.16)	0.0	-16.0, 6.1	0.1555
WEEK 36	24	2.26 (3.84)	1.70 (2.91)	0.1	0.0, 11.1	-0.55 (3.83)	0.0	-12.9, 4.4	0.4862
Low Dose	14	1.77 (3.44)	1.41 (2.99)	0.1	0.0, 11.1	-0.36 (3.50)	0.0	-11.6, 4.4	0.7031
High Dose	10	2.93 (4.44)	2.11 (2.90)	0.2	0.0, 8.1	-0.82 (4.44)	0.0	-12.9, 2.9	0.5742

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:< 65 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 48	31	3.62 (4.95)	2.01 (3.06)	0.7	0.0, 11.9	-1.60 (4.58)	0.0	-12.9, 5.2	0.0606
Low Dose	12	2.07 (3.65)	1.87 (3.58)	0.4	0.0, 11.9	-0.20 (3.87)	0.0	-11.1, 5.2	0.8608
High Dose	19	4.60 (5.48)	2.11 (2.79)	0.7	0.0, 9.8	-2.49 (4.87)	-0.7	-12.9, 4.9	0.0386*
WEEK 60	19	3.07 (4.79)	2.21 (3.06)	0.5	0.0, 11.6	-0.86 (4.12)	0.0	-11.3, 4.8	0.3744
Low Dose	9	2.55 (4.14)	2.83 (3.81)	1.9	0.0, 11.6	0.28 (4.61)	1.9	-11.3, 4.8	0.8595
High Dose	10	3.54 (5.49)	1.65 (2.26)	0.0	0.0, 5.8	-1.89 (3.55)	-0.4	-10.2, 1.0	0.1263
WEEK 72	6	2.97 (6.42)	0.74 (0.83)	0.6	0.0, 1.8	-2.23 (5.91)	0.0	-14.2, 1.2	0.3981
Low Dose	3	0.00 (0.00)	0.41 (0.71)	0.0	0.0, 1.2	0.41 (0.71)	0.0	0.0, 1.2	0.4226
High Dose	3	5.94 (8.76)	1.07 (0.94)	1.5	0.0, 1.8	-4.87 (8.12)	-0.4	-14.2, 0.0	0.4079
WEEK 84	2	0.91 (1.29)	0.00 (0.00)	0.0	0.0, 0.0	-0.91 (1.29)	-0.9	-1.8, 0.0	0.5000
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	1	1.82 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-1.82 (N/A)	-1.8	-1.8, -1.8	
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:< 65 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	57		0.53 (1.90)	0.0	0.0, 13.5				
Low Dose	25		0.73 (2.73)	0.0	0.0, 13.5				
High Dose	32		0.38 (0.84)	0.0	0.0, 3.0				
WEEK 12	43	0.66 (2.17)	0.29 (0.98)	0.0	0.0, 4.4	-0.37 (2.30)	0.0	-13.5, 4.1	0.2970
Low Dose	20	0.91 (3.04)	0.25 (0.97)	0.0	0.0, 4.3	-0.66 (3.25)	0.0	-13.5, 4.1	0.3764
High Dose	23	0.44 (0.93)	0.32 (1.01)	0.0	0.0, 4.4	-0.12 (0.89)	0.0	-3.0, 2.2	0.5302
WEEK 24	43	0.35 (0.83)	0.42 (1.31)	0.0	0.0, 7.8	0.06 (1.29)	0.0	-3.0, 6.4	0.7432
Low Dose	20	0.22 (0.66)	0.54 (1.75)	0.0	0.0, 7.8	0.32 (1.60)	0.0	-2.7, 6.4	0.3806
High Dose	23	0.47 (0.96)	0.31 (0.76)	0.0	0.0, 2.4	-0.16 (0.93)	0.0	-3.0, 1.9	0.4250
WEEK 36	24	0.22 (0.70)	0.19 (0.63)	0.0	0.0, 2.8	-0.02 (0.64)	0.0	-2.7, 1.2	0.8522
Low Dose	14	0.21 (0.71)	0.09 (0.32)	0.0	0.0, 1.2	-0.12 (0.81)	0.0	-2.7, 1.2	0.5738
High Dose	10	0.23 (0.72)	0.34 (0.90)	0.0	0.0, 2.8	0.12 (0.24)	0.0	0.0, 0.6	0.1680

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:< 65 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 48	31	0.44 (0.94)	0.42 (1.22)	0.0	0.0, 6.2	-0.02 (1.46)	0.0	-3.0, 6.2	0.9449
Low Dose	12	0.25 (0.77)	0.08 (0.21)	0.0	0.0, 0.7	-0.17 (0.82)	0.0	-2.7, 0.7	0.4999
High Dose	19	0.57 (1.03)	0.64 (1.53)	0.0	0.0, 6.2	0.07 (1.77)	0.0	-3.0, 6.2	0.8562
WEEK 60	19	0.41 (0.86)	0.18 (0.41)	0.0	0.0, 1.5	-0.23 (0.89)	0.0	-2.7, 1.5	0.2651
Low Dose	9	0.30 (0.89)	0.09 (0.21)	0.0	0.0, 0.6	-0.20 (0.95)	0.0	-2.7, 0.6	0.5402
High Dose	10	0.52 (0.86)	0.25 (0.54)	0.0	0.0, 1.5	-0.26 (0.89)	0.0	-1.5, 1.5	0.3700
WEEK 72	6	0.00 (0.00)	0.09 (0.21)	0.0	0.0, 0.5	0.09 (0.21)	0.0	0.0, 0.5	0.3632
Low Dose	3	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	3	0.00 (0.00)	0.17 (0.30)	0.0	0.0, 0.5	0.17 (0.30)	0.0	0.0, 0.5	0.4226
WEEK 84	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:< 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	57		12.78 (3.59)	13.9	2.5, 16.0				
Low Dose	25		12.05 (3.87)	13.4	2.5, 16.0				
High Dose	32		13.35 (3.31)	15.1	4.5, 16.0				
WEEK 12	43	12.28 (3.86)	12.31 (3.32)	13.3	5.1, 16.0	0.04 (3.66)	0.0	-10.9, 11.6	0.9491
Low Dose	20	11.72 (4.17)	12.66 (2.82)	13.3	5.8, 16.0	0.94 (3.90)	-0.1	-3.8, 11.6	0.2960
High Dose	23	12.76 (3.59)	12.01 (3.73)	13.7	5.1, 16.0	-0.75 (3.33)	0.0	-10.9, 6.4	0.2928
WEEK 24	43	13.09 (2.99)	12.85 (3.28)	13.7	2.6, 16.0	-0.23 (2.77)	0.0	-7.7, 6.1	0.5874
Low Dose	20	12.66 (3.11)	13.20 (2.94)	13.8	5.4, 16.0	0.54 (2.67)	0.0	-3.3, 6.1	0.3758
High Dose	23	13.46 (2.90)	12.56 (3.59)	13.7	2.6, 16.0	-0.90 (2.74)	-0.2	-7.7, 3.3	0.1283
WEEK 36	24	13.67 (2.71)	13.84 (2.20)	14.1	8.3, 16.0	0.17 (1.65)	0.0	-3.6, 3.9	0.6181
Low Dose	14	13.89 (2.10)	13.76 (2.39)	14.1	8.3, 16.0	-0.13 (1.17)	0.0	-2.3, 2.7	0.6828
High Dose	10	13.36 (3.49)	13.95 (2.02)	14.3	11.1, 16.0	0.59 (2.16)	0.0	-3.6, 3.9	0.4091

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:< 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 48	31	13.30 (2.67)	12.63 (3.62)	13.8	1.7, 16.0	-0.67 (2.54)	0.0	-6.2, 2.7	0.1526
Low Dose	12	13.84 (2.15)	14.08 (2.10)	14.7	10.1, 16.0	0.24 (1.64)	0.0	-2.7, 2.7	0.6199
High Dose	19	12.96 (2.96)	11.72 (4.11)	13.5	1.7, 16.0	-1.24 (2.86)	-0.4	-6.2, 2.3	0.0743
WEEK 60	19	12.97 (2.97)	12.95 (2.65)	13.0	7.8, 16.0	-0.01 (1.47)	0.0	-3.9, 2.7	0.9718
Low Dose	9	13.44 (2.32)	13.91 (2.25)	14.5	10.2, 16.0	0.46 (1.15)	0.0	-1.3, 2.7	0.2593
High Dose	10	12.54 (3.53)	12.09 (2.79)	12.5	7.8, 16.0	-0.44 (1.65)	-0.3	-3.9, 2.0	0.4204
WEEK 72	6	13.91 (2.48)	12.89 (3.90)	14.2	5.6, 16.0	-1.02 (2.65)	0.0	-4.4, 1.7	0.3884
Low Dose	3	15.04 (1.44)	15.34 (0.94)	15.8	14.3, 16.0	0.30 (0.50)	0.0	0.0, 0.9	0.4087
High Dose	3	12.77 (3.08)	10.43 (4.36)	11.6	5.6, 14.1	-2.34 (3.47)	-4.3	-4.4, 1.7	0.3629
WEEK 84	2	12.94 (4.33)	10.29 (8.08)	10.3	4.6, 16.0	-2.65 (3.75)	-2.7	-5.3, 0.0	0.5000
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	1	9.87 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-5.30 (N/A)	-5.3	-5.3, -5.3	
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years									
Average Daily Normalized 'Off' Time									
BASELINE	40		2.35 (2.54)	1.3	0.0, 8.1				
Low Dose	20		2.59 (2.18)	2.7	0.0, 6.7				
High Dose	20		2.12 (2.90)	0.5	0.0, 8.1				
WEEK 12	32	2.53 (2.64)	2.42 (2.36)	2.1	0.0, 8.0	-0.11 (1.76)	0.0	-4.3, 4.2	0.7273
Low Dose	18	2.59 (2.30)	2.14 (2.19)	1.7	0.0, 7.3	-0.45 (1.57)	0.0	-4.2, 1.5	0.2420
High Dose	14	2.46 (3.12)	2.79 (2.59)	2.1	0.0, 8.0	0.32 (1.96)	0.3	-4.3, 4.2	0.5454
WEEK 24	32	2.07 (2.31)	3.64 (4.22)	2.4	0.0, 16.0	1.56 (3.13)	0.3	-3.0, 13.3	0.0081**
Low Dose	16	2.90 (2.16)	4.43 (4.90)	2.5	0.0, 16.0	1.53 (4.09)	0.0	-3.0, 13.3	0.1552
High Dose	16	1.24 (2.21)	2.84 (3.38)	2.0	0.0, 10.9	1.60 (1.87)	1.2	-0.2, 6.2	0.0037**
WEEK 36	15	2.52 (2.81)	2.95 (3.36)	1.7	0.0, 12.1	0.43 (2.39)	0.0	-5.5, 5.6	0.5010
Low Dose	7	3.65 (2.93)	3.63 (4.45)	1.2	0.0, 12.1	-0.02 (3.26)	0.0	-5.5, 5.6	0.9860
High Dose	8	1.54 (2.45)	2.36 (2.18)	1.8	0.0, 6.1	0.82 (1.41)	0.5	-0.3, 3.9	0.1430

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 48	21	1.66 (2.30)	2.61 (3.63)	0.6	0.0, 11.0	0.95 (2.54)	0.0	-3.0, 7.4	0.1014
Low Dose	9	2.37 (2.51)	2.95 (4.22)	0.0	0.0, 10.1	0.59 (2.93)	0.0	-3.0, 7.4	0.5652
High Dose	12	1.12 (2.07)	2.35 (3.30)	0.9	0.0, 11.0	1.23 (2.31)	0.0	-1.0, 6.6	0.0924
WEEK 60	10	2.38 (2.47)	3.36 (3.45)	2.2	0.0, 10.4	0.98 (2.09)	1.0	-3.0, 3.9	0.1735
Low Dose	7	3.26 (2.47)	3.97 (3.91)	2.4	0.0, 10.4	0.71 (2.21)	1.0	-3.0, 3.9	0.4305
High Dose	3	0.32 (0.28)	1.94 (1.77)	1.4	0.5, 3.9	1.61 (2.04)	0.9	0.0, 3.9	0.3045
WEEK 72	6	2.83 (3.01)	3.69 (3.12)	3.7	0.0, 8.5	0.87 (2.68)	0.2	-2.2, 5.5	0.4634
Low Dose	3	3.36 (3.03)	2.72 (1.67)	3.7	0.8, 3.7	-0.63 (1.52)	-0.5	-2.2, 0.8	0.5470
High Dose	3	2.30 (3.55)	4.66 (4.33)	5.5	0.0, 8.5	2.37 (2.98)	2.2	-0.5, 5.5	0.3026
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	40		11.47 (4.10)	11.8	0.0, 16.0				
Low Dose	20		11.19 (4.45)	12.4	0.0, 16.0				
High Dose	20		11.75 (3.82)	11.5	1.3, 16.0				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 12	32	11.82 (4.00)	11.57 (4.44)	12.5	0.0, 16.0	-0.24 (2.95)	0.0	-9.6, 6.1	0.6428
Low Dose	18	11.93 (3.89)	12.17 (4.39)	13.2	0.0, 16.0	0.25 (2.93)	0.0	-6.6, 6.1	0.7223
High Dose	14	11.68 (4.27)	10.80 (4.54)	11.0	0.0, 16.0	-0.88 (2.96)	-0.6	-9.6, 2.8	0.2865
WEEK 24	32	11.27 (4.29)	10.58 (5.01)	11.2	0.0, 16.0	-0.70 (4.21)	0.0	-13.3, 7.4	0.3562
Low Dose	16	10.36 (4.55)	10.04 (5.77)	11.2	0.0, 16.0	-0.32 (4.94)	0.5	-13.3, 7.4	0.7963
High Dose	16	12.18 (3.94)	11.11 (4.24)	11.5	4.4, 16.0	-1.07 (3.46)	-1.0	-9.2, 6.5	0.2348
WEEK 36	15	11.50 (3.90)	10.41 (5.39)	11.9	0.0, 16.0	-1.09 (4.20)	0.0	-11.2, 5.5	0.3301
Low Dose	7	12.11 (3.19)	12.13 (4.75)	14.8	3.4, 16.0	0.03 (3.33)	0.0	-5.9, 5.5	0.9847
High Dose	8	10.98 (4.58)	8.90 (5.75)	10.9	0.0, 14.1	-2.07 (4.84)	-0.5	-11.2, 4.5	0.2647
WEEK 48	21	11.68 (4.52)	11.51 (4.62)	12.4	1.1, 16.0	-0.16 (5.16)	0.0	-9.4, 11.4	0.8863
Low Dose	9	9.57 (5.80)	10.16 (5.32)	8.6	1.1, 16.0	0.58 (6.28)	0.0	-8.0, 11.4	0.7880
High Dose	12	13.26 (2.50)	12.53 (3.96)	13.6	5.0, 16.0	-0.72 (4.35)	-0.0	-9.4, 6.5	0.5769
WEEK 60	10	10.65 (4.38)	11.04 (3.28)	11.2	4.5, 16.0	0.39 (4.12)	-0.2	-4.7, 8.0	0.7722
Low Dose	7	9.81 (4.60)	10.27 (3.70)	10.0	4.5, 16.0	0.46 (4.47)	-0.5	-4.7, 8.0	0.7931
High Dose	3	12.60 (3.80)	12.82 (0.79)	12.7	12.1, 13.7	0.22 (4.06)	0.3	-3.9, 4.2	0.9352

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 72	6	10.98 (2.81)	10.07 (4.91)	12.0	1.4, 15.2	-0.92 (4.93)	-0.2	-9.9, 3.6	0.6683
Low Dose	3	12.16 (3.68)	13.12 (1.81)	12.3	11.9, 15.2	0.96 (2.06)	0.5	-0.8, 3.2	0.5031
High Dose	3	9.80 (1.41)	7.01 (5.37)	7.5	1.4, 12.1	-2.79 (6.78)	-2.2	-9.9, 3.6	0.5497
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	40		1.76 (3.57)	0.0	0.0, 16.0				
Low Dose	20		2.04 (4.38)	0.0	0.0, 16.0				
High Dose	20		1.48 (2.60)	0.0	0.0, 9.3				
WEEK 12	32	1.33 (3.32)	1.56 (3.42)	0.0	0.0, 16.0	0.23 (3.06)	0.0	-11.0, 7.4	0.6679
Low Dose	18	1.29 (3.78)	1.06 (2.42)	0.0	0.0, 8.7	-0.23 (3.44)	0.0	-11.0, 7.4	0.7811
High Dose	14	1.37 (2.76)	2.20 (4.40)	0.0	0.0, 16.0	0.83 (2.50)	0.0	-2.2, 6.7	0.2361
WEEK 24	32	2.15 (3.90)	1.40 (3.27)	0.0	0.0, 16.0	-0.76 (2.81)	0.0	-12.0, 5.1	0.1369
Low Dose	16	2.51 (4.81)	1.47 (4.14)	0.0	0.0, 16.0	-1.04 (3.44)	0.0	-12.0, 4.5	0.2442
High Dose	16	1.80 (2.82)	1.32 (2.22)	0.0	0.0, 5.8	-0.48 (2.08)	0.0	-3.9, 5.1	0.3755

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 36	15	1.62 (2.81)	2.49 (5.42)	0.0	0.0, 16.0	0.87 (3.79)	0.0	-5.7, 11.2	0.3876
Low Dose	7	0.24 (0.54)	0.17 (0.30)	0.0	0.0, 0.7	-0.07 (0.32)	0.0	-0.8, 0.3	0.5975
High Dose	8	2.82 (3.47)	4.51 (6.98)	0.1	0.0, 16.0	1.69 (5.19)	0.0	-5.7, 11.2	0.3866
WEEK 48	21	2.47 (4.30)	1.74 (3.73)	0.0	0.0, 14.9	-0.73 (3.51)	0.0	-10.3, 8.0	0.3521
Low Dose	9	3.69 (6.04)	2.86 (5.20)	0.0	0.0, 14.9	-0.82 (4.70)	-0.3	-10.3, 8.0	0.6130
High Dose	12	1.56 (2.22)	0.90 (1.95)	0.0	0.0, 5.5	-0.66 (2.52)	0.0	-5.7, 4.0	0.3842
WEEK 60	10	2.02 (3.70)	1.53 (2.03)	1.0	0.0, 5.7	-0.48 (3.32)	0.0	-7.3, 5.7	0.6564
Low Dose	7	2.46 (4.40)	1.76 (2.39)	0.9	0.0, 5.7	-0.70 (4.00)	0.0	-7.3, 5.7	0.6609
High Dose	3	0.99 (1.13)	1.00 (0.95)	1.1	0.0, 1.9	0.01 (1.11)	0.0	-1.1, 1.1	0.9844
WEEK 72	6	1.15 (1.84)	1.13 (1.71)	0.2	0.0, 4.2	-0.02 (0.81)	0.0	-1.0, 1.4	0.9593
Low Dose	3	0.48 (0.83)	0.15 (0.26)	0.0	0.0, 0.5	-0.33 (0.57)	0.0	-1.0, 0.0	0.4226
High Dose	3	1.82 (2.53)	2.11 (2.08)	2.2	0.0, 4.2	0.29 (1.02)	0.0	-0.5, 1.4	0.6671

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	40		0.42 (1.37)	0.0	0.0, 6.3				
Low Dose	20		0.18 (0.74)	0.0	0.0, 3.3				
High Dose	20		0.65 (1.78)	0.0	0.0, 6.3				
WEEK 12	32	0.33 (1.10)	0.44 (2.00)	0.0	0.0, 11.0	0.12 (2.35)	0.0	-5.3, 11.0	0.7758
Low Dose	18	0.20 (0.78)	0.63 (2.60)	0.0	0.0, 11.0	0.43 (2.76)	0.0	-3.3, 11.0	0.5205
High Dose	14	0.49 (1.42)	0.21 (0.79)	0.0	0.0, 3.0	-0.28 (1.69)	0.0	-5.3, 3.0	0.5521
WEEK 24	32	0.50 (1.52)	0.39 (1.45)	0.0	0.0, 7.2	-0.11 (1.38)	0.0	-5.3, 4.3	0.6620
Low Dose	16	0.22 (0.83)	0.06 (0.14)	0.0	0.0, 0.5	-0.16 (0.85)	0.0	-3.3, 0.3	0.4566
High Dose	16	0.77 (1.98)	0.72 (2.03)	0.0	0.0, 7.2	-0.05 (1.80)	0.0	-5.3, 4.3	0.9055
WEEK 36	15	0.36 (1.38)	0.15 (0.47)	0.0	0.0, 1.8	-0.20 (1.49)	0.0	-5.3, 1.8	0.6043
Low Dose	7	0.00 (0.00)	0.07 (0.17)	0.0	0.0, 0.5	0.07 (0.17)	0.0	0.0, 0.5	0.3559
High Dose	8	0.67 (1.89)	0.23 (0.64)	0.0	0.0, 1.8	-0.44 (2.08)	0.0	-5.3, 1.8	0.5669

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 48	21	0.19 (0.73)	0.14 (0.51)	0.0	0.0, 2.3	-0.06 (0.92)	0.0	-3.3, 2.3	0.7712
Low Dose	9	0.37 (1.10)	0.03 (0.08)	0.0	0.0, 0.2	-0.34 (1.12)	0.0	-3.3, 0.2	0.3840
High Dose	12	0.07 (0.23)	0.22 (0.67)	0.0	0.0, 2.3	0.15 (0.73)	0.0	-0.8, 2.3	0.4805
WEEK 60	10	0.96 (2.13)	0.07 (0.23)	0.0	0.0, 0.7	-0.88 (2.18)	0.0	-6.3, 0.7	0.2319
Low Dose	7	0.47 (1.25)	0.00 (0.00)	0.0	0.0, 0.0	-0.47 (1.25)	0.0	-3.3, 0.0	0.3559
High Dose	3	2.08 (3.61)	0.24 (0.42)	0.0	0.0, 0.7	-1.84 (3.84)	0.0	-6.3, 0.7	0.4933
WEEK 72	6	1.04 (2.55)	1.11 (2.00)	0.0	0.0, 5.0	0.06 (3.02)	0.0	-4.6, 5.0	0.9603
Low Dose	3	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	3	2.08 (3.61)	2.21 (2.52)	1.7	0.0, 5.0	0.13 (4.77)	0.0	-4.6, 5.0	0.9669
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	40		13.23 (2.62)	13.4	7.9, 16.0				
Low Dose	20		13.23 (2.14)	13.2	9.3, 16.0				
High Dose	20		13.23 (3.08)	15.0	7.9, 16.0				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 12	32	13.14 (2.64)	13.13 (2.75)	13.7	5.0, 16.0	-0.01 (2.93)	0.0	-11.0, 5.3	0.9854
Low Dose	18	13.21 (2.26)	13.24 (2.96)	13.7	5.0, 16.0	0.02 (3.20)	0.0	-11.0, 4.2	0.9785
High Dose	14	13.05 (3.15)	13.00 (2.56)	13.1	8.0, 16.0	-0.05 (2.67)	-0.3	-4.2, 5.3	0.9468
WEEK 24	32	13.43 (2.42)	11.97 (4.36)	13.5	0.0, 16.0	-1.46 (3.41)	-0.4	-13.3, 3.8	0.0219*
Low Dose	16	12.87 (2.08)	11.51 (4.93)	13.4	0.0, 16.0	-1.37 (4.31)	-0.0	-13.3, 3.8	0.2231
High Dose	16	13.98 (2.67)	12.44 (3.82)	13.5	5.1, 16.0	-1.55 (2.35)	-1.2	-6.2, 3.0	0.0189*
WEEK 36	15	13.12 (2.80)	12.90 (3.31)	14.2	3.9, 16.0	-0.22 (2.71)	0.0	-5.6, 5.5	0.7556
Low Dose	7	12.35 (2.93)	12.31 (4.50)	14.8	3.9, 16.0	-0.04 (3.28)	0.0	-5.6, 5.5	0.9736
High Dose	8	13.80 (2.69)	13.42 (1.98)	14.1	9.9, 16.0	-0.38 (2.33)	-0.6	-3.9, 4.3	0.6592
WEEK 48	21	14.15 (2.31)	13.26 (3.69)	15.4	5.0, 16.0	-0.89 (2.89)	0.0	-7.4, 3.8	0.1714
Low Dose	9	13.26 (2.45)	13.02 (4.24)	16.0	5.9, 16.0	-0.24 (3.27)	0.0	-7.4, 3.8	0.8298
High Dose	12	14.82 (2.04)	13.43 (3.40)	15.1	5.0, 16.0	-1.38 (2.60)	-0.1	-6.6, 1.0	0.0925
WEEK 60	10	12.67 (2.59)	12.57 (3.39)	13.8	5.6, 16.0	-0.09 (2.90)	-0.4	-3.9, 5.3	0.9200
Low Dose	7	12.27 (2.16)	12.03 (3.91)	13.6	5.6, 16.0	-0.23 (2.27)	0.0	-3.9, 3.0	0.7948
High Dose	3	13.59 (3.77)	13.82 (1.50)	14.6	12.1, 14.8	0.23 (4.70)	-0.7	-3.9, 5.3	0.9403

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Age category:>= 65 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 72	6	12.13 (3.12)	11.20 (3.84)	12.3	5.6, 15.2	-0.93 (5.28)	-0.2	-10.4, 5.1	0.6832
Low Dose	3	12.64 (3.03)	13.28 (1.67)	12.3	12.3, 15.2	0.63 (1.52)	0.5	-0.8, 2.2	0.5470
High Dose	3	11.62 (3.80)	9.12 (4.60)	7.5	5.6, 14.3	-2.50 (7.75)	-2.2	-10.4, 5.1	0.6328
Geographic region:NORTH AMERICA									
Average Daily Normalized 'Off' Time									
BASELINE	40		1.86 (2.44)	0.5	0.0, 8.8				
Low Dose	16		2.65 (2.41)	2.6	0.0, 8.8				
High Dose	24		1.32 (2.35)	0.1	0.0, 8.1				
WEEK 12	27	2.15 (2.68)	2.35 (2.19)	2.1	0.0, 6.8	0.20 (2.30)	0.0	-4.3, 6.8	0.6488
Low Dose	12	2.88 (2.69)	2.42 (1.83)	2.5	0.0, 5.9	-0.47 (1.88)	-0.3	-3.8, 2.8	0.4095
High Dose	15	1.56 (2.60)	2.30 (2.50)	2.0	0.0, 6.8	0.74 (2.52)	0.0	-4.3, 6.8	0.2753
WEEK 24	33	1.63 (2.19)	2.42 (2.92)	1.2	0.0, 10.3	0.79 (2.68)	0.0	-6.0, 7.7	0.0990
Low Dose	13	2.91 (2.43)	2.74 (3.09)	2.4	0.0, 10.3	-0.17 (3.13)	-0.0	-6.0, 7.6	0.8452
High Dose	20	0.79 (1.57)	2.21 (2.86)	0.4	0.0, 8.3	1.42 (2.20)	0.3	-0.5, 7.7	0.0094**

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 36	14	1.32 (1.88)	1.72 (1.98)	1.4	0.0, 6.5	0.40 (0.69)	0.3	-1.1, 1.4	0.0496*
Low Dose	6	2.30 (2.37)	2.85 (2.52)	3.0	0.0, 6.5	0.55 (0.57)	0.4	-0.0, 1.4	0.0639
High Dose	8	0.57 (1.05)	0.86 (0.92)	0.6	0.0, 2.0	0.29 (0.79)	0.1	-1.1, 1.2	0.3349
WEEK 48	20	1.23 (1.66)	1.58 (1.88)	0.8	0.0, 6.0	0.35 (1.77)	0.0	-3.0, 4.5	0.3832
Low Dose	8	1.99 (1.98)	2.00 (2.31)	1.1	0.0, 6.0	0.01 (1.72)	0.1	-3.0, 2.7	0.9839
High Dose	12	0.72 (1.24)	1.30 (1.57)	0.8	0.0, 4.5	0.58 (1.84)	0.0	-2.0, 4.5	0.2982
WEEK 60	12	1.68 (1.96)	2.03 (2.31)	1.7	0.0, 6.9	0.35 (1.45)	0.0	-3.0, 2.4	0.4228
Low Dose	8	2.40 (2.06)	2.50 (2.67)	2.2	0.0, 6.9	0.10 (1.59)	-0.0	-3.0, 1.9	0.8593
High Dose	4	0.24 (0.28)	1.08 (1.07)	0.9	0.0, 2.4	0.84 (1.14)	0.5	0.0, 2.4	0.2382
WEEK 72	9	1.89 (2.23)	2.29 (1.99)	1.9	0.0, 5.5	0.40 (2.56)	-0.5	-2.2, 5.5	0.6524
Low Dose	5	2.59 (2.53)	1.87 (1.79)	1.7	0.0, 3.7	-0.72 (0.92)	-0.5	-2.2, 0.0	0.1553
High Dose	4	1.01 (1.71)	2.81 (2.37)	2.9	0.0, 5.5	1.80 (3.42)	1.7	-1.7, 5.5	0.3700
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	40		10.81 (5.02)	11.8	0.0, 16.0				
Low Dose	16		11.44 (4.00)	12.4	1.3, 16.0				
High Dose	24		10.39 (5.65)	11.2	0.0, 16.0				
WEEK 12	27	10.68 (5.23)	10.79 (4.64)	11.3	0.0, 16.0	0.11 (3.62)	0.3	-9.6, 9.0	0.8742
Low Dose	12	12.18 (3.08)	12.12 (3.56)	13.1	4.5, 16.0	-0.06 (3.44)	0.4	-6.6, 6.1	0.9549
High Dose	15	9.48 (6.31)	9.73 (5.23)	10.1	0.0, 16.0	0.25 (3.87)	0.0	-9.6, 9.0	0.8087
WEEK 24	33	10.74 (5.19)	11.31 (4.61)	11.8	0.0, 16.0	0.57 (4.74)	0.0	-9.6, 13.7	0.4961
Low Dose	13	10.92 (4.23)	11.80 (4.57)	13.6	3.4, 16.0	0.88 (3.68)	1.1	-7.7, 7.4	0.4068
High Dose	20	10.62 (5.84)	10.99 (4.72)	11.2	0.0, 16.0	0.37 (5.41)	0.0	-9.6, 13.7	0.7642

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 36	14	11.66 (5.26)	11.39 (5.41)	13.9	0.0, 16.0	-0.28 (5.45)	-0.3	-11.2, 14.0	0.8530
Low Dose	6	13.46 (2.83)	12.72 (2.99)	12.6	8.4, 16.0	-0.74 (1.01)	-0.3	-2.5, 0.0	0.1319
High Dose	8	10.32 (6.40)	10.40 (6.73)	14.0	0.0, 16.0	0.07 (7.36)	-0.1	-11.2, 14.0	0.9784
WEEK 48	20	11.05 (5.20)	13.07 (3.18)	14.2	5.8, 16.0	2.01 (5.47)	0.2	-9.4, 14.9	0.1168
Low Dose	8	11.48 (5.02)	13.41 (2.89)	14.0	8.6, 16.0	1.93 (5.09)	-0.0	-3.2, 11.4	0.3193
High Dose	12	10.77 (5.52)	12.84 (3.46)	14.2	5.8, 16.0	2.07 (5.94)	0.8	-9.4, 14.9	0.2535
WEEK 60	12	10.53 (5.37)	11.90 (3.22)	11.8	6.3, 16.0	1.37 (3.57)	0.0	-2.6, 8.0	0.2112
Low Dose	8	11.07 (4.81)	11.76 (2.98)	10.6	8.2, 16.0	0.69 (3.80)	-0.2	-2.6, 8.0	0.6215
High Dose	4	9.45 (7.02)	12.17 (4.15)	13.2	6.3, 16.0	2.71 (3.06)	2.3	0.0, 6.3	0.1740
WEEK 72	9	10.87 (4.86)	11.83 (4.36)	12.3	1.4, 16.0	0.96 (5.15)	0.5	-9.9, 9.8	0.5927
Low Dose	5	13.12 (3.03)	13.79 (1.95)	13.0	11.9, 16.0	0.67 (1.46)	0.0	-0.4, 3.2	0.3621
High Dose	4	8.06 (5.62)	9.38 (5.58)	11.0	1.4, 14.1	1.32 (8.22)	2.7	-9.9, 9.8	0.7699
WEEK 84	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	40		2.88 (4.65)	0.6	0.0, 16.0				
Low Dose	16		1.68 (3.17)	0.4	0.0, 12.0				
High Dose	24		3.67 (5.33)	0.6	0.0, 16.0				
WEEK 12	27	2.75 (4.93)	2.66 (4.54)	0.0	0.0, 16.0	-0.08 (4.25)	0.0	-15.8, 7.4	0.9188
Low Dose	12	0.64 (1.05)	1.44 (2.70)	0.0	0.0, 8.7	0.80 (2.67)	0.0	-3.5, 7.4	0.3202
High Dose	15	4.43 (6.12)	3.64 (5.50)	0.7	0.0, 16.0	-0.79 (5.17)	0.0	-15.8, 6.7	0.5622
WEEK 24	33	3.10 (4.81)	1.82 (3.37)	0.0	0.0, 16.0	-1.28 (4.61)	0.0	-16.0, 6.2	0.1213
Low Dose	13	1.90 (3.49)	1.24 (2.35)	0.0	0.0, 6.9	-0.66 (4.38)	0.0	-12.0, 6.2	0.5985
High Dose	20	3.88 (5.45)	2.20 (3.90)	0.0	0.0, 16.0	-1.68 (4.82)	0.0	-16.0, 5.1	0.1353

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 36	14	2.64 (4.11)	2.65 (5.59)	0.0	0.0, 16.0	0.01 (5.41)	0.0	-12.9, 11.2	0.9961
Low Dose	6	0.24 (0.59)	0.15 (0.28)	0.0	0.0, 0.7	-0.09 (0.34)	0.0	-0.8, 0.2	0.5663
High Dose	8	4.44 (4.75)	4.51 (6.98)	0.1	0.0, 16.0	0.08 (7.36)	0.0	-12.9, 11.2	0.9771
WEEK 48	20	3.42 (4.84)	1.14 (1.87)	0.0	0.0, 5.5	-2.28 (4.72)	0.0	-12.9, 4.0	0.0434*
Low Dose	8	2.12 (4.18)	0.47 (0.69)	0.0	0.0, 1.7	-1.65 (3.72)	0.0	-10.3, 0.9	0.2503
High Dose	12	4.29 (5.23)	1.59 (2.28)	0.0	0.0, 5.5	-2.70 (5.40)	-0.4	-12.9, 4.0	0.1105
WEEK 60	12	2.99 (5.33)	1.84 (2.27)	1.0	0.0, 5.8	-1.15 (4.19)	0.0	-10.2, 5.7	0.3622
Low Dose	8	2.12 (4.18)	1.66 (2.29)	0.4	0.0, 5.7	-0.46 (3.80)	0.0	-7.3, 5.7	0.7438
High Dose	4	4.74 (7.56)	2.21 (2.53)	1.5	0.0, 5.8	-2.53 (5.18)	-0.5	-10.2, 1.1	0.3998
WEEK 72	9	2.54 (5.27)	1.09 (1.42)	0.5	0.0, 4.2	-1.46 (4.85)	0.0	-14.2, 1.4	0.3944
Low Dose	5	0.29 (0.65)	0.34 (0.54)	0.0	0.0, 1.2	0.05 (0.79)	0.0	-1.0, 1.2	0.8939
High Dose	4	5.36 (7.39)	2.02 (1.71)	2.0	0.0, 4.2	-3.34 (7.31)	-0.3	-14.2, 1.4	0.4285
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	40		0.45 (1.41)	0.0	0.0, 6.3				
Low Dose	16		0.22 (0.83)	0.0	0.0, 3.3				
High Dose	24		0.61 (1.69)	0.0	0.0, 6.3				
WEEK 12	27	0.42 (1.26)	0.19 (0.68)	0.0	0.0, 3.0	-0.23 (1.35)	0.0	-5.3, 3.0	0.3809
Low Dose	12	0.30 (0.95)	0.02 (0.06)	0.0	0.0, 0.2	-0.28 (0.96)	0.0	-3.3, 0.2	0.3362
High Dose	15	0.53 (1.48)	0.33 (0.90)	0.0	0.0, 3.0	-0.19 (1.63)	0.0	-5.3, 3.0	0.6530
WEEK 24	33	0.54 (1.54)	0.45 (1.44)	0.0	0.0, 7.2	-0.08 (1.43)	0.0	-5.3, 4.3	0.7392
Low Dose	13	0.27 (0.92)	0.23 (0.37)	0.0	0.0, 1.1	-0.05 (1.05)	0.0	-3.3, 1.1	0.8765
High Dose	20	0.71 (1.84)	0.60 (1.82)	0.0	0.0, 7.2	-0.11 (1.65)	0.0	-5.3, 4.3	0.7741

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 36	14	0.38 (1.43)	0.25 (0.56)	0.0	0.0, 1.8	-0.13 (1.60)	0.0	-5.3, 1.8	0.7608
Low Dose	6	0.00 (0.00)	0.28 (0.49)	0.0	0.0, 1.2	0.28 (0.49)	0.0	0.0, 1.2	0.2252
High Dose	8	0.67 (1.89)	0.23 (0.64)	0.0	0.0, 1.8	-0.44 (2.08)	0.0	-5.3, 1.8	0.5669
WEEK 48	20	0.29 (0.91)	0.21 (0.53)	0.0	0.0, 2.3	-0.08 (1.09)	0.0	-3.3, 2.3	0.7367
Low Dose	8	0.41 (1.17)	0.12 (0.26)	0.0	0.0, 0.7	-0.30 (1.25)	0.0	-3.3, 0.7	0.5238
High Dose	12	0.21 (0.74)	0.27 (0.66)	0.0	0.0, 2.3	0.06 (1.00)	0.0	-2.3, 2.3	0.8438
WEEK 60	12	0.80 (1.96)	0.23 (0.46)	0.0	0.0, 1.5	-0.57 (2.11)	0.0	-6.3, 1.5	0.3739
Low Dose	8	0.41 (1.17)	0.07 (0.21)	0.0	0.0, 0.6	-0.34 (1.22)	0.0	-3.3, 0.6	0.4560
High Dose	4	1.56 (3.13)	0.55 (0.70)	0.4	0.0, 1.5	-1.02 (3.54)	0.4	-6.3, 1.5	0.6057
WEEK 72	9	0.69 (2.08)	0.79 (1.66)	0.0	0.0, 5.0	0.10 (2.39)	0.0	-4.6, 5.0	0.9029
Low Dose	5	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	4	1.56 (3.13)	1.79 (2.23)	1.1	0.0, 5.0	0.23 (3.90)	0.3	-4.6, 5.0	0.9151
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	40		13.69 (2.55)	14.7	7.2, 16.0				
Low Dose	16		13.12 (2.37)	13.2	7.2, 16.0				
High Dose	24		14.07 (2.65)	15.5	7.9, 16.0				
WEEK 12	27	13.43 (2.66)	13.45 (2.14)	13.8	9.2, 16.0	0.03 (2.69)	0.0	-6.8, 5.3	0.9586
Low Dose	12	12.82 (2.60)	13.57 (1.82)	13.5	10.1, 16.0	0.74 (1.95)	0.7	-2.8, 3.8	0.2139
High Dose	15	13.91 (2.69)	13.37 (2.42)	13.9	9.2, 16.0	-0.55 (3.11)	0.0	-6.8, 5.3	0.5072
WEEK 24	33	13.84 (2.39)	13.13 (3.26)	13.7	5.2, 16.0	-0.71 (2.93)	0.0	-7.8, 4.9	0.1740
Low Dose	13	12.82 (2.34)	13.03 (3.20)	13.6	5.5, 16.0	0.22 (3.25)	0.0	-7.8, 4.9	0.8118
High Dose	20	14.50 (2.24)	13.19 (3.38)	14.4	5.2, 16.0	-1.31 (2.61)	-0.3	-7.7, 3.0	0.0365*

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 36	14	14.30 (2.12)	14.04 (2.11)	14.3	9.1, 16.0	-0.27 (1.57)	-0.3	-2.3, 4.3	0.5345
Low Dose	6	13.70 (2.37)	12.87 (2.77)	12.6	9.1, 16.0	-0.83 (0.91)	-0.7	-2.3, 0.0	0.0758
High Dose	8	14.76 (1.94)	14.91 (0.90)	14.6	14.0, 16.0	0.15 (1.88)	-0.1	-1.6, 4.3	0.8278
WEEK 48	20	14.48 (1.73)	14.21 (2.14)	15.2	9.7, 16.0	-0.27 (2.38)	-0.1	-5.4, 3.8	0.6167
Low Dose	8	13.60 (1.98)	13.88 (2.48)	14.9	9.7, 16.0	0.28 (2.31)	-0.2	-2.7, 3.8	0.7399
High Dose	12	15.06 (1.32)	14.42 (1.97)	15.2	10.4, 16.0	-0.64 (2.44)	-0.1	-5.4, 2.3	0.3843
WEEK 60	12	13.52 (2.38)	13.74 (2.35)	14.3	9.1, 16.0	0.22 (2.33)	0.0	-3.9, 5.3	0.7528
Low Dose	8	13.19 (1.96)	13.42 (2.68)	13.8	9.1, 16.0	0.24 (1.51)	0.0	-1.8, 3.0	0.6710
High Dose	4	14.19 (3.30)	14.37 (1.63)	14.7	12.1, 16.0	0.18 (3.83)	-0.4	-3.9, 5.3	0.9312
WEEK 72	9	13.42 (2.67)	12.92 (3.14)	14.1	5.6, 16.0	-0.50 (4.47)	0.5	-10.4, 5.1	0.7462
Low Dose	5	13.41 (2.53)	14.13 (1.79)	14.3	12.3, 16.0	0.72 (0.92)	0.5	0.0, 2.2	0.1553
High Dose	4	13.42 (3.25)	11.40 (4.07)	12.8	5.6, 14.3	-2.02 (6.83)	-1.4	-10.4, 5.1	0.5954
WEEK 84	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:NORTH AMERICA (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
Geographic region:EUROPE AND AUSTRALIA									
Average Daily Normalized 'Off' Time									
BASELINE	46		2.64 (3.19)	1.2	0.0, 11.5				
Low Dose	22		2.46 (3.05)	1.3	0.0, 10.9				
High Dose	24		2.79 (3.36)	1.1	0.0, 11.5				
WEEK 12	37	2.78 (3.38)	2.81 (3.18)	1.9	0.0, 10.9	0.04 (2.85)	0.0	-8.2, 10.9	0.9368
Low Dose	19	2.29 (3.19)	1.83 (2.10)	1.5	0.0, 7.3	-0.46 (2.32)	0.0	-8.2, 1.9	0.3964
High Dose	18	3.29 (3.60)	3.85 (3.82)	3.6	0.0, 10.9	0.56 (3.31)	0.0	-6.4, 10.9	0.4797
WEEK 24	33	2.44 (2.62)	3.18 (4.10)	1.7	0.0, 16.0	0.73 (3.26)	0.0	-5.7, 13.3	0.2055
Low Dose	17	2.43 (2.60)	2.81 (4.43)	1.2	0.0, 16.0	0.38 (3.94)	0.0	-5.7, 13.3	0.6947
High Dose	16	2.45 (2.73)	3.56 (3.83)	2.3	0.0, 13.4	1.11 (2.43)	0.3	-3.1, 5.2	0.0878

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 36	20	2.43 (2.82)	2.46 (3.17)	1.4	0.0, 12.1	0.03 (1.99)	0.0	-3.9, 5.6	0.9437
Low Dose	13	2.25 (2.58)	2.59 (3.69)	1.2	0.0, 12.1	0.34 (1.67)	0.0	-1.1, 5.6	0.4772
High Dose	7	2.76 (3.41)	2.22 (2.11)	1.6	0.0, 4.9	-0.54 (2.52)	0.0	-3.9, 3.6	0.5916
WEEK 48	28	2.33 (2.65)	3.42 (4.40)	1.2	0.0, 14.3	1.09 (2.61)	0.0	-2.3, 7.4	0.0353*
Low Dose	12	2.17 (2.67)	2.53 (3.75)	0.2	0.0, 10.1	0.36 (2.50)	0.0	-2.3, 7.4	0.6290
High Dose	16	2.45 (2.73)	4.09 (4.84)	1.2	0.0, 14.3	1.64 (2.63)	0.5	-1.0, 6.6	0.0246*
WEEK 60	14	3.21 (3.10)	3.67 (3.33)	3.0	0.0, 10.4	0.46 (1.64)	0.0	-2.0, 3.9	0.3151
Low Dose	7	3.09 (3.10)	3.15 (3.98)	1.2	0.0, 10.4	0.07 (1.76)	-0.2	-1.2, 3.9	0.9252
High Dose	7	3.34 (3.33)	4.19 (2.75)	3.1	0.0, 7.1	0.85 (1.53)	1.0	-2.0, 2.4	0.1926
WEEK 72	1	0.00 (N/A)	0.80 (N/A)	0.8	0.8, 0.8	0.80 (N/A)	0.8	0.8, 0.8	
Low Dose	1	0.00 (N/A)	0.80 (N/A)	0.8	0.8, 0.8	0.80 (N/A)	0.8	0.8, 0.8	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	46		10.68 (5.08)	12.8	0.0, 16.0				
Low Dose	22		10.89 (5.16)	12.8	0.0, 16.0				
High Dose	24		10.49 (5.11)	12.8	0.4, 16.0				
WEEK 12	37	10.86 (5.18)	11.58 (4.60)	12.7	0.0, 16.0	0.72 (3.73)	0.0	-10.9, 14.2	0.2462
Low Dose	19	10.81 (5.56)	11.93 (4.90)	13.6	0.0, 16.0	1.12 (3.84)	0.0	-1.4, 14.2	0.2212
High Dose	18	10.91 (4.90)	11.21 (4.37)	11.7	3.6, 16.0	0.31 (3.67)	0.0	-10.9, 6.2	0.7269
WEEK 24	33	10.81 (4.83)	10.49 (5.08)	11.3	0.0, 16.0	-0.32 (4.37)	0.0	-13.3, 14.2	0.6806
Low Dose	17	10.94 (4.96)	10.52 (5.82)	13.5	0.0, 16.0	-0.42 (5.32)	0.0	-13.3, 14.2	0.7465
High Dose	16	10.66 (4.85)	10.46 (4.34)	10.7	2.6, 16.0	-0.20 (3.24)	-0.3	-6.3, 5.5	0.8078
WEEK 36	20	11.67 (4.29)	12.08 (4.18)	13.0	3.4, 16.0	0.42 (3.73)	0.0	-5.9, 14.2	0.6219
Low Dose	13	12.11 (4.14)	12.73 (4.29)	14.8	3.4, 16.0	0.61 (4.50)	0.0	-5.9, 14.2	0.6320
High Dose	7	10.84 (4.77)	10.89 (4.01)	11.9	6.4, 16.0	0.06 (1.86)	0.2	-3.6, 2.4	0.9376

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 48	28	10.13 (5.21)	10.01 (5.07)	9.7	0.0, 16.0	-0.12 (4.28)	0.0	-8.0, 13.7	0.8810
Low Dose	12	10.72 (5.33)	10.74 (4.90)	10.4	1.1, 16.0	0.02 (5.54)	0.3	-8.0, 13.7	0.9914
High Dose	16	9.69 (5.25)	9.46 (5.29)	9.3	0.0, 16.0	-0.23 (3.22)	-0.0	-6.6, 5.3	0.7822
WEEK 60	14	9.80 (4.84)	10.75 (4.22)	9.4	4.3, 16.0	0.95 (4.49)	0.1	-4.7, 13.9	0.4411
Low Dose	7	10.18 (4.80)	10.97 (4.81)	9.5	4.5, 16.0	0.78 (6.11)	-0.9	-4.7, 13.9	0.7463
High Dose	7	9.41 (5.22)	10.54 (3.90)	9.2	4.3, 16.0	1.13 (2.51)	1.0	-2.0, 5.8	0.2806
WEEK 72	1	16.00 (N/A)	15.20 (N/A)	15.2	15.2, 15.2	-0.80 (N/A)	-0.8	-0.8, -0.8	
Low Dose	1	16.00 (N/A)	15.20 (N/A)	15.2	15.2, 15.2	-0.80 (N/A)	-0.8	-0.8, -0.8	
High Dose	0								
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	46		2.06 (4.04)	0.1	0.0, 16.0				
Low Dose	22		1.83 (4.11)	0.0	0.0, 16.0				
High Dose	24		2.27 (4.06)	0.4	0.0, 15.6				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 12	37	1.64 (3.64)	1.14 (2.42)	0.0	0.0, 11.6	-0.49 (3.73)	0.0	-11.6, 11.6	0.4290
Low Dose	19	1.96 (4.39)	1.63 (3.21)	0.0	0.0, 11.6	-0.33 (4.75)	0.0	-11.6, 11.6	0.7685
High Dose	18	1.30 (2.71)	0.63 (0.99)	0.0	0.0, 2.8	-0.67 (2.35)	0.0	-8.8, 1.8	0.2464
WEEK 24	33	2.34 (3.97)	1.87 (3.43)	0.0	0.0, 16.0	-0.47 (3.37)	0.0	-11.6, 6.1	0.4246
Low Dose	17	2.37 (4.57)	2.16 (3.92)	0.3	0.0, 16.0	-0.20 (3.14)	0.0	-11.6, 3.3	0.7921
High Dose	16	2.32 (3.38)	1.56 (2.92)	0.0	0.0, 10.2	-0.76 (3.68)	-0.1	-10.7, 6.1	0.4207
WEEK 36	20	1.65 (3.17)	1.29 (2.17)	0.1	0.0, 8.1	-0.36 (2.80)	0.0	-11.6, 2.9	0.5714
Low Dose	13	1.41 (3.25)	0.69 (1.12)	0.0	0.0, 3.0	-0.73 (3.35)	0.0	-11.6, 1.8	0.4499
High Dose	7	2.08 (3.21)	2.40 (3.19)	0.5	0.0, 8.1	0.32 (1.24)	0.0	-1.0, 2.9	0.5229
WEEK 48	28	3.11 (4.86)	2.15 (3.70)	0.4	0.0, 14.9	-0.96 (3.77)	-0.3	-11.1, 8.0	0.1870
Low Dose	12	2.86 (5.31)	2.71 (4.66)	0.4	0.0, 14.9	-0.15 (4.29)	-0.1	-11.1, 8.0	0.9058
High Dose	16	3.30 (4.67)	1.72 (2.87)	0.4	0.0, 9.8	-1.57 (3.33)	-0.6	-9.7, 4.9	0.0782
WEEK 60	14	2.43 (3.97)	1.48 (2.00)	0.3	0.0, 5.8	-0.95 (3.68)	0.0	-11.3, 2.7	0.3532
Low Dose	7	2.35 (4.32)	1.85 (2.15)	1.1	0.0, 5.8	-0.50 (4.87)	0.9	-11.3, 2.7	0.7936
High Dose	7	2.51 (3.94)	1.12 (1.93)	0.0	0.0, 4.3	-1.39 (2.26)	-0.7	-6.4, 0.0	0.1555

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 72	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	46		0.62 (2.08)	0.0	0.0, 13.5				
Low Dose	22		0.81 (2.91)	0.0	0.0, 13.5				
High Dose	24		0.45 (0.83)	0.0	0.0, 3.0				
WEEK 12	37	0.73 (2.30)	0.46 (1.94)	0.0	0.0, 11.0	-0.27 (3.03)	0.0	-13.5, 11.0	0.5931
Low Dose	19	0.94 (3.12)	0.62 (2.53)	0.0	0.0, 11.0	-0.33 (4.16)	0.0	-13.5, 11.0	0.7358
High Dose	18	0.51 (0.90)	0.30 (1.06)	0.0	0.0, 4.4	-0.21 (1.03)	0.0	-3.0, 2.2	0.4068
WEEK 24	33	0.41 (0.85)	0.46 (1.48)	0.0	0.0, 7.8	0.06 (1.42)	0.0	-3.0, 6.4	0.8203
Low Dose	17	0.26 (0.71)	0.51 (1.90)	0.0	0.0, 7.8	0.25 (1.72)	0.0	-2.7, 6.4	0.5624
High Dose	16	0.56 (0.97)	0.42 (0.90)	0.0	0.0, 2.4	-0.15 (1.02)	0.0	-3.0, 1.9	0.5748

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 36	20	0.26 (0.76)	0.17 (0.64)	0.0	0.0, 2.8	-0.09 (0.64)	0.0	-2.7, 0.6	0.5348
Low Dose	13	0.23 (0.74)	0.00 (0.00)	0.0	0.0, 0.0	-0.23 (0.74)	0.0	-2.7, 0.0	0.2885
High Dose	7	0.33 (0.86)	0.49 (1.06)	0.0	0.0, 2.8	0.16 (0.28)	0.0	0.0, 0.6	0.1725
WEEK 48	28	0.43 (0.89)	0.42 (1.29)	0.0	0.0, 6.2	-0.01 (1.48)	0.0	-3.0, 6.2	0.9844
Low Dose	12	0.25 (0.77)	0.02 (0.07)	0.0	0.0, 0.2	-0.23 (0.78)	0.0	-2.7, 0.2	0.3356
High Dose	16	0.56 (0.97)	0.72 (1.66)	0.0	0.0, 6.2	0.16 (1.85)	0.0	-3.0, 6.2	0.7340
WEEK 60	14	0.56 (0.97)	0.09 (0.29)	0.0	0.0, 1.1	-0.46 (0.87)	0.0	-2.7, 0.3	0.0666
Low Dose	7	0.38 (1.01)	0.04 (0.10)	0.0	0.0, 0.3	-0.34 (1.03)	0.0	-2.7, 0.3	0.4102
High Dose	7	0.74 (0.96)	0.15 (0.40)	0.0	0.0, 1.1	-0.59 (0.74)	0.0	-1.5, 0.0	0.0801
WEEK 72	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	46		12.74 (3.67)	14.3	2.5, 16.0				
Low Dose	22		12.72 (3.80)	13.9	2.5, 16.0				
High Dose	24		12.76 (3.63)	14.7	4.5, 16.0				
WEEK 12	37	12.49 (3.93)	12.72 (3.55)	13.9	5.0, 16.0	0.23 (3.94)	0.0	-11.0, 11.6	0.7234
Low Dose	19	12.77 (4.04)	13.56 (2.90)	14.1	5.0, 16.0	0.79 (4.44)	0.0	-11.0, 11.6	0.4481
High Dose	18	12.20 (3.90)	11.84 (4.03)	12.4	5.1, 16.0	-0.36 (3.37)	0.0	-10.9, 6.4	0.6573
WEEK 24	33	13.15 (2.83)	12.36 (4.31)	14.1	0.0, 16.0	-0.79 (3.29)	0.0	-13.3, 5.7	0.1769
Low Dose	17	13.31 (2.65)	12.68 (4.84)	14.8	0.0, 16.0	-0.63 (4.01)	0.0	-13.3, 5.7	0.5272
High Dose	16	12.98 (3.09)	12.02 (3.79)	13.7	2.6, 16.0	-0.96 (2.42)	-0.7	-5.2, 3.3	0.1328
WEEK 36	20	13.31 (2.91)	13.37 (3.18)	14.4	3.9, 16.0	0.06 (2.04)	0.0	-5.6, 3.9	0.9000
Low Dose	13	13.53 (2.49)	13.41 (3.69)	14.8	3.9, 16.0	-0.11 (1.87)	0.0	-5.6, 2.7	0.8314
High Dose	7	12.92 (3.77)	13.29 (2.18)	11.9	11.1, 16.0	0.38 (2.46)	0.0	-3.6, 3.9	0.7003

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:EUROPE AND AUSTRALIA (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 48	28	13.24 (2.84)	12.16 (4.36)	14.1	1.7, 16.0	-1.09 (2.92)	0.0	-7.4, 2.7	0.0598
Low Dose	12	13.59 (2.57)	13.45 (3.74)	15.8	5.9, 16.0	-0.13 (2.66)	0.0	-7.4, 2.7	0.8664
High Dose	16	12.98 (3.09)	11.18 (4.64)	12.6	1.7, 16.0	-1.80 (2.98)	-0.5	-6.6, 1.9	0.0290*
WEEK 60	14	12.23 (3.13)	12.24 (3.41)	13.0	5.6, 16.0	0.01 (1.65)	0.0	-3.9, 2.7	0.9861
Low Dose	7	12.53 (2.81)	12.81 (3.96)	14.5	5.6, 16.0	0.28 (2.05)	1.0	-3.9, 2.7	0.7310
High Dose	7	11.93 (3.62)	11.66 (2.96)	12.9	7.8, 16.0	-0.26 (1.24)	-0.5	-2.0, 2.0	0.5954
WEEK 72	1	16.00 (N/A)	15.20 (N/A)	15.2	15.2, 15.2	-0.80 (N/A)	-0.8	-0.8, -0.8	
Low Dose	1	16.00 (N/A)	15.20 (N/A)	15.2	15.2, 15.2	-0.80 (N/A)	-0.8	-0.8, -0.8	
High Dose	0								
Geographic region:JAPAN									
Average Daily Normalized 'Off' Time									
BASELINE	11		4.73 (2.78)	5.3	0.0, 10.1				
Low Dose	7		5.12 (2.84)	5.3	2.3, 10.1				
High Dose	4		4.06 (2.96)	4.9	0.0, 6.4				

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 12	11	4.73 (2.78)	5.09 (2.09)	5.5	2.1, 8.0	0.36 (2.52)	1.5	-4.2, 3.8	0.6468
Low Dose	7	5.12 (2.84)	5.22 (2.14)	5.8	2.5, 8.0	0.10 (2.91)	0.2	-4.2, 3.8	0.9284
High Dose	4	4.06 (2.96)	4.87 (2.31)	4.9	2.1, 7.6	0.81 (1.95)	1.6	-2.1, 2.1	0.4686
WEEK 24	9	4.70 (3.06)	5.46 (3.02)	4.3	2.5, 10.9	0.76 (3.36)	2.1	-6.1, 4.5	0.5157
Low Dose	6	4.96 (3.08)	5.46 (2.37)	4.8	2.5, 8.8	0.50 (3.34)	2.1	-6.1, 2.5	0.7286
High Dose	3	4.17 (3.62)	5.46 (4.74)	2.8	2.6, 10.9	1.29 (4.10)	2.6	-3.3, 4.5	0.6410
WEEK 36	5	4.32 (2.99)	3.65 (1.75)	3.6	1.2, 6.1	-0.67 (3.62)	-0.3	-5.5, 3.9	0.6997
Low Dose	2	4.55 (3.09)	2.41 (1.71)	2.4	1.2, 3.6	-2.15 (4.80)	-2.1	-5.5, 1.2	0.6410
High Dose	3	4.17 (3.62)	4.48 (1.45)	3.9	3.4, 6.1	0.31 (3.34)	-0.3	-2.7, 3.9	0.8866
WEEK 48	4	3.72 (3.09)	4.64 (1.95)	4.7	2.3, 6.9	0.92 (2.18)	0.4	-1.0, 4.0	0.4612
Low Dose	1	2.37 (N/A)	2.32 (N/A)	2.3	2.3, 2.3	-0.04 (N/A)	-0.0	-0.0, -0.0	
High Dose	3	4.17 (3.62)	5.41 (1.45)	5.3	4.0, 6.9	1.24 (2.56)	0.8	-1.0, 4.0	0.4888
WEEK 60	3	2.83 (3.09)	4.13 (0.61)	3.9	3.7, 4.8	1.30 (2.61)	1.3	-1.3, 3.9	0.4794
Low Dose	1	2.37 (N/A)	3.66 (N/A)	3.7	3.7, 3.7	1.30 (N/A)	1.3	1.3, 1.3	
High Dose	2	3.06 (4.33)	4.36 (0.64)	4.4	3.9, 4.8	1.30 (3.69)	1.3	-1.3, 3.9	0.7059

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 72	2	6.26 (0.18)	9.47 (1.31)	9.5	8.5, 10.4	3.21 (1.49)	3.2	2.2, 4.3	0.2021
Low Dose	0								
High Dose	2	6.26 (0.18)	9.47 (1.31)	9.5	8.5, 10.4	3.21 (1.49)	3.2	2.2, 4.3	0.2021
WEEK 84	1	6.13 (N/A)	11.43 (N/A)	11.4	11.4, 11.4	5.30 (N/A)	5.3	5.3, 5.3	
Low Dose	0								
High Dose	1	6.13 (N/A)	11.43 (N/A)	11.4	11.4, 11.4	5.30 (N/A)	5.3	5.3, 5.3	
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	11		9.98 (3.15)	9.6	4.2, 16.0				
Low Dose	7		9.16 (2.90)	9.3	4.2, 13.0				
High Dose	4		11.41 (3.46)	10.8	8.1, 16.0				
WEEK 12	11	9.98 (3.15)	8.41 (4.26)	8.4	1.0, 13.9	-1.57 (3.70)	-1.5	-6.7, 4.2	0.1894
Low Dose	7	9.16 (2.90)	7.56 (4.61)	8.0	1.0, 13.5	-1.60 (4.00)	-1.5	-6.7, 4.2	0.3298
High Dose	4	11.41 (3.46)	9.90 (3.67)	10.1	5.6, 13.9	-1.51 (3.69)	-0.9	-6.4, 2.1	0.4720

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 24	9	9.86 (3.43)	8.23 (3.60)	8.2	1.0, 13.4	-1.63 (3.68)	-2.5	-5.9, 6.6	0.2195
Low Dose	6	9.18 (3.18)	7.67 (3.56)	8.2	1.0, 10.8	-1.52 (4.21)	-2.4	-5.9, 6.6	0.4184
High Dose	3	11.22 (4.21)	9.35 (4.16)	9.6	5.1, 13.4	-1.87 (3.12)	-2.6	-4.5, 1.6	0.4076
WEEK 36	5	9.97 (3.54)	9.26 (5.09)	9.9	1.3, 14.8	-0.71 (4.33)	0.2	-5.6, 5.5	0.7320
Low Dose	2	8.09 (1.66)	8.05 (9.55)	8.0	1.3, 14.8	-0.04 (7.89)	-0.0	-5.6, 5.5	0.9950
High Dose	3	11.22 (4.21)	10.06 (1.95)	9.9	8.2, 12.1	-1.16 (2.37)	0.2	-3.9, 0.3	0.4870
WEEK 48	4	10.14 (4.06)	7.34 (4.81)	7.8	1.8, 12.0	-2.80 (2.69)	-3.6	-5.1, 1.0	0.1286
Low Dose	1	6.92 (N/A)	1.81 (N/A)	1.8	1.8, 1.8	-5.11 (N/A)	-5.1	-5.1, -5.1	
High Dose	3	11.22 (4.21)	9.19 (3.77)	10.7	4.9, 12.0	-2.03 (2.70)	-3.1	-4.0, 1.0	0.3225
WEEK 60	3	10.32 (4.95)	7.08 (5.76)	8.4	0.8, 12.1	-3.25 (3.27)	-3.9	-6.1, 0.3	0.2275
Low Dose	1	6.92 (N/A)	0.78 (N/A)	0.8	0.8, 0.8	-6.13 (N/A)	-6.1	-6.1, -6.1	
High Dose	2	12.03 (5.62)	10.22 (2.64)	10.2	8.4, 12.1	-1.80 (2.98)	-1.8	-3.9, 0.3	0.5492
WEEK 72	2	8.83 (1.10)	5.81 (2.34)	5.8	4.2, 7.5	-3.03 (1.23)	-3.0	-3.9, -2.2	0.1783
Low Dose	0								
High Dose	2	8.83 (1.10)	5.81 (2.34)	5.8	4.2, 7.5	-3.03 (1.23)	-3.0	-3.9, -2.2	0.1783

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 84	1	8.05 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-3.48 (N/A)	-3.5	-3.5, -3.5	
Low Dose	0								
High Dose	1	8.05 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-3.48 (N/A)	-3.5	-3.5, -3.5	
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	11		1.26 (2.04)	0.3	0.0, 6.7				
Low Dose	7		1.69 (2.45)	0.6	0.0, 6.7				
High Dose	4		0.52 (0.88)	0.1	0.0, 1.8				
WEEK 12	11	1.26 (2.04)	2.10 (3.84)	0.0	0.0, 12.4	0.84 (2.56)	0.0	-2.7, 5.7	0.3033
Low Dose	7	1.69 (2.45)	2.60 (4.56)	0.0	0.0, 12.4	0.91 (2.66)	0.0	-2.7, 5.7	0.3991
High Dose	4	0.52 (0.88)	1.23 (2.46)	0.0	0.0, 4.9	0.71 (2.76)	0.0	-1.8, 4.6	0.6447
WEEK 24	9	1.44 (2.24)	2.29 (4.08)	0.0	0.0, 12.4	0.85 (1.94)	0.0	-0.5, 5.7	0.2260
Low Dose	6	1.86 (2.64)	2.84 (4.88)	0.6	0.0, 12.4	0.98 (2.35)	0.0	-0.5, 5.7	0.3553
High Dose	3	0.61 (1.05)	1.19 (2.07)	0.0	0.0, 3.6	0.59 (1.02)	0.0	0.0, 1.8	0.4226

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 36	5	1.71 (2.91)	3.09 (4.86)	0.0	0.0, 11.1	1.38 (2.00)	0.0	0.0, 4.4	0.1974
Low Dose	2	3.36 (4.75)	5.55 (7.85)	5.5	0.0, 11.1	2.19 (3.10)	2.2	0.0, 4.4	0.5000
High Dose	3	0.61 (1.05)	1.45 (2.52)	0.0	0.0, 4.4	0.85 (1.46)	0.0	0.0, 2.5	0.4226
WEEK 48	4	2.14 (3.17)	4.02 (5.60)	2.1	0.0, 11.9	1.88 (2.45)	1.2	0.0, 5.2	0.2223
Low Dose	1	6.72 (N/A)	11.87 (N/A)	11.9	11.9, 11.9	5.15 (N/A)	5.2	5.2, 5.2	
High Dose	3	0.61 (1.05)	1.40 (2.42)	0.0	0.0, 4.2	0.79 (1.37)	0.0	0.0, 2.4	0.4226
WEEK 60	3	2.85 (3.47)	4.79 (6.02)	2.8	0.0, 11.6	1.95 (2.55)	1.0	0.0, 4.8	0.3170
Low Dose	1	6.72 (N/A)	11.55 (N/A)	11.6	11.6, 11.6	4.83 (N/A)	4.8	4.8, 4.8	
High Dose	2	0.91 (1.29)	1.42 (2.00)	1.4	0.0, 2.8	0.50 (0.71)	0.5	0.0, 1.0	0.5000
WEEK 72	2	0.91 (1.29)	0.73 (1.03)	0.7	0.0, 1.5	-0.18 (0.26)	-0.2	-0.4, 0.0	0.5000
Low Dose	0								
High Dose	2	0.91 (1.29)	0.73 (1.03)	0.7	0.0, 1.5	-0.18 (0.26)	-0.2	-0.4, 0.0	0.5000
WEEK 84	1	1.82 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-1.82 (N/A)	-1.8	-1.8, -1.8	
Low Dose	0								
High Dose	1	1.82 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-1.82 (N/A)	-1.8	-1.8, -1.8	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	11		0.02 (0.07)	0.0	0.0, 0.2				
Low Dose	7		0.03 (0.09)	0.0	0.0, 0.2				
High Dose	4		0.00 (0.00)	0.0	0.0, 0.0				
WEEK 12	11	0.02 (0.07)	0.39 (1.30)	0.0	0.0, 4.3	0.37 (1.23)	0.0	0.0, 4.1	0.3409
Low Dose	7	0.03 (0.09)	0.62 (1.63)	0.0	0.0, 4.3	0.59 (1.55)	0.0	0.0, 4.1	0.3559
High Dose	4	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
WEEK 24	9	0.00 (0.00)	0.02 (0.07)	0.0	0.0, 0.2	0.02 (0.07)	0.0	0.0, 0.2	0.3466
Low Dose	6	0.00 (0.00)	0.04 (0.09)	0.0	0.0, 0.2	0.04 (0.09)	0.0	0.0, 0.2	0.3632
High Dose	3	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
WEEK 36	5	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Low Dose	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	3	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 48	4	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	3	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
WEEK 60	3	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
Low Dose	0								
High Dose	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	0								
High Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	11		11.24 (2.80)	10.7	5.9, 16.0				
Low Dose	7		10.85 (2.86)	10.7	5.9, 13.7				
High Dose	4		11.94 (2.96)	11.1	9.6, 16.0				
WEEK 12	11	11.24 (2.80)	10.51 (2.59)	10.5	5.8, 13.9	-0.73 (2.72)	-1.5	-3.8, 4.2	0.3931
Low Dose	7	10.85 (2.86)	10.16 (2.85)	9.9	5.8, 13.5	-0.69 (3.23)	-1.5	-3.8, 4.2	0.5929
High Dose	4	11.94 (2.96)	11.13 (2.31)	11.1	8.4, 13.9	-0.81 (1.95)	-1.6	-2.1, 2.1	0.4686
WEEK 24	9	11.30 (3.06)	10.52 (3.01)	11.4	5.1, 13.5	-0.79 (3.38)	-2.3	-4.5, 6.1	0.5040
Low Dose	6	11.04 (3.08)	10.51 (2.36)	11.1	7.2, 13.5	-0.54 (3.36)	-2.2	-2.5, 6.1	0.7114
High Dose	3	11.83 (3.62)	10.54 (4.74)	13.2	5.1, 13.4	-1.29 (4.10)	-2.6	-4.5, 3.3	0.6410
WEEK 36	5	11.68 (2.99)	12.35 (1.75)	12.4	9.9, 14.8	0.67 (3.62)	0.3	-3.9, 5.5	0.6997
Low Dose	2	11.45 (3.09)	13.59 (1.71)	13.6	12.4, 14.8	2.15 (4.80)	2.1	-1.2, 5.5	0.6410
High Dose	3	11.83 (3.62)	11.52 (1.45)	12.1	9.9, 12.6	-0.31 (3.34)	0.3	-3.9, 2.7	0.8866

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
Geographic region:JAPAN (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 48	4	12.28 (3.09)	11.36 (1.95)	11.3	9.1, 13.7	-0.92 (2.18)	-0.4	-4.0, 1.0	0.4612
Low Dose	1	13.63 (N/A)	13.68 (N/A)	13.7	13.7, 13.7	0.04 (N/A)	0.0	0.0, 0.0	
High Dose	3	11.83 (3.62)	10.59 (1.45)	10.7	9.1, 12.0	-1.24 (2.56)	-0.8	-4.0, 1.0	0.4888
WEEK 60	3	13.17 (3.09)	11.87 (0.61)	12.1	11.2, 12.3	-1.30 (2.61)	-1.3	-3.9, 1.3	0.4794
Low Dose	1	13.63 (N/A)	12.34 (N/A)	12.3	12.3, 12.3	-1.30 (N/A)	-1.3	-1.3, -1.3	
High Dose	2	12.94 (4.33)	11.64 (0.64)	11.6	11.2, 12.1	-1.30 (3.69)	-1.3	-3.9, 1.3	0.7059
WEEK 72	2	9.74 (0.18)	6.53 (1.31)	6.5	5.6, 7.5	-3.21 (1.49)	-3.2	-4.3, -2.2	0.2021
Low Dose	0								
High Dose	2	9.74 (0.18)	6.53 (1.31)	6.5	5.6, 7.5	-3.21 (1.49)	-3.2	-4.3, -2.2	0.2021
WEEK 84	1	9.87 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-5.30 (N/A)	-5.3	-5.3, -5.3	
Low Dose	0								
High Dose	1	9.87 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-5.30 (N/A)	-5.3	-5.3, -5.3	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years									
Average Daily Normalized 'Off' Time									
BASELINE	56		2.91 (3.24)	1.8	0.0, 11.5				
Low Dose	25		3.42 (3.25)	2.6	0.0, 10.9				
High Dose	31		2.50 (3.23)	0.7	0.0, 11.5				
WEEK 12	47	3.12 (3.37)	3.09 (3.00)	2.3	0.0, 10.9	-0.03 (2.97)	0.0	-8.2, 10.9	0.9459
Low Dose	22	3.44 (3.41)	2.79 (2.51)	2.6	0.0, 8.0	-0.66 (2.71)	0.0	-8.2, 3.8	0.2679
High Dose	25	2.84 (3.38)	3.37 (3.41)	2.3	0.0, 10.9	0.52 (3.13)	0.0	-6.4, 10.9	0.4107
WEEK 24	45	2.68 (2.84)	2.94 (3.17)	2.4	0.0, 13.4	0.26 (2.81)	0.0	-6.1, 7.7	0.5346
Low Dose	21	3.49 (2.90)	2.42 (2.22)	2.4	0.0, 7.8	-1.07 (2.49)	-0.0	-6.1, 2.5	0.0630
High Dose	24	1.97 (2.64)	3.40 (3.80)	2.3	0.0, 13.4	1.43 (2.58)	0.3	-3.1, 7.7	0.0123*
WEEK 36	23	2.68 (2.69)	2.44 (2.41)	1.9	0.0, 7.7	-0.24 (1.27)	0.0	-3.9, 1.2	0.3691
Low Dose	13	2.51 (2.41)	2.65 (2.65)	1.9	0.0, 7.7	0.13 (0.73)	0.0	-1.1, 1.2	0.5219
High Dose	10	2.90 (3.15)	2.17 (2.17)	1.8	0.0, 6.1	-0.73 (1.65)	-0.1	-3.9, 1.2	0.1963

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 48	32	2.37 (2.61)	2.77 (3.78)	1.1	0.0, 14.3	0.39 (2.19)	0.0	-3.0, 6.6	0.3203
Low Dose	13	2.29 (2.42)	1.86 (2.31)	0.7	0.0, 6.0	-0.43 (1.20)	0.0	-3.0, 1.6	0.2226
High Dose	19	2.43 (2.80)	3.38 (4.48)	1.1	0.0, 14.3	0.95 (2.55)	0.0	-2.0, 6.6	0.1205
WEEK 60	20	2.71 (2.78)	2.90 (2.81)	2.4	0.0, 7.1	0.18 (1.41)	0.0	-3.0, 2.4	0.5671
Low Dose	14	2.43 (2.38)	2.38 (2.58)	1.8	0.0, 6.9	-0.05 (1.32)	-0.0	-3.0, 1.9	0.8997
High Dose	6	3.38 (3.73)	4.09 (3.18)	4.6	0.0, 7.1	0.72 (1.58)	1.0	-2.0, 2.4	0.3175
WEEK 72	10	2.34 (2.54)	2.45 (2.64)	1.8	0.0, 8.5	0.11 (1.81)	-0.2	-2.2, 3.9	0.8518
Low Dose	6	2.16 (2.50)	1.69 (1.66)	1.3	0.0, 3.7	-0.47 (1.03)	-0.2	-2.2, 0.8	0.3183
High Dose	4	2.61 (2.97)	3.58 (3.67)	2.9	0.0, 8.5	0.97 (2.52)	0.8	-1.7, 3.9	0.4965
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	56		10.14 (4.98)	10.9	0.0, 16.0				
Low Dose	25		10.25 (4.43)	11.0	1.5, 16.0				
High Dose	31		10.05 (5.46)	9.6	0.0, 16.0				
WEEK 12	47	10.23 (5.03)	10.96 (4.61)	11.7	0.0, 16.0	0.73 (3.88)	0.0	-10.9, 14.2	0.2056
Low Dose	22	10.04 (4.67)	11.31 (4.73)	12.8	1.0, 16.0	1.26 (4.13)	0.2	-5.9, 14.2	0.1655
High Dose	25	10.40 (5.42)	10.65 (4.57)	11.1	0.0, 16.0	0.25 (3.66)	0.0	-10.9, 9.0	0.7334
WEEK 24	45	10.34 (4.84)	10.68 (4.77)	10.7	0.0, 16.0	0.33 (4.53)	0.0	-9.6, 14.2	0.6249
Low Dose	21	10.37 (4.06)	11.15 (4.62)	10.7	1.0, 16.0	0.77 (4.39)	0.0	-5.9, 14.2	0.4293
High Dose	24	10.32 (5.52)	10.26 (4.96)	10.9	0.0, 16.0	-0.05 (4.71)	0.0	-9.6, 13.7	0.9564
WEEK 36	23	10.60 (4.70)	11.74 (4.22)	11.9	1.3, 16.0	1.14 (4.49)	0.0	-5.6, 14.2	0.2370
Low Dose	13	11.41 (4.30)	11.69 (4.65)	11.5	1.3, 16.0	0.28 (4.54)	-0.3	-5.6, 14.2	0.8275
High Dose	10	9.55 (5.23)	11.80 (3.83)	12.9	6.4, 16.0	2.25 (4.39)	0.6	-0.6, 14.0	0.1394

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 48	32	10.02 (5.07)	11.12 (4.95)	10.7	0.0, 16.0	1.10 (4.79)	0.0	-6.6, 14.9	0.2028
Low Dose	13	11.10 (4.33)	12.30 (4.47)	15.3	1.8, 16.0	1.20 (4.90)	0.0	-5.1, 13.7	0.3948
High Dose	19	9.27 (5.50)	10.31 (5.21)	10.7	0.0, 16.0	1.03 (4.84)	0.0	-6.6, 14.9	0.3643
WEEK 60	20	9.92 (4.67)	10.77 (4.39)	10.2	0.8, 16.0	0.85 (4.20)	0.0	-6.1, 13.9	0.3744
Low Dose	14	11.16 (4.16)	11.27 (4.51)	10.6	0.8, 16.0	0.12 (4.68)	-0.7	-6.1, 13.9	0.9272
High Dose	6	7.03 (4.86)	9.61 (4.25)	9.2	4.3, 16.0	2.58 (2.27)	1.8	0.3, 6.3	0.0387*
WEEK 72	10	11.22 (4.89)	12.77 (2.70)	12.7	7.5, 16.0	1.55 (3.41)	0.2	-2.2, 9.8	0.1835
Low Dose	6	13.60 (2.96)	14.03 (1.84)	14.1	11.9, 16.0	0.42 (1.43)	0.0	-0.8, 3.2	0.5010
High Dose	4	7.64 (5.36)	10.88 (2.88)	11.0	7.5, 14.1	3.24 (5.00)	2.7	-2.2, 9.8	0.2854
WEEK 84	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	56		2.34 (4.33)	0.0	0.0, 16.0				
Low Dose	25		1.50 (2.77)	0.0	0.0, 11.8				
High Dose	31		3.02 (5.21)	0.2	0.0, 16.0				
WEEK 12	47	2.04 (4.13)	1.79 (3.59)	0.0	0.0, 16.0	-0.26 (3.82)	0.0	-15.8, 11.6	0.6469
Low Dose	22	1.56 (2.90)	1.91 (3.77)	0.0	0.0, 12.4	0.35 (4.03)	0.0	-11.6, 11.6	0.6910
High Dose	25	2.47 (4.99)	1.68 (3.49)	0.0	0.0, 16.0	-0.79 (3.63)	0.0	-15.8, 4.6	0.2881
WEEK 24	45	2.54 (4.27)	1.89 (3.48)	0.0	0.0, 16.0	-0.64 (4.02)	0.0	-16.0, 6.2	0.2881
Low Dose	21	1.78 (2.94)	1.96 (3.13)	0.2	0.0, 12.4	0.17 (3.45)	0.0	-11.6, 6.2	0.8196
High Dose	24	3.19 (5.14)	1.84 (3.83)	0.0	0.0, 16.0	-1.36 (4.40)	0.0	-16.0, 4.5	0.1434
WEEK 36	23	2.50 (3.96)	1.60 (2.92)	0.0	0.0, 11.1	-0.90 (3.99)	0.0	-12.9, 4.4	0.2891
Low Dose	13	1.87 (3.56)	1.54 (3.08)	0.2	0.0, 11.1	-0.34 (3.62)	0.0	-11.6, 4.4	0.7427
High Dose	10	3.32 (4.49)	1.68 (2.85)	0.0	0.0, 8.1	-1.64 (4.50)	0.0	-12.9, 2.9	0.2798

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 48	32	3.23 (4.80)	1.75 (3.06)	0.0	0.0, 11.9	-1.48 (4.29)	0.0	-12.9, 5.2	0.0598
Low Dose	13	2.14 (3.54)	1.74 (3.46)	0.0	0.0, 11.9	-0.40 (3.82)	0.0	-11.1, 5.2	0.7106
High Dose	19	3.97 (5.47)	1.75 (2.85)	0.0	0.0, 9.8	-2.22 (4.54)	0.0	-12.9, 4.9	0.0469*
WEEK 60	20	2.58 (4.34)	2.16 (3.06)	0.7	0.0, 11.6	-0.41 (4.11)	0.0	-11.3, 5.7	0.6577
Low Dose	14	1.99 (3.45)	2.29 (3.37)	0.7	0.0, 11.6	0.30 (4.06)	0.0	-11.3, 5.7	0.7899
High Dose	6	3.94 (6.11)	1.88 (2.40)	0.9	0.0, 5.8	-2.07 (4.07)	-0.8	-10.2, 1.1	0.2689
WEEK 72	10	1.82 (5.01)	0.56 (0.84)	0.0	0.0, 2.2	-1.26 (4.61)	0.0	-14.2, 1.4	0.4115
Low Dose	6	0.24 (0.59)	0.28 (0.50)	0.0	0.0, 1.2	0.04 (0.71)	0.0	-1.0, 1.2	0.8905
High Dose	4	4.19 (7.88)	0.98 (1.15)	0.9	0.0, 2.2	-3.20 (7.39)	0.0	-14.2, 1.4	0.4497
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	56		0.61 (2.07)	0.0	0.0, 13.5				
Low Dose	25		0.84 (2.78)	0.0	0.0, 13.5				
High Dose	31		0.43 (1.26)	0.0	0.0, 6.3				
WEEK 12	47	0.60 (2.09)	0.16 (0.72)	0.0	0.0, 4.4	-0.44 (2.10)	0.0	-13.5, 2.2	0.1578
Low Dose	22	0.95 (2.95)	0.00 (0.00)	0.0	0.0, 0.0	-0.95 (2.95)	0.0	-13.5, 0.0	0.1451
High Dose	25	0.29 (0.72)	0.30 (0.97)	0.0	0.0, 4.4	0.01 (0.60)	0.0	-1.3, 2.2	0.9224
WEEK 24	45	0.44 (1.21)	0.49 (1.61)	0.0	0.0, 7.8	0.05 (1.27)	0.0	-3.3, 6.4	0.7978
Low Dose	21	0.35 (0.94)	0.48 (1.71)	0.0	0.0, 7.8	0.12 (1.74)	0.0	-3.3, 6.4	0.7469
High Dose	24	0.52 (1.42)	0.50 (1.55)	0.0	0.0, 7.2	-0.02 (0.68)	0.0	-2.1, 1.9	0.9043
WEEK 36	23	0.22 (0.72)	0.22 (0.64)	0.0	0.0, 2.8	0.01 (0.66)	0.0	-2.7, 1.2	0.9610
Low Dose	13	0.21 (0.74)	0.13 (0.35)	0.0	0.0, 1.2	-0.08 (0.85)	0.0	-2.7, 1.2	0.7510
High Dose	10	0.23 (0.72)	0.34 (0.90)	0.0	0.0, 2.8	0.12 (0.24)	0.0	0.0, 0.6	0.1680

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 48	32	0.38 (0.93)	0.37 (1.19)	0.0	0.0, 6.2	-0.01 (1.46)	0.0	-3.3, 6.2	0.9669
Low Dose	13	0.46 (1.13)	0.09 (0.21)	0.0	0.0, 0.7	-0.37 (1.19)	0.0	-3.3, 0.7	0.2859
High Dose	19	0.32 (0.80)	0.56 (1.52)	0.0	0.0, 6.2	0.23 (1.60)	0.0	-2.3, 6.2	0.5333
WEEK 60	20	0.79 (1.65)	0.17 (0.40)	0.0	0.0, 1.5	-0.62 (1.70)	0.0	-6.3, 1.5	0.1180
Low Dose	14	0.43 (1.09)	0.06 (0.17)	0.0	0.0, 0.6	-0.37 (1.13)	0.0	-3.3, 0.6	0.2470
High Dose	6	1.64 (2.44)	0.42 (0.66)	0.0	0.0, 1.5	-1.22 (2.66)	-0.6	-6.3, 1.5	0.3110
WEEK 72	10	0.63 (1.98)	0.22 (0.54)	0.0	0.0, 1.7	-0.41 (1.47)	0.0	-4.6, 0.5	0.4065
Low Dose	6	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	4	1.56 (3.13)	0.55 (0.79)	0.3	0.0, 1.7	-1.01 (2.39)	0.0	-4.6, 0.5	0.4575
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	56		12.48 (3.55)	13.4	2.5, 16.0				
Low Dose	25		11.75 (3.63)	13.0	2.5, 16.0				
High Dose	31		13.07 (3.44)	14.9	4.5, 16.0				
WEEK 12	47	12.28 (3.68)	12.75 (3.11)	13.7	5.1, 16.0	0.47 (3.48)	0.0	-10.9, 11.6	0.3610
Low Dose	22	11.60 (3.80)	13.21 (2.51)	13.4	8.0, 16.0	1.61 (3.50)	1.3	-3.8, 11.6	0.0428*
High Dose	25	12.87 (3.54)	12.33 (3.55)	13.7	5.1, 16.0	-0.54 (3.21)	0.0	-10.9, 6.4	0.4118
WEEK 24	45	12.88 (2.93)	12.57 (3.58)	13.6	2.6, 16.0	-0.31 (2.94)	0.0	-7.7, 6.1	0.4813
Low Dose	21	12.16 (2.78)	13.10 (2.87)	13.6	5.4, 16.0	0.95 (2.68)	0.0	-3.3, 6.1	0.1208
High Dose	24	13.51 (2.97)	12.10 (4.10)	13.7	2.6, 16.0	-1.41 (2.75)	-0.6	-7.7, 3.3	0.0193*
WEEK 36	23	13.10 (2.76)	13.34 (2.50)	14.0	8.3, 16.0	0.24 (1.42)	0.0	-2.3, 3.9	0.4349
Low Dose	13	13.28 (2.29)	13.23 (2.76)	14.1	8.3, 16.0	-0.06 (1.24)	0.0	-2.3, 2.7	0.8717
High Dose	10	12.87 (3.40)	13.48 (2.24)	14.0	9.9, 16.0	0.61 (1.61)	0.1	-1.2, 3.9	0.2570

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:<10 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 48	32	13.25 (2.69)	12.87 (3.85)	14.5	1.7, 16.0	-0.38 (2.66)	0.0	-6.6, 3.8	0.4243
Low Dose	13	13.25 (2.27)	14.04 (2.41)	15.3	9.7, 16.0	0.80 (1.74)	0.0	-2.3, 3.8	0.1238
High Dose	19	13.25 (3.00)	12.06 (4.47)	13.8	1.7, 16.0	-1.19 (2.92)	0.0	-6.6, 2.3	0.0928
WEEK 60	20	12.49 (2.92)	12.94 (2.89)	13.3	7.8, 16.0	0.44 (1.95)	0.0	-3.9, 5.3	0.3259
Low Dose	14	13.15 (2.22)	13.56 (2.58)	14.0	9.1, 16.0	0.41 (1.41)	0.0	-1.8, 3.0	0.2950
High Dose	6	10.98 (3.95)	11.49 (3.30)	10.7	7.8, 16.0	0.51 (3.05)	0.2	-3.9, 5.3	0.7003
WEEK 72	10	13.04 (2.79)	13.33 (2.55)	14.2	7.5, 16.0	0.30 (2.55)	0.2	-4.4, 5.1	0.7218
Low Dose	6	13.84 (2.50)	14.31 (1.66)	14.7	12.3, 16.0	0.47 (1.03)	0.2	-0.8, 2.2	0.3183
High Dose	4	11.83 (3.13)	11.87 (3.19)	12.8	7.5, 14.3	0.04 (4.19)	-0.2	-4.4, 5.1	0.9856
WEEK 84	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								
WEEK 96	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	1	16.00 (N/A)	16.00 (N/A)	16.0	16.0, 16.0	0.00 (N/A)	0.0	0.0, 0.0	
High Dose	0								

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years									
Average Daily Normalized 'Off' Time									
BASELINE	41		2.06 (2.47)	0.7	0.0, 8.1				
Low Dose	20		2.35 (2.36)	2.1	0.0, 6.7				
High Dose	21		1.79 (2.60)	0.5	0.0, 8.1				
WEEK 12	28	2.36 (2.70)	2.79 (2.56)	2.3	0.0, 8.0	0.44 (1.78)	0.3	-4.3, 4.2	0.2042
Low Dose	16	2.38 (2.56)	2.44 (2.17)	2.3	0.0, 7.3	0.05 (1.39)	0.0	-4.2, 1.8	0.8793
High Dose	12	2.32 (2.99)	3.26 (3.05)	2.9	0.0, 8.0	0.95 (2.15)	1.2	-4.3, 4.2	0.1552
WEEK 24	30	1.86 (2.26)	3.38 (4.17)	2.3	0.0, 16.0	1.51 (3.14)	0.1	-3.3, 13.3	0.0131*
Low Dose	15	2.37 (2.32)	4.36 (5.07)	2.5	0.0, 16.0	1.98 (3.95)	0.0	-2.3, 13.3	0.0721
High Dose	15	1.35 (2.15)	2.40 (2.87)	2.3	0.0, 7.7	1.05 (2.08)	0.9	-3.3, 5.2	0.0718
WEEK 36	16	1.68 (2.55)	2.21 (3.05)	1.4	0.0, 12.1	0.53 (2.55)	0.0	-5.5, 5.6	0.4198
Low Dose	8	2.43 (2.86)	2.64 (4.04)	1.6	0.0, 12.1	0.21 (3.01)	0.0	-5.5, 5.6	0.8498
High Dose	8	0.92 (2.12)	1.77 (1.80)	1.4	0.0, 4.1	0.85 (2.14)	0.5	-2.7, 3.9	0.3002

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'Off' Time (Cont.)									
WEEK 48	20	1.44 (1.99)	2.88 (3.34)	1.4	0.0, 10.1	1.44 (2.30)	0.6	-1.4, 7.4	0.0116*
Low Dose	8	1.81 (2.21)	3.05 (4.18)	0.9	0.0, 10.1	1.24 (2.90)	0.0	-1.4, 7.4	0.2641
High Dose	12	1.19 (1.89)	2.76 (2.84)	2.0	0.0, 8.6	1.57 (1.95)	0.7	-0.3, 6.1	0.0175*
WEEK 60	9	2.15 (2.56)	3.35 (3.04)	3.0	0.0, 10.4	1.20 (1.93)	0.5	-1.3, 3.9	0.0987
Low Dose	2	4.58 (2.71)	6.19 (5.93)	6.2	2.0, 10.4	1.61 (3.22)	1.6	-0.7, 3.9	0.6082
High Dose	7	1.45 (2.23)	2.54 (1.74)	3.0	0.0, 4.8	1.09 (1.78)	0.5	-1.3, 3.9	0.1578
WEEK 72	2	3.06 (4.33)	7.92 (3.49)	7.9	5.5, 10.4	4.86 (0.84)	4.9	4.3, 5.5	0.0774
Low Dose	0								
High Dose	2	3.06 (4.33)	7.92 (3.49)	7.9	5.5, 10.4	4.86 (0.84)	4.9	4.3, 5.5	0.0774
WEEK 84	1	6.13 (N/A)	11.43 (N/A)	11.4	11.4, 11.4	5.30 (N/A)	5.3	5.3, 5.3	
Low Dose	0								
High Dose	1	6.13 (N/A)	11.43 (N/A)	11.4	11.4, 11.4	5.30 (N/A)	5.3	5.3, 5.3	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia									
BASELINE	41		11.37 (4.61)	13.3	0.0, 16.0				
Low Dose	20		11.54 (4.51)	12.8	0.0, 16.0				
High Dose	21		11.21 (4.82)	13.3	1.3, 16.0				
WEEK 12	28	11.39 (4.69)	10.61 (4.75)	11.8	0.0, 16.0	-0.77 (3.28)	-0.6	-9.6, 6.2	0.2222
Low Dose	16	12.17 (4.09)	11.01 (4.76)	12.8	0.0, 16.0	-1.16 (2.80)	-0.8	-6.7, 4.2	0.1192
High Dose	12	10.34 (5.38)	10.08 (4.89)	9.8	0.0, 16.0	-0.26 (3.89)	0.0	-9.6, 6.2	0.8202
WEEK 24	30	11.15 (4.80)	10.43 (4.81)	10.7	0.0, 16.0	-0.71 (4.37)	0.0	-13.3, 6.5	0.3800
Low Dose	15	11.02 (4.93)	9.61 (5.84)	11.8	0.0, 16.0	-1.41 (4.65)	-0.1	-13.3, 4.2	0.2600
High Dose	15	11.27 (4.84)	11.26 (3.52)	9.7	6.0, 16.0	-0.01 (4.11)	0.0	-9.2, 6.5	0.9900
WEEK 36	16	12.67 (4.04)	11.09 (5.50)	12.9	0.0, 16.0	-1.58 (3.83)	-0.2	-11.2, 5.5	0.1208
Low Dose	8	13.26 (2.76)	13.23 (4.23)	14.4	3.4, 16.0	-0.03 (3.15)	0.0	-5.9, 5.5	0.9822
High Dose	8	12.07 (5.16)	8.95 (6.04)	10.6	0.0, 16.0	-3.13 (4.01)	-2.5	-11.2, 0.8	0.0631

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time Without Dyskinesia (Cont.)									
WEEK 48	20	11.24 (5.09)	10.76 (4.36)	12.2	1.1, 16.0	-0.48 (4.83)	-0.4	-9.4, 11.4	0.6598
Low Dose	8	10.38 (6.33)	9.75 (5.07)	10.2	1.1, 15.7	-0.63 (6.15)	-0.9	-8.0, 11.4	0.7794
High Dose	12	11.81 (4.29)	11.43 (3.90)	12.2	4.9, 16.0	-0.38 (4.02)	-0.4	-9.4, 5.3	0.7479
WEEK 60	9	10.68 (5.65)	11.01 (3.55)	12.1	4.5, 16.0	0.33 (4.18)	0.0	-4.7, 8.0	0.8209
Low Dose	2	5.29 (5.60)	6.92 (3.41)	6.9	4.5, 9.3	1.63 (9.01)	1.6	-4.7, 8.0	0.8404
High Dose	7	12.22 (4.99)	12.18 (2.79)	13.0	8.4, 16.0	-0.05 (3.00)	0.0	-3.9, 5.8	0.9682
WEEK 72	2	9.67 (2.29)	2.79 (1.93)	2.8	1.4, 4.2	-6.88 (4.22)	-6.9	-9.9, -3.9	0.2606
Low Dose	0								
High Dose	2	9.67 (2.29)	2.79 (1.93)	2.8	1.4, 4.2	-6.88 (4.22)	-6.9	-9.9, -3.9	0.2606
WEEK 84	1	8.05 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-3.48 (N/A)	-3.5	-3.5, -3.5	
Low Dose	0								
High Dose	1	8.05 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-3.48 (N/A)	-3.5	-3.5, -3.5	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia									
BASELINE	41		2.26 (3.93)	0.6	0.0, 16.0				
Low Dose	20		2.07 (4.32)	0.6	0.0, 16.0				
High Dose	21		2.44 (3.62)	0.7	0.0, 10.7				
WEEK 12	28	1.88 (3.81)	1.91 (3.55)	0.1	0.0, 16.0	0.03 (3.74)	0.0	-11.0, 7.4	0.9655
Low Dose	16	1.40 (3.92)	1.53 (2.54)	0.1	0.0, 8.7	0.14 (3.64)	0.0	-11.0, 7.4	0.8817
High Dose	12	2.52 (3.72)	2.41 (4.64)	0.5	0.0, 16.0	-0.11 (4.04)	0.0	-8.8, 6.7	0.9255
WEEK 24	30	2.62 (4.18)	1.91 (3.43)	0.0	0.0, 16.0	-0.71 (3.70)	0.0	-12.0, 6.1	0.3044
Low Dose	15	2.58 (4.91)	1.92 (4.20)	0.0	0.0, 16.0	-0.65 (3.61)	0.0	-12.0, 4.5	0.4944
High Dose	15	2.66 (3.46)	1.90 (2.59)	0.0	0.0, 6.1	-0.76 (3.92)	0.0	-10.7, 6.1	0.4653
WEEK 36	16	1.31 (2.50)	2.59 (5.27)	0.0	0.0, 16.0	1.29 (3.29)	0.0	-2.0, 11.2	0.1384
Low Dose	8	0.27 (0.48)	0.12 (0.23)	0.0	0.0, 0.5	-0.15 (0.57)	0.0	-1.4, 0.5	0.4864
High Dose	8	2.34 (3.28)	5.06 (6.74)	2.3	0.0, 16.0	2.72 (4.26)	1.3	-2.0, 11.2	0.1137

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time With Non-Troublesome Dyskinesia (Cont.)									
WEEK 48	20	3.04 (4.62)	2.16 (3.75)	0.6	0.0, 14.9	-0.88 (4.04)	-0.3	-10.3, 8.0	0.3416
Low Dose	8	3.77 (6.42)	3.20 (5.45)	0.5	0.0, 14.9	-0.57 (4.91)	-0.3	-10.3, 8.0	0.7500
High Dose	12	2.55 (3.15)	1.46 (2.03)	0.6	0.0, 5.5	-1.09 (3.58)	-0.4	-9.7, 4.0	0.3154
WEEK 60	9	3.00 (4.81)	1.56 (1.90)	1.1	0.0, 4.7	-1.44 (3.14)	0.0	-7.3, 1.0	0.2067
Low Dose	2	6.13 (8.31)	2.89 (2.52)	2.9	1.1, 4.7	-3.24 (5.79)	-3.2	-7.3, 0.9	0.5738
High Dose	7	2.10 (3.90)	1.18 (1.74)	0.0	0.0, 4.3	-0.92 (2.47)	0.0	-6.4, 1.0	0.3630
WEEK 72	2	3.26 (2.04)	2.81 (1.91)	2.8	1.5, 4.2	-0.46 (0.13)	-0.5	-0.5, -0.4	0.1220
Low Dose	0								
High Dose	2	3.26 (2.04)	2.81 (1.91)	2.8	1.5, 4.2	-0.46 (0.13)	-0.5	-0.5, -0.4	0.1220
WEEK 84	1	1.82 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-1.82 (N/A)	-1.8	-1.8, -1.8	
Low Dose	0								
High Dose	1	1.82 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	-1.82 (N/A)	-1.8	-1.8, -1.8	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia									
BASELINE	41		0.31 (0.97)	0.0	0.0, 5.3				
Low Dose	20		0.04 (0.09)	0.0	0.0, 0.3				
High Dose	21		0.56 (1.32)	0.0	0.0, 5.3				
WEEK 12	28	0.38 (1.14)	0.69 (2.25)	0.0	0.0, 11.0	0.31 (2.61)	0.0	-5.3, 11.0	0.5400
Low Dose	16	0.05 (0.10)	1.02 (2.88)	0.0	0.0, 11.0	0.97 (2.88)	0.0	-0.3, 11.0	0.1987
High Dose	12	0.82 (1.67)	0.25 (0.86)	0.0	0.0, 3.0	-0.58 (1.99)	0.0	-5.3, 3.0	0.3386
WEEK 24	30	0.37 (1.12)	0.28 (0.88)	0.0	0.0, 4.3	-0.10 (1.41)	0.0	-5.3, 4.3	0.7139
Low Dose	15	0.04 (0.09)	0.12 (0.23)	0.0	0.0, 0.8	0.08 (0.23)	0.0	-0.3, 0.8	0.1990
High Dose	15	0.71 (1.54)	0.44 (1.22)	0.0	0.0, 4.3	-0.27 (2.01)	0.0	-5.3, 4.3	0.6074
WEEK 36	16	0.35 (1.33)	0.11 (0.45)	0.0	0.0, 1.8	-0.24 (1.43)	0.0	-5.3, 1.8	0.5166
Low Dose	8	0.04 (0.10)	0.00 (0.00)	0.0	0.0, 0.0	-0.04 (0.10)	0.0	-0.3, 0.0	0.3506
High Dose	8	0.67 (1.89)	0.23 (0.64)	0.0	0.0, 1.8	-0.44 (2.08)	0.0	-5.3, 1.8	0.5669

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time With Troublesome Dyskinesia (Cont.)									
WEEK 48	20	0.28 (0.75)	0.21 (0.61)	0.0	0.0, 2.3	-0.07 (0.90)	0.0	-3.0, 2.3	0.7176
Low Dose	8	0.04 (0.10)	0.00 (0.00)	0.0	0.0, 0.0	-0.04 (0.10)	0.0	-0.3, 0.0	0.3506
High Dose	12	0.45 (0.94)	0.35 (0.77)	0.0	0.0, 2.3	-0.10 (1.17)	0.0	-3.0, 2.3	0.7762
WEEK 60	9	0.17 (0.52)	0.08 (0.24)	0.0	0.0, 0.7	-0.09 (0.60)	0.0	-1.5, 0.7	0.6588
Low Dose	2	0.00 (0.00)	0.00 (0.00)	0.0	0.0, 0.0	0.00 (0.00)	0.0	0.0, 0.0	
High Dose	7	0.22 (0.59)	0.10 (0.27)	0.0	0.0, 0.7	-0.12 (0.69)	0.0	-1.5, 0.7	0.6672
WEEK 72	2	0.00 (0.00)	2.48 (3.51)	2.5	0.0, 5.0	2.48 (3.51)	2.5	0.0, 5.0	0.5000
Low Dose	0								
High Dose	2	0.00 (0.00)	2.48 (3.51)	2.5	0.0, 5.0	2.48 (3.51)	2.5	0.0, 5.0	0.5000
WEEK 84	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	
Low Dose	0								
High Dose	1	0.00 (N/A)	0.00 (N/A)	0.0	0.0, 0.0	0.00 (N/A)	0.0	0.0, 0.0	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia									
BASELINE	41		13.63 (2.59)	14.6	7.9, 16.0				
Low Dose	20		13.61 (2.38)	13.7	9.3, 16.0				
High Dose	21		13.65 (2.83)	15.2	7.9, 16.0				
WEEK 12	28	13.26 (2.83)	12.52 (3.13)	13.0	5.0, 16.0	-0.74 (3.01)	-0.6	-11.0, 5.3	0.2026
Low Dose	16	13.57 (2.59)	12.55 (3.34)	13.4	5.0, 16.0	-1.02 (3.15)	-0.6	-11.0, 4.2	0.2147
High Dose	12	12.86 (3.21)	12.49 (2.97)	12.1	8.0, 16.0	-0.37 (2.91)	-0.4	-4.2, 5.3	0.6653
WEEK 24	30	13.76 (2.40)	12.34 (4.12)	13.6	0.0, 16.0	-1.42 (3.27)	-0.2	-13.3, 3.3	0.0243*
Low Dose	15	13.59 (2.33)	11.53 (5.12)	13.5	0.0, 16.0	-2.06 (3.99)	-0.2	-13.3, 2.3	0.0651
High Dose	15	13.94 (2.54)	13.16 (2.73)	13.7	8.3, 16.0	-0.77 (2.30)	-0.9	-5.2, 3.3	0.2141
WEEK 36	16	13.97 (2.66)	13.68 (3.00)	14.3	3.9, 16.0	-0.29 (2.83)	0.0	-5.6, 5.5	0.6877
Low Dose	8	13.53 (2.85)	13.36 (4.04)	14.4	3.9, 16.0	-0.17 (3.01)	0.0	-5.6, 5.5	0.8752
High Dose	8	14.41 (2.57)	14.01 (1.65)	14.3	11.9, 16.0	-0.41 (2.84)	-0.6	-3.9, 4.3	0.6975

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 1.3

Change from Baseline to Each Planned Visit in Average Daily Normalized Time in Hours
Based on Parkinson's Disease Diary by Subgroups
(FAS)

Variable / Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
PD duration (time since diagnosis) category:>=10 years (Cont.)									
Average Daily Normalized 'On' Time Without Troublesome Dyskinesia (Cont.)									
WEEK 48	20	14.28 (2.21)	12.91 (3.33)	14.4	5.9, 16.0	-1.36 (2.60)	-0.5	-7.4, 1.9	0.0299*
Low Dose	8	14.16 (2.21)	12.95 (4.18)	15.1	5.9, 16.0	-1.21 (2.93)	0.0	-7.4, 1.7	0.2828
High Dose	12	14.36 (2.30)	12.89 (2.83)	13.7	7.4, 16.0	-1.47 (2.48)	-0.6	-6.1, 1.9	0.0650
WEEK 60	9	13.68 (2.49)	12.57 (2.97)	13.0	5.6, 16.0	-1.11 (1.84)	-0.7	-3.9, 1.3	0.1077
Low Dose	2	11.42 (2.71)	9.81 (5.93)	9.8	5.6, 14.0	-1.61 (3.22)	-1.6	-3.9, 0.7	0.6082
High Dose	7	14.32 (2.20)	13.36 (1.62)	13.0	11.2, 16.0	-0.97 (1.64)	-0.7	-3.9, 1.3	0.1686
WEEK 72	2	12.94 (4.33)	5.60 (0.01)	5.6	5.6, 5.6	-7.34 (4.35)	-7.3	-10.4, -4.3	0.2525
Low Dose	0								
High Dose	2	12.94 (4.33)	5.60 (0.01)	5.6	5.6, 5.6	-7.34 (4.35)	-7.3	-10.4, -4.3	0.2525
WEEK 84	1	9.87 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-5.30 (N/A)	-5.3	-5.3, -5.3	
Low Dose	0								
High Dose	1	9.87 (N/A)	4.57 (N/A)	4.6	4.6, 4.6	-5.30 (N/A)	-5.3	-5.3, -5.3	

Note: A PD diary recording day with no more than 2 hours of missing data (4 or less missing entries) or at least 12 awake hours (i.e., at least 24 'Off' or 'On' time entries) for the entire 24-hour diary is considered as a valid PD diary day.
&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

表2.7.3.6-27　MDS-UPDRSスコア（FAS，日本人部分集団）：M15-741試験（更新時）

[redacted]20[redacted] 10:50 <[redacted]>
ABBV-951
STUDY M15-741 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0153 - CLINICAL/STATISTICAL

TABLE 14.2__2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MDS-UPDRS Total Score of Parts I-III									
BASELINE	27		41.0 (17.88)	37.0	13, 83				
Low dose	22		37.9 (16.32)	37.0	13, 68				
High dose	5		54.6 (19.92)	47.0	35, 83				
DAY 2	26	41.0 (18.23)	37.5 (21.58)	30.5	6, 91	-3.5 (11.09)	-3.5	-37, 24	0.1163
Low dose	21	37.8 (16.70)	32.1 (16.25)	28.0	6, 63	-5.6 (10.19)	-5.0	-37, 13	0.0200*
High dose	5	54.6 (19.92)	59.8 (28.58)	51.0	30, 91	5.2 (11.48)	4.0	-5, 24	0.3683
WEEK 1	25	42.2 (17.67)	47.0 (24.91)	42.0	18, 114	4.8 (20.22)	-2.0	-18, 68	0.2474
Low dose	20	39.1 (16.12)	42.1 (21.08)	40.0	18, 109	3.0 (17.47)	-1.0	-17, 68	0.4457
High dose	5	54.6 (19.92)	66.4 (31.98)	65.0	31, 114	11.8 (30.43)	-2.0	-18, 47	0.4349
WEEK 2	24	43.4 (17.13)	50.0 (26.57)	43.5	19, 114	6.6 (21.88)	-1.5	-25, 60	0.1532
Low dose	19	40.4 (15.58)	47.2 (24.72)	40.0	19, 101	6.8 (19.79)	-1.0	-19, 60	0.1538
High dose	5	54.6 (19.92)	60.6 (33.67)	58.0	30, 114	6.0 (31.47)	-11.0	-25, 47	0.6925
WEEK 3	21	41.3 (17.01)	50.2 (28.13)	44.0	14, 135	8.9 (24.14)	5.0	-28, 94	0.1065
Low dose	18	38.7 (15.12)	50.7 (30.40)	44.5	14, 135	12.0 (24.17)	9.0	-18, 94	0.0504
High dose	3	57.0 (22.72)	47.3 (6.66)	44.0	43, 55	-9.7 (16.07)	-3.0	-28, 2	0.4069
WEEK 4	20	41.5 (17.42)	50.6 (25.42)	46.5	16, 106	9.1 (20.05)	5.5	-27, 56	0.0571
Low dose	17	38.8 (15.58)	52.1 (26.98)	50.0	16, 106	13.3 (18.30)	12.0	-14, 56	0.0084**
High dose	3	57.0 (22.72)	42.0 (13.53)	41.0	29, 56	-15.0 (10.82)	-12.0	-27, -6	0.1383

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
MDS-UPDRS Total Score of Parts I-III									
WEEK 6	18	40.1 (17.19)	48.2 (27.44)	43.0	12, 113	8.1 (25.37)	2.5	-45, 72	0.1929
Low dose	15	36.7 (14.56)	50.7 (29.50)	47.0	12, 113	13.9 (22.37)	11.0	-15, 72	0.0302*
High dose	3	57.0 (22.72)	36.0 (6.24)	38.0	29, 41	-21.0 (21.00)	-12.0	-45, -6	0.2254
WEEK 13	17	41.2 (17.03)	51.9 (24.01)	56.0	13, 96	10.6 (23.19)	17.0	-32, 66	0.0766
Low dose	14	37.9 (14.42)	53.8 (25.22)	59.0	13, 96	15.9 (20.59)	18.0	-19, 66	0.0126*
High dose	3	57.0 (22.72)	43.0 (18.36)	51.0	22, 56	-14.0 (20.95)	-19.0	-32, 9	0.3667
WEEK 26	15	42.6 (17.59)	46.8 (22.02)	42.0	14, 84	4.2 (17.96)	-1.0	-28, 39	0.3803
Low dose	12	39.0 (15.14)	48.5 (23.68)	43.5	14, 84	9.5 (15.39)	9.5	-10, 39	0.0558
High dose	3	57.0 (22.72)	40.0 (15.00)	40.0	25, 55	-17.0 (10.54)	-16.0	-28, -7	0.1077
WEEK 39	12	39.3 (16.95)	42.7 (23.13)	41.5	17, 95	3.3 (21.23)	-1.0	-20, 54	0.5974
Low dose	9	33.4 (10.48)	41.7 (24.43)	40.0	17, 95	8.2 (21.86)	-1.0	-14, 54	0.2919
High dose	3	57.0 (22.72)	45.7 (23.18)	49.0	21, 67	-11.3 (11.72)	-16.0	-20, 2	0.2359
WEEK 52	12	39.3 (16.95)	42.0 (19.02)	46.0	15, 71	2.7 (16.97)	-2.5	-26, 30	0.5970
Low dose	9	33.4 (10.48)	41.4 (17.31)	47.0	17, 66	8.0 (15.22)	0.0	-7, 30	0.1534
High dose	3	57.0 (22.72)	43.7 (28.02)	45.0	15, 71	-13.3 (12.06)	-12.0	-26, -2	0.1955

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
MDS-UPDRS Part I Score									
BASELINE	27		7.9 (4.53)	7.0	2, 19				
Low dose	22		7.3 (4.62)	6.0	2, 19				
High dose	5		10.4 (3.36)	9.0	7, 14				
DAY 2	26	8.0 (4.55)	7.0 (3.89)	6.5	0, 14	-1.0 (2.16)	-1.0	-7, 2	0.0217*
Low dose	21	7.4 (4.68)	6.5 (4.09)	6.0	0, 14	-1.0 (2.18)	-1.0	-7, 2	0.0589
High dose	5	10.4 (3.36)	9.0 (2.12)	9.0	7, 12	-1.4 (2.30)	-1.0	-5, 1	0.2455
WEEK 1	25	8.2 (4.47)	8.4 (5.70)	7.0	1, 22	0.1 (3.76)	-1.0	-4, 11	0.8744
Low dose	20	7.7 (4.62)	7.6 (5.51)	7.0	1, 22	-0.2 (3.23)	-0.5	-4, 9	0.8378
High dose	5	10.4 (3.36)	11.6 (5.86)	10.0	6, 20	1.2 (5.76)	-1.0	-4, 11	0.6657
WEEK 2	24	7.9 (4.53)	7.5 (4.32)	7.0	1, 19	-0.4 (2.99)	0.0	-7, 4	0.5018
Low dose	19	7.2 (4.64)	7.2 (4.67)	6.0	1, 19	0.0 (2.54)	0.0	-4, 4	>0.999
High dose	5	10.4 (3.36)	8.4 (2.79)	7.0	6, 13	-2.0 (4.30)	-2.0	-7, 4	0.3572
WEEK 3	21	7.3 (4.31)	9.0 (6.16)	7.0	1, 23	1.7 (3.62)	2.0	-4, 8	0.0479*
Low dose	18	6.9 (4.36)	8.8 (6.53)	6.5	1, 23	1.9 (3.80)	2.0	-4, 8	0.0442*
High dose	3	9.7 (3.79)	9.7 (4.04)	9.0	6, 14	0.0 (2.00)	0.0	-2, 2	>0.999
WEEK 4	20	7.5 (4.31)	8.9 (6.93)	7.0	1, 29	1.4 (5.03)	0.0	-8, 17	0.2447
Low dose	17	7.1 (4.39)	9.4 (7.43)	8.0	1, 29	2.2 (4.76)	1.0	-3, 17	0.0709
High dose	3	9.7 (3.79)	6.0 (0.00)	6.0	6, 6	-3.7 (3.79)	-2.0	-8, -1	0.2354

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
MDS-UPDRS Part I Score									
WEEK 6	18	7.7 (4.47)	9.0 (6.68)	7.5	1, 25	1.3 (5.28)	0.0	-8, 10	0.3188
Low dose	15	7.3 (4.61)	9.9 (6.92)	9.0	1, 25	2.5 (4.58)	1.0	-4, 10	0.0503
High dose	3	9.7 (3.79)	4.7 (3.21)	6.0	1, 7	-5.0 (4.36)	-7.0	-8, 0	0.1853
WEEK 13	17	7.9 (4.51)	9.2 (5.95)	7.0	0, 20	1.2 (5.43)	1.0	-10, 14	0.3619
Low dose	14	7.6 (4.69)	10.0 (6.21)	8.0	0, 20	2.4 (4.78)	2.0	-7, 14	0.0799
High dose	3	9.7 (3.79)	5.3 (2.31)	4.0	4, 8	-4.3 (5.51)	-4.0	-10, 1	0.3061
WEEK 26	15	8.3 (4.62)	7.9 (5.33)	8.0	1, 23	-0.4 (3.25)	0.0	-6, 4	0.6406
Low dose	12	7.9 (4.89)	8.3 (5.58)	8.5	1, 23	0.4 (3.00)	1.0	-6, 4	0.6397
High dose	3	9.7 (3.79)	6.0 (4.58)	5.0	2, 11	-3.7 (2.08)	-3.0	-6, -2	0.0927
WEEK 39	12	7.1 (3.73)	6.0 (3.77)	6.5	0, 12	-1.1 (3.58)	-1.0	-6, 4	0.3169
Low dose	9	6.2 (3.49)	5.7 (4.33)	5.0	0, 12	-0.6 (3.75)	1.0	-6, 4	0.6681
High dose	3	9.7 (3.79)	7.0 (1.00)	7.0	6, 8	-2.7 (3.06)	-2.0	-6, 0	0.2697
WEEK 52	12	7.1 (3.73)	6.9 (3.73)	6.0	0, 14	-0.2 (4.61)	0.5	-11, 7	0.9026
Low dose	9	6.2 (3.49)	7.3 (4.09)	6.0	0, 14	1.1 (3.55)	1.0	-4, 7	0.3754
High dose	3	9.7 (3.79)	5.7 (2.52)	6.0	3, 8	-4.0 (6.08)	-1.0	-11, 0	0.3727

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
MDS-UPDRS Part II Score									
BASELINE	27		14.4 (7.84)	13.0	1, 33				
Low dose	22		12.9 (7.38)	11.5	1, 27				
High dose	5		21.0 (6.82)	18.0	17, 33				
DAY 2	26	14.7 (7.88)	11.9 (7.77)	11.5	0, 33	-2.8 (3.82)	-1.5	-15, 3	0.0011**
Low dose	21	13.1 (7.48)	9.8 (6.28)	10.0	0, 21	-3.4 (3.90)	-2.0	-15, 3	<=0.001***
High dose	5	21.0 (6.82)	20.8 (7.56)	17.0	14, 33	-0.2 (2.17)	0.0	-3, 3	0.8466
WEEK 1	25	14.6 (7.73)	11.5 (6.75)	10.0	3, 29	-3.1 (5.80)	-3.0	-17, 9	0.0129*
Low dose	20	13.1 (7.24)	10.1 (5.88)	8.5	3, 26	-3.0 (5.03)	-2.5	-17, 4	0.0152*
High dose	5	21.0 (6.82)	17.4 (7.40)	18.0	10, 29	-3.6 (9.04)	-6.0	-15, 9	0.4237
WEEK 2	24	15.7 (7.28)	12.7 (7.62)	11.0	3, 37	-3.0 (7.48)	-3.0	-18, 17	0.0615
Low dose	19	14.3 (6.89)	10.9 (5.60)	9.0	3, 21	-3.3 (5.80)	-3.0	-18, 8	0.0227*
High dose	5	21.0 (6.82)	19.2 (11.19)	17.0	9, 37	-1.8 (12.95)	-6.0	-16, 17	0.7715
WEEK 3	21	15.4 (7.79)	13.0 (7.97)	11.0	3, 37	-2.5 (6.19)	-2.0	-17, 12	0.0819
Low dose	18	14.2 (7.15)	12.8 (8.58)	11.0	3, 37	-1.4 (5.51)	-1.5	-10, 12	0.2817
High dose	3	22.7 (8.96)	14.0 (2.65)	15.0	11, 16	-8.7 (7.64)	-7.0	-17, -2	0.1883
WEEK 4	20	15.6 (7.95)	14.2 (7.42)	14.0	3, 27	-1.4 (5.90)	-1.5	-17, 8	0.3017
Low dose	17	14.4 (7.35)	14.4 (7.99)	14.0	3, 27	0.1 (4.55)	-1.0	-9, 8	0.9581
High dose	3	22.7 (8.96)	13.0 (3.00)	13.0	10, 16	-9.7 (6.66)	-8.0	-17, -4	0.1284

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
MDS-UPDRS Part II Score									
WEEK 6	18	14.8 (7.98)	13.1 (8.29)	11.0	3, 32	-1.7 (6.62)	-0.5	-21, 6	0.2853
Low dose	15	13.3 (7.08)	13.4 (9.09)	10.0	3, 32	0.1 (4.45)	1.0	-9, 6	0.9093
High dose	3	22.7 (8.96)	11.7 (1.53)	12.0	10, 13	-11.0 (8.89)	-8.0	-21, -4	0.1653
WEEK 13	17	15.2 (8.04)	14.1 (7.72)	14.0	1, 29	-1.1 (8.81)	-1.0	-21, 15	0.6081
Low dose	14	13.6 (7.19)	14.4 (8.38)	15.0	1, 29	0.8 (7.59)	0.5	-10, 15	0.7047
High dose	3	22.7 (8.96)	12.7 (4.04)	12.0	9, 17	-10.0 (10.15)	-8.0	-21, -1	0.2300
WEEK 26	15	16.2 (8.07)	12.9 (8.29)	14.0	0, 30	-3.3 (7.38)	-2.0	-18, 13	0.1023
Low dose	12	14.6 (7.35)	13.5 (8.91)	15.5	0, 30	-1.1 (5.93)	-1.0	-8, 13	0.5398
High dose	3	22.7 (8.96)	10.3 (5.69)	12.0	4, 15	-12.3 (6.03)	-13.0	-18, -6	0.0712
WEEK 39	12	15.0 (8.37)	11.5 (8.90)	10.0	1, 28	-3.5 (7.01)	-3.5	-15, 10	0.1118
Low dose	9	12.4 (6.84)	11.8 (9.60)	9.0	1, 28	-0.7 (4.97)	-1.0	-7, 10	0.6982
High dose	3	22.7 (8.96)	10.7 (8.08)	12.0	2, 18	-12.0 (5.20)	-15.0	-15, -6	0.0572
WEEK 52	12	15.0 (8.37)	11.3 (7.00)	9.5	0, 22	-3.8 (6.89)	-3.5	-17, 8	0.0861
Low dose	9	12.4 (6.84)	11.6 (7.76)	10.0	0, 22	-0.9 (4.91)	-1.0	-8, 8	0.6019
High dose	3	22.7 (8.96)	10.3 (5.13)	9.0	6, 16	-12.3 (4.16)	-11.0	-17, -9	0.0359*

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
MDS-UPDRS Part III Score									
BASELINE	27		18.7 (10.66)	18.0	2, 42				
Low dose	22		17.7 (9.78)	17.0	2, 36				
High dose	5		23.2 (14.38)	22.0	9, 42				
DAY 2	26	18.3 (10.67)	18.6 (14.95)	14.0	2, 59	0.3 (8.79)	-0.5	-19, 26	0.8772
Low dose	21	17.2 (9.68)	15.9 (11.30)	14.0	2, 44	-1.3 (7.55)	-1.0	-19, 14	0.4444
High dose	5	23.2 (14.38)	30.0 (23.60)	27.0	6, 59	6.8 (11.50)	5.0	-3, 26	0.2566
WEEK 1	25	19.3 (10.85)	27.1 (18.35)	27.0	0, 76	7.8 (16.56)	1.0	-8, 67	0.0268*
Low dose	20	18.3 (10.01)	24.5 (17.07)	23.0	0, 76	6.2 (16.28)	0.5	-8, 67	0.1041
High dose	5	23.2 (14.38)	37.4 (21.66)	39.0	11, 70	14.2 (17.96)	5.0	-2, 37	0.1519
WEEK 2	24	19.8 (10.49)	29.9 (19.79)	23.5	5, 77	10.1 (17.20)	4.5	-7, 68	0.0087**
Low dose	19	18.9 (9.52)	29.1 (19.78)	23.0	5, 77	10.1 (17.42)	5.0	-5, 68	0.0206*
High dose	5	23.2 (14.38)	33.0 (21.80)	32.0	12, 68	9.8 (18.34)	2.0	-7, 35	0.2977
WEEK 3	21	18.6 (9.77)	28.3 (18.14)	24.0	6, 84	9.7 (17.24)	4.0	-9, 75	0.0178*
Low dose	18	17.6 (8.60)	29.1 (19.29)	24.5	6, 84	11.5 (17.89)	7.0	-4, 75	0.0143*
High dose	3	24.7 (16.17)	23.7 (9.50)	24.0	14, 33	-1.0 (7.00)	2.0	-9, 4	0.8277
WEEK 4	20	18.4 (9.99)	27.5 (15.42)	26.0	6, 62	9.1 (14.33)	3.0	-8, 53	0.0102*
Low dose	17	17.3 (8.79)	28.3 (16.10)	27.0	6, 62	11.1 (14.63)	13.0	-3, 53	0.0067**
High dose	3	24.7 (16.17)	23.0 (12.12)	25.0	10, 34	-1.7 (5.69)	0.0	-8, 3	0.6621

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
MDS-UPDRS Part III Score									
WEEK 6	18	17.6 (9.61)	26.1 (16.34)	24.0	5, 69	8.6 (16.93)	3.0	-17, 60	0.0466*
Low dose	15	16.1 (7.85)	27.4 (17.42)	24.0	5, 69	11.3 (16.88)	10.0	-7, 60	0.0215*
High dose	3	24.7 (16.17)	19.7 (8.39)	24.0	10, 25	-5.0 (10.44)	0.0	-17, 2	0.4941
WEEK 13	17	18.1 (9.65)	28.6 (15.08)	29.0	1, 57	10.5 (12.99)	9.0	-9, 37	0.0042**
Low dose	14	16.6 (7.89)	29.3 (15.69)	27.9	1, 57	12.7 (12.99)	14.0	-9, 37	0.0029**
High dose	3	24.7 (16.17)	25.0 (14.00)	31.0	9, 35	0.3 (8.08)	-1.0	-7, 9	0.9496
WEEK 26	15	18.1 (10.27)	26.1 (15.72)	28.0	4, 51	7.9 (13.75)	1.0	-6, 39	0.0423*
Low dose	12	16.5 (8.50)	26.7 (16.64)	28.0	4, 51	10.2 (14.57)	6.0	-6, 39	0.0341*
High dose	3	24.7 (16.17)	23.7 (14.01)	23.0	10, 38	-1.0 (2.65)	0.0	-4, 1	0.5799
WEEK 39	12	17.3 (10.56)	25.2 (17.46)	24.5	4, 56	7.9 (15.40)	2.0	-7, 47	0.1026
Low dose	9	14.8 (7.77)	24.2 (18.72)	24.0	4, 56	9.4 (17.65)	2.0	-7, 47	0.1471
High dose	3	24.7 (16.17)	28.0 (16.09)	30.0	11, 43	3.3 (4.04)	1.0	1, 8	0.2893
WEEK 52	12	17.3 (10.56)	23.8 (16.38)	28.0	1, 51	6.6 (11.05)	4.5	-9, 23	0.0634
Low dose	9	14.8 (7.77)	22.6 (15.99)	26.0	1, 51	7.8 (12.32)	4.0	-9, 23	0.0948
High dose	3	24.7 (16.17)	27.7 (20.60)	30.0	6, 47	3.0 (6.24)	5.0	-4, 8	0.4929

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
MDS-UPDRS Part IV Score									
BASELINE	27		8.7 (2.84)	9.0	0, 14				
Low dose	22		8.6 (3.02)	8.5	0, 14				
High dose	5		9.0 (2.12)	9.0	7, 12				
DAY 2	26	8.8 (2.85)	6.5 (3.78)	6.0	0, 14	-2.3 (3.76)	-1.0	-12, 6	0.0044**
Low dose	21	8.7 (3.04)	6.5 (3.97)	6.0	0, 14	-2.2 (3.95)	-1.0	-12, 6	0.0172*
High dose	5	9.0 (2.12)	6.4 (3.21)	8.0	1, 9	-2.6 (3.21)	-1.0	-6, 1	0.1443
WEEK 1	25	8.7 (2.95)	7.9 (3.40)	8.0	1, 15	-0.8 (3.76)	-1.0	-8, 9	0.2985
Low dose	20	8.6 (3.17)	8.0 (2.96)	8.0	2, 15	-0.7 (3.65)	-1.0	-6, 9	0.4351
High dose	5	9.0 (2.12)	7.6 (5.22)	6.0	1, 15	-1.4 (4.62)	-1.0	-8, 5	0.5348
WEEK 2	24	8.7 (2.93)	7.4 (2.95)	7.5	2, 12	-1.3 (2.87)	-1.5	-7, 5	0.0375*
Low dose	19	8.6 (3.15)	7.7 (2.67)	8.0	3, 12	-0.9 (2.66)	-1.0	-7, 5	0.1374
High dose	5	9.0 (2.12)	6.4 (4.04)	7.0	2, 12	-2.6 (3.58)	-4.0	-7, 2	0.1795
WEEK 3	21	8.0 (2.84)	8.3 (2.87)	8.0	3, 15	0.2 (3.36)	0.0	-5, 8	0.7488
Low dose	18	8.1 (3.05)	8.5 (3.00)	8.5	3, 15	0.4 (3.52)	0.0	-5, 8	0.6449
High dose	3	7.7 (1.15)	7.0 (1.73)	6.0	6, 9	-0.7 (2.52)	-1.0	-3, 2	0.6914
WEEK 4	20	8.0 (2.90)	6.8 (2.78)	7.0	2, 12	-1.2 (2.76)	-1.0	-5, 5	0.0672
Low dose	17	8.1 (3.13)	7.2 (2.66)	8.0	2, 12	-0.8 (2.65)	-1.0	-5, 5	0.2186
High dose	3	7.7 (1.15)	4.3 (2.52)	4.0	2, 7	-3.3 (2.89)	-5.0	-5, 0	0.1835

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
MDS-UPDRS Part IV Score									
WEEK 6	18	7.8 (3.01)	6.4 (2.73)	6.0	2, 12	-1.4 (3.20)	-1.5	-8, 5	0.0727
Low dose	15	7.9 (3.29)	6.5 (2.88)	6.0	2, 12	-1.3 (3.33)	-1.0	-8, 5	0.1434
High dose	3	7.7 (1.15)	5.7 (2.08)	5.0	4, 8	-2.0 (3.00)	-2.0	-5, 1	0.3675
WEEK 13	17	7.5 (2.67)	6.1 (2.82)	6.0	2, 11	-1.4 (3.97)	-2.0	-6, 10	0.1619
Low dose	14	7.4 (2.93)	6.4 (3.00)	6.5	2, 11	-1.1 (4.25)	-2.0	-6, 10	0.3629
High dose	3	7.7 (1.15)	4.7 (1.15)	4.0	4, 6	-3.0 (2.00)	-3.0	-5, -1	0.1217
WEEK 26	15	7.6 (2.82)	5.8 (3.03)	5.0	2, 12	-1.8 (3.59)	-1.0	-10, 5	0.0725
Low dose	12	7.6 (3.15)	6.1 (3.23)	6.0	2, 12	-1.5 (3.83)	-1.0	-10, 5	0.2016
High dose	3	7.7 (1.15)	4.7 (2.08)	4.0	3, 7	-3.0 (2.65)	-4.0	-5, 0	0.1885
WEEK 39	12	7.3 (3.11)	5.7 (2.90)	5.5	0, 9	-1.7 (3.23)	-2.0	-6, 5	0.1013
Low dose	9	7.2 (3.60)	5.9 (2.85)	6.0	0, 9	-1.3 (3.12)	-2.0	-6, 5	0.2361
High dose	3	7.7 (1.15)	5.0 (3.61)	4.0	2, 9	-2.7 (4.04)	-5.0	-5, 2	0.3715
WEEK 52	12	7.3 (3.11)	5.8 (2.48)	6.0	2, 10	-1.5 (3.75)	-2.5	-5, 6	0.1937
Low dose	9	7.2 (3.60)	6.2 (2.33)	6.0	3, 10	-1.0 (3.91)	-2.0	-5, 6	0.4644
High dose	3	7.7 (1.15)	4.7 (3.06)	4.0	2, 8	-3.0 (3.46)	-5.0	-5, 1	0.2724

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

表2.7.3.6-28　MDS-UPDRSスコア（FAS，日本人部分集団）：M15-737試験（更新時）

[redacted]20[redacted] 10:46 <[redacted]>
ABBV-951
STUDY M15-737 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0154 - CLINICAL/STATISTICAL

TABLE 14.2__2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MDS-UPDRS Part I Score									
BASELINE	11		7.1 (3.86)	6.0	0, 14				
Low dose	7		7.3 (4.50)	6.0	0, 14				
High dose	4		6.8 (2.99)	7.0	3, 10				
WEEK 24	7	7.6 (3.55)	9.4 (5.44)	7.0	5, 21	1.9 (3.34)	2.0	-4, 7	0.1914
Low dose	4	9.0 (3.83)	11.0 (6.88)	8.5	6, 21	2.0 (4.69)	2.5	-4, 7	0.4564
High dose	3	5.7 (2.52)	7.3 (2.52)	7.0	5, 10	1.7 (0.58)	2.0	1, 2	0.0377*
WEEK 48	4	5.8 (2.06)	7.3 (2.75)	7.5	4, 10	1.5 (1.29)	1.5	0, 3	0.1027
Low dose	1	6.0 (N/A)	6.0 (N/A)	6.0	6, 6	0.0 (N/A)	0.0	0, 0	
High dose	3	5.7 (2.52)	7.7 (3.21)	9.0	4, 10	2.0 (1.00)	2.0	1, 3	0.0742
WEEK 72	2	5.5 (3.54)	11.0 (2.83)	11.0	9, 13	5.5 (0.71)	5.5	5, 6	0.0577
Low dose	0								
High dose	2	5.5 (3.54)	11.0 (2.83)	11.0	9, 13	5.5 (0.71)	5.5	5, 6	0.0577
MDS-UPDRS Part II Score									
BASELINE	11		11.6 (7.20)	10.0	0, 22				
Low dose	7		11.0 (8.04)	10.0	0, 22				
High dose	4		12.8 (6.40)	12.5	6, 20				
WEEK 24	7	11.3 (5.94)	14.3 (8.71)	11.0	5, 32	3.0 (3.79)	2.0	-1, 10	0.0809
Low dose	4	12.0 (7.16)	16.5 (10.41)	12.0	10, 32	4.5 (4.43)	4.0	0, 10	0.1354
High dose	3	10.3 (5.13)	11.3 (6.51)	11.0	5, 18	1.0 (1.73)	2.0	-1, 2	0.4226

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	P-Value &
MDS-UPDRS Part II Score									
WEEK 48	4	9.0 (4.97)	11.5 (6.14)	11.5	4, 19	2.5 (3.70)	2.5	-2, 7	0.2691
Low dose	1	5.0 (N/A)	12.0 (N/A)	12.0	12, 12	7.0 (N/A)	7.0	7, 7	
High dose	3	10.3 (5.13)	11.3 (7.51)	11.0	4, 19	1.0 (2.65)	2.0	-2, 3	0.5799
WEEK 72	2	11.0 (7.07)	18.0 (12.73)	18.0	9, 27	7.0 (5.66)	7.0	3, 11	0.3305
Low dose	0								
High dose	2	11.0 (7.07)	18.0 (12.73)	18.0	9, 27	7.0 (5.66)	7.0	3, 11	0.3305
MDS-UPDRS Part III Score									
BASELINE	11		21.4 (14.65)	26.0	1, 47				
Low dose	7		19.3 (13.72)	26.0	1, 34				
High dose	4		25.0 (17.64)	23.5	6, 47				
WEEK 24	7	22.4 (15.94)	26.4 (18.60)	30.0	6, 52	4.0 (8.31)	2.0	-3, 22	0.2498
Low dose	4	18.5 (13.30)	26.3 (21.11)	22.5	8, 52	7.8 (9.60)	3.5	2, 22	0.2050
High dose	3	27.7 (20.60)	26.7 (19.22)	30.0	6, 44	-1.0 (1.73)	0.0	-3, 0	0.4226
WEEK 48	4	22.3 (20.01)	22.3 (18.71)	19.5	5, 45	0.0 (2.16)	-0.5	-2, 3	>0.999
Low dose	1	6.0 (N/A)	9.0 (N/A)	9.0	9, 9	3.0 (N/A)	3.0	3, 3	
High dose	3	27.7 (20.60)	26.7 (20.21)	30.0	5, 45	-1.0 (1.00)	-1.0	-2, 0	0.2254
WEEK 72	2	26.5 (28.99)	30.5 (34.65)	30.5	6, 55	4.0 (5.66)	4.0	0, 8	0.5000
Low dose	0								
High dose	2	26.5 (28.99)	30.5 (34.65)	30.5	6, 55	4.0 (5.66)	4.0	0, 8	0.5000

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MDS-UPDRS Part IV Score									
BASELINE	11		6.1 (2.43)	6.0	2, 10				
Low dose	7		6.1 (1.77)	6.0	3, 8				
High dose	4		6.0 (3.65)	6.0	2, 10				
WEEK 24	7	5.6 (2.57)	6.1 (3.08)	6.0	2, 11	0.6 (1.13)	0.0	0, 3	0.2308
Low dose	4	6.3 (2.36)	7.3 (2.99)	7.0	4, 11	1.0 (1.41)	0.5	0, 3	0.2522
High dose	3	4.7 (3.06)	4.7 (3.06)	4.0	2, 8	0.0 (0.00)	0.0	0, 0	
WEEK 48	4	5.5 (3.00)	6.0 (2.94)	6.0	3, 9	0.5 (0.58)	0.5	0, 1	0.1817
Low dose	1	8.0 (N/A)	8.0 (N/A)	8.0	8, 8	0.0 (N/A)	0.0	0, 0	
High dose	3	4.7 (3.06)	5.3 (3.21)	4.0	3, 9	0.7 (0.58)	1.0	0, 1	0.1835
WEEK 72	2	6.0 (2.83)	7.0 (1.41)	7.0	6, 8	1.0 (1.41)	1.0	0, 2	0.5000
Low dose	0								
High dose	2	6.0 (2.83)	7.0 (1.41)	7.0	6, 8	1.0 (1.41)	1.0	0, 2	0.5000
MDS-UPDRS Total Score of Parts I-III									
BASELINE	11		40.1 (18.71)	45.0	15, 71				
Low dose	7		37.6 (17.31)	32.0	17, 66				
High dose	4		44.5 (22.94)	46.0	15, 71				
WEEK 24	7	41.3 (22.84)	50.1 (30.37)	48.0	16, 105	8.9 (13.72)	3.0	1, 39	0.1384
Low dose	4	39.5 (22.58)	53.8 (35.75)	42.0	26, 105	14.3 (16.88)	8.5	1, 39	0.1899
High dose	3	43.7 (28.02)	45.3 (28.10)	48.0	16, 72	1.7 (1.15)	1.0	1, 3	0.1296

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 2.1.J

Change from Baseline to Each Planned Visit in Parkinson's Disease Symptoms as Assessed
by The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Score by Part and Total
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MDS-UPDRS Total Score of Parts I-III									
WEEK 48	4	37.0 (26.48)	41.0 (26.77)	38.5	13, 74	4.0 (4.97)	4.0	-2, 10	0.2056
Low dose	1	17.0 (N/A)	27.0 (N/A)	27.0	27, 27	10.0 (N/A)	10.0	10, 10	
High dose	3	43.7 (28.02)	45.7 (30.73)	50.0	13, 74	2.0 (3.61)	3.0	-2, 5	0.4380
WEEK 72	2	43.0 (39.60)	59.5 (50.20)	59.5	24, 95	16.5 (10.61)	16.5	9, 24	0.2716
Low dose	0								
High dose	2	43.0 (39.60)	59.5 (50.20)	59.5	24, 95	16.5 (10.61)	16.5	9, 24	0.2716

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

表2.7.3.6-29　PDSS-2スコア（FAS，日本人部分集団）：M15-741試験（更新時）

[redacted]20[redacted] 10:50 <[redacted]>
ABBV-951
STUDY M15-741 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0153 - CLINICAL/STATISTICAL

TABLE 14.2__3.J

Change from Baseline to Each Planned Visit in Sleep Symptoms as Assessed
by The Parkinson's Disease Sleep Scale - 2
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PDSS-2 Total Score									
BASELINE	27		16.1 (6.58)	14.0	5.0, 29.0				
Low dose	22		15.4 (6.45)	13.5	5.0, 26.0				
High dose	5		19.2 (6.94)	21.0	12.0, 29.0				
WEEK 6	19	16.3 (7.13)	17.9 (10.61)	15.0	4.0, 45.0	1.6 (10.82)	-1.0	-15.0, 27.0	0.5327
Low dose	16	15.4 (6.88)	18.2 (11.33)	15.5	4.0, 45.0	2.8 (10.94)	0.0	-11.0, 27.0	0.3306
High dose	3	21.0 (8.00)	16.3 (6.81)	14.0	11.0, 24.0	-4.7 (9.29)	-2.0	-15.0, 3.0	0.4761
WEEK 13	17	16.4 (6.59)	18.0 (8.66)	17.0	0.0, 36.0	1.6 (11.02)	1.0	-18.0, 17.0	0.5608
Low dose	14	15.4 (6.14)	18.7 (9.41)	19.5	0.0, 36.0	3.3 (11.08)	3.5	-18.0, 17.0	0.2871
High dose	3	21.0 (8.00)	14.7 (2.08)	14.0	13.0, 17.0	-6.3 (7.77)	-4.0	-15.0, 0.0	0.2934
WEEK 26	15	17.1 (6.60)	21.0 (8.68)	19.0	8.0, 42.0	3.9 (9.32)	3.0	-12.0, 19.0	0.1304
Low dose	12	16.2 (6.22)	22.1 (8.59)	19.5	8.0, 42.0	5.9 (8.90)	6.5	-8.0, 19.0	0.0418*
High dose	3	21.0 (8.00)	16.7 (9.29)	14.0	9.0, 27.0	-4.3 (6.81)	-2.0	-12.0, 1.0	0.3851
WEEK 39	12	17.3 (7.00)	15.6 (4.70)	16.5	7.0, 22.0	-1.8 (8.85)	-2.5	-16.0, 12.0	0.5077
Low dose	9	16.1 (6.68)	16.0 (4.85)	18.0	7.0, 22.0	-0.1 (9.57)	4.0	-16.0, 12.0	0.9731
High dose	3	21.0 (8.00)	14.3 (4.93)	12.0	11.0, 20.0	-6.7 (4.04)	-9.0	-9.0, -2.0	0.1038
WEEK 52	12	17.3 (7.00)	17.7 (4.79)	16.5	9.0, 25.0	0.3 (8.73)	-0.5	-14.0, 14.0	0.8972
Low dose	9	16.1 (6.68)	17.3 (5.24)	16.0	9.0, 25.0	1.2 (9.68)	3.0	-14.0, 14.0	0.7147
High dose	3	21.0 (8.00)	18.7 (3.79)	17.0	16.0, 23.0	-2.3 (5.51)	-5.0	-6.0, 4.0	0.5394

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 3.J

Change from Baseline to Each Planned Visit in Sleep Symptoms as Assessed
by The Parkinson's Disease Sleep Scale - 2
(FAS - Japan Subjects)

Parameter Time Point Dose Category	N	Baseline Mean (SD)	Visit Mean (SD)	Visit Median	Visit Min, Max	Change from Baseline Mean (SD)	Change from Baseline Median	Change from Baseline Min, Max	Change from Baseline P-Value &
PDSS-2 Motor Symptoms at Night Score									
BASELINE	27		3.1 (3.07)	2.0	0.0, 9.0				
Low dose	22		2.7 (2.77)	2.0	0.0, 9.0				
High dose	5		5.0 (3.94)	4.0	0.0, 9.0				
WEEK 6	19	3.1 (2.79)	4.7 (4.08)	5.0	0.0, 13.0	1.6 (4.21)	0.0	-6.0, 10.0	0.1081
Low dose	16	2.7 (2.60)	4.8 (4.31)	5.0	0.0, 13.0	2.1 (4.03)	0.5	-3.0, 10.0	0.0522
High dose	3	5.3 (3.21)	4.3 (3.21)	3.0	2.0, 8.0	-1.0 (5.00)	-1.0	-6.0, 4.0	0.7621
WEEK 13	17	3.2 (2.81)	4.2 (3.85)	4.0	0.0, 13.0	1.1 (4.67)	1.0	-9.0, 9.0	0.3638
Low dose	14	2.7 (2.61)	4.6 (4.07)	4.5	0.0, 13.0	1.9 (4.28)	1.5	-6.0, 9.0	0.1281
High dose	3	5.3 (3.21)	2.7 (2.52)	3.0	0.0, 5.0	-2.7 (5.51)	0.0	-9.0, 1.0	0.4899
WEEK 26	15	3.6 (2.72)	5.7 (4.15)	5.0	0.0, 16.0	2.1 (4.53)	2.0	-4.0, 11.0	0.0988
Low dose	12	3.2 (2.55)	6.4 (4.21)	7.0	0.0, 16.0	3.3 (4.18)	3.5	-3.0, 11.0	0.0209*
High dose	3	5.3 (3.21)	2.7 (2.52)	3.0	0.0, 5.0	-2.7 (2.31)	-4.0	-4.0, 0.0	0.1835
WEEK 39	12	3.8 (2.83)	3.3 (2.22)	3.5	0.0, 7.0	-0.5 (3.12)	-1.0	-5.0, 4.0	0.5898
Low dose	9	3.2 (2.68)	3.6 (2.30)	4.0	0.0, 7.0	0.3 (3.04)	0.0	-4.0, 4.0	0.7508
High dose	3	5.3 (3.21)	2.3 (2.08)	3.0	0.0, 4.0	-3.0 (2.00)	-3.0	-5.0, -1.0	0.1217
WEEK 52	12	3.8 (2.83)	4.3 (2.39)	4.0	1.0, 10.0	0.6 (4.17)	0.5	-6.0, 10.0	0.6372
Low dose	9	3.2 (2.68)	4.7 (2.50)	4.0	2.0, 10.0	1.4 (4.42)	2.0	-6.0, 10.0	0.3555
High dose	3	5.3 (3.21)	3.3 (2.08)	4.0	1.0, 5.0	-2.0 (2.00)	-2.0	-4.0, 0.0	0.2254

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 3.J

Change from Baseline to Each Planned Visit in Sleep Symptoms as Assessed
by The Parkinson's Disease Sleep Scale - 2
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PDSS-2 PD Symptoms at Night Score									
BASELINE	27		4.0 (2.90)	3.0	0.0, 10.0				
Low dose	22		3.9 (2.96)	3.0	0.0, 10.0				
High dose	5		4.8 (2.77)	6.0	1.0, 8.0				
WEEK 6	19	4.4 (2.99)	4.0 (4.77)	2.0	0.0, 18.0	-0.4 (4.02)	-1.0	-6.0, 12.0	0.6533
Low dose	16	4.3 (2.98)	4.1 (5.09)	2.0	0.0, 18.0	-0.3 (4.34)	-1.0	-6.0, 12.0	0.8210
High dose	3	5.0 (3.61)	3.7 (3.21)	5.0	0.0, 6.0	-1.3 (1.53)	-1.0	-3.0, 0.0	0.2697
WEEK 13	17	4.3 (2.71)	4.0 (3.26)	4.0	0.0, 10.0	-0.3 (4.25)	0.0	-7.0, 7.0	0.7792
Low dose	14	4.1 (2.63)	4.3 (3.36)	4.0	0.0, 10.0	0.1 (4.31)	1.0	-7.0, 7.0	0.9032
High dose	3	5.0 (3.61)	2.7 (2.89)	1.0	1.0, 6.0	-2.3 (4.04)	0.0	-7.0, 0.0	0.4226
WEEK 26	15	4.7 (2.55)	5.7 (3.43)	5.0	1.0, 12.0	1.0 (3.21)	1.0	-3.0, 6.0	0.2472
Low dose	12	4.7 (2.42)	6.0 (3.25)	5.5	1.0, 12.0	1.3 (3.37)	1.5	-3.0, 6.0	0.1974
High dose	3	5.0 (3.61)	4.7 (4.73)	3.0	1.0, 10.0	-0.3 (2.52)	0.0	-3.0, 2.0	0.8399
WEEK 39	12	4.3 (2.71)	3.7 (2.46)	4.0	0.0, 8.0	-0.7 (3.37)	-1.5	-6.0, 6.0	0.5069
Low dose	9	4.1 (2.57)	3.8 (2.44)	4.0	0.0, 8.0	-0.3 (3.87)	0.0	-6.0, 6.0	0.8028
High dose	3	5.0 (3.61)	3.3 (3.06)	4.0	0.0, 6.0	-1.7 (0.58)	-2.0	-2.0, -1.0	0.0377*
WEEK 52	12	4.3 (2.71)	3.8 (1.82)	4.0	0.0, 7.0	-0.6 (2.94)	-2.0	-3.0, 5.0	0.5058
Low dose	9	4.1 (2.57)	3.4 (1.94)	4.0	0.0, 7.0	-0.7 (3.12)	-2.0	-3.0, 5.0	0.5397
High dose	3	5.0 (3.61)	4.7 (1.15)	4.0	4.0, 6.0	-0.3 (2.89)	-2.0	-2.0, 3.0	0.8600

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

TABLE 14.2 3.J

Change from Baseline to Each Planned Visit in Sleep Symptoms as Assessed
by The Parkinson's Disease Sleep Scale - 2
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
PDSS-2 Disturbed Sleep Score									
BASELINE	27		9.0 (3.11)	9.0	2.0, 14.0				
Low dose	22		8.9 (3.30)	9.0	2.0, 14.0				
High dose	5		9.4 (2.30)	9.0	6.0, 12.0				
WEEK 6	19	8.8 (3.29)	9.2 (3.64)	9.0	3.0, 19.0	0.4 (5.00)	0.0	-6.0, 17.0	0.7519
Low dose	16	8.4 (3.44)	9.3 (3.89)	9.0	3.0, 19.0	0.9 (5.19)	0.0	-4.0, 17.0	0.5102
High dose	3	10.7 (1.53)	8.3 (2.08)	9.0	6.0, 10.0	-2.3 (3.21)	-1.0	-6.0, 0.0	0.3356
WEEK 13	17	8.9 (3.23)	9.8 (4.32)	10.0	0.0, 15.0	0.8 (4.84)	1.0	-7.0, 11.0	0.4928
Low dose	14	8.6 (3.41)	9.9 (4.59)	11.0	0.0, 15.0	1.3 (5.09)	1.0	-7.0, 11.0	0.3619
High dose	3	10.7 (1.53)	9.3 (3.51)	9.0	6.0, 13.0	-1.3 (3.21)	0.0	-5.0, 1.0	0.5471
WEEK 26	15	8.8 (3.08)	9.6 (2.47)	10.0	5.0, 14.0	0.8 (3.05)	1.0	-5.0, 8.0	0.3272
Low dose	12	8.3 (3.23)	9.7 (2.46)	10.0	5.0, 14.0	1.3 (2.90)	1.0	-2.0, 8.0	0.1398
High dose	3	10.7 (1.53)	9.3 (3.06)	10.0	6.0, 12.0	-1.3 (3.21)	0.0	-5.0, 1.0	0.5471
WEEK 39	12	9.3 (2.53)	8.7 (2.71)	9.0	4.0, 13.0	-0.6 (4.25)	-1.0	-7.0, 7.0	0.6439
Low dose	9	8.8 (2.68)	8.7 (2.74)	9.0	4.0, 13.0	-0.1 (4.46)	-1.0	-7.0, 7.0	0.9422
High dose	3	10.7 (1.53)	8.7 (3.21)	10.0	5.0, 11.0	-2.0 (4.00)	-2.0	-6.0, 2.0	0.4778
WEEK 52	12	9.3 (2.53)	9.6 (2.61)	10.5	6.0, 13.0	0.3 (3.47)	0.0	-5.0, 6.0	0.7458
Low dose	9	8.8 (2.68)	9.2 (2.73)	10.0	6.0, 13.0	0.4 (3.78)	0.0	-5.0, 6.0	0.7333
High dose	3	10.7 (1.53)	10.7 (2.31)	12.0	8.0, 12.0	0.0 (3.00)	0.0	-3.0, 3.0	>0.999

&: P-value is obtained from two-sided paired-sample t-test.
* P-value <= 0.05; ** P-value <= 0.01; *** P-value <= 0.001.

Program Source Code: [redacted]

表2.7.3.6-30　MMSEスコア（FAS，日本人部分集団）：M15-737試験（更新時）

[redacted]20[redacted] 10:46 <[redacted]>
ABBV-951
STUDY M15-737 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0154 - CLINICAL/STATISTICAL

TABLE 14.2__5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Attention/Calculation									
BASELINE	11		4.5 (0.82)	5.0	3.0, 5.0				
Low dose	7		4.3 (0.95)	5.0	3.0, 5.0				
High dose	4		5.0 (0.00)	5.0	5.0, 5.0				
WEEK 24	7	4.7 (0.76)	4.4 (1.51)	5.0	1.0, 5.0	-0.3 (0.76)	0.0	-2.0, 0.0	0.3559
Low dose	4	4.5 (1.00)	4.0 (2.00)	5.0	1.0, 5.0	-0.5 (1.00)	0.0	-2.0, 0.0	0.3910
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	5.0 (N/A)	5.0 (N/A)	5.0	5.0, 5.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	4.7 (0.76)	4.4 (1.51)	5.0	1.0, 5.0	-0.3 (0.76)	0.0	-2.0, 0.0	0.3559
Low dose	4	4.5 (1.00)	4.0 (2.00)	5.0	1.0, 5.0	-0.5 (1.00)	0.0	-2.0, 0.0	0.3910
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	4.7 (0.76)	4.4 (1.51)	5.0	1.0, 5.0	-0.3 (0.76)	0.0	-2.0, 0.0	0.3559
Low dose	4	4.5 (1.00)	4.0 (2.00)	5.0	1.0, 5.0	-0.5 (1.00)	0.0	-2.0, 0.0	0.3910
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Comprehension									
BASELINE	11		3.0 (0.00)	3.0	3.0, 3.0				
Low dose	7		3.0 (0.00)	3.0	3.0, 3.0				
High dose	4		3.0 (0.00)	3.0	3.0, 3.0				
WEEK 24	7	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	3.0 (N/A)	3.0 (N/A)	3.0	3.0, 3.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Drawing									
BASELINE	11		1.0 (0.00)	1.0	1.0, 1.0				
Low dose	7		1.0 (0.00)	1.0	1.0, 1.0				
High dose	4		1.0 (0.00)	1.0	1.0, 1.0				
WEEK 24	7	1.0 (0.00)	0.9 (0.38)	1.0	0.0, 1.0	-0.1 (0.38)	0.0	-1.0, 0.0	0.3559
Low dose	4	1.0 (0.00)	0.8 (0.50)	1.0	0.0, 1.0	-0.3 (0.50)	0.0	-1.0, 0.0	0.3910
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	1.0 (N/A)	1.0 (N/A)	1.0	1.0, 1.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	1.0 (0.00)	0.9 (0.38)	1.0	0.0, 1.0	-0.1 (0.38)	0.0	-1.0, 0.0	0.3559
Low dose	4	1.0 (0.00)	0.8 (0.50)	1.0	0.0, 1.0	-0.3 (0.50)	0.0	-1.0, 0.0	0.3910
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	1.0 (0.00)	0.9 (0.38)	1.0	0.0, 1.0	-0.1 (0.38)	0.0	-1.0, 0.0	0.3559
Low dose	4	1.0 (0.00)	0.8 (0.50)	1.0	0.0, 1.0	-0.3 (0.50)	0.0	-1.0, 0.0	0.3910
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Naming									
BASELINE	11		2.0 (0.00)	2.0	2.0, 2.0				
Low dose	7		2.0 (0.00)	2.0	2.0, 2.0				
High dose	4		2.0 (0.00)	2.0	2.0, 2.0				
WEEK 24	7	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	2.0 (N/A)	2.0 (N/A)	2.0	2.0, 2.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	2.0 (0.00)	2.0 (0.00)	2.0	2.0, 2.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Orientation to Place									
BASELINE	11		4.6 (0.92)	5.0	2.0, 5.0				
Low dose	7		4.6 (1.13)	5.0	2.0, 5.0				
High dose	4		4.8 (0.50)	5.0	4.0, 5.0				
WEEK 24	7	4.6 (1.13)	4.4 (1.51)	5.0	1.0, 5.0	-0.1 (0.38)	0.0	-1.0, 0.0	0.3559
Low dose	4	4.3 (1.50)	4.0 (2.00)	5.0	1.0, 5.0	-0.3 (0.50)	0.0	-1.0, 0.0	0.3910
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	5.0 (N/A)	5.0 (N/A)	5.0	5.0, 5.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	4.6 (1.13)	4.4 (1.51)	5.0	1.0, 5.0	-0.1 (0.38)	0.0	-1.0, 0.0	0.3559
Low dose	4	4.3 (1.50)	4.0 (2.00)	5.0	1.0, 5.0	-0.3 (0.50)	0.0	-1.0, 0.0	0.3910
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	4.6 (1.13)	4.4 (1.51)	5.0	1.0, 5.0	-0.1 (0.38)	0.0	-1.0, 0.0	0.3559
Low dose	4	4.3 (1.50)	4.0 (2.00)	5.0	1.0, 5.0	-0.3 (0.50)	0.0	-1.0, 0.0	0.3910
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Orientation to Time									
BASELINE	11		4.5 (1.21)	5.0	2.0, 5.0				
Low dose	7		4.6 (1.13)	5.0	2.0, 5.0				
High dose	4		4.3 (1.50)	5.0	2.0, 5.0				
WEEK 24	7	4.6 (1.13)	4.3 (1.50)	5.0	1.0, 5.0	-0.3 (0.49)	0.0	-1.0, 0.0	0.1723
Low dose	4	4.3 (1.50)	3.8 (1.89)	4.5	1.0, 5.0	-0.5 (0.58)	-0.5	-1.0, 0.0	0.1817
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	5.0 (N/A)	5.0 (N/A)	5.0	5.0, 5.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	4.6 (1.13)	4.3 (1.50)	5.0	1.0, 5.0	-0.3 (0.49)	0.0	-1.0, 0.0	0.1723
Low dose	4	4.3 (1.50)	3.8 (1.89)	4.5	1.0, 5.0	-0.5 (0.58)	-0.5	-1.0, 0.0	0.1817
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	4.6 (1.13)	4.3 (1.50)	5.0	1.0, 5.0	-0.3 (0.49)	0.0	-1.0, 0.0	0.1723
Low dose	4	4.3 (1.50)	3.8 (1.89)	4.5	1.0, 5.0	-0.5 (0.58)	-0.5	-1.0, 0.0	0.1817
High dose	3	5.0 (0.00)	5.0 (0.00)	5.0	5.0, 5.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Reading									
BASELINE	11		1.0 (0.00)	1.0	1.0, 1.0				
Low dose	7		1.0 (0.00)	1.0	1.0, 1.0				
High dose	4		1.0 (0.00)	1.0	1.0, 1.0				
WEEK 24	7	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	1.0 (N/A)	1.0 (N/A)	1.0	1.0, 1.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Recall									
BASELINE	11		2.5 (0.69)	3.0	1.0, 3.0				
Low dose	7		2.7 (0.49)	3.0	2.0, 3.0				
High dose	4		2.3 (0.96)	2.5	1.0, 3.0				
WEEK 24	7	2.6 (0.79)	2.6 (0.79)	3.0	1.0, 3.0	0.0 (1.00)	0.0	-1.0, 2.0	>0.999
Low dose	4	2.8 (0.50)	2.3 (0.96)	2.5	1.0, 3.0	-0.5 (0.58)	-0.5	-1.0, 0.0	0.1817
High dose	3	2.3 (1.15)	3.0 (0.00)	3.0	3.0, 3.0	0.7 (1.15)	0.0	0.0, 2.0	0.4226
WEEK 48	4	2.5 (1.00)	2.8 (0.50)	3.0	2.0, 3.0	0.3 (0.50)	0.0	0.0, 1.0	0.3910
Low dose	1	3.0 (N/A)	3.0 (N/A)	3.0	3.0, 3.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	2.3 (1.15)	2.7 (0.58)	3.0	2.0, 3.0	0.3 (0.58)	0.0	0.0, 1.0	0.4226
WEEK 72	2	2.0 (1.41)	2.0 (1.41)	2.0	1.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	2.0 (1.41)	2.0 (1.41)	2.0	1.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	2.6 (0.79)	2.3 (0.95)	3.0	1.0, 3.0	-0.3 (0.49)	0.0	-1.0, 0.0	0.1723
Low dose	4	2.8 (0.50)	2.3 (0.96)	2.5	1.0, 3.0	-0.5 (0.58)	-0.5	-1.0, 0.0	0.1817
High dose	3	2.3 (1.15)	2.3 (1.15)	3.0	1.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	2.6 (0.79)	2.6 (0.79)	3.0	1.0, 3.0	0.0 (1.00)	0.0	-1.0, 2.0	>0.999
Low dose	4	2.8 (0.50)	2.3 (0.96)	2.5	1.0, 3.0	-0.5 (0.58)	-0.5	-1.0, 0.0	0.1817
High dose	3	2.3 (1.15)	3.0 (0.00)	3.0	3.0, 3.0	0.7 (1.15)	0.0	0.0, 2.0	0.4226

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Registration									
BASELINE	11		3.0 (0.00)	3.0	3.0, 3.0				
Low dose	7		3.0 (0.00)	3.0	3.0, 3.0				
High dose	4		3.0 (0.00)	3.0	3.0, 3.0				
WEEK 24	7	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	3.0 (N/A)	3.0 (N/A)	3.0	3.0, 3.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	3.0 (0.00)	3.0 (0.00)	3.0	3.0, 3.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Repetition									
BASELINE	11		1.0 (0.00)	1.0	1.0, 1.0				
Low dose	7		1.0 (0.00)	1.0	1.0, 1.0				
High dose	4		1.0 (0.00)	1.0	1.0, 1.0				
WEEK 24	7	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	1.0 (N/A)	1.0 (N/A)	1.0	1.0, 1.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Total									
BASELINE	11		28.2 (2.86)	30.0	21.0, 30.0				
Low dose	7		28.1 (3.29)	30.0	21.0, 30.0				
High dose	4		28.3 (2.36)	29.0	25.0, 30.0				
WEEK 24	7	28.4 (3.36)	27.6 (5.59)	30.0	15.0, 30.0	-0.9 (2.54)	0.0	-6.0, 2.0	0.4072
Low dose	4	27.8 (4.50)	25.8 (7.23)	29.0	15.0, 30.0	-2.0 (2.83)	-1.0	-6.0, 0.0	0.2522
High dose	3	29.3 (1.15)	30.0 (0.00)	30.0	30.0, 30.0	0.7 (1.15)	0.0	0.0, 2.0	0.4226
WEEK 48	4	29.5 (1.00)	29.8 (0.50)	30.0	29.0, 30.0	0.3 (0.50)	0.0	0.0, 1.0	0.3910
Low dose	1	30.0 (N/A)	30.0 (N/A)	30.0	30.0, 30.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	29.3 (1.15)	29.7 (0.58)	30.0	29.0, 30.0	0.3 (0.58)	0.0	0.0, 1.0	0.4226
WEEK 72	2	29.0 (1.41)	29.0 (1.41)	29.0	28.0, 30.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	29.0 (1.41)	29.0 (1.41)	29.0	28.0, 30.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	28.4 (3.36)	27.3 (5.50)	30.0	15.0, 30.0	-1.1 (2.27)	0.0	-6.0, 0.0	0.2308
Low dose	4	27.8 (4.50)	25.8 (7.23)	29.0	15.0, 30.0	-2.0 (2.83)	-1.0	-6.0, 0.0	0.2522
High dose	3	29.3 (1.15)	29.3 (1.15)	30.0	28.0, 30.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	28.4 (3.36)	27.6 (5.59)	30.0	15.0, 30.0	-0.9 (2.54)	0.0	-6.0, 2.0	0.4072
Low dose	4	27.8 (4.50)	25.8 (7.23)	29.0	15.0, 30.0	-2.0 (2.83)	-1.0	-6.0, 0.0	0.2522
High dose	3	29.3 (1.15)	30.0 (0.00)	30.0	30.0, 30.0	0.7 (1.15)	0.0	0.0, 2.0	0.4226

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

TABLE 14.2 5.J

Change from Baseline to Each Planned Visit
in Mini-Mental State Examination (MMSE) Total Score
(FAS - Japan Subjects)

Parameter / Time Point / Dose Category	N	Baseline Mean (SD)	Visit: Mean (SD)	Visit: Median	Visit: Min, Max	Change from Baseline: Mean (SD)	Change from Baseline: Median	Change from Baseline: Min, Max	P-Value &
MMSE - Writing									
BASELINE	11		1.0 (0.00)	1.0	1.0, 1.0				
Low dose	7		1.0 (0.00)	1.0	1.0, 1.0				
High dose	4		1.0 (0.00)	1.0	1.0, 1.0				
WEEK 24	7	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 48	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	1	1.0 (N/A)	1.0 (N/A)	1.0	1.0, 1.0	0.0 (N/A)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
WEEK 72	2	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	0								
High dose	2	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MINIMUM	7	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
POST-BASELINE MAXIMUM	7	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
Low dose	4	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	
High dose	3	1.0 (0.00)	1.0 (0.00)	1.0	1.0, 1.0	0.0 (0.00)	0.0	0.0, 0.0	

&: P-value is obtained from two-sided paired-sample t-test.

Program Source Code: [redacted]

2.7.4 臨床的安全性

目次

2.7.4 臨床的安全性 1
2.7.4.1 医薬品への曝露 7
2.7.4.1.1 総括的安全性評価計画及び安全性試験の記述 7
2.7.4.1.1.1 安全性の評価に使用した臨床試験 7
2.7.4.1.1.2 安全性に関する評価方法 10
2.7.4.1.1.2.1 解析対象 10
2.7.4.1.1.2.1.1 個々の試験の解析対象集団 10
2.7.4.1.1.2.1.2 日本人部分集団 10
2.7.4.1.1.2.2 有害事象 10
2.7.4.1.1.2.3 臨床検査 15
2.7.4.1.1.2.4 その他の安全性評価項目 16
2.7.4.1.1.2.4.1 バイタルサイン及び体重 16
2.7.4.1.1.2.4.2 心電図 17
2.7.4.1.1.2.4.3 注入部位反応 18
2.7.4.1.1.2.4.4 衝動制御障害 19
2.7.4.1.1.2.4.5 コロンビア自殺評価スケール 19
2.7.4.1.2 全般的な曝露状況 20
2.7.4.1.2.1 M15-741 試験 20
2.7.4.1.2.2 M15-737 試験 23
2.7.4.1.2.3 M15-736 試験 25
2.7.4.1.3 被験者の内訳 27
2.7.4.1.3.1 M15-741 試験 27
2.7.4.1.3.2 M15-737 試験 27
2.7.4.1.3.3 M15-736 試験 28
2.7.4.1.4 治験対象集団の人口統計学的特性及びその他の特性 28
2.7.4.1.4.1 M15-741 試験 28
2.7.4.1.4.2 M15-737 試験 29
2.7.4.1.4.3 M15-736 試験 29
2.7.4.2 有害事象 30
2.7.4.2.1 有害事象の解析 30
2.7.4.2.1.1 有害事象の概要 30
2.7.4.2.1.1.1 M15-741 試験 30

2.7.4.2.1.1.2 M15-737 試験 44
2.7.4.2.1.1.3 M15-736 試験 51
2.7.4.2.1.2 比較的よくみられる有害事象 54
2.7.4.2.1.2.1 M15-741 試験 54
2.7.4.2.1.2.2 M15-737 試験 54
2.7.4.2.1.2.3 M15-736 試験 54
2.7.4.2.1.3 治験薬と関連ありの有害事象 55
2.7.4.2.1.3.1 M15-741 試験 55
2.7.4.2.1.3.2 M15-737 試験 55
2.7.4.2.1.3.3 M15-736 試験 55
2.7.4.2.1.4 重症度別の有害事象 56
2.7.4.2.1.4.1 M15-741 試験 56
2.7.4.2.1.4.2 M15-737 試験 56
2.7.4.2.1.4.3 M15-736 試験 56
2.7.4.2.1.5 発現時期別の有害事象 57
2.7.4.2.1.5.1 M15-741 試験 57
2.7.4.2.1.5.2 M15-737 試験 57
2.7.4.2.1.6 死亡 58
2.7.4.2.1.6.1 M15-741 試験 58
2.7.4.2.1.6.2 M15-737 試験 58
2.7.4.2.1.6.3 M15-736 試験 58
2.7.4.2.1.6.4 第 I 相試験 59
2.7.4.2.1.7 その他の重篤な有害事象 59
2.7.4.2.1.7.1 M15-741 試験 59
2.7.4.2.1.7.2 M15-737 試験 59
2.7.4.2.1.7.3 M15-736 試験 60
2.7.4.2.1.7.4 第 I 相試験 60
2.7.4.2.1.8 その他の重要な有害事象 60
2.7.4.2.1.8.1 投与中止に至った有害事象 60
2.7.4.2.1.8.1.1 M15-741 試験 60
2.7.4.2.1.8.1.2 M15-737 試験 61
2.7.4.2.1.8.1.3 M15-736 試験 61
2.7.4.2.1.8.2 治験薬又は治験機器の不具合に関連した有害事象 61
2.7.4.2.1.8.2.1 M15-741 試験 61
2.7.4.2.1.8.2.2 M15-737 試験 62

2.7.4.2.1.8.2.3 M15-736 試験 62
2.7.4.2.1.9 器官別又は症候群別有害事象の解析 62
2.7.4.2.1.9.1 注入部位感染 63
2.7.4.2.1.9.1.1 M15-741 試験 63
2.7.4.2.1.9.1.2 M15-737 試験 64
2.7.4.2.1.9.1.3 M15-736 試験 64
2.7.4.2.1.9.2 注入部位非感染反応 65
2.7.4.2.1.9.2.1 M15-741 試験 65
2.7.4.2.1.9.2.2 M15-737 試験 66
2.7.4.2.1.9.2.3 M15-736 試験 66
2.7.4.2.1.9.3 幻覚及び精神病 67
2.7.4.2.1.9.3.1 M15-741 試験 67
2.7.4.2.1.9.3.2 M15-737 試験 68
2.7.4.2.1.9.3.3 M15-736 試験 68
2.7.4.2.1.9.4 多発ニューロパチー 69
2.7.4.2.1.9.4.1 M15-741 試験 69
2.7.4.2.1.9.4.2 M15-737 試験 69
2.7.4.2.1.9.4.3 M15-736 試験 69
2.7.4.2.1.9.5 転倒及び関連する損傷 70
2.7.4.2.1.9.5.1 M15-741 試験 70
2.7.4.2.1.9.5.2 M15-737 試験 71
2.7.4.2.1.9.5.3 M15-736 試験 72
2.7.4.2.1.9.6 傾眠 73
2.7.4.2.1.9.6.1 M15-741 試験 73
2.7.4.2.1.9.6.2 M15-737 試験 73
2.7.4.2.1.9.6.3 M15-736 試験 73
2.7.4.2.1.9.7 体重減少 74
2.7.4.2.1.9.7.1 M15-741 試験 74
2.7.4.2.1.9.7.2 M15-737 試験 74
2.7.4.2.1.9.7.3 M15-736 試験 75
2.7.4.2.1.9.8 COVID-19 に関連する有害事象 75
2.7.4.2.1.9.8.1 M15-741 試験 75
2.7.4.2.1.9.8.2 M15-737 試験 75
2.7.4.2.1.9.8.3 M15-736 試験 75
2.7.4.2.2 個別有害事象の文章による説明 76

2.7.4.3 臨床検査値の評価 76
2.7.4.3.1 M15-741 試験 76
2.7.4.3.2 M15-737 試験 77
2.7.4.3.3 M15-736 試験 77
2.7.4.4 バイタルサイン，身体的所見及び安全性に関連する他の観察項目 77
2.7.4.4.1 バイタルサイン 77
2.7.4.4.2 心電図 78
2.7.4.4.3 自殺傾向 78
2.7.4.5 特別な患者集団及び状況下における安全性 79
2.7.4.5.1 日本人部分集団における安全性 79
2.7.4.5.1.1 全般的な曝露状況 79
2.7.4.5.1.1.1 M15-741 試験 79
2.7.4.5.1.1.2 M15-737 試験 80
2.7.4.5.1.2 有害事象 81
2.7.4.5.1.2.1 M15-741 試験 81
2.7.4.5.1.2.2 M15-737 試験 85
2.7.4.5.1.3 比較的よくみられる有害事象 92
2.7.4.5.1.3.1 M15-741 試験 92
2.7.4.5.1.3.2 M15-737 試験 95
2.7.4.5.1.4 死亡 95
2.7.4.5.1.4.1 M15-741 試験 95
2.7.4.5.1.4.2 M15-737 試験 95
2.7.4.5.1.5 その他の重篤な有害事象 96
2.7.4.5.1.5.1 M15-741 試験 96
2.7.4.5.1.5.2 M15-737 試験 96
2.7.4.5.1.6 その他の重要な有害事象 96
2.7.4.5.1.6.1 M15-741 試験 96
2.7.4.5.1.6.2 M15-737 試験 97
2.7.4.5.1.7 器官別又は症候群別有害事象の解析 97
2.7.4.5.1.7.1 注入部位感染 97
2.7.4.5.1.7.1.1 M15-741 試験 97
2.7.4.5.1.7.1.2 M15-737 試験 97
2.7.4.5.1.7.2 注入部位非感染反応 98
2.7.4.5.1.7.2.1 M15-741 試験 98
2.7.4.5.1.7.2.2 M15-737 試験 98

2.7.4.5.1.7.3 幻覚及び精神病 99
2.7.4.5.1.7.3.1 M15-741 試験 99
2.7.4.5.1.7.3.2 M15-737 試験 99
2.7.4.5.1.7.4 多発ニューロパチー 100
2.7.4.5.1.7.4.1 M15-741 試験 100
2.7.4.5.1.7.4.2 M15-737 試験 100
2.7.4.5.1.7.5 転倒及び関連する損傷 100
2.7.4.5.1.7.5.1 M15-741 試験 100
2.7.4.5.1.7.5.2 M15-737 試験 101
2.7.4.5.1.7.6 傾眠 102
2.7.4.5.1.7.6.1 M15-741 試験 102
2.7.4.5.1.7.6.2 M15-737 試験 102
2.7.4.5.1.7.7 体重減少 102
2.7.4.5.1.7.7.1 M15-741 試験 102
2.7.4.5.1.7.7.2 M15-737 試験 102
2.7.4.5.2 内因性要因 103
2.7.4.5.3 外因性要因 103
2.7.4.5.4 薬物相互作用 104
2.7.4.5.5 妊娠及び授乳時の使用 105
2.7.4.5.6 過量投与 105
2.7.4.5.7 薬物乱用 106
2.7.4.5.8 離脱症状及び反跳現象 107
2.7.4.5.9 自動車運転及び機械操作に対する影響又は精神機能の障害 107
2.7.4.6 市販後データ 107
2.7.4.7 付録 108

略語及び定義一覧

略語又は用語	省略していない表現又は説明（英語）	省略していない表現又は説明（日本語）
ABBV-951	Foslevodopa/Foscarbidopa hydrate	ホスレボドパ・ホスカルビドパ水和物
AESI	adverse events of special interest	特に注目すべき有害事象
BMI	body mass index	体格指数
CD	Carbidopa	カルビドパ
CD/LD	Carbidopa/levodopa	カルビドパ／レボドパ
CMQ	company MedDRA query	--
COVID-19	coronavirus disease-2019	新型コロナウイルス感染症
CSCI	continuous subcutaneous infusion	持続皮下注入
CSR	clinical study report	治験総括報告書
C-SSRS	Columbia-Suicide Severity Rating Scale	コロンビア自殺評価スケール
CTCAE	Common Terminology Criteria for Adverse Events	有害事象共通用語規準
DDS	dopamine dysregulation syndrome	ドーパミン調節障害症候群
DLP	data lock point	データロックポイント
ECG	electrocardiogram	心電図
FDA	Food and Drug Administration	米国食品医薬品局
ICD	impulse control disorder	衝動制御障害
ICH	The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use	医薬品規制調和国際会議
LCIG	levodopa-carbidopa intestinal gel	レボドパ・カルビドパ水和物配合経腸用液
LD	Levodopa	レボドパ
MedDRA	medical dictionary for regulatory activities	ICH 国際医薬用語集
PCS	potentially clinically significant	臨床的に重要と考えられる
PD	Parkinson's disease	パーキンソン病
PT	preferred term	基本語
RMP	Risk Management Plan	医薬品リスク管理計画
QUIP-RS	Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale	パーキンソン病における衝動制御障害の評価尺度
SD	standard deviation	標準偏差
SE	standard error	標準誤差
SMQ	standard MedDRA query	MedDRA 標準検索式

2.7.4.1 医薬品への曝露

2.7.4.1.1 総括的安全性評価計画及び安全性試験の記述

2.7.4.1.1.1 安全性の評価に使用した臨床試験

ホスレボドパ・ホスカルビドパ水和物（以下「ABBV-951」）の臨床データパッケージは，第 I 相の 7 試験及び第 III 相の 3 試験のデータから構成されている（表 2.7.4-1）。

ABBV-951 を 1 日 24 時間の持続皮下注入（以下「CSCI」）したときの安全性は，国際共同第 III 相試験の非盲検法により実施した M15-741 試験（5.3.5.2-1 項［申請時］及び 5.3.5.2-1-2 項［更新時］），その継続投与試験である M15-737 試験（5.3.5.2-2 項［申請時］及び 5.3.5.2-2-2 項［更新時］）及び海外で二重盲検法により実施した第 III 相試験の M15-736 試験（5.3.5.1-1 項）の臨床成績を評価資料として評価し，更に海外で非盲検法により実施した第 I 相試験の M16-769 試験（5.3.3.3-1 項）及び M17-220 試験（5.3.1.2-1 項）の臨床成績を評価資料として評価した。

また，海外で実施された第 I 相試験の 5 試験（M15-739［5.3.3.2-2 項］，M15-738［5.3.3.2-1 項］，M15-733［5.3.3.1-1 項］，M18-763［5.3.4.1-1 項］及び M18-764 試験［5.3.1.2-2 項］）の臨床成績を参考資料として評価した。

評価資料とした臨床試験の概略及び参考資料とした臨床試験の概略を表 2.7.4-1 に示す（詳細は表 2.7.3-1 参照）。

評価資料とした第 III 相試験の M15-741 試験は，経口パーキンソン病（以下「PD」）治療薬では運動症状を十分にコントロールできないレボドパ（以下「LD」）反応性の特発性 PD 患者（1 日あたりの「オフ」時間が 2.5 時間以上認められる）を対象とした非盲検の単群による日本人を含む国際共同試験であり，主要目的として 52 週間投与時の長期安全性及び忍容性を評価し，副次目的は有効性の評価であった。本試験は実施中であり，本試験の治験総括報告書（以下「CSR」）のデータカットオフ日は，20[redacted] 年 [redacted] 月 [redacted] 日であった。申請後に更新した CSR（CSR update）のデータカットオフ日は，20[redacted] 年 [redacted] 月 [redacted] 日であった。

M15-741 試験の継続投与試験である M15-737 試験（第 III 相）は，M15-741 試験を完了した成人被験者を対象とした非盲検の単群による ABBV-951 単群の日本人を含む第 III 相の国際共同試験であり，主要目的は，最大 144 週間（96 週間の投与期間＋48 週間の延長投与期間）投与時の長期安全性及び忍容性の評価であり，副次目的は有効性の評価であった。本試験は実施中であり，本試験の CSR のデータカットオフ日は，20[redacted] 年 [redacted] 月 [redacted] 日であった。申請後に更新した CSR（CSR update）のデータカットオフ日は，20[redacted] 年 [redacted] 月 [redacted] 日であった。

海外で実施された二重盲検法によるカルビドパ／レボドパ（以下「CD/LD」）速放性製剤を対照薬とした並行群間比較試験である M15-736 試験（第 III 相）は，現在の治療ではコントロール不十分な運動症状の日内変動を有する進行期 PD 患者（PD 日誌に基づく 1 日あたりの「オフ」時間が 3 日間連続で 2.5 時間以上認められる）を対象とし，12 週間投与時の ABBV-951 CSCI の優越性を示すことを主要目的とし，安全性及び忍容性を副次目的とした。

なお，評価資料及び参考資料で用いた第 I 相試験 7 試験（M16-769，M17-220，M15-739，M15-738，M15-733，M18-763 及び M18-764 試験）の安全性に関する評価方法及び臨床試験成績は，2.7.6 項に示し，本項では，死亡を含む重篤な有害事象についてのみ示す。

表 2.7.4-1. 安全性評価に用いた臨床試験の概要

評価 / 参考資料	試験番号 資料番号	国内 / 海外試験	対象患者	試験の相	比較 / 非盲検試験	試験の進行状況 報告書の種類
評価資料	M15-741 5.3.5.2-1 5.3.5.2-1-2	日本人を含む国際共同試験	パーキンソン病患者	第 III 相	非盲検試験	継続中 治験総括報告書（データカットオフ日：20[redacted] 年 [redacted] 月 [redacted] 日） 治験総括報告書（データカットオフ日：20[redacted] 年 [redacted] 月 [redacted] 日）
評価資料	M15-737 5.3.5.2-2 5.3.5.2-2-2	日本人を含む国際共同試験	パーキンソン病患者	第 III 相	非盲検試験	継続中 治験総括報告書（データカットオフ日：20[redacted] 年 [redacted] 月 [redacted] 日） 治験総括報告書（データカットオフ日：20[redacted] 年 [redacted] 月 [redacted] 日）
評価資料	M15-736 5.3.5.1-1	海外多施設共同試験	パーキンソン病患者	第 III 相	比較試験	終了 治験総括報告書
評価資料	M16-769 5.3.3.3-1	日本人を含む海外試験	日本人，中国人及び白人の健康被験者	第 I 相	非盲検試験	終了 治験総括報告書
評価資料	M17-220 5.3.1.2-1	海外試験	健康被験者	第 I 相	非盲検試験	終了 治験総括報告書
参考資料	M15-739 5.3.3.2-2	海外多施設共同試験	パーキンソン病患者	第 I 相	非盲検試験	終了 治験総括報告書
参考資料	M15-738 5.3.3.2-1	海外多施設共同試験	パーキンソン病患者	第 I 相	比較試験	終了 治験総括報告書
参考資料	M15-733 5.3.3.1-1	海外試験	健康被験者	第 I 相	比較 / 非盲検試験	終了 治験総括報告書
参考資料	M18-763 5.3.4.1-1	海外試験	健康被験者	第 I 相	比較試験	終了 治験総括報告書
参考資料	M18-764 5.3.1.2-2	海外試験	健康被験者	第 I 相	非盲検試験	終了 治験総括報告書

2.7.4.1.1.2 安全性に関する評価方法

2.7.4.1.1.2.1 解析対象

2.7.4.1.1.2.1.1 個々の試験の解析対象集団

安全性評価に用いた第 III 相試験 3 試験（M15-741，M15-737 及び M15-736 試験）の安全性の解析は，治験薬を投与されたすべての被験者を安全性解析対象集団として実施した。二重盲検試験である M15-736 試験では，二重盲検期に治験薬が投与されたすべての被験者を安全性解析対象集団とし，また，被験者はいずれの投与群に割り付けられたかにかかわらず，実際に投与された治験薬に基づいた投与群に割り振られた。

2.7.4.1.1.2.1.2 日本人部分集団

M15-741 及び M15-737 試験は，日本人を含む国際共同第 III 相試験であり，日本人のデータのみを抽出した日本人部分集団を解析対象として部分集団解析を行った（M15-741 試験 CSR Appendix 16.1__9.3 Japan Study Data，M15-741 試験 CSR update，M15-737 試験 CSR Appendix 16.1__9.3 Japan Study Data，M15-737 試験 CSR update）。

2.7.4.1.1.2.2 有害事象

以下に，安全性評価で評価資料とした第 III 相試験 3 試験（M15-741，M15-737 及び M15-736 試験）の有害事象の評価方法及び解析方法を示す。

<u>有害事象の収集期間</u>

有害事象の調査は，M15-741 及び M15-737 試験では，治験薬の投与開始から最終投与日の 30 日後までとし，M15-736 試験では，経口 CD/LD 安定化期の経口 CD/LD の初回投与から二重盲検期の治験薬の投与開始前まで，また，二重盲検期の治験薬投与開始から二重盲検期の投与終了後 30 日までとし，調査結果か被験者の自発報告であるかにかかわらず収集した。また，治験薬投与を早期に中止した被験者についても，追跡調査を行った（治験参加同意の撤回を除く）。治験手順と関連した重篤及び非重篤な有害事象は，被験者の同意を文書で取得した時点から調査した。

<u>有害事象の定義</u>

M15-741 及び M15-737 試験では，治験薬投与後に発現した有害事象は，治験薬投与開始日から投与終了後 30 日までに発現した又は重症度が悪化した有害事象と定義した。M15-736 試験では，経口 CD/LD 安定化期の経口 CD/LD の初回投与から二重盲検期の治験薬の投与開始前までに発現した又は重症度が悪化した有害事象とし，また，二重盲検期の治験薬投与開始から二重盲検期の投与終了後 30 日までに発現した又は重症度が悪化した有害事象とした。

本項では特に記載のない限り，M15-741 及び M15-737 試験では治験薬投与後に発現した有害事象，M15-736 試験では二重盲検期の治験薬投与後に発現した有害事象を示した。

有害事象の集計方法（有害事象の発現割合）

M15-741，M15-737 及び M15-736 試験では，すべての有害事象は，医薬品規制調和国際会議（以下「ICH」）国際医薬用語集（以下「MedDRA」）の最新版 version 24.0（有害事象和訳辞書は MedDRA/J）を用いてコード化し，有害事象が発現した被験者数及びその割合を MedDRA 器官別大分類（「SOC」）別及び基本語（以下「PT」）別に集計した。また，重症度別並びに治験責任（分担）医師の評価に基づく治験薬との因果関係別に示した。更に，重篤な有害事象，死亡に至った有害事象，治験薬の投与中止に至った有害事象，特に注目すべき有害事象（以下「AESI」）及び新型コロナウイルス感染症（以下「COVID-19」）に関連した有害事象の被験者数及びその割合を要約した。なお，M15-741 試験では，有害事象の被験者数及びその割合を最適化期別，維持期別及び全期間別に要約した。また，M15-741 試験では，予想を上回る脱落・中止例が認められ，その根本原因は注入部位の有害事象の発現及び投与システム使用の困難が考えられたことから，無菌操作を含む注入セットの使用方法に関する再教育を実施するとともに，使いやすさがより優れていると考えられる注入セット（Neria Guard）も使用できるように治験実施計画書の改訂（20[redacted]年[redacted]月[redacted]日）を行った。これらの改善策は 20[redacted]年[redacted]月[redacted]日までに完全に実施されたことから，それよりも前に登録された被験者を Sample 1，それ以降に登録された被験者を Sample 2 として登録時期別に有害事象を要約した。

M15-741，M15-737 及び M15-736 試験では，製品の品質に関する苦情・不具合に関連した有害事象が発現した被験者数及びその割合を以下の製品リスト（表 2.7.4-2）ごとに要約した。

11

表 2.7.4-2. 臨床試験で用いた製品リスト

M15-741 及び M15-737 試験	M15-736 試験
ABBV-951	ABBV-951 又はプラセボ溶液
NA	CD/LD IR 又はプラセボカプセル
NA	速放性の CD/LD（非盲検）
注入ポンプ	注入ポンプ
バイアルアダプター	バイアルアダプター
シリンジ	シリンジ
[redacted] 注入セット（6 mm カニューレ，チューブ）	NA
[redacted] 注入セット（9 mm カニューレ，チューブ）	NA
Neria Guard 注入セット （6 mm カニューレ，チューブ）	Neria Guard 注入セット （6 mm カニューレ，チューブ）
Neria Guard 注入セット （9 mm カニューレ，チューブ）	Neria Guard 注入セット （9 mm カニューレ，チューブ）
[redacted]	[redacted]

ABBV-951 = ホスレボドパ・ホスカルビドパ水和物，CD/LD = カルビドパ／レボドパ，IR = 速放性の，NA = 該当なし，[redacted] = [redacted] or [redacted] (United States)

重症度

安全性評価で用いた第 III 相試験 3 試験の重症度の定義を以下に示した。

治験責任（分担）医師は，次の定義を用いて，それぞれの有害事象の重症度を軽度，中等度，重度に分類した。

- 軽度：一過性かつ被験者が容易に耐えられる。
- 中等度：不快感を伴い，被験者の通常の活動を妨げる。
- 重度：被験者の通常の活動を大きく妨げ，身体機能障害を伴う又は生命を脅かすおそれがある。

因果関係

安全性評価で用いた第 III 相試験 3 試験の因果関係の定義を以下に示した。

治験責任（分担）医師は，次の定義を用いて，有害事象と治験薬の使用との因果関係を評価した。

- 関連あり－有害事象の発現時期，生物学的妥当性，臨床的判断，潜在的代替要因を含む要因を考慮した上で，因果関係を示唆する十分な証拠（情報）がある。
- 関連なし－有害事象の発現時期，生物学的妥当性，臨床的判断，潜在的代替要因を含む要因を考慮した上で，因果関係を示唆する証拠（情報）は不十分である。

重篤な有害事象

安全性評価で用いた第 III 相試験 3 試験の重篤な有害事象の定義を以下に示した。
次の基準に有害事象が該当した場合，重篤な有害事象とした。

- 被験者の死亡：被験者が死亡した事象
- 生命を脅かすもの：適切な処置をしなければ患者が死の危険にさらされていたと判断される事象。その事象がもっと重症なものであった場合，死に至ったかもしれないという仮定的な意味ではない。
- 治療による入院又は入院期間の延長：期間の長短にかかわらず，被験者を入院又は入院中についてはその期間延長に至らしめた事象。救急救命室や外来措置となった事象はこれに該当しない。
- 先天性異常：出産時又は出産後に認められた奇形，あるいは胎児死亡に至った事象
- 永続的又は顕著な障害 / 機能不全：被験者の日常生活の活動に支障をきたす永続的又は顕著な障害 / 機能不全。医学的重要性が比較的低い事象，例えば頭痛，嘔気，嘔吐，下痢，インフルエンザ又は足首の捻挫などの突発的な外傷などは該当しない。
- 重篤な転帰を防ぐために内科的，又は外科的処置を必要とする医学的に重要な事象：直ちに生命を脅かす，あるいは死に至る，又は入院が必要とはならない場合でも，医学的判断から被験者を臨床上好ましくない状態に至らしめる事象，あるいは上記の転帰（死亡，生命を脅かすもの，入院又は入院期間の延長，先天性の異常，永続的又は顕著な障害 / 機能不全）に至らないように内科的又は外科的処置を必要とする事象。更に，自然流産，人工流産，死産はすべて医学的に重要な事象とする。これには救急救命室又は自宅にて集中治療を必要とするアレルギー性気管支痙攣，入院には至らない悪液質又は痙攣，あるいは薬物依存又は薬物乱用が該当する。

MedDRA バージョン

M15-741，M15-737 及び M15-736 試験では，有害事象は，MedDRA の version 24.0（有害事象和訳辞書は MedDRA/J）を用いてコード化した。

治験薬又は治験機器の不具合に関連した有害事象

安全性評価で用いた第 III 相試験 3 試験では，製品の品質に関する苦情・不具合とは，治験薬の成分又は治験機器に関連する苦情・不具合とした。M15-741，M15-737 及び M15-736 試験での当該苦情・不具合に関する記載を以下に示した。

製品又は包装の損傷 / 破損，ラベル表示と一致しない製品の色や印字を含む製品の外観，ラベル表示の不一致や不適切なラベル / 指示（例：判読できない印字），コンポーネント / 製品の欠品，機器の動作不良，梱包の問題などが含まれるが，これらに限定しない。

治験薬又は治験機器に関する苦情・不具合は，実施医療機関が当該事象を知ってから 1 営業日以内に治験依頼者に報告しなければならない。治験期間中に発生した製品の品質に関する苦情・不具合は，十分な結論が得られるまで追跡した。

治験機器の場合，製品の品質に関する苦情・不具合には以下も含まれる。

- 当該機器を使用した被験者のすべての死亡
- 当該機器の使用付近で発生したすべての疾患，傷害又は有害事象
- 当該機器の使用により発現した可能性がある有害事象
- 当該機器を使用中に，入院を含む内科的又は外科的処置を必要としたすべての事象
- 故障，誤使用，製造者から提供された情報の不備

特に注目すべき有害事象

M15-741，M15-737 及び M15-736 試験で，定義した特に注目すべき有害事象を表 2.7.4-3 に示す。

表 2.7.4-3. 特に注目すべき有害事象

特に注目すべき有害事象	検索基準
注入部位感染	CMQ「注入部位感染」
注入部位非感染反応	CMQ「注入部位非感染反応」
幻覚及び精神病	CMQ「幻覚」及び SMQ「精神病及び精神障害」（狭域検索）
多発ニューロパチー	SMQ「末梢性ニューロパチー」（広義及び狭域検索）
転倒及び関連する損傷	CMQ「転倒及び関連する損傷」 起立性低血圧に関する PT「外来血圧低下」，「起立血圧」，「起立血圧低下」，「めまい」，「体位性めまい」，「起立性低血圧」，「失神」
傾眠	PT「傾眠」，「過眠症」，「マイクロスリープ」，「突発的睡眠」，「身体疾患による睡眠障害，過眠症型」，「睡眠発作」
体重減少	CMQ「体重減少」

本項では，多発ニューロパチーに関しては狭域検索の結果のみを示す。

CMQ : company MedDRA queary , SMQ : standard MedDRA query , PT : preferred term

注入部位評価は規定来院時に実施するほか，規定外来院時にも実施した。注入部位刺激感 / 注入部位反応（注入部位評価尺度で 2 を超える又は C を超える）が認められた場合，有害事象として記録した。その他の注入部位関連の反応（蜂巣炎 / 膿瘍形成，斑状出血，皮下結節，瘢痕など）も，評価の上，有害事象として記録した。中等度及び重度の注入部位関連の反応については，独立した評価を実施した。

これらの AESI を選択した理由を以下に示す。

- 注入部位感染及び注入部位非感染反応：治験薬 / 注入システム及び投与経路による。
- 他の AESI については，PD 患者の LD/CD による治療で一般的に知られているクラスリスクである。

COVID-19 感染に関連する有害事象

M15-741，M15-737 及び M15-736 試験では，治験薬投与後に発現した COVID-19 感染に関連した有害事象及び COVID-19 に関連した死亡を有害事象として評価し，集計した。

部分集団解析（内因性 / 外因性因子）

M15-741 及び M15-737 試験では，すべての有害事象について，以下に定義した内因性要因及び外因性要因を層別因子として部分集団解析を行った。

用量（低用量及び高用量），性別（男性及び女性），人種（白人，アジア人及びその他），年齢（65 歳未満及び 65 歳以上），PD 罹病期間（診断後経過期間，10 年未満及び 10 年以上），地域（北米，欧州及びオーストラリア，並びに日本）を因子とした。

M15-736 試験では，すべての有害事象，重篤な有害事象，中止に至った有害事象，特に注目すべき有害事象及び中止に至った特に注目すべき有害事象について，以下に定義した内因性要因及び外因性要因を層別因子として部分集団解析を行った。

用量（低用量及び高用量），年齢（65 歳未満及び 65 歳以上），性別（男性及び女性），人種（白人及びその他），PD 罹病期間（診断後経過期間，10 年未満及び 10 年以上），体格指数（以下「BMI」）（25 未満及び 25 以上），ドパミンアゴニスト併用の有無，実施国（米国及びオーストラリア）を因子とした。

2.7.4.1.1.2.3 臨床検査

安全性評価に用いた第 III 相試験 3 試験の臨床検査項目は，それぞれの治験実施計画書に示した。

臨床検査値のベースラインは，M15-741 試験では，ABBV-951 CSCI 開始前の最後の臨床検査値とし，M15-737 試験では，親試験（M15-741 試験）の最終来院で得られた臨床検査値とし，M15-736 試験では，ランダム化前 1 週間の臨床検査値とした。

M15-741 及び M15-737 試験では，血液学的検査，血液生化学検査，尿検査パラメータ及び特別な臨床検査に関して，ベースラインから各来院日との変化量，最小値，最大値及び最終値との変化量を記述的に要約した。ベースラインからの変化量について，症例数，ベースラインの平均値，来院日の平均値及びベースラインからの変化量の要約統計量（平均値，標準偏差［以下「SD」］及び中央値）を示した。ベースラインからの変化量の要約統計量は，ベースライン値及び来院日の両方の値が得られた被験者についてのみ計算した。

M15-741 及び M15-737 試験では，臨床検査値の変化が，有害事象共通用語規準（以下「CTCAE」）又は各臨床検査値の正常範囲に基づく低値，正常値又は高値の分類によるシフトテーブルで表示された。試験中にベースラインから悪化した値（CTCAE 基準に基づく）又は最小値及び最大値（正常範囲に基づく）のシフトテーブルが作成された。

M15-741 及び M15-737 試験では，選択した臨床検査項目（M15-741 試験 統計解析計画書 Appendix B 及び M15-737 試験 統計解析計画書 Appendix B）に対して，CTCAE 基準（version 4.03）を用いて臨床的に重要と考えられる（以下「PCS」）臨床検査値の基準を定義した。投与後に PCS 基準に適合し，ベースラインと比較して顕著な値を少なくともひとつ有した被験者数及びその割合の要約を示した。

M15-736 試験では，ベースラインから二重盲検期の最終値までの平均変化量を症例数，ベースラインの平均値及び来院日の平均値についてサブグループ別（年齢，性別，人種，実施国，PD の罹病期間，BMI，ドパミンアゴニスト併用の有無，用量）に要約した。各投与群内のベースラインからの変化量及び投与群間の差に関して，ベースラインからの変化量の平均値，標準誤差（以下「SE」）及び 95%信頼区間を示した。

ベースラインから最終値の臨床検査値の変化が，CTCAE 又は各臨床検査値の正常範囲に基づく低値，正常値若しくは高値の分類によるシフトテーブルを用いて示された。臨床検査値の異常値について，治験依頼者及び米国食品医薬品局（以下「FDA」）の PCS 基準（M15-736 試験統計解析計画書 Appendix C）を用いて，該当した被験者数及びその割合の要約を上述した部分集団別に示した。

2.7.4.1.1.2.4 その他の安全性評価項目

2.7.4.1.1.2.4.1 バイタルサイン及び体重

バイタルサイン（体温，収縮期血圧，拡張期血圧及び脈拍数），体重及び BMI のベースラインは，M15-741 試験では，ABBV-951 の CSCI 開始日前の値とし，M15-737 試験では，親試験（M15-741 試験）の最終来院日に得られた値とし，M15-736 試験では，ランダム化前 1 週間の値とした。なお，M15-741 及び M15-736 試験では，バイタルサインとして体温に加え，臥位，立位及び起立性の収縮期血圧，拡張期血圧及び脈拍数を評価し，起立性の収縮期血圧，拡張期血圧及び脈拍数を立位から臥位への変化量として，それぞれ計算した。

M15-741 及び M15-737 試験では，バイタルサイン，体重及び BMI に関して，ベースラインから各来院日との変化量，最小値，最大値及び最終値との変化量を記述的に要約した。ベースラインからの変化量について，症例数，ベースラインの平均値，来院日の平均値並びに各変化量の要約統計量（平均値，SD 及び中央値）を示した。

M15-741 及び M15-737 試験では，選択したバイタルサイン，体重及び BMI の項目に，PCS 基準を定義した（表 2.7.4-4）。投与後に PCS 基準に適合し，ベースラインと比較して顕著な検査値を少なくともひとつ有した被験者数及びその割合の要約を示した。

M15-736 試験では，各バイタルサインの測定値は，すべての時点（ベースラインを含む）について，非欠損値数，平均値，SD，中央値，最小値及び最大値を要約した。

二重盲検期におけるバイタルサイン及び体重に関して，ベースラインから各来院日の平均変化量を部分集団別（年齢，性別，人種，実施国，PD の罹病期間，BMI，ドパミンアゴニスト併用の有無，用量）に，症例数，ベースラインの平均値及び来院日の平均値と共に要約した。

各投与群内でのベースラインからの平均変化量及び両群間の差に関して，ベースラインからの変化量の平均値，SE 及び 95%信頼区間を示した。FDA からの要求により，血圧及び脈拍数に関して，来院日ごとにバイタルサインの値及びベースラインからの変化量を投与量，非欠損値数，平均値，SD，中央値，最小値及び最大値と共に要約した。

また，治験依頼者又は FDA の PCS 基準（M15-736 試験 統計解析計画書 Appendix C）を用いて，該当した被験者数及びその割合の要約を上述した部分集団別に示した。

表 2.7.4-4. 治験依頼者のバイタルサインの PCS 基準

Vital Signs	Unit	Very Low (VL)	Very High (VH)
Systolic blood pressure (supine and standing)	mmHg	≤ 80 and decreased ≥ 45 from baseline	≥ 160 and increased ≥ 45 from baseline
Orthostatic systolic blood pressure	mmHg	Decrease ≥ 30 from supine to standing	NA
Diastolic blood pressure (supine and standing)	mmHg	≤ 50 and decreased ≥ 40 from baseline	≥ 95 and increased ≥ 40 from baseline
Orthostatic diastolic blood pressure	mmHg	Decrease ≥ 20 from supine to standing	NA
Pulse rate (supine and standing)	bpm	≤ 45 and decreased ≥ 35 from baseline	≥ 120 and increased ≥ 35 from baseline
Orthostatic pulse rate	bpm		Increase ≥ 30 from supine to standing
Temperature	degrees C	NA	≥ 38.3 and increase ≥ 1.1 from baseline
Weight	kg	Decreased ≥ 7% from baseline	Increased ≥ 7% from baseline

NA = 該当なし，起立性収縮期血圧及び起立性拡張期血圧は M15-741 及び M15-736 試験のみ

2.7.4.1.1.2.4.2 心電図

M15-741 試験のベースラインは，ABBV-951 の CSCI 開始後，投与 1 日目とし，M15-737 試験では，親試験（M15-741 試験）の最終来院で得られた心電図（以下「ECG」）とし，M15-736 試験では，ランダム化の 1 週間前の ECG とした。

M15-741 及び M15-737 試験では，ECG の変数（心拍数，PR 間隔，QRS 間隔，QT 間隔及び QTcF［補正式による補正 QT 間隔］）に関して，ベースラインから各来院日との変化量，最小値，最大値及び最終値との変化量を記述的に要約した。ベースラインからの変化量について，

症例数，ベースラインの平均値，来院日の平均値，各変化量の平均値，SD 及び中央値を示した。これらの試験では，選択した ECG の変数に，臨床的に重要と考えられる心電図の基準（心電図の PCS 基準）を定義した（表 2.7.4-5）。投与後に PCS 基準に適合し，ベースラインと比較して顕著な値を少なくともひとつ有した被験者数及びその割合を示した。

M15-736 試験でも，ECG の変数に関して，ベースラインから各来院日との変化量，最小値，最大値及び最終値との変化量を記述的に要約した。ベースラインからの変化量について，症例数，ベースラインの平均値，来院日の平均値，各変化量の平均値，SD 及び中央値を部分集団別（年齢，性別，人種，実施国，PD の罹病期間，BMI，ドパミンアゴニスト併用の有無及び用量）に要約した。また，投与後に PCS 基準（表 2.7.4-5）に適合し，ベースラインと比較して顕著な値を少なくともひとつ有した被験者数及びその割合の要約を上述した部分集団別に示した。

表 2.7.4-5. 治験依頼者の心電図の PCS 基準

ECG Parameters	Unit	Very Low (VL)	Very High (VH)
Heart rate	bpm	≤ 45 and decreased ≥ 35 from baseline	≥ 120 and increased ≥ 35 from baseline
PQ (PR)	ms	≤ 120	≥ 220
QTcF Interval	ms	NA	≥ 480 OR Increased ≥ 60 from baseline

ECG = electrocardiogram，NA = 該当なし，QTcF ＝ QTc using Fridericia's correction formula Fridericia

2.7.4.1.1.2.4.3 注入部位反応

注入部位反応は，注入部位評価尺度（Infusion Site Evaluation Scale）を用いて評価した。M15-741 試験のベースラインは，ABBV-951 の CSCI 開始後，投与 1 日目とし，M15-737 試験では，親試験（M15-741 試験）の最終来院で得られた評価とし，M15-736 試験では，二重盲検期の 2 日目の評価とした。

M15-741 及び M15-737 試験では，注入部位反応を規定来院時に加え，規定外来院時にも評価した。数値グレード及びレターグレードが得られた被験者数及びその割合を各来院日ごとに示した。本試験期間中の全来院日について，数値グレードが 5 以上又はレターグレードが D 以上の被験者数及びその割合を示した。

M15-736 試験では，二重盲検期の全来院日について，数値グレードが 5 以上又はレターグレードが D 以上の被験者数及びその割合を各投与群別及び両群を合わせた全群で示した。

2.7.4.1.1.2.4.4 衝動制御障害

パーキンソン病における衝動制御障害の評価尺度（以下「QUIP-RS」）は，衝動制御障害（以下「ICD」）の症状及び PD で発生することが報告されている関連行動の重症度を評価するための簡潔な，自己完結型又は評価者による評価尺度である。

M15-741 試験のベースラインは，ABBV-951 投与 1 日目（投与前）とし，M15-737 試験では，治験薬投与開始前の最後の評価とし，M15-736 試験では，ランダム化前 1 週間の評価とした。

M15-741 及び M15-737 試験では，QUIP-RS の合計スコア及びドメインスコアに関して，ベースラインから各来院日までの変化量及び最終値との変化量の要約を示した。ベースラインからの各変化量について，被験者数，ベースラインの平均値，来院日の平均値及び各変化量の要約統計量（平均値，SD 及び中央値）を示した。

M15-736 試験では，QUIP-RS の合計スコア及びドメインスコアに関して，ベースラインから二重盲検期の各来院日との変化量を記述的に要約した。ベースラインからの各変化量について，被験者数，ベースラインの平均値，来院日の平均値及び各変化量の要約統計量（平均値，SD 及び中央値）を示した。

2.7.4.1.1.2.4.5 コロンビア自殺評価スケール

コロンビア自殺評価スケール（以下「C-SSRS」）は，自殺行為及び自殺念慮を評価し，すべての自殺に関する事象並びに自殺企図の致死性を追跡・評価する評価尺度であり，安全性評価に用いた臨床試験 10 試験では，C-SSRS を用いて，自殺行為及び自殺念慮を評価した。

M15-741 試験のベースラインは，ABBV-951 の投与 1 日目（投与前）とし，M15-737 試験では，治験薬投与開始前の最後の評価（M15-741 試験の最後の評価）とし，M15-736 試験では，ランダム化前の 1 週間の評価とした。

M15-741 試験では，C-SSRS は各来院日で評価され，スクリーニング時点及び各来院日で C-SSRS に関する回答を要約した。M15-737 試験では，各来院日で評価され，C-SSRS に関する回答を要約した。M15-736 試験では，C-SSRS は各来院日で評価され，スクリーニング時点及び各来院日で回答を投与群ごとに要約した。

これらの試験では，自殺念慮の 5 つの質問のそれぞれ，自殺行為の 6 つの質問のそれぞれ，自殺念慮の 5 つの質問のいずれか，自殺行為の 6 つの質問のいずれか，自殺念慮や行動に関するあらゆる質問及び非自殺的自傷行為の質問に対するひとつ以上の回答を示した被験者数とその割合を要約した。

2.7.4.1.2 全般的な曝露状況

2.7.4.1.2.1 M15-741 試験

申請時

本試験の全体集団の曝露状況を表 2.7.4-6 に示す。被験者（244 例）が治験薬に曝露された平均日数は，投与の中断を含めたときに 229.7 日，投与の中断を除いたときに 223.6 日であった。投与の中断を含めた場合あるいは中断を除いた場合でも（以下「治験薬の中断期間の包含・除外に関わらず」），被験者の約 50%は，治験薬に 274 日以上曝露され，被験者の約 70%は，92 日以上曝露された。投与の中断を含めて 145 例（59.4%）の被験者が少なくとも 6 ヵ月間（180 日）ABBV-951 に曝露され，投与の中断を除いて 137 例（56.1%）の被験者が少なくとも 6 ヵ月間 ABBV-951 に曝露された。被験者 115 例（47.1%）が 52 週間の投与期間を完了した（M15-741 試験 CSR Table 14.1__1.1.1）。

なお，LD の 1 日あたりの投与量（負荷量及び救済療法を含む）を表 2.7.4.7-1 に示す。

更新時

本試験の全体集団の曝露状況を表 2.7.4-7 に示す。被験者（244 例）が治験薬に曝露された平均日数は，投与の中断を含めたときに 238.2 日，投与の中断を除いたときに 232.0 日であった。投与の中断を含めた場合あるいは中断を除いた場合でも（以下「治験薬の中断期間の包含・除外に関わらず」），被験者の約 55%は，治験薬に 274 日以上曝露され，被験者の約 70%は，92 日以上曝露された。投与の中断を含めて 153 例（62.7%）の被験者が少なくとも 6 ヵ月間（180 日）ABBV-951 に曝露され，投与の中断を除いて 145 例（59.4%）の被験者が少なくとも 6 ヵ月間 ABBV-951 に曝露された。被験者 125 例（51.2%）が 52 週間の投与期間を完了した（M15-741 試験 CSR update Table 14.1__1.1.1）。

なお，LD の 1 日あたりの投与量（負荷量及び救済療法を含む）を表 2.7.4.7-43 に示す。

表 2.7.4-6. 治験薬曝露期間（安全性解析対象集団）：M15-741 試験

	Dose Category		
	Low Dose (N=132)	High Dose (N=112)	All Subjects (N=244)
Duration of ABBV-951 exposure (days) &			
n	132	112	244
Mean (SD)	229.1 (151.37)	230.5 (146.68)	229.7 (148.93)
Median	328.0	281.5	307.5
Min, Max	3, 438	4, 389	3, 438
By time intervals - n(%) &			
1 - 7 Days	5 (3.8)	2 (1.8)	7 (2.9)
8 - 14 Days	3 (2.3)	7 (6.3)	10 (4.1)
15 - 21 Days	10 (7.6)	3 (2.7)	13 (5.3)
22 - 28 Days	3 (2.3)	5 (4.5)	8 (3.3)
29 - 42 Days	7 (5.3)	4 (3.6)	11 (4.5)
43 - 91 Days	10 (7.6)	10 (8.9)	20 (8.2)
92 - 182 Days	18 (13.6)	14 (12.5)	32 (13.1)
183 - 273 Days	7 (5.3)	10 (8.9)	17 (7.0)
>= 274 Days	69 (52.3)	57 (50.9)	126 (51.6)
At least 6 months (>= 180 days)	77 (58.3)	68 (60.7)	145 (59.4)
At least 1 year (>= 360 days)	61 (46.2)	51 (45.5)	112 (45.9)
Patient-years of exposure &	82.8	70.7	153.5

Note: Percentages calculated on non-missing values.
&: Duration of ABBV-951 exposure (days) = Date of ABBV-951 stopped - Date of ABBV-951 started + 1.
*: Duration of ABBV-951 exposure (days) excluding study drug interruption = Duration of ABBV-951 exposure (days) - Duration of interruption (days).

Cross References：M15-741 試験 CSR Table 14.1__10

表 2.7.4-7. 治験薬曝露期間（安全性解析対象集団）：M15-741 試験（更新時）

	Dose Category		
	Low Dose (N=132)	High Dose (N=112)	All Subjects (N=244)
Duration of ABBV-951 exposure (days) &			
n	132	112	244
Mean (SD)	239.1 (151.76)	237.2 (147.89)	238.2 (149.69)
Median	360.0	348.0	357.5
Min, Max	3, 450	4, 389	3, 450
By time intervals - n(%) &			
1 - 7 Days	5 (3.8)	2 (1.8)	7 (2.9)
8 - 14 Days	3 (2.3)	7 (6.3)	10 (4.1)
15 - 21 Days	10 (7.6)	3 (2.7)	13 (5.3)
22 - 28 Days	3 (2.3)	5 (4.5)	8 (3.3)
29 - 42 Days	7 (5.3)	4 (3.6)	11 (4.5)
43 - 91 Days	8 (6.1)	10 (8.9)	18 (7.4)
92 - 182 Days	14 (10.6)	12 (10.7)	26 (10.7)
183 - 273 Days	7 (5.3)	7 (6.3)	14 (5.7)
>= 274 Days	75 (56.8)	62 (55.4)	137 (56.1)
At least 6 months (>= 180 days)	83 (62.9)	70 (62.5)	153 (62.7)
At least 1 year (>= 360 days)	66 (50.0)	53 (47.3)	119 (48.8)
Patient-years of exposure &	86.4	72.7	159.1

Note: Percentages calculated on non-missing values.
&: Duration of ABBV-951 exposure (days) = Date of ABBV-951 stopped - Date of ABBV-951 started + 1.
*: Duration of ABBV-951 exposure (days) excluding study drug interruption = Duration of ABBV-951 exposure (days) - Duration of interruption (days).

Cross References：M15-741 試験 CSR update Table 14.1__10

2.7.4.1.2.2 M15-737 試験

申請時

本試験の全体集団の曝露状況を表 2.7.4-8 に示す。被験者（105 例）が治験薬に曝露された平均日数は，投与の中断を含めたときに 239.1 日，投与の中断を除いたときに 238.6 日であった。被験者の 69.5%は，治験薬の中断期間の包含・除外に関わらず，治験薬に 169 日以上曝露された。

なお，LD の 1 日あたりの投与量（負荷量と救済療法を含む）を表 2.7.4.7-2 に示す。

更新時

本試験の全体集団の曝露状況を表 2.7.4-9 に示す。被験者（116 例）が治験薬に曝露された平均日数は，投与の中断を含めたときに 320.8 日，投与の中断を除いたときに 320.1 日であった。被験者の 71.6%は，治験薬の中断期間の包含・除外に関わらず，治験薬に 169 日以上曝露された。

なお，LD の 1 日あたりの投与量（負荷量と救済療法を含む）を表 2.7.4.7-44 に示す。

表 2.7.4-8. 治験薬曝露期間（安全性解析対象集団）：M15-737 試験

	Dose Category		
	Low Dose (N=45)	High Dose (N=60)	All Subjects (N=105)
Duration of ABBV-951 exposure (days) &			
n	45	60	105
Mean (SD)	222.3 (151.08)	251.8 (146.53)	239.1 (148.50)
Median	274.0	289.0	288.0
Min, Max	2, 509	1, 516	1, 516
By time intervals - n(%) &			
1 - 84 Days	14 (31.1)	16 (26.7)	30 (28.6)
85 - 168 Days	2 (4.4)	0	2 (1.9)
169 - 252 Days	6 (13.3)	5 (8.3)	11 (10.5)
253 - 336 Days	11 (24.4)	19 (31.7)	30 (28.6)
337 - 420 Days	11 (24.4)	16 (26.7)	27 (25.7)
421 - 504 Days	0	2 (3.3)	2 (1.9)
505 - 588 Days	1 (2.2)	2 (3.3)	3 (2.9)
589 - 672 Days	0	0	0
>= 673 Days	0	0	0
Patient-years of exposure &	27.4	41.4	68.7

Note: Percentages calculated on non-missing values.
&: Duration of ABBV-951 exposure (days) = Date of ABBV-951 stopped - Date of ABBV-951 started + 1.
*: Duration of ABBV-951 exposure (days) excluding study drug interruption = Duration of ABBV-951 exposure (days) - Duration of interruption (days).

Cross References：M15-737 試験 CSR Table 14.1__10

23

表 2.7.4-9. 治験薬曝露期間（安全性解析対象集団）：M15-737 試験（更新時）

	Dose Category		
	Low Dose (N=55)	High Dose (N=61)	All Subjects (N=116)
Duration of ABBV-951 exposure (days) &			
n	55	61	116
Mean (SD)	293.7 (166.04)	345.1 (164.00)	320.8 (166.26)
Median	314.0	406.0	392.0
Min, Max	3, 626	70, 633	3, 633
By time intervals - n(%) &			
1 - 84 Days	4 (7.3)	2 (3.3)	6 (5.2)
85 - 168 Days	14 (25.5)	13 (21.3)	27 (23.3)
169 - 252 Days	8 (14.5)	7 (11.5)	15 (12.9)
253 - 336 Days	3 (5.5)	1 (1.6)	4 (3.4)
337 - 420 Days	9 (16.4)	15 (24.6)	24 (20.7)
421 - 504 Days	13 (23.6)	15 (24.6)	28 (24.1)
505 - 588 Days	3 (5.5)	5 (8.2)	8 (6.9)
589 - 672 Days	1 (1.8)	3 (4.9)	4 (3.4)
>= 673 Days	0	0	0
Patient-years of exposure &	44.2	57.6	101.9

Note: Percentages calculated on non-missing values.
&: Duration of ABBV-951 exposure (days) = Date of ABBV-951 stopped - Date of ABBV-951 started + 1.
*: Duration of ABBV-951 exposure (days) excluding study drug interruption = Duration of ABBV-951 exposure (days) - Duration of interruption (days).

Cross References：M15-737 試験 CSR update Table 14.1__10

2.7.4.1.2.3 M15-736 試験

本試験の ABBV-951 24 時間 CSCI 群（以下「ABBV-951 投与群」）及びカルビドパ／レボドパ速放性製剤経口投与群（以下「CD/LD 経口投与群」）の曝露状況を表 2.7.4-10 に示す。

被験者が治験薬に曝露された平均日数は，ABBV-951 投与群（74 例）で 62.4 日，CD/LD 経口投与群（67 例）で 81.5 日であった。ABBV-951 投与群の被験者の 64.9%及び CD/LD 経口投与群の被験者の 94.0%は治験薬に 58 日以上曝露され（表 2.7.4-10），それぞれ被験者の 64.9%及び 92.5%は，12 週間の投与期間を完了した（M15-736 試験 CSR Table 14.1__1.1）。

予想されたとおり，ABBV-951 は 1 日 24 時間連続投与されるため，CD/LD 経口投与群の方が ABBV-951 投与群よりも LD の 1 日あたりの投与量が少なかった（表 2.7.4.7-3）。

表 2.7.4-10. 二重盲検期の治験薬曝露期間（安全性解析対象集団）：M15-736 試験

	Oral CD/LD			ABBV-951		
	Low Dose (N=56)	High Dose (N=11)	All (N=67)	Low Dose (N=45)	High Dose (N=29)	All (N=74)
Duration of study drug exposure (days)						
n	56	11	67	45	29	74
Mean (SD)	80.5 (20.59)	86.5 (3.21)	81.5 (18.97)	59.7 (32.53)	66.4 (29.11)	62.4 (31.20)
Median	85.0	85.0	85.0	83.0	85.0	84.0
Min, Max	3, 106	83, 94	3, 106	3, 89	8, 92	3, 92
By time intervals - n(%)						
Day 1 - 7	1 (1.8)	0	1 (1.5)	4 (8.9)	0	4 (5.4)
Day 8 - 14	2 (3.6)	0	2 (3.0)	3 (6.7)	2 (6.9)	5 (6.8)
Day 15 - 21	1 (1.8)	0	1 (1.5)	2 (4.4)	2 (6.9)	4 (5.4)
Day 22 - 28	0	0	0	5 (11.1)	0	5 (6.8)
Day 29 - 57	0	0	0	3 (6.7)	5 (17.2)	8 (10.8)
Day >= 58	52 (92.9)	11 (100)	63 (94.0)	28 (62.2)	20 (69.0)	48 (64.9)
Patient-years of exposure	12.3	2.6	14.9	7.4	5.3	12.6

Note: Blinded drug solution for ABBV-951 and blinded drug capsules for oral CD/LD.

Cross References：M15-736 試験 CSR Table 14.1__10

26

2.7.4.1.3 被験者の内訳

2.7.4.1.3.1 M15-741 試験

申請時

本試験の被験者の内訳を 2.7.3.3.1.1.1 項に示す。

全体集団で 244 例に治験薬が投与され，治験薬の投与が 103 例（42.2%）で中止され，52 週間の投与期間を完了した被験者は，115 例（47.1%）であった。安全性解析対象集団は，244 例であった。また，92 例で投与が中断されたが，これらのうち，63.0%（58 例）の被験者では 2 日未満の投与中断であった（M15-741 試験 CSR Table 14.1__1.1.1 及び Table 14.1__12.2）。

登録時期について，Sample 1（20[redacted] 年 [redacted] 月 [redacted] 日より前に登録された）の被験者数は 157 例であり，治験薬の投与を完了した被験者の割合は，全体で 33.2%（81 例），投与継続中は 0.0%（0 例），治験薬の投与中止は 31.1%（76 例）であった。一方，Sample 2（20[redacted] 年 [redacted] 月 [redacted] 日以降に登録された）の被験者数は 87 例であり，治験薬の投与を完了した被験者の割合は，全体で 13.9%（34 例），投与継続中は 10.7%（26 例），治験薬の投与中止は 11.1%（27 例）であった（M15-741 試験 CSR Table 14.1__1.1.1 及び Table 14.1__1.1.2）。

更新時

本試験の被験者の内訳を 2.7.3.3.1.1.1 項に示す。

全体集団で 244 例に治験薬が投与され，治験薬の投与が 107 例（43.9%）で中止され，52 週間の投与期間を完了した被験者は，125 例（51.2%）であった。安全性解析対象集団は，244 例であった。また，94 例で投与が中断されたが，これらのうち，62.8%（59 例）の被験者では 2 日未満の投与中断であった（M15-741 試験 CSR update Table 14.1__1.1.1 及び Table 14.1__12.2）。

登録時期について，Sample 1（20[redacted] 年 [redacted] 月 [redacted] 日より前に登録された）の被験者数は 157 例であり，治験薬の投与を完了した被験者の割合は，全体で 33.2%（81 例），投与継続中は 0.0%（0 例），治験薬の投与中止は 31.1%（76 例）であった。一方，Sample 2（20[redacted] 年 [redacted] 月 [redacted] 日以降に登録された）の被験者数は 87 例であり，治験薬の投与を完了した被験者の割合は，全体で 18.0%（44 例），投与継続中は 4.9%（12 例），治験薬の投与中止は 12.7%（31 例）であった（M15-741 試験 CSR update Table 14.1__1.1.1 及び Table 14.1__1.1.2）。

2.7.4.1.3.2 M15-737 試験

申請時

本試験の被験者の内訳を 2.7.3.3.1.1.2 項に示す。

全体集団で被験者 105 例に治験薬が投与され，データカットオフ時点で治験薬の投与が中止された被験者は 8 例（7.6%）であった。安全性解析対象集団は，105 例であった。また，被験者 11 例で投与が中断されたが，これらのうち 8 例（72.7%）の被験者で，中断は 1 日未満であった（M15-737 試験 CSR Table 14.1__1.1 及び Table 14.1__12.2）。

更新時

本試験の被験者の内訳を 2.7.3.3.1.1.2 項に示す。

全体集団で被験者 116 例に治験薬が投与され，データカットオフ時点で治験薬の投与が中止された被験者は 11 例（9.5%）であった。安全性解析対象集団は，116 例であった。また，被験者 15 例で投与が中断されたが，これらのうち 10 例（66.7%）の被験者で，中断は 1 日未満であった（M15-737 試験 CSR update Table 14.1__1.1 及び Table 14.1__12.2）。

2.7.4.1.3.3 M15-736 試験

本試験の被験者の内訳を 2.7.3.3.1.1.3 項に示す。

本試験では，145 例がランダム化され，141 例に治験薬が投与され，治験薬の投与が 31 例（22.0%）で中止され，治験薬の投与を完了した被験者は 110 例（78.0%）であった。安全性解析対象集団は 141 例であった。また，42 例（29.8%）で治験薬の投与が中断された（ABBV-951 投与群で 22 例，CD/LD 経口投与群で 20 例）が，中断は多くの被験者で 1 日未満であった（M15-736 試験 CSR Table 14.1__1.1）。

ABBV-951 投与群では，74 例に治験薬が投与され，治験薬の投与が 26 例（35.1%）で中止され，治験薬の投与を完了した被験者は 48 例（64.9%）であった。CD/LD 経口投与群では，67 例に治験薬が投与され，治験薬の投与が 5 例（7.5%）で中止され，治験薬の投与を完了した被験者は 62 例（92.5%）であった（M15-736 試験 CSR Table 14.1__1.1）。

治験薬の投与中断の平均日数は，ABBV-951 投与群で 4.9 日，CD/LD 経口投与群で 2.5 日であった（M15-736 試験 CSR Table 14.1__10）。

2.7.4.1.4 治験対象集団の人口統計学的特性及びその他の特性

2.7.4.1.4.1 M15-741 試験

本試験の申請時及び更新時の安全性解析対象集団（いずれも 244 例）の人口統計学的特性及びその他の基準値の特性の概略を 2.7.3.3.1.2.1 項に示す。

申請時

全体集団の被験者の平均年齢（範囲）は 63.9 歳（34～86 歳）であり，被験者の 51.2%（125 例）が 65 歳以上，被験者の 11.1%（27 例）が 75 歳以上であった。被験者の 84.8%（207 例）が白人であり，被験者の 59.8%（146 例）が男性であった。PD の罹病期間が 10 年以上の被験者の割合は 46.3%（113 例）であった。LD に反応があった期間が 5 年間を超えていた被験者の割合は 84.8%（207 例）であった（M15-741 試験 CSR Table 14.1__2 及び Table 14.1__3.1）。

ABBV-951 の投与期間中，被験者の 88.1%（215 例）にドパミン作動薬が投与され，そのうち 61.9%（151 例）の被験者にドパミンアゴニストが投与された（M15-741 試験 CSR Table 14.1__3.2.5）。

更新時

更新時の安全性解析対象集団（244 例）の人口統計学的特性及びその他の基準値の特性は，申請時と同様であった（M15-741 試験 CSR update Table 14.1__2.1，Table 14.1__3.1.1 及び Table 14.1__3.2.5）。

2.7.4.1.4.2 M15-737 試験

本試験の申請時の安全性解析対象集団（105 例）及び更新時の安全性解析対象集団（116 例）の人口統計学的特性及びその他の基準値の特性の概略を 2.7.3.3.1.2.2 項に示す。

申請時

全体集団の被験者の平均年齢（範囲）は 62.4 歳（34～86 歳）であり，被験者の 42.9%（45 例）が 65 歳以上，被験者の 9.5%（10 例）が 75 歳以上であった。被験者の 85.7%（90 例）が白人であり，被験者の 64.8%（68 例）が男性であった。PD の罹病期間が 10 年以上であった被験者の割合は 41.0%（43 例）であった。LD に反応があった期間が 5 年間を超えていた被験者の割合は 81.9%（86 例）であった（M15-737 試験 CSR Table 14.1__2 及び CSR Table 14.1__3.1）。

ABBV-951 の投与期間中，被験者の 71.4%（75 例）にドパミン作動薬が投与され，そのうち 41.0%（43 例）の被験者にドパミンアゴニストが投与された（M15-737 試験 CSR Table 14.1__3.2.1）。

更新時

全体集団の被験者の平均年齢（範囲）は 62.7 歳（34～86 歳）であり，被験者の 44.8%（52 例）が 65 歳以上，被験者の 9.5%（11 例）が 75 歳以上であった。被験者の 85.3%（99 例）が白人であり，被験者の 63.8%（74 例）が男性であった。PD の罹病期間が 10 年以上であった被験者の割合は 44.0%（51 例）であった。LD に反応があった期間が 5 年間を超えていた被験者の割合は 83.6%（97 例）であった（M15-737 試験 CSR update Table 14.1__2 及び CSR update Table 14.1__3.1）。

ABBV-951 の投与期間中，被験者の 75.0%（87 例）にドパミン作動薬が投与され，そのうち 44.0%（51 例）の被験者にドパミンアゴニストが投与された（M15-737 試験 CSR update Table 14.1__3.2.1）。

2.7.4.1.4.3 M15-736 試験

本試験の安全性解析対象集団（ABBV-951 投与群及び CD/LD 経口投与群を合計した全体集団で 141 例）の人口統計学的特性及びその他の基準値の特性の概略を 2.7.3.3.1.2.3 項に示す。

人口統計学的特性及びその他の基準値の特性は，全般的に ABBV-951 投与群及び CD/LD 経口投与群の両群間で同様であった。被験者の平均年齢（範囲）は 66.4 歳（39～85 歳）であり，被験者の 63.8%（90 例）が 65 歳以上であった。被験者の 92.9%（131 例）が白人であり，被験者の 70.2%（99 例）が男性であった。PD の罹病期間が 10 年以上の被験者の割合は 32.6%（46 例）

であった。LD に反応があった期間が 5 年間を超えていた被験者の割合は 73.0%（103 例）であった（M15-736 試験 CSR Table 14.1__2.1 及び Table 14.1__3.1）。

ABBV-951 の投与期間中，被験者の 68.8%（97 例）にドパミン作動薬が投与され，そのうち 41.8%（59 例）の被験者にドパミンアゴニストが投与された（M15-736 試験 CSR Table 14.1__3.2.4）。

2.7.4.2 有害事象

2.7.4.2.1 有害事象の解析

2.7.4.2.1.1 有害事象の概要

2.7.4.2.1.1.1 M15-741 試験

申請時

本試験の投与期間中の有害事象の概要を表 2.7.4-11 に，登録時期別の有害事象の概要を表 2.7.4-12 に示す。全体集団（244 例）での投与期間中の有害事象の発現割合は，すべての有害事象が 94.3%（230 例），重篤な有害事象が 25.0%（61 例），死亡に至った有害事象が 1.2%（3 例），投与中止に至った有害事象が 25.4%（62 例），治験薬と関連ありの有害事象が 91.8%（224 例），治験薬又は治験機器の不具合に関連した有害事象が 70.1%（171 例）であった。ほとんどが重篤な有害事象でなく，重症度は重度が 25.4%（62 例）であり，他は軽度又は中等度であった。

登録時期別での有害事象の発現割合は，Sample 1（157 例）で，すべての有害事象が 96.8%（152 例），重篤な有害事象が 28.0%（44 例），死亡に至った有害事象が 1.9%（3 例），投与中止に至った有害事象が 31.2%（49 例），治験薬と関連ありの有害事象が 94.9%（149 例），治験薬又は治験機器の不具合に関連した有害事象が 82.2%（129 例）であった。

また，Sample 2（87 例）では，すべての有害事象が 89.7%（78 例），重篤な有害事象が 19.5%（17 例），投与中止に至った有害事象が 14.9%（13 例），治験薬と関連ありの有害事象が 86.2%（75 例），治験薬又は治験機器の不具合に関連した有害事象が 48.3%（42 例）であった。死亡に至った有害事象は認められなかった。

更新時

本試験の投与期間中の有害事象の概要を表 2.7.4-13 に，登録時期別の有害事象の概要を表 2.7.4-14 に示す。全体集団（244 例）での投与期間中の有害事象の発現割合は，すべての有害事象が 94.3%（230 例），重篤な有害事象が 25.8%（63 例），死亡に至った有害事象が 1.2%（3 例），投与中止に至った有害事象が 25.8%（63 例），治験薬と関連ありの有害事象が 91.8%（224 例），治験薬又は治験機器の不具合に関連した有害事象が 70.9%（173 例）であった。ほとんどが重篤な有害事象でなく，重症度は重度が 25.8%（63 例）であり，他は軽度又は中等度であった。

登録時期別での有害事象の発現割合は，Sample 1（157 例）で，すべての有害事象が 96.8%（152 例），重篤な有害事象が 28.0%（44 例），死亡に至った有害事象が 1.9%（3 例），投与中止に至った有害事象が 31.2%（49 例），治験薬と関連ありの有害事象が 94.9%（149 例），治験薬又は治験機器の不具合に関連した有害事象が 82.8%（130 例）であった。

また，Sample 2（87 例）では，すべての有害事象が 89.7%（78 例），重篤な有害事象が 21.8%（19 例），投与中止に至った有害事象が 16.1%（14 例），治験薬と関連ありの有害事象が 86.2%（75 例），治験薬又は治験機器の不具合に関連した有害事象が 49.4%（43 例）であった。死亡に至った有害事象は認められなかった。

表 2.7.4-11. 有害事象の概要（安全性解析対象集団）：M15-741 試験

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period	N=132	N=112	N=244
Subjects with:			
Any TEAE	122 (92.4)	108 (96.4)	230 (94.3)
Any severe TEAE	26 (19.7)	36 (32.1)	62 (25.4)
Any TEAE that is considered associated with study drug$	118 (89.4)	106 (94.6)	224 (91.8)
Any TEAE that is considered associated with product complaint$	91 (68.9)	80 (71.4)	171 (70.1)
ABBV-951	52 (39.4)	43 (38.4)	95 (38.9)
Infusion pump	9 (6.8)	8 (7.1)	17 (7.0)
Vial adapter	0	1 (0.9)	1 (0.4)
Syringes	0	0	0
[redacted] infusion set (total)	51 (38.6)	40 (35.7)	91 (37.3)
[redacted] infusion set 6 mm	37 (28.0)	26 (23.2)	63 (25.8)
Cleo 90 infusion set 9 mm	25 (18.9)	23 (20.5)	48 (19.7)
Neria guard infusion set (total)	14 (10.6)	16 (14.3)	30 (12.3)
Neria guard infusion set 6 mm	8 (6.1)	9 (8.0)	17 (7.0)
Neria guard infusion set 9 mm	9 (6.8)	12 (10.7)	21 (8.6)
[redacted]	3 (2.3)	4 (3.6)	7 (2.9)
Any TEAE that is considered associated with loading dose$	2 (1.5)	5 (4.5)	7 (2.9)
Any TEAE that is considered associated with rescue dose$	4 (3.0)	8 (7.1)	12 (4.9)
Any TEAE that is considered associated with COVID-19 infection	2 (1.5)	1 (0.9)	3 (1.2)
Any TEAE leading to prematurely discontinuation of study drug	32 (24.2)	30 (26.8)	62 (25.4)
Any TEAE leading to death (fatal TEAE)	0	3 (2.7)	3 (1.2)
Any serious TEAE	31 (23.5)	30 (26.8)	61 (25.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
COVID-19 = coronavirus disease-2019, [redacted] = [redacted] or [redacted] (United States), TEAE = treatment-emergent adverse events

表 2.7.4-11. 有害事象の概要（安全性解析対象集団）：M15-741 試験（続き）

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	14 (10.6)	8 (7.1)	22 (9.0)
Possible	6 (4.5)	5 (4.5)	11 (4.5)
Probable	5 (3.8)	3 (2.7)	8 (3.3)
Causal relationship	7 (5.3)	2 (1.8)	9 (3.7)
Any SAE that is considered associated with [redacted] infusion set$	1 (0.8)	1 (0.9)	2 (0.8)
Possible	1 (0.8)	1 (0.9)	2 (0.8)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	2 (1.5)	1 (0.9)	3 (1.2)
Possible	1 (0.8)	1 (0.9)	2 (0.8)
Probable	0	0	0
Causal relationship	1 (0.8)	0	1 (0.4)
Any SAE that is considered associated with product complaint$	11 (8.3)	7 (6.3)	18 (7.4)
ABBV-951	4 (3.0)	3 (2.7)	7 (2.9)
Infusion pump	2 (1.5)	1 (0.9)	3 (1.2)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	3 (2.3)	2 (1.8)	5 (2.0)
[redacted] infusion set 6 mm	2 (1.5)	1 (0.9)	3 (1.2)
[redacted] infusion set 9 mm	1 (0.8)	1 (0.9)	2 (0.8)
Neria guard infusion set (total)	2 (1.5)	1 (0.9)	3 (1.2)
Neria guard infusion set 6 mm	2 (1.5)	1 (0.9)	3 (1.2)
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
[redacted] = [redacted] or [redacted] (United States), SAE = serious adverse events

表 2.7.4-11. 有害事象の概要（安全性解析対象集団）：M15-741 試験（続き）

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
All deaths#	0	5 (4.5)	5 (2.0)
All TE-deaths	0	3 (2.7)	3 (1.2)
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	2 (1.5)	6 (5.4)	8 (3.3)
AESI: weight loss	12 (9.1)	13 (11.6)	25 (10.2)
AESI: hallucinations/psychosis	32 (24.2)	27 (24.1)	59 (24.2)
AESI: somnolence	9 (6.8)	3 (2.7)	12 (4.9)
AESI: infusion site related infections	41 (31.1)	43 (38.4)	84 (34.4)
AESI: infusion site related non infection reactions	103 (78.0)	96 (85.7)	199 (81.6)
AESI: falls and associated injuries	35 (26.5)	36 (32.1)	71 (29.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
# Includes non treatment-emergent deaths.
AESI = adverse events of special interest, COVID-19 = coronavirus disease-2019

Cross References：M15-741 試験 CSR Table 14.3__1.1

表 2.7.4-12. 登録時期別の有害事象の概要（安全性解析対象集団）：M15-741 試験

	Sample 1 (N=157) n (%)	Sample 2 (N=87) n (%)	All Subjects (N=244) n (%)
Entire study			
Subjects with:			
Any TEAE	152 (96.8)	78 (89.7)	230 (94.3)
Any severe TEAE	48 (30.6)	14 (16.1)	62 (25.4)
Any TEAE that is considered associated with study drug$	149 (94.9)	75 (86.2)	224 (91.8)
Any TEAE that is considered associated with product complaint$	129 (82.2)	42 (48.3)	171 (70.1)
ABBV-951	74 (47.1)	21 (24.1)	95 (38.9)
Infusion pump	13 (8.3)	4 (4.6)	17 (7.0)
Vial adapter	1 (0.6)	0	1 (0.4)
Syringes	0	0	0
[redacted] infusion set (total)	82 (52.2)	9 (10.3)	91 (37.3)
[redacted] infusion set 6 mm	58 (36.9)	5 (5.7)	63 (25.8)
[redacted] infusion set 9 mm	44 (28.0)	4 (4.6)	48 (19.7)
Neria guard infusion set (total)	7 (4.5)	23 (26.4)	30 (12.3)
Neria guard infusion set 6 mm	2 (1.3)	15 (17.2)	17 (7.0)
Neria guard infusion set 9 mm	5 (3.2)	16 (18.4)	21 (8.6)
[redacted]	5 (3.2)	2 (2.3)	7 (2.9)
Any TEAE that is considered associated with loading dose$	5 (3.2)	2 (2.3)	7 (2.9)
Any TEAE that is considered associated with rescue dose$	8 (5.1)	4 (4.6)	12 (4.9)
Any TEAE that is considered associated with COVID-19 infection	1 (0.6)	2 (2.3)	3 (1.2)
Any TEAE leading to prematurely discontinuation of study drug	49 (31.2)	13 (14.9)	62 (25.4)
Any TEAE leading to death (fatal TEAE)	3 (1.9)	0	3 (1.2)
Any serious TEAE	44 (28.0)	17 (19.5)	61 (25.0)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
COVID-19 = coronavirus disease-2019, [redacted] = [redacted] or [redacted] (United States), TEAE = treatment-emergent adverse events

35

表 2.7.4-12. 登録時期別の有害事象の概要（安全性解析対象集団）：M15-741 試験（続き）

	Sample 1 (N=157) n (%)	Sample 2 (N=87) n (%)	All Subjects (N=244) n (%)
Entire study (cont'd)			
Any SAE that is considered associated with infusion pump$	15 (9.6)	7 (8.0)	22 (9.0)
Possible	6 (3.8)	5 (5.7)	11 (4.5)
Probable	6 (3.8)	2 (2.3)	8 (3.3)
Causal relationship	6 (3.8)	3 (3.4)	9 (3.7)
Any SAE that is considered associated with [redacted] infusion set$	2 (1.3)	0	2 (0.8)
Possible	2 (1.3)	0	2 (0.8)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	3 (3.4)	3 (1.2)
Possible	0	2 (2.3)	2 (0.8)
Probable	0	0	0
Causal relationship	0	1 (1.1)	1 (0.4)
Any SAE that is considered associated with product complaint$	15 (9.6)	3 (3.4)	18 (7.4)
ABBV-951	7 (4.5)	0	7 (2.9)
Infusion pump	3 (1.9)	0	3 (1.2)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	5 (3.2)	0	5 (2.0)
[redacted] infusion set 6 mm	3 (1.9)	0	3 (1.2)
[redacted] infusion set 9 mm	2 (1.3)	0	2 (0.8)
Neria guard infusion set (total)	0	3 (3.4)	3 (1.2)
Neria guard infusion set 6 mm	0	3 (3.4)	3 (1.2)
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
[redacted] = [redacted] or [redacted] (United States), SAE = serious adverse events

表 2.7.4-12. 登録時期別の有害事象の概要（安全性解析対象集団）：M15-741 試験（続き）

	Sample 1 (N=157) n (%)	Sample 2 (N=87) n (%)	All Subjects (N=244) n (%)
Entire study (cont'd)			
All deaths#	5 (3.2)	0	5 (2.0)
All TE-deaths	3 (1.9)	0	3 (1.2)
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	4 (2.5)	4 (4.6)	8 (3.3)
AESI: weight loss	21 (13.4)	4 (4.6)	25 (10.2)
AESI: hallucinations/psychosis	40 (25.5)	19 (21.8)	59 (24.2)
AESI: somnolence	7 (4.5)	5 (5.7)	12 (4.9)
AESI: infusion site related infections	59 (37.6)	25 (28.7)	84 (34.4)
AESI: infusion site related non infection reactions	139 (88.5)	60 (69.0)	199 (81.6)
AESI: falls and associated injuries	48 (30.6)	23 (26.4)	71 (29.1)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
# Includes non treatment-emergent deaths.
AESI = adverse events of special interest, COVID-19 = coronavirus disease-2019

Cross References：M15-741 試験 CSR Table 14.3 1.5

37

表 2.7.4-13. 有害事象の概要（安全性解析対象集団）：M15-741 試験（更新時）

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period	N=132	N=112	N=244
Subjects with:			
Any TEAE	122 (92.4)	108 (96.4)	230 (94.3)
Any severe TEAE	27 (20.5)	36 (32.1)	63 (25.8)
Any TEAE that is considered associated with study drug$	118 (89.4)	106 (94.6)	224 (91.8)
Any TEAE that is considered associated with product complaint$	91 (68.9)	82 (73.2)	173 (70.9)
ABBV-951	52 (39.4)	44 (39.3)	96 (39.3)
Infusion pump	9 (6.8)	9 (8.0)	18 (7.4)
Vial adapter	0	1 (0.9)	1 (0.4)
Syringes	0	0	0
[redacted] infusion set (total)	51 (38.6)	41 (36.6)	92 (37.7)
[redacted] infusion set 6 mm	37 (28.0)	26 (23.2)	63 (25.8)
[redacted] infusion set 9 mm	25 (18.9)	24 (21.4)	49 (20.1)
Neria guard infusion set (total)	14 (10.6)	18 (16.1)	32 (13.1)
Neria guard infusion set 6 mm	8 (6.1)	9 (8.0)	17 (7.0)
Neria guard infusion set 9 mm	9 (6.8)	14 (12.5)	23 (9.4)
[redacted]	3 (2.3)	4 (3.6)	7 (2.9)
Any TEAE that is considered associated with loading dose$	2 (1.5)	5 (4.5)	7 (2.9)
Any TEAE that is considered associated with rescue dose$	4 (3.0)	8 (7.1)	12 (4.9)
Any TEAE that is considered associated with COVID-19 infection	2 (1.5)	1 (0.9)	3 (1.2)
Any TEAE leading to prematurely discontinuation of study drug	33 (25.0)	30 (26.8)	63 (25.8)
Any TEAE leading to death (fatal TEAE)	0	3 (2.7)	3 (1.2)
Any serious TEAE	33 (25.0)	30 (26.8)	63 (25.8)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

表 2.7.4-13. 有害事象の概要（安全性解析対象集団）：M15-741 試験（更新時）（続き）

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	14 (10.6)	8 (7.1)	22 (9.0)
Possible	6 (4.5)	5 (4.5)	11 (4.5)
Probable	5 (3.8)	3 (2.7)	8 (3.3)
Causal relationship	7 (5.3)	2 (1.8)	9 (3.7)
Any SAE that is considered associated with [redacted] infusion set$	1 (0.8)	1 (0.9)	2 (0.8)
Possible	1 (0.8)	1 (0.9)	2 (0.8)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	2 (1.5)	1 (0.9)	3 (1.2)
Possible	1 (0.8)	1 (0.9)	2 (0.8)
Probable	0	0	0
Causal relationship	1 (0.8)	0	1 (0.4)
Any SAE that is considered associated with product complaint$	11 (8.3)	9 (8.0)	20 (8.2)
ABBV-951	4 (3.0)	4 (3.6)	8 (3.3)
Infusion pump	2 (1.5)	2 (1.8)	4 (1.6)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	3 (2.3)	2 (1.8)	5 (2.0)
[redacted] infusion set 6 mm	2 (1.5)	1 (0.9)	3 (1.2)
[redacted] infusion set 9 mm	1 (0.8)	1 (0.9)	2 (0.8)
Neria guard infusion set (total)	2 (1.5)	1 (0.9)	3 (1.2)
Neria guard infusion set 6 mm	2 (1.5)	1 (0.9)	3 (1.2)
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

39

表 2.7.4-13. 有害事象の概要（安全性解析対象集団）：M15-741 試験（更新時）（続き）

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
All deaths#	0	5 (4.5)	5 (2.0)
All TE-deaths	0	3 (2.7)	3 (1.2)
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	2 (1.5)	6 (5.4)	8 (3.3)
AESI: weight loss	12 (9.1)	15 (13.4)	27 (11.1)
AESI: hallucinations/psychosis	32 (24.2)	29 (25.9)	61 (25.0)
AESI: somnolence	9 (6.8)	3 (2.7)	12 (4.9)
AESI: infusion site related infections	42 (31.8)	44 (39.3)	86 (35.2)
AESI: infusion site related non infection reactions	104 (78.8)	96 (85.7)	200 (82.0)
AESI: falls and associated injuries	36 (27.3)	37 (33.0)	73 (29.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Cross References：M15-741 試験 CSR update Table 14.3__1.1

40

表 2.7.4-14. 登録時期別の有害事象の概要（安全性解析対象集団）：M15-741 試験（更新時）

	Sample 1 (N=157) n (%)	Sample 2 (N=87) n (%)	All Subjects (N=244) n (%)
Entire study			
Subjects with:			
Any TEAE	152 (96.8)	78 (89.7)	230 (94.3)
Any severe TEAE	48 (30.6)	15 (17.2)	63 (25.8)
Any TEAE that is considered associated with study drug$	149 (94.9)	75 (86.2)	224 (91.8)
Any TEAE that is considered associated with product complaint$	130 (82.8)	43 (49.4)	173 (70.9)
ABBV-951	75 (47.8)	21 (24.1)	96 (39.3)
Infusion pump	14 (8.9)	4 (4.6)	18 (7.4)
Vial adapter	1 (0.6)	0	1 (0.4)
Syringes	0	0	0
[redacted] infusion set (total)	82 (52.2)	10 (11.5)	92 (37.7)
[redacted] infusion set 6 mm	58 (36.9)	5 (5.7)	63 (25.8)
[redacted] infusion set 9 mm	44 (28.0)	5 (5.7)	49 (20.1)
Neria guard infusion set (total)	7 (4.5)	25 (28.7)	32 (13.1)
Neria guard infusion set 6 mm	2 (1.3)	15 (17.2)	17 (7.0)
Neria guard infusion set 9 mm	5 (3.2)	18 (20.7)	23 (9.4)
[redacted]	5 (3.2)	2 (2.3)	7 (2.9)
Any TEAE that is considered associated with loading dose$	5 (3.2)	2 (2.3)	7 (2.9)
Any TEAE that is considered associated with rescue dose$	8 (5.1)	4 (4.6)	12 (4.9)
Any TEAE that is considered associated with COVID-19 infection	1 (0.6)	2 (2.3)	3 (1.2)
Any TEAE leading to prematurely discontinuation of study drug	49 (31.2)	14 (16.1)	63 (25.8)
Any TEAE leading to death (fatal TEAE)	3 (1.9)	0	3 (1.2)
Any serious TEAE	44 (28.0)	19 (21.8)	63 (25.8)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

表 2.7.4-14. 登録時期別の有害事象の概要（安全性解析対象集団）：M15-741 試験（更新時）（続き）

	Sample 1 (N=157) n (%)	Sample 2 (N=87) n (%)	All Subjects (N=244) n (%)
Entire study (cont'd)			
Any SAE that is considered associated with infusion pump$	15 (9.6)	7 (8.0)	22 (9.0)
Possible	6 (3.8)	5 (5.7)	11 (4.5)
Probable	6 (3.8)	2 (2.3)	8 (3.3)
Causal relationship	6 (3.8)	3 (3.4)	9 (3.7)
Any SAE that is considered associated with [redacted] infusion set$	2 (1.3)	0	2 (0.8)
Possible	2 (1.3)	0	2 (0.8)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	3 (3.4)	3 (1.2)
Possible	0	2 (2.3)	2 (0.8)
Probable	0	0	0
Causal relationship	0	1 (1.1)	1 (0.4)
Any SAE that is considered associated with product complaint$	17 (10.8)	3 (3.4)	20 (8.2)
ABBV-951	8 (5.1)	0	8 (3.3)
Infusion pump	4 (2.5)	0	4 (1.6)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	5 (3.2)	0	5 (2.0)
[redacted] infusion set 6 mm	3 (1.9)	0	3 (1.2)
[redacted] infusion set 9 mm	2 (1.3)	0	2 (0.8)
Neria guard infusion set (total)	0	3 (3.4)	3 (1.2)
Neria guard infusion set 6 mm	0	3 (3.4)	3 (1.2)
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

表 2.7.4-14. 登録時期別の有害事象の概要（安全性解析対象集団）：M15-741 試験（更新時）（続き）

	Sample 1 (N=157) n (%)	Sample 2 (N=87) n (%)	All Subjects (N=244) n (%)
Entire study (cont'd)			
All deaths#	5 (3.2)	0	5 (2.0)
All TE-deaths	3 (1.9)	0	3 (1.2)
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	4 (2.5)	4 (4.6)	8 (3.3)
AESI: weight loss	21 (13.4)	6 (6.9)	27 (11.1)
AESI: hallucinations/psychosis	40 (25.5)	21 (24.1)	61 (25.0)
AESI: somnolence	7 (4.5)	5 (5.7)	12 (4.9)
AESI: infusion site related infections	59 (37.6)	27 (31.0)	86 (35.2)
AESI: infusion site related non infection reactions	139 (88.5)	61 (70.1)	200 (82.0)
AESI: falls and associated injuries	48 (30.6)	25 (28.7)	73 (29.9)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Cross References：M15-741 試験 CSR update Table 14.3__1.5.1

2.7.4.2.1.1.2 M15-737 試験

申請時

本試験の有害事象の概要を表 2.7.4-15 に示す。全体集団（105 例）での有害事象の発現割合は，すべての有害事象が 62.9%（66 例），重篤な有害事象が 16.2%（17 例），死亡に至った有害事象が 2.9%（3 例），投与中止に至った有害事象が 4.8%（5 例），治験薬と関連ありの有害事象が 41.9%（44 例），治験薬又は治験機器の不具合に関連した有害事象が 24.8%（26 例）であった。

更新時

本試験の有害事象の概要を表 2.7.4-16 に示す。全体集団（116 例）での有害事象の発現割合は，すべての有害事象が 75.9%（88 例），重篤な有害事象が 22.4%（26 例），死亡に至った有害事象が 2.6%（3 例），投与中止に至った有害事象が 6.0%（7 例），治験薬と関連ありの有害事象が 51.7%（60 例），治験薬又は治験機器の不具合に関連した有害事象が 37.1%（43 例）であった。

表 2.7.4-15. 有害事象の概要（安全性解析対象集団）：M15-737 試験

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Subjects with:			
Any TEAE	25 (55.6)	41 (68.3)	66 (62.9)
Any severe TEAE	4 (8.9)	8 (13.3)	12 (11.4)
Any TEAE that is considered associated with study drug$	16 (35.6)	28 (46.7)	44 (41.9)
Any TEAE that is considered associated with product complaint$	11 (24.4)	15 (25.0)	26 (24.8)
ABBV-951	3 (6.7)	9 (15.0)	12 (11.4)
Infusion pump	0	1 (1.7)	1 (1.0)
Vial adapter	0	0	0
Syringes	0	1 (1.7)	1 (1.0)
[redacted] infusion set (total)	4 (8.9)	2 (3.3)	6 (5.7)
[redacted] infusion set 6 mm	1 (2.2)	1 (1.7)	2 (1.9)
[redacted] infusion set 9 mm	3 (6.7)	1 (1.7)	4 (3.8)
Neria guard infusion set (total)	5 (11.1)	8 (13.3)	13 (12.4)
Neria guard infusion set 6 mm	3 (6.7)	2 (3.3)	5 (4.8)
Neria guard infusion set 9 mm	2 (4.4)	7 (11.7)	9 (8.6)
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	2 (3.3)	2 (1.9)
Any TEAE that is considered associated with COVID-19 infection	0	1 (1.7)	1 (1.0)
Any TEAE leading to prematurely discontinuation of study drug	1 (2.2)	4 (6.7)	5 (4.8)
Any TEAE leading to death (fatal TEAE)	1 (2.2)	2 (3.3)	3 (2.9)
Any serious TEAE	7 (15.6)	10 (16.7)	17 (16.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
COVID-19 = coronavirus disease-2019, TEAE = treatment-emergent adverse events

45

表 2.7.4-15. 有害事象の概要（安全性解析対象集団）：M15-737 試験（続き）

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Any SAE that is considered associated with infusion pump$	1 (2.2)	1 (1.7)	2 (1.9)
Possible	0	0	0
Probable	0	1 (1.7)	1 (1.0)
Causal relationship	1 (2.2)	0	1 (1.0)
Any SAE that is considered associated with neria guards infusion set$	1 (2.2)	1 (1.7)	2 (1.9)
Possible	0	1 (1.7)	1 (1.0)
Probable	1 (2.2)	0	1 (1.0)
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	2 (4.4)	1 (1.7)	3 (2.9)
ABBV-951	1 (2.2)	0	1 (1.0)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	1 (2.2)	1 (1.7)	2 (1.9)
Neria guard infusion set 6 mm	1 (2.2)	0	1 (1.0)
Neria guard infusion set 9 mm	0	1 (1.7)	1 (1.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
SAE = serious adverse events

46

表 2.7.4-15. 有害事象の概要（安全性解析対象集団）：M15-737 試験（続き）

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
All deaths#	1 (2.2)	2 (3.3)	3 (2.9)
All TE-deaths	1 (2.2)	2 (3.3)	3 (2.9)
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	1 (2.2)	3 (5.0)	4 (3.8)
AESI: hallucinations/psychosis	4 (8.9)	6 (10.0)	10 (9.5)
AESI: somnolence	0	0	0
AESI: infusion site related infections	8 (17.8)	9 (15.0)	17 (16.2)
AESI: infusion site related non infection reactions	11 (24.4)	17 (28.3)	28 (26.7)
AESI: falls and associated injuries	4 (8.9)	11 (18.3)	15 (14.3)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
# Includes non treatment-emergent deaths.
AESI = adverse events of special interest, COVID-19 = coronavirus disease-2019

Cross References：M15-737 試験 CSR Table 14.3__1.1

47

表 2.7.4-16. 有害事象の概要（安全性解析対象集団）：M15-737 試験（更新時）

	Dose Category		
	Low Dose (N=55) n (%)	High Dose (N=61) n (%)	All Subjects (N=116) n (%)
Subjects with:			
Any TEAE	39 (70.9)	49 (80.3)	88 (75.9)
Any severe TEAE	10 (18.2)	10 (16.4)	20 (17.2)
Any TEAE that is considered associated with study drug$	27 (49.1)	33 (54.1)	60 (51.7)
Any TEAE that is considered associated with product complaint$	21 (38.2)	22 (36.1)	43 (37.1)
ABBV-951	6 (10.9)	10 (16.4)	16 (13.8)
Infusion pump	3 (5.5)	3 (4.9)	6 (5.2)
Vial adapter	0	0	0
Syringes	0	1 (1.6)	1 (0.9)
[redacted] infusion set (total)	5 (9.1)	4 (6.6)	9 (7.8)
[redacted] infusion set 6 mm	1 (1.8)	3 (4.9)	4 (3.4)
[redacted] infusion set 9 mm	4 (7.3)	1 (1.6)	5 (4.3)
Neria guard infusion set (total)	10 (18.2)	11 (18.0)	21 (18.1)
Neria guard infusion set 6 mm	7 (12.7)	4 (6.6)	11 (9.5)
Neria guard infusion set 9 mm	3 (5.5)	8 (13.1)	11 (9.5)
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	2 (3.3)	2 (1.7)
Any TEAE that is considered associated with COVID-19 infection	1 (1.8)	6 (9.8)	7 (6.0)
Any TEAE leading to prematurely discontinuation of study drug	3 (5.5)	4 (6.6)	7 (6.0)
Any TEAE leading to death (fatal TEAE)	1 (1.8)	2 (3.3)	3 (2.6)
Any serious TEAE	14 (25.5)	12 (19.7)	26 (22.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

48

表 2.7.4-16. 有害事象の概要（安全性解析対象集団）：M15-737 試験（更新時）（続き）

	Dose Category		
	Low Dose (N=55) n (%)	High Dose (N=61) n (%)	All Subjects (N=116) n (%)
Any SAE that is considered associated with infusion pump$	4 (7.3)	2 (3.3)	6 (5.2)
Possible	2 (3.6)	0	2 (1.7)
Probable	0	1 (1.6)	1 (0.9)
Causal relationship	2 (3.6)	1 (1.6)	3 (2.6)
Any SAE that is considered associated with neria guards infusion set$	2 (3.6)	2 (3.3)	4 (3.4)
Possible	0	1 (1.6)	1 (0.9)
Probable	2 (3.6)	0	2 (1.7)
Causal relationship	0	1 (1.6)	1 (0.9)
Any SAE that is considered associated with product complaint$	6 (10.9)	4 (6.6)	10 (8.6)
ABBV-951	2 (3.6)	3 (4.9)	5 (4.3)
Infusion pump	2 (3.6)	1 (1.6)	3 (2.6)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	3 (5.5)	1 (1.6)	4 (3.4)
Neria guard infusion set 6 mm	2 (3.6)	0	2 (1.7)
Neria guard infusion set 9 mm	1 (1.8)	1 (1.6)	2 (1.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

49

表 2.7.4-16. 有害事象の概要（安全性解析対象集団）：M15-737 試験（更新時）（続き）

	Dose Category		
	Low Dose (N=55) n (%)	High Dose (N=61) n (%)	All Subjects (N=116) n (%)
All deaths#	1 (1.8)	2 (3.3)	3 (2.6)
All TE-deaths	1 (1.8)	2 (3.3)	3 (2.6)
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	1 (1.8)	5 (8.2)	6 (5.2)
AESI: hallucinations/psychosis	8 (14.5)	8 (13.1)	16 (13.8)
AESI: somnolence	0	0	0
AESI: infusion site related infections	11 (20.0)	11 (18.0)	22 (19.0)
AESI: infusion site related non infection reactions	18 (32.7)	21 (34.4)	39 (33.6)
AESI: falls and associated injuries	8 (14.5)	15 (24.6)	23 (19.8)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Cross References：M15-737 試験 CSR update Table 14.3__1.1

50

2.7.4.2.1.1.3 M15-736 試験

本試験の二重盲検期に発現した有害事象の概要を表 2.7.4-17 に示す。二重盲検期の有害事象の発現割合は，ABBV-951 投与群及び CD/LD 経口投与群でそれぞれ，すべての有害事象が 85.1%（63/74 例）及び 62.7%（42/67 例），重篤な有害事象が 8.1%（6 例）及び 6.0%（4 例），死亡に至った有害事象が 0.0%（0 例）及び 1.5%（1 例），投与中止に至った有害事象が 21.6%（16 例）及び 1.5%（1 例），治験薬と関連ありの有害事象が 70.3%（52 例）及び 22.4%（15 例），治験薬又は治験機器の不具合に関連した有害事象が 62.2%（46 例）及び 11.9%（8 例）であった。

表 2.7.4-17. 二重盲検期に発現した有害事象の概要（安全性解析対象集団）：M15-736 試験

	Oral CD/LD			ABBV-951			
	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Double-blind treatment period	N=56	N=11	N=67	N=45	N=29	N=74	N=141
Subjects with:							
Any TEAE	35 (62.5)	7 (63.6)	42 (62.7)	39 (86.7)	24 (82.8)	63 (85.1)	105 (74.5)
Any TEAE that is							
Mild	31 (55.4)	6 (54.5)	37 (55.2)	33 (73.3)	19 (65.5)	52 (70.3)	89 (63.1)
Moderate	9 (16.1)	3 (27.3)	12 (17.9)	25 (55.6)	17 (58.6)	42 (56.8)	54 (38.3)
Severe	1 (1.8)	0	1 (1.5)	2 (4.4)	5 (17.2)	7 (9.5)	8 (5.7)
Any TEAE considered related with study drug$	12 (21.4)	3 (27.3)	15 (22.4)	32 (71.1)	20 (69.0)	52 (70.3)	67 (47.5)
Any TEAE associated with any product complaint$	7 (12.5)	1 (9.1)	8 (11.9)	29 (64.4)	17 (58.6)	46 (62.2)	54 (38.3)
ABBV-951 or Placebo solution*	1 (1.8)	1 (9.1)	2 (3.0)	20 (44.4)	8 (27.6)	28 (37.8)	30 (21.3)
CD/LD IR or Placebo capsules	0	0	0	0	0	0	0
Open label CD/LD IR tablets	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
Infusion pump	1 (1.8)	0	1 (1.5)	5 (11.1)	2 (6.9)	7 (9.5)	8 (5.7)
Vial adapter	0	0	0	0	0	0	0
Syringes	0	0	0	0	0	0	0
Neria guard infusion set 6 mm	1 (1.8)	0	1 (1.5)	5 (11.1)	2 (6.9)	7 (9.5)	8 (5.7)
Neria guard infusion set 9 mm	4 (7.1)	0	4 (6.0)	10 (22.2)	10 (34.5)	20 (27.0)	24 (17.0)
[redacted]	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
Any TEAE considered associated with COVID-19 infection	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
Any TEAE leading to premature discontinuation of study drug	1 (1.8)	0	1 (1.5)	12 (26.7)	4 (13.8)	16 (21.6)	17 (12.1)
Any TEAE leading to death	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
Any serious TEAE	3 (5.4)	1 (9.1)	4 (6.0)	3 (6.7)	3 (10.3)	6 (8.1)	10 (7.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
* ABBV-951 or placebo solution associates with ABBV-951 for ABBV-951 group, associates with placebo solution for Oral CD/LD group.
COVID-19 = coronavirus disease-2019, TEAE = treatment-emergent adverse events

表 2.7.4-17. 二重盲検期に発現した有害事象の概要（安全性解析対象集団）：M15-736 試験（続き）

	Oral CD/LD			ABBV-951			
	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Any SAE considered related with infusion pump$	0	0	0	1 (2.2)	2 (6.9)	3 (4.1)	3 (2.1)
Possible	0	0	0	0	0	0	0
Probable	0	0	0	0	2 (6.9)	2 (2.7)	2 (1.4)
Causal relationship	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
All deaths#	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
Deaths related to COVID-19	0	0	0	0	0	0	0
AESI: Any AESI	21 (37.5)	4 (36.4)	25 (37.3)	39 (86.7)	20 (69.0)	59 (79.7)	84 (59.6)
AESI: Infusion Related Infections	2 (3.6)	0	2 (3.0)	14 (31.1)	7 (24.1)	21 (28.4)	23 (16.3)
AESI: Infusion Related Reactions	5 (8.9)	0	5 (7.5)	31 (68.9)	15 (51.7)	46 (62.2)	51 (36.2)
AESI: Hallucinations/psychosis	1 (1.8)	1 (9.1)	2 (3.0)	5 (11.1)	6 (20.7)	11 (14.9)	13 (9.2)
AESI: Polyneuropathy	2 (3.6)	0	2 (3.0)	2 (4.4)	0	2 (2.7)	4 (2.8)
AESI: Somnolence	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
AESI: Falls and associated injuries	13 (23.2)	4 (36.4)	17 (25.4)	8 (17.8)	5 (17.2)	13 (17.6)	30 (21.3)
AESI: Weight loss	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
# Includes non treatment-emergent deaths. Same subject with the death on 14.3_1.1.1.
AESI = adverse events of special interest, COVID-19 = coronavirus disease-2019, SAE = serious adverse events

Cross References：M15-736 試験 CSR Table 14.3__1.1.2

2.7.4.2.1.2 比較的よくみられる有害事象

2.7.4.2.1.2.1 M15-741 試験

申請時

全体集団（244 例）で発現割合が 2%以上の有害事象を表 2.7.4.7-4 に，すべての有害事象を 2.7.6 項に示す。有害事象は 94.3%（230 例）の被験者で報告された。発現割合が 10%以上の有害事象は，注入部位紅斑 51.2%（125 例），注入部位結節 27.9%（68 例），注入部位蜂巣炎 23.0%（56 例），注入部位浮腫 19.3%（47 例），幻覚 16.8%（41 例），転倒 16.0%（39 例），注入部位疼痛 15.6%（38 例），注入部位反応 12.7%（31 例），不安 11.5%（28 例），注入部位膿瘍 10.7%（26 例）及び浮動性めまい 10.2%（25 例）であった。

更新時

全体集団（244 例）で発現割合が 2%以上の有害事象を表 2.7.4.7-45 に，すべての有害事象を 2.7.6 項に示す。有害事象は 94.3%（230 例）の被験者で報告された。発現割合が 10%以上の有害事象は，注入部位紅斑 51.6%（126 例），注入部位結節 28.3%（69 例），注入部位蜂巣炎 23.0%（56 例），注入部位浮腫 19.3%（47 例），幻覚 17.2%（42 例），転倒 16.4%（40 例），注入部位疼痛 15.6%（38 例），注入部位反応 12.3%（30 例），不安 11.9%（29 例），注入部位膿瘍 11.1%（27 例）及び浮動性めまい 10.2%（25 例）であった。

2.7.4.2.1.2.2 M15-737 試験

申請時

全体集団（105 例）で 2 例以上発現した有害事象を表 2.7.4.7-5 に，すべての有害事象を 2.7.6 項に示す。有害事象は 62.9%（66 例）の被験者で報告された。5 例以上発現した有害事象は，注入部位紅斑が 13 例（12.4%），転倒及び注入部位蜂巣炎が各 12 例（11.4%），幻覚が 7 例（6.7%），便秘及びオンオフ現象が各 5 例（4.8%）であった。

更新時

全体集団（116 例）で 2 例以上発現した有害事象を表 2.7.4.7-46 に，すべての有害事象を 2.7.6 項に示す。有害事象は 75.9%（88 例）の被験者で報告された。5 例以上発現した有害事象は，注入部位紅斑が 19 例（16.4%），注入部位蜂巣炎が 16 例（13.8%），転倒が 14 例（12.1%），幻覚が 9 例（7.8%），不安が 8 例（6.9%），オンオフ現象及びパーキンソン病が各 7 例（6.0%），便秘，注入部位内出血，注入部位結節，COVID-19 及び尿路感染が各 5 例（4.3%）であった。

2.7.4.2.1.2.3 M15-736 試験

二重盲検期に発現したすべての有害事象を表 2.7.4.7-6 に示す。有害事象は ABBV-951 投与群（74 例）で 85.1%（63 例），CD/LD 経口投与群（67 例）で 62.7%（42 例）の被験者で報告され

た。発現割合が 10%以上の有害事象は，ABBV-951 投与群では，注入部位の有害事象（注入部位紅斑 27.0%［20 例］，注入部位疼痛 25.7%［19 例］，注入部位蜂巣炎 18.9%［14 例］，注入部位浮腫 12.2%［9 例］）及びジスキネジア 10.8%（8 例）であり，CD/LD 経口投与群では，転倒 17.9%（12 例）であった。

2.7.4.2.1.3 治験薬と関連ありの有害事象

2.7.4.2.1.3.1 M15-741 試験

申請時

治験薬と関連ありの有害事象の発現割合は 91.8%（224/244 例）であり，発現割合が 10%以上の有害事象は，注入部位紅斑 48.4%（118 例），注入部位結節 27.9%（68 例），注入部位蜂巣炎 21.3%（52 例），注入部位浮腫 18.9%（46 例），幻覚 14.8%（36 例），注入部位疼痛 13.9%（34 例）及び注入部位反応 12.7%（31 例）であった（M15-741 試験 CSR Table 14.3__1.6）。

更新時

治験薬と関連ありの有害事象の発現割合は 91.8%（224/244 例）であり，発現割合が 10%以上の有害事象は，注入部位紅斑 48.8%（119 例），注入部位結節 28.3%（69 例），注入部位蜂巣炎 21.3%（52 例），注入部位浮腫 18.9%（46 例），幻覚 15.2%（37 例），注入部位疼痛 13.9%（34 例），注入部位反応 12.3%（30 例）及び注入部位膿瘍 10.2%（25 例）であった（M15-741 試験 CSR update Table 14.3__1.6）。

2.7.4.2.1.3.2 M15-737 試験

申請時

治験薬と関連ありの有害事象の発現割合は 41.9%（44/105 例）であり，5 例以上発現した有害事象は，注入部位蜂巣炎が 11 例（10.5%），注入部位紅斑が 10 例（9.5%）及びオンオフ現象が 5 例（4.8%）であった（M15-737 試験 CSR Table 14.3__1.6）。

更新時

治験薬と関連ありの有害事象の発現割合は 51.7%（60/116 例）であり，5 例以上発現した有害事象は，注入部位紅斑が 16 例（13.8%），注入部位蜂巣炎が 15 例（12.9%），オンオフ現象が 7 例（6.0%），注入部位結節，注入部位内出血及び幻覚が各 5 例（4.3%）であった（M15-737 試験 CSR update Table 14.3__1.6）。

2.7.4.2.1.3.3 M15-736 試験

治験薬と関連ありの有害事象の発現割合は ABBV-951 投与群で 70.3%（52/74 例），CD/LD 経口投与群で 22.4%（15/67 例）であった。発現割合が 10%以上の有害事象は，ABBV-951 投与群

55

で注入部位紅斑 21.6%（16 例），注入部位疼痛 18.9%（14 例）及び注入部位蜂巣炎 16.2%（12 例）であった。CD/LD 経口投与群では認められなかった（M15-736 試験 CSR Table 14.3__1.5）。

2.7.4.2.1.4 重症度別の有害事象

2.7.4.2.1.4.1 M15-741 試験

申請時

重度の有害事象は 25.4%（62/244 例）の被験者で報告された。有害事象の大半は軽度又は中等度であった。3 例以上発現した重度の有害事象は，注入部位蜂巣炎，精神病性障害及びパーキンソン病が各 2.0%（5 例），注入部位紅斑，注入部位膿瘍，注入部位感染及び幻覚が各 1.6%（4 例），注入部位結節，尿路感染，転倒，ジスキネジア及びジストニアが各 1.2%（3 例）であった（M15-741 試験 CSR Table 14.3__1.4）。

更新時

重度の有害事象は 25.8%（63/244 例）の被験者で報告された。有害事象の大半は軽度又は中等度であった。3 例以上発現した重度の有害事象は，注入部位蜂巣炎，精神病性障害及びパーキンソン病が各 2.0%（5 例），注入部位紅斑，注入部位膿瘍，注入部位感染及び幻覚が各 1.6%（4 例），注入部位結節，尿路感染，転倒，関節痛，ジスキネジア，ジストニア及び不安が各 1.2%（3 例）であった（M15-741 試験 CSR update Table 14.3__1.4）。

2.7.4.2.1.4.2 M15-737 試験

申請時

重度の有害事象は 11.4%（12/105 例）の被験者で報告された。有害事象のほとんどが軽度又は中等度であった。投与期間中に 2 例以上発現した重度の有害事象は，注入部位蜂巣炎，パーキンソン病及び精神病性障害が各 1.9%（2 例）であった（M15-737 試験 CSR Table 14.3__1.4）。

更新時

重度の有害事象は 17.2%（20/116 例）の被験者で報告された。有害事象のほとんどが軽度又は中等度であった。投与期間中に 2 例以上発現した重度の有害事象は，注入部位蜂巣炎及びパーキンソン病が各 2.6%（3 例），オンオフ現象及び精神病性障害が各 1.7%（2 例）であった（M15-737 試験 CSR update Table 14.3__1.4）。

2.7.4.2.1.4.3 M15-736 試験

重度の有害事象は，ABBV-951 投与群の 9.5%（7/74 例）及び CD/LD 経口投与群の 1.5%（1/67 例）の被験者で報告された。有害事象の重症度は，各投与群の大多数の被験者で軽度又は中等

度であった。いずれかの投与群で 2 例以上発現した重度の有害事象は認められなかった（M15-736 試験 CSR Table 14.3__1.4）。

2.7.4.2.1.5 発現時期別の有害事象

有害事象の初回発現割合の解析では，ある被験者に発現した特定の事象を初回発現が認められた時間枠のみで集計した。ある被験者に同じ基本語の事象が複数件発現した場合には初回発現のみを含め，その被験者は同じ基本語に関するその後の時間枠では分母に含めなかった。有病割合の解析では，各被験者を特定の有害事象が持続しているすべての時間枠で集計し，各時間枠での分母には，その時間枠において有害事象のリスクのあるすべての被験者を含めた。有病割合の解析では，ある被験者に同じ基本語の有害事象が再発した場合，その再発事象も当該有害事象が持続しているすべての時間枠で集計した。

2.7.4.2.1.5.1 M15-741 試験

申請時

有害事象の 90 日間ごとの初回発現割合は，投与後 90 日までが 92.2%（225/244 例）と最も高く，その後，発現割合は減少した。90 日間ごとの有病割合は，投与後 90 日までが 92.2%（225/244 例）と最も高く，その後減少した（M15-741 試験 CSR Japan Study Data Table 14.3__1.16.1 及び Table 14.3__1.16.2）。

更新時

有害事象の 90 日間ごとの初回発現割合は，投与後 90 日までが 92.2%（225/244 例）と最も高く，その後，発現割合は減少した。90 日間ごとの有病割合は，投与後 90 日までが 92.2%（225/244 例）と最も高く，その後減少した（M15-741 試験 CSR update Table 14.3__1.16.1 及び Table 14.3__1.16.2）。

2.7.4.2.1.5.2 M15-737 試験

申請時

有害事象の 90 日間ごとの初回発現割合は，投与後 90 日までが 41.0%（43/105 例）と最も高く，その後，発現割合は減少した。90 日間ごとの有病割合は，投与後 90 日までが 41.0%（43/105 例），91 日～180 日が 58.7%（44/75 例），181 日～270 日が 65.8%（48/73 例），271 日～360 日が 59.7%（37/62 例）であった（M15-737 試験 CSR Japan Study Data Table 14.3__1.16.1.J 及び Table 14.3__1.16.2.J）。

更新時

有害事象の 90 日間ごとの初回発現割合は，投与後 90 日までが 49.1%（57/116 例）と最も高く，その後，発現割合は減少した。90 日間ごとの有病割合は，投与後 90 日までが 49.1%（57/116

例），91 日～180 日が 58.0%（65/112 例），181 日～270 日が 73.1%（57/78 例），271 日～360 日が 75.4%（52/69 例）であった（M15-737 試験 CSR update Table 14.3__1.16.1.J 及び Table 14.3__1.16.2.J）。

2.7.4.2.1.6 死亡

2.7.4.2.1.6.1 M15-741 試験

申請時

死亡した被験者一覧を表 2.7.4.7-7 に示す。死亡に至った有害事象が 1.2%（3/244 例）の被験者で報告された。これら 3 例の死亡は，ABBV-951 の最終投与後 30 日以内であった（心肺停止，脳圧排効果及び硬膜下血腫，脳血管発作）。ABBV-951 の最終投与後 30 日以降の死亡は 2 例（多臓器機能不全症候群及び悪液質）であった。これらの有害事象のいずれも治験薬と関連なしと判定された。死亡例の詳細は，2.7.6 項に示した。

更新時

申請時データカットオフ以降に死亡した被験者はいなかった（M15-741 試験 CSR update Table 14.3__2.1）。

2.7.4.2.1.6.2 M15-737 試験

申請時

死亡した被験者一覧を表 2.7.4.7-8 に示す。死亡に至った有害事象が 2.9%（3/105 例）の被験者で報告された。これら 3 例の死亡に至った有害事象は，2 例でパーキンソン病，1 例で誤嚥及び窒息であり，いずれも治験薬と関連なしと判定された。死亡例の詳細は，2.7.6 項に示した。

更新時

死亡に至った有害事象が 2.6%（3/116 例）の被験者で報告された。これら 3 例の死亡に至った有害事象は申請時と同一であり，申請時データカットオフ以降に死亡した被験者はいなかった（M15-737 試験 CSR update Table 14.3__2.1）。死亡例の詳細は，2.7.6 項に示した。

2.7.4.2.1.6.3 M15-736 試験

二重盲検期間中に，死亡した被験者一覧を表 2.7.4.7-9 に示す。ABBV-951 投与群では死亡例は認められず，CD/LD 経口投与群では，急性呼吸不全による死亡が 1.5%（1/67 例）の被験者で認められた。急性呼吸不全は，治験責任医師により治験薬と関連なしと判定された。死亡例の詳細は，2.7.6 項に示した。

2.7.4.2.1.6.4 第 I 相試験

第 I 相試験の 7 試験（M16-769，M17-220，M15-739，M15-738，M15-733，M18-763 及び M18-764 試験）で，死亡した被験者の報告はなかった（M16-769 試験 CSR Table 14.3__2.3，M17-220 試験 CSR Table 14.3__2.3，M15-739 試験 CSR Table 14.3__2.3，M15-738 試験 CSR Table 14.3__2.3.1，14.3__2.3.2，M15-733 試験 CSR Table 14.3__2.3.1～14.3__2.3.4，M18-763 試験 CSR Table 14.3__2.3，M18-764 試験 CSR Table 14.3__2.3.1～14.3__2.3.3）。

2.7.4.2.1.7 その他の重篤な有害事象

2.7.4.2.1.7.1 M15-741 試験

申請時

重篤な有害事象が 25.0%（61/244 例）の被験者で報告された（表 2.7.4.7-10）。発現例数が 3 例以上の重篤な有害事象は，注入部位蜂巣炎が 10 例（4.1%），注入部位膿瘍が 8 例（3.3%），幻覚が 7 例（2.9%），パーキンソン病及び精神病性障害が各 6 例（2.5%），敗血症及び尿路感染が各 4 例（1.6%），肺炎が 3 例（1.2%）であった（M15-741 試験 CSR Table 14.3__1.11.1）。重篤な有害事象を発現した被験者の詳細は，2.7.6 項に示した。

更新時

重篤な有害事象が 25.8%（63/244 例）の被験者で報告された（表 2.7.4.7-47）。発現例数が 3 例以上の重篤な有害事象は，注入部位蜂巣炎が 10 例（4.1%），注入部位膿瘍が 8 例（3.3%），幻覚が 7 例（2.9%），パーキンソン病及び精神病性障害が各 6 例（2.5%），尿路感染が 4 例（1.6%），肺炎及び敗血症が各 3 例（1.2%）であった（M15-741 試験 CSR update Table 14.3__1.11.1）。なお，申請時データで敗血症を発現した 4 例のうちの 1 例の有害事象名が四肢膿瘍に修正された。重篤な有害事象を発現した被験者の詳細は，2.7.6 項に示した。

2.7.4.2.1.7.2 M15-737 試験

申請時

重篤な有害事象が 16.2%（17/105 例）の被験者で報告された（表 2.7.4.7-11）。発現例数が 2 例以上の重篤な有害事象は，注入部位蜂巣炎，転倒，股関節部骨折，パーキンソン病及び精神病性障害が各 2 例（1.9%）であった（M15-737 試験 CSR Table 14.3__1.11.1）。重篤な有害事象を発現した被験者の詳細は，2.7.6 項に示した。

更新時

重篤な有害事象が 22.4%（26/116 例）の被験者で報告された（表 2.7.4.7-48）。発現例数が 2 例以上の重篤な有害事象は，注入部位蜂巣炎が 5 例（4.3%），転倒及びパーキンソン病が各 3 例（2.6%），股関節部骨折，変形性関節症及び精神病性障害が各 2 例（1.7%）であった

（M15-737 試験 CSR update Table 14.3__1.11.1）。重篤な有害事象を発現した被験者の詳細は，2.7.6 項に示した。

2.7.4.2.1.7.3 M15-736 試験

重篤な有害事象は，ABBV-951 投与群の 8.1%（6/74 例）及び CD/LD 経口投与群の 6.0%（4/67 例）の被験者で報告された（表 2.7.4.7-12）。重篤な有害事象は，ABBV-951 投与群では，カテーテル留置部位蜂巣炎，注入部位蜂巣炎，脱水，片頭痛，妄想，妄想症，精神病性障害及び前立腺腫大が各 1.4%（1 例），CD/LD 経口投与群では，COVID-19 肺炎，蜂巣炎，挫傷，転倒，腎結石症及び急性呼吸不全が各 1.5%（1 例）であった（M15-736 試験 CSR Table 14.3__1.3.2.1）。重篤な有害事象を発現した被験者の詳細は，2.7.6 項に示した。

2.7.4.2.1.7.4 第 I 相試験

第 I 相試験の 3 試験（M15-739，M17-220 及び M18-763 試験）で，重篤な有害事象が各 1 例報告された。M17-220 試験では痙攣発作（重度）が，M15-739 試験では蜂巣炎（重度）及び腹部膿瘍（中等度）が，M18-763 試験では筋骨格痛（重度）が認められた（表 2.7.4.7-13，表 2.7.4.7-14 及び表 2.7.4.7-15）。

2.7.4.2.1.8 その他の重要な有害事象

2.7.4.2.1.8.1 投与中止に至った有害事象

2.7.4.2.1.8.1.1 M15-741 試験

申請時

治験薬の投与中止に至った有害事象の発現割合は 25.4%（62/244 例）であった。発現割合が 2%以上の治験薬の投与中止に至った有害事象は，幻覚が 4.1%（10 例），注入部位紅斑及び注入部位蜂巣炎が各 3.7%（9 例），ジスキネジアが 2.0%（5 例）であった（M15-741 試験 CSR Table 14.3__1.8.1）。治験薬の投与中止に至った有害事象の多くは，重症度が中等度であり，治験責任医師により治験薬と関連ありと判定された（M15-741 試験 CSR Table 14.3__2.4）。

更新時

治験薬の投与中止に至った有害事象の発現割合は 25.8%（63/244 例）であった。発現割合が 2%以上の治験薬の投与中止に至った有害事象は，幻覚が 4.1%（10 例），注入部位紅斑及び注入部位蜂巣炎が各 3.7%（9 例），注入部位結節及びジスキネジアが各 2.0%（5 例）であった（M15-741 試験 CSR update Table 14.3__1.8.1）。治験薬の投与中止に至った有害事象の多くは，重症度が中等度であり，治験責任医師により治験薬と関連ありと判定された（M15-741 試験 CSR update Table 14.3__2.4）。

2.7.4.2.1.8.1.2 M15-737 試験

申請時

治験薬の投与中止に至った有害事象の発現割合は 4.8%（5/105 例）であった（M15-737 試験 CSR Table 14.3__1.8.1）。治験薬の投与中止に至った有害事象は，パーキンソン病が 1.9%（2 例），注入部位発疹，注入部位蜂巣炎，誤嚥及び窒息が各 1.0%（1 例）であった。これらの有害事象は，すべて重度であり，注入部位発疹を除き重篤であった。注入部位発疹及び注入部位蜂巣炎は治験責任医師により治験薬と関連ありと判定された（M15-737 試験 CSR Table 14.3__2.4）。

更新時

治験薬の投与中止に至った有害事象の発現割合は 6.0%（7/116 例）であった（M15-737 試験 CSR update Table 14.3__1.8.1）。治験薬の投与中止に至った有害事象は，パーキンソン病及び注入部位蜂巣炎が各 1.7%（2 例），注入部位発疹，注入部位膿瘍，誤嚥及び窒息が各 0.9%（1 例）であった。これらの有害事象は，注入部位膿瘍を除き重度であり，また，注入部位膿瘍及び注入部位発疹を除き重篤であった。注入部位発疹，注入部位蜂巣炎及び注入部位膿瘍は治験責任医師により治験薬と関連ありと判定された（M15-737 試験 CSR update Table 14.3__2.4）。

2.7.4.2.1.8.1.3 M15-736 試験

治験薬の投与中止に至った有害事象の発現割合は，ABBV-951 投与群で 21.6%（16/74 例）及び CD/LD 経口投与群で 1.5%（1/67 例）であった。発現割合が 2%以上の投与中止に至った有害事象は ABBV-951 投与群のみであり，注入部位の有害事象（注入部位蜂巣炎 5.4%［4 例］，注入部位疼痛 4.1%［3 例］，注入部位内出血，注入部位出血及び注入部位浮腫が各 2.7%［2 例］）であった（M15-736 試験 CSR Table 14.3__1.3.3.1）。治験薬の投与中止に至った有害事象のほとんどが，重症度は軽度又は中等度であり，治験責任医師により治験薬と関連ありと判定された（M15-736 試験 CSR Table 14.3__1.4）。

2.7.4.2.1.8.2 治験薬又は治験機器の不具合に関連した有害事象

2.7.4.2.1.8.2.1 M15-741 試験

申請時

治験薬又は治験機器の不具合に関連した有害事象が 70.1%（171/244 例）の被験者で報告された（表 2.7.4-11）。発現割合が 10%以上の当該有害事象は，ABBV-951 に関連した有害事象で注入部位紅斑 19.3%（47 例），注入部位結節 13.1%（32 例），[redacted] 注入セットに関連した有害事象で注入部位紅斑 21.3%（52 例）であった（M15-741 試験 CSR Table 14.3__1.10.5）。

更新時

治験薬又は治験機器の不具合に関連した有害事象が 70.9%（173/244 例）の被験者で報告された（表 2.7.4-13）。発現割合が 10%以上の当該有害事象は，ABBV-951 に関連した有害事象で注入部位紅斑 19.3%（47 例），注入部位結節 13.1%（32 例），[redacted] 注入セットに関連した有害事象で注入部位紅斑 21.3%（52 例）であった（M15-741 試験 CSR update Table 14.3__1.10.5）。

2.7.4.2.1.8.2.2 M15-737 試験

申請時

治験薬又は治験機器の不具合に関連した有害事象が 24.8%（26/105 例）の被験者で報告された（表 2.7.4-15）。発現が 3 例以上の当該有害事象は，ABBV-951 の不具合に関連した有害事象で注入部位蜂巣炎 3.8%（4 例）及び注入部位紅斑 2.9%（3 例），Neria guard 注入セットの不具合に関連した有害事象で注入部位蜂巣炎 4.8%（5 例）及び注入部位紅斑 2.9%（3 例）であった（M15-737 試験 CSR Table 14.3__1.5.3）。

更新時

治験薬又は治験機器の不具合に関連した有害事象が 37.1%（43/116 例）の被験者で報告された（表 2.7.4-16）。発現が 3 例以上の当該有害事象は，ABBV-951 の不具合に関連した有害事象で注入部位蜂巣炎 6.9%（8 例）及び注入部位紅斑 4.3%（5 例），Neria guard 注入セットの不具合に関連した有害事象で注入部位蜂巣炎 6.0%（7 例），注入部位紅斑 5.2%（6 例），カテーテル留置部位内出血及び注入部位結節が各 2.6%（3 例），[redacted] 注入セットの不具合に関連した有害事象でオンオフ現象 2.6%（3 例）であった（M15-737 試験 CSR update Table 14.3__1.5.3）。

2.7.4.2.1.8.2.3 M15-736 試験

治験薬又は治験機器の不具合に関連した有害事象が ABBV-951 投与群の 62.2%（46/74 例）及び CD/LD 経口投与群の 11.9%（8/67 例）の被験者で報告された（表 2.7.4-17 及び M15-736 試験 CSR Table 14.3__1.8.5）。発現割合が 10%以上の治験薬又は治験機器の不具合に関連した有害事象は，ABBV-951 投与群のみで認められ，ABBV-951 の不具合に関連した有害事象で注入部位疼痛 17.6%（13 例）及び注入部位紅斑 14.9%（11 例），Neria guard 注入セットの不具合に関連した有害事象で注入部位疼痛 12.2%（9 例）であった（M15-736 試験 CSR Table 14.3__1.8.1）。

2.7.4.2.1.9 器官別又は症候群別有害事象の解析

本項で評価した特に注目すべき有害事象及び検索基準を 2.7.4.1.1.2.2 項に示した。特に注目すべき有害事象の概要を表 2.7.4.7-16，表 2.7.4.7-17，表 2.7.4.7-18，表 2.7.4.7-49 及び表 2.7.4.7-50 に示す。

2.7.4.2.1.9.1 注入部位感染

2.7.4.2.1.9.1.1 M15-741 試験

申請時

注入部位感染は，被験者の 34.4%（84/244 例）で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位蜂巣炎 23.0%（56 例），注入部位膿瘍 10.7%（26 例）及び注入部位感染 7.0%（17 例）であった（表 2.7.4.7-19）。治験薬と関連ありの注入部位感染は 32.4%（79 例）の被験者で報告された。注入部位感染は，多くの被験者で重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-16）。

重篤な注入部位感染は，6.6%（16 例）の被験者で報告されたが，後に蜂巣炎の 1 例は注入部位の感染ではないことが判明した。注入部位蜂巣炎が 4.1%（10 例），注入部位膿瘍が 3.3%（8 例），注入部位感染及び蜂巣炎が各 0.4%（1 例）であった（M15-741 試験 CSR Table 14.3__1.12.9）。

注入部位感染のために，治験薬の投与が 4.9%（12 例）の被験者で中止された（表 2.7.4.7-16）。致死的又は生命を脅かす注入部位感染は報告されなかった。

注入部位感染が発現するまでの期間は 43.0 日（中央値）で，多数の被験者が 15.0 日間（中央値）で回復した（M15-741 試験 CSR Table 14.3__1.12.16）。

登録時期別での注入部位感染は，Sample 1 で 37.6%（59/157 例），Sample 2 で 28.7%（25/87 例）の被験者で報告された（表 2.7.4-12）。

更新時

注入部位感染は，被験者の 35.2%（86/244 例）で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位蜂巣炎 23.0%（56 例），注入部位膿瘍 11.1%（27 例）及び注入部位感染 7.4%（18 例）であった（表 2.7.4.7-51）。治験薬と関連ありの注入部位感染は 32.8%（80 例）の被験者で報告された。注入部位感染は，多くの被験者で重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-49）。

重篤な注入部位感染は，6.6%（16 例）の被験者で報告されたが，後に蜂巣炎の 1 例は注入部位の感染ではないことが判明した。注入部位蜂巣炎が 4.1%（10 例），注入部位膿瘍が 3.3%（8 例），注入部位感染及び蜂巣炎が各 0.4%（1 例）であった（M15-741 試験 CSR update Table 14.3__1.12.9）。

注入部位感染のために，治験薬の投与が 4.9%（12 例）の被験者で中止された（表 2.7.4.7-49）。致死的又は生命を脅かす注入部位感染は報告されなかった。

注入部位感染が発現するまでの期間は 43.5 日（中央値）で，多数の被験者が 15.0 日間（中央値）で回復した（M15-741 試験 CSR update Table 14.3__1.12.16）。

登録時期別での注入部位感染は，Sample 1 で 37.6%（59/157 例），Sample 2 で 31.0%（27/87 例）の被験者で報告された（表 2.7.4-14）。

2.7.4.2.1.9.1.2 M15-737 試験

申請時

注入部位感染は，被験者の 16.2%（17/105 例）で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位蜂巣炎 11.4%（12 例）であった（表 2.7.4.7-20）。治験薬と関連ありの注入部位感染は 14.3%（15 例）であった。注入部位感染は，ほとんどの被験者で，重篤ではなく，重症度も軽度又は中等度であり，また，治験薬の投与が中止された被験者は 1.0%（1 例）であった。致死的又は生命を脅かす注入部位感染は報告されなかった（表 2.7.4.7-17）。

重篤な注入部位感染は，2.9%（3 例）の被験者で報告され，注入部位蜂巣炎 1.9%（2 例）及び注入部位膿瘍 1.0%（1 例）であった（M15-737 試験 CSR Table 14.3__1.12.9）。

更新時

注入部位感染は，被験者の 19.0%（22/116 例）で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位蜂巣炎 13.8%（16 例）であった（表 2.7.4.7-52）。治験薬と関連ありの注入部位感染は 17.2%（20 例）であった。注入部位感染は，ほとんどの被験者で，重篤ではなく，重症度も軽度又は中等度であり，また，治験薬の投与が中止された被験者は 2.6%（3 例）であった。致死的又は生命を脅かす注入部位感染は報告されなかった（表 2.7.4.7-50）。

重篤な注入部位感染は，5.2%（6 例）の被験者で報告され，注入部位蜂巣炎 4.3%（5 例）及び注入部位膿瘍 0.9%（1 例）であった（M15-737 試験 CSR update Table 14.3__1.12.9）。

2.7.4.2.1.9.1.3 M15-736 試験

注入部位感染は，ABBV-951 投与群の 28.4%（21/74 例）及び CD/LD 経口投与群の 3.0%（2/67 例）の被験者で報告された。発現割合が 5%以上の有害事象（PT）は，CD/LD 経口投与群では認められず，ABBV-951 投与群で，注入部位蜂巣炎 18.9%（14 例）及び注入部位感染 5.4%（4 例）であった（表 2.7.4.7-18）。治験薬と関連ありの注入部位感染は ABBV-951 投与群のみで認められ，発現割合は 23.0%（17 例）であった（M15-736 試験 CSR Table 14.3__1.1.3）。各投与群の被験者のほとんどで，注入部位感染は，重篤ではなく，重症度は軽度又は中等度であり，当該事象の過半数以上は回復し，治験薬に対する処置は行われなかった。被験者の中には抗生物質又は切開排膿による治療を必要とした者もいた（M15-736 試験 CSR Table 14.3__1.1.3 及び Table 14.3__2.4）。

重篤な注入部位感染は，ABBV-951 投与群の 2.7%（2/74 例）及び CD/LD 経口投与群の 1.5%（1/67 例）の被験者で報告された。ABBV-951 投与群で，カテーテル留置部位蜂巣炎及び注入部位蜂巣炎が各 1.4%（1 例），CD/LD 経口投与群で，蜂巣炎が 1.5%（1 例）であった（M15-736 試験 CSR Table 14.3__1.9.2.1）。

注入部位感染のために，治験薬の投与が ABBV-951 投与群で 5.4%（4 例）及び CD/LD 経口投与群で 1.5%（1 例）の被験者で中止された。いずれの投与群でも，致死的又は生命を脅かす注入部位感染は報告されなかった（M15-736 試験 CSR Table 14.3__1.1.3）。

注入部位感染（全体集団）が発現するまでの期間は 32.0 日（中央値）で，ほとんどの被験者は，16.5 日間（中央値）で回復した（M15-736 試験 CSR Table 14.3__1.12.1）。

2.7.4.2.1.9.2 注入部位非感染反応

2.7.4.2.1.9.2.1 M15-741 試験

申請時

注入部位非感染反応は，被験者の 81.6%（199/244 例）で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位紅斑が 51.2%（125 例），注入部位結節が 27.9%（68 例），注入部位浮腫が 19.3%（47 例），注入部位疼痛が 15.6%（38 例），注入部位反応が 12.7%（31 例），注入部位血管外漏出が 8.2%（20 例），注入部位内出血及び注入部位丘疹が各 7.4%（18 例），注入部位血腫が 6.6%（16 例），注射部位紅斑が 5.7%（14 例）であった（表 2.7.4.7-21）。治験薬との関連ありと判定された注入部位非感染反応は，79.5%（194 例）の被験者で報告された。注入部位非感染反応は，多くの被験者で重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-16）。

重篤な注入部位非感染反応が 1.2%（3 例）の被験者で報告され（表 2.7.4.7-16），注入部位損傷 0.8%（2 例）及び注入部位血腫 0.4%（1 例）であった（M15-741 試験 CSR Table 14.3__1.12.10）。

注入部位非感染反応のために治験薬の投与が 8.2%（20 例）の被験者で中止された。致死的又は生命を脅かす注入部位非感染反応は報告されなかった（表 2.7.4.7-16）。

注入部位非感染反応は，多数の被験者で回復と報告された（M15-741 試験 CSR Table 14.3__1.12.17）。

登録時期別での注入部位非感染反応は，Sample 1 で 88.5%（139/157 例），Sample 2 で 69.0%（60/87 例）の被験者で報告された（表 2.7.4-12）。

更新時

注入部位非感染反応は，被験者の 82.0%（200/244 例）で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位紅斑が 51.6%（126 例），注入部位結節が 28.3%（69 例），注入部位浮腫が 19.3%（47 例），注入部位疼痛が 15.6%（38 例），注入部位反応が 12.3%（30 例），注入部位血管外漏出が 8.2%（20 例），注入部位内出血，注入部位血腫及び注入部位丘疹が各 7.4%（18 例），注射部位紅斑が 5.7%（14 例）であった（表 2.7.4.7-53）。なお，申請時データで注入部位反応と報告された 31 例のうち 1 例の有害事象名が注入部位蒼白に修正された（M15-741 試験 CSR update Table 14.3__2.5.2）。治験薬との関連ありと判定された注入部位非感染反応は，79.9%（195 例）の被験者で報告された。注入部位非感染反応は，多くの被験者で重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-49）。

重篤な注入部位非感染反応が 0.8%（2 例）の被験者で報告され（表 2.7.4.7-49），注入部位血腫及び注入部位損傷が各 0.4%（1 例）であった（M15-741 試験 CSR update Table 14.3__1.12.10）。

なお，申請時データで重篤な注入部位損傷を発現した 2 例のうち 1 例で，注入部位損傷は同時に発現した注入部位膿瘍の症状の 1 つと判断され，当該事象の有害事象報告が取り下げられた。

注入部位非感染反応のために治験薬の投与が 8.2%（20 例）の被験者で中止された。致死的又は生命を脅かす注入部位非感染反応は報告されなかった（表 2.7.4.7-49）。

注入部位非感染反応は，多数の被験者で回復と報告された（M15-741 試験 CSR update Table 14.3__1.12.17）。

登録時期別での注入部位非感染反応は，Sample 1 で 88.5%（139/157 例），Sample 2 で 70.1%（61/87 例）の被験者で報告された（表 2.7.4-14）。

2.7.4.2.1.9.2.2 M15-737 試験

申請時

注入部位非感染反応は，被験者の 26.7%（28/105 例）で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位紅斑 12.4%（13 例）であった。注入部位結節は 1.9%（2 例）の被験者で報告された（表 2.7.4.7-22）。

重篤な注入部位非感染反応は，認められなかった。注入部位非感染反応の多くの重症度は軽度又は中等度であった。治験薬との関連ありと治験責任医師により判定された注入部位非感染反応は，24.8%（26 例）の被験者で報告された。治験薬の投与中止は 1.0%（1 例）の被験者で報告された。致死的又は生命を脅かす注入部位非感染反応は報告されなかった（表 2.7.4.7-17）。

注入部位非感染反応は，多数の被験者で回復と報告された（M15-737 試験 CSR Table 14.3__1.12.17）。

更新時

注入部位非感染反応は，被験者の 33.6%（39/116 例）で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位紅斑 16.4%（19 例）であった。注入部位結節は 4.3%（5 例）の被験者で報告された（表 2.7.4.7-54）。

重篤な注入部位非感染反応は，認められなかった。注入部位非感染反応の多くの重症度は軽度又は中等度であった。治験薬との関連ありと治験責任医師により判定された注入部位非感染反応は，31.9%（37 例）の被験者で報告された。治験薬の投与中止は 0.9%（1 例）の被験者で報告された。致死的又は生命を脅かす注入部位非感染反応は報告されなかった（表 2.7.4.7-50）。

注入部位非感染反応は，多数の被験者で回復と報告された（M15-737 試験 CSR update Table 14.3__1.12.17）。

2.7.4.2.1.9.2.3 M15-736 試験

注入部位非感染反応は，ABBV-951 投与群の 62.2%（46/74 例）及び CD/LD 経口投与群の 7.5%（5/67 例）の被験者で報告された。発現割合が 5%以上の有害事象（PT）は，CD/LD 経口投与群では認められず，ABBV-951 投与群で，注入部位紅斑が 27.0%（20 例），注入部位疼痛が

25.7%（19 例），注入部位浮腫が 12.2%（9 例），注入部位内出血，注入部位出血及び注入部位結節が各 8.1%（6 例），注入部位硬結及び注入部位そう痒感が各 5.4%（4 例）の被験者で報告された（表 2.7.4.7-18）。治験薬と関連ありの注入部位非感染反応は ABBV-951 投与群で 47.3%（35 例）及び CD/LD 経口投与群で 6.0%（4 例）であった（M15-736 試験 CSR Table 14.3__1.1.3）。各投与群の被験者のほとんどで，注入部位非感染反応は，重症度は軽度又は中等度であり，治療を行い又は治療を行うことなく回復し，治験薬に対する処置は行われなかった（M15-736 試験 CSR Table 14.3__1.1.3 及び Table 14.3__2.4）。

いずれの投与群でも，重篤な，致死的又は生命を脅かす注入部位非感染反応は報告されなかった（M15-736 試験 CSR Table 14.3__1.1.3）。

2.7.4.2.1.9.3 幻覚及び精神病

2.7.4.2.1.9.3.1 M15-741 試験

申請時

幻覚及び精神病は，被験者の 24.2%（59/244 例）で報告された。発現割合が 2%以上の有害事象（PT）は，幻覚が 16.8%（41 例），幻視が 6.1%（15 例），妄想が 4.1%（10 例），幻聴及び精神病性障害が各 2.5%（6 例）であった（表 2.7.4.7-23）。治験薬との関連ありと判定された幻覚及び精神病は，22.1%（54 例）の被験者で認められた。幻覚及び精神病は，多くの被験者で重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-16）。

重篤な幻覚及び精神病が 5.7%（14 例）の被験者で報告され，幻覚 2.9%（7 例），精神病性障害 2.5%（6 例），妄想 0.8%（2 例）及び妄想性障害、詳細不明 0.4%（1 例）であった（M15-741 試験 CSR Table 14.3__1.12.13）。治験薬の投与が 5.3%（13 例）の被験者で中止された。これらの有害事象はすべて，治験薬との関連ありと治験責任医師により判定された（M15-741 試験 CSR Table 14.3__2.5.5）。

致死的又は生命を脅かす幻覚及び精神病は報告されなかった（表 2.7.4.7-16）。幻覚及び精神病の転帰は，多数の被験者で回復と報告された（M15-741 試験 CSR Table 14.3__1.12.20）。

更新時

幻覚及び精神病は，被験者の 25.0%（61/244 例）で報告された。発現割合が 2%以上の有害事象（PT）は，幻覚が 17.2%（42 例），幻視が 6.1%（15 例），妄想が 4.1%（10 例），幻聴及び精神病性障害が各 2.5%（6 例）であった（表 2.7.4.7-55）。治験薬との関連ありと判定された幻覚及び精神病は，22.5%（55 例）の被験者で認められた。幻覚及び精神病は，多くの被験者で重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-49）。

重篤な幻覚及び精神病が 5.7%（14 例）の被験者で報告され，幻覚 2.9%（7 例），精神病性障害 2.5%（6 例），妄想 0.8%（2 例）及び妄想性障害、詳細不明 0.4%（1 例）であった（M15-741 試験 CSR update Table 14.3__1.12.13）。治験薬の投与が 5.3%（13 例）の被験者で中止された。

これらの有害事象はすべて，治験薬との関連ありと治験責任医師により判定された（M15-741 試験 CSR update Table 14.3__2.5.5）。

致死的又は生命を脅かす幻覚及び精神病は報告されなかった（表 2.7.4.7-49）。幻覚及び精神病の転帰は，多数の被験者で回復と報告された（M15-741 試験 CSR update Table 14.3__1.12.20）。

2.7.4.2.1.9.3.2 M15-737 試験

申請時

幻覚及び精神病は，被験者の 9.5%（10/105 例）で報告された。発現割合が 2%以上の有害事象（PT）は，幻覚 6.7%（7 例）であった（表 2.7.4.7-24）。重篤な幻覚及び精神病は，1.9%（2 例）の被験者で認められ，精神病性障害が 1.9%（2 例）及び幻覚が 1.0%（1 例）であり（M15-737 試験 CSR Table 14.3__1.12.13），治験薬との関連ありと判定され，回復と報告された。重症度は，ほとんどの被験者で軽度又は中等度であった。治験薬との関連ありと治験責任医師により判定された幻覚及び精神病は，6.7%（7 例）の被験者で報告された。治験薬の投与が中止された被験者の報告はなかった（表 2.7.4.7-17）。

半数を超える幻覚及び精神病の転帰が回復と報告された（M15-737 試験 CSR Table 14.3__1.12.20）。

更新時

幻覚及び精神病は，被験者の 13.8%（16/116 例）で報告された。発現割合が 2%以上の有害事象（PT）は，幻覚 7.8%（9 例）であった（表 2.7.4.7-56）。重篤な幻覚及び精神病は，1.7%（2 例）の被験者で認められ，精神病性障害が 1.7%（2 例）及び幻覚が 0.9%（1 例）であり（M15-737 試験 CSR update Table 14.3__1.12.13），治験薬との関連ありと判定され，回復と報告された。重症度は，ほとんどの被験者で軽度又は中等度であった。治験薬との関連ありと治験責任医師により判定された幻覚及び精神病は，9.5%（11 例）の被験者で報告された。治験薬の投与が中止された被験者の報告はなかった（表 2.7.4.7-50）。

幻覚及び精神病の有害事象の 41.7%が回復と報告された（M15-737 試験 CSR update Table 14.3__1.12.20）。

2.7.4.2.1.9.3.3 M15-736 試験

幻覚及び精神病は，ABBV-951 投与群の 14.9%（11/74 例）及び CD/LD 経口投与群の 3.0%（2/67 例）で報告された。ABBV-951 投与群の幻覚及び精神病を有する 11 例のうち 6 例がドパミンアゴニストを服用し，二重盲検期間中も併用していた（M15-736 試験 CSR Table 14.3__1.11.1.1 及び Appendix 16.2__7.6.2）。発現割合が 2%以上の有害事象（PT）は，CD/LD 経口投与群では認められず，ABBV-951 投与群で，幻覚 6.8%（5 例），幻視 5.4%（4 例），精神病性障害 4.1%（3 例）であった（表 2.7.4.7-18）。治験薬と関連ありの幻覚及び精神病は ABBV-951 投与群で 12.2%（9 例）及び CD/LD 経口投与群で 3.0%（2 例）であった（M15-736 試験 CSR Table 14.3__1.1.3）。

68

重篤な幻覚及び精神病が，ABBV-951 投与群の 1.4%（1 例）で報告された（M15-736 試験 CSR Table 14.3__1.1.3）。有害事象は，妄想，妄想症及び精神病性障害であった。これらの有害事象により入院し，その後回復した（M15-736 試験 CSR Table 14.3__1.9.2.1）。

いずれの投与群でも，致死的又は生命を脅かす幻覚及び精神病は報告されなかった（M15-736 試験 CSR Table 14.3__1.1.3）。

幻覚及び精神病の発現割合は，CD/LD 経口投与群よりも ABBV-951 投与群の方が高かったが，これらの有害事象のほとんどは，重篤ではなく，重症度は軽度又は中等度であり，治験薬に対する処置は行われなかった（M15-736 試験 CSR Table 14.3__1.1.3 及び Table 14.3__2.4）。

2.7.4.2.1.9.4 多発ニューロパチー

2.7.4.2.1.9.4.1 M15-741 試験

申請時

多発ニューロパチーは，3.3%（8/244 例）の被験者で報告された（表 2.7.4.7-25）。すべての多発ニューロパチーは，重篤ではなく，重症度はほとんどの被験者で軽度又は中等度であった。治験薬との関連ありの有害事象は 1.6%（4 例）の被験者で認められた。治験薬の投与中止はなく，致死的又は生命を脅かす多発ニューロパチーも報告されなかった（表 2.7.4.7-16）。

更新時

多発ニューロパチーは，3.3%（8/244 例）の被験者で報告された（表 2.7.4.7-57）。すべての多発ニューロパチーは，重篤ではなく，重症度はほとんどの被験者で軽度又は中等度であった。治験薬との関連ありの有害事象は 1.6%（4 例）の被験者で認められた。治験薬の投与中止はなく，致死的又は生命を脅かす多発ニューロパチーも報告されなかった（表 2.7.4.7-49）。

2.7.4.2.1.9.4.2 M15-737 試験

申請時

多発ニューロパチーは，報告されなかった（M15-737 試験 CSR Table 14.3__1.12.4）。

更新時

多発ニューロパチーは，報告されなかった（M15-737 試験 CSR update Table 14.3__1.12.4）。

2.7.4.2.1.9.4.3 M15-736 試験

多発ニューロパチーは，ABBV-951 投与群では認められず，CD/LD 経口投与群の 1.5%（1/67 例）の被験者で報告された（M15-736 試験 CSR Table 14.3__1.1.3）。

69

2.7.4.2.1.9.5 転倒及び関連する損傷

2.7.4.2.1.9.5.1 M15-741 試験

転倒及び関連する損傷

申請時

転倒及び関連する損傷は，被験者の 16.8%（41/244 例）で報告された。発現割合が 2%以上の有害事象（PT）は，転倒 16.0%（39 例），挫傷 3.3%（8 例）及び皮膚裂傷 2.9%（7 例）であった（表 2.7.4.7-26）。転倒及び関連する損傷は，多くの被験者で重篤ではなく，重症度は軽度又は中等度であった。また，治験薬の投与中止の報告はなかった（表 2.7.4.7-16）。治験薬と関連ありと判定された転倒及び関連する損傷は，4.1%（10 例）の被験者で報告された。

重篤な転倒及び関連する損傷が 0.8%（2 例）の被験者で報告され，1 例が転倒，もう 1 例が転倒及び顔面損傷であった（M15-741 試験 CSR Table 14.3__1.12.15）。

転倒後の脳圧排効果及び硬膜下血腫による死亡が 1 例報告されたが，当該被験者は，高血圧，うつ病，関節炎，両側の膝置換術及び日中の傾眠の病歴を有しており，ベッドから出ようとしたときに転倒したため，重篤ではなく，また，治験薬との関連なしと判定された（M15-741 試験 CSR Section 14.3__3）。死亡例の詳細は，2.7.6 項に示した。

多くの転倒及び関連する損傷の転帰は，回復と報告された（M15-741 試験 CSR Table 14.3__1.12.22）。

更新時

転倒及び関連する損傷は，被験者の 17.2%（42/244 例）で報告された。発現割合が 2%以上の有害事象（PT）は，転倒 16.4%（40 例），挫傷 3.3%（8 例），皮膚裂傷 2.9%（7 例）及び頭部損傷 2.0%（5 例）であった（表 2.7.4.7-58）。転倒及び関連する損傷は，多くの被験者で重篤ではなく，重症度は軽度又は中等度であった。また，治験薬の投与中止の報告はなかった（表 2.7.4.7-49）。治験薬と関連ありと判定された転倒及び関連する損傷は，4.1%（10 例）の被験者で報告された。

重篤な転倒及び関連する損傷が 0.8%（2 例）の被験者で報告され，1 例が転倒，もう 1 例が転倒及び顔面損傷であった（M15-741 試験 CSR update Table 14.3__1.12.15）。

転倒後の脳圧排効果及び硬膜下血腫による死亡が 1 例報告された。当該死亡例は申請時と同一であり，申請時データカットオフ以降に死亡した被験者はいなかった（M15-741 試験 CSR update Section 14.3__3）。死亡例の詳細は，2.7.6 項に示した。

多くの転倒及び関連する損傷の転帰は，回復と報告された（M15-741 試験 CSR update Table 14.3__1.12.22）。

起立性低血圧

申請時

起立性低血圧は，16.0%（39/244 例）の被験者で報告された。発現割合が 2%以上の有害事象（PT）は，浮動性めまい 10.2%（25 例），起立性低血圧 4.9%（12 例）及び体位性めまい 2.0%（5 例）であった（M15-741 試験 CSR Table 14.3__1.12.8）。多数の被験者では，起立性低血圧は重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-16）。

重篤な起立性低血圧は，0.8%（2 例）で発現し，起立性低血圧及び浮動性めまい（転倒と同時）が各 1 例であった（M15-741 試験 CSR Table 14.3__1.12.15）。

更新時

起立性低血圧は，16.4%（40/244 例）の被験者で報告された。発現割合が 2%以上の有害事象（PT）は，浮動性めまい 10.2%（25 例），起立性低血圧 5.3%（13 例）及び体位性めまい 2.0%（5 例）であった（表 2.7.4.7-58）。多数の被験者では，起立性低血圧は重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-49）。

重篤な起立性低血圧は，0.8%（2 例）で発現し，起立性低血圧及び浮動性めまい（転倒と同時）が各 1 例であった（M15-741 試験 CSR update Table 14.3__1.12.15）。

2.7.4.2.1.9.5.2 M15-737 試験

転倒及び関連する損傷

申請時

転倒及び関連する損傷は，被験者の 13.3%（14/105 例）で報告された。発現割合が 2%以上の有害事象（PT）は，転倒 11.4%（12 例）であった（表 2.7.4.7-27）。治験薬と関連ありと判定された転倒及び関連する損傷は，1.0%（1 例）の被験者で報告された。転倒及び関連する損傷は，多くの被験者で重篤ではなく，重症度も軽度又は中等度であった。治験薬の投与中止の報告もなかった。また，致死的又は生命を脅かす転倒及び関連する損傷も報告されなかった（表 2.7.4.7-17）。

重篤な転倒及び関連する損傷は，4.8%（5 例）の被験者で報告され，転倒及び股関節部骨折が各 1.9%（2 例），転位骨折及び肩甲骨骨折が各 1.0%（1 例）であった（M15-737 試験 CSR Table 14.3__1.12.15）。

転倒及び関連する損傷の転帰は，多くの被験者で回復と報告された（M15-737 試験 CSR Table 14.3__1.12.22）。

更新時

転倒及び関連する損傷は，被験者の 16.4%（19/116 例）で報告された。発現割合が 2%以上の有害事象（PT）は，転倒 12.1%（14 例）及び手骨折 2.6%（3 例）であった（表 2.7.4.7-59）。治験薬と関連ありと判定された転倒及び関連する損傷は，1.7%（2 例）の被験者で報告された。転倒及び関連する損傷は，多くの被験者で重篤ではなく，重症度も軽度又は中等度であった。治

験薬の投与中止の報告もなかった。また，致死的又は生命を脅かす転倒及び関連する損傷も報告されなかった（表 2.7.4.7-50）。

重篤な転倒及び関連する損傷は，6.0%（7 例）の被験者で報告され，転倒 2.6%（3 例），股関節部骨折 1.7%（2 例），大腿骨頚部骨折，大腿骨骨折，転位骨折，上腕骨骨折，肩甲骨骨折及び外傷性頭蓋内出血が各 0.9%（1 例）であった（M15-737 試験 CSR update Table 14.3__1.12.15）。

転倒及び関連する損傷の転帰は，多くの被験者で回復と報告された（M15-737 試験 CSR update Table 14.3__1.12.22）。

起立性低血圧

申請時

起立性低血圧は，2.9%（3/105 例）の被験者で報告された。有害事象（PT）は，起立性低血圧及び失神が各 1.9%（2 例）であった（M15-737 試験 CSR Table 14.3__1.12.8）。すべての起立性低血圧は重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-17）。

更新時

起立性低血圧は，5.2%（6/116 例）の被験者で報告された。有害事象（PT）は，起立性低血圧 2.6%（3 例），浮動性めまい及び失神が各 1.7%（2 例）であった（表 2.7.4.7-59）。すべての起立性低血圧は重篤ではなく，重症度は軽度又は中等度であった（表 2.7.4.7-50）。

2.7.4.2.1.9.5.3 M15-736 試験

転倒及び関連する損傷

転倒及び関連する損傷は，ABBV-951 投与群の 12.2%（9/74 例）及び CD/LD 経口投与群の 22.4%（15/67 例）の被験者で報告された。発現割合が 2%以上の有害事象（PT）は，ABBV-951 投与群で，転倒が 8.1%（6 例），挫傷及び皮膚裂傷が各 2.7%（2 例）であり，CD/LD 経口投与群で転倒が 17.9%（12 例）及び靭帯捻挫が 3.0%（2 例）であった（表 2.7.4.7-18）。

起立性低血圧

起立性低血圧は，ABBV-951 投与群の 5.4%（4/74 例）及び CD/LD 経口投与群の 7.5%（5/67 例）の被験者で報告された。発現割合が 2%以上の有害事象（PT）は，ABBV-951 投与群で，浮動性めまいが 4.1%（3 例）であり，CD/LD 経口投与群で浮動性めまいが 4.5%（3 例）及び起立性低血圧が 3.0%（2 例）であった（表 2.7.4.7-18）。

ABBV-951 投与群では，重篤な転倒及び関連する損傷並びに起立性低血圧は認められなかったが，CD/LD 経口投与群で 1.5%（1 例）認められた（M15-736 試験 CSR Table 14.3__1.1.3 及び Table 14.3__1.9.2.1）。各投与群の当該有害事象の重症度は，多くが軽度又は中等度であった（M15-736 試験 CSR Table 14.3__1.1.3）。

治験薬と関連ありと判定された転倒及び関連する損傷並びに起立性低血圧は，ABBV-951 投与群の 5.4%（4 例）及び CD/LD 経口投与群の 6.0%（4 例）の被験者で報告された。治験薬の投与中止は，ABBV-951 投与群で 1.4%（1 例）の被験者で報告された（M15-736 試験 CSR Table 14.3__1.1.3）。

2.7.4.2.1.9.6 傾眠

2.7.4.2.1.9.6.1 M15-741 試験

申請時

傾眠は，被験者の 4.9%（12/244 例）で報告された（表 2.7.4.7-28）。重症度は，12 例の被験者すべてが軽度又は中等度であった。治験薬との関連ありと判定された傾眠は 3.3%（8 例）の被験者で認められた（表 2.7.4.7-16）。傾眠の転帰は，多数の被験者で回復と報告された（M15-741 試験 CSR Table 14.3__1.12.21）。傾眠に関して，重篤な有害事象も投与中止に至った有害事象も認められず，また，致死的又は生命を脅かす有害事象も認められなかった（表 2.7.4.7-16）。

更新時

傾眠は，被験者の 4.9%（12/244 例）で報告された（表 2.7.4.7-60）。重症度は，12 例の被験者すべてが軽度又は中等度であった。治験薬との関連ありと判定された傾眠は 3.3%（8 例）の被験者で認められた（表 2.7.4.7-49）。傾眠の転帰は，多数の被験者で回復と報告された（M15-741 試験 CSR update Table 14.3__1.12.21）。傾眠に関して，重篤な有害事象も投与中止に至った有害事象も認められず，また，致死的又は生命を脅かす有害事象も認められなかった（表 2.7.4.7-49）。

2.7.4.2.1.9.6.2 M15-737 試験

申請時

傾眠は，報告されなかった（M15-737 試験 CSR Table 14.3__1.12.7）。

更新時

傾眠は，報告されなかった（M15-737 試験 CSR update Table 14.3__1.12.7）。

2.7.4.2.1.9.6.3 M15-736 試験

傾眠は，ABBV-951 投与群の 1.4%（1/74 例）及び CD/LD 経口投与群の 1.5%（1/67 例）で報告された（表 2.7.4.7-18）。いずれの投与群でも，重症度は軽度であり，重篤ではなかった。ABBV-951 投与群で報告された傾眠 1 例は，治験責任医師により治験薬との関連ありと判定され

た（M15-736 試験 CSR Table 14.3__1.1.3，Table 14.3__1.4 及び Table 14.3__1.5）。転帰は回復と報告され，治験薬に対する処置は行われなかった（M15-736 試験 CSR Table 14.3__2.4）。

2.7.4.2.1.9.7 体重減少

2.7.4.2.1.9.7.1 M15-741 試験

申請時

体重減少は，10.2%（25/244 例）の被験者で報告された（表 2.7.4.7-29）。最も多く報告された有害事象（PT）は，体重減少 9.0%（22 例）であった。重症度は，重度の 1 例を除くすべての被験者で軽度又は中等度であり，6.6%（16 例）の被験者が治験薬と関連ありと判定された（表 2.7.4.7-16）。体重減少の転帰は，ほぼ半数の被験者で回復と報告された（M15-741 試験 CSR Table 14.3__1.12.19）。体重減少に関して，重篤な有害事象も投与中止に至った有害事象も，また，致死的又は生命を脅かす有害事象も報告されなかった（表 2.7.4.7-16）。

更新時

体重減少は，11.1%（27/244 例）の被験者で報告された（表 2.7.4.7-61）。最も多く報告された有害事象（PT）は，体重減少 9.8%（24 例）であった。重症度は，重度の 1 例を除くすべての被験者で軽度又は中等度であり，6.6%（16 例）の被験者が治験薬と関連ありと判定された（表 2.7.4.7-49）。体重減少の転帰は，ほぼ半数の被験者で回復と報告された（M15-741 試験 CSR update Table 14.3__1.12.19）。体重減少に関して，重篤な有害事象も投与中止に至った有害事象も，また，致死的又は生命を脅かす有害事象も報告されなかった（表 2.7.4.7-49）。

2.7.4.2.1.9.7.2 M15-737 試験

申請時

体重減少は，3.8%（4/105 例）の被験者で報告され，報告された有害事象（PT）は，体重減少 2.9%（3 例）及び嚥下障害 1.0%（1 例）であった（表 2.7.4.7-30）。重症度は，いずれも軽度であり，1.9%（2 例）の被験者が治験薬と関連ありと判定された。また，重篤な有害事象及び治験薬の投与中止の報告はなかった（表 2.7.4.7-17）。

更新時

体重減少は，5.2%（6/116 例）の被験者で報告され，報告された有害事象（PT）は，体重減少及び嚥下障害が各 2.6%（3 例），食欲減退 0.9%（1 例）であった（表 2.7.4.7-62）。重症度は，重度の 1 例を除き，いずれも軽度又は中等度であり，1.7%（2 例）の被験者が治験薬と関連ありと判定された。また，重篤な有害事象（嚥下障害）が 1 例（0.9%）報告されたが，治験薬の投与中止の報告はなかった（表 2.7.4.7-50）。

2.7.4.2.1.9.7.3 M15-736 試験

体重減少は，ABBV-951 投与群の 1.4%（1/74 例）及び CD/LD 経口投与群の 1.5%（1/67 例）の被験者で報告された。ABBV-951 投与群の有害事象（PT）は，体重減少及び食欲減退であり，CD/LD 経口投与群では，食欲減退であった（表 2.7.4.7-18）。いずれの投与群でも，重症度は軽度又は中等度であり，重篤ではなく，治験薬に対する処置は行われなかった。ABBV-951 投与群の体重減少は，治験責任医師により治験薬との関連ありと判定された（M15-736 試験 CSR Table 14.3__1.4，Table 14.3__2.4 及び Table 14.3__1.5）。

2.7.4.2.1.9.8 COVID-19 に関連する有害事象

2.7.4.2.1.9.8.1 M15-741 試験

申請時

COVID-19 に関連する有害事象（PT）は，1.2%（3/244 例）の被験者で報告された。これらのうち 1 例の有害事象は，重度で，重篤であり，治験責任医師により治験薬との関連なしと判定された（M15-741 試験 CSR Table 14.3__1.14.1 及び CSR Table 14.3__1.14.5）。

更新時

COVID-19 に関連する有害事象（PT）は，1.2%（3/244 例）の被験者で報告された。これらのうち 1 例の有害事象は，重度で，重篤であり，治験責任医師により治験薬との関連なしと判定された（M15-741 試験 CSR update Table 14.3__1.14.1 及び CSR update Table 14.3__1.14.5）。

2.7.4.2.1.9.8.2 M15-737 試験

申請時

COVID-19 に関連する有害事象（PT）は，1.0%（1/105 例）の被験者で報告された。当該有害事象は，中等度で，重篤ではなかった。また，治験責任医師により治験薬との関連なしと判定された（M15-737 試験 CSR Table 14.3__1.14.1 及び CSR Table 14.3__1.14.5）。

更新時

COVID-19 に関連する有害事象（PT）は，6.0%（7/116 例）の被験者で報告された。重篤な有害事象は 2 例（1.7%）報告された。他のすべての有害事象は，軽度又は中等度で，重篤ではなかった。また，すべての当該有害事象は，治験責任医師により治験薬との関連なしと判定された（M15-737 試験 CSR update Table 14.3__1.14.1 及び CSR update Table 14.3__1.14.5）。

2.7.4.2.1.9.8.3 M15-736 試験

COVID-19 に関連する有害事象（PT）は，CD/LD 経口投与群で 1.5%（1 例）の被験者で報告された（M15-736 試験 CSR Table 14.3__1.16.1）。有害事象は，COVID-19 肺炎であり，重症度

は中等度であり，重篤であった。治験責任医師により治験薬と関連なしと判定された（M15-736 試験 CSR Table 14.3__1.3.2.1，Table 14.3__1.4 及び Table 14.3__1.5）。

2.7.4.2.2 個別有害事象の文章による説明

M15-741，M15-737 及び M15-736 試験での死亡例及び重篤な有害事象発現例の詳細（叙述）は，2.7.6 項及び各試験の CSR（M15-741 試験：Section 14.3__3，M15-737 試験：Section 14.3__3，M15-736 試験：Section 14.3__3）及び CSR update（M15-741 試験：Section 14.3__3，M15-737 試験：Section 14.3__3）に示す。

2.7.4.3 臨床検査値の評価

2.7.4.3.1 M15-741 試験

申請時

ヘマトクリット，ヘモグロビン及び血小板のベースラインからの平均変化量は小さく，臨床的意義のある変化とは考えられなかった。他の血液学的検査パラメータについても一貫した又は臨床的に関連する所見を認められなかった（M15-741 試験 CSR Table 14.3__4.1.1）。

肝トランスアミナーゼ，アルカリホスファターゼ又はビリルビンのベースラインからの平均変化量に一貫した又は臨床的に関連する所見はなかった（M15-741 試験 CSR Table 14.3__4.1.2）。尿検査のベースラインからの平均変化量にも，臨床的に意義のある変化はなかった（M15-741 試験 CSR Table 14.3__4.1.3）。Hy's law の基準を満たす被験者はいなかった。

多発ニューロパチーの危険因子であると報告されているため，特別な臨床検査パラメータ（ビタミン B_{12}，ビタミン B_6，メチルマロン酸，ホモシステイン及び葉酸）が評価された。ベースラインからの平均変化量に一貫した又は臨床的に関連する所見はなかった（M15-741 試験 CSR Table 14.3__4.1.4）。

更新時

ヘマトクリット，ヘモグロビン及び血小板のベースラインからの平均変化量は小さく，臨床的意義のある変化とは考えられなかった。他の血液学的検査パラメータについても一貫した又は臨床的に関連する所見は認められなかった（M15-741 試験 CSR update Table 14.3__4.1.1）。

肝トランスアミナーゼ，アルカリホスファターゼ又はビリルビンのベースラインからの平均変化量に一貫した又は臨床的に関連する所見はなかった（M15-741 試験 CSR update Table 14.3__4.1.2）。尿検査のベースラインからの平均変化量にも，臨床的に意義のある変化はなかった（M15-741 試験 CSR update Table 14.3__4.1.3）。Hy's law の基準に該当する被験者はいなかった。

多発ニューロパチーの危険因子であると報告されているため，特別な臨床検査パラメータ（ビタミン B_{12}，ビタミン B_6，メチルマロン酸，ホモシステイン及び葉酸）が評価された。ベー

スラインからの平均変化量に一貫した又は臨床的に関連する所見はなかった（M15-741 試験 CSR update Table 14.3__4.1.4）。

2.7.4.3.2 M15-737 試験

申請時

中間報告のデータカットオフ（20[redacted] 年 [redacted] 月 [redacted] 日）時点で，臨床検査値が収集された最初の時点の 24 週目の評価を 68 例の被験者が完了した。現時点のデータの検討から，臨床検査値の変動に傾向は認められず，安全性の懸念も特定されなかった（M15-737 試験 CSR Table 14.3__4.1.1, Table 14.3__4.1.2, Table 14.3__4.1.3 及び Table 14.3__4.1.4）。

更新時

申請後に更新した CSR（CSR update）のデータカットオフ（20[redacted] 年 [redacted] 月 [redacted] 日）時点で，血液学的検査，血液生化学検査，尿検査及び特別な臨床検査パラメータのベースラインからの臨床的に意義のある変化は認められず，また，安全性の懸念も特定されなかった（M15-737 試験 CSR update Table 14.3__4.1.1，Table 14.3__4.1.2，Table 14.3__4.1.3 及び Table 14.3__4.1.4）。

2.7.4.3.3 M15-736 試験

ABBV-951 投与群及び CD/LD 経口投与群のいずれの投与群でも，血液学的検査，血液生化学検査，尿検査及び特別な臨床検査パラメータ（ビタミン B_{12}，ビタミン B_6，メチルマロン酸，ホモシステイン及び葉酸）のベースラインからの臨床的に意義のある変化は認められなかった。また，安全性の懸念も認められなかった（M15-736 試験 CSR Table 14.3__4.1.1，Table 14.3__4.1.2，Table 14.3__4.1.3 及び Table 14.3__4.1.4）。

2.7.4.4 バイタルサイン，身体的所見及び安全性に関連する他の観察項目

2.7.4.4.1 バイタルサイン

申請時

M15-741 及び M15-737 試験では，ベースラインから投与期間中のバイタルサインの変化量は小さく，臨床的に意義のある変化は認められなかった（M15-741 試験 CSR Table 14.3__4.5.1 及び M15-737 試験 CSR Table 14.3__4.5.1）。また，M15-736 試験では，ABBV-951 投与群及び CD/LD 経口投与群のいずれでも投与期間中のバイタルサインのベースラインからの経時的な変化量は小さく，臨床的に意義のある変化は認められなかった（M15-736 試験 CSR Table 14.3__5.1.1）。

更新時

M15-741 及び M15-737 試験では，ベースラインから投与期間中のバイタルサインの変化量は小さく，臨床的に意義のある変化は認められなかった（M15-741 試験 CSR update Table 14.3__4.5.1 及び M15-737 試験 CSR update Table 14.3__4.5.1）。また，M15-736 試験では，ABBV-951 投与群及び CD / LD 経口投与群のいずれでも投与期間中のバイタルサインのベースラインからの経時的な変化量は小さく，臨床的に意義のある変化は認められなかった（M15-736 試験 CSR Table 14.3__5.1.1）。

2.7.4.4.2 心電図

申請時

ベースラインから投与期間中の ECG パラメータの変化量に臨床的に意義のある変化は認められなかった（M15-741 試験 CSR Table 14.3__4.6.1，M15-737 試験 CSR Table 14.3__4.6.1 及び M15-736 試験 CSR Table 14.3__6.1.1）。

更新時

ベースラインから投与期間中の ECG パラメータの変化量に臨床的に意義のある変化は認められなかった（M15-741 試験 CSR update Table 14.3__4.6.1，M15-737 試験 CSR update Table 14.3__4.6.1 及び M15-736 試験 CSR Table 14.3__6.1.1）。

2.7.4.4.3 自殺傾向

申請時

M15-741 試験では，C-SSRS の結果から，自殺念慮が 27 例（11.1%），自傷行為が 1 例（0.4%）示された（M15-741 試験 CSR Table 14.3__4.9.1）。非重篤の自殺念慮が 3 例（1.2%）報告され（M15-741 試験 CSR Table 14.3__1.2），重篤な有害事象である自殺企図が 1 例（0.4%）報告された（M15-741 試験 CSR Table 14.3__1.11.1）。自殺企図は，治験責任医師により治験薬との関連なしと判定された（M15-741 試験 CSR Table 14.3__1.6）。これらの有害事象はいずれも治験薬の投与は中止されなかった（M15-741 試験 CSR Table 14.3__1.8.1）。重篤な有害事象の詳細は，2.7.6 項に記載した。有害事象及び現在の C-SSRS データの検討から，ABBV-951 による自殺傾向の増加のエビデンスは認められなかった。

M15-737 試験では，C-SSRS の結果から，自殺念慮が 2 例（1.9%）報告された（M15-737 試験 CSR Table 14.3__4.9.1）。自殺念慮又は自殺行動の有害事象は報告されなかった（M15-737 試験 CSR Table 14.3__1.2）。C-SSRS データの検討から，ABBV-951 による自殺傾向の増加のエビデンスは認められなかった。

M15-736 試験では，C-SSRS の結果から，ABBV-951 投与群で自殺念慮が 5 例（6.8%）報告され，CD/LD 経口投与群で自殺念慮が 2 例（3.0%）報告された（M15-736 試験 CSR Table 14.3__9.1）。いずれの投与群でも自殺念慮又は自殺行為に関する有害事象は報告されなかった

（M15-736 試験 CSR Table 14.3__1.3.1.1）。C-SSRS データの検討から，ABBV-951 による自殺の増加のエビデンスは認められなかった。

更新時

M15-741 試験では，C-SSRS の結果から，自殺念慮が 28 例（11.5%），自傷行為が 1 例（0.4%）示された（M15-741 試験 CSR update Table 14.3__4.9.1）。非重篤の自殺念慮が 3 例（1.2%）報告され（M15-741 試験 CSR update Table 14.3__1.2），重篤な有害事象である自殺企図が 1 例（0.4%）報告された（M15-741 試験 CSR update Table 14.3__1.11.1）。自殺企図は，治験責任医師により治験薬との関連なしと判定された（M15-741 試験 CSR update Table 14.3__1.6）。これらの有害事象はいずれも治験薬の投与は中止されなかった（M15-741 試験 CSR update Table 14.3__1.8.1）。重篤な有害事象の詳細は，2.7.6 項に記載した。有害事象及び現在の C-SSRS データの検討から，ABBV-951 による自殺傾向の増加のエビデンスは認められなかった。

M15-737 試験では，C-SSRS の結果から，自殺念慮が 3 例（2.6%）報告された（M15-737 試験 CSR update Table 14.3__4.9.1）。自殺念慮又は自殺行動の有害事象は報告されなかった（M15-737 試験 CSR update Table 14.3__1.2）。C-SSRS データの検討から，ABBV-951 による自殺傾向の増加のエビデンスは認められなかった。

M15-736 試験では，C-SSRS の結果から，ABBV-951 投与群で自殺念慮が 5 例（6.8%）報告され，CD / LD 経口投与群で自殺念慮が 2 例（3.0%）報告された（M15-736 試験 CSR Table 14.3__9.1）。いずれの投与群でも自殺念慮又は自殺行為に関する有害事象は報告されなかった（M15-736 試験 CSR Table 14.3__1.3.1.1）。C-SSRS データの検討から，ABBV-951 による自殺の増加のエビデンスは認められなかった。

2.7.4.5 特別な患者集団及び状況下における安全性

2.7.4.5.1 日本人部分集団における安全性

2.7.4.5.1.1 全般的な曝露状況

2.7.4.5.1.1.1 M15-741 試験

申請時

本試験では，日本人被験者 27 例に治験薬が投与され，治験薬の投与が 15 例（55.6%）の被験者で中止され，52 週間の投与期間を完了したのは，11 例（40.7%）の被験者であった。安全性解析対象集団は，27 例であった（M15-741 試験 CSR Japan Study Data Table 14.1__1.1.1.J）。

登録時期について，Sample 1（20[redacted]年[redacted]月[redacted]日より前に登録された）の被験者数は 18 例であり，治験薬の投与を完了した被験者の割合は全体で 18.5%（5 例），現在投与中の被験者はおらず，治験薬の投与中止は 48.1%（13 例）であった。一方，Sample 2（20[redacted]年[redacted]月[redacted]日以降に登録された）の被験者数は 9 例であり，治験薬の投与を完了した被験者の割合は全体で 22.2%（6 例），投与継続中は 3.7%（1 例），治験薬の投与中止は 7.4%（2 例）であった（M15-741 試験 CSR Japan Study Data Table 14.1__1.1.1.J）。

日本人部分集団の被験者が治験薬に曝露された平均日数は，投与の中断を含めたときに 199.2 日，投与の中断を除いたときに 188.3 日であった。被験者の 44.4%（12/27 例）は，治験薬の中断期間の包含・除外に関わらず，治験薬に 274 日以上曝露され，治験薬の中断を含めると被験者の約 63%，治験薬の中断を除くと被験者の約 59%が 92 日以上曝露された。被験者の 51.9%（14 例）が投与の中断を含めて少なくとも 6 ヵ月間（180 日）ABBV-951 に曝露され，被験者の 44.4%（12 例）が投与の中断を除いて少なくとも 6 ヵ月間 ABBV-951 に曝露された（表 2.7.4.7-31）。

なお，LD の 1 日あたりの投与量（負荷量及び救済療法を含む）を表 2.7.4.7-32 に示す。

更新時

本試験では，日本人被験者 27 例に治験薬が投与され，治験薬の投与が 15 例（55.6%）の被験者で中止され，52 週間の投与期間を完了したのは，12 例（44.4%）の被験者であった。安全性解析対象集団は，27 例であった（M15-741 試験 CSR update Table 14.1__1.1.1.J）。

登録時期について，Sample 1（20[redacted]年[redacted]月[redacted]日より前に登録された）の被験者数は 18 例であり，治験薬の投与を完了した被験者の割合は全体で 18.5%（5 例），現在投与中の被験者はおらず，治験薬の投与中止は 48.1%（13 例）であった。一方，Sample 2（20[redacted]年[redacted]月[redacted]日以降に登録された）の被験者数は 9 例であり，治験薬の投与を完了した被験者の割合は全体で 25.9%（7 例），投与中の被験者はおらず，治験薬の投与中止は 7.4%（2 例）であった（M15-741 試験 CSR update Table 14.1__1.1.1.J）。

日本人部分集団の被験者が治験薬に曝露された平均日数は，投与の中断を含めたときに 200.7 日，投与の中断を除いたときに 189.8 日であった。被験者の 44.4%（12/27 例）は，治験薬の中断期間の包含・除外に関わらず，治験薬に 274 日以上曝露され，治験薬の中断を含めると被験者の約 63%，治験薬の中断を除くと被験者の約 59%が 92 日以上曝露された。被験者の 51.9%（14 例）が投与の中断を含めて少なくとも 6 ヵ月間（180 日）ABBV-951 に曝露され，被験者の 44.4%（12 例）が投与の中断を除いて少なくとも 6 ヵ月間 ABBV-951 に曝露された（表 2.7.4.7-63）。

なお，LD の 1 日あたりの投与量（負荷量及び救済療法を含む）を表 2.7.4.7-64 に示す。

2.7.4.5.1.1.2 M15-737 試験

申請時

本試験では，日本人被験者 11 例に治験薬が投与され，投与継続中は 10 例（90.9%），投与中止が 1 例（9.1%）であった。安全性解析対象集団は，11 例であった（M15-737 試験 CSR Japan Study Data Table 14.1__1.1.J）。

日本人部分集団の被験者が治験薬に曝露された平均日数は，投与の中断を含めたときに 185.5 日，投与の中断を除いたときに 185.4 日であった。治験薬の中断期間の包含・除外に関わらず，被験者の 45.5%（5 例）は，治験薬に 169 日以上曝露された（表 2.7.4.7-33）。

なお，LD の 1 日あたりの投与量（負荷量及び救済療法を含む）を表 2.7.4.7-34 に示す。

更新時

本試験では，日本人被験者 12 例に治験薬が投与され，投与継続中は 11 例（91.7%），投与中止が 1 例（8.3%）であった。安全性解析対象集団は，12 例であった（M15-737 試験 CSR update Table 14.1__1.1.J）。

日本人部分集団の被験者が治験薬に曝露された平均日数は，投与の中断を含めたときに 274.1 日，投与の中断を除いたときに 274.0 日であった。治験薬の中断期間の包含・除外に関わらず，被験者の 58.3%（7 例）は，治験薬に 169 日以上曝露された（表 2.7.4.7-65）。

なお，LD の 1 日あたりの投与量（負荷量及び救済療法を含む）を表 2.7.4.7-66 に示す。

2.7.4.5.1.2 有害事象

2.7.4.5.1.2.1 M15-741 試験

申請時

日本人部分集団（27 例）での有害事象の発現割合は，すべての有害事象が 92.6%（25 例），重篤な有害事象が 25.9%（7 例），死亡に至った有害事象はなく，投与中止に至った有害事象が 25.9%（7 例），治験薬と関連ありの有害事象が 92.6%（25 例）及び治験薬又は治験機器の不具合に関連した有害事象が 74.1%（20 例）であった（表 2.7.4-18）。

登録時期別の有害事象の発現割合は，Sample 1（18 例）で，すべての有害事象が 94.4%（17 例），重篤な有害事象が 27.8%（5 例），死亡に至った有害事象はなく，投与中止に至った有害事象が 33.3%（6 例），治験薬と関連ありの有害事象が 94.4%（17 例）及び治験薬又は治験機器の不具合に関連した有害事象が 77.8%（14 例）であった。また，Sample 2（9 例）では，すべての有害事象が 88.9%（8 例），重篤な有害事象が 22.2%（2 例），死亡に至った有害事象はなく，投与中止に至った有害事象が 11.1%（1 例），治験薬と関連ありの有害事象が 88.9%（8 例）及び治験薬又は治験機器の不具合に関連した有害事象が 66.7%（6 例）であった（表 2.7.4.7-35）。

更新時

日本人部分集団（27 例）での有害事象の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.1.J，及び Table 14.3__1.5.1.J）。

表 2.7.4-18. 有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-741 試験

	Japan		
	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period	N=22	N=5	N=27
Subjects with:			
Any TEAE	20 (90.9)	5 (100)	25 (92.6)
Any severe TEAE	3 (13.6)	1 (20.0)	4 (14.8)
Any TEAE that is considered associated with study drug$	20 (90.9)	5 (100)	25 (92.6)
Any TEAE that is considered associated with product complaint$	17 (77.3)	3 (60.0)	20 (74.1)
ABBV-951	10 (45.5)	2 (40.0)	12 (44.4)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	7 (31.8)	3 (60.0)	10 (37.0)
[redacted] infusion set 6 mm	6 (27.3)	1 (20.0)	7 (25.9)
[redacted] infusion set 9 mm	1 (4.5)	3 (60.0)	4 (14.8)
Neria guard infusion set (total)	4 (18.2)	0	4 (14.8)
Neria guard infusion set 6 mm	1 (4.5)	0	1 (3.7)
Neria guard infusion set 9 mm	3 (13.6)	0	3 (11.1)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	6 (27.3)	1 (20.0)	7 (25.9)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	6 (27.3)	1 (20.0)	7 (25.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
COVID-19 = coronavirus disease-2019, [redacted] = [redacted] or [redacted] (United States), TEAE = treatment-emergent adverse events

表 2.7.4-18. 有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-741 試験（続き）

	Japan		
	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	3 (13.6)	0	3 (11.1)
Possible	0	0	0
Probable	1 (4.5)	0	1 (3.7)
Causal relationship	2 (9.1)	0	2 (7.4)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
[redacted] = [redacted] or [redacted] (United States), SAE = serious adverse events

83

表 2.7.4-18. 有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-741 試験（続き）

	Japan		
	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
All deaths#	0	0	0
All TE-deaths	0	0	0
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	1 (4.5)	0	1 (3.7)
AESI: hallucinations/psychosis	10 (45.5)	2 (40.0)	12 (44.4)
AESI: somnolence	0	0	0
AESI: infusion site related infections	3 (13.6)	2 (40.0)	5 (18.5)
AESI: infusion site related non infection reactions	17 (77.3)	3 (60.0)	20 (74.1)
AESI: falls and associated injuries	8 (36.4)	3 (60.0)	11 (40.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
# Includes non treatment-emergent deaths.
AESI = adverse events of special interest, COVID-19 = coronavirus disease-2019

Cross References：M15-741 試験 CSR Japan Study Data Table 14.3__1.1.J

2.7.4.5.1.2.2 M15-737 試験

申請時

日本人部分集団（11 例）の有害事象の発現割合は，すべての有害事象が 72.7%（8 例），重篤な有害事象が 18.2%（2 例），治験薬と関連ありの有害事象が 45.5%（5 例），治験薬又は治験機器の不具合に関連した有害事象が 27.3%（3 例）であった。死亡に至った有害事象及び投与中止に至った有害事象は，それぞれ 9.1%（1 例）の被験者で報告された（表 2.7.4-19）。

更新時

日本人部分集団（12 例）の有害事象の発現割合は，すべての有害事象が 75.0%（9 例），重篤な有害事象が 33.3%（4 例），治験薬と関連ありの有害事象が 58.3%（7 例），治験薬又は治験機器の不具合に関連した有害事象が 50.0%（6 例）であった。死亡に至った有害事象及び投与中止に至った有害事象は，それぞれ 8.3%（1 例）の被験者で報告された（表 2.7.4-20）。

表 2.7.4-19. 有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-737 試験

	Japan		
	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Subjects with:			
Any TEAE	5 (71.4)	3 (75.0)	8 (72.7)
Any severe TEAE	1 (14.3)	0	1 (9.1)
Any TEAE that is considered associated with study drug$	3 (42.9)	2 (50.0)	5 (45.5)
Any TEAE that is considered associated with product complaint$	1 (14.3)	2 (50.0)	3 (27.3)
ABBV-951	1 (14.3)	1 (25.0)	2 (18.2)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	2 (50.0)	2 (18.2)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	2 (50.0)	2 (18.2)
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	1 (14.3)	0	1 (9.1)
Any TEAE leading to death (fatal TEAE)	1 (14.3)	0	1 (9.1)
Any serious TEAE	1 (14.3)	1 (25.0)	2 (18.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
COVID-19 = coronavirus disease-2019, TEAE = treatment-emergent adverse events

86

表 2.7.4-19. 有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-737 試験（続き）

	Japan		
	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.
SAE = serous adverse events

表 2.7.4-19. 有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-737 試験（続き）

	Japan		
	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
All deaths#	1 (14.3)	0	1 (9.1)
All TE-deaths	1 (14.3)	0	1 (9.1)
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	0	0	0
AESI: hallucinations/psychosis	1 (14.3)	0	1 (9.1)
AESI: somnolence	0	0	0
AESI: infusion site related infections	0	1 (25.0)	1 (9.1)
AESI: infusion site related non infection reactions	1 (14.3)	2 (50.0)	3 (27.3)
AESI: falls and associated injuries	0	1 (25.0)	1 (9.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
# Includes non treatment-emergent deaths.
AESI = adverse events of special interest, COVID-19 = coronavirus disease-2019

Cross References：M15-737 試験 CSR Japan Study Data Table 14.3 1.1.J

88

表 2.7.4-20. 有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-737 試験（更新時）

	Japan		
	Dose Category		
	Low Dose (N=8) n (%)	High Dose (N=4) n (%)	All Subjects (N=12) n (%)
Subjects with:			
Any TEAE	5 (62.5)	4 (100)	9 (75.0)
Any severe TEAE	1 (12.5)	0	1 (8.3)
Any TEAE that is considered associated with study drug$	4 (50.0)	3 (75.0)	7 (58.3)
Any TEAE that is considered associated with product complaint$	3 (37.5)	3 (75.0)	6 (50.0)
ABBV-951	2 (25.0)	2 (50.0)	4 (33.3)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	1 (12.5)	2 (50.0)	3 (25.0)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	1 (12.5)	2 (50.0)	3 (25.0)
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	1 (12.5)	0	1 (8.3)
Any TEAE leading to prematurely discontinuation of study drug	1 (12.5)	0	1 (8.3)
Any TEAE leading to death (fatal TEAE)	1 (12.5)	0	1 (8.3)
Any serious TEAE	2 (25.0)	2 (50.0)	4 (33.3)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

89

表 2.7.4-20. 有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-737 試験（更新時）（続き）

	Japan		
	Dose Category		
	Low Dose (N=8) n (%)	High Dose (N=4) n (%)	All Subjects (N=12) n (%)
Any SAE that is considered associated with infusion pump$	0	1 (25.0)	1 (8.3)
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	1 (25.0)	1 (8.3)
Any SAE that is considered associated with neria guards infusion set$	0	1 (25.0)	1 (8.3)
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	1 (25.0)	1 (8.3)
Any SAE that is considered associated with product complaint$	1 (12.5)	1 (25.0)	2 (16.7)
ABBV-951	1 (12.5)	1 (25.0)	2 (16.7)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

90

表 2.7.4-20. 有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-737 試験（更新時）（続き）

	Japan		
	Dose Category		
	Low Dose (N=8) n (%)	High Dose (N=4) n (%)	All Subjects (N=12) n (%)
All deaths#	1 (12.5)	0	1 (8.3)
All TE-deaths	1 (12.5)	0	1 (8.3)
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	0	0	0
AESI: hallucinations/psychosis	2 (25.0)	0	2 (16.7)
AESI: somnolence	0	0	0
AESI: infusion site related infections	1 (12.5)	2 (50.0)	3 (25.0)
AESI: infusion site related non infection reactions	2 (25.0)	3 (75.0)	5 (41.7)
AESI: falls and associated injuries	0	1 (25.0)	1 (8.3)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Cross References：M15-737 試験 CSR update Table 14.3__1.1.J

2.7.4.5.1.3 比較的よくみられる有害事象

2.7.4.5.1.3.1 M15-741 試験

申請時

日本人部分集団（27 例）におけるすべての有害事象を 2.7.6 項に，2 例以上の被験者に発現した有害事象を表 2.7.4-21 に示す。有害事象は 92.6%（25 例）の被験者で報告された。発現割合が 10%以上の有害事象は，注入部位紅斑が 37.0%（10 例），幻覚が 33.3%（9 例），転倒が 29.6%（8 例），注入部位硬結及び妄想が各 18.5%（5 例），下痢，注入部位蜂巣炎及びパーキンソン病が各 14.8%（4 例），注入部位腫瘤及び浮動性めまいが各 11.1%（3 例）であった。

治験薬と関連ありの有害事象の発現割合は 92.6%（25 例）であり，発現割合が 10%以上の有害事象は，注入部位紅斑及び幻覚が各 33.3%（9 例），注入部位硬結及び妄想が各 18.5%（5 例），注入部位蜂巣炎が 14.8%（4 例），注入部位腫瘤及び浮動性めまいが各 11.1%（3 例）であった（M15-741 試験 CSR Japan Study Data Table 14.3__1.6.J）。

重度の有害事象は 14.8%（4 例）の被験者で認められ，報告された有害事象の多くの重症度は，軽度又は中等度であった。投与期間中に 3 例以上発現した重度の有害事象は確認されなかった（M15-741 試験 CSR Japan Study Data Table 14.3__1.4.J）。

更新時

日本人部分集団（27 例）での有害事象の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.15.J，Table 14.3__1.6.J，及び Table 14.3__1.4.J）。すべての有害事象を 2.7.6 項に示した。

表 2.7.4-21. 2 例以上の被験者に発現した有害事象（安全性解析対象集団，日本人部分集団）：M15-741 試験

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period	N=22	N=5	N=27
Any adverse event	20 (90.9)	5 (100)	25 (92.6)
眼障害	1 (4.5)	1 (20.0)	2 (7.4)
白内障	1 (4.5)	1 (20.0)	2 (7.4)
胃腸障害	5 (22.7)	1 (20.0)	6 (22.2)
便秘	2 (9.1)	0	2 (7.4)
下痢	3 (13.6)	1 (20.0)	4 (14.8)
悪心	2 (9.1)	0	2 (7.4)
一般・全身障害および投与部位の状態	14 (63.6)	3 (60.0)	17 (63.0)
注入部位皮膚炎	2 (9.1)	0	2 (7.4)
注入部位紅斑	7 (31.8)	3 (60.0)	10 (37.0)
注入部位硬結	4 (18.2)	1 (20.0)	5 (18.5)
注入部位腫瘤	2 (9.1)	1 (20.0)	3 (11.1)
注入部位発疹	1 (4.5)	1 (20.0)	2 (7.4)
注射部位腫脹	1 (4.5)	1 (20.0)	2 (7.4)
末梢性浮腫	1 (4.5)	1 (20.0)	2 (7.4)
穿刺部位硬結	2 (9.1)	0	2 (7.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

93

表 2.7.4-21. 2 例以上の被験者に発現した有害事象（安全性解析対象集団，日本人部分集団）：M15-741 試験（続き）

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=22	N=5	N=27
感染症および寄生虫症	3 (13.6)	1 (20.0)	4 (14.8)
注入部位蜂巣炎	3 (13.6)	1 (20.0)	4 (14.8)
傷害、中毒および処置合併症	6 (27.3)	2 (40.0)	8 (29.6)
転倒	6 (27.3)	2 (40.0)	8 (29.6)
肋骨骨折	1 (4.5)	1 (20.0)	2 (7.4)
代謝および栄養障害	1 (4.5)	1 (20.0)	2 (7.4)
ビタミン B6 欠乏	1 (4.5)	1 (20.0)	2 (7.4)
筋骨格系および結合組織障害	2 (9.1)	0	2 (7.4)
四肢痛	2 (9.1)	0	2 (7.4)
神経系障害	8 (36.4)	1 (20.0)	9 (33.3)
浮動性めまい	2 (9.1)	1 (20.0)	3 (11.1)
頭痛	2 (9.1)	0	2 (7.4)
パーキンソン病	4 (18.2)	0	4 (14.8)
精神障害	9 (40.9)	2 (40.0)	11 (40.7)
妄想	5 (22.7)	0	5 (18.5)
幻覚	8 (36.4)	1 (20.0)	9 (33.3)
幻視	1 (4.5)	1 (20.0)	2 (7.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Cross References：M15-741 試験 CSR Japan Study Data Table 14.3__1.15.J

94

2.7.4.5.1.3.2 M15-737 試験

申請時

日本人部分集団（11 例）で報告されたすべての有害事象を 2.7.6 項に示す。有害事象は 72.7%（8 例）の被験者で報告された。日本人部分集団で 2 例以上発現した有害事象は認められなかった（M15-737 試験 CSR Japan Study Data Table 14.3__1.15.J）。治験薬と関連ありの有害事象の発現割合は 45.5%（5 例）であった（M15-737 試験 CSR Japan Study Data Table 14.3__1.6.J）。重度の有害事象は 1 例のみで他の有害事象の重症度は，すべて軽度又は中等度であった（表 2.7.4-19）。

更新時

日本人部分集団（12 例）で報告されたすべての有害事象を 2.7.6 項に示す。有害事象は 75.0%（9 例）の被験者で報告された。日本人部分集団で 2 例以上発現した有害事象は，注入部位蜂巣炎が 25.0%（3 例），注入部位紅斑及び注入部位硬結が各 16.7%（2 例）であった（M15-737 試験 CSR update Table 14.3__1.15.J）。治験薬と関連ありの有害事象の発現割合は 58.3%（7 例）であった（M15-737 試験 CSR update Table 14.3__1.6.J）。重度の有害事象は 1 例のみで他の有害事象の重症度は，すべて軽度又は中等度であった（表 2.7.4-20）。

2.7.4.5.1.4 死亡

2.7.4.5.1.4.1 M15-741 試験

申請時

日本人部分集団（27 例）で死亡に至った有害事象の報告はなかった（表 2.7.4-18）。

更新時

日本人部分集団（27 例）で死亡に至った有害事象の報告はなかった（M15-741 試験 CSR update Table 14.3__1.1.J）。

2.7.4.5.1.4.2 M15-737 試験

申請時

日本人部分集団（11 例）で死亡に至った有害事象が 9.1%（1 例）報告され，その有害事象は誤嚥及び窒息であった（表 2.7.4.7-8 及び表 2.7.4-19）。死亡例の詳細は，2.7.6 項に示した。

更新時

日本人部分集団（12 例）で死亡に至った有害事象が 8.3%（1 例）報告された。その有害事象は申請時と同一であり，申請時データカットオフ以降に死亡した被験者はいなかった（M15-737 試験 CSR update Table 14.3__2.1 及び表 2.7.4-20）。死亡例の詳細は，2.7.6 項に示した。

2.7.4.5.1.5 その他の重篤な有害事象

2.7.4.5.1.5.1 M15-741 試験

申請時

日本人部分集団の 25.9%（7/27 例）の被験者で，重篤な有害事象が報告され，その内訳は，パーキンソン病及び幻覚が各 11.1%（3 例），蜂巣炎，横紋筋融解症，意識消失及び妄想が各 3.7%（1 例）であった（M15-741 試験 CSR Japan Study Data Table 14.3__1.11.1.J）。重篤な有害事象を発現した被験者の詳細は，2.7.6 項に示した。

更新時

日本人部分集団（27 例）での重篤な有害事象の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.11.1.J）。重篤な有害事象を発現した被験者の詳細は，2.7.6 項に示した。

2.7.4.5.1.5.2 M15-737 試験

申請時

日本人部分集団の 18.2%（2/11 例）の被験者で，重篤な有害事象が報告され，その内訳は，肩甲骨骨折，窒息及び誤嚥が各 9.1%（1 例）であった（M15-737 試験 CSR Japan Study Data Table 14.3__1.11.1.J）。重篤な有害事象を発現した被験者の詳細は，2.7.6 項に示した。

更新時

日本人部分集団の 33.3%（4/12 例）の被験者で，重篤な有害事象が報告され，その内訳は，注入部位蜂巣炎，COVID-19，肩甲骨骨折，窒息及び誤嚥が各 8.3%（1 例）であった（M15-737 試験 CSR update Table 14.3__1.11.1.J）。重篤な有害事象を発現した被験者の詳細は，2.7.6 項に示した。

2.7.4.5.1.6 その他の重要な有害事象

2.7.4.5.1.6.1 M15-741 試験

申請時

日本人部分集団で治験薬の投与中止に至った有害事象の発現割合は 25.9%（7/27 例）であり，その有害事象は，パーキンソン病が 7.4%（2 例），注入部位腫瘤，注入部位発疹，横紋筋融解症，パーキンソニズム，幻覚，幻視及び蕁麻疹が各 3.7%（1 例）であった（M15-741 試験 CSR Japan Study Data Table 14.3__1.8.1.J）。

更新時

日本人部分集団（27 例）での治験薬の投与中止に至った有害事象の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.8.1.J）。

2.7.4.5.1.6.2 M15-737 試験

申請時

日本人部分集団で治験薬の投与中止に至った有害事象の発現割合は 9.1%（1/11 例）であり，その有害事象は窒息及び誤嚥が各 9.1%（1 例）であった（M15-737 試験 CSR Japan Study Data Table 14.3__1.8.1.J）。

更新時

日本人部分集団で治験薬の投与中止に至った有害事象の発現割合は 8.3%（1/12 例）であり，その有害事象は窒息及び誤嚥が各 8.3%（1 例）であった（M15-737 試験 CSR update Table 14.3__1.8.1.J）。

2.7.4.5.1.7 器官別又は症候群別有害事象の解析

特に注目すべき有害事象及び検索基準を 2.7.4.1.1.2.2 項に示した。M15-741 試験の日本人部分集団 27 例の被験者における特に注目すべき有害事象の概要を表 2.7.4.7-36 に，M15-737 試験の日本人部分集団 11 例（申請時）及び 12 例（更新時）の被験者における特に注目すべき有害事象の概要を表 2.7.4.7-37 及び表 2.7.4.7-67 にそれぞれ示す。

2.7.4.5.1.7.1 注入部位感染

2.7.4.5.1.7.1.1 M15-741 試験

申請時

注入部位感染は，日本人部分集団の 18.5%（5/27 例）の被験者で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位蜂巣炎 14.8%（4 例）であった（表 2.7.4.7-38）。治験薬と関連ありと判定された注入部位感染は 14.8%（4 例）の被験者で報告された。重篤な有害事象は 1 例（3.7%）認められ，重症度は重度 1 例（3.7%）のみで，ほとんどが軽度又は中等度であった。治験薬の投与中止に至った有害事象はなかった（表 2.7.4.7-36）。

更新時

日本人部分集団（27 例）での注入部位感染の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.12.1.J 及び Table 14.3__1.12.2.1.J）。

2.7.4.5.1.7.1.2 M15-737 試験

申請時

注入部位感染は，日本人部分集団 11 例中の 1 例（9.1%）で注入部位蜂巣炎が報告された（M15-737 試験 CSR Japan Study Data Table 14.3__1.12.2.J）。当該有害事象は治験薬と関連あり

97

と判定され，重篤な有害事象ではなく，重症度も重度ではなく，治験薬の投与中止もされなかった（表 2.7.4.7-37）。

更新時

注入部位感染は，日本人部分集団 12 例中の 3 例（25.0%）で，注入部位蜂巣炎 3 例（25.0%）及び注射部位蜂巣炎 1 例（8.3%）が報告された（M15-737 試験 CSR update Table 14.3__1.12.2.J）。治験薬と関連ありと判定された注入部位感染は 25.0%（3 例）の被験者で報告され，その内容は注入部位蜂巣炎 3 例及び注射部位蜂巣炎 1 例であった（M15-737 試験 CSR update Table 14.3__2.5.1）。重篤な有害事象（注入部位蜂巣炎）は 1 例（8.3%）報告された。重症度はすべて軽度又は中等度であり，治験薬の投与中止はなかった（表 2.7.4.7-67）。

2.7.4.5.1.7.2 注入部位非感染反応

2.7.4.5.1.7.2.1 M15-741 試験

申請時

注入部位非感染反応は，日本人部分集団の 74.1%（20/27 例）の被験者で報告された。発現割合が 5%以上の有害事象（PT）は，注入部位紅斑が 37.0%（10 例），注入部位硬結が 18.5%（5 例），注入部位腫瘤が 11.1%（3 例），注入部位皮膚炎，注入部位発疹，注射部位腫脹及び穿刺部位硬結が各 7.4%（2 例）であった（表 2.7.4.7-39）。治験薬と関連ありと判定された注入部位非感染反応は 66.7%（18 例）の被験者で報告された。重篤な有害事象は認められず，重症度は，すべて軽度又は中等度であった。治験薬の投与中止に至った有害事象の発現割合は 7.4%（2 例）であった（表 2.7.4.7-36）。

更新時

日本人部分集団（27 例）での注入部位非感染反応の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.12.1.J 及び Table 14.3__1.12.3.J）。

2.7.4.5.1.7.2.2 M15-737 試験

申請時

注入部位非感染反応は，日本人部分集団の 27.3%（3/11 例）の被験者で報告された。認められた有害事象は，注入部位皮膚炎，注入部位硬結，注射部位紅斑及び注射部位硬結が各 9.1%（1 例）であった（表 2.7.4.7-40）。治験薬と関連ありと判定された注入部位非感染反応は 27.3%（3 例）の被験者で報告された。重篤な有害事象は認められず，重症度が重度の有害事象も認められず，また，治験薬の投与中止に至った有害事象もなかった（表 2.7.4.7-37）。

更新時

注入部位非感染反応は，日本人部分集団の 41.7%（5/12 例）の被験者で報告された。認められた有害事象は，注入部位硬結及び注射部位紅斑が各 16.7%（2 例），注入部位皮膚炎及び注射部位硬結が各 8.3%（1 例）であった（表 2.7.4.7-68）。治験薬と関連ありと判定された注入部位非感染反応は 41.7%（5 例）の被験者で報告された。重篤な有害事象は認められず，重症度が重度の有害事象も認められず，また，治験薬の投与中止に至った有害事象もなかった（表 2.7.4.7-67）。

2.7.4.5.1.7.3 幻覚及び精神病

2.7.4.5.1.7.3.1 M15-741 試験

申請時

幻覚及び精神病は，日本人部分集団の 44.4%（12/27 例）の被験者で報告された。発現割合が2%以上の有害事象（PT）は，幻覚 33.3%（9 例），妄想 18.5%（5 例），幻視 7.4%（2 例）及び嫉妬妄想 3.7%（1 例）であった（表 2.7.4.7-41）。治験薬と関連ありと判定された幻覚及び精神病は 40.7%（11 例）の被験者で報告された。重篤な幻覚及び精神病は 11.1%（3 例）認められ，重症度は重度 1 例を除き，軽度又は中等度であった。また，治験薬の投与中止に至った有害事象の発現割合は 7.4%（2 例）であった（表 2.7.4.7-36）。

更新時

日本人部分集団（27 例）での幻覚及び精神病の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.12.1.J 及び Table 14.3__1.12.6.J）。

2.7.4.5.1.7.3.2 M15-737 試験

申請時

幻覚及び精神病は，日本人部分集団 11 例中の 1 例（9.1%）で報告され，有害事象（PT）は，幻覚 9.1%（1 例）であった（M15-737 試験 CSR Japan Study Data Table 14.3__1.12.6.J）。当該有害事象は，重篤ではなく，重症度も重度ではなく，治験薬の投与中止もされなかったが，治験薬と関連ありと判定された（表 2.7.4.7-37）。

更新時

幻覚及び精神病は，日本人部分集団 12 例中の 2 例（16.7%）で報告され，有害事象（PT）は，幻覚及び妄想が各 8.3%（1 例）であった（M15-737 試験 CSR update Table 14.3__1.12.6.J）。重篤な有害事象の報告はなく，重症度も重度ではなく，治験薬の投与中止もなかったが，1 例（8.3%）が治験薬と関連ありと判定された（表 2.7.4.7-67）。

2.7.4.5.1.7.4 多発ニューロパチー

2.7.4.5.1.7.4.1 M15-741 試験

申請時

日本人部分集団では，多発ニューロパチーは報告されなかった（M15-741 試験 CSR Japan Study Data Table 14.3__1.12.4.J）。

更新時

日本人部分集団では，多発ニューロパチーは報告されなかった（M15-741 試験 CSR update Table 14.3__1.12.4.J）。

2.7.4.5.1.7.4.2 M15-737 試験

申請時

日本人部分集団では，多発ニューロパチーは報告されなかった（M15-737 試験 CSR Japan Study Data Table 14.3__1.12.4.J）。

更新時

日本人部分集団では，多発ニューロパチーは報告されなかった（M15-737 試験 CSR update Table 14.3__1.12.4.J）。

2.7.4.5.1.7.5 転倒及び関連する損傷

2.7.4.5.1.7.5.1 M15-741 試験

転倒及び関連する損傷

申請時

転倒及び関連する損傷は，日本人部分集団の 29.6%（8/27 例）の被験者で報告された。有害事象（PT）の内訳は，転倒が 29.6%（8 例），肋骨骨折が 7.4%（2 例），脳挫傷，挫傷，頭部損傷，靭帯捻挫及び皮膚損傷が各 3.7%（1 例）であった（表 2.7.4.7-42）。治験薬と関連ありと判定された転倒及び関連する損傷は 3.7%（1 例）の被験者で報告された。重篤な転倒及び関連する損傷は認められず，また，重症度もすべての被験者で軽度又は中等度であった。治験薬の投与中止に至った有害事象はなかった（表 2.7.4.7-36）。

更新時

日本人部分集団（27 例）での転倒及び関連する損傷の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.12.1.J 及び Table 14.3__1.12.8.J）。

起立性低血圧

申請時

起立性低血圧は，日本人部分集団の 11.1%（3/27 例）の被験者で報告され，有害事象（PT）は，浮動性めまいが 11.1%（3 例）であった（表 2.7.4.7-42）。

重篤な起立性低血圧は認められず，投与中止例も認められず，重症度は軽度又は中等度であった（表 2.7.4.7-36）。

更新時

日本人部分集団（27 例）での起立性低血圧の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.12.1.J 及び Table 14.3__1.12.8.J）。

2.7.4.5.1.7.5.2 M15-737 試験

転倒及び関連する損傷

申請時

転倒及び関連する損傷は，日本人部分集団 11 例中の 1 例（9.1%）で報告され，有害事象（PT）は，転倒及び肩甲骨骨折が各 9.1%（1 例）であった（M15-737 試験 CSR Japan Study Data Table 14.3__1.12.8.J）。治験薬と関連ありと判定された転倒及び関連する損傷は認められなかった。肩甲骨骨折は重篤であったが，重症度は重度ではなかった。いずれの有害事象も治験薬と関連なしと判定され，重症度は軽度又は中等度であり，また，治験薬の投与中止に至った有害事象もなかった（表 2.7.4.7-37）。

更新時

転倒及び関連する損傷は，日本人部分集団 12 例中の 1 例（8.3%）で報告され，有害事象（PT）は，転倒及び肩甲骨骨折が各 8.3%（1 例）であった（M15-737 試験 CSR update Table 14.3__1.12.8.J）。治験薬と関連ありと判定された転倒及び関連する損傷は認められなかった。肩甲骨骨折は重篤であったが，重症度は重度ではなかった。いずれの有害事象も治験薬と関連なしと判定され，重症度は軽度又は中等度であり，また，治験薬の投与中止に至った有害事象もなかった（表 2.7.4.7-67）。

起立性低血圧

申請時

起立性低血圧は，認められなかった（M15-737 試験 CSR Japan Study Data Table 14.3__1.12.8.J）。

更新時

起立性低血圧は，認められなかった（M15-737 試験 CSR update Table 14.3__1.12.8.J）。

2.7.4.5.1.7.6 傾眠

2.7.4.5.1.7.6.1 M15-741 試験

申請時

傾眠は，報告されなかった（M15-741 試験 CSR Japan Study Data Table 14.3__1.12.7.J）。

更新時

傾眠は，報告されなかった（M15-741 試験 CSR update Table 14.3__1.12.7.J）。

2.7.4.5.1.7.6.2 M15-737 試験

申請時

傾眠は，報告されなかった（M15-737 試験 CSR Japan Study Data Table 14.3__1.12.7.J）。

更新時

傾眠は，報告されなかった（M15-737 試験 CSR update Table 14.3__1.12.7.J）。

2.7.4.5.1.7.7 体重減少

2.7.4.5.1.7.7.1 M15-741 試験

申請時

体重減少は，日本人部分集団の 3.7%（1/27 例）の被験者で報告された（M15-741 試験 CSR Japan Study Data Table 14.3__1.12.5.J）。報告された有害事象（PT）は，体重減少 3.7%（1 例）であった。当該有害事象は，治験薬と関連なしと判定され，重篤ではなく，重症度は軽度であり，また，治験薬の投与中止もなかった（表 2.7.4.7-36）。

更新時

日本人部分集団（27 例）での体重減少の発現割合及びその内容は申請時と同一であった（M15-741 試験 CSR update Table 14.3__1.12.1.J，Table 14.3__1.12.5.J 及び Table 14.3__1.4.J）。

2.7.4.5.1.7.7.2 M15-737 試験

申請時

体重減少は，報告されなかった（M15-737 試験 CSR Japan Study Data Table 14.3__1.12.5.J）。

更新時

体重減少は，報告されなかった（M15-737 試験 CSR update Table 14.3__1.12.5.J）。

2.7.4.5.2 内因性要因

M15-741 及び M15-737 試験

M15-741 及び M15-737 試験では，すべての有害事象について，内因性要因（年齢，人種，性別及び PD 罹病期間）を因子とした部分集団解析を実施した。なお，日本人部分集団についての部分集団解析の結果は，2.7.4.5.1 項に示した。

内因性要因（年齢，人種，性別及び PD 罹病期間）を因子とした部分集団での有害事象の発現割合は，全体集団での発現割合と同様であった（M15-741 試験 CSR Table 14.3__1.3 及び Table 14.3__1.2，M15-737 試験 CSR Table 14.3__1.3 及び Table 14.3__1.2）。

更新時データも申請時データと同様の結果であった（M15-741 試験 CSR update Table 14.3__1.3 及び Table 14.3__1.2，M15-737 試験 CSR update Table 14.3__1.3 及び Table 14.3__1.2）。

M15-736 試験

すべての有害事象ついて，内因性要因（年齢，人種，性別，BMI 及び PD 罹病期間）を因子とした部分集団解析を実施した。有害事象について，年齢，人種，性別，BMI 及び PD 罹病期間の部分集団で ABBV-951 投与群及び CD/LD 経口投与群間に意義のある差は示されなかった（M15-736 試験 CSR Table 14.3__1.10.1.1）。

2.7.4.5.3 外因性要因

M15-741 及び M15-737 試験

M15-741 及び M15-737 試験では，すべての有害事象について，外因性要因（ABBV-951 の用量及び地域）を因子とした部分集団解析を実施した。

外因性要因（ABBV-951 の用量及び地域）を因子とした部分集団解析で，有害事象の発現割合は，ABBV-951 の低用量と高用量で同様であった（M15-741 試験 CSR Table 14.3__1.2）。また，部分集団（地域）での有害事象の発現割合は，全体集団での有害事象の発現割合と同様であった（M15-741 試験 CSR Table 14.3__1.3 及び Table 14.3__1.2，M15-737 試験 CSR Table 14.3__1.3 及び Table 14.3__1.2）。

更新時データも申請時データと同様の結果であった（M15-741 試験 CSR update Table 14.3__1.3 及び Table 14.3__1.2，M15-737 試験 CSR update Table 14.3__1.3 及び Table 14.3__1.2）。

M15-736 試験

M15-736 試験では，すべての有害事象について，外因性要因（ABBV-951 の用量，ドパミンアゴニスト併用の有無及び実施国）を因子とした部分集団解析を実施した。有害事象について，

103

外因性要因の部分集団で ABBV-951 投与群及び CD/LD 経口投与群間に意義のある差は示されなかった（M15-736 試験 CSR Table 14.3　1.10.1.1）。

2.7.4.5.4　薬物相互作用

治験薬の代謝物及び分解物：潜在的なヒドラジンの毒性

ヒドラジンはカルビドパ（以下「CD」）の分解物であり，ABBV-951 に存在すると予想される。ヒドラジンは，国際がん研究機関（IARC）により，前臨床データに基づきヒト発がん性物質の可能性があると考えられている（ただし，ヒドラジンの発がん性に関するヒトのデータは限定的である）。ICH M7 ガイダンスで定義されているヒドラジンの 1 日あたりの許容摂取量は，生涯曝露量（70 年）に基づくと 1/100000 のリスクで 39 µg/日である。提案されているホスレボドパ/ホスカルビドパの 1 日あたりの最大推奨用量は，6000/300 mg/日であり，1 日あたりのヒドラジンの曝露量は 525 µg/日を超えないと考えられる。ヒドラジンのリスク評価は 2 つの方法を用いて計算され，2.6.6 項に詳細を記載した。最大 20 年間の曝露を考慮して，適切な調整が行われた場合，結果として生じるリスクは，曝露期間に依存して 0.1～3.8/100000 になる。

進行期 PD 患者における ABBV-951 による治療のベネフィットは，疾患の重症度及び進行期 PD 患者の利用可能な治療選択肢が限られていることを踏まえると，ABBV-951 によるヒドラジンの曝露に関連する潜在的なリスクを上回る。

ABBV-951 臨床開発プログラムにおける悪性腫瘍

ヒドラジンの潜在的な発がん性が懸念されるため，MedDRA（version 24.0）標準検索式（以下「SMQ」）悪性疾患を用いて，ABBV-951 臨床開発プログラムにおける悪性腫瘍を要約した。

悪性腫瘍が 6 例（基底細胞癌 4 例，ケラトアカントーマ 1 例及び皮膚有棘細胞癌 1 例）報告された。これらのうち 5 例の悪性腫瘍の重症度は軽度であった。悪性腫瘍 6 例は，重篤ではなく，治験責任医師により，治験薬との関連はないと考えられた。また，治験薬の投与中止に至ることもなかった。

レボドパ・カルビドパ水和物配合経腸用液の市販後安全性データベースにおける悪性腫瘍

ABBV-951 から予想されるヒドラジン曝露量は，レボドパ・カルビドパ水和物配合経腸用液（以下「LCIG」）製剤と比較して，ヒドラジンレベルが 12 分の 1 に減少することを表している。ヒドラジン含有量の臨床的関連性は，2010 年に重要な欠落情報として LCIG リスク管理計画（以下「RMP」）に追加された。

LCIG RMP version 7.2 では，LCIG 市販後安全性データベースの悪性腫瘍の発現割合が公表されているがん発現率と比較された。最初の発売以来，77 件の新生物の報告があった（SMQ 悪性疾患；データロックポイント［以下「DLP」］20[redacted] 年 [redacted] 月 [redacted] 日）。様々ながんの種類と部位のスペクトルが，明らかなクラスター化なしに報告された。新生物の 77 の自然発現が，最初の発

売以来，LCIG への市販後曝露の推定 19096 人年から報告され，LCIG 曝露の 10 万人年あたり約 403 例のがんの発現が示された。米国では，2008 年から 2012 年の 70～74 歳の年齢層のがん（非黒色腫皮膚癌を除くすべてのタイプ）の発現割合は，人口 10 万人あたり 2030.3 人であった（国立衛生研究所 Surveillance, Epidemiology, and End Results program 2015 から）。英国では，同じ年齢層のがん発現割合は，女性 10 万人あたり 1477.3 人から男性 10 万人あたり 2310.9 人の範囲であった（英国国家統計局 2012）。したがって，LCIG の市販後安全性データベースの例数が，同様の年齢集団で予想される発現例数を超えるということは示されなかった。

7 年以上の綿密なモニタリングの間に，LCIG プログラムでは悪性腫瘍に関連する安全性シグナルは特定されず，LCIG RMP version 8.0（DLP 20[redacted] 年 [redacted] 月 [redacted] 日）では，ヒドラジンの毒性の臨床的関連性は重要な欠落情報として削除された。

ABBV-951 の臨床データ及び LCIG の臨床データ及び市販後データに基づき，ヒドラジン曝露による ABBV-951 の発がんリスクは低いと考えられた。

2.7.4.5.5 妊娠及び授乳時の使用

ABBV-951 の試験は，妊娠中又は授乳中の女性では実施されなかった。ABBV-951 の臨床開発プログラムでは，これまで妊娠の報告はなかった。

妊娠した女性におけるホスレボドパ/ホスカルビドパの使用に関連した発生リスクに関する十分なデータはない。動物実験において，LD/CD は，臨床的に適切な用量で発生毒性（催奇形効果を含む）が認められている。器官形成を通して妊娠ウサギに投与したとき，LD/CD は，用いた LD/CD のすべての用量及び用量比で，胎児に内臓奇形及び骨格奇形を引き起こした。LD/CD を妊娠中のマウスに器官形成を通して投与した場合，催奇形効果は認められなかった。器官形成中に LD/CD を投与されたラットが出産した生存個体数は減少した。

LD は，CD/LD の投与後にヒト乳汁中から検出される。CD は，ヒト乳汁中に検出されたデータはないが，ラットにおいては乳汁中に一部排泄されることが知られている。授乳を介した乳児に対する LD 又は CD の影響あるいは乳汁産生への影響に関するデータはない。しかしながら，LD はヒトのプロラクチンの分泌を減少させるため，授乳に支障をきたす可能性がある。

母乳育児の発達上及び健康上の利点は，ホスレボドパ/ホスカルビドパに対する母親の臨床的必要性及びホスレボドパ/ホスカルビドパ又は母親の状態による母乳育児中の乳児への潜在的な悪影響とともに考慮する必要がある。

2.7.4.5.6 過量投与

不安の病歴のある 1 例の被験者は，ABBV-951 投与中に，経口 LD/CD（100/25 mg ［1 日 3 錠］）を過剰に服用し，パニックを感じた。治験責任医師により，これは ABBV-951 の過量投与とはされなかった。過量投与及びパニック反応の両有害事象は，重篤ではなく，重症度は軽度であり，ABBV-951 に対する処置なしに回復した（M15-741 試験 CSR Appendix 16.2　7.1）。

105

2.7.4.5.7 薬物乱用

ABBV-951 は，乱用，忍容性又は身体的依存の可能性について，動物又はヒトで体系的に研究されていない。LD を含む医薬品は規制物質ではない。乱用及び依存性の市販後の報告は稀である。

FDA 2017 及び欧州医薬品庁 2006 のガイドラインでは，開発中の医薬品は安全性パッケージの構成要素として乱用の可能性について評価されることを推奨している。AbbVie 社は，FDA の製薬企業のための薬物乱用の可能性のガイダンスの評価に基づいて MedDRA（version 24.0）の company MedDRA query（以下「CMQ」）薬物乱用傾向を用い調査した。FDA ガイダンスで要求されているように，乱用傾向 CMQ には，多幸気分，浮動性めまい，激越，過量投与，精神病性障害，落ち着きのなさ，傾眠及び錯乱状態を含む広い範囲の PT が含まれており，MedDRA の薬物乱用および依存 SMQ よりもはるかに広範囲である。

AbbVie 社の乱用傾向 CMQ に含まれた有害事象は，ABBV-951 臨床開発プログラムで 22.4%（138 例）の被験者で報告され，被験者の多くは，重篤な有害事象ではなく，重症度は軽度又は中等度であった。これらの有害事象の多くは，PD 又は LD の既知の影響（例：浮動性めまい，幻覚及び傾眠）であり，乱用を示唆するものではない。MedDRA の薬物乱用および依存の SMQ でも報告された有害事象は，被験者 1 例で前述した過量投与及びドーパミン調節障害症候群（以下「DDS」）のみであった。DDS は，治験責任医師により治験薬との関連なしと判定され，治験薬の投与中止には至らなかった。この有害事象の叙述は，M15-741 試験 CSR Section 14.3__3 に記載されている。

入手可能なデータ及び ABBV-951 の作用機序の理解に基づいて，ABBV-951 の乱用傾向又は依存性の可能性のエビデンスはなかった。

衝動-強迫行動

DDS，病的賭博，強迫的性行動，反復常同行動，強迫性購買及び暴食などの衝動-強迫行動は，PD 患者の 7 例中 1 例以上に影響を及ぼすドパミン作動薬による治療の合併症として知られている[1]。PD 患者での ICD の有病率は，正確には不明だが，14%～40%との報告がある[2-4]。

ICD CMQ を用いて衝動-強迫行動に関連する有害事象を特定し，QUIP-RS を第 III 相試験で評価した。QUIP-RS は，PD 患者における ICD 及び関連症状の経時的変化をモニタリングするために特別に開発された質問票である。ICD 及び関連障害のスコアは 0～16 の範囲であり，スコアが高いほど症状の重症度（頻度）が高いことを示す。

衝動-強迫性行動に関連する有害事象は，第 III 相試験の 14 例（3.7%）の被験者で報告された。これらの有害事象の大半は，非重篤であり，重症度は軽度又は中等度であった。治験薬の投与中止に至った有害事象はなかった。重篤な有害事象は DDS が 1 件のみであり，当該事象については上記の AbbVie 社の乱用傾向 CMQ に含まれた有害事象の中に記載した。

各評価時点で QUIP-RS のスコアは各 ICD 及び関連行動パラメータで低く，ほとんどがベースラインからの平均減少量は小さかった。

2.7.4.5.8 離脱症状及び反跳現象

ABBV-951 による離脱症状又は反跳現象は検討されなかった。薬物離脱症候群の MedDRA PT による有害事象は，ABBV-951 臨床開発プログラムで 2 例（0.3%）の被験者で報告された。これらの有害事象は，ABBV-951 ではなく，ドパミンアゴニストの併用に関連していた（M15-741 試験 CSR Appendix 16.2　7.1）。

2.7.4.5.9 自動車運転及び機械操作に対する影響又は精神機能の障害

ABBV-951 の運転能力及び機械操作能力に及ぼす影響に関する検討は行われなかった。

2.7.4.6 市販後データ

ABBV-951 の使用は，いずれの国でも承認されていない。

参考文献

1. Averbeck BB, O'Sullivan SS, Djamshidian A. Impulsive and compulsive behaviors in Parkinson's disease. Annu Rev Clin Psychol. 2014;10:553-80.
2. Baig F, Kelly MJ, Lawton MA, et al. Impulse control disorders in Parkinson disease and RBD: A longitudinal study of severity. Neurology. 2019;93(7):e675-e687.
3. Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13-20.
4. Sáez-Francàs N, Martí Andrés G, Ramírez N, et al. [Clinical and psychopathological factors associated with impulse control disorders in Parkinson's disease]. Neurologia. 2016;31(4):231-8.

2.7.4.7 付録

表2.7.4.7-1　LDの1日あたりの投与量（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.1__8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 1								
WEEK 1	n	141	84	141	19	3	20	141
	Mean	1662.5	83.0	1711.9	128.9	133.3	142.5	1732.1
	SD	671.01	66.86	676.53	60.82	57.74	63.40	687.97
	Median	1507.7	56.3	1579.4	100.0	100.0	100.0	1579.4
	Min	682.1	18.8	682.1	100.0	100.0	100.0	682.1
	Max	3524.3	327.8	3562.7	300.0	200.0	300.0	3710.4
WEEK 2	n	142	94	142	19	3	21	142
	Mean	1753.1	82.9	1808.0	163.2	133.3	166.7	1832.6
	SD	673.97	65.24	676.79	107.81	57.74	102.88	687.42
	Median	1608.5	64.0	1646.2	100.0	100.0	100.0	1648.4
	Min	696.7	18.8	696.7	100.0	100.0	100.0	696.7
	Max	4072.4	368.8	4136.4	450.0	200.0	450.0	4136.4
WEEK 3	n	124	81	124	15	2	17	124
	Mean	1824.6	72.3	1871.8	126.7	100.0	123.5	1888.7
	SD	689.78	57.33	695.35	41.69	0.00	39.99	697.95
	Median	1669.0	51.2	1723.3	100.0	100.0	100.0	1741.7
	Min	696.7	18.8	696.7	100.0	100.0	100.0	696.7
	Max	4021.2	333.0	4059.6	200.0	100.0	200.0	4059.6
WEEK 4	n	117	79	117	13	0	13	117
	Mean	1883.3	66.0	1927.8	134.6		134.6	1942.8
	SD	716.71	54.18	719.31	89.87		89.87	727.83
	Median	1762.1	48.7	1794.6	100.0		100.0	1803.1
	Min	696.7	18.8	696.7	100.0		100.0	696.7
	Max	4080.9	281.7	4106.5	400.0		400.0	4106.5

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 1 (Cont.)								
WEEK 6	n	113	77	113	18	3	21	113
	Mean	1879.3	61.5	1921.2	144.4	200.0	152.4	1949.5
	SD	711.17	39.35	719.94	118.68	86.60	114.54	728.05
	Median	1762.1	48.7	1791.2	100.0	250.0	100.0	1872.3
	Min	800.8	18.8	800.8	100.0	100.0	100.0	800.8
	Max	4055.3	204.9	4119.3	600.0	250.0	600.0	4119.3
WEEK 13	n	103	69	103	20	5	24	103
	Mean	1910.7	59.8	1950.8	155.0	190.0	168.8	1990.1
	SD	747.27	52.29	751.94	190.50	54.77	174.34	764.78
	Median	1797.1	41.0	1844.1	100.0	200.0	100.0	1862.9
	Min	898.1	18.8	973.3	100.0	100.0	100.0	973.3
	Max	4098.0	307.4	4116.8	950.0	250.0	950.0	4316.8
WEEK 26	n	91	54	91	16	8	20	91
	Mean	1874.6	57.0	1908.4	146.9	156.3	180.0	1948.0
	SD	745.34	39.92	753.39	118.98	77.63	127.11	772.86
	Median	1691.2	41.0	1732.2	100.0	100.0	100.0	1769.8
	Min	851.4	18.8	898.3	100.0	100.0	100.0	898.3
	Max	4098.0	230.5	4098.0	550.0	250.0	550.0	4098.0
WEEK 39	n	79	50	79	15	7	17	79
	Mean	1896.3	67.0	1938.6	150.0	164.3	200.0	1981.7
	SD	704.01	61.38	709.80	114.95	85.22	126.24	736.35
	Median	1747.6	49.9	1769.0	100.0	100.0	150.0	1828.0
	Min	837.5	18.8	888.5	100.0	100.0	100.0	888.5
	Max	3961.4	307.4	3987.0	550.0	300.0	550.0	3987.0

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample / Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 1 (Cont.)								
WEEK 52	n	70	41	70	14	4	17	70
	Mean	1922.9	67.1	1962.2	100.0	162.5	120.6	1991.5
	SD	685.08	57.15	686.16	0.00	75.00	58.79	692.49
	Median	1829.2	51.2	1854.8	100.0	150.0	100.0	1910.6
	Min	856.8	18.8	945.1	100.0	100.0	100.0	954.2
	Max	3682.7	266.4	3721.2	100.0	250.0	300.0	3721.2

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 2								
WEEK 1	n	79	54	79	9	1	10	79
	Mean	1415.2	67.1	1461.1	138.9	150.0	140.0	1478.8
	SD	593.58	53.82	592.24	69.72	NA	65.83	598.97
	Median	1352.3	44.8	1393.3	100.0	150.0	100.0	1393.3
	Min	430.3	18.8	486.6	100.0	150.0	100.0	486.6
	Max	3279.8	256.1	3279.8	300.0	150.0	300.0	3379.8
WEEK 2	n	78	61	78	14	2	15	78
	Mean	1508.9	77.3	1569.4	182.1	137.5	188.3	1605.6
	SD	597.64	59.61	604.60	72.34	17.68	67.39	617.16
	Median	1506.0	51.2	1522.2	200.0	137.5	200.0	1594.0
	Min	630.1	18.8	668.5	100.0	125.0	100.0	668.5
	Max	3606.2	281.7	3606.2	300.0	150.0	300.0	3606.2
WEEK 3	n	76	58	76	8	1	9	76
	Mean	1527.1	75.7	1584.9	150.0	100.0	144.4	1602.0
	SD	575.97	51.23	587.08	88.64	NA	84.57	594.64
	Median	1527.2	62.8	1560.4	100.0	100.0	100.0	1593.3
	Min	686.5	18.8	686.5	100.0	100.0	100.0	686.5
	Max	3016.4	225.4	3053.9	350.0	100.0	350.0	3053.9
WEEK 4	n	75	57	75	7	0	7	75
	Mean	1593.7	66.7	1644.3	192.9		192.9	1662.3
	SD	590.16	44.28	597.86	101.77		101.77	598.57
	Median	1615.3	51.2	1650.5	200.0		200.0	1694.4
	Min	672.0	18.8	703.8	100.0		100.0	703.8
	Max	2932.2	204.9	3096.1	350.0		350.0	3096.1

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 2 (Cont.)								
WEEK 6	n	70	52	70	8	1	8	70
	Mean	1642.4	62.4	1688.8	175.0	100.0	187.5	1710.2
	SD	609.50	43.53	616.01	125.36	NA	121.74	615.80
	Median	1689.2	44.8	1725.8	100.0	100.0	150.0	1762.6
	Min	672.0	18.8	686.5	100.0	100.0	100.0	686.5
	Max	2984.7	204.9	3107.7	450.0	100.0	450.0	3107.7
WEEK 13	n	69	47	69	10	0	10	69
	Mean	1631.4	65.8	1676.2	135.0		135.0	1695.8
	SD	632.82	41.33	636.83	52.97		52.97	644.77
	Median	1634.1	51.2	1699.5	100.0		100.0	1714.9
	Min	682.1	18.8	697.3	100.0		100.0	697.3
	Max	3269.9	204.9	3392.8	250.0		250.0	3392.8
WEEK 26	n	61	44	61	14	2	15	61
	Mean	1628.4	62.8	1673.6	121.4	100.0	126.7	1704.8
	SD	654.14	42.26	654.22	37.80	0.00	56.27	659.89
	Median	1610.5	51.2	1705.3	100.0	100.0	100.0	1762.1
	Min	669.1	18.8	705.3	100.0	100.0	100.0	705.3
	Max	3176.0	179.3	3252.8	200.0	100.0	300.0	3252.8
WEEK 39	n	49	36	49	14	0	14	49
	Mean	1527.9	68.1	1577.9	139.3		139.3	1617.7
	SD	639.49	42.72	637.47	62.57		62.57	657.23
	Median	1575.7	56.3	1613.0	100.0		100.0	1643.8
	Min	657.0	18.8	657.0	100.0		100.0	657.0
	Max	2968.3	178.4	2996.5	300.0		300.0	3110.6

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample / Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 2 (Cont.)								
WEEK 52	n	39	23	39	8	2	10	39
	Mean	1601.7	65.1	1640.1	112.5	187.5	127.5	1672.8
	SD	720.59	51.61	722.44	35.36	88.39	53.29	739.48
	Median	1557.2	41.0	1557.2	100.0	187.5	100.0	1557.2
	Min	669.1	18.8	669.1	100.0	125.0	100.0	716.5
	Max	3385.4	230.5	3404.2	200.0	250.0	250.0	3404.2

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample	Week	ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Both Enrollment Samples								
	WEEK 1 n	220	138	220	28	4	30	220
	Mean	1573.7	76.8	1621.9	132.1	137.5	141.7	1641.2
	SD	653.80	62.36	657.31	62.68	47.87	63.09	667.22
	Median	1440.8	56.3	1501.4	100.0	125.0	100.0	1521.0
	Min	430.3	18.8	486.6	100.0	100.0	100.0	486.6
	Max	3524.3	327.8	3562.7	300.0	200.0	300.0	3710.4
	WEEK 2 n	220	155	220	33	5	36	220
	Mean	1666.6	80.7	1723.4	171.2	135.0	175.7	1752.1
	SD	657.07	62.94	660.70	93.57	41.83	89.34	670.83
	Median	1572.8	61.5	1629.4	100.0	125.0	175.0	1646.2
	Min	630.1	18.8	668.5	100.0	100.0	100.0	668.5
	Max	4072.4	368.8	4136.4	450.0	200.0	450.0	4136.4
	WEEK 3 n	200	139	200	23	3	26	200
	Mean	1711.5	73.7	1762.8	134.8	100.0	130.8	1779.8
	SD	663.38	54.70	669.51	61.12	0.00	58.44	673.67
	Median	1595.9	51.2	1657.6	100.0	100.0	100.0	1665.9
	Min	686.5	18.8	686.5	100.0	100.0	100.0	686.5
	Max	4021.2	333.0	4059.6	350.0	100.0	350.0	4059.6
	WEEK 4 n	192	136	192	20	0	20	192
	Mean	1770.2	66.2	1817.1	155.0		155.0	1833.3
	SD	683.36	50.10	686.98	95.83		95.83	692.36
	Median	1687.1	51.2	1740.2	100.0		100.0	1752.0
	Min	672.0	18.8	696.7	100.0		100.0	696.7
	Max	4080.9	281.7	4106.5	400.0		400.0	4106.5

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample / Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Both Enrollment Samples (Cont.)								
WEEK 6	n	183	129	183	26	4	29	183
	Mean	1788.7	61.9	1832.3	153.8	175.0	162.1	1858.0
	SD	682.20	40.92	689.68	119.10	86.60	115.46	695.38
	Median	1721.2	48.7	1762.1	100.0	175.0	100.0	1831.5
	Min	672.0	18.8	686.5	100.0	100.0	100.0	686.5
	Max	4055.3	204.9	4119.3	600.0	250.0	600.0	4119.3
WEEK 13	n	172	116	172	30	5	34	172
	Mean	1798.7	62.3	1840.6	148.3	190.0	158.8	1872.0
	SD	714.97	48.05	718.85	157.28	54.77	148.97	731.52
	Median	1720.2	51.2	1783.0	100.0	200.0	100.0	1820.3
	Min	682.1	18.8	697.3	100.0	100.0	100.0	697.3
	Max	4098.0	307.4	4116.8	950.0	250.0	950.0	4316.8
WEEK 26	n	152	98	152	30	10	35	152
	Mean	1775.8	59.6	1814.2	135.0	145.0	157.1	1850.4
	SD	718.19	40.88	722.29	90.16	72.46	105.12	737.12
	Median	1652.9	47.8	1720.7	100.0	100.0	100.0	1765.0
	Min	669.1	18.8	705.3	100.0	100.0	100.0	705.3
	Max	4098.0	230.5	4098.0	550.0	250.0	550.0	4098.0
WEEK 39	n	128	86	128	29	7	31	128
	Mean	1755.2	67.4	1800.6	144.8	164.3	172.6	1842.3
	SD	700.91	54.07	702.85	91.95	85.22	105.55	726.50
	Median	1677.4	51.2	1726.0	100.0	100.0	100.0	1751.2
	Min	657.0	18.8	657.0	100.0	100.0	100.0	657.0
	Max	3961.4	307.4	3987.0	550.0	300.0	550.0	3987.0

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample / Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Both Enrollment Samples (Cont.)								
WEEK 52	n	109	64	109	22	6	27	109
	Mean	1808.0	66.4	1847.0	104.5	170.8	123.1	1877.5
	SD	711.67	54.82	713.09	21.32	71.44	55.87	722.73
	Median	1719.9	49.9	1762.1	100.0	162.5	100.0	1767.4
	Min	669.1	18.8	669.1	100.0	100.0	100.0	716.5
	Max	3682.7	266.4	3721.2	200.0	250.0	300.0	3721.2

Program Source Code: [redacted]

表2.7.4.7-2　LDの1日あたりの投与量（安全性解析対象集団）：M15-737試験

[redacted]20[redacted] 07:19 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.1__8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

		ABBV-951 CSCI			Oral			
Week		Continuous Infusion	Extra Dose	Total	Rescue Dose	Loading Dose	Total	Overall Total
WEEK 12	n	66	35	66	10	0	10	66
	Mean	1953.3	76.9	1994.0	110.0		110.0	2010.7
	SD	803.28	70.31	808.67	31.62		31.62	809.08
	Median	1829.8	48.7	1870.4	100.0		100.0	1870.4
	Min	664.7	18.8	664.7	100.0		100.0	664.7
	Max	4049.3	307.4	4074.9	200.0		200.0	4074.9
WEEK 24	n	64	37	64	8	3	11	64
	Mean	1996.2	78.8	2041.7	137.5	158.3	143.2	2066.3
	SD	684.62	75.38	693.84	74.40	80.36	72.54	706.36
	Median	1958.1	51.2	1985.1	100.0	125.0	100.0	2020.5
	Min	865.4	18.8	949.4	100.0	100.0	100.0	949.4
	Max	3613.8	333.0	3637.7	300.0	250.0	300.0	3737.7
WEEK 36	n	62	28	62	5	1	6	62
	Mean	2040.1	68.4	2071.0	110.0	250.0	133.3	2083.9
	SD	709.17	55.28	707.48	22.36	N/A	60.55	705.55
	Median	1978.4	51.2	2017.4	100.0	250.0	100.0	2017.4
	Min	857.5	18.8	954.2	100.0	250.0	100.0	954.2
	Max	3725.4	256.1	3725.4	150.0	250.0	250.0	3725.4
WEEK 48	n	43	24	43	1	1	2	43
	Mean	2098.4	77.5	2141.7	100.0	250.0	175.0	2149.8
	SD	734.09	77.37	738.04	N/A	N/A	106.07	736.56
	Median	2031.8	37.6	2107.6	100.0	250.0	175.0	2107.6
	Min	855.8	18.8	953.1	100.0	250.0	100.0	953.1
	Max	4031.9	281.7	4057.5	100.0	250.0	250.0	4057.5

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Week		ABBV-951 CSCI			Oral			Overall Total
		Continuous Infusion	Extra Dose	Total	Rescue Dose	Loading Dose	Total	
WEEK 60	n	15	6	15	1	0	1	15
	Mean	1899.8	63.5	1925.2	100.0		100.0	1931.9
	SD	724.19	56.98	761.30	N/A		N/A	766.89
	Median	1973.9	41.0	1973.9	100.0		100.0	1973.9
	Min	876.6	32.4	876.6	100.0		100.0	876.6
	Max	3738.7	179.3	3918.0	100.0		100.0	3918.0
WEEK 72	n	4	4	4	0	0	0	4
	Mean	2457.7	47.6	2505.3				2505.3
	SD	1010.29	14.33	1005.87				1005.87
	Median	2343.5	46.1	2380.3				2380.3
	Min	1349.5	32.4	1415.3				1415.3
	Max	3794.1	65.7	3845.3				3845.3
WEEK 84	n	2	2	2	0	0	0	2
	Mean	1817.0	39.3	1856.2				1856.2
	SD	665.03	2.41	667.44				667.44
	Median	1817.0	39.3	1856.2				1856.2
	Min	1346.7	37.6	1384.3				1384.3
	Max	2287.2	41.0	2328.2				2328.2

Program Source Code: [redacted]

表2.7.4.7-3　二重盲検期のLDの1日あたりの投与量（安全性解析対象集団）：M15-736試験

[redacted]20[redacted] 19:30 <[redacted]>
ABBV-951
STUDY M15-736
R&D/20/1640 - CLINICAL/STATISTICAL

TABLE 14.1__8.1

Daily Levodopa Dose during Double-Blind Treatment Period from Dosing Diary
(Safety Analysis Set)

	Oral CD/LD			ABBV-951				
Days	Oral Encapsulated CD/LD	Rescue Dose	Total	Loading Dose	Continuous Infusion	ABBV-951 Total	Rescue Dose	Total
1 - 7								
n	46	12	46	0	58	58	19	58
Mean	1037.0	187.5	1085.9		1587.6	1587.6	174.6	1644.8
SD	616.09	104.23	648.42		773.53	773.53	102.49	778.14
Median	816.7	150.0	816.7		1379.2	1379.2	150.0	1488.9
Min	100.0	100.0	400.0		641.5	641.5	100.0	641.5
Max	2700.0	366.7	2866.7		4069.0	4069.0	466.7	4069.0
8 - 14								
n	51	14	51	0	53	53	23	53
Mean	1088.2	266.7	1159.5		1595.7	1595.7	221.0	1691.6
SD	602.00	193.92	681.24		704.25	704.25	159.09	758.95
Median	1000.0	200.0	1000.0		1477.5	1477.5	166.7	1626.9
Min	200.0	100.0	200.0		634.0	634.0	100.0	634.0
Max	2666.7	700.0	3066.7		3721.6	3721.6	600.0	3821.6
15 - 21								
n	43	16	43	0	51	51	22	51
Mean	998.4	207.3	1075.6		1634.5	1634.5	217.4	1728.3
SD	610.63	143.11	664.52		683.03	683.03	147.42	750.06
Median	866.7	133.3	900.0		1516.3	1516.3	166.7	1743.0
Min	200.0	100.0	200.0		640.1	640.1	100.0	640.1
Max	2500.0	500.0	2900.0		3694.0	3694.0	700.0	3927.3

Note: LDP doses from ABBV-951 are converted to levodopa dose using molecular weight conversion 100 mg LDP = 71 mg levodopa.
Data of 3 closest valid dosing diary day to visits day 8, 15, 22, 29, 57, 85, and final visit was used.

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose during Double-Blind Treatment Period from Dosing Diary
(Safety Analysis Set)

	Oral CD/LD			ABBV-951				
Days	Oral Encapsulated CD/LD	Rescue Dose	Total	Loading Dose	Continuous Infusion	ABBV-951 Total	Rescue Dose	Total
22 - 28								
n	52	18	52	0	45	45	24	45
Mean	1139.7	240.7	1223.1		1690.1	1690.1	204.9	1799.4
SD	645.01	186.93	713.63		762.75	762.75	127.17	794.34
Median	1000.0	150.0	1025.0		1479.6	1479.6	166.7	1766.8
Min	200.0	100.0	200.0		644.8	644.8	100.0	644.8
Max	2633.3	700.0	3066.7		3910.1	3910.1	566.7	4043.4
29 - 56								
n	53	16	53	0	38	38	22	38
Mean	1099.4	252.1	1175.5		1777.1	1777.1	187.9	1885.9
SD	630.51	180.52	675.40		799.98	799.98	111.17	851.37
Median	933.3	200.0	933.3		1630.7	1630.7	158.3	1774.2
Min	200.0	100.0	200.0		643.7	643.7	100.0	643.7
Max	2600.0	733.3	2833.3		3880.5	3880.5	566.7	4180.5
>= 57								
n	50	15	50	0	38	38	18	38
Mean	1169.7	287.8	1256.0		1762.0	1762.0	168.5	1841.8
SD	597.27	191.33	659.59		771.11	771.11	98.67	814.19
Median	1000.0	200.0	1050.0		1609.0	1609.0	116.7	1737.3
Min	400.0	100.0	400.0		678.3	678.3	100.0	678.3
Max	2600.0	700.0	2966.7		3978.1	3978.1	466.7	4272.0

Note: LDP doses from ABBV-951 are converted to levodopa dose using molecular weight conversion 100 mg LDP = 71 mg levodopa.
Data of 3 closest valid dosing diary day to visits day 8, 15, 22, 29, 57, 85, and final visit was used.

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose during Double-Blind Treatment Period from Dosing Diary
(Safety Analysis Set)

	Oral CD/LD			ABBV-951				
Days	Oral Encapsulated CD/LD	Rescue Dose	Total	Loading Dose	Continuous Infusion	ABBV-951 Total	Rescue Dose	Total
Final								
n	58	17	58	0	61	61	28	61
Mean	1131.9	277.5	1213.2		1703.7	1703.7	195.2	1793.3
SD	577.83	184.74	631.43		749.48	749.48	117.14	790.57
Median	1000.0	200.0	1050.0		1613.6	1613.6	166.7	1729.6
Min	400.0	100.0	400.0		643.7	643.7	100.0	643.7
Max	2600.0	700.0	2966.7		3978.1	3978.1	466.7	4272.0

Note: LDP doses from ABBV-951 are converted to levodopa dose using molecular weight conversion 100 mg LDP = 71 mg levodopa.
Data of 3 closest valid dosing diary day to visits day 8, 15, 22, 29, 57, 85, and final visit was used.

Program Source Code: [redacted]

表2.7.4.7-4　2%以上の被験者に発現した有害事象（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 16:20 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period	N=132	N=112	N=244
Any adverse event	121 (91.7)	106 (94.6)	227 (93.0)
耳および迷路障害	3 (2.3)	2 (1.8)	5 (2.0)
回転性めまい	3 (2.3)	2 (1.8)	5 (2.0)
眼障害	1 (0.8)	3 (2.7)	4 (1.6)
ドライアイ	1 (0.8)	3 (2.7)	4 (1.6)
胃腸障害	22 (16.7)	27 (24.1)	49 (20.1)
腹部膨満	1 (0.8)	3 (2.7)	4 (1.6)
便秘	8 (6.1)	12 (10.7)	20 (8.2)
下痢	6 (4.5)	3 (2.7)	9 (3.7)
口内乾燥	3 (2.3)	5 (4.5)	8 (3.3)
悪心	8 (6.1)	11 (9.8)	19 (7.8)
嘔吐	3 (2.3)	3 (2.7)	6 (2.5)
一般・全身障害および投与部位の状態	99 (75.0)	94 (83.9)	193 (79.1)
無力症	3 (2.3)	0	3 (1.2)
疲労	6 (4.5)	3 (2.7)	9 (3.7)
注入部位内出血	10 (7.6)	8 (7.1)	18 (7.4)
注入部位不快感	3 (2.3)	1 (0.9)	4 (1.6)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
一般・全身障害および投与部位の状態 (Cont.)			
注入部位紅斑	65 (49.2)	60 (53.6)	125 (51.2)
注入部位皮膚剥脱	3 (2.3)	3 (2.7)	6 (2.5)
注入部位血管外漏出	8 (6.1)	12 (10.7)	20 (8.2)
注入部位血腫	8 (6.1)	8 (7.1)	16 (6.6)
注入部位出血	4 (3.0)	5 (4.5)	9 (3.7)
注入部位硬結	7 (5.3)	3 (2.7)	10 (4.1)
注入部位炎症	3 (2.3)	6 (5.4)	9 (3.7)
注入部位刺激感	1 (0.8)	4 (3.6)	5 (2.0)
注入部位腫瘤	5 (3.8)	3 (2.7)	8 (3.3)
注入部位結節	34 (25.8)	34 (30.4)	68 (27.9)
注入部位浮腫	19 (14.4)	28 (25.0)	47 (19.3)
注入部位疼痛	18 (13.6)	20 (17.9)	38 (15.6)
注入部位蒼白	3 (2.3)	1 (0.9)	4 (1.6)
注入部位丘疹	7 (5.3)	11 (9.8)	18 (7.4)
注入部位そう痒感	5 (3.8)	2 (1.8)	7 (2.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
一般・全身障害および投与部位の状態 (Cont.)			
注入部位発疹	3 (2.3)	4 (3.6)	7 (2.9)
注入部位反応	13 (9.8)	18 (16.1)	31 (12.7)
注入部位腫脹	4 (3.0)	2 (1.8)	6 (2.5)
注射部位紅斑	6 (4.5)	8 (7.1)	14 (5.7)
注射部位炎症	2 (1.5)	4 (3.6)	6 (2.5)
注射部位結節	3 (2.3)	6 (5.4)	9 (3.7)
注射部位浮腫	2 (1.5)	3 (2.7)	5 (2.0)
注射部位疼痛	2 (1.5)	6 (5.4)	8 (3.3)
末梢性浮腫	5 (3.8)	4 (3.6)	9 (3.7)
末梢腫脹	0	4 (3.6)	4 (1.6)
穿刺部位紅斑	0	3 (2.7)	3 (1.2)
感染症および寄生虫症	48 (36.4)	50 (44.6)	98 (40.2)
注入部位膿瘍	13 (9.8)	13 (11.6)	26 (10.7)
注入部位蜂巣炎	29 (22.0)	27 (24.1)	56 (23.0)
注入部位感染	6 (4.5)	11 (9.8)	17 (7.0)
注射部位蜂巣炎	0	3 (2.7)	3 (1.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
感染症および寄生虫症 (Cont.)			
上咽頭炎	5 (3.8)	5 (4.5)	10 (4.1)
肺炎	3 (2.3)	1 (0.9)	4 (1.6)
敗血症	3 (2.3)	1 (0.9)	4 (1.6)
尿路感染	8 (6.1)	11 (9.8)	19 (7.8)
傷害、中毒および処置合併症	16 (12.1)	23 (20.5)	39 (16.0)
挫傷	2 (1.5)	6 (5.4)	8 (3.3)
転倒	16 (12.1)	23 (20.5)	39 (16.0)
皮膚裂傷	1 (0.8)	6 (5.4)	7 (2.9)
臨床検査	15 (11.4)	17 (15.2)	32 (13.1)
ビタミンB6減少	5 (3.8)	6 (5.4)	11 (4.5)
体重減少	10 (7.6)	12 (10.7)	22 (9.0)
代謝および栄養障害	7 (5.3)	12 (10.7)	19 (7.8)
食欲減退	3 (2.3)	2 (1.8)	5 (2.0)
脱水	1 (0.8)	3 (2.7)	4 (1.6)
低カリウム血症	0	3 (2.7)	3 (1.2)
ビタミンB6欠乏	3 (2.3)	5 (4.5)	8 (3.3)
筋骨格系および結合組織障害	19 (14.4)	14 (12.5)	33 (13.5)
関節痛	3 (2.3)	3 (2.7)	6 (2.5)
背部痛	8 (6.1)	4 (3.6)	12 (4.9)
筋痙縮	2 (1.5)	3 (2.7)	5 (2.0)
筋力低下	4 (3.0)	1 (0.9)	5 (2.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
筋骨格系および結合組織障害 (Cont.)			
変形性関節症	1 (0.8)	4 (3.6)	5 (2.0)
四肢痛	3 (2.3)	3 (2.7)	6 (2.5)
神経系障害	51 (38.6)	37 (33.0)	88 (36.1)
平衡障害	0	4 (3.6)	4 (1.6)
認知障害	4 (3.0)	2 (1.8)	6 (2.5)
浮動性めまい	15 (11.4)	10 (8.9)	25 (10.2)
体位性めまい	5 (3.8)	0	5 (2.0)
構語障害	0	3 (2.7)	3 (1.2)
ジスキネジア	12 (9.1)	6 (5.4)	18 (7.4)
ジストニア	2 (1.5)	5 (4.5)	7 (2.9)
すくみ現象	4 (3.0)	0	4 (1.6)
頭痛	7 (5.3)	7 (6.3)	14 (5.7)
オンオフ現象	4 (3.0)	4 (3.6)	8 (3.3)
錯感覚	4 (3.0)	3 (2.7)	7 (2.9)
パーキンソン病	12 (9.1)	5 (4.5)	17 (7.0)
パーキンソニズム	0	3 (2.7)	3 (1.2)
坐骨神経痛	0	3 (2.7)	3 (1.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
神経系障害 (Cont.)			
傾眠	9 (6.8)	3 (2.7)	12 (4.9)
失神	0	3 (2.7)	3 (1.2)
精神障害	40 (30.3)	47 (42.0)	87 (35.7)
不安	10 (7.6)	18 (16.1)	28 (11.5)
錯乱状態	4 (3.0)	4 (3.6)	8 (3.3)
譫妄	1 (0.8)	4 (3.6)	5 (2.0)
妄想	8 (6.1)	2 (1.8)	10 (4.1)
幻覚	20 (15.2)	21 (18.8)	41 (16.8)
幻聴	3 (2.3)	3 (2.7)	6 (2.5)
幻視	10 (7.6)	5 (4.5)	15 (6.1)
衝動制御障害	0	4 (3.6)	4 (1.6)
不眠症	9 (6.8)	9 (8.0)	18 (7.4)
パニック発作	0	3 (2.7)	3 (1.2)
精神病性障害	4 (3.0)	2 (1.8)	6 (2.5)
腎および尿路障害	6 (4.5)	3 (2.7)	9 (3.7)
切迫性尿失禁	3 (2.3)	0	3 (1.2)
尿失禁	3 (2.3)	2 (1.8)	5 (2.0)
尿閉	0	3 (2.7)	3 (1.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
呼吸器、胸郭および縦隔障害	2 (1.5)	6 (5.4)	8 (3.3)
呼吸困難	2 (1.5)	6 (5.4)	8 (3.3)
皮膚および皮下組織障害	1 (0.8)	3 (2.7)	4 (1.6)
紅斑	1 (0.8)	3 (2.7)	4 (1.6)
血管障害	10 (7.6)	10 (8.9)	20 (8.2)
高血圧	3 (2.3)	3 (2.7)	6 (2.5)
低血圧	2 (1.5)	4 (3.6)	6 (2.5)
起立性低血圧	6 (4.5)	6 (5.4)	12 (4.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period	N=132	N=112	N=244
Any adverse event	99 (75.0)	91 (81.3)	190 (77.9)
胃腸障害	7 (5.3)	8 (7.1)	15 (6.1)
口内乾燥	2 (1.5)	3 (2.7)	5 (2.0)
悪心	5 (3.8)	5 (4.5)	10 (4.1)
一般・全身障害および投与部位の状態	80 (60.6)	75 (67.0)	155 (63.5)
疲労	3 (2.3)	2 (1.8)	5 (2.0)
注入部位内出血	3 (2.3)	7 (6.3)	10 (4.1)
注入部位紅斑	50 (37.9)	45 (40.2)	95 (38.9)
注入部位血管外漏出	4 (3.0)	7 (6.3)	11 (4.5)
注入部位血腫	4 (3.0)	4 (3.6)	8 (3.3)
注入部位出血	0	3 (2.7)	3 (1.2)
注入部位硬結	4 (3.0)	1 (0.9)	5 (2.0)
注入部位炎症	1 (0.8)	3 (2.7)	4 (1.6)
注入部位腫瘤	4 (3.0)	1 (0.9)	5 (2.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period (Cont.)	N=132	N=112	N=244
一般・全身障害および投与部位の状態 (Cont.)			
注入部位結節	20 (15.2)	18 (16.1)	38 (15.6)
注入部位浮腫	14 (10.6)	16 (14.3)	30 (12.3)
注入部位疼痛	13 (9.8)	14 (12.5)	27 (11.1)
注入部位丘疹	1 (0.8)	4 (3.6)	5 (2.0)
注入部位反応	9 (6.8)	12 (10.7)	21 (8.6)
注入部位腫脹	3 (2.3)	1 (0.9)	4 (1.6)
注射部位紅斑	5 (3.8)	5 (4.5)	10 (4.1)
注射部位疼痛	2 (1.5)	4 (3.6)	6 (2.5)
末梢性浮腫	1 (0.8)	3 (2.7)	4 (1.6)
感染症および寄生虫症	13 (9.8)	22 (19.6)	35 (14.3)
注入部位膿瘍	3 (2.3)	5 (4.5)	8 (3.3)
注入部位蜂巣炎	10 (7.6)	13 (11.6)	23 (9.4)
注入部位感染	1 (0.8)	3 (2.7)	4 (1.6)
上咽頭炎	0	3 (2.7)	3 (1.2)
尿路感染	3 (2.3)	3 (2.7)	6 (2.5)
傷害、中毒および処置合併症	7 (5.3)	9 (8.0)	16 (6.6)
転倒	7 (5.3)	9 (8.0)	16 (6.6)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Optimization period (Cont.)	N=132	N=112	N=244
筋骨格系および結合組織障害	3 (2.3)	1 (0.9)	4 (1.6)
背部痛	3 (2.3)	1 (0.9)	4 (1.6)
神経系障害	27 (20.5)	17 (15.2)	44 (18.0)
浮動性めまい	10 (7.6)	8 (7.1)	18 (7.4)
体位性めまい	3 (2.3)	0	3 (1.2)
ジスキネジア	6 (4.5)	3 (2.7)	9 (3.7)
すくみ現象	3 (2.3)	0	3 (1.2)
頭痛	4 (3.0)	2 (1.8)	6 (2.5)
オンオフ現象	3 (2.3)	3 (2.7)	6 (2.5)
パーキンソン病	5 (3.8)	3 (2.7)	8 (3.3)
精神障害	21 (15.9)	19 (17.0)	40 (16.4)
不安	2 (1.5)	8 (7.1)	10 (4.1)
幻覚	13 (9.8)	5 (4.5)	18 (7.4)
幻視	4 (3.0)	1 (0.9)	5 (2.0)
不眠症	7 (5.3)	3 (2.7)	10 (4.1)
パニック発作	0	3 (2.7)	3 (1.2)
血管障害	1 (0.8)	4 (3.6)	5 (2.0)
起立性低血圧	1 (0.8)	4 (3.6)	5 (2.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period	N=111	N=95	N=206
Any adverse event	95 (85.6)	85 (89.5)	180 (87.4)
眼障害	3 (2.7)	4 (4.2)	7 (3.4)
白内障	2 (1.8)	2 (2.1)	4 (1.9)
ドライアイ	1 (0.9)	3 (3.2)	4 (1.9)
胃腸障害	13 (11.7)	19 (20.0)	32 (15.5)
腹部膨満	1 (0.9)	2 (2.1)	3 (1.5)
便秘	6 (5.4)	10 (10.5)	16 (7.8)
下痢	4 (3.6)	1 (1.1)	5 (2.4)
口内乾燥	1 (0.9)	3 (3.2)	4 (1.9)
悪心	4 (3.6)	7 (7.4)	11 (5.3)
嘔吐	1 (0.9)	2 (2.1)	3 (1.5)
一般・全身障害および投与部位の状態	65 (58.6)	71 (74.7)	136 (66.0)
投与部位漏出	0	2 (2.1)	2 (1.0)
疲労	3 (2.7)	1 (1.1)	4 (1.9)
インフルエンザ様疾患	1 (0.9)	2 (2.1)	3 (1.5)
注入部位内出血	7 (6.3)	2 (2.1)	9 (4.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
一般・全身障害および投与部位の状態 (Cont.)			
注入部位皮膚炎	2 (1.8)	2 (2.1)	4 (1.9)
注入部位紅斑	35 (31.5)	43 (45.3)	78 (37.9)
注入部位皮膚剥脱	3 (2.7)	2 (2.1)	5 (2.4)
注入部位血管外漏出	5 (4.5)	6 (6.3)	11 (5.3)
注入部位血腫	4 (3.6)	4 (4.2)	8 (3.9)
注入部位出血	4 (3.6)	2 (2.1)	6 (2.9)
注入部位硬結	5 (4.5)	2 (2.1)	7 (3.4)
注入部位炎症	2 (1.8)	6 (6.3)	8 (3.9)
注入部位損傷	1 (0.9)	2 (2.1)	3 (1.5)
注入部位刺激感	1 (0.9)	4 (4.2)	5 (2.4)
注入部位腫瘤	1 (0.9)	2 (2.1)	3 (1.5)
注入部位結節	20 (18.0)	25 (26.3)	45 (21.8)
注入部位浮腫	8 (7.2)	18 (18.9)	26 (12.6)
注入部位疼痛	8 (7.2)	11 (11.6)	19 (9.2)
注入部位丘疹	6 (5.4)	8 (8.4)	14 (6.8)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
一般・全身障害および投与部位の状態 (Cont.)			
注入部位異常感覚	0	2 (2.1)	2 (1.0)
注入部位そう痒感	3 (2.7)	1 (1.1)	4 (1.9)
注入部位発疹	1 (0.9)	3 (3.2)	4 (1.9)
注入部位反応	8 (7.2)	11 (11.6)	19 (9.2)
注入部位小水疱	0	2 (2.1)	2 (1.0)
注射部位紅斑	5 (4.5)	5 (5.3)	10 (4.9)
注射部位炎症	2 (1.8)	4 (4.2)	6 (2.9)
注射部位結節	3 (2.7)	5 (5.3)	8 (3.9)
注射部位疼痛	0	2 (2.1)	2 (1.0)
注射部位腫脹	1 (0.9)	2 (2.1)	3 (1.5)
非心臓性胸痛	0	2 (2.1)	2 (1.0)
末梢性浮腫	4 (3.6)	1 (1.1)	5 (2.4)
末梢腫脹	0	3 (3.2)	3 (1.5)
穿刺部位紅斑	0	2 (2.1)	2 (1.0)
感染症および寄生虫症	38 (34.2)	38 (40.0)	76 (36.9)
注入部位膿瘍	10 (9.0)	9 (9.5)	19 (9.2)
注入部位蜂巣炎	21 (18.9)	19 (20.0)	40 (19.4)
注入部位感染	5 (4.5)	9 (9.5)	14 (6.8)
注射部位蜂巣炎	0	2 (2.1)	2 (1.0)
上咽頭炎	5 (4.5)	2 (2.1)	7 (3.4)
尿路感染	5 (4.5)	11 (11.6)	16 (7.8)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
傷害、中毒および処置合併症	11 (9.9)	18 (18.9)	29 (14.1)
挫傷	1 (0.9)	6 (6.3)	7 (3.4)
転倒	11 (9.9)	17 (17.9)	28 (13.6)
頭部損傷	1 (0.9)	2 (2.1)	3 (1.5)
皮膚擦過傷	0	2 (2.1)	2 (1.0)
皮膚裂傷	1 (0.9)	4 (4.2)	5 (2.4)
臨床検査	16 (14.4)	15 (15.8)	31 (15.0)
血中葉酸減少	1 (0.9)	2 (2.1)	3 (1.5)
血中ホモシステイン増加	1 (0.9)	2 (2.1)	3 (1.5)
ビタミンB6減少	5 (4.5)	4 (4.2)	9 (4.4)
体重減少	10 (9.0)	11 (11.6)	21 (10.2)
代謝および栄養障害	4 (3.6)	8 (8.4)	12 (5.8)
脱水	1 (0.9)	2 (2.1)	3 (1.5)
低カリウム血症	0	2 (2.1)	2 (1.0)
ビタミンB12欠乏	0	2 (2.1)	2 (1.0)
ビタミンB6欠乏	3 (2.7)	5 (5.3)	8 (3.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
筋骨格系および結合組織障害	11 (9.9)	10 (10.5)	21 (10.2)
背部痛	5 (4.5)	3 (3.2)	8 (3.9)
関節滲出液	0	2 (2.1)	2 (1.0)
筋痙縮	2 (1.8)	3 (3.2)	5 (2.4)
変形性関節症	1 (0.9)	4 (4.2)	5 (2.4)
四肢痛	3 (2.7)	2 (2.1)	5 (2.4)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	2 (2.1)	2 (1.0)
基底細胞癌	0	2 (2.1)	2 (1.0)
神経系障害	30 (27.0)	26 (27.4)	56 (27.2)
平衡障害	0	4 (4.2)	4 (1.9)
認知障害	2 (1.8)	2 (2.1)	4 (1.9)
浮動性めまい	6 (5.4)	2 (2.1)	8 (3.9)
体位性めまい	3 (2.7)	0	3 (1.5)
構語障害	0	2 (2.1)	2 (1.0)
ジスキネジア	7 (6.3)	3 (3.2)	10 (4.9)
ジストニア	1 (0.9)	4 (4.2)	5 (2.4)
頭痛	3 (2.7)	6 (6.3)	9 (4.4)
感覚鈍麻	1 (0.9)	2 (2.1)	3 (1.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
神経系障害 (Cont.)			
記憶障害	0	2 (2.1)	2 (1.0)
錯感覚	4 (3.6)	2 (2.1)	6 (2.9)
パーキンソン病	7 (6.3)	2 (2.1)	9 (4.4)
パーキンソニズム	0	2 (2.1)	2 (1.0)
側反弓	1 (0.9)	2 (2.1)	3 (1.5)
多発ニューロパチー	0	2 (2.1)	2 (1.0)
坐骨神経痛	0	3 (3.2)	3 (1.5)
傾眠	8 (7.2)	1 (1.1)	9 (4.4)
失神	0	3 (3.2)	3 (1.5)
精神障害	30 (27.0)	34 (35.8)	64 (31.1)
不安	9 (8.1)	12 (12.6)	21 (10.2)
錯乱状態	4 (3.6)	3 (3.2)	7 (3.4)
譫妄	0	2 (2.1)	2 (1.0)
妄想	7 (6.3)	1 (1.1)	8 (3.9)
うつ病	2 (1.8)	2 (2.1)	4 (1.9)
幻覚	12 (10.8)	18 (18.9)	30 (14.6)
幻聴	3 (2.7)	2 (2.1)	5 (2.4)
幻視	6 (5.4)	4 (4.2)	10 (4.9)
衝動制御障害	0	4 (4.2)	4 (1.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
精神障害 (Cont.)			
不眠症	2 (1.8)	6 (6.3)	8 (3.9)
精神病性障害	3 (2.7)	2 (2.1)	5 (2.4)
自殺念慮	1 (0.9)	2 (2.1)	3 (1.5)
腎および尿路障害	1 (0.9)	3 (3.2)	4 (1.9)
尿失禁	1 (0.9)	2 (2.1)	3 (1.5)
尿閉	0	3 (3.2)	3 (1.5)
呼吸器、胸郭および縦隔障害	2 (1.8)	9 (9.5)	11 (5.3)
発声障害	0	2 (2.1)	2 (1.0)
呼吸困難	2 (1.8)	5 (5.3)	7 (3.4)
肺塞栓症	0	2 (2.1)	2 (1.0)
皮膚および皮下組織障害	1 (0.9)	4 (4.2)	5 (2.4)
紅斑	1 (0.9)	2 (2.1)	3 (1.5)
丘疹	0	2 (2.1)	2 (1.0)
血管障害	9 (8.1)	6 (6.3)	15 (7.3)
高血圧	1 (0.9)	2 (2.1)	3 (1.5)
低血圧	2 (1.8)	2 (2.1)	4 (1.9)
起立性低血圧	6 (5.4)	3 (3.2)	9 (4.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

表2.7.4.7-5　2例以上の被験者に発現した有害事象（安全性解析対象集団）：M15-737試験

[redacted]20[redacted] 04:22 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.3__1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2 subjects or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose (N=45) n (%)	Dose Category High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Any adverse event	21 (46.7)	36 (60.0)	57 (54.3)
胃腸障害	3 (6.7)	2 (3.3)	5 (4.8)
便秘	3 (6.7)	2 (3.3)	5 (4.8)
一般・全身障害および投与部位の状態	10 (22.2)	14 (23.3)	24 (22.9)
注入部位内出血	2 (4.4)	2 (3.3)	4 (3.8)
注入部位紅斑	6 (13.3)	7 (11.7)	13 (12.4)
注入部位血管外漏出	0	2 (3.3)	2 (1.9)
注入部位血腫	1 (2.2)	1 (1.7)	2 (1.9)
注入部位硬結	0	2 (3.3)	2 (1.9)
注入部位結節	0	2 (3.3)	2 (1.9)
注入部位浮腫	1 (2.2)	1 (1.7)	2 (1.9)
注入部位疼痛	1 (2.2)	1 (1.7)	2 (1.9)
注入部位丘疹	1 (2.2)	3 (5.0)	4 (3.8)
注射部位紅斑	1 (2.2)	1 (1.7)	2 (1.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2 subjects or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose (N=45) n (%)	 High Dose (N=60) n (%)	 All Subjects (N=105) n (%)
感染症および寄生虫症	8 (17.8)	10 (16.7)	18 (17.1)
胃腸炎	1 (2.2)	1 (1.7)	2 (1.9)
注入部位蜂巣炎	4 (8.9)	8 (13.3)	12 (11.4)
注入部位感染	3 (6.7)	1 (1.7)	4 (3.8)
尿路感染	0	2 (3.3)	2 (1.9)
傷害、中毒および処置合併症	3 (6.7)	9 (15.0)	12 (11.4)
転倒	3 (6.7)	9 (15.0)	12 (11.4)
手骨折	0	2 (3.3)	2 (1.9)
股関節部骨折	1 (2.2)	1 (1.7)	2 (1.9)
臨床検査	3 (6.7)	3 (5.0)	6 (5.7)
血中ホモシステイン増加	2 (4.4)	0	2 (1.9)
ビタミンB6減少	2 (4.4)	0	2 (1.9)
体重減少	0	3 (5.0)	3 (2.9)
代謝および栄養障害	2 (4.4)	4 (6.7)	6 (5.7)
鉄欠乏	1 (2.2)	1 (1.7)	2 (1.9)
ビタミンB12欠乏	1 (2.2)	3 (5.0)	4 (3.8)
筋骨格系および結合組織障害	1 (2.2)	3 (5.0)	4 (3.8)
背部痛	0	2 (3.3)	2 (1.9)
骨粗鬆症	1 (2.2)	1 (1.7)	2 (1.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2 subjects or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose (N=45) n (%)	 High Dose (N=60) n (%)	 All Subjects (N=105) n (%)
神経系障害	3 (6.7)	11 (18.3)	14 (13.3)
認知障害	1 (2.2)	1 (1.7)	2 (1.9)
すくみ現象	1 (2.2)	1 (1.7)	2 (1.9)
反射減弱	1 (2.2)	1 (1.7)	2 (1.9)
記憶障害	0	2 (3.3)	2 (1.9)
オンオフ現象	1 (2.2)	4 (6.7)	5 (4.8)
パーキンソン病	1 (2.2)	3 (5.0)	4 (3.8)
失神	0	2 (3.3)	2 (1.9)
精神障害	5 (11.1)	7 (11.7)	12 (11.4)
不安	1 (2.2)	2 (3.3)	3 (2.9)
うつ病	2 (4.4)	1 (1.7)	3 (2.9)
幻覚	2 (4.4)	5 (8.3)	7 (6.7)
精神病性障害	1 (2.2)	1 (1.7)	2 (1.9)
皮膚および皮下組織障害	1 (2.2)	1 (1.7)	2 (1.9)
湿疹	1 (2.2)	1 (1.7)	2 (1.9)
血管障害	0	2 (3.3)	2 (1.9)
起立性低血圧	0	2 (3.3)	2 (1.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

表2.7.4.7-6　二重盲検期に発現したすべての有害事象（安全性解析対象集団）：M15-736試験

[redacted]20[redacted] 19:32 <[redacted]>
ABBV-951
STUDY M15-736
R&D/20/1640 - CLINICAL/STATISTICAL

TABLE 14.3__1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Any adverse event	35 (62.5)	7 (63.6)	42 (62.7)	39 (86.7)	24 (82.8)	63 (85.1)	105 (74.5)
注入部位紅斑	1 (1.8)	0	1 (1.5)	14 (31.1)	6 (20.7)	20 (27.0)	21 (14.9)
注入部位疼痛	1 (1.8)	0	1 (1.5)	13 (28.9)	6 (20.7)	19 (25.7)	20 (14.2)
注入部位蜂巣炎	0	0	0	10 (22.2)	4 (13.8)	14 (18.9)	14 (9.9)
注入部位浮腫	0	0	0	8 (17.8)	1 (3.4)	9 (12.2)	9 (6.4)
ジスキネジア	3 (5.4)	1 (9.1)	4 (6.0)	4 (8.9)	4 (13.8)	8 (10.8)	12 (8.5)
転倒	8 (14.3)	4 (36.4)	12 (17.9)	3 (6.7)	3 (10.3)	6 (8.1)	18 (12.8)
注入部位内出血	2 (3.6)	0	2 (3.0)	4 (8.9)	2 (6.9)	6 (8.1)	8 (5.7)
注入部位出血	0	0	0	5 (11.1)	1 (3.4)	6 (8.1)	6 (4.3)
注入部位結節	0	0	0	4 (8.9)	2 (6.9)	6 (8.1)	6 (4.3)
オンオフ現象	0	0	0	2 (4.4)	4 (13.8)	6 (8.1)	6 (4.3)
幻覚	0	1 (9.1)	1 (1.5)	3 (6.7)	2 (6.9)	5 (6.8)	6 (4.3)
平衡障害	0	0	0	4 (8.9)	0	4 (5.4)	4 (2.8)
便秘	0	0	0	3 (6.7)	1 (3.4)	4 (5.4)	4 (2.8)
幻視	0	0	0	1 (2.2)	3 (10.3)	4 (5.4)	4 (2.8)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
注入部位硬結	0	0	0	2 (4.4)	2 (6.9)	4 (5.4)	4 (2.8)
注入部位感染	0	0	0	1 (2.2)	3 (10.3)	4 (5.4)	4 (2.8)
注入部位そう痒感	0	0	0	4 (8.9)	0	4 (5.4)	4 (2.8)
末梢腫脹	0	0	0	3 (6.7)	1 (3.4)	4 (5.4)	4 (2.8)
激越	0	1 (9.1)	1 (1.5)	2 (4.4)	1 (3.4)	3 (4.1)	4 (2.8)
不安	3 (5.4)	0	3 (4.5)	2 (4.4)	1 (3.4)	3 (4.1)	6 (4.3)
浮動性めまい	2 (3.6)	1 (9.1)	3 (4.5)	2 (4.4)	1 (3.4)	3 (4.1)	6 (4.3)
呼吸困難	0	0	0	2 (4.4)	1 (3.4)	3 (4.1)	3 (2.1)
注入部位丘疹	0	0	0	2 (4.4)	1 (3.4)	3 (4.1)	3 (2.1)
注入部位反応	0	0	0	1 (2.2)	2 (6.9)	3 (4.1)	3 (2.1)
注射部位疼痛	0	0	0	2 (4.4)	1 (3.4)	3 (4.1)	3 (2.1)
不眠症	1 (1.8)	0	1 (1.5)	2 (4.4)	1 (3.4)	3 (4.1)	4 (2.8)
悪心	2 (3.6)	0	2 (3.0)	2 (4.4)	1 (3.4)	3 (4.1)	5 (3.5)
精神病性障害	0	0	0	1 (2.2)	2 (6.9)	3 (4.1)	3 (2.1)
発疹	2 (3.6)	0	2 (3.0)	2 (4.4)	1 (3.4)	3 (4.1)	5 (3.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
背部痛	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
カテーテル留置部位内出血	1 (1.8)	0	1 (1.5)	2 (4.4)	0	2 (2.7)	3 (2.1)
挫傷	1 (1.8)	0	1 (1.5)	1 (2.2)	1 (3.4)	2 (2.7)	3 (2.1)
すくみ現象	0	0	0	1 (2.2)	1 (3.4)	2 (2.7)	2 (1.4)
運動低下	0	0	0	1 (2.2)	1 (3.4)	2 (2.7)	2 (1.4)
注入部位血管外漏出	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
注入部位炎症	0	0	0	1 (2.2)	1 (3.4)	2 (2.7)	2 (1.4)
注入部位腫瘤	0	0	0	1 (2.2)	1 (3.4)	2 (2.7)	2 (1.4)
注入部位熱感	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
四肢不快感	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
筋痙縮	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
筋骨格系胸痛	0	0	0	1 (2.2)	1 (3.4)	2 (2.7)	2 (1.4)
四肢痛	0	0	0	0	2 (6.9)	2 (2.7)	2 (1.4)
パニック発作	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
皮膚裂傷	1 (1.8)	0	1 (1.5)	1 (2.2)	1 (3.4)	2 (2.7)	3 (2.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
脱毛症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
肛門カンジダ症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
怒り	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
動物による引っかき傷	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
関節痛	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
節足動物咬傷	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
無力症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
血中アルカリホスファターゼ増加	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
血中ホモシステイン増加	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
血中トリグリセリド増加	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
骨腫脹	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
運動緩慢	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
滑液包炎	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
カンジダ感染	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
手根管症候群	1 (1.8)	0	1 (1.5)	0	1 (3.4)	1 (1.4)	2 (1.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
白内障	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位蜂巣炎	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位紅斑	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位出血	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
カテーテル留置部位硬結	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位疼痛	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位小水疱	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
蜂巣炎	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)
認知障害	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
食欲減退	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
脱水	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
妄想	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
接触皮膚炎	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
横隔膜筋力低下	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
下痢	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
注意力障害	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
体位性めまい	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
薬物過敏症	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
口内乾燥	0	1 (9.1)	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
異常感覚	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
味覚不全	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
発声障害	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
不快気分	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
ジストニア	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
感情的苦悩	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
疲労	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)
熱感	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
潮紅	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
消化管内細菌過剰増殖	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
消化器カンジダ症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
胃食道逆流性疾患	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
幻嗅	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
頭痛	2 (3.6)	1 (9.1)	3 (4.5)	0	1 (3.4)	1 (1.4)	4 (2.8)
高血圧	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
感覚鈍麻	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
インフルエンザ様疾患	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注入部位膿瘍	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注入部位血腫	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注入部位蒼白	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注入部位発疹	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注入部位腫脹	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位内出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位蜂巣炎	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位紅斑	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
注射部位漏出	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位硬結	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位炎症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
不安定血圧	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
日常活動における個人の自立の喪失	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
倦怠感	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
医療機器使用部位そう痒感	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
半月板損傷	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
中期不眠症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
片頭痛	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
運動性低下	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
筋骨格内異物	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
悪夢	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
末梢性浮腫	0	1 (9.1)	1 (1.5)	0	1 (3.4)	1 (1.4)	2 (1.4)
起立性低血圧	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
妄想症	1 (1.8)	0	1 (1.5)	0	1 (3.4)	1 (1.4)	2 (1.4)
パーキンソン病	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
パーキンソニズム	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
前立腺腫大	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
穿刺部位内出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
穿刺部位出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
下肢静止不能症候群	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
皮膚擦過傷	0	1 (9.1)	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
傾眠	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
頻呼吸	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
上気道咳症候群	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
尿管結石症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
尿失禁	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)
尿路感染	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)
静脈瘤	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
回転性めまい	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
ビタミンB6減少	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
尋常性白斑	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
硝子体浮遊物	0	1 (9.1)	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
外陰部腟カンジダ症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
体重減少	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
腹部不快感	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
動作時振戦	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
急性呼吸不全	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
無感情	2 (3.6)	0	2 (3.0)	0	0	0	2 (1.4)
血圧上昇	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
骨嚢腫	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
徐脈	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
COVID-19肺炎	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
頚髄神経根障害	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
咳嗽	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
振動覚低下	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
齲歯	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
うつ病	2 (3.6)	0	2 (3.0)	0	0	0	2 (1.4)
複視	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
おくび	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
紅斑	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
眼刺激	2 (3.6)	0	2 (3.0)	0	0	0	2 (1.4)
体温変動感	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
鼓腸	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
真菌感染	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
歩行障害	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
麦粒腫	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
眼圧上昇	0	1 (9.1)	1 (1.5)	0	0	0	1 (0.7)
易刺激性	0	1 (9.1)	1 (1.5)	0	0	0	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.6.1

Subjects with Treatment-Emergent Adverse Events during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group
by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
関節損傷	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
嗜眠	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
靭帯捻挫	2 (3.6)	0	2 (3.0)	0	0	0	2 (1.4)
四肢損傷	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
腎結石症	0	1 (9.1)	1 (1.5)	0	0	0	1 (0.7)
食道食物嵌入	0	1 (9.1)	1 (1.5)	0	0	0	1 (0.7)
錯感覚	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
頻尿	2 (3.6)	0	2 (3.0)	0	0	0	2 (1.4)
引っかき傷	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
副鼻腔炎	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
失神	0	1 (9.1)	1 (1.5)	0	0	0	1 (0.7)
思考異常	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
振戦	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
心室性期外収縮	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

表2.7.4.7-7　死亡した被験者一覧（All Screened Subjects）：M15-741試験

TABLE 14.3__2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE [redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	FU	57 TO 63	119	R: MULTIPLE ORGAN FAILURE S: 一般・全身障害および投与部位の状態 P: 多臓器機能不全症候群 L: Multiple organ failure	E: 119 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Death of subject R: UNLIKELY O: GENERAL IMPAIRMENT, PROGRESS IN PARKINSON'S DISEASE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 108	108	108	R: CARDIORESPIRATORY ARREST S: 心臓障害 P: 心肺停止 L: Cardio-respiratory arrest	E: 108 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Death of subject R: NOT RELATED O: DETERIORATION OF THE GENERAL STATE OF HEALTH A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE [redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg							
	FU	275 TO 37	311	R: CAQUEXIA. S: 代謝および栄養障害 P: 悪液質 L: Cachexia	E: 322 L: 12 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Life threatening, Death of subject, Hospitalization or prolonged hospitalization, Other medically important serious event, Persistent or significant disability/incapacity R: NOT RELATED O: IT HAS BEEN IN THE CONTEXT OF URINARY INFECTION, 2 RESPIRATORY INFECTIONS AND PROLONGED BEDDING. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 289	289	289	R: ACUTE LARGE RIGHT CEREBRAL SUBDURAL HEMATOMA S: 傷害、中毒および処置合併症 P: 硬膜下血腫 L: Acute subdural hematoma	E: 289 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN	S: Yes, Life threatening, Death of subject R: NOT RELATED O: PATIENT DOES NOT HAVE GOOD MOBILITY DUE TO PARKINSON'S DISEASE AND GOT OUT OF BED WITHOUT ASSISTANCE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]#	Age: 6[redacted]	Sex: Female	Race: WHITE	Weight: 4[redacted].[redacted] kg					
	TRT	1 TO 289	289	289		R: CEREBRAL MARKED MASS EFFECT S: 神経系障害 P: 脳圧排効果 L: Cerebral mass effect	E: 289 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN	S: Yes, Life threatening, Death of subject R: NOT RELATED O: PATIENT DOES NOT HAVE GOOD MOBILITY DUE TO PARKINSON'S DISEASE AND GOT OUT OF BED WITHOUT ASSISTANCE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 10[redacted].[redacted] kg									
	TRT	1 TO 117	117	117		R: CEREBRAL VASCULAR ACCIDENT S: 神経系障害 P: 脳血管発作 L: Cerebrovascular accident	E: 117 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Life threatening, Death of subject, Other medically important serious event, Persistent or significant disability/incapacity R: NOT RELATED O: MEDICAL HISTORY OF: CAD, INFERIOR MI [redacted]/[redacted]/20[redacted], INFRARENAL ABDOMINAL AORTIC ANEURYSM, BILATERAL LOWER LOBE CAP, EMPHYSEMA/COPD A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

表2.7.4.7-8　死亡した被験者一覧（All Screened Subjects）：M15-737試験

[redacted]20[redacted] 04:22 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.3__2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 174	174	174	R: END STAGE PARKINSON DISEASE S: 神経系障害 P: パーキンソン病 L: End stage Parkinson's disease	E: 174 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Death of subject R: NOT RELATED O: CARDIO RESPIRATORY FAILURE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]#	Age: 7[redacted] Sex: Female Race: ASIAN Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 243	243	243		R: DUE TO ASPIRATION S: 呼吸器、胸郭および縦隔障害 P: 誤嚥 L: Aspiration	E: 243 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Death of subject R: NOT RELATED O: ASPIRATION ACCIDENTALLY A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE [redacted]# Age: 7[redacted] Sex: Female Race: ASIAN Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 243	243	243	R: SUFFOCATION S: 呼吸器、胸郭および縦隔障害 P: 窒息 L: Suffocation	E: 243 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Death of subject R: NOT RELATED O: ASPIRATION ACCIDENTALLY A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.1

Listing of All Deaths
(All Screened Subjects)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 233	232	232	R: END STAGE PARKINSON'S DISEASE S: 神経系障害 P: パーキンソン病 L: End stage Parkinson's disease	E: 234 L: 3 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: MULTIPLE: (CONCOMITANT MEDICATION OR THERAPY DISCONTINUED; Other: SUBJECT WAS PLACED ON HOSPICE AND DIED AT HOME ON [redacted] 20[redacted]; CONCOMITANT MEDICATION OR THERAPY STARTED)	S: Yes, Death of subject R: NOT RELATED O: PROGRESSION OF HER PARKINSON'S TO DEATH

Subject prematurely discontinued.

Program Source Code: [redacted]

表2.7.4.7-9　死亡した被験者一覧（All Screened Subjects）：M15-736試験

[redacted]20[redacted] 19:32 <[redacted]>
ABBV-951
STUDY M15-736
R&D/20/1640 - CLINICAL/STATISTICAL

TABLE 14.3__2.1

Listing of All Deaths
(All Subjects Screened)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ORAL CD/LD LOW DOSE									
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg Country: UNITED STATES									
	TRT	1 TO 70	68	68		R: CELLULITIS OF THE RIGHT LEG S: 感染症および寄生虫症 P: 蜂巣炎 L: Cellulitis of leg	O: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: SUBJECT BUMPED HER KNEE RESULTING IN INFECTION A: NO REASONABLE POSSIBILITY

* from oral stablization period.
\# Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.1

Listing of All Deaths
(All Subjects Screened)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ORAL CD/LD LOW DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg Country: UNITED STATES								
	FU	71 TO 21	91		R: ACUTE RESPIRATORY FAILURE S: 呼吸器、胸郭および縦隔障害 P: 急性呼吸不全 L: Acute respiratory failure	E: 98 L: 8 DAYS	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R4: No A1: Other: SUBJECT HAD PREVIOUSLY STOPPED STUDY DRUG, ORAL AND ABBV-951 AT PREVIOUS HOSPITAL STAY O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Life threatening, Death of subject, Hospitalization or prolonged hospitalization R: NOT RELATED O: SEPSIS A: NO REASONABLE POSSIBILITY

* from oral stablization period.
\# Subject prematurely discontinued.

Program Source Code: [redacted]

表2.7.4.7-10　重篤な有害事象を発現した被験者一覧（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg								
	TRT	1 TO 366	234	234	R: PAROTID ABSCESS S: 感染症および寄生虫症 P: 耳下腺膿瘍 L: Parotid abscess	E: 254 L: 21 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: RISK FACTOR MRSA A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg									
	TRT	1 TO 108	107	107		R: COGNITIVE DECLINE S: 神経系障害 P: 認知障害 L: Cognitive deterioration	O: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: COGNITIVE DECLINE > DIFFICULTIES HANDLING THE PUMP > DRUG WITHDRAWN A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 8[redacted] Sex: Male Race: WHITE Weight: 5[redacted].[redacted] kg									
	TRT	1 TO 362	158	158		R: HALLUCINATIONS S: 精神障害 P: 幻覚 L: Hallucinations	O: Yes I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 201	149	149	R: PARANOID DELUSIONS S: 精神障害 P: 妄想 L: Paranoid delusions	E: 159 L: 11 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED A1: Other: RECOMMENDED USING LOWER FLOW SETTINGS O: REDUCED DOSE ROPINIROL	S: Yes, Hospitalization or prolonged hospitalization, Other medically important serious event, Persistent or significant disability/incapacity R: POSSIBLE O: MARITIAL CRISIS IN COMBINATION WITH A GAMBLING WIN AND POOR SLEEP MAY HAVE CONTRIBUTED BUT MAIN REASON IS BELIEVED TO BE THE START OF ROPINIROL, POSSIBLY IN COMBINATION WITH DULOXETINE. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 86	55	55	R: FROM HITTING ABDOMEN/INFUSION SITE ON TABLE S: 一般・全身障害および投与部位の状態 P: 注入部位損傷 L: Infusion site injury	O: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 86	55	55	R: SUPERFICIAL CELLULITIS RIGHT ABDOMEN AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	O: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 86	83	83	R: INFUSION SITE ABSCESS L SIDE ABDOMEN O: Yes S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess		S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 86	86	86	R: INFUSION SITE ABSCESS LEFT ABDOMEN. S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	O: Yes	S: MODERATE R1: REASONABLE POSSIBILITY A1: Other: DRUG WITHDRAWN WITH PREVIOUS AE O: ABDOMINAL ULTRASOUND - RESULTS PENDING	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 4[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 8	5	5	R: HYPERVENTILATION S: 呼吸器、胸郭および縦隔障害 P: 過換気 L: Hyperventilation	E: 45 L: 41 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN O: BREATHING EXERCISE.	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: WORSENING PD A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 4[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 8	5	5	R: HYPOKALAMIA S: 代謝および栄養障害 P: 低カリウム血症 L: Hypokalemia	E: 6 L: 2 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: HYPERVENTILATION A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 4[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
	FU	9 TO	15	23	R: PARKINSON DISEASE. S: 神経系障害 P: パーキンソン病 L: Parkinson's disease	O: Yes I: Yes	S: MILD R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: DUE TO INITIATION OF A NEW DRUGTHERAPY, THE SUBJECT WAS ADMITTED. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE [redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg							
	FU	65 TO 1	65	R: WORSENING PARKINSONS DISEASE S: 神経系障害 P: パーキンソン病 L: Parkinson's disease aggravated	E: 67 L: 3 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: CHANGE IN CON MEDS. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg								
	FU	65 TO 9	73		R: WORSENING PARKINSONS DISEASE S: 神経系障害 P: パーキンソン病 L: Parkinson's disease aggravated	E: 74 L: 2 Days	S: MILD R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: CHANGE IN CON MEDS. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg									
	TRT	1 TO 365	304	304		R: CHEST PAIN OF UNDETERMINED ETIOLOGY S: 一般・全身障害および投与部位の状態 P: 胸痛 L: Unspecified chest pain	O: Yes I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: PT WAS HOSPITALISED ON [redacted]20[redacted]	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: HOSPITAL PHYSICIAN ORDERED A CONSULTATION IN GASTROENTEROLOGY, SO GASTRIC ORIGIN SUSPECTED A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 183	34	34	R: DELUSIONAL DISORDER UNSPECIFIED S: 精神障害 P: 妄想性障害、詳細不明 L: Delusional disorder, unspecified type	E: 94 L: 61 Days	S: SEVERE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: Other: INFUSION RATE REDUCED A2: DOSE NOT CHANGED O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
[redacted]	TRT	1 TO 23	21	21	R: ABSCESS RIGHT LOWER QUADRANT OF ABDOMEN AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	O: Yes I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN O: SUBJECT WAS HOSPITALIZED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: CAREGIVER HAD TO GIVE MULTIPLE STICKS OF THE [redacted] NEEDLE, THIS IS THE AREA OF INFECTION. EVENTUALLY THEY WERE ABLE TO FIND AN INFUSION SITE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]#	Age: 7[redacted]	Sex: Male	Race: WHITE	Weight: 8[redacted].[redacted] kg					
	TRT	1 TO 23	21	21		R: CELLULITIS RIGHT LOWER QUADRANT OF ABDOMEN AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 34 L: 14 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: CAREGIVER DID MULTIPLE STICKS WITH THE [redacted] NEEDLE UNSUCCESSFULLY, THIS IS THE AREA OF INFECTION. ULTIMATELY WAS ABLE FIND AN INFUSION SITE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted])									
TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
		TRT	1 TO 23	23	23	R: ACUTE DELIRIUM S: 精神障害 P: 譫妄 L: Acute delirium	E: 54 L: 32 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: NOT RELATED TO STUDY PROCEDURES, TEMPORAL IMPLAUSIBILITY. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted])								
TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
[redacted]	TRT	1 TO 23	23	23	R: COGNITIVE CONFUSION S: 精神障害 P: 錯乱状態 L: Mental confusion	O: Yes I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 309	19	19	R: CELLULITIS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 120 L: 102 Days	S: SEVERE R1: REASONABLE POSSIBILITY A1: DOSE NOT CHANGED O: CHANGE INSERTION SITE, NO CHANGES RELATED WITH ABBV-951	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg									
	TRT	1 TO 364	169	169		R: DIFFICULTY BREATHING S: 呼吸器、胸郭および縦隔障害 P: 呼吸困難 L: Difficulty breathing	E: 171 L: 3 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: ECG, CHEST X-RAY, TROPONIN, D DIMERS.	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 364	169	169	R: DYSTONIA S: 神経系障害 P: ジストニア L: Dystonia	E: 170 L: 2 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: Other: PUMP CHANGE WITH CHANGE OF SYRINGE AND SET (PAUSED FOR 20 MINUTES WHILST CHANGING ITEMS).	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 364	169	169	R: FEELING OF PRESSURE ON CHEST S: 一般・全身障害および投与部位の状態 P: 胸部不快感 L: Chest pressure sensation of	E: 171 L: 3 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: ECG, CHEST X-RAY, TROPONIN, D DIMERS.	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 364	249	249	R: CHEST DYSTONIA S: 神経系障害 P: ジストニア L: Dystonia	E: 250 L: 2 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 167	15	15	R: HEMIPARESIS RIGHT SIDE S: 神経系障害 P: 不全片麻痺 L: Hemiparesis (right)	E: 15 L: 1 Day	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 167	15	15	R: TRANSIENT RIGHT-SIDED HEMIHYPO-AESTHESIA S: 神経系障害 P: 片側感覚消失 L: Hemihypoesthesia	E: 15 L: 1 Day	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 167	15	15	R: TRANSIENT RIGHT-SIDED HEMIPARESIS S: 神経系障害 P: 不全片麻痺 L: Hemiparesis transient	E: 15 L: 1 Day	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 167	144	144	R: PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis	O: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: MULTIPLE: (CONCOMITANT MEDICATION OR THERAPY DISCONTINUED; Other: HOSPITALISED, NO FURTHER INFO AVAILABLE AT THIS MOMENT IN TIME; CONCOMITANT MEDICATION OR THERAPY STARTED)	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE [redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 22	15	15	R: INFUSION SITE LEFT ARM - ABSCESS S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	O: Yes I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: Other: INFUSION SITE ROTATED AND MOVED TO FLANKS AS ABDOMEN NOT AN OPTION DUE TO SEVERE SCOLIOSIS A2: DOSE NOT CHANGED	S: Yes, Other medically important serious event R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	3	3	R: HYPOTHERMIA S: 一般・全身障害および投与部位の状態 P: 低体温 L: Hypothermia	E: 30 L: 28 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: PREVIOUS EPISODES OF HYPOTHERMIA (PRIOR TO STUDY COMMENCEMENT) WERE RELATED TO AN INFECTION.THE PI FEELS THIS WAS DUE TO INFECTION WHICH HAS BEEN CLASSIFIED AS PNEUMONIA; PATHOGEN UNKNOWN AT THIS TIME A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg									
	TRT	1 TO 393	3	3		R: PNEUMONIA S: 感染症および寄生虫症 P: 肺炎 L: Pneumonia	E: 30 L: 28 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Life threatening, Hospitalization or prolonged hospitalization, Other medically important serious event R: NOT RELATED O: PATHOGEN UNKNOWN, BACTERIAL CULTURES NO GROWTH. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE							
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg							
[redacted]	TRT	1 TO 393	3	R: SEPSIS S: 感染症および寄生虫症 P: 敗血症 L: Sepsis	E: 30 L: 28 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: PREVIOUS EPISODES OF HYPOTHERMIA (PRIOR TO STUDY COMMENCEMENT) WERE RELATED TO AN INFECTION.THE PI FEELS THIS WAS DUE TO INFECTION WHICH HAS BEEN CLASSIFIED AS PNEUMONIA; PATHOGEN UNKNOWN AT THIS TIME A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	3	3	R: SEPTIC SHOCK S: 感染症および寄生虫症 P: 敗血症性ショック L: Septic shock	E: 30 L: 28 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: NONE	S: Yes, Life threatening, Hospitalization or prolonged hospitalization, Other medically important serious event R: NOT RELATED O: PNEUMONIA A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	10	10	R: DELIRIUM S: 精神障害 P: 譫妄 L: Delirium	E: 30 L: 21 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization, Other medically important serious event R: UNLIKELY O: MOST LIKELY CAUSE OF EVENT IS THE SEPSIS AND ICU ADMISSION FOR ALMOST A WEEK. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	10	10	R: HALLUCINATIONS S: 精神障害 P: 幻覚 L: Hallucinations	E: 30 L: 21 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization, Other medically important serious event R: UNLIKELY O: UTI A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg									
		TRT	1 TO 393	268	268	R: PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis	E: 370 L: 103 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg									
		TRT	1 TO 393	370	370	R: WORSENING OF PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis aggravated	O: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: QUETIAPINE INCREASED TO 25MG OD	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch: Name	Epoch: Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE							
[redacted] Age: 7[redacted] Sex: Male Race: AMERICAN INDIAN OR ALASKA NATIVE Weight: 5[redacted].[redacted] kg							
	TRT	1 TO 381	38	R: LOW SODIUM S: 臨床検査 P: 血中ナトリウム減少 L: Sodium low	O: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE							
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg							
[redacted]	TRT	1 TO 362	34	R: HEMATOMA AT INFUSION SITE. S: 一般・全身障害および投与部位の状態 P: 注入部位血腫 L: Infusion site hematoma	E: 49 L: 16 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NEW INJECTION SITE. GETS TREATMENT AT THE EMERGENCY ROOM FOR INFECTED HEMATOMA. HOSPITALIZED OVERNIGHT.	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
[redacted]	TRT	1 TO 362	34	34	R: INFECTION AT INFUSION SITE. S: 感染症および寄生虫症 P: 注入部位感染 L: Infusion site infection	E: 49 L: 16 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NEW INJECTION SITE. GETS TREATMENT AT THE EMERGENCY ROOM FOR INFECTED HEMATOMA. HOSPITALIZED OVERNIGHT.	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 330	262	262	R: REACTIVE ARTHRITIS IN RIGHT KNEE S: 筋骨格系および結合組織障害 P: 反応性関節炎 L: Reactive arthritis	O: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization, Persistent or significant disability/incapacity R: NOT RELATED O: P.I SUSPECT THIS AE IS CAUSED AND DUE TO INFLAMMATION (AE [redacted]) A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE							
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg							
[redacted]	TRT	1 TO 365	191	R: CORONARY ARTERY DISEASE S: 心臓障害 P: 冠動脈疾患 L: Coronary artery disease	O: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: SUBJECT HAD 2 CORONARY STENT PLACEMENT COMPLETED FAMILY HISTORY OF HEART PROBLEMS.	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: RISK FACTORS, FAMILY HISTORY A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted])								
TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 365	195	195	R: ATRIAL FIBRILLATION S: 心臓障害 P: 心房細動 L: Atrial fibrillation	O: Yes I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: RISK FACTOR, NEW DIAGNOSIS OF CORONARY ARTERY DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
	TRT	1 TO 365	195	195		R: URINARY TRACT INFECTION S: 感染症および寄生虫症 P: 尿路感染 L: Urinary tract infection	E: 199 L: 5 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: RISK FACTOR, URINARY RETENTION DUE TO PARKINSON'S DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
	TRT	1 TO 365	333	333		R: PULMONARY EMBOLI S: 呼吸器、胸郭および縦隔障害 P: 肺塞栓症 L: Pulmonary embolism	O: Yes I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: SUBJECT HAS A HISTORY OF ATRIAL FIBRILLATION, PER LAST AE, NEW SINCE SIGNING CONSENT A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg								
	TRT	1 TO 127	56	56	R: CELLULITIS TO LEFT UPPER/LOWER ABDOMINAL QUADERANT AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 100 L: 45 Days	S: SEVERE R1: REASONABLE POSSIBILITY A1: DRUG INTERRUPTED A1: Other: DRUG WILL BE STOPPED FOR ABOUT 6 HOURS FOR SURGICAL INTERVENTION	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE							
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 10[redacted].[redacted] kg							
[redacted]	TRT	1 TO 374	269	R: CELLULITIS TO MID-LOWER ABDOMINAL INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 271 L: 3 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg									
	TRT	1 TO 366	309	309		R: LARGE LEFT THIGH HEMATOMA S: 血管障害 P: 血腫 L: Hematoma	E: 312 L: 4 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: FALL A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO	346	346	R: COVID S: 感染症および寄生虫症 P: COVID-19 L: COVID-19	E: 358 L: 13 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: Yes A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: VOID 19 VIRUS

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg									
	TRT	1 TO 365	217	217		R: BRONCHIECTASIS WORSENING S: 呼吸器、胸郭および縦隔障害 P: 気管支拡張症 L: Bronchiectasis	E: 232 L: 16 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization, Persistent or significant disability/incapacity R: NOT RELATED O: SECONDARY INFECTION A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg									
		TRT	1 TO 56	52	52	R: DYSTONIC REACTION S: 神経系障害 P: ジストニア L: Dystonic reaction	E: 53 L: 2 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: GENERAL DETERIORATION OF THE SUBJECT (SEE SAE [redacted]) A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 56	56	56	R: PARKINSONISM S: 神経系障害 P: パーキンソニズム L: Parkinsonism	E: 119 L: 64 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE O: PROGRESSIVE GENERAL DETERIORATION A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 108	108	108	R: CARDIORESPIRATORY ARREST S: 心臓障害 P: 心肺停止 L: Cardio-respiratory arrest	E: 108 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Death of subject R: NOT RELATED O: DETERIORATION OF THE GENERAL STATE OF HEALTH A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 117	15	15	R: URINARY TRACT INFECTION S: 感染症および寄生虫症 P: 尿路感染 L: Urinary tract infection	E: 27 L: 13 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: MICROBE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]#	Age: 6[redacted]	Sex: Female	Race: WHITE	Weight: 5[redacted].[redacted] kg					
	TRT	1 TO 117	25	25		R: COGNITIVE DETERIORATION S: 神経系障害 P: 認知障害 L: Cognitive deterioration	E: 27 L: 3 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]#	Age: 6[redacted]	Sex: Female	Race: WHITE	Weight: 5[redacted].[redacted] kg					
	TRT	1 TO 117	25	25		R: PSYCHOTIC DISORDER S: 精神障害 P: 精神病性障害 L: Psychotic disorder	E: 27 L: 3 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 4[redacted] Sex: Male Race: ASIAN Weight: 8[redacted].[redacted] kg									
	TRT	1 TO 365	71	71		R: PSEUDOSEIZURE S: 神経系障害 P: 心因性発作 L: Pseudoseizure	E: 72 L: 2 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: DOPAMINE AGONIST WITHDRAWAL SYNDROME A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
	TRT	1 TO 360 + 315	315			R: WORSENING L5 AND S1 COMPRESSIVE RADICULOPATHY S: 神経系障害 P: 腰仙部神経根障害 L: Lumbosacral radiculopathy	E: 339 L: 25 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: LUMBAR DISC HERNIATION A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 4[redacted] Sex: Female Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 368	284	284	R: SUICIDE ATTEMPT S: 精神障害 P: 自殺企図 L: Suicide attempt	E: 284 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Life threatening R: UNLIKELY O: DEPRESSIVE EPISODE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: ASIAN Weight: 4[redacted].[redacted] kg									
		TRT	1 TO 364	172	172	R: FURTHER WORSENING OF HALLUCINATIONS S: 精神障害 P: 幻覚 L: Hallucinations aggravated	E: 183 L: 12 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: ASIAN Weight: 4[redacted].[redacted] kg									
		TRT	1 TO 364	357	357	R: WORSENING OF ORTHOSTATIC HYPOTENSION S: 血管障害 P: 起立性低血圧 L: Hypotension postural aggravated	O: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: Other: ABBV-951 RATE REDUCED. O: IV FLUIDS COMMENCED.	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE O: REFLUX OESOPHAGITIS

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 5[redacted] Sex: Female Race: WHITE Weight: 9[redacted].[redacted] kg									
		TRT	1 TO 371	25	25	R: LEFT SACROILIAC JOINT INCOMPETENCE . S: 筋骨格系および結合組織障害 P: 仙腸関節機能障害 L: Sacroiliac joint dysfunction	E: 27 L: 3 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: STRUCTURAL DEGENERATIVE CHANGES TO SACROILIAC JOINT ASSOCIATED WITH SEVERAL TENDON ENTHESOPATHIES AND HIP IMPINGEMENT A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity R1: ABBV-951 Relationship R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]#	Age: 7[redacted]	Sex: Female	Race: WHITE	Weight: 6[redacted].[redacted] kg				
	TRT	1 TO 52	38	38	R: SUDDEN OFF STATE RELATED TO PARKINSONS DISEASE S: 神経系障害 P: オンオフ現象 L: On and off phenomenon	E: 45 L: 8 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: RESCUE MEDICATION, HOSPITAL ADMISSION UPON FAILURE OF SYMPTOM IMPROVEMENT	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: WORSENING OF PARKINSONS SYMPTOMES A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg									
		FU	53 TO	1	53	R: WORSENING OF MOTORFLUCTUATION S: 神経系障害 P: オンオフ現象 L: Motor fluctuations	E: 77 L: 25 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: HOSPITALIZATION	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: DISCONTINUATION OF SUBCUTANEOUS LEVODOPA INFUSION A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 274	260	260	R: URINARY TRACT INFECTION S: 感染症および寄生虫症 P: 尿路感染 L: Urinary tract infection	E: 288 L: 29 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: THIS IS A URINARY TRACT INFECTION. THE URINE SEDIMENT IS PATHOLOGICAL, THE URINE CULTURE IS PENDING. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Rx Day of Preferred Term	R: Reported Term S: System Organ Class P: MedDRA 24.0 L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE [redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg									
	FU	275 TO	1	275		R: GENERALIZED TONIC-CLONIC SEIZURE S: 神経系障害 P: 全身性強直性間代性発作 L: Generalized tonic-clonic seizure	E: 315 L: 41 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: Other: THE DRUG WAS PREVIOUSLY INTERRUPTED. SO, AT THAT MOMENT THE PATIENT WAS TAKING ORAL L-DOPA. SHE WAS AT THE EMERGENCY DEPARTMENT WAITING FOR HOSPITALIZATION DUE TO URINARY TRACT INFECTION.	S: Yes, Life threatening, Hospitalization or prolonged hospitalization, Other medically important serious event, Persistent or significant disability/incapacity R: NOT RELATED O: THE PATIENT PRESENTED HOSPITALIZATION WITH RESPIRATORY INFECTION, GENERAL IMPAIRMENT AND CAQUEXIA. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 9[redacted].[redacted] kg								
	TRT	1 TO 365	7	7	R: PSYCHOSIS. S: 精神障害 P: 精神病性障害 L: Psychosis	E: 23 L: 17 Days	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: Other: THE DOSE OF THE DRUG WAS REDUCED TO 0.55 ML/H. O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
	TRT	1 TO 366	43	43		R: CELLULITIS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 59 L: 17 Days	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED A1: Other: STOPPED INFUSION AND REMOVED SITE CONNECTOR AND INSERTED SUBCUTANEOUS NEEDLE. O: SWAB OF INFECTED INFUSION SITE TAKEN AND SENT FOR ANALYSIS	S: Yes, Hospitalization or prolonged hospitalization, Other medically important serious event, Persistent or significant disability/incapacity R: NOT RELATED A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 43	43	43	R: PERFORATION OF SKIN AT INFUSION SITE S: 一般・全身障害および投与部位の状態 P: 注入部位損傷 L: Infusion site injury	E: 70 L: 28 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: SURGERY. INCISION OF SUBCUTANEOUS ABSCESS WITH DRAINING OF PUS	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]#	Age: 6[redacted]	Sex: Female	Race: WHITE	Weight: 8[redacted].[redacted] kg				
	TRT	1 TO 43	43	43	R: SUBCUTANEOUS ABSCESS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	E: 70 L: 28 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: SURGERY. INCISION OF SUBCUTANEOUS ABSCESS WITH DRAINING OF PUS	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 364	46	46	R: CELLULITIS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 62 L: 17 Days I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Other medically important serious event R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg									
		TRT	1 TO 364	63	63	R: PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis	E: 86 L: 24 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: Other: DOSE WAS LOWERED O: HOSPITALIZATION AT THE PSYCHIATRIC WARD	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg									
	TRT	1 TO 289	289	289		R: ACUTE LARGE RIGHT CEREBRAL SUBDURAL HEMATOMA S: 傷害、中毒および処置合併症 P: 硬膜下血腫 L: Acute subdural hematoma	E: 289 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN	S: Yes, Life threatening, Death of subject R: NOT RELATED O: PATIENT DOES NOT HAVE GOOD MOBILITY DUE TO PARKINSON'S DISEASE AND GOT OUT OF BED WITHOUT ASSISTANCE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]#	Age: 6[redacted]	Sex: Female	Race: WHITE	Weight: 4[redacted].[redacted] kg					
		TRT	1 TO 289	289	289	R: CEREBRAL MARKED MASS EFFECT S: 神経系障害 P: 脳圧排効果 L: Cerebral mass effect	E: 289 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN	S: Yes, Life threatening, Death of subject R: NOT RELATED O: PATIENT DOES NOT HAVE GOOD MOBILITY DUE TO PARKINSON'S DISEASE AND GOT OUT OF BED WITHOUT ASSISTANCE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg									
	TRT	1 TO 366	191	191		R: HALLUCINATIONS S: 精神障害 P: 幻覚 L: Hallucinations	E: 192 L: 2 Days	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: PD PROGRESSION VS LEVODOPA COMPLICATION A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg									
	TRT	1 TO 364	199	199		R: CELLULITIS(LEFT LOWER LIMB) S: 感染症および寄生虫症 P: 蜂巣炎 L: Cellulitis of leg	E: 219 L: 21 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: INFECTION. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 5[redacted] Sex: Female Race: ASIAN Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 167	18	18	R: HALLUCINATION S: 精神障害 P: 幻覚 L: Hallucination	E: 83 L: 66 Days	S: SEVERE R1: REASONABLE POSSIBILITY A1: DOSE NOT CHANGED O: CONCOMITANT MEDICATION CHANGE.	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: ASIAN Weight: 3[redacted].[redacted] kg								
	TRT	1 TO 364	70	70	R: WORSENING OF PARKINSON'S DISEASE S: 神経系障害 P: パーキンソン病 L: Parkinson's disease aggravated	E: 94 L: 25 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: DUE TO THE SPREAD OF COVID-19 INFECTION, THE USUAL REHABILITATION COULD NOT BE PERFORMED, AND THE PATIENT WAS HOSPITALIZED FOR IMPROVEMENT OF MOTOR SYMPTOMS. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 5[redacted] Sex: Female Race: WHITE Weight: 9[redacted].[redacted] kg									
	TRT	1 TO 32	2	2		R: RIGHT ARM PARESTESIAS S: 神経系障害 P: 錯感覚 L: Paresthesia upper limb	E: 4 L: 3 Days	S: MODERATE R1: REASONABLE POSSIBILITY A1: Other: FLOW CHANGES FROM 0.50 ML/H TO 0.35 ML/H AND AFTER TO 0.45 ML/H O: CT-SCAN	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE							
[redacted]# Age: 5[redacted] Sex: Female Race: WHITE Weight: 9[redacted].[redacted] kg							
	TRT	1 TO 32	2	R: SEVERE DYSARTRIA S: 神経系障害 P: 構語障害 L: Dysarthria	E: 4 L: 3 Days	S: MODERATE R1: REASONABLE POSSIBILITY A1: Other: FLOW CHANGES FROM 0.50 ML/H TO 0.35 ML/H AND AFTER TO 0.45 ML/H O: CT-SCAN	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 4[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 365	28	28	R: WORSENING OF DELUSION S: 精神障害 P: 妄想 L: Delusion	E: 42 L: 15 Days I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 4[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg									
	TRT	1 TO 365	28	28		R: WORSENING OF HALLUCINATION S: 精神障害 P: 幻覚 L: Hallucinations aggravated	E: 42 L: 15 Days I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]#	Age: 6[redacted] Sex: Female Race: ASIAN Weight: 5[redacted].[redacted] kg								
		TRT	1 TO 18	14	14	R: HALLUCINATION S: 精神障害 P: 幻覚 L: Hallucination	E: 84 L: 71 Days	S: MODERATE R1: REASONABLE POSSIBILITY A1: DRUG WITHDRAWN O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: ASIAN Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 18	14	14	R: RHABDOMYOLYSIS S: 筋骨格系および結合組織障害 P: 横紋筋融解症 L: Rhabdomyolysis	E: 22 L: 9 Days	S: SEVERE R1: REASONABLE POSSIBILITY A1: DRUG WITHDRAWN O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]#	Age: 6[redacted] Sex: Female Race: ASIAN Weight: 5[redacted].[redacted] kg								
		TRT	1 TO 18	18	18	R: WORSENING OF PARKINSON'S SYMPTOMS S: 神経系障害 P: パーキンソン病 L: Parkinson's disease aggravated	E: 84 L: 67 Days	S: SEVERE R1: REASONABLE POSSIBILITY A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]#	Age: 5[redacted]	Sex: Male	Race: ASIAN	Weight: 4[redacted].[redacted] kg					
	TRT	1 TO 16	15	15		R: WORSENING OF PARKINSON'S SYMPTOMS S: 神経系障害 P: パーキンソン病 L: Parkinson's disease aggravated	E: 91 L: 77 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: ASIAN Weight: 3[redacted].[redacted] kg								
	TRT	1 TO 103	102	102	R: LOSS OF CONSCIOUSNESS ATTACK S: 神経系障害 P: 意識消失 L: Loss of consciousness	E: 103 L: 2 Days	S: MODERATE R1: REASONABLE POSSIBILITY A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted])								
TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 117	12	12	R: BILATERAL PNEUMONIA S: 感染症および寄生虫症 P: 肺炎 L: Bilateral pneumonia	E: 61 L: 50 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DOSE NOT CHANGED O: ADMITTED TO HOSPITAL, STARTED ON IV ANTIBIOTICS	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: PT HISTORY OF ASPIRATION PNEUMONIA IN PAST AS WELL AS COPD MEDICAL CONDITION. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted])								
TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 117	114	114	R: PNEUMONIA S: 感染症および寄生虫症 P: 肺炎 L: Pneumonia	E: 116 L: 3 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: COPD, HISTORY OF ASPIRATION PNEUMONIA A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 10[redacted].[redacted] kg									
		TRT	1 TO 117	117	117	R: CEREBRAL VASCULAR ACCIDENT S: 神経系障害 P: 脳血管発作 L: Cerebrovascular accident	E: 117 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Life threatening, Death of subject, Other medically important serious event, Persistent or significant disability/incapacity R: NOT RELATED O: MEDICAL HISTORY OF: CAD, INFERIOR MI [redacted]/[redacted]/20[redacted], INFRARENAL ABDOMINAL AORTIC ANEURYSM, BILATERAL LOWER LOBE CAP, EMPHYSEMA/COPD A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 365	258	258	R: RIGHT GLUTEAL ABSCESS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	E: 269 L: 12 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 365	336	336	R: DOPAMINERGIC DYSREGULATION S: 精神障害 P: ドーパミン調節障害症候群 L: Dopamine dysregulation syndrome	E: 346 L: 11 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: CONTROL OF SINEMET INTAKE IN HOSPITALIZATION AND TREATMENT OF INCREASED ANXIETY	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: PARKINSON'S DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 149	81	81	R: ABSCESS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	E: 101 L: 21 Days	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 149	81	81	R: CELLULITIS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 101 L: 21 Days	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]#	Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
		TRT	1 TO 149	81	81	R: SEPSIS S: 感染症および寄生虫症 P: 敗血症 L: Sepsis	E: 101 L: 21 Days	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg								
	TRT	1 TO	33	33	R: SUBCUTANEOUS ABSCESS ABDOMINAL AN INFUSION SITE S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	E: 42 L: 10 Days I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: SURGERY	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg								
	TRT	1 TO 129	129	129	R: INTESTINAL BLEEDING S: 胃腸障害 P: 腸出血 L: Intestinal bleeding	E: 133 L: 5 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: ISCHAEMIC COLITIS AS A RESULT OF AN OCCLUSIVE EMBOLISM A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
	TRT	1 TO	129	129	R: ISCHEMIC COLITIS WITH S: 胃腸障害 P: 虚血性大腸炎 L: Ischemic colitis	E: 133 L: 5 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: ISCHAEMIC COLITIS AS A RESULT OF AN OCCLUSIVE EMBOLISM A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg								
	TRT	1 TO	236	236	R: PNEUMONIA S: 感染症および寄生虫症 P: 肺炎 L: Pneumonia	E: 240 L: 5 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: BACTERIAL INFECTION OF THE LUNGS

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg									
	TRT	1 TO 365	224	224		R: WORSENING RIGHT SHOULDER DEGENERATIVE JOINT DISEASE S: 筋骨格系および結合組織障害 P: 変形性関節症 L: Osteoarthritis aggravated	E: 224 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: RIGHT SHOULDER TOTAL ARTHROPLASTY (SHOULDER HARDWARE PLACED)	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: PATIENT HAS SEVERE DJD AND THUS REQUIRED TOTAL SHOULDER ARTHROPLASTY AFTER SEVERAL NON-SURGICAL OPTIONS FAILED. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 367	104	104	R: DEHYDRATION S: 代謝および栄養障害 P: 脱水 L: Dehydration	E: 107 L: 4 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: URINARY TRACT INFECTION (UTI) CAUSED BY BACTERIA, WITH DEHYDRATION AND WEAKNESS SECONDARY TO UTI. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 367	104	104	R: URINARY TRACT INFECTION S: 感染症および寄生虫症 P: 尿路感染 L: Urinary tract infection	E: 107 L: 4 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: URINARY TRACT INFECTION (UTI) CAUSED BY BACTERIA, WITH DEHYDRATION AND WEAKNESS SECONDARY TO UTI. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 367	104	104	R: WEAKNESS S: 一般・全身障害および投与部位の状態 P: 無力症 L: Weakness	E: 107 L: 4 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: URINARY TRACT INFECTION (UTI) CAUSED BY BACTERIA, WITH DEHYDRATION AND WEAKNESS SECONDARY TO UTI. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 367	281	281	R: CELLULITIS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 367 L: 87 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 367	281	281	R: SEPSIS S: 感染症および寄生虫症 P: 敗血症 L: Sepsis	E: 289 L: 9 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 363	326	326	R: HYPONATREMIA S: 代謝および栄養障害 P: 低ナトリウム血症 L: Hyponatremia	E: 335 L: 10 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: HYPONATREMIA DUE TO DEHYDRATION AND POOR PO INTAKE (WHICH COULD BE DUE TO NSTEMI). A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg									
	TRT	1 TO 363	326	326		R: NSTEMI S: 心臓障害 P: 急性心筋梗塞 L: Non ST segment elevation myocardial infarction	E: 326 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: MULTIPLE: (CONCOMITANT MEDICATION OR THERAPY DISCONTINUED; Other: CARDIAC CATHETERIZATION; CONCOMITANT MEDICATION OR THERAPY STARTED)	S: Yes, Life threatening, Hospitalization or prolonged hospitalization, Other medically important serious event R: UNLIKELY O: LIKELY UNDERLYING CORONARY ARTERY DISEASE (FOR NSTEMI). HYPONATREMIA DUE TO DEHYDRATION AND POOR PO INTAKE (WHICH COULD BE DUE TO NSTEMI). RHABDOMYOLYSIS IS DUE TO STATIN THERAPY (DISCONTINUED) A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 363	328	328	R: CORONARY ARTERY DISEASE S: 心臓障害 P: 冠動脈疾患 L: Coronary artery disease	O: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: CABG PERFORMED ON [redacted]20[redacted].	S: Yes, Life threatening, Hospitalization or prolonged hospitalization, Other medically important serious event R: NOT RELATED O: PATIENT HAD AN NSTEMI RECENTLY (SEE SEPARATE SAE REPORT PREVIOUSLY ENTERED) AND WAS FOUND TO HAVE DIFFUSE DISEASE FROM HIS DM1. RECOMMENDED TO HAVE CABG WHICH WAS COMPLETED [redacted]20[redacted] A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg									
		TRT	1 TO 363	336	336	R: CARDIAC ARREST S: 心臓障害 P: 心停止 L: Cardiac arrest	E: 336 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: CPR	S: Yes, Life threatening, Hospitalization or prolonged hospitalization, Other medically important serious event R: NOT RELATED O: POST-SURGICAL VASOVAGAL REACTION A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 153	23	23	R: DIZZINESS S: 神経系障害 P: 浮動性めまい L: Dizziness	E: 23 L: 1 Day I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: PHYSICAL EXAMINATION, BLOOD TESTS, ORTHOSTATIC BP - ALL UNREMARKABLE (BP RAISED)	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 153	23	23	R: FALL (ACCIDENTAL), NO TRIP OR SLIP. S: 傷害、中毒および処置合併症 P: 転倒 L: Fall	E: 23 L: 1 Day	S: MILD R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 228	228		R: SEPSIS S: 感染症および寄生虫症 P: 敗血症 L: Sepsis		S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: DIRTY SPLINTER WAS ACQURED DURING GARDENING. A SEVERE WOUND INFECTION OCCURRED, SURGERY WAS NECESSARY TO REMOVE THE DIRTY WOODEN PARTICLES. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg									
	FU	20 TO	25	44		R: WORSENING OF PD SYMPTOMS S: 神経系障害 P: パーキンソン病 L: Parkinson's disease aggravated	E: 49 L: 6 Days	S: MILD R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: ADJUSTMENT OF PD MEDICATION A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]#	Age: 6[redacted]	Sex: Male	Race: WHITE	Weight: 7[redacted].[redacted] kg					
	TRT	1 TO 196	33	33		R: MULTIPLE SMALL NO DRAINABLE POST INFLAMMATORY ABSCESSES (INFUSION SITE ABSCESSES) S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	E: 120 L: 88 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 196	48	48	R: ABCESS OF ABDOMINAL WALL (BILATERAL) AT INFUSION SITE THIS DIAGNOSIS HAS BEEN TAKEN DIRECTLY FROM THE DISCHARGE SUMMARY. S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	E: 120 L: 73 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: INCISION AND DRAINAGE OF ABCESS	S: Yes, Hospitalization or prolonged hospitalization, Other medically important serious event R: PROBABLE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg									
		TRT	1 TO 196	195	195	R: CELLULITS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 205 L: 11 Days	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 5[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 353	294	294	R: PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis	E: 295 L: 2 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
		TRT	1 TO 367	108	108	R: ACTIVE FACIAL BLEEDING RELATED TO AE [redacted] S: 血管障害 P: 出血 L: Bleeding	E: 120 L: 13 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: GAIT DISORDER A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
	TRT	1 TO 367	108	108		R: FALL (ACCIDENTAL) S: 傷害、中毒および処置合併症 P: 転倒 L: Fall	E: 108 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: GAIT DISORDER PARKINSON DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
	TRT	1 TO 367	108	108		R: LOSS OF CONSCIOUSNESS S: 神経系障害 P: 意識消失 L: Loss of consciousness	E: 108 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: GAIT DISORDER PARKINSON DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
		TRT	1 TO 367	108	108	R: PAIN SURROUNDING EYE RELATED TO AE [redacted] S: 眼障害 P: 眼窩周囲痛 L: Periorbital pain	E: 120 L: 13 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: GAIT DISORDER A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
	TRT	1 TO 367	108	108		R: RIGHT FACE TRAUMA S: 傷害、中毒および処置合併症 P: 顔面損傷 L: Face injury	E: 108 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: GAIT DISORDER PARKINSON DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
	TRT	1 TO 367	108	108		R: RIGHT PERIORBITAL SWELLING S: 眼障害 P: 眼窩周囲腫脹 L: Periorbital swelling	E: 108 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: GAIT DISORDER PARKINSON DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

表2.7.4.7-11　重篤な有害事象を発現した被験者一覧（安全性解析対象集団）：M15-737試験

TABLE 14.3__2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch / Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 160	160	160	R: CLOSED DISPLACED FRACTURE OF LEFT FEMORAL NECK S: 傷害、中毒および処置合併症 P: 転位骨折 L: Fracture displacement	E: 162 L: 3 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: LEFT HIP REPLACEMENT SURGERY	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: MECHANICAL FALL A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg									
		TRT	1 TO	160	160	R: MECHANICAL FALL S: 傷害、中毒および処置合併症 P: 転倒 L: Fall	E: 160 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: POOR BALANCE DUE TO PD A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 14	14	14	R: TRONCHATERITIS LEFT S: 筋骨格系および結合組織障害 P: 滑液包炎 L: Trochanteritis		S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: EVENT CAUSED BY FALL, THIS IS DUE TO PARKINSON DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 174	15	15	R: DIVERTICULAR HEMORRHAGE S: 胃腸障害 P: 出血性腸憩室 L: Diverticulum intestinal hemorrhagic	E: 19 L: 5 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: HISTORY OF DIVERTICULAR BLEEDING A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 174	22	22	R: DIVERTICULAR HEMMORHAGE S: 胃腸障害 P: 出血性腸憩室 L: Diverticulum intestinal hemorrhagic	E: 134 L: 113 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: HISTORY OF DIVERTICULAR BLEEDING A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE [redacted]# Age: 8[redacted] Sex: Male Race: WHITE Weight: 5[redacted].[redacted] kg							
	TRT	1 TO 174	32	R: HIP FRACTURE S: 傷害、中毒および処置合併症 P: 股関節部骨折 L: Hip fracture	E: 32 L: 1 Day	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: ACCIDENTAL FALL A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 174	174	174	R: END STAGE PARKINSON DISEASE S: 神経系障害 P: パーキンソン病 L: End stage Parkinson's disease	E: 174 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Death of subject R: NOT RELATED O: CARDIO RESPIRATORY FAILURE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg									
		TRT	1 TO	178	178	R: INCREASED HALLUCINATIONS S: 精神障害 P: 幻覚 L: Hallucinations aggravated	E: 200 L: 23 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: Other: FLOW RATE LOWERED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 178	178		R: PSYCHOTIC STATE S: 精神障害 P: 精神病性障害 L: Psychotic state	E: 200 L: 23 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: Other: FLOW RATE LOWERED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]	Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
		TRT	1 TO	59	59	R: TRANSIENT ISCHEMIC ATTACK S: 神経系障害 P: 一過性脳虚血発作 L: Transient ischemic attack		S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: AGE AND STRESED AT THE TIME OF EVENT, A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 5[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO	148	148	R: POSTOPERATIVE/PROCEDURAL PAIN S: 傷害、中毒および処置合併症 P: 処置による疼痛 L: Procedural pain	E: 315 L: 168 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: THIS WAS A CONSEQUENCE OF THE FIRST SURGERY A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 4[redacted] Sex: Female Race: WHITE Weight: 8[redacted].[redacted] kg									
	TRT	1 TO	270	270		R: WORSENING OF LEFT ABDOMINAL ABSCESS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	E: 271 L: 2 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: INCISION AND DRAINAGE OF ABSCESS PERFORMED. WOUND CULTURES TAKEN AND SENT TO PATHOLOGY.	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg									
		TRT	1 TO	162	162	R: WORSENING PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis aggravated	E: 176 L: 15 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: Other: INFUSION RATE F2 LOWERED O: HOSPITALISATION PSYCHIATRIC WARD	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg									
	TRT	1 TO	254	254		R: FALL W/ SEQUALAE S: 傷害、中毒および処置合併症 P: 転倒 L: Fall	E: 254 L: 1 Day	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: FALL RELATED TO IMBALANCE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE [redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg									
	TRT	1 TO	254	254	R: INTRACRANIAL HEMORRHAGE S: 神経系障害 P: 頭蓋内出血 L: Intracranial hemorrhage		S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: IMBALANCE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 5[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
		TRT	1 TO	182	182	R: GASTROENTERITIS S: 感染症および寄生虫症 P: 胃腸炎 L: Gastroenteritis	E: 183 L: 2 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: PI DETERMINED THAT THE PATIENT WAS ADMITTED FOR GASTROENTERITIS BASED ON LAB, IMAGING AND ADMISSIONS A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg								
	TRT	1 TO	73	73	R: RIGHT SCAPULA FRACTURE S: 傷害、中毒および処置合併症 P: 肩甲骨骨折 L: Scapula fracture	E: 97 L: 25 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: REHABILITATION THERAPY, EXTERNAL IMMOBILIZATION IN A SLING	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: ACCIDENTAL FALL A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 69	69		R: ABDOMINAL WALL CELLULITIS, RIGHT FLANK, AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis		S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: PROBABLY RELATED TO THE CANNULA A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: ASIAN Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 243	243	243	R: DUE TO ASPIRATION S: 呼吸器、胸郭および縦隔障害 P: 誤嚥 L: Aspiration	E: 243 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Death of subject R: NOT RELATED O: ASPIRATION ACCIDENTALLY A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE [redacted]# Age: 7[redacted] Sex: Female Race: ASIAN Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 243	243	243	R: SUFFOCATION S: 呼吸器、胸郭および縦隔障害 P: 窒息 L: Suffocation	E: 243 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Death of subject R: NOT RELATED O: ASPIRATION ACCIDENTALLY A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 233	232	232	R: END STAGE PARKINSON'S DISEASE S: 神経系障害 P: パーキンソン病 L: End stage Parkinson's disease	E: 234 L: 3 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: MULTIPLE: (CONCOMITANT MEDICATION OR THERAPY DISCONTINUED; Other: SUBJECT WAS PLACED ON HOSPICE AND DIED AT HOME ON [redacted] 20[redacted]; CONCOMITANT MEDICATION OR THERAPY STARTED)	S: Yes, Death of subject R: NOT RELATED O: PROGRESSION OF HER PARKINSON'S TO DEATH

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 140	140		R: FRACTURED HIP S: 傷害、中毒および処置合併症 P: 股関節部骨折 L: Fractured hip		S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: SUBJECT TRIPPED A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 294	294		R: PAIN LEFT LEG S: 筋骨格系および結合組織障害 P: 四肢痛 L: Leg pain		S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: HIP RADIOGRAPHY THAT SHOWED ONLY ARTHROSIS (KNOWN IN MH)	S: Yes, Hospitalization or prolonged hospitalization, Persistent or significant disability/incapacity R: NOT RELATED O: PATIENT HOSPITALIZED IN ORDER TO BE EVALUATED BY KINESIOLOGIST AND LOGOPEDE. THIS IS MORE LIKE AND HOSPITALIZATION TO REVIEW THE PATIENT'S CONDITION THEN A SEVERE AE THAT NEEDED TO BE HOSPITALIZED A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
		TRT	1 TO	183	183	R: CELLULITIS AT THE INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 197 L: 15 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: BLOOD CX, WOUND CX PERFORMED AWAITING RESULTS TO BOTH	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

表2.7.4.7-12　重篤な有害事象を発現した被験者一覧（安全性解析対象集団）：M15-736試験

[redacted]20[redacted] 19:32 <[redacted]>
ABBV-951
STUDY M15-736
R&D/20/1640 - CLINICAL/STATISTICAL

TABLE 14.3__2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 5[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 87	60	60	R: DELUSIONS S: 精神障害 P: 妄想 L: Delusions	E: 76 L: 17 DAYS	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: REASONABLE POSSIBILITY R3: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED A2: DRUG INTERRUPTED O: MULTIPLE: (CONCOMITANT MEDICATION OR THERAPY DISCONTINUED; Other: SEROQUEL STARTED 12.5 MG BID AND INCREASED TO 25 MG BID, REDUCTION OF DOPAMINE AGONIST (ROPINIROLE) TO 1MG TID; CONCOMITANT MEDICATION OR THERAPY STARTED)	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 5[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg Country: UNITED STATES									
		TRT	1 TO 87	60	60	R: PARANOIA S: 精神障害 P: 妄想症 L: Paranoia	E: 76 L: 17 DAYS	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: REASONABLE POSSIBILITY R3: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED A2: DRUG INTERRUPTED O: MULTIPLE: (CONCOMITANT MEDICATION OR THERAPY DISCONTINUED; Other: SEROQUEL STARTED 12.5 MG BID AND INCREASED TO 25 MG BID, REDUCTION OF DOPAMINE AGONIST (ROPINIROLE) TO 1MG TID; CONCOMITANT MEDICATION OR THERAPY STARTED)	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 5[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg Country: UNITED STATES									
	TRT	1 TO 87	60	60		R: PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis	E: 76 L: 17 DAYS	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: REASONABLE POSSIBILITY R3: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED A2: DRUG INTERRUPTED O: MULTIPLE: (CONCOMITANT MEDICATION OR THERAPY DISCONTINUED; Other: SEROQUEL STARTED 12.5 MG BID AND INCREASED TO 25 MG BID, REDUCTION OF DOPAMINE AGONIST (ROPINIROLE) TO 1MG TID; CONCOMITANT MEDICATION OR THERAPY STARTED)	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ORAL CD/LD LOW DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 87	59	59	R: ACCIDENTAL FALL S: 傷害、中毒および処置合併症 P: 転倒 L: Fall	E: 59 L: 1 DAYS	S: MODERATE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED A2: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: UNSTEADINESS AND POOR BALANCE DUE TO PARKINSON'S DISEASE. A: NO REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ORAL CD/LD LOW DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 87	59	59	R: CONTUSION RIGHT HIP S: 傷害、中毒および処置合併症 P: 挫傷 L: Contusion of hip	E: 72 L: 14 DAYS	S: MODERATE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED A2: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: SUBJECT LOST HIS BALANCE AND FELL WHILE CARRYING A LARGE, CUMBERSOME AND FAIRLY HEAVY BAG OF STUDY SUPPLIES UP THE GARAGE STAIRS AND INTO THE HOUSE. A: NO REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ORAL CD/LD LOW DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 87	59	59	R: CONTUSION TO BACK (THORACIC-JUST BELOW LEFT SCAPULA). S: 傷害、中毒および処置合併症 P: 挫傷 L: Contusion of back	E: 72 L: 14 DAYS	S: MODERATE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED A2: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: ACCIDENTAL FALL DUE TO PARKINSON'S DISEASE. SUBJECT LOST HIS BALANCE AND FELL WHILE CARRYING A LARGE, CUMBERSOME AND FAIRLY HEAVY BAG OF STUDY SUPPLIES UP THE GARAGE STAIRS AND INTO THE HOUSE. A: NO REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ORAL CD/LD LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 19	9	9	R: COVID-19 PNEUMONIA INFECTION S: 感染症および寄生虫症 P: COVID-19肺炎 L: COVID-19 pneumonia	O: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R4: Yes A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

* from oral stablization period.
\# Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 26	26	26	R: WORSENING OF DEHYDRATION S: 代謝および栄養障害 P: 脱水 L: Dehydration	E: 27 L: 2 DAYS	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: LOSS OF AUTONOMIC FUNCTION LEADING TO DEHYDRATION, NO SENSE OF THIRST A: NO REASONABLE POSSIBILITY

* from oral stablization period.
\# Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ORAL CD/LD HIGH DOSE								
[redacted] Age: 5[redacted] Sex: Male Race: WHITE Weight: 10[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 85	28	28	R: KIDNEY STONES S: 腎および尿路障害 P: 腎結石症 L: Kidney stones	E: 31 L: 4 DAYS I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: NATURAL CAUSES POSSIBLY DUE TO OBESITY A: NO REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 5[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg Country: AUSTRALIA								
	TRT	1 TO 84	17	17	R: INFUSION SITE CELLULITIS S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	O: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: BLOOD CULTURE	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 5[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 92	87	87	R: ATYPICAL MIGRAINE S: 神経系障害 P: 片頭痛 L: Migraine	E: 88 L: 2 DAYS	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: UNDETERMINED AT THIS TIME A: NO REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ORAL CD/LD LOW DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 70	68	68	R: CELLULITIS OF THE RIGHT LEG S: 感染症および寄生虫症 P: 蜂巣炎 L: Cellulitis of leg	O: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: SUBJECT BUMPED HER KNEE RESULTING IN INFECTION A: NO REASONABLE POSSIBILITY

* from oral stablization period.
\# Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ORAL CD/LD LOW DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg Country: UNITED STATES								
	FU	71 TO 91	21		R: ACUTE RESPIRATORY FAILURE S: 呼吸器、胸郭および縦隔障害 P: 急性呼吸不全 L: Acute respiratory failure	E: 98 L: 8 DAYS	S: SEVERE R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R4: No A1: Other: SUBJECT HAD PREVIOUSLY STOPPED STUDY DRUG, ORAL AND ABBV-951 AT PREVIOUS HOSPITAL STAY O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Life threatening, Death of subject, Hospitalization or prolonged hospitalization R: NOT RELATED O: SEPSIS A: NO REASONABLE POSSIBILITY

* from oral stablization period.
# Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 11[redacted].[redacted] kg Country: UNITED STATES								
	TRT	1 TO 82	59	59	R: CELLULITIS OF THE ABDOMEN AT CANULA SITE S: 感染症および寄生虫症 P: カテーテル留置部位蜂巣炎 L: Catheter site cellulitis	O: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R2: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: PUMP HAS CONTINUED AT ANOTHER SITE NOT INFECTED. HOSPITALIZED WITH IV ANTIBIOTICS.	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: Open-Label CD/LD IR* R2: Study Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with Study Drug from ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg Country: UNITED STATES								
[redacted]	TRT	1 TO 85	8	8	R: ENLARGED PROSTATE S: 生殖系および乳房障害 P: 前立腺腫大 L: Enlarged prostate	E: 9 L: 2 DAYS	S: MILD R1: NO REASONABLE POSSIBILITY R2: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: PARKINSON'S DISEASE A: NO REASONABLE POSSIBILITY

* from oral stablization period.

Program Source Code: [redacted]

表 2.7.4.7-13　重篤な有害事象を発現した被験者一覧（安全性解析対象集団）：M15-739 試験

TABLE 14.3__2.1

LISTING OF TREATMENT-EMERGENT SERIOUS ADVERSE EVENTS
(SAFETY ANALYSIS SET)

SUBJECT NUMBER	EPOCH NAME	EPOCH INTERVAL	EPOCH DAY	RX DAY/ TIME OF ONSET@	R:REPORTED TERM S:SYSTEM ORGAN CLASS P:MEDDRA 21.1 PREFERRED TERM L:LOWER LEVEL TERM	E:RX DAY/TIME ENDED O:ONGOING AT THE END OF STUDY? L:LENGTH I:INTERMITTENT?	S:SEVERITY R:RELATIONSHIP TO STUDY DRUG A:ACTION TAKEN WITH STUDY TREATMENT O:OTHER ACTIONS TAKEN C:CONCOMITTANT MEDICATION OR THERAPY STARTED?	S:SERIOUS AE? O:OTHER CAUSE OF EVENT
INV: [redacted], [redacted] ([redacted])								
TRT: ABBV-951								
[redacted]#	AGE:4[redacted] SEX:MALE RACE:WHITE WEIGHT:8[redacted].[redacted] KG							
	TRT	1 TO 22	22	22 [59:35]	R:UPPER RIGHT AND LOWER LEFT QUADRANT ABDOMINAL WALL CELLULITIS S:INFECTIONS AND INFESTATIONS P:蜂巣炎 L:CELLULITIS OF ABDOMINAL WALL	E:93 L:72 DAYS	S:SEVERE R:REASONABLE POSSIBILITY A:DRUG WITHDRAWN O:MULTIPLE C:CONCOMITANT OR ADDITIONAL TREATMENT GIVEN	S:YES, HOSPITAL

TRT = TREATMENT; POST = POST-TREATMENT.
# SUBJECT PREMATURELY DISCONTINUED.
@ TIME RELATIVE TO MOST RECENT DOSE IN [].

Program Source Code: [redacted]

TABLE 14.3__2.1

LISTING OF TREATMENT-EMERGENT SERIOUS ADVERSE EVENTS
(SAFETY ANALYSIS SET)

SUBJECT NUMBER	EPOCH NAME	EPOCH INTERVAL	EPOCH DAY	RX DAY/ TIME OF ONSET@	R:REPORTED TERM S:SYSTEM ORGAN CLASS P:MEDDRA 21.1 PREFERRED TERM L:LOWER LEVEL TERM	E:RX DAY/TIME ENDED O:ONGOING AT THE END OF STUDY? L:LENGTH I:INTERMITTENT?	S:SEVERITY R:RELATIONSHIP TO STUDY DRUG A:ACTION TAKEN WITH STUDY TREATMENT O:OTHER ACTIONS TAKEN C:CONCOMITTANT MEDICATION OR THERAPY STARTED?	S:SERIOUS AE? O:OTHER CAUSE OF EVENT
INV: [redacted], [redacted] ([redacted])								
TRT: ABBV-951								
[redacted]#	AGE:4[redacted] SEX:MALE RACE:WHITE WEIGHT:8[redacted].[redacted] KG							
(CONT.)	POST	23 TO	8	30 [251:35]	R:2 ABDOMINAL ABSCESSES - RUQ AND LLQ. S:INFECTIONS AND INFESTATIONS P:腹部膿瘍 L:ABDOMINAL ABSCESS	E:93 L:64 DAYS	S:MODERATE R:REASONABLE POSSIBILITY A:DOSE NOT CHANGED O:CONCOMITANT MEDICATION OR THERAPY DISCONTINUED C:CONCOMITANT OR ADDITIONAL TREATMENT GIVEN	S:YES, HOSPITAL

TRT = TREATMENT; POST = POST-TREATMENT.
# SUBJECT PREMATURELY DISCONTINUED.
@ TIME RELATIVE TO MOST RECENT DOSE IN [].

Program Source Code: [redacted]

表 2.7.4.7-14　重篤な有害事象を発現した被験者一覧（安全性解析対象集団）：M17-220 試験

TABLE 14.3__2.1

Listing of Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	----- Name	Epoch Interval	---- Day	Rx Day/ Time of Onset@	R:Reported Term S:System Organ Class P:MedDRA 22.1 Preferred Term L:Lower Level Term	E:RX Day/Time Ended O:Ongoing at the End of Study L:Length I:Intermittent?	S:Severity T:Toxicity Grade Relationship To R1:Regimen A R2:Regimen B A:Action Taken with Study Treatment O:Other Actions Taken C:Concomitant Medication or Therapy Started?	S:Serious AE? O:Other Cause of Event
INV: [redacted]. [redacted] ([redacted]) SEQ: BA								
[redacted]#	AGE:6[redacted]	SEX:MALE	RACE:MULTIPLE		WEIGHT:8[redacted].[redacted] KG			
	CO P1	1 TO 2	2	2 9:20 [26:38]	R:GENERALIZED SEIZURE S:NERVOUS SYSTEM DISORDERS P:痙攣発作 L:SEIZURE	E:2 / 9:23 L:1 DAYS I:SINGLE EVENT	S:SEVERE T:UNKNOWN R2:NO REASONABLE POSSIBILITY A:DRUG WITHDRAWN O:ADMITTED TO HOSPITAL	S:YES, REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Regimen A: LCIG (12.5/50 MG CD/LD loading dose followed by 87.5/350 MG CD/LD over 16 hours followed by two 25/100 MG CD/LD oral doses).
Regimen B: ABBV-951 (4/80 MG CDP/LDP loading dose followed by 35/700 MG CDP/LDP over 24 hours).
@ Time relative to most recent dose in [].
CO P1 = Crossover Period 1.
Subject prematurely discontinued.
Program Source Code: [redacted]

表 2.7.4.7-15　重篤な有害事象を発現した被験者一覧（安全性解析対象集団）：M18-763 試験

TABLE 14.3__2.1

LISTING OF TREATMENT-EMERGENT SERIOUS ADVERSE EVENTS
(SAFETY ANALYSIS SET)

SUBJECT NUMBER	EPOCH NAME	EPOCH INTERVAL	DAY	RX DAY/ TIME OF ONSET@	R:REPORTED TERM S:SYSTEM ORGAN CLASS P:MEDDRA 21.0 PREFERRED TERM L:LOWER LEVEL TERM	E:RX DAY/TIME ENDED O:ONGOING AT THE END OF STUDY? L:LENGTH I:INTERMITTENT?	S:SEVERITY T:TOXICITY GRADE RELATIONSHIP TO R:ABBV-951/PLACEBO A:ACTION TAKEN WITH STUDY TREATMENT O:OTHER ACTIONS TAKEN C:CONCOMITANT MEDICATION OR THERAPY STARTED?	S:SERIOUS AE? O:OTHER CAUSE OF EVENT
INV: [redacted], [redacted] ([redacted])								
TRT: ABBV-951/PLACEBO								
[redacted]	AGE:6[redacted] SEX:FEMALE RACE:BLACK OR AFRICAN AMERICAN WEIGHT:7[redacted].[redacted] KG							
	FUP	12 TO 59	4	15 19:00 [125:12]	R:LEFT SHOULDER PAIN S:MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS P:筋骨格痛 L:SHOULDER PAIN	E:48 / 8:00 L:34 DAYS I:SINGLE EVENT	S:SEVERE T:GRADE 3 R:NO REASONABLE POSSIBILITY A:DOSE NOT CHANGED O:MULTIPLE C:YES	S:YES, HOSPITALIZATION OR PROLONGED HOSPITALIZATION

FUP = FOLLOW-UP.
@ TIME RELATIVE TO MOST RECENT DOSE IN [].

Program Source Code: [redacted]

表2.7.4.7-16　特に注目すべき有害事象の概要（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 06:15 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - polyneuropathy (narrow)	N=132	N=112	N=244
Subjects with:			
Any TEAE	2 (1.5)	6 (5.4)	8 (3.3)
Any severe TEAE	0	1 (0.9)	1 (0.4)
Any TEAE that is considered associated with study drug$	1 (0.8)	3 (2.7)	4 (1.6)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - polyneuropathy (narrow)	N=132	N=112	N=244
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - polyneuropathy (narrow)	N=111	N=95	N=206
Subjects with:			
Any TEAE	2 (1.8)	6 (6.3)	8 (3.9)
Any severe TEAE	0	1 (1.1)	1 (0.5)
Any TEAE that is considered associated with study drug$	1 (0.9)	3 (3.2)	4 (1.9)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - weight loss	N=132	N=112	N=244
Subjects with:			
Any TEAE	12 (9.1)	13 (11.6)	25 (10.2)
Any severe TEAE	0	1 (0.9)	1 (0.4)
Any TEAE that is considered associated with study drug$	5 (3.8)	11 (9.8)	16 (6.6)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	1 (0.9)	1 (0.4)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - weight loss	N=132	N=112	N=244
Subjects with:			
Any TEAE	1 (0.8)	1 (0.9)	2 (0.8)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	1 (0.8)	1 (0.9)	2 (0.8)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - weight loss	N=111	N=95	N=206
Subjects with:			
Any TEAE	11 (9.9)	12 (12.6)	23 (11.2)
Any severe TEAE	0	1 (1.1)	1 (0.5)
Any TEAE that is considered associated with study drug$	4 (3.6)	10 (10.5)	14 (6.8)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	1 (1.1)	1 (0.5)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - hallucinations/psychosis	N=132	N=112	N=244
Subjects with:			
Any TEAE	32 (24.2)	27 (24.1)	59 (24.2)
Any severe TEAE	5 (3.8)	6 (5.4)	11 (4.5)
Any TEAE that is considered associated with study drug$	32 (24.2)	22 (19.6)	54 (22.1)
Any TEAE that is considered associated with product complaint$	2 (1.5)	0	2 (0.8)
ABBV-951	1 (0.8)	0	1 (0.4)
Infusion pump	1 (0.8)	0	1 (0.4)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	7 (5.3)	6 (5.4)	13 (5.3)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	9 (6.8)	5 (4.5)	14 (5.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	5 (3.8)	3 (2.7)	8 (3.3)
Possible	3 (2.3)	2 (1.8)	5 (2.0)
Probable	2 (1.5)	0	2 (0.8)
Causal relationship	1 (0.8)	1 (0.9)	2 (0.8)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	2 (1.5)	0	2 (0.8)
ABBV-951	1 (0.8)	0	1 (0.4)
Infusion pump	1 (0.8)	0	1 (0.4)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - hallucinations/psychosis	N=132	N=112	N=244
Subjects with:			
Any TEAE	17 (12.9)	8 (7.1)	25 (10.2)
Any severe TEAE	2 (1.5)	0	2 (0.8)
Any TEAE that is considered associated with study drug$	16 (12.1)	5 (4.5)	21 (8.6)
Any TEAE that is considered associated with product complaint$	2 (1.5)	0	2 (0.8)
ABBV-951	1 (0.8)	0	1 (0.4)
Infusion pump	1 (0.8)	0	1 (0.4)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	3 (2.3)	1 (0.9)	4 (1.6)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	6 (4.5)	0	6 (2.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	2 (1.5)	0	2 (0.8)
Possible	2 (1.5)	0	2 (0.8)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	2 (1.5)	0	2 (0.8)
ABBV-951	1 (0.8)	0	1 (0.4)
Infusion pump	1 (0.8)	0	1 (0.4)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - hallucinations/psychosis	N=111	N=95	N=206
Subjects with:			
Any TEAE	23 (20.7)	21 (22.1)	44 (21.4)
Any severe TEAE	3 (2.7)	6 (6.3)	9 (4.4)
Any TEAE that is considered associated with study drug$	23 (20.7)	18 (18.9)	41 (19.9)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	4 (3.6)	5 (5.3)	9 (4.4)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	4 (3.6)	5 (5.3)	9 (4.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	3 (2.7)	3 (3.2)	6 (2.9)
Possible	1 (0.9)	2 (2.1)	3 (1.5)
Probable	2 (1.8)	0	2 (1.0)
Causal relationship	1 (0.9)	1 (1.1)	2 (1.0)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - somnolence	N=132	N=112	N=244
Subjects with:			
Any TEAE	9 (6.8)	3 (2.7)	12 (4.9)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	5 (3.8)	3 (2.7)	8 (3.3)
Any TEAE that is considered associated with product complaint$	1 (0.8)	0	1 (0.4)
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	1 (0.8)	0	1 (0.4)
[redacted] infusion set 6 mm	1 (0.8)	0	1 (0.4)
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - somnolence	N=132	N=112	N=244
Subjects with:			
Any TEAE	2 (1.5)	2 (1.8)	4 (1.6)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	2 (1.5)	2 (1.8)	4 (1.6)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Maintenance period - somnolence	N=111	N=95	N=206
Subjects with:			
Any TEAE	8 (7.2)	1 (1.1)	9 (4.4)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	3 (2.7)	1 (1.1)	4 (1.9)
Any TEAE that is considered associated with product complaint$	1 (0.9)	0	1 (0.5)
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	1 (0.9)	0	1 (0.5)
[redacted] infusion set 6 mm	1 (0.9)	0	1 (0.5)
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - infusion site related infections	N=132	N=112	N=244
Subjects with:			
Any TEAE	41 (31.1)	43 (38.4)	84 (34.4)
Any severe TEAE	6 (4.5)	7 (6.3)	13 (5.3)
Any TEAE that is considered associated with study drug$	39 (29.5)	40 (35.7)	79 (32.4)
Any TEAE that is considered associated with product complaint$	30 (22.7)	31 (27.7)	61 (25.0)
ABBV-951	14 (10.6)	16 (14.3)	30 (12.3)
Infusion pump	0	3 (2.7)	3 (1.2)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	14 (10.6)	12 (10.7)	26 (10.7)
[redacted] infusion set 6 mm	7 (5.3)	5 (4.5)	12 (4.9)
[redacted] infusion set 9 mm	8 (6.1)	8 (7.1)	16 (6.6)
Neria guard infusion set (total)	6 (4.5)	4 (3.6)	10 (4.1)
Neria guard infusion set 6 mm	3 (2.3)	1 (0.9)	4 (1.6)
Neria guard infusion set 9 mm	3 (2.3)	3 (2.7)	6 (2.5)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	1 (0.9)	1 (0.4)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	5 (3.8)	7 (6.3)	12 (4.9)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	8 (6.1)	8 (7.1)	16 (6.6)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	6 (4.5)	3 (2.7)	9 (3.7)
Possible	1 (0.8)	0	1 (0.4)
Probable	1 (0.8)	2 (1.8)	3 (1.2)
Causal relationship	4 (3.0)	1 (0.9)	5 (2.0)
Any SAE that is considered associated with [redacted] infusion set$	1 (0.8)	1 (0.9)	2 (0.8)
Possible	1 (0.8)	1 (0.9)	2 (0.8)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	1 (0.8)	0	1 (0.4)
Possible	1 (0.8)	0	1 (0.4)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	7 (5.3)	6 (5.4)	13 (5.3)
ABBV-951	3 (2.3)	3 (2.7)	6 (2.5)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	2 (1.5)	2 (1.8)	4 (1.6)
[redacted] infusion set 6 mm	1 (0.8)	1 (0.9)	2 (0.8)
[redacted] infusion set 9 mm	1 (0.8)	1 (0.9)	2 (0.8)
Neria guard infusion set (total)	2 (1.5)	1 (0.9)	3 (1.2)
Neria guard infusion set 6 mm	2 (1.5)	1 (0.9)	3 (1.2)
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - infusion site related infections	N=132	N=112	N=244
Subjects with:			
Any TEAE	11 (8.3)	18 (16.1)	29 (11.9)
Any severe TEAE	2 (1.5)	1 (0.9)	3 (1.2)
Any TEAE that is considered associated with study drug$	9 (6.8)	15 (13.4)	24 (9.8)
Any TEAE that is considered associated with product complaint$	8 (6.1)	15 (13.4)	23 (9.4)
ABBV-951	4 (3.0)	5 (4.5)	9 (3.7)
Infusion pump	0	2 (1.8)	2 (0.8)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	3 (2.3)	8 (7.1)	11 (4.5)
[redacted] infusion set 6 mm	2 (1.5)	3 (2.7)	5 (2.0)
[redacted] infusion set 9 mm	1 (0.8)	5 (4.5)	6 (2.5)
Neria guard infusion set (total)	2 (1.5)	1 (0.9)	3 (1.2)
Neria guard infusion set 6 mm	1 (0.8)	0	1 (0.4)
Neria guard infusion set 9 mm	1 (0.8)	1 (0.9)	2 (0.8)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	3 (2.3)	3 (2.7)	6 (2.5)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (0.8)	2 (1.8)	3 (1.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	1 (0.8)	1 (0.9)	2 (0.8)
Possible	0	0	0
Probable	0	1 (0.9)	1 (0.4)
Causal relationship	1 (0.8)	0	1 (0.4)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	1 (0.8)	2 (1.8)	3 (1.2)
ABBV-951	1 (0.8)	0	1 (0.4)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	2 (1.8)	2 (0.8)
[redacted] infusion set 6 mm	0	1 (0.9)	1 (0.4)
[redacted] infusion set 9 mm	0	1 (0.9)	1 (0.4)
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - infusion site related infections	N=111	N=95	N=206
Subjects with:			
Any TEAE	33 (29.7)	33 (34.7)	66 (32.0)
Any severe TEAE	4 (3.6)	6 (6.3)	10 (4.9)
Any TEAE that is considered associated with study drug$	31 (27.9)	32 (33.7)	63 (30.6)
Any TEAE that is considered associated with product complaint$	25 (22.5)	23 (24.2)	48 (23.3)
ABBV-951	10 (9.0)	13 (13.7)	23 (11.2)
Infusion pump	0	1 (1.1)	1 (0.5)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	12 (10.8)	9 (9.5)	21 (10.2)
[redacted] infusion set 6 mm	5 (4.5)	3 (3.2)	8 (3.9)
[redacted] infusion set 9 mm	7 (6.3)	7 (7.4)	14 (6.8)
Neria guard infusion set (total)	6 (5.4)	3 (3.2)	9 (4.4)
Neria guard infusion set 6 mm	3 (2.7)	1 (1.1)	4 (1.9)
Neria guard infusion set 9 mm	3 (2.7)	2 (2.1)	5 (2.4)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	1 (1.1)	1 (0.5)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	2 (1.8)	4 (4.2)	6 (2.9)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	7 (6.3)	6 (6.3)	13 (6.3)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	5 (4.5)	2 (2.1)	7 (3.4)
Possible	1 (0.9)	0	1 (0.5)
Probable	1 (0.9)	1 (1.1)	2 (1.0)
Causal relationship	3 (2.7)	1 (1.1)	4 (1.9)
Any SAE that is considered associated with [redacted] infusion set$	1 (0.9)	1 (1.1)	2 (1.0)
Possible	1 (0.9)	1 (1.1)	2 (1.0)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	1 (0.9)	0	1 (0.5)
Possible	1 (0.9)	0	1 (0.5)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	6 (5.4)	4 (4.2)	10 (4.9)
ABBV-951	2 (1.8)	3 (3.2)	5 (2.4)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	2 (1.8)	0	2 (1.0)
[redacted] infusion set 6 mm	1 (0.9)	0	1 (0.5)
[redacted] infusion set 9 mm	1 (0.9)	0	1 (0.5)
Neria guard infusion set (total)	2 (1.8)	1 (1.1)	3 (1.5)
Neria guard infusion set 6 mm	2 (1.8)	1 (1.1)	3 (1.5)
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period - infusion site related non infection reactions	N=132	N=112	N=244
Subjects with:			
Any TEAE	103 (78.0)	96 (85.7)	199 (81.6)
Any severe TEAE	4 (3.0)	5 (4.5)	9 (3.7)
Any TEAE that is considered associated with study drug$	99 (75.0)	95 (84.8)	194 (79.5)
Any TEAE that is considered associated with product complaint$	84 (63.6)	72 (64.3)	156 (63.9)
ABBV-951	44 (33.3)	39 (34.8)	83 (34.0)
Infusion pump	2 (1.5)	4 (3.6)	6 (2.5)
Vial adapter	0	1 (0.9)	1 (0.4)
Syringes	0	0	0
[redacted] infusion set (total)	48 (36.4)	37 (33.0)	85 (34.8)
[redacted] infusion set 6 mm	37 (28.0)	23 (20.5)	60 (24.6)
[redacted] infusion set 9 mm	20 (15.2)	21 (18.8)	41 (16.8)
Neria guard infusion set (total)	12 (9.1)	14 (12.5)	26 (10.7)
Neria guard infusion set 6 mm	6 (4.5)	9 (8.0)	15 (6.1)
Neria guard infusion set 9 mm	9 (6.8)	10 (8.9)	19 (7.8)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	1 (0.8)	0	1 (0.4)
Any TEAE that is considered associated with rescue dose$	4 (3.0)	5 (4.5)	9 (3.7)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	13 (9.8)	7 (6.3)	20 (8.2)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (0.8)	2 (1.8)	3 (1.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	1 (0.9)	1 (0.4)
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	1 (0.9)	1 (0.4)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	1 (0.8)	1 (0.9)	2 (0.8)
ABBV-951	1 (0.8)	0	1 (0.4)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	1 (0.9)	1 (0.4)
Neria guard infusion set 6 mm	0	1 (0.9)	1 (0.4)
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - infusion site related non infection reactions	N=132	N=112	N=244
Subjects with:			
Any TEAE	87 (65.9)	82 (73.2)	169 (69.3)
Any severe TEAE	1 (0.8)	1 (0.9)	2 (0.8)
Any TEAE that is considered associated with study drug$	81 (61.4)	79 (70.5)	160 (65.6)
Any TEAE that is considered associated with product complaint$	62 (47.0)	57 (50.9)	119 (48.8)
ABBV-951	32 (24.2)	30 (26.8)	62 (25.4)
Infusion pump	1 (0.8)	1 (0.9)	2 (0.8)
Vial adapter	0	1 (0.9)	1 (0.4)
Syringes	0	0	0
[redacted] infusion set (total)	37 (28.0)	28 (25.0)	65 (26.6)
[redacted] infusion set 6 mm	27 (20.5)	13 (11.6)	40 (16.4)
[redacted] infusion set 9 mm	15 (11.4)	16 (14.3)	31 (12.7)
Neria guard infusion set (total)	4 (3.0)	6 (5.4)	10 (4.1)
Neria guard infusion set 6 mm	2 (1.5)	5 (4.5)	7 (2.9)
Neria guard infusion set 9 mm	2 (1.5)	3 (2.7)	5 (2.0)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	1 (0.8)	0	1 (0.4)
Any TEAE that is considered associated with rescue dose$	2 (1.5)	1 (0.9)	3 (1.2)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	6 (4.5)	2 (1.8)	8 (3.3)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - infusion site related non infection reactions	N=111	N=95	N=206
Subjects with:			
Any TEAE	64 (57.7)	70 (73.7)	134 (65.0)
Any severe TEAE	3 (2.7)	4 (4.2)	7 (3.4)
Any TEAE that is considered associated with study drug$	63 (56.8)	69 (72.6)	132 (64.1)
Any TEAE that is considered associated with product complaint$	53 (47.7)	55 (57.9)	108 (52.4)
ABBV-951	25 (22.5)	30 (31.6)	55 (26.7)
Infusion pump	1 (0.9)	3 (3.2)	4 (1.9)
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	26 (23.4)	26 (27.4)	52 (25.2)
[redacted] infusion set 6 mm	19 (17.1)	15 (15.8)	34 (16.5)
[redacted] infusion set 9 mm	12 (10.8)	13 (13.7)	25 (12.1)
Neria guard infusion set (total)	11 (9.9)	12 (12.6)	23 (11.2)
Neria guard infusion set 6 mm	4 (3.6)	7 (7.4)	11 (5.3)
Neria guard infusion set 9 mm	8 (7.2)	9 (9.5)	17 (8.3)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	2 (1.8)	4 (4.2)	6 (2.9)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	7 (6.3)	5 (5.3)	12 (5.8)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (0.9)	2 (2.1)	3 (1.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	1 (1.1)	1 (0.5)
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	1 (1.1)	1 (0.5)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	1 (0.9)	1 (1.1)	2 (1.0)
ABBV-951	1 (0.9)	0	1 (0.5)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	1 (1.1)	1 (0.5)
Neria guard infusion set 6 mm	0	1 (1.1)	1 (0.5)
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - Falls and associated injuries (combined CMQ)	N=132	N=112	N=244
Subjects with:			
Any TEAE	35 (26.5)	36 (32.1)	71 (29.1)
Any severe TEAE	0	4 (3.6)	4 (1.6)
Any TEAE that is considered associated with study drug$	22 (16.7)	17 (15.2)	39 (16.0)
Any TEAE that is considered associated with product complaint$	2 (1.5)	0	2 (0.8)
ABBV-951	2 (1.5)	0	2 (0.8)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	2 (1.8)	2 (0.8)
Any TEAE that is considered associated with rescue dose$	0	1 (0.9)	1 (0.4)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	2 (1.5)	1 (0.9)	3 (1.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	2 (1.5)	0	2 (0.8)
Possible	2 (1.5)	0	2 (0.8)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - Falls and associated injuries (combined CMQ)	N=132	N=112	N=244
Subjects with:			
Any TEAE	19 (14.4)	19 (17.0)	38 (15.6)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	14 (10.6)	10 (8.9)	24 (9.8)
Any TEAE that is considered associated with product complaint$	1 (0.8)	0	1 (0.4)
ABBV-951	1 (0.8)	0	1 (0.4)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	2 (1.8)	2 (0.8)
Any TEAE that is considered associated with rescue dose$	0	1 (0.9)	1 (0.4)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (0.8)	0	1 (0.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	1 (0.8)	0	1 (0.4)
Possible	1 (0.8)	0	1 (0.4)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - Falls and associated injuries (combined CMQ)	N=111	N=95	N=206
Subjects with:			
Any TEAE	21 (18.9)	24 (25.3)	45 (21.8)
Any severe TEAE	0	4 (4.2)	4 (1.9)
Any TEAE that is considered associated with study drug$	9 (8.1)	8 (8.4)	17 (8.3)
Any TEAE that is considered associated with product complaint$	1 (0.9)	0	1 (0.5)
ABBV-951	1 (0.9)	0	1 (0.5)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (0.9)	1 (1.1)	2 (1.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	1 (0.9)	0	1 (0.5)
Possible	1 (0.9)	0	1 (0.5)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - Falls and associated injuries CMQ	N=132	N=112	N=244
Subjects with:			
Any TEAE	17 (12.9)	24 (21.4)	41 (16.8)
Any severe TEAE	0	3 (2.7)	3 (1.2)
Any TEAE that is considered associated with study drug$	5 (3.8)	5 (4.5)	10 (4.1)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (0.8)	1 (0.9)	2 (0.8)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	1 (0.8)	0	1 (0.4)
Possible	1 (0.8)	0	1 (0.4)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - Falls and associated injuries CMQ	N=132	N=112	N=244
Subjects with:			
Any TEAE	7 (5.3)	10 (8.9)	17 (7.0)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	2 (1.5)	3 (2.7)	5 (2.0)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (0.8)	0	1 (0.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	1 (0.8)	0	1 (0.4)
Possible	1 (0.8)	0	1 (0.4)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - Falls and associated injuries CMQ	N=111	N=95	N=206
Subjects with:			
Any TEAE	12 (10.8)	19 (20.0)	31 (15.0)
Any severe TEAE	0	3 (3.2)	3 (1.5)
Any TEAE that is considered associated with study drug$	3 (2.7)	3 (3.2)	6 (2.9)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	1 (1.1)	1 (0.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - Orthostatic hypotension CMQ	N=132	N=112	N=244
Subjects with:			
Any TEAE	22 (16.7)	17 (15.2)	39 (16.0)
Any severe TEAE	0	1 (0.9)	1 (0.4)
Any TEAE that is considered associated with study drug$	18 (13.6)	13 (11.6)	31 (12.7)
Any TEAE that is considered associated with product complaint$	2 (1.5)	0	2 (0.8)
ABBV-951	2 (1.5)	0	2 (0.8)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	2 (1.8)	2 (0.8)
Any TEAE that is considered associated with rescue dose$	0	1 (0.9)	1 (0.4)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	2 (1.5)	0	2 (0.8)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	2 (1.5)	0	2 (0.8)
Possible	2 (1.5)	0	2 (0.8)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - Orthostatic hypotension CMQ	N=132	N=112	N=244
Subjects with:			
Any TEAE	14 (10.6)	11 (9.8)	25 (10.2)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	13 (9.8)	8 (7.1)	21 (8.6)
Any TEAE that is considered associated with product complaint$	1 (0.8)	0	1 (0.4)
ABBV-951	1 (0.8)	0	1 (0.4)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	2 (1.8)	2 (0.8)
Any TEAE that is considered associated with rescue dose$	0	1 (0.9)	1 (0.4)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (0.8)	0	1 (0.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	1 (0.8)	0	1 (0.4)
Possible	1 (0.8)	0	1 (0.4)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - Orthostatic hypotension CMQ	N=111	N=95	N=206
Subjects with:			
Any TEAE	10 (9.0)	7 (7.4)	17 (8.3)
Any severe TEAE	0	1 (1.1)	1 (0.5)
Any TEAE that is considered associated with study drug$	6 (5.4)	5 (5.3)	11 (5.3)
Any TEAE that is considered associated with product complaint$	1 (0.9)	0	1 (0.5)
ABBV-951	1 (0.9)	0	1 (0.5)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (0.9)	0	1 (0.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	1 (0.9)	0	1 (0.5)
Possible	1 (0.9)	0	1 (0.5)
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

表2.7.4.7-17　特に注目すべき有害事象の概要（安全性解析対象集団）：M15-737試験

[redacted]20[redacted] 07:21 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Polyneuropathy (narrow)			
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Polyneuropathy (narrow)			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Weight loss			
Subjects with:			
Any TEAE	1 (2.2)	3 (5.0)	4 (3.8)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	2 (3.3)	2 (1.9)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Weight loss			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Hallucinations/psychosis			
Subjects with:			
Any TEAE	4 (8.9)	6 (10.0)	10 (9.5)
Any severe TEAE	1 (2.2)	1 (1.7)	2 (1.9)
Any TEAE that is considered associated with study drug$	4 (8.9)	3 (5.0)	7 (6.7)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (2.2)	1 (1.7)	2 (1.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Hallucinations/psychosis			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Somnolence			
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Somnolence			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Infusion site related infections			
Subjects with:			
Any TEAE	8 (17.8)	9 (15.0)	17 (16.2)
Any severe TEAE	2 (4.4)	1 (1.7)	3 (2.9)
Any TEAE that is considered associated with study drug$	6 (13.3)	9 (15.0)	15 (14.3)
Any TEAE that is considered associated with product complaint$	5 (11.1)	8 (13.3)	13 (12.4)
ABBV-951	1 (2.2)	5 (8.3)	6 (5.7)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	1 (1.7)	1 (1.0)
[redacted] infusion set (total)	2 (4.4)	0	2 (1.9)
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	2 (4.4)	0	2 (1.9)
Neria guard infusion set (total)	2 (4.4)	5 (8.3)	7 (6.7)
Neria guard infusion set 6 mm	1 (2.2)	1 (1.7)	2 (1.9)
Neria guard infusion set 9 mm	1 (2.2)	4 (6.7)	5 (4.8)
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	2 (3.3)	2 (1.9)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	1 (1.7)	1 (1.0)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	2 (4.4)	1 (1.7)	3 (2.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category: Low Dose (N=45) n (%)	Dose Category: High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Infusion site related infections			
Any SAE that is considered associated with infusion pump$	1 (2.2)	1 (1.7)	2 (1.9)
Possible	0	0	0
Probable	0	1 (1.7)	1 (1.0)
Causal relationship	1 (2.2)	0	1 (1.0)
Any SAE that is considered associated with neria guards infusion set$	1 (2.2)	1 (1.7)	2 (1.9)
Possible	0	1 (1.7)	1 (1.0)
Probable	1 (2.2)	0	1 (1.0)
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	2 (4.4)	1 (1.7)	3 (2.9)
ABBV-951	1 (2.2)	0	1 (1.0)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	1 (2.2)	1 (1.7)	2 (1.9)
Neria guard infusion set 6 mm	1 (2.2)	0	1 (1.0)
Neria guard infusion set 9 mm	0	1 (1.7)	1 (1.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Infusion site related non infection reactions			
Subjects with:			
Any TEAE	11 (24.4)	17 (28.3)	28 (26.7)
Any severe TEAE	0	1 (1.7)	1 (1.0)
Any TEAE that is considered associated with study drug$	10 (22.2)	16 (26.7)	26 (24.8)
Any TEAE that is considered associated with product complaint$	8 (17.8)	10 (16.7)	18 (17.1)
ABBV-951	2 (4.4)	6 (10.0)	8 (7.6)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	3 (6.7)	0	3 (2.9)
[redacted] infusion set 6 mm	1 (2.2)	0	1 (1.0)
[redacted] infusion set 9 mm	2 (4.4)	0	2 (1.9)
Neria guard infusion set (total)	4 (8.9)	5 (8.3)	9 (8.6)
Neria guard infusion set 6 mm	2 (4.4)	1 (1.7)	3 (2.9)
Neria guard infusion set 9 mm	2 (4.4)	4 (6.7)	6 (5.7)
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	2 (3.3)	2 (1.9)
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	1 (1.7)	1 (1.0)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Infusion site related non infection reactions			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Falls and associated injuries (combined CMQ)			
Subjects with:			
Any TEAE	4 (8.9)	11 (18.3)	15 (14.3)
Any severe TEAE	0	1 (1.7)	1 (1.0)
Any TEAE that is considered associated with study drug$	0	2 (3.3)	2 (1.9)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	2 (4.4)	3 (5.0)	5 (4.8)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Falls and associated injuries (combined CMQ)			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Falls and associated injuries CMQ			
Subjects with:			
Any TEAE	4 (8.9)	10 (16.7)	14 (13.3)
Any severe TEAE	0	1 (1.7)	1 (1.0)
Any TEAE that is considered associated with study drug$	0	1 (1.7)	1 (1.0)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	2 (4.4)	3 (5.0)	5 (4.8)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Falls and associated injuries CMQ			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Orthostatic hypotension CMQ			
Subjects with:			
Any TEAE	0	3 (5.0)	3 (2.9)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	1 (1.7)	1 (1.0)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set)

	Dose Category		
	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Orthostatic hypotension CMQ			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

表2.7.4.7-18　二重盲検期に発現した特に注目すべき有害事象（安全性解析対象集団）：M15-736試験

[redacted]20[redacted] 19:32 <[redacted]>
ABBV-951
STUDY M15-736
R&D/20/1640 - CLINICAL/STATISTICAL

TABLE 14.3__1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Overall							
Any adverse event	21 (37.5)	4 (36.4)	25 (37.3)	39 (86.7)	20 (69.0)	59 (79.7)	84 (59.6)
注入部位紅斑	1 (1.8)	0	1 (1.5)	14 (31.1)	6 (20.7)	20 (27.0)	21 (14.9)
注入部位疼痛	1 (1.8)	0	1 (1.5)	13 (28.9)	6 (20.7)	19 (25.7)	20 (14.2)
注入部位蜂巣炎	0	0	0	10 (22.2)	4 (13.8)	14 (18.9)	14 (9.9)
注入部位浮腫	0	0	0	8 (17.8)	1 (3.4)	9 (12.2)	9 (6.4)
転倒	8 (14.3)	4 (36.4)	12 (17.9)	3 (6.7)	3 (10.3)	6 (8.1)	18 (12.8)
注入部位内出血	2 (3.6)	0	2 (3.0)	4 (8.9)	2 (6.9)	6 (8.1)	8 (5.7)
注入部位出血	0	0	0	5 (11.1)	1 (3.4)	6 (8.1)	6 (4.3)
注入部位結節	0	0	0	4 (8.9)	2 (6.9)	6 (8.1)	6 (4.3)
幻覚	0	1 (9.1)	1 (1.5)	3 (6.7)	2 (6.9)	5 (6.8)	6 (4.3)
幻視	0	0	0	1 (2.2)	3 (10.3)	4 (5.4)	4 (2.8)
注入部位硬結	0	0	0	2 (4.4)	2 (6.9)	4 (5.4)	4 (2.8)
注入部位感染	0	0	0	1 (2.2)	3 (10.3)	4 (5.4)	4 (2.8)
注入部位そう痒感	0	0	0	4 (8.9)	0	4 (5.4)	4 (2.8)
浮動性めまい	2 (3.6)	1 (9.1)	3 (4.5)	2 (4.4)	1 (3.4)	3 (4.1)	6 (4.3)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Overall (Cont.)							
注入部位丘疹	0	0	0	2 (4.4)	1 (3.4)	3 (4.1)	3 (2.1)
注入部位反応	0	0	0	1 (2.2)	2 (6.9)	3 (4.1)	3 (2.1)
注射部位疼痛	0	0	0	2 (4.4)	1 (3.4)	3 (4.1)	3 (2.1)
精神病性障害	0	0	0	1 (2.2)	2 (6.9)	3 (4.1)	3 (2.1)
カテーテル留置部位内出血	1 (1.8)	0	1 (1.5)	2 (4.4)	0	2 (2.7)	3 (2.1)
挫傷	1 (1.8)	0	1 (1.5)	1 (2.2)	1 (3.4)	2 (2.7)	3 (2.1)
注入部位血管外漏出	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
注入部位炎症	0	0	0	1 (2.2)	1 (3.4)	2 (2.7)	2 (1.4)
注入部位腫瘤	0	0	0	1 (2.2)	1 (3.4)	2 (2.7)	2 (1.4)
注入部位熱感	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
皮膚裂傷	1 (1.8)	0	1 (1.5)	1 (2.2)	1 (3.4)	2 (2.7)	3 (2.1)
カテーテル留置部位蜂巣炎	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位紅斑	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位出血	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
カテーテル留置部位硬結	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位疼痛	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Overall (Cont.)							
カテーテル留置部位小水疱	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
蜂巣炎	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)
食欲減退	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
妄想	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
体位性めまい	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
異常感覚	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
幻嗅	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
感覚鈍麻	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注入部位膿瘍	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注入部位血腫	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注入部位蒼白	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注入部位発疹	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注入部位腫脹	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位内出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位蜂巣炎	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位紅斑	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Overall (Cont.)							
注射部位漏出	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位硬結	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位炎症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
半月板損傷	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
筋骨格内異物	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
起立性低血圧	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)
妄想症	1 (1.8)	0	1 (1.5)	0	1 (3.4)	1 (1.4)	2 (1.4)
穿刺部位内出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
穿刺部位出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
傾眠	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
体重減少	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
振動覚低下	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
歩行障害	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
関節損傷	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
靱帯捻挫	2 (3.6)	0	2 (3.0)	0	0	0	2 (1.4)
四肢損傷	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Overall (Cont.)							
錯感覚	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
引っかき傷	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
失神	0	1 (9.1)	1 (1.5)	0	0	0	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Infusion Site Related Infections							
Any adverse event	2 (3.6)	0	2 (3.0)	14 (31.1)	7 (24.1)	21 (28.4)	23 (16.3)
注入部位蜂巣炎	0	0	0	10 (22.2)	4 (13.8)	14 (18.9)	14 (9.9)
注入部位感染	0	0	0	1 (2.2)	3 (10.3)	4 (5.4)	4 (2.8)
カテーテル留置部位蜂巣炎	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
蜂巣炎	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)
注入部位膿瘍	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注射部位蜂巣炎	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Infusion Site Related Non-Infection Reactions							
Any adverse event in infusion site related non infection reactions CMQ	5 (8.9)	0	5 (7.5)	31 (68.9)	15 (51.7)	46 (62.2)	51 (36.2)
Nodule PTs@	0	0	0	4 (8.9)	2 (6.9)	6 (8.1)	6 (4.3)
注入部位結節	0	0	0	4 (8.9)	2 (6.9)	6 (8.1)	6 (4.3)
Other PTs	5 (8.9)	0	5 (7.5)	30 (66.7)	14 (48.3)	44 (59.5)	49 (34.8)
注入部位紅斑	1 (1.8)	0	1 (1.5)	14 (31.1)	6 (20.7)	20 (27.0)	21 (14.9)
注入部位疼痛	1 (1.8)	0	1 (1.5)	13 (28.9)	6 (20.7)	19 (25.7)	20 (14.2)
注入部位浮腫	0	0	0	8 (17.8)	1 (3.4)	9 (12.2)	9 (6.4)
注入部位内出血	2 (3.6)	0	2 (3.0)	4 (8.9)	2 (6.9)	6 (8.1)	8 (5.7)
注入部位出血	0	0	0	5 (11.1)	1 (3.4)	6 (8.1)	6 (4.3)
注入部位硬結	0	0	0	2 (4.4)	2 (6.9)	4 (5.4)	4 (2.8)
注入部位そう痒感	0	0	0	4 (8.9)	0	4 (5.4)	4 (2.8)
注入部位丘疹	0	0	0	2 (4.4)	1 (3.4)	3 (4.1)	3 (2.1)
注入部位反応	0	0	0	1 (2.2)	2 (6.9)	3 (4.1)	3 (2.1)
注射部位疼痛	0	0	0	2 (4.4)	1 (3.4)	3 (4.1)	3 (2.1)
カテーテル留置部位内出血	1 (1.8)	0	1 (1.5)	2 (4.4)	0	2 (2.7)	3 (2.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
@ All PTS that include the text 'Nodule'.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Infusion Site Related Non-Infection Reactions (Cont.)							
注入部位血管外漏出	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
注入部位炎症	0	0	0	1 (2.2)	1 (3.4)	2 (2.7)	2 (1.4)
注入部位腫瘤	0	0	0	1 (2.2)	1 (3.4)	2 (2.7)	2 (1.4)
注入部位熱感	0	0	0	2 (4.4)	0	2 (2.7)	2 (1.4)
カテーテル留置部位紅斑	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位出血	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
カテーテル留置部位硬結	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位疼痛	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
カテーテル留置部位小水疱	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注入部位血腫	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注入部位蒼白	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注入部位発疹	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
注入部位腫脹	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位内出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位紅斑	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位漏出	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
@ All PTS that include the text 'Nodule'.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Infusion Site Related Non-Infection Reactions (Cont.)							
注射部位硬結	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
注射部位炎症	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
穿刺部位内出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
穿刺部位出血	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
@ All PTS that include the text 'Nodule'.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Hallucinations/Psychosis							
Any adverse event in the hallucinations CMQ or psychosis and psychotic disorder SMQ	1 (1.8)	1 (9.1)	2 (3.0)	5 (11.1)	6 (20.7)	11 (14.9)	13 (9.2)
Hallucination PTs@	0	1 (9.1)	1 (1.5)	4 (8.9)	5 (17.2)	9 (12.2)	10 (7.1)
幻覚	0	1 (9.1)	1 (1.5)	3 (6.7)	2 (6.9)	5 (6.8)	6 (4.3)
幻視	0	0	0	1 (2.2)	3 (10.3)	4 (5.4)	4 (2.8)
幻嗅	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
Other PTs	1 (1.8)	0	1 (1.5)	1 (2.2)	2 (6.9)	3 (4.1)	4 (2.8)
精神病性障害	0	0	0	1 (2.2)	2 (6.9)	3 (4.1)	3 (2.1)
妄想	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
妄想症	1 (1.8)	0	1 (1.5)	0	1 (3.4)	1 (1.4)	2 (1.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
@ all PTs that include the text 'hallucination'.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Polyneuropathy							
Any adverse event	2 (3.6)	0	2 (3.0)	2 (4.4)	0	2 (2.7)	4 (2.8)
異常感覚	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
感覚鈍麻	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
振動覚低下	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
歩行障害	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
錯感覚	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Somnolence							
Any adverse event	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
傾眠	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Falls and Associated Injuries							
Any adverse event in either the falls and associated injuries CMQ or the orthostatic hypotension CMQ	13 (23.2)	4 (36.4)	17 (25.4)	8 (17.8)	5 (17.2)	13 (17.6)	30 (21.3)
Falls and associated injuries CMQ	11 (19.6)	4 (36.4)	15 (22.4)	5 (11.1)	4 (13.8)	9 (12.2)	24 (17.0)
転倒	8 (14.3)	4 (36.4)	12 (17.9)	3 (6.7)	3 (10.3)	6 (8.1)	18 (12.8)
挫傷	1 (1.8)	0	1 (1.5)	1 (2.2)	1 (3.4)	2 (2.7)	3 (2.1)
皮膚裂傷	1 (1.8)	0	1 (1.5)	1 (2.2)	1 (3.4)	2 (2.7)	3 (2.1)
半月板損傷	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
筋骨格内異物	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)
関節損傷	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
靱帯捻挫	2 (3.6)	0	2 (3.0)	0	0	0	2 (1.4)
四肢損傷	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
引っかき傷	1 (1.8)	0	1 (1.5)	0	0	0	1 (0.7)
Orthostatic hypotension CMQ	4 (7.1)	1 (9.1)	5 (7.5)	3 (6.7)	1 (3.4)	4 (5.4)	9 (6.4)
浮動性めまい	2 (3.6)	1 (9.1)	3 (4.5)	2 (4.4)	1 (3.4)	3 (4.1)	6 (4.3)
体位性めまい	0	0	0	0	1 (3.4)	1 (1.4)	1 (0.7)
起立性低血圧	2 (3.6)	0	2 (3.0)	1 (2.2)	0	1 (1.4)	3 (2.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.9.1.1

Subjects with Each Treatment-Emergent Adverse Events of Special Interest (AESI) during Double-Blind Treatment Period
in Descending Frequency for ABBV-951 Group by Preferred Term
(Safety Analysis Set)

	Oral CD/LD			ABBV-951			
MedDRA 24.0 Preferred Term	Low Dose (N=56) n (%)	High Dose (N=11) n (%)	All (N=67) n (%)	Low Dose (N=45) n (%)	High Dose (N=29) n (%)	All (N=74) n (%)	Total (N=141) n (%)
Falls and Associated Injuries (Cont.)							
失神	0	1 (9.1)	1 (1.5)	0	0	0	1 (0.7)
Weight Loss							
Any adverse event	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
食欲減退	1 (1.8)	0	1 (1.5)	1 (2.2)	0	1 (1.4)	2 (1.4)
体重減少	0	0	0	1 (2.2)	0	1 (1.4)	1 (0.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

表2.7.4.7-19　注入部位感染の発現割合（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 06:16 <[redacted]
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3 1.12.2

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Related Infections
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 Preferred Term	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period	N=132	N=112	N=244
Any adverse event	41 (31.1)	43 (38.4)	84 (34.4)
注入部位蜂巣炎	29 (22.0)	27 (24.1)	56 (23.0)
注入部位膿瘍	13 (9.8)	13 (11.6)	26 (10.7)
注入部位感染	6 (4.5)	11 (9.8)	17 (7.0)
注射部位蜂巣炎	0	3 (2.7)	3 (1.2)
蜂巣炎	1 (0.8)	1 (0.9)	2 (0.8)
カテーテル留置部位感染	1 (0.8)	0	1 (0.4)
Optimization period	N=132	N=112	N=244
Any adverse event	11 (8.3)	18 (16.1)	29 (11.9)
注入部位蜂巣炎	10 (7.6)	13 (11.6)	23 (9.4)
注入部位膿瘍	3 (2.3)	5 (4.5)	8 (3.3)
注入部位感染	1 (0.8)	3 (2.7)	4 (1.6)
注射部位蜂巣炎	0	1 (0.9)	1 (0.4)
Maintenance period	N=111	N=95	N=206
Any adverse event	33 (29.7)	33 (34.7)	66 (32.0)
注入部位蜂巣炎	21 (18.9)	19 (20.0)	40 (19.4)
注入部位膿瘍	10 (9.0)	9 (9.5)	19 (9.2)
注入部位感染	5 (4.5)	9 (9.5)	14 (6.8)
蜂巣炎	1 (0.9)	1 (1.1)	2 (1.0)
注射部位蜂巣炎	0	2 (2.1)	2 (1.0)
カテーテル留置部位感染	1 (0.9)	0	1 (0.5)

Program Source Code: [redacted]

表2.7.4.7-20　注入部位感染の発現割合（安全性解析対象集団）：M15-737試験

[redacted]20[redacted] 04:21 <[redacted]
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.2

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Related Infections
in Descending Frequency by Preferred Term
(Safety Analysis Set)

	Dose Category		
MedDRA 24.0 Preferred Term	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Any adverse event	8 (17.8)	9 (15.0)	17 (16.2)
注入部位蜂巣炎	4 (8.9)	8 (13.3)	12 (11.4)
注入部位感染	3 (6.7)	1 (1.7)	4 (3.8)
注入部位膿瘍	1 (2.2)	0	1 (1.0)
注射部位感染	0	1 (1.7)	1 (1.0)

Program Source Code: [redacted]

表2.7.4.7-21　注入部位非感染反応の発現割合（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 04:29 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period	N=132	N=112	N=244
Any adverse event in infusion site related non infection reactions CMQ	103 (78.0)	96 (85.7)	199 (81.6)
Nodule PTs@	36 (27.3)	37 (33.0)	73 (29.9)
注入部位結節	34 (25.8)	34 (30.4)	68 (27.9)
注射部位結節	3 (2.3)	6 (5.4)	9 (3.7)
小結節	1 (0.8)	0	1 (0.4)
Other PTs	97 (73.5)	91 (81.3)	188 (77.0)
注入部位紅斑	65 (49.2)	60 (53.6)	125 (51.2)
注入部位浮腫	19 (14.4)	28 (25.0)	47 (19.3)
注入部位疼痛	18 (13.6)	20 (17.9)	38 (15.6)
注入部位反応	13 (9.8)	18 (16.1)	31 (12.7)
注入部位血管外漏出	8 (6.1)	12 (10.7)	20 (8.2)
注入部位内出血	10 (7.6)	8 (7.1)	18 (7.4)
注入部位丘疹	7 (5.3)	11 (9.8)	18 (7.4)
注入部位血腫	8 (6.1)	8 (7.1)	16 (6.6)
注射部位紅斑	6 (4.5)	8 (7.1)	14 (5.7)
注入部位硬結	7 (5.3)	3 (2.7)	10 (4.1)
注入部位出血	4 (3.0)	5 (4.5)	9 (3.7)
注入部位炎症	3 (2.3)	6 (5.4)	9 (3.7)
注入部位腫瘤	5 (3.8)	3 (2.7)	8 (3.3)
注射部位疼痛	2 (1.5)	6 (5.4)	8 (3.3)
注入部位そう痒感	5 (3.8)	2 (1.8)	7 (2.9)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
注入部位発疹	3 (2.3)	4 (3.6)	7 (2.9)
注入部位皮膚剥脱	3 (2.3)	3 (2.7)	6 (2.5)
注入部位腫脹	4 (3.0)	2 (1.8)	6 (2.5)
注射部位炎症	2 (1.5)	4 (3.6)	6 (2.5)
注入部位刺激感	1 (0.8)	4 (3.6)	5 (2.0)
注射部位浮腫	2 (1.5)	3 (2.7)	5 (2.0)
注入部位皮膚炎	2 (1.5)	2 (1.8)	4 (1.6)
注入部位不快感	3 (2.3)	1 (0.9)	4 (1.6)
注入部位蒼白	3 (2.3)	1 (0.9)	4 (1.6)
注射部位腫脹	2 (1.5)	2 (1.8)	4 (1.6)
注入部位損傷	1 (0.8)	2 (1.8)	3 (1.2)
注射部位内出血	2 (1.5)	1 (0.9)	3 (1.2)
穿刺部位紅斑	0	3 (2.7)	3 (1.2)
投与部位漏出	0	2 (1.8)	2 (0.8)
カテーテル留置部位紅斑	1 (0.8)	1 (0.9)	2 (0.8)
カテーテル留置部位疼痛	0	2 (1.8)	2 (0.8)
注入部位分泌物	1 (0.8)	1 (0.9)	2 (0.8)
注入部位変色	2 (1.5)	0	2 (0.8)
注入部位びらん	1 (0.8)	1 (0.9)	2 (0.8)
注入部位異常感覚	0	2 (1.8)	2 (0.8)
注入部位小水疱	0	2 (1.8)	2 (0.8)
注射部位漏出	1 (0.8)	1 (0.9)	2 (0.8)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
注射部位反応	1 (0.8)	1 (0.9)	2 (0.8)
穿刺部位硬結	2 (1.5)	0	2 (0.8)
投与部位内出血	0	1 (0.9)	1 (0.4)
投与部位紅斑	1 (0.8)	0	1 (0.4)
カテーテル留置部位漏出	1 (0.8)	0	1 (0.4)
カテーテル留置部位出血	0	1 (0.9)	1 (0.4)
カテーテル留置部位炎症	0	1 (0.9)	1 (0.4)
カテーテル留置部位刺激感	0	1 (0.9)	1 (0.4)
カテーテル留置部位浮腫	0	1 (0.9)	1 (0.4)
注入に伴う反応	1 (0.8)	0	1 (0.4)
注入部位壊死	0	1 (0.9)	1 (0.4)
注入部位膿疱	0	1 (0.9)	1 (0.4)
注入部位痂皮	0	1 (0.9)	1 (0.4)
注入部位熱感	0	1 (0.9)	1 (0.4)
注射部位変色	1 (0.8)	0	1 (0.4)
注射部位血腫	0	1 (0.9)	1 (0.4)
注射部位出血	0	1 (0.9)	1 (0.4)
注射部位丘疹	0	1 (0.9)	1 (0.4)
注射部位蕁麻疹	0	1 (0.9)	1 (0.4)
滴下投与部位熱傷	0	1 (0.9)	1 (0.4)
滴下投与部位痛	0	1 (0.9)	1 (0.4)
処置後挫傷	1 (0.8)	0	1 (0.4)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
穿刺部位内出血	1 (0.8)	0	1 (0.4)
穿刺部位出血	1 (0.8)	0	1 (0.4)
穿刺部位浮腫	0	1 (0.9)	1 (0.4)
穿刺部位腫脹	0	1 (0.9)	1 (0.4)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period	N=132	N=112	N=244
Any adverse event in infusion site related non infection reactions CMQ	87 (65.9)	82 (73.2)	169 (69.3)
Nodule PTs@	22 (16.7)	19 (17.0)	41 (16.8)
注入部位結節	20 (15.2)	18 (16.1)	38 (15.6)
注射部位結節	1 (0.8)	2 (1.8)	3 (1.2)
小結節	1 (0.8)	0	1 (0.4)
Other PTs	79 (59.8)	76 (67.9)	155 (63.5)
注入部位紅斑	50 (37.9)	45 (40.2)	95 (38.9)
注入部位浮腫	14 (10.6)	16 (14.3)	30 (12.3)
注入部位疼痛	13 (9.8)	14 (12.5)	27 (11.1)
注入部位反応	9 (6.8)	12 (10.7)	21 (8.6)
注入部位血管外漏出	4 (3.0)	7 (6.3)	11 (4.5)
注入部位内出血	3 (2.3)	7 (6.3)	10 (4.1)
注射部位紅斑	5 (3.8)	5 (4.5)	10 (4.1)
注入部位血腫	4 (3.0)	4 (3.6)	8 (3.3)
注射部位疼痛	2 (1.5)	4 (3.6)	6 (2.5)
注入部位硬結	4 (3.0)	1 (0.9)	5 (2.0)
注入部位腫瘤	4 (3.0)	1 (0.9)	5 (2.0)
注入部位丘疹	1 (0.8)	4 (3.6)	5 (2.0)
注入部位炎症	1 (0.8)	3 (2.7)	4 (1.6)
注入部位腫脹	3 (2.3)	1 (0.9)	4 (1.6)
注射部位浮腫	2 (1.5)	2 (1.8)	4 (1.6)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
注入部位不快感	2 (1.5)	1 (0.9)	3 (1.2)
注入部位出血	0	3 (2.7)	3 (1.2)
注入部位そう痒感	2 (1.5)	1 (0.9)	3 (1.2)
注入部位発疹	2 (1.5)	1 (0.9)	3 (1.2)
注射部位炎症	1 (0.8)	2 (1.8)	3 (1.2)
カテーテル留置部位疼痛	0	2 (1.8)	2 (0.8)
注入部位分泌物	1 (0.8)	1 (0.9)	2 (0.8)
注入部位変色	2 (1.5)	0	2 (0.8)
注入部位蒼白	2 (1.5)	0	2 (0.8)
注射部位漏出	1 (0.8)	1 (0.9)	2 (0.8)
投与部位紅斑	1 (0.8)	0	1 (0.4)
カテーテル留置部位紅斑	0	1 (0.9)	1 (0.4)
カテーテル留置部位炎症	0	1 (0.9)	1 (0.4)
注入に伴う反応	1 (0.8)	0	1 (0.4)
注入部位びらん	0	1 (0.9)	1 (0.4)
注入部位皮膚剥脱	0	1 (0.9)	1 (0.4)
注入部位壊死	0	1 (0.9)	1 (0.4)
注入部位異常感覚	0	1 (0.9)	1 (0.4)
注射部位内出血	1 (0.8)	0	1 (0.4)
注射部位血腫	0	1 (0.9)	1 (0.4)
注射部位反応	0	1 (0.9)	1 (0.4)
注射部位腫脹	1 (0.8)	0	1 (0.4)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
滴下投与部位熱傷	0	1 (0.9)	1 (0.4)
処置後挫傷	1 (0.8)	0	1 (0.4)
穿刺部位内出血	1 (0.8)	0	1 (0.4)
穿刺部位紅斑	0	1 (0.9)	1 (0.4)
穿刺部位出血	1 (0.8)	0	1 (0.4)
穿刺部位硬結	1 (0.8)	0	1 (0.4)
穿刺部位浮腫	0	1 (0.9)	1 (0.4)
穿刺部位腫脹	0	1 (0.9)	1 (0.4)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period	N=111	N=95	N=206
Any adverse event in infusion site related non infection reactions CMQ	64 (57.7)	70 (73.7)	134 (65.0)
Nodule PTs@	21 (18.9)	28 (29.5)	49 (23.8)
注入部位結節	20 (18.0)	25 (26.3)	45 (21.8)
注射部位結節	3 (2.7)	5 (5.3)	8 (3.9)
Other PTs	60 (54.1)	66 (69.5)	126 (61.2)
注入部位紅斑	35 (31.5)	43 (45.3)	78 (37.9)
注入部位浮腫	8 (7.2)	18 (18.9)	26 (12.6)
注入部位疼痛	8 (7.2)	11 (11.6)	19 (9.2)
注入部位反応	8 (7.2)	11 (11.6)	19 (9.2)
注入部位丘疹	6 (5.4)	8 (8.4)	14 (6.8)
注入部位血管外漏出	5 (4.5)	6 (6.3)	11 (5.3)
注射部位紅斑	5 (4.5)	5 (5.3)	10 (4.9)
注入部位内出血	7 (6.3)	2 (2.1)	9 (4.4)
注入部位血腫	4 (3.6)	4 (4.2)	8 (3.9)
注入部位炎症	2 (1.8)	6 (6.3)	8 (3.9)
注入部位硬結	5 (4.5)	2 (2.1)	7 (3.4)
注入部位出血	4 (3.6)	2 (2.1)	6 (2.9)
注射部位炎症	2 (1.8)	4 (4.2)	6 (2.9)
注入部位皮膚剥脱	3 (2.7)	2 (2.1)	5 (2.4)
注入部位刺激感	1 (0.9)	4 (4.2)	5 (2.4)
注入部位皮膚炎	2 (1.8)	2 (2.1)	4 (1.9)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
注入部位そう痒感	3 (2.7)	1 (1.1)	4 (1.9)
注入部位発疹	1 (0.9)	3 (3.2)	4 (1.9)
注入部位損傷	1 (0.9)	2 (2.1)	3 (1.5)
注入部位腫瘤	1 (0.9)	2 (2.1)	3 (1.5)
注入部位腫脹	2 (1.8)	1 (1.1)	3 (1.5)
注射部位腫脹	1 (0.9)	2 (2.1)	3 (1.5)
投与部位漏出	0	2 (2.1)	2 (1.0)
カテーテル留置部位紅斑	1 (0.9)	1 (1.1)	2 (1.0)
注入部位蒼白	1 (0.9)	1 (1.1)	2 (1.0)
注入部位異常感覚	0	2 (2.1)	2 (1.0)
注入部位小水疱	0	2 (2.1)	2 (1.0)
注射部位内出血	1 (0.9)	1 (1.1)	2 (1.0)
注射部位浮腫	1 (0.9)	1 (1.1)	2 (1.0)
注射部位疼痛	0	2 (2.1)	2 (1.0)
穿刺部位紅斑	0	2 (2.1)	2 (1.0)
穿刺部位硬結	2 (1.8)	0	2 (1.0)
投与部位内出血	0	1 (1.1)	1 (0.5)
カテーテル留置部位漏出	1 (0.9)	0	1 (0.5)
カテーテル留置部位出血	0	1 (1.1)	1 (0.5)
カテーテル留置部位刺激感	0	1 (1.1)	1 (0.5)
カテーテル留置部位浮腫	0	1 (1.1)	1 (0.5)
カテーテル留置部位疼痛	0	1 (1.1)	1 (0.5)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
注入部位分泌物	0	1 (1.1)	1 (0.5)
注入部位不快感	1 (0.9)	0	1 (0.5)
注入部位びらん	1 (0.9)	0	1 (0.5)
注入部位膿疱	0	1 (1.1)	1 (0.5)
注入部位痂皮	0	1 (1.1)	1 (0.5)
注入部位熱感	0	1 (1.1)	1 (0.5)
注射部位変色	1 (0.9)	0	1 (0.5)
注射部位出血	0	1 (1.1)	1 (0.5)
注射部位丘疹	0	1 (1.1)	1 (0.5)
注射部位反応	1 (0.9)	0	1 (0.5)
注射部位蕁麻疹	0	1 (1.1)	1 (0.5)
滴下投与部位痛	0	1 (1.1)	1 (0.5)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

表2.7.4.7-22　注入部位非感染反応の発現割合（安全性解析対象集団）：M15-737試験

[redacted]20[redacted] 04:22 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions
in Descending Frequency by Preferred Term
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose (N=45) n (%)	Dose Category High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Any adverse event in infusion site related non infection reactions CMQ	11 (24.4)	17 (28.3)	28 (26.7)
Nodule PTs@	0	2 (3.3)	2 (1.9)
注入部位結節	0	2 (3.3)	2 (1.9)
Other PTs	11 (24.4)	16 (26.7)	27 (25.7)
注入部位紅斑	6 (13.3)	7 (11.7)	13 (12.4)
注入部位内出血	2 (4.4)	2 (3.3)	4 (3.8)
注入部位丘疹	1 (2.2)	3 (5.0)	4 (3.8)
注入部位血管外漏出	0	2 (3.3)	2 (1.9)
注入部位血腫	1 (2.2)	1 (1.7)	2 (1.9)
注入部位硬結	0	2 (3.3)	2 (1.9)
注入部位浮腫	1 (2.2)	1 (1.7)	2 (1.9)
注入部位疼痛	1 (2.2)	1 (1.7)	2 (1.9)
注射部位紅斑	1 (2.2)	1 (1.7)	2 (1.9)
投与部位漏出	1 (2.2)	0	1 (1.0)
注入部位皮膚炎	1 (2.2)	0	1 (1.0)
注入部位出血	0	1 (1.7)	1 (1.0)
注入部位炎症	0	1 (1.7)	1 (1.0)
注入部位刺激感	1 (2.2)	0	1 (1.0)
注入部位腫瘤	1 (2.2)	0	1 (1.0)
注入部位異常感覚	0	1 (1.7)	1 (1.0)
注入部位発疹	0	1 (1.7)	1 (1.0)
注入部位反応	0	1 (1.7)	1 (1.0)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions in Descending Frequency by Preferred Term
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose (N=45) n (%)	 High Dose (N=60) n (%)	 All Subjects (N=105) n (%)
注入部位腫脹	0	1 (1.7)	1 (1.0)
注射部位内出血	1 (2.2)	0	1 (1.0)
注射部位硬結	0	1 (1.7)	1 (1.0)
注射部位炎症	0	1 (1.7)	1 (1.0)
注射部位浮腫	0	1 (1.7)	1 (1.0)
穿刺部位紅斑	1 (2.2)	0	1 (1.0)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

表2.7.4.7-23　幻覚及び精神病の発現割合（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 04:29 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.6

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Hallucinations/Psychosis
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period	N=132	N=112	N=244
Any adverse event in the hallucinations CMQ or psychosis and psychotic disorder SMQ	32 (24.2)	27 (24.1)	59 (24.2)
Hallucination PTs@	29 (22.0)	26 (23.2)	55 (22.5)
幻覚	20 (15.2)	21 (18.8)	41 (16.8)
幻視	10 (7.6)	5 (4.5)	15 (6.1)
幻聴	3 (2.3)	3 (2.7)	6 (2.5)
幻嗅	0	1 (0.9)	1 (0.4)
混合性幻覚	1 (0.8)	0	1 (0.4)
Other PTs	14 (10.6)	5 (4.5)	19 (7.8)
妄想	8 (6.1)	2 (1.8)	10 (4.1)
精神病性障害	4 (3.0)	2 (1.8)	6 (2.5)
妄想症	2 (1.5)	0	2 (0.8)
寄生虫妄想	1 (0.8)	0	1 (0.4)
妄想性障害、詳細不明	0	1 (0.9)	1 (0.4)
錯覚	1 (0.8)	0	1 (0.4)
嫉妬妄想	1 (0.8)	0	1 (0.4)
精神病症状	1 (0.8)	0	1 (0.4)

@ All PTs that include the text 'hallucination'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the hallucinations CMQ and psychosis and psychotic disorders SMQ - narrow search.

Program Source Code: [redacted]

TABLE 14.3 1.12.6

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Hallucinations/Psychosis
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period	N=132	N=112	N=244
Any adverse event in the hallucinations CMQ or psychosis and psychotic disorder SMQ	17 (12.9)	8 (7.1)	25 (10.2)
Hallucination PTs@	16 (12.1)	7 (6.3)	23 (9.4)
幻覚	13 (9.8)	5 (4.5)	18 (7.4)
幻視	4 (3.0)	1 (0.9)	5 (2.0)
幻聴	0	1 (0.9)	1 (0.4)
Other PTs	4 (3.0)	1 (0.9)	5 (2.0)
妄想	1 (0.8)	1 (0.9)	2 (0.8)
精神病性障害	2 (1.5)	0	2 (0.8)
嫉妬妄想	1 (0.8)	0	1 (0.4)

@ All PTs that include the text 'hallucination'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the hallucinations CMQ and psychosis and psychotic disorders SMQ - narrow search.

Program Source Code: [redacted]

TABLE 14.3 1.12.6

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Hallucinations/Psychosis
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Maintenance period	N=111	N=95	N=206
Any adverse event in the hallucinations CMQ or psychosis and psychotic disorder SMQ	23 (20.7)	21 (22.1)	44 (21.4)
Hallucination PTs@	19 (17.1)	21 (22.1)	40 (19.4)
幻覚	12 (10.8)	18 (18.9)	30 (14.6)
幻視	6 (5.4)	4 (4.2)	10 (4.9)
幻聴	3 (2.7)	2 (2.1)	5 (2.4)
幻嗅	0	1 (1.1)	1 (0.5)
混合性幻覚	1 (0.9)	0	1 (0.5)
Other PTs	11 (9.9)	4 (4.2)	15 (7.3)
妄想	7 (6.3)	1 (1.1)	8 (3.9)
精神病性障害	3 (2.7)	2 (2.1)	5 (2.4)
妄想症	2 (1.8)	0	2 (1.0)
寄生虫妄想	1 (0.9)	0	1 (0.5)
妄想性障害、詳細不明	0	1 (1.1)	1 (0.5)
錯覚	1 (0.9)	0	1 (0.5)
精神病症状	1 (0.9)	0	1 (0.5)

@ All PTs that include the text 'hallucination'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the hallucinations CMQ and psychosis and psychotic disorders SMQ - narrow search.

Program Source Code: [redacted]

表2.7.4.7-24　幻覚及び精神病の発現割合（安全性解析対象集団）：M15-737試験

[redacted]20[redacted] 04:22 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.6

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Hallucinations/Psychosis
in Descending Frequency by Preferred Term
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose (N=45) n (%)	Dose Category High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Any adverse event in the hallucinations CMQ or psychosis and psychotic disorder SMQ	4 (8.9)	6 (10.0)	10 (9.5)
Hallucination PTs@	3 (6.7)	5 (8.3)	8 (7.6)
幻覚	2 (4.4)	5 (8.3)	7 (6.7)
幻視	1 (2.2)	0	1 (1.0)
Other PTs	2 (4.4)	2 (3.3)	4 (3.8)
精神病性障害	1 (2.2)	1 (1.7)	2 (1.9)
妄想	0	1 (1.7)	1 (1.0)
錯覚	1 (2.2)	0	1 (1.0)
妄想症	1 (2.2)	0	1 (1.0)

@ All PTs that include the text 'hallucination'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the hallucinations CMQ and psychosis and psychotic disorders SMQ - narrow search.

Program Source Code: [redacted]

表2.7.4.7-25　多発ニューロパチーの発現割合（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 04:29 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.4

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Polyneuropathy
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period	N=132	N=112	N=244
Any PT in the SMQ broad search	13 (9.8)	14 (12.5)	27 (11.1)
Any PT in the SMQ narrow search	2 (1.5)	6 (5.4)	8 (3.3)
末梢性ニューロパチー	1 (0.8)	1 (0.9)	2 (0.8)
多発ニューロパチー	0	2 (1.8)	2 (0.8)
振動覚低下	1 (0.8)	0	1 (0.4)
神経痛	0	1 (0.9)	1 (0.4)
感覚障害	0	1 (0.9)	1 (0.4)
感覚消失	0	1 (0.9)	1 (0.4)
Any other PT	11 (8.3)	9 (8.0)	20 (8.2)
錯感覚	4 (3.0)	3 (2.7)	7 (2.9)
筋力低下	4 (3.0)	1 (0.9)	5 (2.0)
感覚鈍麻	1 (0.8)	2 (1.8)	3 (1.2)
反射減弱	2 (1.5)	1 (0.9)	3 (1.2)
歩行障害	0	2 (1.8)	2 (0.8)
筋萎縮	0	1 (0.9)	1 (0.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the peripheral neuropathy SMQ - broad search.

Program Source Code: [redacted]

TABLE 14.3 1.12.4

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Polyneuropathy
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period	N=132	N=112	N=244
Any PT in the SMQ broad search	2 (1.5)	2 (1.8)	4 (1.6)
Any PT in the SMQ narrow search	0	0	0
Any other PT	2 (1.5)	2 (1.8)	4 (1.6)
筋力低下	2 (1.5)	0	2 (0.8)
歩行障害	0	1 (0.9)	1 (0.4)
錯感覚	0	1 (0.9)	1 (0.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the peripheral neuropathy SMQ - broad search.

Program Source Code: [redacted]

TABLE 14.3 1.12.4

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Polyneuropathy
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period	N=111	N=95	N=206
Any PT in the SMQ broad search	11 (9.9)	12 (12.6)	23 (11.2)
Any PT in the SMQ narrow search	2 (1.8)	6 (6.3)	8 (3.9)
末梢性ニューロパチー	1 (0.9)	1 (1.1)	2 (1.0)
多発ニューロパチー	0	2 (2.1)	2 (1.0)
振動覚低下	1 (0.9)	0	1 (0.5)
神経痛	0	1 (1.1)	1 (0.5)
感覚障害	0	1 (1.1)	1 (0.5)
感覚消失	0	1 (1.1)	1 (0.5)
Any other PT	9 (8.1)	7 (7.4)	16 (7.8)
錯感覚	4 (3.6)	2 (2.1)	6 (2.9)
感覚鈍麻	1 (0.9)	2 (2.1)	3 (1.5)
反射減弱	2 (1.8)	1 (1.1)	3 (1.5)
筋力低下	2 (1.8)	1 (1.1)	3 (1.5)
歩行障害	0	1 (1.1)	1 (0.5)
筋萎縮	0	1 (1.1)	1 (0.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the peripheral neuropathy SMQ - broad search.

Program Source Code: [redacted]

表2.7.4.7-26　転倒及び関連する損傷の発現割合（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 04:29 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.8

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Falls and Associated Injuries
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period	N=132	N=112	N=244
Any adverse event in either the falls and associated injuries CMQ or the orthostatic hypotension CMQ	35 (26.5)	36 (32.1)	71 (29.1)
Falls and associated injuries CMQ	17 (12.9)	24 (21.4)	41 (16.8)
転倒	16 (12.1)	23 (20.5)	39 (16.0)
挫傷	2 (1.5)	6 (5.4)	8 (3.3)
皮膚裂傷	1 (0.8)	6 (5.4)	7 (2.9)
頭部損傷	2 (1.5)	2 (1.8)	4 (1.6)
肋骨骨折	1 (0.8)	2 (1.8)	3 (1.2)
骨挫傷	1 (0.8)	1 (0.9)	2 (0.8)
顔面骨骨折	0	2 (1.8)	2 (0.8)
靭帯捻挫	1 (0.8)	1 (0.9)	2 (0.8)
腱断裂	1 (0.8)	1 (0.9)	2 (0.8)
足関節部骨折	0	1 (0.9)	1 (0.4)
脳挫傷	1 (0.8)	0	1 (0.4)
眼挫傷	0	1 (0.9)	1 (0.4)
顔面損傷	0	1 (0.9)	1 (0.4)
関節脱臼	0	1 (0.9)	1 (0.4)
腰椎骨折	0	1 (0.9)	1 (0.4)
皮膚損傷	1 (0.8)	0	1 (0.4)
ストレス骨折	1 (0.8)	0	1 (0.4)
Orthostatic hypotension CMQ	22 (16.7)	17 (15.2)	39 (16.0)
浮動性めまい	15 (11.4)	10 (8.9)	25 (10.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the falls and associated injuries CMQ and orthostatic hypotension CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.8

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Falls and Associated Injuries in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
起立性低血圧	6 (4.5)	6 (5.4)	12 (4.9)
体位性めまい	5 (3.8)	0	5 (2.0)
失神	0	3 (2.7)	3 (1.2)
起立血圧低下	1 (0.8)	0	1 (0.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the falls and associated injuries CMQ and orthostatic hypotension CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.8

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Falls and Associated Injuries in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Optimization period	N=132	N=112	N=244
Any adverse event in either the falls and associated injuries CMQ or the orthostatic hypotension CMQ	19 (14.4)	19 (17.0)	38 (15.6)
Falls and associated injuries CMQ	7 (5.3)	10 (8.9)	17 (7.0)
転倒	7 (5.3)	9 (8.0)	16 (6.6)
顔面骨骨折	0	2 (1.8)	2 (0.8)
皮膚裂傷	0	2 (1.8)	2 (0.8)
挫傷	1 (0.8)	0	1 (0.4)
頭部損傷	1 (0.8)	0	1 (0.4)
腰椎骨折	0	1 (0.9)	1 (0.4)
肋骨骨折	0	1 (0.9)	1 (0.4)
Orthostatic hypotension CMQ	14 (10.6)	11 (9.8)	25 (10.2)
浮動性めまい	10 (7.6)	8 (7.1)	18 (7.4)
起立性低血圧	1 (0.8)	4 (3.6)	5 (2.0)
体位性めまい	3 (2.3)	0	3 (1.2)
起立血圧低下	1 (0.8)	0	1 (0.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the falls and associated injuries CMQ and orthostatic hypotension CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.8

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Falls and Associated Injuries in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period	N=111	N=95	N=206
Any adverse event in either the falls and associated injuries CMQ or the orthostatic hypotension CMQ	21 (18.9)	24 (25.3)	45 (21.8)
Falls and associated injuries CMQ	12 (10.8)	19 (20.0)	31 (15.0)
転倒	11 (9.9)	17 (17.9)	28 (13.6)
挫傷	1 (0.9)	6 (6.3)	7 (3.4)
皮膚裂傷	1 (0.9)	4 (4.2)	5 (2.4)
頭部損傷	1 (0.9)	2 (2.1)	3 (1.5)
骨挫傷	1 (0.9)	1 (1.1)	2 (1.0)
靭帯捻挫	1 (0.9)	1 (1.1)	2 (1.0)
肋骨骨折	1 (0.9)	1 (1.1)	2 (1.0)
腱断裂	1 (0.9)	1 (1.1)	2 (1.0)
足関節部骨折	0	1 (1.1)	1 (0.5)
脳挫傷	1 (0.9)	0	1 (0.5)
眼挫傷	0	1 (1.1)	1 (0.5)
顔面損傷	0	1 (1.1)	1 (0.5)
関節脱臼	0	1 (1.1)	1 (0.5)
皮膚損傷	1 (0.9)	0	1 (0.5)
ストレス骨折	1 (0.9)	0	1 (0.5)
Orthostatic hypotension CMQ	10 (9.0)	7 (7.4)	17 (8.3)
起立性低血圧	6 (5.4)	3 (3.2)	9 (4.4)
浮動性めまい	6 (5.4)	2 (2.1)	8 (3.9)
体位性めまい	3 (2.7)	0	3 (1.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the falls and associated injuries CMQ and orthostatic hypotension CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.8

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Falls and Associated Injuries in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
失神	0	3 (3.2)	3 (1.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the falls and associated injuries CMQ and orthostatic hypotension CMQ.

Program Source Code: [redacted]

表2.7.4.7-27　転倒及び関連する損傷の発現割合（安全性解析対象集団）：M15-737試験

[redacted]20[redacted] 04:22 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.8

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Falls and Associated Injuries
in Descending Frequency by Preferred Term
(Safety Analysis Set)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose (N=45) n (%)	Dose Category High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Any adverse event in either the falls and associated injuries CMQ or the orthostatic hypotension CMQ	4 (8.9)	11 (18.3)	15 (14.3)
Falls and associated injuries CMQ	4 (8.9)	10 (16.7)	14 (13.3)
転倒	3 (6.7)	9 (15.0)	12 (11.4)
手骨折	0	2 (3.3)	2 (1.9)
股関節部骨折	1 (2.2)	1 (1.7)	2 (1.9)
顔面骨骨折	0	1 (1.7)	1 (1.0)
転位骨折	0	1 (1.7)	1 (1.0)
上腕骨骨折	0	1 (1.7)	1 (1.0)
四肢損傷	0	1 (1.7)	1 (1.0)
肉離れ	1 (2.2)	0	1 (1.0)
肩甲骨骨折	0	1 (1.7)	1 (1.0)
Orthostatic hypotension CMQ	0	3 (5.0)	3 (2.9)
起立性低血圧	0	2 (3.3)	2 (1.9)
失神	0	2 (3.3)	2 (1.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the falls and associated injuries CMQ and orthostatic hypotension CMQ.

Program Source Code: [redacted]

表2.7.4.7-28　傾眠の発現割合（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.7

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Somnolence
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 Preferred Term	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period	N=132	N=112	N=244
Any adverse event	9 (6.8)	3 (2.7)	12 (4.9)
傾眠	9 (6.8)	3 (2.7)	12 (4.9)
Optimization period	N=132	N=112	N=244
Any adverse event	2 (1.5)	2 (1.8)	4 (1.6)
傾眠	2 (1.5)	2 (1.8)	4 (1.6)
Maintenance period	N=111	N=95	N=206
Any adverse event	8 (7.2)	1 (1.1)	9 (4.4)
傾眠	8 (7.2)	1 (1.1)	9 (4.4)

Program Source Code: [redacted]

表2.7.4.7-29　体重減少の発現割合（安全性解析対象集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.5

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Weight Loss
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set)

MedDRA 24.0 Preferred Term	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period	N=132	N=112	N=244
Any adverse event	12 (9.1)	13 (11.6)	25 (10.2)
体重減少	10 (7.6)	12 (10.7)	22 (9.0)
食欲減退	3 (2.3)	2 (1.8)	5 (2.0)
悪液質	1 (0.8)	0	1 (0.4)
嚥下障害	0	1 (0.9)	1 (0.4)
栄養障害	0	1 (0.9)	1 (0.4)
Optimization period	N=132	N=112	N=244
Any adverse event	1 (0.8)	1 (0.9)	2 (0.8)
食欲減退	1 (0.8)	1 (0.9)	2 (0.8)
体重減少	0	1 (0.9)	1 (0.4)
Maintenance period	N=111	N=95	N=206
Any adverse event	11 (9.9)	12 (12.6)	23 (11.2)
体重減少	10 (9.0)	11 (11.6)	21 (10.2)
食欲減退	2 (1.8)	1 (1.1)	3 (1.5)
悪液質	1 (0.9)	0	1 (0.5)
嚥下障害	0	1 (1.1)	1 (0.5)
栄養障害	0	1 (1.1)	1 (0.5)

Program Source Code: [redacted]

表2.7.4.7-30　体重減少の発現割合（安全性解析対象集団）：M15-737試験

[redacted]20[redacted] 04:21 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.5

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Weight Loss
in Descending Frequency by Preferred Term
(Safety Analysis Set)

	Dose Category		
MedDRA 24.0 Preferred Term	Low Dose (N=45) n (%)	High Dose (N=60) n (%)	All Subjects (N=105) n (%)
Any adverse event	1 (2.2)	3 (5.0)	4 (3.8)
体重減少	0	3 (5.0)	3 (2.9)
嚥下障害	1 (2.2)	0	1 (1.0)

Program Source Code: [redacted]

表2.7.4.7-31　治験薬曝露期間（安全性解析対象集団，日本人部分集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.1__10.J

Duration of Study Drug Exposure
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=22)	High Dose (N=5)	All Subjects (N=27)
Duration of ABBV-951 exposure (days) &			
n	22	5	27
Mean (SD)	193.0 (155.09)	226.4 (189.34)	199.2 (158.49)
Median	178.5	364.0	190.0
Min, Max	3, 366	17, 365	3, 366
By time intervals - n(%) &			
1 - 7 Days	1 (4.5)	0	1 (3.7)
8 - 14 Days	1 (4.5)	0	1 (3.7)
15 - 21 Days	2 (9.1)	2 (40.0)	4 (14.8)
22 - 28 Days	1 (4.5)	0	1 (3.7)
29 - 42 Days	2 (9.1)	0	2 (7.4)
43 - 91 Days	1 (4.5)	0	1 (3.7)
92 - 182 Days	3 (13.6)	0	3 (11.1)
183 - 273 Days	2 (9.1)	0	2 (7.4)
>= 274 Days	9 (40.9)	3 (60.0)	12 (44.4)
At least 6 months (>= 180 days)	11 (50.0)	3 (60.0)	14 (51.9)
At least 1 year (>= 360 days)	8 (36.4)	3 (60.0)	11 (40.7)
Patient-years of exposure &	11.6	3.1	14.7

Note: Percentages calculated on non-missing values.
&: Duration of ABBV-951 exposure (days) = Date of ABBV-951 stopped - Date of ABBV-951 started + 1.
*: Duration of ABBV-951 exposure (days) excluding study drug interruption = Duration of ABBV-951 exposure (days) - Duration of interruption (days).

Program Source Code: [redacted]

TABLE 14.1 10.J

Duration of Study Drug Exposure
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=22)	High Dose (N=5)	All Subjects (N=27)
Duration of ABBV-951 exposure (days) without interruption *			
n	22	5	27
Mean (SD)	179.8 (152.13)	226.0 (188.97)	188.3 (156.59)
Median	143.0	363.0	167.0
Min, Max	3, 366	17, 365	3, 366
By time intervals - n(%) *			
1 - 7 Days	1 (4.5)	0	1 (3.7)
8 - 14 Days	1 (4.5)	0	1 (3.7)
15 - 21 Days	2 (9.1)	2 (40.0)	4 (14.8)
22 - 28 Days	1 (4.5)	0	1 (3.7)
29 - 42 Days	3 (13.6)	0	3 (11.1)
43 - 91 Days	1 (4.5)	0	1 (3.7)
92 - 182 Days	4 (18.2)	0	4 (14.8)
183 - 273 Days	0	0	0
>= 274 Days	9 (40.9)	3 (60.0)	12 (44.4)
At least 6 months (>= 180 days)	9 (40.9)	3 (60.0)	12 (44.4)
At least 1 year (>= 360 days)	6 (27.3)	3 (60.0)	9 (33.3)
Patient-years of exposure *	10.8	3.1	13.9

Note: Percentages calculated on non-missing values.
&: Duration of ABBV-951 exposure (days) = Date of ABBV-951 stopped - Date of ABBV-951 started + 1.
*: Duration of ABBV-951 exposure (days) excluding study drug interruption = Duration of ABBV-951 exposure (days) - Duration of interruption (days).

Program Source Code: [redacted]

表2.7.4.7-32　LDの1日あたりの投与量（安全性解析対象集団，日本人部分集団）：M15-741試験

[redacted]20[redacted] 04:27 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.1__8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 1								
WEEK 1	n	18	8	18	1	0	1	18
	Mean	1255.4	77.9	1290.0	100.0		100.0	1295.5
	SD	363.89	42.18	380.69	NA		NA	380.06
	Median	1195.4	81.1	1227.9	100.0		100.0	1253.5
	Min	682.1	28.2	682.1	100.0		100.0	682.1
	Max	2213.3	153.7	2294.5	100.0		100.0	2294.5
WEEK 2	n	17	9	17	2	1	2	17
	Mean	1438.9	94.1	1488.7	100.0	100.0	150.0	1506.3
	SD	276.36	64.54	310.25	0.00	NA	70.71	311.71
	Median	1354.7	81.1	1494.9	100.0	100.0	150.0	1494.9
	Min	1030.5	32.4	1030.5	100.0	100.0	100.0	1030.5
	Max	1977.8	210.9	2162.2	100.0	100.0	200.0	2262.2
WEEK 3	n	15	9	15	3	1	4	15
	Mean	1467.0	63.4	1505.0	150.0	100.0	137.5	1541.7
	SD	379.74	23.74	392.72	50.00	NA	47.87	403.15
	Median	1338.0	61.5	1370.4	150.0	100.0	125.0	1520.4
	Min	1024.5	32.4	1056.6	100.0	100.0	100.0	1056.6
	Max	2345.3	97.3	2426.4	200.0	100.0	200.0	2426.4
WEEK 4	n	11	6	11	0	0	0	11
	Mean	1483.6	78.5	1526.5				1526.5
	SD	380.31	28.87	388.68				388.68
	Median	1423.7	81.1	1423.7				1423.7
	Min	1001.1	32.4	1001.1				1001.1
	Max	2099.9	112.7	2099.9				2099.9

Program Source Code: [redacted]

TABLE 14.1 8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 1 (Cont.)								
WEEK 6	n	10	6	10	2	0	2	10
	Mean	1533.5	77.8	1580.2	350.0		350.0	1650.2
	SD	450.68	22.61	457.00	353.55		353.55	532.52
	Median	1716.7	81.1	1759.1	350.0		350.0	1809.0
	Min	800.8	41.0	800.8	100.0		100.0	800.8
	Max	2179.6	102.5	2179.6	600.0		600.0	2446.7
WEEK 13	n	10	8	10	2	1	3	10
	Mean	1519.2	68.5	1574.1	525.0	200.0	416.7	1699.1
	SD	415.30	28.98	415.51	601.04	NA	464.58	461.13
	Median	1654.6	62.8	1725.0	525.0	200.0	200.0	1913.6
	Min	937.2	32.4	1034.6	100.0	200.0	100.0	1034.6
	Max	1992.7	113.5	1993.4	950.0	200.0	950.0	2193.4
WEEK 26	n	9	7	9	1	0	1	9
	Mean	1426.6	55.0	1469.4	100.0		100.0	1480.5
	SD	386.50	31.97	389.38	NA		NA	390.74
	Median	1401.5	41.0	1467.3	100.0		100.0	1567.3
	Min	932.8	25.6	997.4	100.0		100.0	997.4
	Max	1919.0	97.3	1951.4	100.0		100.0	1951.4
WEEK 39	n	6	4	6	1	0	1	6
	Mean	1450.2	81.1	1504.2	150.0		150.0	1529.2
	SD	479.65	22.95	452.92	NA		NA	488.69
	Median	1539.8	73.4	1572.7	150.0		150.0	1572.7
	Min	837.5	64.0	951.1	150.0		150.0	951.1
	Max	1930.6	113.5	2003.1	150.0		150.0	2153.1

Program Source Code: [redacted]

TABLE 14.1 8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 1 (Cont.)								
WEEK 52	n	5	4	5	1	0	1	5
	Mean	1558.2	82.6	1624.3	100.0		100.0	1644.3
	SD	419.36	33.56	407.70	NA		NA	423.80
	Median	1627.5	97.3	1660.2	100.0		100.0	1660.2
	Min	856.8	32.4	954.2	100.0		100.0	954.2
	Max	1930.2	103.3	2027.5	100.0		100.0	2027.5

Program Source Code: [redacted]

TABLE 14.1 8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 2								
WEEK 1	n	9	7	9	1	0	1	9
	Mean	945.1	57.4	989.8	200.0		200.0	1012.0
	SD	196.29	25.89	198.52	NA		NA	221.28
	Median	1007.4	65.7	1078.6	200.0		200.0	1078.6
	Min	644.1	18.8	702.3	200.0		200.0	702.3
	Max	1183.3	84.5	1220.9	200.0		200.0	1291.9
WEEK 2	n	8	8	8	0	0	0	8
	Mean	1023.9	53.7	1077.6				1077.6
	SD	205.34	26.60	219.36				219.36
	Median	1068.1	49.5	1101.0				1101.0
	Min	683.6	18.8	721.2				721.2
	Max	1311.4	89.6	1386.5				1386.5
WEEK 3	n	8	7	8	1	1	2	8
	Mean	1070.6	67.9	1130.1	100.0	100.0	100.0	1155.1
	SD	258.37	32.71	274.68	NA	NA	0.00	291.86
	Median	1093.9	61.5	1122.0	100.0	100.0	100.0	1172.0
	Min	686.5	18.8	737.7	100.0	100.0	100.0	737.7
	Max	1413.8	122.9	1488.9	100.0	100.0	100.0	1488.9
WEEK 4	n	8	8	8	0	0	0	8
	Mean	1118.0	57.1	1175.1				1175.1
	SD	333.19	31.82	341.05				341.05
	Median	1174.2	53.8	1198.5				1198.5
	Min	672.0	18.8	709.6				709.6
	Max	1638.0	102.5	1694.4				1694.4

Program Source Code: [redacted]

TABLE 14.1 8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 2 (Cont.)								
WEEK 6	n	8	7	8	1	0	1	8
	Mean	1133.9	55.9	1182.8	100.0		100.0	1195.3
	SD	349.28	39.18	357.13	NA		NA	338.73
	Median	1106.5	51.2	1148.2	100.0		100.0	1148.2
	Min	672.0	18.8	690.8	100.0		100.0	779.6
	Max	1617.9	122.9	1646.0	100.0		100.0	1646.0
WEEK 13	n	8	8	8	1	0	1	8
	Mean	1058.5	66.4	1124.9	100.0		100.0	1137.4
	SD	200.18	28.24	221.80	NA		NA	197.15
	Median	1083.1	64.0	1145.1	100.0		100.0	1145.1
	Min	682.1	37.6	719.7	100.0		100.0	819.7
	Max	1324.2	102.5	1426.6	100.0		100.0	1426.6
WEEK 26	n	8	7	8	3	0	3	8
	Mean	1083.3	91.2	1163.1	100.0		100.0	1200.6
	SD	290.92	56.78	343.02	0.00		0.00	383.06
	Median	1038.5	76.8	1102.5	100.0		100.0	1140.2
	Min	669.1	37.6	706.6	100.0		100.0	706.6
	Max	1610.5	179.3	1764.2	100.0		100.0	1864.2
WEEK 39	n	8	7	8	0	0	0	8
	Mean	1120.3	78.9	1189.4				1189.4
	SD	325.58	46.71	365.02				365.02
	Median	1053.4	64.0	1091.8				1091.8
	Min	672.0	18.8	690.8				690.8
	Max	1788.9	153.7	1917.0				1917.0

Program Source Code: [redacted]

TABLE 14.1 8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Enrollment Sample Week		ABBV-951 CSCI Continuous Infusion	ABBV-951 CSCI Extra Dose	ABBV-951 CSCI Total	Oral Rescue Dose	Oral Loading Dose	Oral Total	Overall Total
Sample 2 (Cont.)								
WEEK 52	n	7	5	7	0	0	0	7
	Mean	1150.2	115.1	1232.4				1232.4
	SD	302.98	77.58	360.00				360.00
	Median	1099.5	89.6	1099.5				1099.5
	Min	689.4	37.6	727.0				727.0
	Max	1686.0	230.5	1839.7				1839.7

Program Source Code: [redacted]

TABLE 14.1 8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Enrollment Sample	Week	ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Both Enrollment Samples								
WEEK 1	n	27	15	27	2	0	2	27
	Mean	1151.9	68.4	1189.9	150.0		150.0	1201.0
	SD	347.35	35.90	357.33	70.71		70.71	357.86
	Median	1121.1	76.8	1162.2	150.0		150.0	1220.9
	Min	644.1	18.8	682.1	100.0		100.0	682.1
	Max	2213.3	153.7	2294.5	200.0		200.0	2294.5
WEEK 2	n	25	17	25	2	1	2	25
	Mean	1306.1	75.1	1357.1	100.0	100.0	150.0	1369.1
	SD	319.75	53.15	341.33	0.00	NA	70.71	347.09
	Median	1292.2	64.9	1343.5	100.0	100.0	150.0	1343.5
	Min	683.6	18.8	721.2	100.0	100.0	100.0	721.2
	Max	1977.8	210.9	2162.2	100.0	100.0	200.0	2262.2
WEEK 3	n	23	16	23	4	2	6	23
	Mean	1329.1	65.4	1374.6	137.5	100.0	125.0	1407.2
	SD	387.65	27.09	394.34	47.87	0.00	41.83	407.41
	Median	1221.7	61.5	1303.9	125.0	100.0	100.0	1403.9
	Min	686.5	18.8	737.7	100.0	100.0	100.0	737.7
	Max	2345.3	122.9	2426.4	200.0	100.0	200.0	2426.4
WEEK 4	n	19	14	19	0	0	0	19
	Mean	1329.7	66.3	1378.5				1378.5
	SD	397.39	31.42	401.15				401.15
	Median	1258.6	71.3	1329.5				1329.5
	Min	672.0	18.8	709.6				709.6
	Max	2099.9	112.7	2099.9				2099.9

Program Source Code: [redacted]

TABLE 14.1 8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Enrollment Sample	Week	ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Both Enrollment Samples (Cont.)								
WEEK 6	n	18	13	18	3	0	3	18
	Mean	1355.9	66.0	1403.6	266.7		266.7	1448.0
	SD	446.68	33.32	452.09	288.68		288.68	501.49
	Median	1391.4	64.0	1468.8	100.0		100.0	1468.8
	Min	672.0	18.8	690.8	100.0		100.0	779.6
	Max	2179.6	122.9	2179.6	600.0		600.0	2446.7
WEEK 13	n	18	16	18	3	1	4	18
	Mean	1314.5	67.4	1374.4	383.3	200.0	337.5	1449.4
	SD	404.12	27.66	405.48	490.75	NA	411.05	459.42
	Median	1138.0	62.8	1213.8	100.0	200.0	150.0	1277.6
	Min	682.1	32.4	719.7	100.0	200.0	100.0	819.7
	Max	1992.7	113.5	1993.4	950.0	200.0	950.0	2193.4
WEEK 26	n	17	14	17	4	0	4	17
	Mean	1265.0	73.1	1325.3	100.0		100.0	1348.8
	SD	378.05	48.09	390.02	0.00		0.00	401.58
	Median	1065.5	58.5	1167.4	100.0		100.0	1192.1
	Min	669.1	25.6	706.6	100.0		100.0	706.6
	Max	1919.0	179.3	1951.4	100.0		100.0	1951.4
WEEK 39	n	14	11	14	1	0	1	14
	Mean	1261.7	79.7	1324.3	150.0		150.0	1335.0
	SD	417.44	38.32	420.46	NA		NA	440.52
	Median	1082.3	65.7	1144.2	150.0		150.0	1144.2
	Min	672.0	18.8	690.8	150.0		150.0	690.8
	Max	1930.6	153.7	2003.1	150.0		150.0	2153.1

Program Source Code: [redacted]

TABLE 14.1 8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Enrollment Sample	Week	ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Both Enrollment Samples (Cont.)								
WEEK 52	n	12	9	12	1	0	1	12
	Mean	1320.2	100.6	1395.7	100.0		100.0	1404.1
	SD	397.69	61.03	414.54	NA		NA	425.42
	Median	1245.9	97.3	1406.0	100.0		100.0	1406.0
	Min	689.4	32.4	727.0	100.0		100.0	727.0
	Max	1930.2	230.5	2027.5	100.0		100.0	2027.5

Program Source Code: [redacted]

表2.7.4.7-33　治験薬曝露期間（安全性解析対象集団，日本人部分集団）：M15-737試験

[redacted]20[redacted] 04:20 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.1__10.J

Duration of Study Drug Exposure
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7)	High Dose (N=4)	All Subjects (N=11)
Duration of ABBV-951 exposure (days) &			
n	7	4	11
Mean (SD)	114.7 (135.57)	309.3 (181.61)	185.5 (174.80)
Median	53.0	395.5	66.0
Min, Max	17, 366	37, 409	17, 409
By time intervals - n(%) &			
1 - 84 Days	5 (71.4)	1 (25.0)	6 (54.5)
85 - 168 Days	0	0	0
169 - 252 Days	1 (14.3)	0	1 (9.1)
253 - 336 Days	0	0	0
337 - 420 Days	1 (14.3)	3 (75.0)	4 (36.4)
421 - 504 Days	0	0	0
505 - 588 Days	0	0	0
589 - 672 Days	0	0	0
>= 673 Days	0	0	0
Patient-years of exposure &	2.2	3.4	5.6

Note: Percentages calculated on non-missing values.
&: Duration of ABBV-951 exposure (days) = Date of ABBV-951 stopped - Date of ABBV-951 started + 1.
*: Duration of ABBV-951 exposure (days) excluding study drug interruption = Duration of ABBV-951 exposure (days) - Duration of interruption (days).

Program Source Code: [redacted]

TABLE 14.1 10.J

Duration of Study Drug Exposure
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7)	High Dose (N=4)	All Subjects (N=11)
Duration of ABBV-951 exposure (days) without interruption *			
n	7	4	11
Mean (SD)	114.7 (135.57)	309.0 (181.45)	185.4 (174.68)
Median	53.0	395.0	66.0
Min, Max	17, 366	37, 409	17, 409
By time intervals - n(%) *			
1 - 84 Days	5 (71.4)	1 (25.0)	6 (54.5)
85 - 168 Days	0	0	0
169 - 252 Days	1 (14.3)	0	1 (9.1)
253 - 336 Days	0	0	0
337 - 420 Days	1 (14.3)	3 (75.0)	4 (36.4)
421 - 504 Days	0	0	0
505 - 588 Days	0	0	0
589 - 672 Days	0	0	0
>= 673 Days	0	0	0
Patient-years of exposure *	2.2	3.4	5.6

Note: Percentages calculated on non-missing values.
&: Duration of ABBV-951 exposure (days) = Date of ABBV-951 stopped - Date of ABBV-951 started + 1.
*: Duration of ABBV-951 exposure (days) excluding study drug interruption = Duration of ABBV-951 exposure (days) - Duration of interruption (days).

Program Source Code: [redacted]

表2.7.4.7-34　LDの1日あたりの投与量（安全性解析対象集団，日本人部分集団）：M15-737試験

[redacted]20[redacted] 04:20 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.1__8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

		ABBV-951 CSCI			Oral			
Week		Continuous Infusion	Extra Dose	Total	Rescue Dose	Loading Dose	Total	Overall Total
WEEK 12	n	7	6	7	2	0	2	7
	Mean	1536.0	71.6	1597.4	100.0		100.0	1625.9
	SD	491.47	25.42	468.45	0.00		0.00	452.35
	Median	1548.7	70.9	1595.7	100.0		100.0	1695.7
	Min	866.4	41.0	963.7	100.0		100.0	963.7
	Max	2178.8	102.5	2243.7	100.0		100.0	2243.7
WEEK 24	n	5	4	5	1	0	1	5
	Mean	1663.1	76.4	1724.3	100.0		100.0	1744.3
	SD	560.21	16.30	544.45	N/A		N/A	529.34
	Median	1949.2	73.4	1949.2	100.0		100.0	1949.2
	Min	865.4	61.5	962.7	100.0		100.0	962.7
	Max	2183.5	97.3	2264.6	100.0		100.0	2264.6
WEEK 36	n	5	3	5	0	0	0	5
	Mean	1605.6	77.4	1652.0				1652.0
	SD	583.12	34.50	570.13				570.13
	Median	1839.8	97.3	1839.8				1839.8
	Min	857.5	37.6	954.8				954.8
	Max	2183.5	97.3	2280.8				2280.8
WEEK 48	n	4	3	4	0	0	0	4
	Mean	1743.1	57.2	1786.0				1786.0
	SD	621.90	36.61	591.05				591.05
	Median	1919.5	48.7	1932.3				1932.3
	Min	855.8	25.6	953.1				953.1
	Max	2277.5	97.3	2326.1				2326.1

Program Source Code: [redacted]

TABLE 14.1 8.1.J

Daily Levodopa Dose (mg LD)
(Safety Analysis Set - Japan Subjects)

Week		ABBV-951 CSCI			Oral			Overall Total
		Continuous Infusion	Extra Dose	Total	Rescue Dose	Loading Dose	Total	
WEEK 60	n	3	1	3	0	0	0	3
	Mean	1728.2	32.4	1739.0				1739.0
	SD	759.59	N/A	772.68				772.68
	Median	1972.2	32.4	1972.2				1972.2
	Min	876.6	32.4	876.6				876.6
	Max	2335.9	32.4	2368.3				2368.3

Program Source Code: [redacted]

表2.7.4.7-35　登録時期別の有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
Entire study			
Subjects with:			
Any TEAE	17 (94.4)	8 (88.9)	25 (92.6)
Any severe TEAE	4 (22.2)	0	4 (14.8)
Any TEAE that is considered associated with study drug$	17 (94.4)	8 (88.9)	25 (92.6)
Any TEAE that is considered associated with product complaint$	14 (77.8)	6 (66.7)	20 (74.1)
ABBV-951	10 (55.6)	2 (22.2)	12 (44.4)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	9 (50.0)	1 (11.1)	10 (37.0)
[redacted] infusion set 6 mm	7 (38.9)	0	7 (25.9)
[redacted] infusion set 9 mm	3 (16.7)	1 (11.1)	4 (14.8)
Neria guard infusion set (total)	0	4 (44.4)	4 (14.8)
Neria guard infusion set 6 mm	0	1 (11.1)	1 (3.7)
Neria guard infusion set 9 mm	0	3 (33.3)	3 (11.1)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	6 (33.3)	1 (11.1)	7 (25.9)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	5 (27.8)	2 (22.2)	7 (25.9)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
Entire study (cont'd)			
Any SAE that is considered associated with infusion pump$	3 (16.7)	0	3 (11.1)
Possible	0	0	0
Probable	1 (5.6)	0	1 (3.7)
Causal relationship	2 (11.1)	0	2 (7.4)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
Entire study (cont'd)			
All deaths#	0	0	0
All TE-deaths	0	0	0
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	1 (5.6)	0	1 (3.7)
AESI: hallucinations/psychosis	8 (44.4)	4 (44.4)	12 (44.4)
AESI: somnolence	0	0	0
AESI: infusion site related infections	3 (16.7)	2 (22.2)	5 (18.5)
AESI: infusion site related non infection reactions	14 (77.8)	6 (66.7)	20 (74.1)
AESI: falls and associated injuries	8 (44.4)	3 (33.3)	11 (40.7)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 12 weeks			
Subjects with:			
Any TEAE	17 (94.4)	6 (66.7)	23 (85.2)
Any severe TEAE	3 (16.7)	0	3 (11.1)
Any TEAE that is considered associated with study drug$	17 (94.4)	6 (66.7)	23 (85.2)
Any TEAE that is considered associated with product complaint$	14 (77.8)	2 (22.2)	16 (59.3)
ABBV-951	10 (55.6)	1 (11.1)	11 (40.7)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	8 (44.4)	0	8 (29.6)
[redacted] infusion set 6 mm	7 (38.9)	0	7 (25.9)
[redacted] infusion set 9 mm	2 (11.1)	0	2 (7.4)
Neria guard infusion set (total)	0	1 (11.1)	1 (3.7)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	1 (11.1)	1 (3.7)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	6 (33.3)	0	6 (22.2)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	3 (16.7)	2 (22.2)	5 (18.5)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 12 weeks (cont'd)			
Any SAE that is considered associated with infusion pump$	2 (11.1)	0	2 (7.4)
Possible	0	0	0
Probable	0	0	0
Causal relationship	2 (11.1)	0	2 (7.4)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 12 weeks (cont'd)			
All deaths#	0	0	0
All TE-deaths	0	0	0
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	0	0	0
AESI: hallucinations/psychosis	7 (38.9)	4 (44.4)	11 (40.7)
AESI: somnolence	0	0	0
AESI: infusion site related infections	1 (5.6)	0	1 (3.7)
AESI: infusion site related non infection reactions	14 (77.8)	2 (22.2)	16 (59.3)
AESI: falls and associated injuries	6 (33.3)	2 (22.2)	8 (29.6)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 10 weeks			
Subjects with:			
Any TEAE	17 (94.4)	6 (66.7)	23 (85.2)
Any severe TEAE	3 (16.7)	0	3 (11.1)
Any TEAE that is considered associated with study drug$	17 (94.4)	6 (66.7)	23 (85.2)
Any TEAE that is considered associated with product complaint$	14 (77.8)	2 (22.2)	16 (59.3)
ABBV-951	10 (55.6)	1 (11.1)	11 (40.7)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	8 (44.4)	0	8 (29.6)
[redacted] infusion set 6 mm	7 (38.9)	0	7 (25.9)
[redacted] infusion set 9 mm	2 (11.1)	0	2 (7.4)
Neria guard infusion set (total)	0	1 (11.1)	1 (3.7)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	1 (11.1)	1 (3.7)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	6 (33.3)	0	6 (22.2)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	3 (16.7)	2 (22.2)	5 (18.5)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 10 weeks (cont'd)			
Any SAE that is considered associated with infusion pump$	2 (11.1)	0	2 (7.4)
Possible	0	0	0
Probable	0	0	0
Causal relationship	2 (11.1)	0	2 (7.4)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 10 weeks (cont'd)			
All deaths#	0	0	0
All TE-deaths	0	0	0
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	0	0	0
AESI: hallucinations/psychosis	7 (38.9)	4 (44.4)	11 (40.7)
AESI: somnolence	0	0	0
AESI: infusion site related infections	1 (5.6)	0	1 (3.7)
AESI: infusion site related non infection reactions	14 (77.8)	2 (22.2)	16 (59.3)
AESI: falls and associated injuries	6 (33.3)	2 (22.2)	8 (29.6)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 6 weeks			
Subjects with:			
Any TEAE	16 (88.9)	5 (55.6)	21 (77.8)
Any severe TEAE	3 (16.7)	0	3 (11.1)
Any TEAE that is considered associated with study drug$	15 (83.3)	5 (55.6)	20 (74.1)
Any TEAE that is considered associated with product complaint$	13 (72.2)	2 (22.2)	15 (55.6)
ABBV-951	8 (44.4)	1 (11.1)	9 (33.3)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	7 (38.9)	0	7 (25.9)
[redacted] infusion set 6 mm	6 (33.3)	0	6 (22.2)
[redacted] infusion set 9 mm	2 (11.1)	0	2 (7.4)
Neria guard infusion set (total)	0	1 (11.1)	1 (3.7)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	1 (11.1)	1 (3.7)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	5 (27.8)	0	5 (18.5)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	3 (16.7)	1 (11.1)	4 (14.8)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 6 weeks (cont'd)			
Any SAE that is considered associated with infusion pump$	2 (11.1)	0	2 (7.4)
Possible	0	0	0
Probable	0	0	0
Causal relationship	2 (11.1)	0	2 (7.4)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 6 weeks (cont'd)			
All deaths#	0	0	0
All TE-deaths	0	0	0
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	0	0	0
AESI: hallucinations/psychosis	6 (33.3)	3 (33.3)	9 (33.3)
AESI: somnolence	0	0	0
AESI: infusion site related infections	1 (5.6)	0	1 (3.7)
AESI: infusion site related non infection reactions	13 (72.2)	2 (22.2)	15 (55.6)
AESI: falls and associated injuries	6 (33.3)	2 (22.2)	8 (29.6)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 4 weeks			
Subjects with:			
Any TEAE	14 (77.8)	5 (55.6)	19 (70.4)
Any severe TEAE	3 (16.7)	0	3 (11.1)
Any TEAE that is considered associated with study drug$	14 (77.8)	5 (55.6)	19 (70.4)
Any TEAE that is considered associated with product complaint$	12 (66.7)	2 (22.2)	14 (51.9)
ABBV-951	6 (33.3)	1 (11.1)	7 (25.9)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	7 (38.9)	0	7 (25.9)
[redacted] infusion set 6 mm	5 (27.8)	0	5 (18.5)
[redacted] infusion set 9 mm	2 (11.1)	0	2 (7.4)
Neria guard infusion set (total)	0	1 (11.1)	1 (3.7)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	1 (11.1)	1 (3.7)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	5 (27.8)	0	5 (18.5)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	3 (16.7)	1 (11.1)	4 (14.8)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 4 weeks (cont'd)			
Any SAE that is considered associated with infusion pump$	2 (11.1)	0	2 (7.4)
Possible	0	0	0
Probable	0	0	0
Causal relationship	2 (11.1)	0	2 (7.4)
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 4 weeks (cont'd)			
All deaths#	0	0	0
All TE-deaths	0	0	0
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	0	0	0
AESI: hallucinations/psychosis	5 (27.8)	3 (33.3)	8 (29.6)
AESI: somnolence	0	0	0
AESI: infusion site related infections	0	0	0
AESI: infusion site related non infection reactions	12 (66.7)	2 (22.2)	14 (51.9)
AESI: falls and associated injuries	3 (16.7)	2 (22.2)	5 (18.5)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 2 weeks			
Subjects with:			
Any TEAE	11 (61.1)	4 (44.4)	15 (55.6)
Any severe TEAE	1 (5.6)	0	1 (3.7)
Any TEAE that is considered associated with study drug$	11 (61.1)	4 (44.4)	15 (55.6)
Any TEAE that is considered associated with product complaint$	9 (50.0)	2 (22.2)	11 (40.7)
ABBV-951	5 (27.8)	1 (11.1)	6 (22.2)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	5 (27.8)	0	5 (18.5)
[redacted] infusion set 6 mm	3 (16.7)	0	3 (11.1)
[redacted] infusion set 9 mm	2 (11.1)	0	2 (7.4)
Neria guard infusion set (total)	0	1 (11.1)	1 (3.7)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	1 (11.1)	1 (3.7)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	3 (16.7)	0	3 (11.1)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	1 (5.6)	0	1 (3.7)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 2 weeks (cont'd)			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 2 weeks (cont'd)			
All deaths#	0	0	0
All TE-deaths	0	0	0
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	0	0	0
AESI: hallucinations/psychosis	3 (16.7)	2 (22.2)	5 (18.5)
AESI: somnolence	0	0	0
AESI: infusion site related infections	0	0	0
AESI: infusion site related non infection reactions	9 (50.0)	2 (22.2)	11 (40.7)
AESI: falls and associated injuries	3 (16.7)	2 (22.2)	5 (18.5)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 1 week			
Subjects with:			
Any TEAE	7 (38.9)	3 (33.3)	10 (37.0)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	6 (33.3)	3 (33.3)	9 (33.3)
Any TEAE that is considered associated with product complaint$	5 (27.8)	2 (22.2)	7 (25.9)
ABBV-951	2 (11.1)	1 (11.1)	3 (11.1)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	3 (16.7)	0	3 (11.1)
[redacted] infusion set 6 mm	2 (11.1)	0	2 (7.4)
[redacted] infusion set 9 mm	1 (5.6)	0	1 (3.7)
Neria guard infusion set (total)	0	1 (11.1)	1 (3.7)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	1 (11.1)	1 (3.7)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	2 (11.1)	0	2 (7.4)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 1 week (cont'd)			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.5.1.J

Overview of Treatment-Emergent Adverse Events and All Deaths by Enrollment Sample by Time Interval
(Safety Analysis Set - Japan Subjects)

	Sample 1 (N=18) n (%)	Sample 2 (N=9) n (%)	All Subjects (N=27) n (%)
First 1 week (cont'd)			
All deaths#	0	0	0
All TE-deaths	0	0	0
Deaths related to COVID-19 infection	0	0	0
AESI: polyneuropathy (narrow)	0	0	0
AESI: weight loss	0	0	0
AESI: hallucinations/psychosis	1 (5.6)	1 (11.1)	2 (7.4)
AESI: somnolence	0	0	0
AESI: infusion site related infections	0	0	0
AESI: infusion site related non infection reactions	5 (27.8)	2 (22.2)	7 (25.9)
AESI: falls and associated injuries	3 (16.7)	1 (11.1)	4 (14.8)

Note: Sample 1 contains subjects who were enrolled prior to [redacted]20[redacted].
Sample 2 contains subjects who were enrolled on or after [redacted]20[redacted].
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes non treatment-emergent deaths.

Program Source Code: [redacted]

表2.7.4.7-36　特に注目すべき有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - polyneuropathy (narrow)	N=22	N=5	N=27
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Optimization period - polyneuropathy (narrow)	N=22	N=5	N=27
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - polyneuropathy (narrow)	N=17	N=3	N=20
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - weight loss	N=22	N=5	N=27
Subjects with:			
Any TEAE	1 (4.5)	0	1 (3.7)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Optimization period - weight loss	N=22	N=5	N=27
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Maintenance period - weight loss	N=17	N=3	N=20
Subjects with:			
Any TEAE	1 (5.9)	0	1 (5.0)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period - hallucinations/psychosis	N=22	N=5	N=27
Subjects with:			
Any TEAE	10 (45.5)	2 (40.0)	12 (44.4)
Any severe TEAE	1 (4.5)	0	1 (3.7)
Any TEAE that is considered associated with study drug$	10 (45.5)	1 (20.0)	11 (40.7)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	2 (9.1)	0	2 (7.4)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	3 (13.6)	0	3 (11.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Optimization period - hallucinations/psychosis	N=22	N=5	N=27
Subjects with:			
Any TEAE	6 (27.3)	2 (40.0)	8 (29.6)
Any severe TEAE	1 (4.5)	0	1 (3.7)
Any TEAE that is considered associated with study drug$	6 (27.3)	1 (20.0)	7 (25.9)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	1 (4.5)	0	1 (3.7)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	3 (13.6)	0	3 (11.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Maintenance period - hallucinations/psychosis	N=17	N=3	N=20
Subjects with:			
Any TEAE	8 (47.1)	0	8 (40.0)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	8 (47.1)	0	8 (40.0)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	1 (5.9)	0	1 (5.0)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - somnolence	N=22	N=5	N=27
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - somnolence	N=22	N=5	N=27
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - somnolence	N=17	N=3	N=20
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - infusion site related infections	N=22	N=5	N=27
Subjects with:			
Any TEAE	3 (13.6)	2 (40.0)	5 (18.5)
Any severe TEAE	0	1 (20.0)	1 (3.7)
Any TEAE that is considered associated with study drug$	3 (13.6)	1 (20.0)	4 (14.8)
Any TEAE that is considered associated with product complaint$	3 (13.6)	1 (20.0)	4 (14.8)
ABBV-951	2 (9.1)	0	2 (7.4)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	1 (20.0)	1 (3.7)
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	1 (20.0)	1 (3.7)
Neria guard infusion set (total)	1 (4.5)	0	1 (3.7)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	1 (4.5)	0	1 (3.7)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	1 (20.0)	1 (3.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - infusion site related infections	N=22	N=5	N=27
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - infusion site related infections	N=17	N=3	N=20
Subjects with:			
Any TEAE	3 (17.6)	2 (66.7)	5 (25.0)
Any severe TEAE	0	1 (33.3)	1 (5.0)
Any TEAE that is considered associated with study drug$	3 (17.6)	1 (33.3)	4 (20.0)
Any TEAE that is considered associated with product complaint$	3 (17.6)	1 (33.3)	4 (20.0)
ABBV-951	2 (11.8)	0	2 (10.0)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	1 (33.3)	1 (5.0)
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	1 (33.3)	1 (5.0)
Neria guard infusion set (total)	1 (5.9)	0	1 (5.0)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	1 (5.9)	0	1 (5.0)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	1 (33.3)	1 (5.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - infusion site related non infection reactions	N=22	N=5	N=27
Subjects with:			
Any TEAE	17 (77.3)	3 (60.0)	20 (74.1)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	15 (68.2)	3 (60.0)	18 (66.7)
Any TEAE that is considered associated with product complaint$	16 (72.7)	3 (60.0)	19 (70.4)
ABBV-951	9 (40.9)	2 (40.0)	11 (40.7)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	7 (31.8)	2 (40.0)	9 (33.3)
[redacted] infusion set 6 mm	6 (27.3)	1 (20.0)	7 (25.9)
[redacted] infusion set 9 mm	1 (4.5)	2 (40.0)	3 (11.1)
Neria guard infusion set (total)	4 (18.2)	0	4 (14.8)
Neria guard infusion set 6 mm	1 (4.5)	0	1 (3.7)
Neria guard infusion set 9 mm	3 (13.6)	0	3 (11.1)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	2 (9.1)	0	2 (7.4)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Optimization period - infusion site related non infection reactions	N=22	N=5	N=27
Subjects with:			
Any TEAE	12 (54.5)	2 (40.0)	14 (51.9)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	10 (45.5)	2 (40.0)	12 (44.4)
Any TEAE that is considered associated with product complaint$	11 (50.0)	2 (40.0)	13 (48.1)
ABBV-951	6 (27.3)	0	6 (22.2)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	5 (22.7)	2 (40.0)	7 (25.9)
[redacted] infusion set 6 mm	5 (22.7)	0	5 (18.5)
[redacted] infusion set 9 mm	0	2 (40.0)	2 (7.4)
Neria guard infusion set (total)	1 (4.5)	0	1 (3.7)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	1 (4.5)	0	1 (3.7)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	2 (9.1)	0	2 (7.4)
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - infusion site related non infection reactions	N=17	N=3	N=20
Subjects with:			
Any TEAE	10 (58.8)	3 (100)	13 (65.0)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	10 (58.8)	2 (66.7)	12 (60.0)
Any TEAE that is considered associated with product complaint$	9 (52.9)	3 (100)	12 (60.0)
ABBV-951	6 (35.3)	2 (66.7)	8 (40.0)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	2 (11.8)	1 (33.3)	3 (15.0)
[redacted] infusion set 6 mm	1 (5.9)	1 (33.3)	2 (10.0)
[redacted] infusion set 9 mm	1 (5.9)	0	1 (5.0)
Neria guard infusion set (total)	3 (17.6)	0	3 (15.0)
Neria guard infusion set 6 mm	1 (5.9)	0	1 (5.0)
Neria guard infusion set 9 mm	2 (11.8)	0	2 (10.0)
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Entire study period - Falls and associated injuries (combined CMQ)	N=22	N=5	N=27
Subjects with:			
Any TEAE	8 (36.4)	3 (60.0)	11 (40.7)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	3 (13.6)	1 (20.0)	4 (14.8)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Optimization period - Falls and associated injuries (combined CMQ)	N=22	N=5	N=27
Subjects with:			
Any TEAE	4 (18.2)	1 (20.0)	5 (18.5)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	2 (9.1)	0	2 (7.4)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Maintenance period - Falls and associated injuries (combined CMQ)	N=17	N=3	N=20
Subjects with:			
Any TEAE	5 (29.4)	2 (66.7)	7 (35.0)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	1 (5.9)	1 (33.3)	2 (10.0)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period - Falls and associated injuries CMQ	N=22	N=5	N=27
Subjects with:			
Any TEAE	6 (27.3)	2 (40.0)	8 (29.6)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	1 (4.5)	0	1 (3.7)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Optimization period - Falls and associated injuries CMQ	N=22	N=5	N=27
Subjects with:			
Any TEAE	2 (9.1)	1 (20.0)	3 (11.1)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Maintenance period - Falls and associated injuries CMQ	N=17	N=3	N=20
Subjects with:			
Any TEAE	5 (29.4)	1 (33.3)	6 (30.0)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	1 (5.9)	0	1 (5.0)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period - Orthostatic hypotension CMQ	N=22	N=5	N=27
Subjects with:			
Any TEAE	2 (9.1)	1 (20.0)	3 (11.1)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	2 (9.1)	1 (20.0)	3 (11.1)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Optimization period - Orthostatic hypotension CMQ	N=22	N=5	N=27
Subjects with:			
Any TEAE	2 (9.1)	0	2 (7.4)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	2 (9.1)	0	2 (7.4)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Maintenance period - Orthostatic hypotension CMQ	N=17	N=3	N=20
Subjects with:			
Any TEAE	0	1 (33.3)	1 (5.0)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	1 (33.3)	1 (5.0)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI and by Time Interval
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose n (%)	High Dose n (%)	All Subjects n (%)
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with [redacted] infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
[redacted]	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

表2.7.4.7-37　特に注目すべき有害事象の概要（安全性解析対象集団，日本人部分集団）：M15-737試験

TABLE 14.3__1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Polyneuropathy (narrow)			
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose (N=7) n (%)	Dose Category: High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Polyneuropathy (narrow)			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Weight loss			
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Weight loss			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Hallucinations/psychosis			
Subjects with:			
Any TEAE	1 (14.3)	0	1 (9.1)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	1 (14.3)	0	1 (9.1)
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose (N=7) n (%)	Dose Category: High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Hallucinations/psychosis			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Somnolence			
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose (N=7) n (%)	Dose Category: High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Somnolence			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Infusion site related infections			
Subjects with:			
Any TEAE	0	1 (25.0)	1 (9.1)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	1 (25.0)	1 (9.1)
Any TEAE that is considered associated with product complaint$	0	1 (25.0)	1 (9.1)
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	1 (25.0)	1 (9.1)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	1 (25.0)	1 (9.1)
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose (N=7) n (%)	Dose Category: High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Infusion site related infections			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Infusion site related non infection reactions			
Subjects with:			
Any TEAE	1 (14.3)	2 (50.0)	3 (27.3)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	1 (14.3)	2 (50.0)	3 (27.3)
Any TEAE that is considered associated with product complaint$	1 (14.3)	2 (50.0)	3 (27.3)
ABBV-951	1 (14.3)	1 (25.0)	2 (18.2)
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	1 (25.0)	1 (9.1)
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	1 (25.0)	1 (9.1)
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Infusion site related non infection reactions			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose (N=7) n (%)	Dose Category: High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Falls and associated injuries (combined CMQ)			
Subjects with:			
Any TEAE	0	1 (25.0)	1 (9.1)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	1 (25.0)	1 (9.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Falls and associated injuries (combined CMQ)			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Falls and associated injuries CMQ			
Subjects with:			
Any TEAE	0	1 (25.0)	1 (9.1)
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	1 (25.0)	1 (9.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Falls and associated injuries CMQ			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category		
	Low Dose (N=7) n (%)	High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Orthostatic hypotension CMQ			
Subjects with:			
Any TEAE	0	0	0
Any severe TEAE	0	0	0
Any TEAE that is considered associated with study drug$	0	0	0
Any TEAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0
Any TEAE that is considered associated with loading dose$	0	0	0
Any TEAE that is considered associated with rescue dose$	0	0	0
Any TEAE that is considered associated with COVID-19 infection	0	0	0
Any TEAE leading to prematurely discontinuation of study drug	0	0	0
Any TEAE leading to death (fatal TEAE)	0	0	0
Any serious TEAE	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

TABLE 14.3 1.12.1.J

Overview of Treatment-Emergent Adverse Events by AESI
(Safety Analysis Set - Japan Subjects)

	Dose Category: Low Dose (N=7) n (%)	Dose Category: High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Orthostatic hypotension CMQ			
Any SAE that is considered associated with infusion pump$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with neria guards infusion set$	0	0	0
Possible	0	0	0
Probable	0	0	0
Causal relationship	0	0	0
Any SAE that is considered associated with product complaint$	0	0	0
ABBV-951	0	0	0
Infusion pump	0	0	0
Vial adapter	0	0	0
Syringes	0	0	0
[redacted] infusion set (total)	0	0	0
[redacted] infusion set 6 mm	0	0	0
[redacted] infusion set 9 mm	0	0	0
Neria guard infusion set (total)	0	0	0
Neria guard infusion set 6 mm	0	0	0
Neria guard infusion set 9 mm	0	0	0

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
$ As assessed by investigator.

Program Source Code: [redacted]

表2.7.4.7-38　注入部位感染の発現割合（安全性解析対象集団，日本人部分集団）：M15-741試験

[redacted]20[redacted] 16:20 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.2.1.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Related Infections
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 Preferred Term	Dose Category: Low Dose n (%)	Dose Category: High Dose n (%)	All Subjects n (%)
Entire study period	N=22	N=5	N=27
Any adverse event	3 (13.6)	2 (40.0)	5 (18.5)
注入部位蜂巣炎	3 (13.6)	1 (20.0)	4 (14.8)
蜂巣炎	0	1 (20.0)	1 (3.7)
Optimization period	N=22	N=5	N=27
Any adverse event	0	0	0
Maintenance period	N=17	N=3	N=20
Any adverse event	3 (17.6)	2 (66.7)	5 (25.0)
注入部位蜂巣炎	3 (17.6)	1 (33.3)	4 (20.0)
蜂巣炎	0	1 (33.3)	1 (5.0)

Program Source Code: [redacted]

表2.7.4.7-39　注入部位非感染反応の発現割合（安全性解析対象集団，日本人部分集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.3.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period	N=22	N=5	N=27
Any adverse event in infusion site related non infection reactions CMQ	17 (77.3)	3 (60.0)	20 (74.1)
Nodule PTs@	0	0	0
Other PTs	17 (77.3)	3 (60.0)	20 (74.1)
注入部位紅斑	7 (31.8)	3 (60.0)	10 (37.0)
注入部位硬結	4 (18.2)	1 (20.0)	5 (18.5)
注入部位腫瘤	2 (9.1)	1 (20.0)	3 (11.1)
注入部位皮膚炎	2 (9.1)	0	2 (7.4)
注入部位発疹	1 (4.5)	1 (20.0)	2 (7.4)
注射部位腫脹	1 (4.5)	1 (20.0)	2 (7.4)
穿刺部位硬結	2 (9.1)	0	2 (7.4)
投与部位紅斑	1 (4.5)	0	1 (3.7)
注入部位内出血	1 (4.5)	0	1 (3.7)
注入部位疼痛	1 (4.5)	0	1 (3.7)
注入部位腫脹	1 (4.5)	0	1 (3.7)
注射部位紅斑	1 (4.5)	0	1 (3.7)
穿刺部位内出血	1 (4.5)	0	1 (3.7)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period	N=22	N=5	N=27
Any adverse event in infusion site related non infection reactions CMQ	12 (54.5)	2 (40.0)	14 (51.9)
Nodule PTs@	0	0	0
Other PTs	12 (54.5)	2 (40.0)	14 (51.9)
注入部位紅斑	5 (22.7)	2 (40.0)	7 (25.9)
注入部位硬結	3 (13.6)	0	3 (11.1)
注入部位腫瘤	2 (9.1)	0	2 (7.4)
投与部位紅斑	1 (4.5)	0	1 (3.7)
注入部位疼痛	1 (4.5)	0	1 (3.7)
注入部位発疹	1 (4.5)	0	1 (3.7)
注射部位紅斑	1 (4.5)	0	1 (3.7)
穿刺部位内出血	1 (4.5)	0	1 (3.7)
穿刺部位硬結	1 (4.5)	0	1 (3.7)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.3.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Maintenance period	N=17	N=3	N=20
Any adverse event in infusion site related non infection reactions CMQ	10 (58.8)	3 (100)	13 (65.0)
Nodule PTs@	0	0	0
Other PTs	10 (58.8)	3 (100)	13 (65.0)
注入部位紅斑	4 (23.5)	1 (33.3)	5 (25.0)
注入部位硬結	3 (17.6)	1 (33.3)	4 (20.0)
注入部位皮膚炎	2 (11.8)	0	2 (10.0)
注射部位腫脹	1 (5.9)	1 (33.3)	2 (10.0)
穿刺部位硬結	2 (11.8)	0	2 (10.0)
注入部位内出血	1 (5.9)	0	1 (5.0)
注入部位腫瘤	0	1 (33.3)	1 (5.0)
注入部位発疹	0	1 (33.3)	1 (5.0)
注入部位腫脹	1 (5.9)	0	1 (5.0)
注射部位紅斑	1 (5.9)	0	1 (5.0)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

表2.7.4.7-40　注入部位非感染反応の発現割合（安全性解析対象集団，日本人部分集団）：M15-737試験

[redacted]20[redacted] 04:22 <[redacted]>
ABBV-951
STUDY M15-737 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1639 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.3.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Infusion Site Non Infection Reactions
in Descending Frequency by Preferred Term
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose (N=7) n (%)	Dose Category High Dose (N=4) n (%)	All Subjects (N=11) n (%)
Any adverse event in infusion site related non infection reactions CMQ	1 (14.3)	2 (50.0)	3 (27.3)
Nodule PTs@	0	0	0
Other PTs	1 (14.3)	2 (50.0)	3 (27.3)
注入部位皮膚炎	1 (14.3)	0	1 (9.1)
注入部位硬結	0	1 (25.0)	1 (9.1)
注射部位紅斑	0	1 (25.0)	1 (9.1)
注射部位硬結	0	1 (25.0)	1 (9.1)

@ All PTs that include the text 'nodule'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the infusion site related non infection reactions CMQ.

Program Source Code: [redacted]

表2.7.4.7-41　幻覚及び精神病の発現割合（安全性解析対象集団，日本人部分集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.6.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Hallucinations/Psychosis
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period	N=22	N=5	N=27
Any adverse event in the hallucinations CMQ or psychosis and psychotic disorder SMQ	10 (45.5)	2 (40.0)	12 (44.4)
Hallucination PTs@	9 (40.9)	2 (40.0)	11 (40.7)
幻覚	8 (36.4)	1 (20.0)	9 (33.3)
幻視	1 (4.5)	1 (20.0)	2 (7.4)
Other PTs	6 (27.3)	0	6 (22.2)
妄想	5 (22.7)	0	5 (18.5)
嫉妬妄想	1 (4.5)	0	1 (3.7)

@ All PTs that include the text 'hallucination'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the hallucinations CMQ and psychosis and psychotic disorders SMQ - narrow search.

Program Source Code: [redacted]

TABLE 14.3 1.12.6.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Hallucinations/Psychosis
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period	N=22	N=5	N=27
Any adverse event in the hallucinations CMQ or psychosis and psychotic disorder SMQ	6 (27.3)	2 (40.0)	8 (29.6)
Hallucination PTs@	5 (22.7)	2 (40.0)	7 (25.9)
幻覚	5 (22.7)	1 (20.0)	6 (22.2)
幻視	0	1 (20.0)	1 (3.7)
Other PTs	2 (9.1)	0	2 (7.4)
妄想	1 (4.5)	0	1 (3.7)
嫉妬妄想	1 (4.5)	0	1 (3.7)

@ All PTs that include the text 'hallucination'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the hallucinations CMQ and psychosis and psychotic disorders SMQ - narrow search.

Program Source Code: [redacted]

TABLE 14.3 1.12.6.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Hallucinations/Psychosis
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Maintenance period	N=17	N=3	N=20
Any adverse event in the hallucinations CMQ or psychosis and psychotic disorder SMQ	8 (47.1)	0	8 (40.0)
Hallucination PTs@	6 (35.3)	0	6 (30.0)
幻覚	5 (29.4)	0	5 (25.0)
幻視	1 (5.9)	0	1 (5.0)
Other PTs	4 (23.5)	0	4 (20.0)
妄想	4 (23.5)	0	4 (20.0)

@ All PTs that include the text 'hallucination'.
Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the hallucinations CMQ and psychosis and psychotic disorders SMQ - narrow search.

Program Source Code: [redacted]

表2.7.4.7-42　転倒及び関連する損傷の発現割合（安全性解析対象集団，日本人部分集団）：M15-741試験

[redacted]20[redacted] 04:28 <[redacted]>
ABBV-951
STUDY M15-741 - SECOND INTERIM (CUTOFF [redacted]20[redacted])
R&D/20/1632 - CLINICAL/STATISTICAL

TABLE 14.3__1.12.8.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Falls and Associated Injuries
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Entire study period	N=22	N=5	N=27
Any adverse event in either the falls and associated injuries CMQ or the orthostatic hypotension CMQ	8 (36.4)	3 (60.0)	11 (40.7)
Falls and associated injuries CMQ	6 (27.3)	2 (40.0)	8 (29.6)
転倒	6 (27.3)	2 (40.0)	8 (29.6)
肋骨骨折	1 (4.5)	1 (20.0)	2 (7.4)
脳挫傷	1 (4.5)	0	1 (3.7)
挫傷	1 (4.5)	0	1 (3.7)
頭部損傷	1 (4.5)	0	1 (3.7)
靭帯捻挫	1 (4.5)	0	1 (3.7)
皮膚損傷	1 (4.5)	0	1 (3.7)
Orthostatic hypotension CMQ	2 (9.1)	1 (20.0)	3 (11.1)
浮動性めまい	2 (9.1)	1 (20.0)	3 (11.1)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the falls and associated injuries CMQ and orthostatic hypotension CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.8.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Falls and Associated Injuries
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period	N=22	N=5	N=27
Any adverse event in either the falls and associated injuries CMQ or the orthostatic hypotension CMQ	4 (18.2)	1 (20.0)	5 (18.5)
Falls and associated injuries CMQ	2 (9.1)	1 (20.0)	3 (11.1)
転倒	2 (9.1)	1 (20.0)	3 (11.1)
Orthostatic hypotension CMQ	2 (9.1)	0	2 (7.4)
浮動性めまい	2 (9.1)	0	2 (7.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the falls and associated injuries CMQ and orthostatic hypotension CMQ.

Program Source Code: [redacted]

TABLE 14.3 1.12.8.J

Subjects with Treatment-Emergent Adverse Events: Adverse Events of Special Interest (AESI) - Falls and Associated Injuries
in Descending Frequency by Preferred Term by Time Interval
(Safety Analysis Set - Japan Subjects)

MedDRA 24.0 search strategy Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Maintenance period	N=17	N=3	N=20
Any adverse event in either the falls and associated injuries CMQ or the orthostatic hypotension CMQ	5 (29.4)	2 (66.7)	7 (35.0)
Falls and associated injuries CMQ	5 (29.4)	1 (33.3)	6 (30.0)
転倒	5 (29.4)	1 (33.3)	6 (30.0)
肋骨骨折	1 (5.9)	1 (33.3)	2 (10.0)
脳挫傷	1 (5.9)	0	1 (5.0)
挫傷	1 (5.9)	0	1 (5.0)
頭部損傷	1 (5.9)	0	1 (5.0)
靭帯捻挫	1 (5.9)	0	1 (5.0)
皮膚損傷	1 (5.9)	0	1 (5.0)
Orthostatic hypotension CMQ	0	1 (33.3)	1 (5.0)
浮動性めまい	0	1 (33.3)	1 (5.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.
Includes events in the falls and associated injuries CMQ and orthostatic hypotension CMQ.

Program Source Code: [redacted]

表2.7.4.7-43　LDの1日あたりの投与量（安全性解析対象集団）：M15-741試験（更新時）

[redacted]20[redacted] 10:41 <[redacted]>
ABBV-951
STUDY M15-741 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0153 - CLINICAL/STATISTICAL

TABLE 14.1__8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 1								
WEEK 1	n	141	84	141	19	3	20	141
	Mean	1662.5	83.0	1711.9	128.9	133.3	142.5	1732.1
	SD	671.01	66.86	676.53	60.82	57.74	63.40	687.97
	Median	1507.7	56.3	1579.4	100.0	100.0	100.0	1579.4
	Min	682.1	18.8	682.1	100.0	100.0	100.0	682.1
	Max	3524.3	327.8	3562.7	300.0	200.0	300.0	3710.4
WEEK 2	n	142	94	142	19	3	21	142
	Mean	1753.1	82.9	1808.0	163.2	133.3	166.7	1832.6
	SD	673.97	65.24	676.79	107.81	57.74	102.88	687.42
	Median	1608.5	64.0	1646.2	100.0	100.0	100.0	1648.4
	Min	696.7	18.8	696.7	100.0	100.0	100.0	696.7
	Max	4072.4	368.8	4136.4	450.0	200.0	450.0	4136.4
WEEK 3	n	124	81	124	15	2	17	124
	Mean	1824.6	72.3	1871.8	126.7	100.0	123.5	1888.7
	SD	689.78	57.33	695.35	41.69	0.00	39.99	697.95
	Median	1669.0	51.2	1723.3	100.0	100.0	100.0	1741.7
	Min	696.7	18.8	696.7	100.0	100.0	100.0	696.7
	Max	4021.2	333.0	4059.6	200.0	100.0	200.0	4059.6
WEEK 4	n	117	79	117	13	0	13	117
	Mean	1883.3	66.0	1927.8	134.6		134.6	1942.8
	SD	716.71	54.18	719.31	89.87		89.87	727.83
	Median	1762.1	48.7	1794.6	100.0		100.0	1803.1
	Min	696.7	18.8	696.7	100.0		100.0	696.7
	Max	4080.9	281.7	4106.5	400.0		400.0	4106.5

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 1 (Cont.)								
WEEK 6	n	113	77	113	18	3	21	113
	Mean	1879.3	61.5	1921.2	144.4	200.0	152.4	1949.5
	SD	711.17	39.35	719.94	118.68	86.60	114.54	728.05
	Median	1762.1	48.7	1791.2	100.0	250.0	100.0	1872.3
	Min	800.8	18.8	800.8	100.0	100.0	100.0	800.8
	Max	4055.3	204.9	4119.3	600.0	250.0	600.0	4119.3
WEEK 13	n	103	68	103	20	4	23	103
	Mean	1911.1	60.4	1951.0	155.0	187.5	167.4	1988.4
	SD	746.85	52.44	751.01	190.50	62.92	178.13	758.65
	Median	1797.1	46.1	1844.1	100.0	200.0	100.0	1862.9
	Min	898.1	18.8	973.3	100.0	100.0	100.0	973.3
	Max	4098.0	307.4	4098.0	950.0	250.0	950.0	4098.0
WEEK 26	n	91	55	91	16	9	21	91
	Mean	1874.6	56.3	1908.6	146.9	161.1	181.0	1950.4
	SD	745.34	39.88	754.00	118.98	74.07	123.97	779.93
	Median	1691.2	41.0	1732.2	100.0	100.0	100.0	1769.8
	Min	851.4	18.8	898.3	100.0	100.0	100.0	898.3
	Max	4098.0	230.5	4116.8	550.0	250.0	550.0	4316.8
WEEK 39	n	79	50	79	15	7	17	79
	Mean	1896.3	67.0	1938.6	150.0	164.3	200.0	1981.7
	SD	704.01	61.38	709.80	114.95	85.22	126.24	736.35
	Median	1747.6	49.9	1769.0	100.0	100.0	150.0	1828.0
	Min	837.5	18.8	888.5	100.0	100.0	100.0	888.5
	Max	3961.4	307.4	3987.0	550.0	300.0	550.0	3987.0

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample / Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 1 (Cont.)								
WEEK 52	n	70	41	70	14	4	17	70
	Mean	1922.9	67.1	1962.2	100.0	162.5	120.6	1991.5
	SD	685.08	57.15	686.16	0.00	75.00	58.79	692.49
	Median	1829.2	51.2	1854.8	100.0	150.0	100.0	1910.6
	Min	856.8	18.8	945.1	100.0	100.0	100.0	954.2
	Max	3682.7	266.4	3721.2	100.0	250.0	300.0	3721.2

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 2								
WEEK 1	n	79	54	79	9	1	10	79
	Mean	1415.2	67.1	1461.1	138.9	150.0	140.0	1478.8
	SD	593.58	53.82	592.24	69.72	NA	65.83	598.97
	Median	1352.3	44.8	1393.3	100.0	150.0	100.0	1393.3
	Min	430.3	18.8	486.6	100.0	150.0	100.0	486.6
	Max	3279.8	256.1	3279.8	300.0	150.0	300.0	3379.8
WEEK 2	n	78	61	78	14	2	15	78
	Mean	1508.9	77.3	1569.4	182.1	137.5	188.3	1605.6
	SD	597.64	59.61	604.60	72.34	17.68	67.39	617.16
	Median	1506.0	51.2	1522.2	200.0	137.5	200.0	1594.0
	Min	630.1	18.8	668.5	100.0	125.0	100.0	668.5
	Max	3606.2	281.7	3606.2	300.0	150.0	300.0	3606.2
WEEK 3	n	76	58	76	8	1	9	76
	Mean	1527.1	75.7	1584.9	150.0	100.0	144.4	1602.0
	SD	575.97	51.23	587.08	88.64	NA	84.57	594.64
	Median	1527.2	62.8	1560.4	100.0	100.0	100.0	1593.3
	Min	686.5	18.8	686.5	100.0	100.0	100.0	686.5
	Max	3016.4	225.4	3053.9	350.0	100.0	350.0	3053.9
WEEK 4	n	75	57	75	7	0	7	75
	Mean	1594.1	66.7	1644.7	192.9		192.9	1662.7
	SD	589.95	44.28	597.67	101.77		101.77	598.38
	Median	1615.3	51.2	1650.5	200.0		200.0	1694.4
	Min	672.0	18.8	703.8	100.0		100.0	703.8
	Max	2932.2	204.9	3096.1	350.0		350.0	3096.1

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 2 (Cont.)								
WEEK 6	n	70	52	70	8	1	8	70
	Mean	1642.4	62.4	1688.8	175.0	100.0	187.5	1710.2
	SD	609.50	43.53	616.01	125.36	NA	121.74	615.80
	Median	1689.2	44.8	1725.8	100.0	100.0	150.0	1762.6
	Min	672.0	18.8	686.5	100.0	100.0	100.0	686.5
	Max	2984.7	204.9	3107.7	450.0	100.0	450.0	3107.7
WEEK 13	n	69	47	69	10	0	10	69
	Mean	1632.6	68.3	1679.1	135.0		135.0	1698.7
	SD	632.04	41.73	634.88	52.97		52.97	642.76
	Median	1634.1	51.2	1699.5	100.0		100.0	1714.9
	Min	682.1	18.8	697.3	100.0		100.0	697.3
	Max	3269.9	204.9	3392.8	250.0		250.0	3392.8
WEEK 26	n	63	46	63	15	2	16	63
	Mean	1612.3	62.6	1658.0	120.0	100.0	125.0	1689.7
	SD	660.22	43.32	660.03	36.84	0.00	54.77	665.05
	Median	1591.6	49.9	1624.0	100.0	100.0	100.0	1705.6
	Min	669.1	18.8	705.3	100.0	100.0	100.0	705.3
	Max	3385.1	179.3	3462.0	200.0	100.0	300.0	3462.0
WEEK 39	n	58	43	58	17	0	17	58
	Mean	1578.8	75.3	1634.7	132.4		132.4	1673.5
	SD	681.99	47.69	682.02	58.47		58.47	693.99
	Median	1573.2	64.9	1591.8	100.0		100.0	1630.2
	Min	657.0	18.8	657.0	100.0		100.0	657.0
	Max	3439.8	192.1	3439.8	300.0		300.0	3439.8

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample / Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Sample 2 (Cont.)								
WEEK 52	n	48	33	48	10	2	12	48
	Mean	1634.4	66.7	1680.3	110.0	187.5	122.9	1711.0
	SD	695.08	50.59	694.24	31.62	88.39	49.38	706.19
	Median	1573.4	51.2	1585.7	100.0	187.5	100.0	1604.0
	Min	669.1	18.8	669.1	100.0	125.0	100.0	709.6
	Max	3385.4	230.5	3404.2	200.0	250.0	250.0	3404.2

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample	Week	ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Both Enrollment Samples								
	WEEK 1 n	220	138	220	28	4	30	220
	Mean	1573.7	76.8	1621.9	132.1	137.5	141.7	1641.2
	SD	653.80	62.36	657.31	62.68	47.87	63.09	667.22
	Median	1440.8	56.3	1501.4	100.0	125.0	100.0	1521.0
	Min	430.3	18.8	486.6	100.0	100.0	100.0	486.6
	Max	3524.3	327.8	3562.7	300.0	200.0	300.0	3710.4
	WEEK 2 n	220	155	220	33	5	36	220
	Mean	1666.6	80.7	1723.4	171.2	135.0	175.7	1752.1
	SD	657.07	62.94	660.70	93.57	41.83	89.34	670.83
	Median	1572.8	61.5	1629.4	100.0	125.0	175.0	1646.2
	Min	630.1	18.8	668.5	100.0	100.0	100.0	668.5
	Max	4072.4	368.8	4136.4	450.0	200.0	450.0	4136.4
	WEEK 3 n	200	139	200	23	3	26	200
	Mean	1711.5	73.7	1762.8	134.8	100.0	130.8	1779.8
	SD	663.38	54.70	669.51	61.12	0.00	58.44	673.67
	Median	1595.9	51.2	1657.6	100.0	100.0	100.0	1665.9
	Min	686.5	18.8	686.5	100.0	100.0	100.0	686.5
	Max	4021.2	333.0	4059.6	350.0	100.0	350.0	4059.6
	WEEK 4 n	192	136	192	20	0	20	192
	Mean	1770.3	66.2	1817.3	155.0		155.0	1833.4
	SD	683.25	50.10	686.89	95.83		95.83	692.26
	Median	1687.1	51.2	1740.2	100.0		100.0	1752.0
	Min	672.0	18.8	696.7	100.0		100.0	696.7
	Max	4080.9	281.7	4106.5	400.0		400.0	4106.5

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample	Week	ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Both Enrollment Samples (Cont.)								
	WEEK 6 n	183	129	183	26	4	29	183
	Mean	1788.7	61.9	1832.3	153.8	175.0	162.1	1858.0
	SD	682.20	40.92	689.68	119.10	86.60	115.46	695.38
	Median	1721.2	48.7	1762.1	100.0	175.0	100.0	1831.5
	Min	672.0	18.8	686.5	100.0	100.0	100.0	686.5
	Max	4055.3	204.9	4119.3	600.0	250.0	600.0	4119.3
	WEEK 13 n	172	115	172	30	4	33	172
	Mean	1799.4	63.6	1841.9	148.3	187.5	157.6	1872.2
	SD	714.36	48.31	717.34	157.28	62.92	151.10	726.55
	Median	1720.2	51.2	1783.0	100.0	200.0	100.0	1820.3
	Min	682.1	18.8	697.3	100.0	100.0	100.0	697.3
	Max	4098.0	307.4	4098.0	950.0	250.0	950.0	4098.0
	WEEK 26 n	154	101	154	31	11	37	154
	Mean	1767.3	59.1	1806.1	133.9	150.0	156.8	1843.8
	SD	721.22	41.39	725.43	88.87	70.71	102.85	744.02
	Median	1645.2	41.0	1716.5	100.0	100.0	100.0	1760.0
	Min	669.1	18.8	705.3	100.0	100.0	100.0	705.3
	Max	4098.0	230.5	4116.8	550.0	250.0	550.0	4316.8
	WEEK 39 n	137	93	137	32	7	34	137
	Mean	1761.9	70.8	1810.0	140.6	164.3	166.2	1851.2
	SD	709.91	55.34	711.78	88.39	85.22	102.78	732.25
	Median	1669.7	51.2	1713.6	100.0	100.0	100.0	1747.6
	Min	657.0	18.8	657.0	100.0	100.0	100.0	657.0
	Max	3961.4	307.4	3987.0	550.0	300.0	550.0	3987.0

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Enrollment Sample / Week		ABBV-951 CSCI: Continuous Infusion	ABBV-951 CSCI: Extra Dose	ABBV-951 CSCI: Total	Oral: Rescue Dose	Oral: Loading Dose	Oral: Total	Overall Total
Both Enrollment Samples (Cont.)								
WEEK 52	n	118	74	118	24	6	29	118
	Mean	1805.6	67.0	1847.5	104.2	170.8	121.6	1877.4
	SD	700.81	53.96	700.45	20.41	71.44	54.17	708.73
	Median	1708.7	51.2	1779.9	100.0	162.5	100.0	1807.6
	Min	669.1	18.8	669.1	100.0	100.0	100.0	709.6
	Max	3682.7	266.4	3721.2	200.0	250.0	300.0	3721.2

Program Source Code: [redacted]

表2.7.4.7-44　LDの1日あたりの投与量（安全性解析対象集団）：M15-737試験（更新時）

[redacted]20[redacted] 10:45 <[redacted]>
ABBV-951
STUDY M15-737 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0154 - CLINICAL/STATISTICAL

TABLE 14.1__8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

		ABBV-951 CSCI			Oral			
Week		Continuous Infusion	Extra Dose	Total	Rescue Dose	Loading Dose	Total	Overall Total
WEEK 12	n	88	48	88	16	0	16	88
	Mean	1872.6	76.5	1914.3	115.6		115.6	1935.3
	SD	795.71	63.65	799.00	35.21		35.21	801.28
	Median	1752.4	56.3	1836.5	100.0		100.0	1836.5
	Min	685.0	18.8	753.9	100.0		100.0	753.9
	Max	4098.0	307.4	4116.8	200.0		200.0	4216.8
WEEK 24	n	85	49	85	11	3	14	85
	Mean	1926.1	81.7	1973.2	154.5	158.3	155.4	1998.8
	SD	731.56	69.07	737.01	82.02	80.36	78.56	744.65
	Median	1885.1	61.5	1949.2	100.0	125.0	100.0	1952.3
	Min	688.0	18.8	688.0	100.0	100.0	100.0	688.0
	Max	3886.3	333.0	3942.6	300.0	250.0	300.0	3942.6
WEEK 36	n	67	30	67	6	1	7	67
	Mean	2020.3	66.1	2049.9	108.3	250.0	128.6	2063.3
	SD	719.70	54.18	719.12	20.41	N/A	56.69	716.65
	Median	1967.0	51.2	1998.0	100.0	250.0	100.0	1998.0
	Min	857.5	18.8	954.2	100.0	250.0	100.0	954.2
	Max	3725.4	256.1	3725.4	150.0	250.0	250.0	3725.4
WEEK 48	n	59	32	59	2	1	3	59
	Mean	2011.8	75.9	2052.9	150.0	250.0	183.3	2062.3
	SD	719.27	71.90	729.76	70.71	N/A	76.38	736.05
	Median	1959.4	41.0	2031.8	150.0	250.0	200.0	2031.8
	Min	855.8	18.8	953.1	100.0	250.0	100.0	953.1
	Max	4014.5	307.4	4040.1	200.0	250.0	250.0	4040.1

Program Source Code: [redacted]

TABLE 14.1 8.1

Daily Levodopa Dose (mg LD)
(Safety Analysis Set)

Week		ABBV-951 CSCI			Oral			Overall Total
		Continuous Infusion	Extra Dose	Total	Rescue Dose	Loading Dose	Total	
WEEK 60	n	44	23	44	6	1	6	44
	Mean	1982.4	73.2	2020.6	150.0	200.0	183.3	2045.6
	SD	700.53	72.20	714.52	63.25	N/A	81.65	718.81
	Median	1978.1	48.7	1978.1	125.0	200.0	175.0	1994.4
	Min	847.3	18.8	872.9	100.0	200.0	100.0	872.9
	Max	3961.4	307.4	4012.6	250.0	200.0	300.0	4012.6
WEEK 72	n	26	13	26	1	0	1	26
	Mean	1824.7	40.5	1844.9	100.0		100.0	1848.8
	SD	669.28	18.37	669.82	N/A		N/A	668.01
	Median	1855.1	32.4	1864.6	100.0		100.0	1864.6
	Min	819.6	18.8	819.6	100.0		100.0	819.6
	Max	3794.1	76.8	3845.3	100.0		100.0	3845.3
WEEK 84	n	3	3	3	0	0	0	3
	Mean	1631.0	50.1	1681.1				1681.1
	SD	597.01	11.99	606.13				606.13
	Median	1352.3	51.2	1389.9				1389.9
	Min	1224.3	37.6	1275.5				1275.5
	Max	2316.4	61.5	2377.9				2377.9
WEEK 96	n	2	1	2	1	0	1	2
	Mean	1905.9	82.0	1946.8	100.0		100.0	1996.8
	SD	559.92	N/A	617.88	N/A		N/A	547.17
	Median	1905.9	82.0	1946.8	100.0		100.0	1996.8
	Min	1509.9	82.0	1509.9	100.0		100.0	1609.9
	Max	2301.8	82.0	2383.8	100.0		100.0	2383.8

Program Source Code: [redacted]

表2.7.4.7-45　2%以上の被験者に発現した有害事象（安全性解析対象集団）：M15-741試験（更新時）

[redacted]20[redacted] 10:56 <[redacted]>
ABBV-951
STUDY M15-741 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0153 - CLINICAL/STATISTICAL

TABLE 14.3__1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period	N=132	N=112	N=244
Any adverse event	121 (91.7)	106 (94.6)	227 (93.0)
耳および迷路障害	3 (2.3)	2 (1.8)	5 (2.0)
回転性めまい	3 (2.3)	2 (1.8)	5 (2.0)
眼障害	3 (2.3)	4 (3.6)	7 (2.9)
複視	3 (2.3)	1 (0.9)	4 (1.6)
ドライアイ	1 (0.8)	3 (2.7)	4 (1.6)
胃腸障害	22 (16.7)	27 (24.1)	49 (20.1)
腹部膨満	1 (0.8)	3 (2.7)	4 (1.6)
便秘	8 (6.1)	12 (10.7)	20 (8.2)
下痢	6 (4.5)	3 (2.7)	9 (3.7)
口内乾燥	3 (2.3)	5 (4.5)	8 (3.3)
悪心	8 (6.1)	11 (9.8)	19 (7.8)
嘔吐	3 (2.3)	3 (2.7)	6 (2.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
一般・全身障害および投与部位の状態	100 (75.8)	94 (83.9)	194 (79.5)
無力症	3 (2.3)	0	3 (1.2)
疲労	6 (4.5)	3 (2.7)	9 (3.7)
注入部位内出血	10 (7.6)	8 (7.1)	18 (7.4)
注入部位不快感	3 (2.3)	1 (0.9)	4 (1.6)
注入部位紅斑	65 (49.2)	61 (54.5)	126 (51.6)
注入部位皮膚剥脱	3 (2.3)	3 (2.7)	6 (2.5)
注入部位血管外漏出	8 (6.1)	12 (10.7)	20 (8.2)
注入部位血腫	10 (7.6)	8 (7.1)	18 (7.4)
注入部位出血	4 (3.0)	5 (4.5)	9 (3.7)
注入部位硬結	7 (5.3)	3 (2.7)	10 (4.1)
注入部位炎症	3 (2.3)	6 (5.4)	9 (3.7)
注入部位刺激感	1 (0.8)	4 (3.6)	5 (2.0)
注入部位腫瘤	5 (3.8)	3 (2.7)	8 (3.3)
注入部位結節	35 (26.5)	34 (30.4)	69 (28.3)
注入部位浮腫	19 (14.4)	28 (25.0)	47 (19.3)
注入部位疼痛	18 (13.6)	20 (17.9)	38 (15.6)
注入部位蒼白	3 (2.3)	2 (1.8)	5 (2.0)
注入部位丘疹	7 (5.3)	11 (9.8)	18 (7.4)
注入部位そう痒感	5 (3.8)	2 (1.8)	7 (2.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
一般・全身障害および投与部位の状態 (Cont.)			
注入部位発疹	3 (2.3)	4 (3.6)	7 (2.9)
注入部位反応	13 (9.8)	17 (15.2)	30 (12.3)
注入部位腫脹	4 (3.0)	2 (1.8)	6 (2.5)
注射部位紅斑	6 (4.5)	8 (7.1)	14 (5.7)
注射部位炎症	2 (1.5)	4 (3.6)	6 (2.5)
注射部位結節	3 (2.3)	6 (5.4)	9 (3.7)
注射部位浮腫	2 (1.5)	3 (2.7)	5 (2.0)
注射部位疼痛	2 (1.5)	6 (5.4)	8 (3.3)
末梢性浮腫	5 (3.8)	4 (3.6)	9 (3.7)
末梢腫脹	0	4 (3.6)	4 (1.6)
穿刺部位紅斑	0	3 (2.7)	3 (1.2)
感染症および寄生虫症	48 (36.4)	49 (43.8)	97 (39.8)
注入部位膿瘍	14 (10.6)	13 (11.6)	27 (11.1)
注入部位蜂巣炎	29 (22.0)	27 (24.1)	56 (23.0)
注入部位感染	7 (5.3)	11 (9.8)	18 (7.4)
注射部位蜂巣炎	0	3 (2.7)	3 (1.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
感染症および寄生虫症 (Cont.)			
上咽頭炎	5 (3.8)	5 (4.5)	10 (4.1)
肺炎	3 (2.3)	1 (0.9)	4 (1.6)
敗血症	3 (2.3)	0	3 (1.2)
尿路感染	8 (6.1)	11 (9.8)	19 (7.8)
傷害、中毒および処置合併症	16 (12.1)	24 (21.4)	40 (16.4)
挫傷	2 (1.5)	6 (5.4)	8 (3.3)
転倒	16 (12.1)	24 (21.4)	40 (16.4)
頭部損傷	2 (1.5)	3 (2.7)	5 (2.0)
皮膚裂傷	1 (0.8)	6 (5.4)	7 (2.9)
臨床検査	15 (11.4)	19 (17.0)	34 (13.9)
ビタミンB6減少	5 (3.8)	6 (5.4)	11 (4.5)
体重減少	10 (7.6)	14 (12.5)	24 (9.8)
代謝および栄養障害	7 (5.3)	13 (11.6)	20 (8.2)
食欲減退	3 (2.3)	3 (2.7)	6 (2.5)
脱水	1 (0.8)	3 (2.7)	4 (1.6)
低カリウム血症	0	3 (2.7)	3 (1.2)
ビタミンB6欠乏	3 (2.3)	5 (4.5)	8 (3.3)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
筋骨格系および結合組織障害	19 (14.4)	15 (13.4)	34 (13.9)
関節痛	3 (2.3)	5 (4.5)	8 (3.3)
背部痛	8 (6.1)	5 (4.5)	13 (5.3)
筋痙縮	2 (1.5)	3 (2.7)	5 (2.0)
筋力低下	4 (3.0)	1 (0.9)	5 (2.0)
変形性関節症	1 (0.8)	4 (3.6)	5 (2.0)
四肢痛	3 (2.3)	3 (2.7)	6 (2.5)
神経系障害	51 (38.6)	38 (33.9)	89 (36.5)
平衡障害	0	4 (3.6)	4 (1.6)
認知障害	4 (3.0)	2 (1.8)	6 (2.5)
浮動性めまい	15 (11.4)	10 (8.9)	25 (10.2)
体位性めまい	5 (3.8)	0	5 (2.0)
構語障害	0	3 (2.7)	3 (1.2)
ジスキネジア	12 (9.1)	6 (5.4)	18 (7.4)
ジストニア	2 (1.5)	5 (4.5)	7 (2.9)
すくみ現象	4 (3.0)	0	4 (1.6)
頭痛	7 (5.3)	7 (6.3)	14 (5.7)
オンオフ現象	4 (3.0)	5 (4.5)	9 (3.7)
錯感覚	4 (3.0)	3 (2.7)	7 (2.9)
パーキンソン病	12 (9.1)	5 (4.5)	17 (7.0)
パーキンソニズム	0	3 (2.7)	3 (1.2)
坐骨神経痛	0	3 (2.7)	3 (1.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
神経系障害 (Cont.)			
傾眠	9 (6.8)	3 (2.7)	12 (4.9)
失神	0	3 (2.7)	3 (1.2)
精神障害	42 (31.8)	50 (44.6)	92 (37.7)
不安	11 (8.3)	18 (16.1)	29 (11.9)
錯乱状態	4 (3.0)	5 (4.5)	9 (3.7)
譫妄	1 (0.8)	4 (3.6)	5 (2.0)
妄想	8 (6.1)	2 (1.8)	10 (4.1)
うつ病	3 (2.3)	2 (1.8)	5 (2.0)
幻覚	20 (15.2)	22 (19.6)	42 (17.2)
幻聴	3 (2.3)	3 (2.7)	6 (2.5)
幻視	10 (7.6)	5 (4.5)	15 (6.1)
衝動制御障害	0	4 (3.6)	4 (1.6)
不眠症	9 (6.8)	9 (8.0)	18 (7.4)
パニック発作	0	3 (2.7)	3 (1.2)
精神病性障害	4 (3.0)	2 (1.8)	6 (2.5)
腎および尿路障害	6 (4.5)	3 (2.7)	9 (3.7)
切迫性尿失禁	3 (2.3)	0	3 (1.2)
尿失禁	3 (2.3)	2 (1.8)	5 (2.0)
尿閉	0	3 (2.7)	3 (1.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Entire study period (Cont.)	N=132	N=112	N=244
呼吸器、胸郭および縦隔障害	2 (1.5)	6 (5.4)	8 (3.3)
呼吸困難	2 (1.5)	6 (5.4)	8 (3.3)
皮膚および皮下組織障害	1 (0.8)	3 (2.7)	4 (1.6)
紅斑	1 (0.8)	3 (2.7)	4 (1.6)
血管障害	11 (8.3)	10 (8.9)	21 (8.6)
高血圧	3 (2.3)	3 (2.7)	6 (2.5)
低血圧	2 (1.5)	4 (3.6)	6 (2.5)
起立性低血圧	7 (5.3)	6 (5.4)	13 (5.3)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period	N=132	N=112	N=244
Any adverse event	100 (75.8)	91 (81.3)	191 (78.3)
胃腸障害	7 (5.3)	8 (7.1)	15 (6.1)
口内乾燥	2 (1.5)	3 (2.7)	5 (2.0)
悪心	5 (3.8)	5 (4.5)	10 (4.1)
一般・全身障害および投与部位の状態	81 (61.4)	75 (67.0)	156 (63.9)
疲労	3 (2.3)	2 (1.8)	5 (2.0)
注入部位内出血	3 (2.3)	7 (6.3)	10 (4.1)
注入部位紅斑	50 (37.9)	45 (40.2)	95 (38.9)
注入部位血管外漏出	4 (3.0)	7 (6.3)	11 (4.5)
注入部位血腫	4 (3.0)	4 (3.6)	8 (3.3)
注入部位出血	0	3 (2.7)	3 (1.2)
注入部位硬結	4 (3.0)	1 (0.9)	5 (2.0)
注入部位炎症	1 (0.8)	3 (2.7)	4 (1.6)
注入部位腫瘤	4 (3.0)	1 (0.9)	5 (2.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Optimization period (Cont.)	N=132	N=112	N=244
一般・全身障害および投与部位の状態 (Cont.)			
注入部位結節	21 (15.9)	18 (16.1)	39 (16.0)
注入部位浮腫	14 (10.6)	16 (14.3)	30 (12.3)
注入部位疼痛	13 (9.8)	14 (12.5)	27 (11.1)
注入部位丘疹	1 (0.8)	4 (3.6)	5 (2.0)
注入部位反応	9 (6.8)	11 (9.8)	20 (8.2)
注入部位腫脹	3 (2.3)	1 (0.9)	4 (1.6)
注射部位紅斑	5 (3.8)	5 (4.5)	10 (4.1)
注射部位疼痛	2 (1.5)	4 (3.6)	6 (2.5)
末梢性浮腫	1 (0.8)	3 (2.7)	4 (1.6)
感染症および寄生虫症	13 (9.8)	22 (19.6)	35 (14.3)
注入部位膿瘍	3 (2.3)	5 (4.5)	8 (3.3)
注入部位蜂巣炎	10 (7.6)	13 (11.6)	23 (9.4)
注入部位感染	1 (0.8)	3 (2.7)	4 (1.6)
上咽頭炎	0	3 (2.7)	3 (1.2)
尿路感染	3 (2.3)	3 (2.7)	6 (2.5)
傷害、中毒および処置合併症	7 (5.3)	9 (8.0)	16 (6.6)
転倒	7 (5.3)	9 (8.0)	16 (6.6)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Optimization period (Cont.)	N=132	N=112	N=244
筋骨格系および結合組織障害	3 (2.3)	1 (0.9)	4 (1.6)
背部痛	3 (2.3)	1 (0.9)	4 (1.6)
神経系障害	27 (20.5)	17 (15.2)	44 (18.0)
浮動性めまい	10 (7.6)	8 (7.1)	18 (7.4)
体位性めまい	3 (2.3)	0	3 (1.2)
ジスキネジア	6 (4.5)	3 (2.7)	9 (3.7)
すくみ現象	3 (2.3)	0	3 (1.2)
頭痛	4 (3.0)	2 (1.8)	6 (2.5)
オンオフ現象	3 (2.3)	3 (2.7)	6 (2.5)
パーキンソン病	5 (3.8)	3 (2.7)	8 (3.3)
精神障害	21 (15.9)	19 (17.0)	40 (16.4)
不安	2 (1.5)	8 (7.1)	10 (4.1)
幻覚	13 (9.8)	5 (4.5)	18 (7.4)
幻視	4 (3.0)	1 (0.9)	5 (2.0)
不眠症	7 (5.3)	3 (2.7)	10 (4.1)
パニック発作	0	3 (2.7)	3 (1.2)
血管障害	1 (0.8)	4 (3.6)	5 (2.0)
起立性低血圧	1 (0.8)	4 (3.6)	5 (2.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period	N=111	N=95	N=206
Any adverse event	97 (87.4)	87 (91.6)	184 (89.3)
心臓障害	0	2 (2.1)	2 (1.0)
心房細動	0	2 (2.1)	2 (1.0)
眼障害	3 (2.7)	4 (4.2)	7 (3.4)
白内障	2 (1.8)	2 (2.1)	4 (1.9)
ドライアイ	1 (0.9)	3 (3.2)	4 (1.9)
胃腸障害	13 (11.7)	19 (20.0)	32 (15.5)
腹部膨満	1 (0.9)	2 (2.1)	3 (1.5)
便秘	6 (5.4)	10 (10.5)	16 (7.8)
下痢	4 (3.6)	1 (1.1)	5 (2.4)
口内乾燥	1 (0.9)	3 (3.2)	4 (1.9)
悪心	4 (3.6)	7 (7.4)	11 (5.3)
嘔吐	1 (0.9)	2 (2.1)	3 (1.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
一般・全身障害および投与部位の状態	65 (58.6)	72 (75.8)	137 (66.5)
疲労	3 (2.7)	1 (1.1)	4 (1.9)
インフルエンザ様疾患	1 (0.9)	2 (2.1)	3 (1.5)
注入部位内出血	7 (6.3)	2 (2.1)	9 (4.4)
注入部位皮膚炎	2 (1.8)	2 (2.1)	4 (1.9)
注入部位紅斑	36 (32.4)	44 (46.3)	80 (38.8)
注入部位皮膚剥脱	3 (2.7)	2 (2.1)	5 (2.4)
注入部位血管外漏出	5 (4.5)	6 (6.3)	11 (5.3)
注入部位血腫	6 (5.4)	4 (4.2)	10 (4.9)
注入部位出血	4 (3.6)	2 (2.1)	6 (2.9)
注入部位硬結	5 (4.5)	2 (2.1)	7 (3.4)
注入部位炎症	2 (1.8)	6 (6.3)	8 (3.9)
注入部位損傷	0	2 (2.1)	2 (1.0)
注入部位刺激感	1 (0.9)	4 (4.2)	5 (2.4)
注入部位腫瘤	1 (0.9)	2 (2.1)	3 (1.5)
注入部位結節	20 (18.0)	25 (26.3)	45 (21.8)
注入部位浮腫	8 (7.2)	18 (18.9)	26 (12.6)
注入部位疼痛	8 (7.2)	11 (11.6)	19 (9.2)
注入部位丘疹	6 (5.4)	8 (8.4)	14 (6.8)
注入部位異常感覚	0	2 (2.1)	2 (1.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
一般・全身障害および投与部位の状態 (Cont.)			
注入部位そう痒感	3 (2.7)	1 (1.1)	4 (1.9)
注入部位発疹	1 (0.9)	3 (3.2)	4 (1.9)
注入部位反応	8 (7.2)	11 (11.6)	19 (9.2)
注入部位小水疱	0	2 (2.1)	2 (1.0)
注射部位紅斑	5 (4.5)	5 (5.3)	10 (4.9)
注射部位炎症	2 (1.8)	4 (4.2)	6 (2.9)
注射部位結節	3 (2.7)	5 (5.3)	8 (3.9)
注射部位疼痛	0	2 (2.1)	2 (1.0)
注射部位丘疹	0	2 (2.1)	2 (1.0)
注射部位腫脹	1 (0.9)	2 (2.1)	3 (1.5)
非心臓性胸痛	0	2 (2.1)	2 (1.0)
末梢性浮腫	4 (3.6)	1 (1.1)	5 (2.4)
末梢腫脹	0	3 (3.2)	3 (1.5)
穿刺部位紅斑	0	2 (2.1)	2 (1.0)
感染症および寄生虫症	39 (35.1)	40 (42.1)	79 (38.3)
蜂巣炎	1 (0.9)	2 (2.1)	3 (1.5)
注入部位膿瘍	11 (9.9)	9 (9.5)	20 (9.7)
注入部位蜂巣炎	21 (18.9)	19 (20.0)	40 (19.4)
注入部位感染	6 (5.4)	9 (9.5)	15 (7.3)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
感染症および寄生虫症 (Cont.)			
注射部位蜂巣炎	0	2 (2.1)	2 (1.0)
上咽頭炎	5 (4.5)	2 (2.1)	7 (3.4)
尿路感染	5 (4.5)	11 (11.6)	16 (7.8)
傷害、中毒および処置合併症	11 (9.9)	19 (20.0)	30 (14.6)
挫傷	1 (0.9)	6 (6.3)	7 (3.4)
転倒	11 (9.9)	18 (18.9)	29 (14.1)
頭部損傷	1 (0.9)	3 (3.2)	4 (1.9)
皮膚擦過傷	0	2 (2.1)	2 (1.0)
皮膚裂傷	1 (0.9)	4 (4.2)	5 (2.4)
臨床検査	16 (14.4)	16 (16.8)	32 (15.5)
血中ホモシステイン増加	1 (0.9)	2 (2.1)	3 (1.5)
ビタミンB6減少	5 (4.5)	4 (4.2)	9 (4.4)
体重減少	10 (9.0)	13 (13.7)	23 (11.2)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
代謝および栄養障害	6 (5.4)	10 (10.5)	16 (7.8)
食欲減退	2 (1.8)	2 (2.1)	4 (1.9)
脱水	1 (0.9)	2 (2.1)	3 (1.5)
低カリウム血症	0	2 (2.1)	2 (1.0)
ビタミンB12欠乏	0	2 (2.1)	2 (1.0)
ビタミンB6欠乏	3 (2.7)	5 (5.3)	8 (3.9)
筋骨格系および結合組織障害	12 (10.8)	12 (12.6)	24 (11.7)
関節痛	1 (0.9)	3 (3.2)	4 (1.9)
背部痛	5 (4.5)	4 (4.2)	9 (4.4)
関節滲出液	0	2 (2.1)	2 (1.0)
筋痙縮	2 (1.8)	3 (3.2)	5 (2.4)
変形性関節症	1 (0.9)	4 (4.2)	5 (2.4)
四肢痛	3 (2.7)	2 (2.1)	5 (2.4)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	2 (2.1)	2 (1.0)
基底細胞癌	0	2 (2.1)	2 (1.0)
神経系障害	30 (27.0)	28 (29.5)	58 (28.2)
平衡障害	0	4 (4.2)	4 (1.9)
認知障害	2 (1.8)	2 (2.1)	4 (1.9)
浮動性めまい	6 (5.4)	2 (2.1)	8 (3.9)
体位性めまい	3 (2.7)	0	3 (1.5)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
神経系障害 (Cont.)			
構語障害	0	2 (2.1)	2 (1.0)
ジスキネジア	7 (6.3)	3 (3.2)	10 (4.9)
ジストニア	1 (0.9)	4 (4.2)	5 (2.4)
頭痛	3 (2.7)	6 (6.3)	9 (4.4)
感覚鈍麻	1 (0.9)	2 (2.1)	3 (1.5)
記憶障害	0	2 (2.1)	2 (1.0)
オンオフ現象	1 (0.9)	2 (2.1)	3 (1.5)
錯感覚	4 (3.6)	2 (2.1)	6 (2.9)
パーキンソン病	7 (6.3)	2 (2.1)	9 (4.4)
パーキンソニズム	0	2 (2.1)	2 (1.0)
側反弓	1 (0.9)	2 (2.1)	3 (1.5)
多発ニューロパチー	0	2 (2.1)	2 (1.0)
坐骨神経痛	0	3 (3.2)	3 (1.5)
傾眠	8 (7.2)	1 (1.1)	9 (4.4)
失神	0	3 (3.2)	3 (1.5)
精神障害	32 (28.8)	36 (37.9)	68 (33.0)
不安	10 (9.0)	12 (12.6)	22 (10.7)
錯乱状態	4 (3.6)	4 (4.2)	8 (3.9)
譫妄	0	2 (2.1)	2 (1.0)
妄想	7 (6.3)	1 (1.1)	8 (3.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	Dose Category High Dose n (%)	All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
精神障害 (Cont.)			
うつ病	3 (2.7)	2 (2.1)	5 (2.4)
幻覚	12 (10.8)	19 (20.0)	31 (15.0)
幻聴	3 (2.7)	2 (2.1)	5 (2.4)
幻視	6 (5.4)	4 (4.2)	10 (4.9)
衝動制御障害	0	4 (4.2)	4 (1.9)
不眠症	2 (1.8)	6 (6.3)	8 (3.9)
精神病性障害	3 (2.7)	2 (2.1)	5 (2.4)
自殺念慮	1 (0.9)	2 (2.1)	3 (1.5)
腎および尿路障害	1 (0.9)	3 (3.2)	4 (1.9)
尿失禁	1 (0.9)	2 (2.1)	3 (1.5)
尿閉	0	3 (3.2)	3 (1.5)
呼吸器、胸郭および縦隔障害	2 (1.8)	9 (9.5)	11 (5.3)
発声障害	0	2 (2.1)	2 (1.0)
呼吸困難	2 (1.8)	5 (5.3)	7 (3.4)
肺塞栓症	0	2 (2.1)	2 (1.0)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2% or Higher Frequency
by Primary System Organ Class and Preferred Term by Time Interval
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose n (%)	 High Dose n (%)	 All Subjects n (%)
Maintenance period (Cont.)	N=111	N=95	N=206
皮膚および皮下組織障害	3 (2.7)	6 (6.3)	9 (4.4)
紅斑	1 (0.9)	2 (2.1)	3 (1.5)
丘疹	0	2 (2.1)	2 (1.0)
そう痒症	2 (1.8)	2 (2.1)	4 (1.9)
血管障害	10 (9.0)	6 (6.3)	16 (7.8)
高血圧	1 (0.9)	2 (2.1)	3 (1.5)
低血圧	2 (1.8)	2 (2.1)	4 (1.9)
起立性低血圧	7 (6.3)	3 (3.2)	10 (4.9)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

表2.7.4.7-46　2例以上の被験者に発現した有害事象（安全性解析対象集団）：M15-737試験（更新時）

[redacted]20[redacted] 10:48 <[redacted]>
ABBV-951
STUDY M15-737 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0154 - CLINICAL/STATISTICAL

TABLE 14.3__1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2 subjects or Higher Frequency
by Primary System Organ Class and Preferred Term
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose (N=55) n (%)	 High Dose (N=61) n (%)	 All Subjects (N=116) n (%)
Any adverse event	35 (63.6)	46 (75.4)	81 (69.8)
耳および迷路障害	0	2 (3.3)	2 (1.7)
回転性めまい	0	2 (3.3)	2 (1.7)
眼障害	0	2 (3.3)	2 (1.7)
眼充血	0	2 (3.3)	2 (1.7)
胃腸障害	5 (9.1)	5 (8.2)	10 (8.6)
便秘	3 (5.5)	2 (3.3)	5 (4.3)
嚥下障害	1 (1.8)	2 (3.3)	3 (2.6)
悪心	2 (3.6)	2 (3.3)	4 (3.4)
一般・全身障害および投与部位の状態	19 (34.5)	18 (29.5)	37 (31.9)
カテーテル留置部位内出血	1 (1.8)	2 (3.3)	3 (2.6)
疲労	3 (5.5)	0	3 (2.6)
注入部位内出血	2 (3.6)	3 (4.9)	5 (4.3)
注入部位紅斑	11 (20.0)	8 (13.1)	19 (16.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2 subjects or Higher Frequency
by Primary System Organ Class and Preferred Term
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose (N=55) n (%)	 High Dose (N=61) n (%)	 All Subjects (N=116) n (%)
注入部位血管外漏出	0	2 (3.3)	2 (1.7)
注入部位血腫	1 (1.8)	1 (1.6)	2 (1.7)
注入部位硬結	1 (1.8)	2 (3.3)	3 (2.6)
注入部位刺激感	2 (3.6)	0	2 (1.7)
注入部位結節	2 (3.6)	3 (4.9)	5 (4.3)
注入部位浮腫	1 (1.8)	1 (1.6)	2 (1.7)
注入部位疼痛	1 (1.8)	1 (1.6)	2 (1.7)
注入部位丘疹	1 (1.8)	3 (4.9)	4 (3.4)
注入部位腫脹	1 (1.8)	1 (1.6)	2 (1.7)
注射部位内出血	1 (1.8)	1 (1.6)	2 (1.7)
注射部位紅斑	1 (1.8)	2 (3.3)	3 (2.6)
感染症および寄生虫症	14 (25.5)	16 (26.2)	30 (25.9)
無症候性COVID-19	0	2 (3.3)	2 (1.7)
COVID-19	1 (1.8)	4 (6.6)	5 (4.3)
胃腸炎	1 (1.8)	1 (1.6)	2 (1.7)
注入部位膿瘍	3 (5.5)	0	3 (2.6)
注入部位蜂巣炎	6 (10.9)	10 (16.4)	16 (13.8)
注入部位感染	3 (5.5)	0	3 (2.6)
上咽頭炎	1 (1.8)	1 (1.6)	2 (1.7)
尿路感染	1 (1.8)	4 (6.6)	5 (4.3)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2 subjects or Higher Frequency
by Primary System Organ Class and Preferred Term
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose (N=55) n (%)	 High Dose (N=61) n (%)	 All Subjects (N=116) n (%)
傷害、中毒および処置合併症	6 (10.9)	9 (14.8)	15 (12.9)
転倒	5 (9.1)	9 (14.8)	14 (12.1)
手骨折	1 (1.8)	2 (3.3)	3 (2.6)
股関節部骨折	1 (1.8)	1 (1.6)	2 (1.7)
上腕骨骨折	1 (1.8)	1 (1.6)	2 (1.7)
臨床検査	3 (5.5)	6 (9.8)	9 (7.8)
血中葉酸減少	0	2 (3.3)	2 (1.7)
血中ホモシステイン増加	2 (3.6)	0	2 (1.7)
ビタミンB12減少	1 (1.8)	1 (1.6)	2 (1.7)
ビタミンB6減少	2 (3.6)	0	2 (1.7)
体重減少	0	3 (4.9)	3 (2.6)
代謝および栄養障害	2 (3.6)	5 (8.2)	7 (6.0)
低カリウム血症	1 (1.8)	1 (1.6)	2 (1.7)
低マグネシウム血症	1 (1.8)	1 (1.6)	2 (1.7)
鉄欠乏	1 (1.8)	1 (1.6)	2 (1.7)
ビタミンB12欠乏	1 (1.8)	3 (4.9)	4 (3.4)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2 subjects or Higher Frequency
by Primary System Organ Class and Preferred Term
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose (N=55) n (%)	Dose Category High Dose (N=61) n (%)	All Subjects (N=116) n (%)
筋骨格系および結合組織障害	7 (12.7)	4 (6.6)	11 (9.5)
背部痛	1 (1.8)	2 (3.3)	3 (2.6)
筋力低下	0	2 (3.3)	2 (1.7)
変形性関節症	3 (5.5)	0	3 (2.6)
骨粗鬆症	2 (3.6)	0	2 (1.7)
四肢痛	2 (3.6)	0	2 (1.7)
肩回旋筋腱板症候群	2 (3.6)	0	2 (1.7)
神経系障害	9 (16.4)	14 (23.0)	23 (19.8)
認知障害	1 (1.8)	2 (3.3)	3 (2.6)
浮動性めまい	1 (1.8)	1 (1.6)	2 (1.7)
すくみ現象	3 (5.5)	0	3 (2.6)
頭部不快感	0	2 (3.3)	2 (1.7)
頭痛	1 (1.8)	1 (1.6)	2 (1.7)
感覚鈍麻	1 (1.8)	1 (1.6)	2 (1.7)
反射減弱	1 (1.8)	1 (1.6)	2 (1.7)
記憶障害	0	2 (3.3)	2 (1.7)
オンオフ現象	2 (3.6)	5 (8.2)	7 (6.0)
錯感覚	1 (1.8)	1 (1.6)	2 (1.7)
パーキンソン病	2 (3.6)	5 (8.2)	7 (6.0)
失神	0	2 (3.3)	2 (1.7)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

TABLE 14.3 1.15

Subjects with Treatment-Emergent Adverse Events Occurred in 2 subjects or Higher Frequency
by Primary System Organ Class and Preferred Term
(Safety Analysis Set)

System Organ Class MedDRA 24.0 Preferred Term	Dose Category Low Dose (N=55) n (%)	 High Dose (N=61) n (%)	 All Subjects (N=116) n (%)
精神障害	13 (23.6)	15 (24.6)	28 (24.1)
不安	4 (7.3)	4 (6.6)	8 (6.9)
譫妄	0	2 (3.3)	2 (1.7)
妄想	1 (1.8)	1 (1.6)	2 (1.7)
うつ病	2 (3.6)	1 (1.6)	3 (2.6)
幻覚	4 (7.3)	5 (8.2)	9 (7.8)
幻視	1 (1.8)	1 (1.6)	2 (1.7)
錯覚	1 (1.8)	1 (1.6)	2 (1.7)
不眠症	1 (1.8)	1 (1.6)	2 (1.7)
パニック発作	1 (1.8)	1 (1.6)	2 (1.7)
精神病性障害	1 (1.8)	1 (1.6)	2 (1.7)
皮膚および皮下組織障害	1 (1.8)	1 (1.6)	2 (1.7)
湿疹	1 (1.8)	1 (1.6)	2 (1.7)
血管障害	2 (3.6)	3 (4.9)	5 (4.3)
低血圧	1 (1.8)	1 (1.6)	2 (1.7)
起立性低血圧	1 (1.8)	2 (3.3)	3 (2.6)

Note: Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

表2.7.4.7-47　重篤な有害事象を発現した被験者一覧（安全性解析対象集団）：M15-741試験（更新時）

[redacted]20[redacted] 10:57 <[redacted]>
ABBV-951
STUDY M15-741 - THIRD INTERIM (CUTOFF [redacted]20[redacted])
R&D/22/0153 - CLINICAL/STATISTICAL

TABLE 14.3__2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg								
	TRT	1 TO 366	234	234	R: PAROTID ABSCESS S: 感染症および寄生虫症 P: 耳下腺膿瘍 L: Parotid abscess	E: 254 L: 21 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: RISK FACTOR MRSA A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg									
		TRT	1 TO 108	107	107	R: COGNITIVE DECLINE S: 神経系障害 P: 認知障害 L: Cognitive deterioration	O: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: COGNITIVE DECLINE > DIFFICULTIES HANDLING THE PUMP > DRUG WITHDRAWN A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 8[redacted] Sex: Male Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 362	158	158	R: HALLUCINATIONS S: 精神障害 P: 幻覚 L: Hallucinations	O: Yes I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE [redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 201	149	149	R: PARANOID DELUSIONS S: 精神障害 P: 妄想 L: Paranoid delusions	E: 159 L: 11 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED A1: Other: RECOMMENDED USING LOWER FLOW SETTINGS O: REDUCED DOSE ROPINIROL	S: Yes, Hospitalization or prolonged hospitalization, Other medically important serious event, Persistent or significant disability/incapacity R: POSSIBLE O: MARITIAL CRISIS IN COMBINATION WITH A GAMBLING WIN AND POOR SLEEP MAY HAVE CONTRIBUTED BUT MAIN REASON IS BELIEVED TO BE THE START OF ROPINIROL, POSSIBLY IN COMBINATION WITH DULOXETINE. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 86	55	55	R: FROM HITTING ABDOMEN/INFUSION SITE ON TABLE S: 一般・全身障害および投与部位の状態 P: 注入部位損傷 L: Infusion site injury	O: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 86	55	55	R: SUPERFICIAL CELLULITIS RIGHT ABDOMEN AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	O: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 86	83	83	R: INFUSION SITE ABSCESS L SIDE ABDOMEN O: Yes S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess		S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 8[redacted] Sex: Male Race: ASIAN Weight: 7[redacted].[redacted] kg									
		TRT	1 TO 86	86	86	R: INFUSION SITE ABSCESS LEFT ABDOMEN. S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	O: Yes	S: MODERATE R1: REASONABLE POSSIBILITY A1: Other: DRUG WITHDRAWN WITH PREVIOUS AE O: ABDOMINAL ULTRASOUND - RESULTS PENDING	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 4[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
		TRT	1 TO 8	5	5	R: HYPERVENTILATION S: 呼吸器、胸郭および縦隔障害 P: 過換気 L: Hyperventilation	E: 45 L: 41 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN O: BREATHING EXERCISE.	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: WORSENING PD A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch / Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE							
[redacted]# Age: 4[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg							
	TRT	1 TO 8	5	R: HYPOKALAMIA S: 代謝および栄養障害 P: 低カリウム血症 L: Hypokalemia	E: 6 L: 2 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: HYPERVENTILATION A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE							
[redacted]# Age: 4[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg							
	FU	9 TO 15	23	R: PARKINSON DISEASE. S: 神経系障害 P: パーキンソン病 L: Parkinson's disease	O: Yes I: Yes	S: MILD R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: DUE TO INITIATION OF A NEW DRUGTHERAPY, THE SUBJECT WAS ADMITTED. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 7[redacted].[redacted] kg									
		FU	65 TO	1	65	R: WORSENING PARKINSONS DISEASE S: 神経系障害 P: パーキンソン病 L: Parkinson's disease aggravated	E: 67 L: 3 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: CHANGE IN CON MEDS. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]#	Age: 7[redacted]	Sex: Male	Race: WHITE	Weight: 7[redacted].[redacted] kg					
	FU	65 TO	9	73		R: WORSENING PARKINSONS DISEASE S: 神経系障害 P: パーキンソン病 L: Parkinson's disease aggravated	E: 74 L: 2 Days	S: MILD R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: CHANGE IN CON MEDS. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 365	304	304	R: CHEST PAIN OF UNDETERMINED ETIOLOGY S: 一般・全身障害および投与部位の状態 P: 胸痛 L: Unspecified chest pain	O: Yes I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: PT WAS HOSPITALISED ON [redacted] 20[redacted]	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: HOSPITAL PHYSICIAN ORDERED A CONSULTATION IN GASTROENTEROLOGY, SO GASTRIC ORIGIN SUSPECTED A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 183	34	34	R: DELUSIONAL DISORDER UNSPECIFIED S: 精神障害 P: 妄想性障害、詳細不明 L: Delusional disorder, unspecified type	E: 94 L: 61 Days	S: SEVERE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: Other: INFUSION RATE REDUCED A2: DOSE NOT CHANGED O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 23	21	21	R: ABSCESS RIGHT LOWER QUADRANT OF ABDOMEN AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	O: Yes I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN O: SUBJECT WAS HOSPITALIZED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: CAREGIVER HAD TO GIVE MULTIPLE STICKS OF THE CLEO NEEDLE, THIS IS THE AREA OF INFECTION. EVENTUALLY THEY WERE ABLE TO FIND AN INFUSION SITE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
		TRT	1 TO 23	21	21	R: CELLULITIS RIGHT LOWER QUADRANT OF ABDOMEN AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 34 L: 14 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: CAREGIVER DID MULTIPLE STICKS WITH THE CLEO NEEDLE UNSUCCESSFULLY, THIS IS THE AREA OF INFECTION. ULTIMATELY WAS ABLE FIND AN INFUSION SITE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 23	23	23	R: ACUTE DELIRIUM S: 精神障害 P: 譫妄 L: Acute delirium	E: 54 L: 32 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: NOT RELATED TO STUDY PROCEDURES, TEMPORAL IMPLAUSIBILITY. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
[redacted]	TRT	1 TO 23	23	23	R: COGNITIVE CONFUSION S: 精神障害 P: 錯乱状態 L: Mental confusion	O: Yes I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE							
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg							
	TRT	1 TO 309	19	19	R: CELLULITIS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 120 L: 102 Days	S: SEVERE R1: REASONABLE POSSIBILITY A1: DOSE NOT CHANGED O: CHANGE INSERTION SITE, NO CHANGES RELATED WITH ABBV-951	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE							
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg							
[redacted]	TRT	1 TO 364	169	R: DIFFICULTY BREATHING S: 呼吸器、胸郭および縦隔障害 P: 呼吸困難 L: Difficulty breathing	E: 171 L: 3 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: ECG, CHEST X-RAY, TROPONIN, D DIMERS.	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 364	169	169	R: DYSTONIA S: 神経系障害 P: ジストニア L: Dystonia	E: 170 L: 2 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: Other: PUMP CHANGE WITH CHANGE OF SYRINGE AND SET (PAUSED FOR 20 MINUTES WHILST CHANGING ITEMS).	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch / Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 364	169	169	R: FEELING OF PRESSURE ON CHEST S: 一般・全身障害および投与部位の状態 P: 胸部不快感 L: Chest pressure sensation of	E: 171 L: 3 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: ECG, CHEST X-RAY, TROPONIN, D DIMERS.	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 364	249	249	R: CHEST DYSTONIA S: 神経系障害 P: ジストニア L: Dystonia	E: 250 L: 2 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 167	15	15	R: HEMIPARESIS RIGHT SIDE S: 神経系障害 P: 不全片麻痺 L: Hemiparesis (right)	E: 15 L: 1 Day	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 167	15	15	R: TRANSIENT RIGHT-SIDED HEMIHYPO-AESTHESIA S: 神経系障害 P: 片側感覚消失 L: Hemihypoesthesia	E: 15 L: 1 Day	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 167	15	15	R: TRANSIENT RIGHT-SIDED HEMIPARESIS S: 神経系障害 P: 不全片麻痺 L: Hemiparesis transient	E: 15 L: 1 Day	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 8[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 167	144	144	R: PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis	O: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: MULTIPLE: (CONCOMITANT MEDICATION OR THERAPY DISCONTINUED; Other: HOSPITALISED, NO FURTHER INFO AVAILABLE AT THIS MOMENT IN TIME; CONCOMITANT MEDICATION OR THERAPY STARTED)	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg									
[redacted]	TRT	1 TO 22	15	15		R: INFUSION SITE LEFT ARM - ABSCESS S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	O: Yes I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: Other: INFUSION SITE ROTATED AND MOVED TO FLANKS AS ABDOMEN NOT AN OPTION DUE TO SEVERE SCOLIOSIS A2: DOSE NOT CHANGED	S: Yes, Other medically important serious event R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	3	3	R: HYPOTHERMIA S: 一般・全身障害および投与部位の状態 P: 低体温 L: Hypothermia	E: 30 L: 28 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: PREVIOUS EPISODES OF HYPOTHERMIA (PRIOR TO STUDY COMMENCEMENT) WERE RELATED TO AN INFECTION.THE PI FEELS THIS WAS DUE TO INFECTION WHICH HAS BEEN CLASSIFIED AS PNEUMONIA; PATHOGEN UNKNOWN AT THIS TIME A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	3	3	R: PNEUMONIA S: 感染症および寄生虫症 P: 肺炎 L: Pneumonia	E: 30 L: 28 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Life threatening, Hospitalization or prolonged hospitalization, Other medically important serious event R: NOT RELATED O: PATHOGEN UNKNOWN, BACTERIAL CULTURES NO GROWTH. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	3	3	R: SEPSIS S: 感染症および寄生虫症 P: 敗血症 L: Sepsis	E: 30 L: 28 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: PREVIOUS EPISODES OF HYPOTHERMIA (PRIOR TO STUDY COMMENCEMENT) WERE RELATED TO AN INFECTION.THE PI FEELS THIS WAS DUE TO INFECTION WHICH HAS BEEN CLASSIFIED AS PNEUMONIA; PATHOGEN UNKNOWN AT THIS TIME A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	3	3	R: SEPTIC SHOCK S: 感染症および寄生虫症 P: 敗血症性ショック L: Septic shock	E: 30 L: 28 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: NONE	S: Yes, Life threatening, Hospitalization or prolonged hospitalization, Other medically important serious event R: NOT RELATED O: PNEUMONIA A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	10	10	R: DELIRIUM S: 精神障害 P: 譫妄 L: Delirium	E: 30 L: 21 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization, Other medically important serious event R: UNLIKELY O: MOST LIKELY CAUSE OF EVENT IS THE SEPSIS AND ICU ADMISSION FOR ALMOST A WEEK. A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch / Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	10	10	R: HALLUCINATIONS S: 精神障害 P: 幻覚 L: Hallucinations	E: 30 L: 21 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization, Other medically important serious event R: UNLIKELY O: UTI A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 393	268	268	R: PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis	E: 370 L: 103 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 10[redacted].[redacted] kg									
		TRT	1 TO 393	370	370	R: WORSENING OF PSYCHOSIS S: 精神障害 P: 精神病性障害 L: Psychosis aggravated	O: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED O: QUETIAPINE INCREASED TO 25MG OD	S: Yes, Hospitalization or prolonged hospitalization R: PROBABLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: AMERICAN INDIAN OR ALASKA NATIVE Weight: 5[redacted].[redacted] kg									
		TRT	1 TO 381	38	38	R: LOW SODIUM S: 臨床検査 P: 血中ナトリウム減少 L: Sodium low	O: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity R1: ABBV-951 Relationship R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 362	34	34	R: HEMATOMA AT INFUSION SITE. S: 一般・全身障害および投与部位の状態 P: 注入部位血腫 L: Infusion site hematoma	E: 49 L: 16 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NEW INJECTION SITE. GETS TREATMENT AT THE EMERGENCY ROOM FOR INFECTED HEMATOMA. HOSPITALIZED OVERNIGHT.	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE [redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 362	34	34	R: INFECTION AT INFUSION SITE. S: 感染症および寄生虫症 P: 注入部位感染 L: Infusion site infection	E: 49 L: 16 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NEW INJECTION SITE. GETS TREATMENT AT THE EMERGENCY ROOM FOR INFECTED HEMATOMA. HOSPITALIZED OVERNIGHT.	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 330	262	262	R: REACTIVE ARTHRITIS IN RIGHT KNEE S: 筋骨格系および結合組織障害 P: 反応性関節炎 L: Reactive arthritis	O: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization, Persistent or significant disability/incapacity R: NOT RELATED O: P.I SUSPECT THIS AE IS CAUSED AND DUE TO INFLAMMATION (AE [redacted]) A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 365	191	191	R: CORONARY ARTERY DISEASE S: 心臓障害 P: 冠動脈疾患 L: Coronary artery disease	O: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: SUBJECT HAD 2 CORONARY STENT PLACEMENT COMPLETED FAMILY HISTORY OF HEART PROBLEMS.	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: RISK FACTORS, FAMILY HISTORY A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 365	195	195	R: ATRIAL FIBRILLATION S: 心臓障害 P: 心房細動 L: Atrial fibrillation	O: Yes I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: RISK FACTOR, NEW DIAGNOSIS OF CORONARY ARTERY DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
	TRT	1 TO 365	195	195		R: URINARY TRACT INFECTION S: 感染症および寄生虫症 P: 尿路感染 L: Urinary tract infection	E: 199 L: 5 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: RISK FACTOR, URINARY RETENTION DUE TO PARKINSON'S DISEASE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 7[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
	TRT	1 TO 365	333	333		R: PULMONARY EMBOLI S: 呼吸器、胸郭および縦隔障害 P: 肺塞栓症 L: Pulmonary embolism	O: Yes I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: SUBJECT HAS A HISTORY OF ATRIAL FIBRILLATION, PER LAST AE, NEW SINCE SIGNING CONSENT A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 6[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg								
	TRT	1 TO 127	56	56	R: CELLULITIS TO LEFT UPPER/LOWER ABDOMINAL QUADERANT AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 100 L: 45 Days	S: SEVERE R1: REASONABLE POSSIBILITY A1: DRUG INTERRUPTED A1: Other: DRUG WILL BE STOPPED FOR ABOUT 6 HOURS FOR SURGICAL INTERVENTION	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 10[redacted].[redacted] kg								
	TRT	1 TO 374	269	269	R: CELLULITIS TO MID-LOWER ABDOMINAL INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 271 L: 3 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch / Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 366	309	309	R: LARGE LEFT THIGH HEMATOMA S: 血管障害 P: 血腫 L: Hematoma	E: 312 L: 4 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: FALL A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Epoch Name	Epoch Interval	Rx Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
[redacted]	TRT	1 TO 363	346	346	R: COVID S: 感染症および寄生虫症 P: COVID-19 L: COVID-19	E: 358 L: 13 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: Yes A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: COVID 19 VIRUS A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 6[redacted].[redacted] kg									
	TRT	1 TO 365	217	217		R: BRONCHIECTASIS WORSENING S: 呼吸器、胸郭および縦隔障害 P: 気管支拡張症 L: Bronchiectasis	E: 232 L: 16 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization, Persistent or significant disability/incapacity R: NOT RELATED O: SECONDARY INFECTION A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted])								
TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 56	52	52	R: DYSTONIC REACTION S: 神経系障害 P: ジストニア L: Dystonic reaction	E: 53 L: 2 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: GENERAL DETERIORATION OF THE SUBJECT (SEE SAE [redacted]) A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE							
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg							
	TRT	1 TO 56	56	R: PARKINSONISM S: 神経系障害 P: パーキンソニズム L: Parkinsonism	E: 119 L: 64 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE O: PROGRESSIVE GENERAL DETERIORATION A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 108	108	108	R: CARDIORESPIRATORY ARREST S: 心臓障害 P: 心肺停止 L: Cardio-respiratory arrest	E: 108 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: NONE	S: Yes, Death of subject R: NOT RELATED O: DETERIORATION OF THE GENERAL STATE OF HEALTH A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 117	15	15	R: URINARY TRACT INFECTION S: 感染症および寄生虫症 P: 尿路感染 L: Urinary tract infection	E: 27 L: 13 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: MICROBE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg									
	TRT	1 TO 117	25	25		R: COGNITIVE DETERIORATION S: 神経系障害 P: 認知障害 L: Cognitive deterioration	E: 27 L: 3 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 6[redacted] Sex: Female Race: WHITE Weight: 5[redacted].[redacted] kg								
	TRT	1 TO 117	25	25	R: PSYCHOTIC DISORDER S: 精神障害 P: 精神病性障害 L: Psychotic disorder	E: 27 L: 3 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted] Age: 4[redacted] Sex: Male Race: ASIAN Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 365	71	71	R: PSEUDOSEIZURE S: 神経系障害 P: 心因性発作 L: Pseudoseizure	E: 72 L: 2 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: DOPAMINE AGONIST WITHDRAWAL SYNDROME A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE									
[redacted] Age: 4[redacted] Sex: Male Race: WHITE Weight: 9[redacted].[redacted] kg									
	TRT	1 TO 363	315	315		R: WORSENING L5 AND S1 COMPRESSIVE RADICULOPATHY S: 神経系障害 P: 腰仙部神経根障害 L: Lumbosacral radiculopathy	E: 339 L: 25 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: NONE	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: LUMBAR DISC HERNIATION A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 4[redacted] Sex: Female Race: WHITE Weight: 8[redacted].[redacted] kg								
	TRT	1 TO 368	284	284	R: SUICIDE ATTEMPT S: 精神障害 P: 自殺企図 L: Suicide attempt	E: 284 L: 1 Day	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Life threatening R: UNLIKELY O: DEPRESSIVE EPISODE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: ASIAN Weight: 4[redacted].[redacted] kg								
	TRT	1 TO 364	172	172	R: FURTHER WORSENING OF HALLUCINATIONS S: 精神障害 P: 幻覚 L: Hallucinations aggravated	E: 183 L: 12 Days I: Yes	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	Day	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Female Race: ASIAN Weight: 4[redacted].[redacted] kg									
		TRT	1 TO 364	357	357	R: WORSENING OF ORTHOSTATIC HYPOTENSION S: 血管障害 P: 起立性低血圧 L: Hypotension postural aggravated	O: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: Other: ABBV-951 RATE REDUCED. O: IV FLUIDS COMMENCED.	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE O: REFLUX OESOPHAGITIS A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 5[redacted] Sex: Female Race: WHITE Weight: 9[redacted].[redacted] kg									
	TRT	1 TO 371	25	25		R: LEFT SACROILIAC JOINT INCOMPETENCE . S: 筋骨格系および結合組織障害 P: 仙腸関節機能障害 L: Sacroiliac joint dysfunction	E: 27 L: 3 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Hospitalization or prolonged hospitalization R: UNLIKELY O: STRUCTURAL DEGENERATIVE CHANGES TO SACROILIAC JOINT ASSOCIATED WITH SEVERAL TENDON ENTHESOPATHIES AND HIP IMPINGEMENT A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 52	38	38	R: SUDDEN OFF STATE RELATED TO PARKINSONS DISEASE S: 神経系障害 P: オンオフ現象 L: On and off phenomenon	E: 45 L: 8 Days I: Yes	S: SEVERE R1: NO REASONABLE POSSIBILITY R3: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: RESCUE MEDICATION, HOSPITAL ADMISSION UPON FAILURE OF SYMPTOM IMPROVEMENT	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: WORSENING OF PARKINSONS SYMPTOMES A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg								
	FU	53 TO	1	53	R: WORSENING OF MOTORFLUCTUATION S: 神経系障害 P: オンオフ現象 L: Motor fluctuations	E: 77 L: 25 Days	S: SEVERE R1: NO REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED O: HOSPITALIZATION	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: DISCONTINUATION OF SUBCUTANEOUS LEVODOPA INFUSION A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch / Interval	Rx Day of Day	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE								
[redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg								
	TRT	1 TO 274	260	260	R: URINARY TRACT INFECTION S: 感染症および寄生虫症 P: 尿路感染 L: Urinary tract infection	E: 288 L: 29 Days	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED O: THIS IS A URINARY TRACT INFECTION. THE URINE SEDIMENT IS PATHOLOGICAL, THE URINE CULTURE IS PENDING. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 HIGH DOSE [redacted]# Age: 7[redacted] Sex: Female Race: WHITE Weight: 6[redacted].[redacted] kg								
	FU	275 TO	1	275	R: GENERALIZED TONIC-CLONIC SEIZURE S: 神経系障害 P: 全身性強直性間代性発作 L: Generalized tonic-clonic seizure	E: 315 L: 41 Days I: Yes	S: MODERATE R1: NO REASONABLE POSSIBILITY R4: No A1: Other: THE DRUG WAS PREVIOUSLY INTERRUPTED. SO, AT THAT MOMENT THE PATIENT WAS TAKING ORAL L-DOPA. SHE WAS AT THE EMERGENCY DEPARTMENT WAITING FOR HOSPITALIZATION DUE TO URINARY TRACT INFECTION.	S: Yes, Life threatening, Hospitalization or prolonged hospitalization, Other medically important serious event, Persistent or significant disability/incapacity R: NOT RELATED O: THE PATIENT PRESENTED HOSPITALIZATION WITH RESPIRATORY INFECTION, GENERAL IMPAIRMENT AND CAQUEXIA. A: NO REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 7[redacted] Sex: Female Race: WHITE Weight: 9[redacted].[redacted] kg								
	TRT	1 TO 365	7	7	R: PSYCHOSIS. S: 精神障害 P: 精神病性障害 L: Psychosis	E: 23 L: 17 Days	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: Other: THE DOSE OF THE DRUG WAS REDUCED TO 0.55 ML/H. O: CONCOMITANT MEDICATION OR THERAPY DISCONTINUED	S: Yes, Hospitalization or prolonged hospitalization R: POSSIBLE A: NO REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day	Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE									
[redacted] Age: 6[redacted] Sex: Male Race: WHITE Weight: 8[redacted].[redacted] kg									
		TRT	1 TO 366	43	43	R: CELLULITIS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 59 L: 17 Days	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DRUG INTERRUPTED A1: Other: STOPPED INFUSION AND REMOVED SITE CONNECTOR AND INSERTED SUBCUTANEOUS NEEDLE. O: SWAB OF INFECTED INFUSION SITE TAKEN AND SENT FOR ANALYSIS	S: Yes, Hospitalization or prolonged hospitalization, Other medically important serious event, Persistent or significant disability/incapacity R: NOT RELATED A: REASONABLE POSSIBILITY

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted]#	Age: 6[redacted]	Sex: Female	Race: WHITE	Weight: 8[redacted].[redacted] kg				
	TRT	1 TO 43	43	43	R: SUBCUTANEOUS ABSCESS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位膿瘍 L: Infusion site abscess	E: 70 L: 28 Days	S: SEVERE R1: REASONABLE POSSIBILITY R4: No A1: DRUG WITHDRAWN O: SURGERY. INCISION OF SUBCUTANEOUS ABSCESS WITH DRAINING OF PUS	S: Yes, Hospitalization or prolonged hospitalization R: NOT RELATED A: REASONABLE POSSIBILITY

Subject prematurely discontinued.

Program Source Code: [redacted]

TABLE 14.3 2.2

Listing of All Treatment-Emergent Serious Adverse Events
(Safety Analysis Set)

Subject Number	Name	Epoch	Interval	Rx Day of Onset	R: Reported Term S: System Organ Class P: MedDRA 24.0 Preferred Term L: Lower Level Term	E: Rx Day Ended O: Ongoing at the End of Study? L: Length I: Intermittent?	S: Severity ----- Relationship to ----- R1: ABBV-951 R2: Loading Dose Drug R3: Rescue Dose Drug R4: COVID-19 Infection A1: Action Taken with ABBV-951 A2: Action Taken with Rescue Dose Treatment O: Other Actions Taken	S: Serious AE? R: Relationship to Infusion Pump? O: Other Cause of Event A: AbbVie Opinion of Causality
INV: [redacted], [redacted] ([redacted]) TRT: ABBV-951 LOW DOSE								
[redacted] Age: 6[redacted] Sex: Female Race: WHITE Weight: 7[redacted].[redacted] kg								
	TRT	1 TO 364	46	46	R: CELLULITIS AT INFUSION SITE S: 感染症および寄生虫症 P: 注入部位蜂巣炎 L: Infusion site cellulitis	E: 62 L: 17 Days I: Yes	S: MODERATE R1: REASONABLE POSSIBILITY R4: No A1: DOSE NOT CHANGED	S: Yes, Other medically important serious event R: CAUSAL RELATIONSHIP A: REASONABLE POSSIBILITY

Program Source Code: [redacted]